Word	Tag
he	O
was	O
clinical	O
and	O
research	O
fellow	O
and	O
instructor	O
at	O
harvard	O
medical	O
school	O
before	O
joining	O
the	O
faculty	O
at	O
the	O
university	O
of	O
utah	O
in	O
dr	O
abel	O
has	O
earned	O
many	O
awards	O
including	O
the	O
van	O
meter	O
prize	O
of	O
the	O
american	O
thyroid	ENTITY
association	ENTITY
in	ENTITY
and	ENTITY
the	ENTITY
gerald	ENTITY
aurbach	ENTITY
award	ENTITY
from	ENTITY
the	ENTITY
endocrine	ENTITY
society	ENTITY
for	ENTITY
outstanding	ENTITY
contributions	ENTITY
to	ENTITY
endocrine	ENTITY
.	O
he	O
was	O
elected	O
chair	O
of	O
the	O
board	O
of	O
scientific	O
counselors	O
of	O
the	O
nih	O
national	O
institute	O
of	O
diabetes	ENTITY
and	ENTITY
digestive	ENTITY
and	ENTITY
kidney	ENTITY
diseases	ENTITY
and	O
now	O
serves	O
as	O
member	O
of	O
the	O
advisory	O
council	O
of	O
the	O
national	O
heart	ENTITY
lung	ENTITY
.	O
he	O
was	O
chair	O
of	O
the	O
sarnoff	O
cardiovascular	ENTITY
.	O
he	O
was	O
recently	O
elected	O
as	O
president	O
of	O
the	O
endocrine	ENTITY
.	O
dr	O
.	O
he	O
was	O
elected	O
to	O
the	O
national	O
academy	O
of	O
medicine	O
in	O
october	O
for	O
more	O
information	O
go	O
to	O
asp	ENTITY
.	O
the	O
blood	ENTITY
sugar	ENTITY
concentration	O
or	O
blood	ENTITY
glucose	ENTITY
level	ENTITY
is	O
the	O
amount	O
of	O
glucose	ENTITY
sugar	ENTITY
present	O
in	O
the	O
blood	ENTITY
of	ENTITY
human	ENTITY
.	O
the	O
body	O
naturally	O
tightly	O
regulates	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
.	O
abnormal	O
blood	ENTITY
sugar	ENTITY
level	ENTITY
also	O
gives	O
rise	O
to	O
many	O
more	O
disorders	O
.	O
aimil	O
is	O
presentation	O
where	O
renowned	O
ayurvedic	O
expert	O
dr	O
nitika	O
kohli	O
guides	O
on	O
how	O
to	O
overcome	O
diabetes	ENTITY
.	O
careworldtv	O
channel	O
is	O
the	O
destination	O
for	O
fitness	O
lifestyle	O
content	O
on	O
youtube	O
.	O
careworldtv	O
helps	O
you	O
become	O
better	O
you	O
with	O
how	O
to	O
videos	O
covering	O
everything	O
from	O
exercise	O
diet	O
and	O
healthy	O
living	O
to	O
style	O
makeup	O
and	O
fashion	O
tips	O
.	O
stay	O
tuned	O
to	O
watch	O
more	O
how	O
to	O
beauty	O
health	O
lifestyle	O
videos	O
.	O
subscribe	O
list	O
plug	O
hbjc	O
bbindauwm	O
fuaxtbbcyfyfii	O
.	O
what	O
is	O
diabetic	ENTITY
cardiomyopathy	ENTITY
.	O
what	O
does	O
diabetic	ENTITY
cardiomyopathy	ENTITY
.	O
diabetic	ENTITY
cardiomyopathy	ENTITY
meaning	O
diabetic	ENTITY
cardiomyopathy	ENTITY
.	O
source	O
wikipedia	O
org	O
article	O
adapted	O
under	O
diabetic	ENTITY
cardiomyopathy	ENTITY
is	O
disorder	ENTITY
of	ENTITY
the	ENTITY
heart	ENTITY
muscle	ENTITY
in	O
people	O
with	O
diabetes	ENTITY
.	O
it	O
can	O
lead	O
to	O
inability	O
of	O
the	O
heart	ENTITY
to	ENTITY
circulate	ENTITY
blood	ENTITY
through	ENTITY
the	ENTITY
body	ENTITY
effectively	ENTITY
state	ENTITY
known	ENTITY
as	ENTITY
heart	ENTITY
failure	ENTITY
with	O
accumulation	O
of	O
fluid	O
in	O
the	O
lungs	ENTITY
pulmonary	ENTITY
edema	ENTITY
or	O
legs	O
.	O
most	O
heart	ENTITY
failure	ENTITY
in	O
people	O
with	O
diabetes	ENTITY
results	ENTITY
from	ENTITY
coronary	ENTITY
artery	ENTITY
disease	ENTITY
and	O
diabetic	ENTITY
cardiomyopathy	ENTITY
is	O
only	O
said	O
to	O
exist	O
if	O
there	O
is	O
no	O
coronary	ENTITY
artery	ENTITY
disease	ENTITY
to	O
explain	O
the	O
heart	ENTITY
muscle	ENTITY
disorder	ENTITY
.	O
one	O
particularity	O
of	O
dcm	O
is	O
the	O
long	O
latent	O
phase	O
during	O
which	O
the	O
disease	ENTITY
.	O
in	O
most	O
cases	O
dcm	O
is	O
detected	O
with	O
concomitant	O
hypertension	ENTITY
or	ENTITY
coronary	ENTITY
artery	ENTITY
disease	ENTITY
.	O
one	O
of	O
the	O
earliest	O
signs	O
is	O
mild	O
left	ENTITY
ventricular	ENTITY
diastolic	ENTITY
dysfunction	ENTITY
with	O
little	O
effect	O
on	O
ventricular	ENTITY
.	O
also	O
the	O
diabetic	ENTITY
patient	ENTITY
may	O
show	O
subtle	O
signs	O
of	O
dcm	O
related	O
to	O
decreased	O
left	ENTITY
ventricular	ENTITY
compliance	O
or	O
left	ENTITY
ventricular	ENTITY
hypertrophy	ENTITY
.	O
prominent	O
wave	O
can	O
also	O
be	O
noted	O
in	O
the	O
jugular	O
venous	O
pulse	O
and	O
the	O
cardiac	ENTITY
.	O
after	O
the	O
development	O
of	O
systolic	ENTITY
dysfunction	ENTITY
left	ENTITY
ventricular	ENTITY
dilation	ENTITY
and	O
symptomatic	ENTITY
heart	ENTITY
failure	ENTITY
.	O
systolic	ENTITY
mitral	ENTITY
murmur	ENTITY
is	O
not	O
uncommon	O
in	O
these	O
cases	O
.	O
these	O
changes	O
are	O
accompanied	O
by	O
variety	O
of	O
electroc	O
ardiographic	O
changes	O
that	O
may	O
be	O
associated	O
with	O
dcm	O
in	O
of	O
patients	O
without	O
structural	ENTITY
heart	ENTITY
disease	ENTITY
.	O
later	O
in	O
the	O
progression	O
prolonged	O
qt	O
interval	O
may	O
be	O
indicative	O
of	O
fibrosis	ENTITY
.	O
given	O
that	O
dcm	O
definition	O
excludes	O
concomitant	O
atherosclerosis	ENTITY
or	ENTITY
hypertension	ENTITY
there	ENTITY
are	ENTITY
no	ENTITY
changes	ENTITY
in	ENTITY
perfusion	ENTITY
or	ENTITY
in	ENTITY
atrial	ENTITY
natriuretic	ENTITY
peptide	ENTITY
levels	O
up	O
until	O
the	O
very	O
late	O
stages	O
of	O
the	O
disease	O
when	O
the	O
hypertrophy	ENTITY
and	ENTITY
fibrosis	ENTITY
.	O
defects	O
in	O
cellular	O
processes	O
such	O
as	O
autophagy	ENTITY
and	ENTITY
mitophagy	ENTITY
are	ENTITY
thought	ENTITY
to	ENTITY
contribute	ENTITY
to	ENTITY
the	ENTITY
development	ENTITY
of	ENTITY
diabetic	ENTITY
cardiomyopathy	ENTITY
.	O
diabetic	ENTITY
cardiomyopathy	ENTITY
is	O
characterized	O
functionally	O
by	O
ventricular	ENTITY
dilation	ENTITY
enlargement	O
of	O
heart	ENTITY
cells	ENTITY
prominent	O
interstitial	O
fibrosis	ENTITY
and	ENTITY
decreased	ENTITY
or	ENTITY
preserved	ENTITY
.	O
while	O
it	O
has	O
been	O
evident	O
for	O
long	O
time	O
that	O
the	O
complications	O
seen	O
in	O
diabetes	ENTITY
are	ENTITY
related	ENTITY
to	ENTITY
the	ENTITY
hyperglycemia	ENTITY
associated	ENTITY
to	ENTITY
it	ENTITY
several	ENTITY
factors	ENTITY
have	ENTITY
been	ENTITY
implicated	ENTITY
in	ENTITY
the	ENTITY
pathogenesis	ENTITY
of	ENTITY
the	ENTITY
disease	ENTITY
.	O
etiologically	ENTITY
four	ENTITY
main	ENTITY
causes	ENTITY
are	ENTITY
responsible	ENTITY
for	ENTITY
the	ENTITY
development	ENTITY
of	ENTITY
heart	ENTITY
failure	ENTITY
in	O
dcm	O
microangiopathy	ENTITY
and	ENTITY
related	ENTITY
endothelial	ENTITY
dysfunction	ENTITY
autonomic	O
neuropathy	O
metabolic	O
alterations	O
that	O
include	O
abnormal	O
glucose	ENTITY
use	ENTITY
and	ENTITY
increased	ENTITY
fatty	ENTITY
acid	ENTITY
oxidation	ENTITY
generation	O
and	O
accumulation	O
of	O
free	ENTITY
radicals	ENTITY
.	O
microangiopathy	ENTITY
can	ENTITY
be	ENTITY
characterized	ENTITY
as	ENTITY
subendothelial	ENTITY
and	ENTITY
endothelial	ENTITY
fibrosis	ENTITY
in	O
the	O
coronary	ENTITY
microvasculature	ENTITY
of	ENTITY
the	ENTITY
heart	ENTITY
.	O
this	O
endothelial	ENTITY
dysfunction	ENTITY
leads	O
to	O
impaired	ENTITY
myocardial	ENTITY
blood	ENTITY
.	O
about	O
of	O
diabetics	O
with	O
dcm	O
show	O
pathologic	O
evidence	O
for	O
microangiopathy	ENTITY
such	ENTITY
as	ENTITY
sub	ENTITY
endothelial	ENTITY
and	ENTITY
endothelial	ENTITY
fibrosis	ENTITY
compared	O
to	O
only	O
of	O
non	O
diabetic	O
heart	ENTITY
failure	ENTITY
.	O
over	O
the	O
years	O
several	O
hypotheses	O
were	O
postulated	O
to	O
explain	O
the	O
endothelial	ENTITY
dysfunction	ENTITY
observed	O
in	O
diabetes	ENTITY
.	O
it	O
was	O
hypothesized	O
that	O
the	O
extracellular	O
hyperglycemia	ENTITY
leads	ENTITY
to	ENTITY
an	ENTITY
intracellular	ENTITY
hyperglycemia	ENTITY
in	ENTITY
cells	ENTITY
unable	ENTITY
to	ENTITY
regulate	ENTITY
their	ENTITY
glucose	ENTITY
uptake	ENTITY
most	ENTITY
predominantly	ENTITY
endothelial	ENTITY
cells	ENTITY
.	O
indeed	O
while	O
hepatocytes	ENTITY
and	ENTITY
myocytes	ENTITY
have	ENTITY
mechanisms	ENTITY
allowing	ENTITY
them	ENTITY
to	ENTITY
internalize	ENTITY
their	ENTITY
glucose	ENTITY
transporter	ENTITY
endothelial	ENTITY
cells	ENTITY
do	O
not	O
possess	O
.	O
the	O
consequences	O
of	O
increased	O
intracellular	O
glucose	ENTITY
concentration	ENTITY
are	O
fourfold	O
all	O
resulting	O
from	O
increasing	O
concentration	O
of	O
glycolytic	ENTITY
intermediates	ENTITY
upstream	ENTITY
of	ENTITY
the	ENTITY
rate	ENTITY
limiting	ENTITY
glyceraldehyde	ENTITY
phosphate	ENTITY
reaction	O
which	O
is	O
inhibited	O
by	O
mechanisms	O
activated	O
by	O
increased	O
free	O
radical	O
formation	O
common	O
in	O
diabetes	ENTITY
.	O
four	O
pathways	O
enumerated	O
below	O
all	O
explain	O
part	O
of	O
the	O
diabetic	ENTITY
complications	ENTITY
.	O
in	O
this	O
video	O
we	O
re	O
going	O
to	O
learn	O
about	O
how	O
the	O
concentration	O
of	O
hormones	ENTITY
.	O
by	O
ryan	O
patton	O
.	O
created	O
by	O
ryan	O
scott	O
patton	O
.	O
watch	O
the	O
next	O
lesson	O
add	O
user	O
khanacademy	O
.	O
controlled	O
diabetics	O
high	ENTITY
sugar	ENTITY
levels	ENTITY
in	ENTITY
blood	ENTITY
with	O
days	O
treatment	O
nadipathy	O
diabetes	ENTITY
treatment	ENTITY
in	ENTITY
nadipathy	ENTITY
what	ENTITY
is	ENTITY
diabetes	ENTITY
it	ENTITY
is	ENTITY
the	ENTITY
condition	ENTITY
that	ENTITY
body	ENTITY
cannot	ENTITY
balance	ENTITY
the	ENTITY
glucose	ENTITY
levels	ENTITY
due	O
to	O
lack	O
of	O
energy	O
to	O
pancreas	ENTITY
or	ENTITY
the	ENTITY
body	ENTITY
cannot	ENTITY
utilize	ENTITY
insulin	ENTITY
to	ENTITY
maintain	ENTITY
glucose	ENTITY
homeostasis	ENTITY
.	O
it	O
was	O
first	O
known	O
in	O
the	O
th	O
century	O
.	O
again	O
diabetes	ENTITY
is	ENTITY
differentiated	ENTITY
in	ENTITY
to	ENTITY
two	ENTITY
types	ENTITY
diabetes	ENTITY
mellitus	ENTITY
and	O
diabetes	ENTITY
insipidus	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
mainly	O
caused	O
by	O
deficiency	O
of	O
insulin	ENTITY
due	ENTITY
to	ENTITY
either	ENTITY
lack	ENTITY
of	ENTITY
energy	ENTITY
in	ENTITY
pancreas	ENTITY
or	ENTITY
any	ENTITY
auto	ENTITY
immune	ENTITY
disease	ENTITY
.	O
while	O
diabetes	ENTITY
insipidus	ENTITY
is	O
caused	O
by	O
defect	O
in	O
secretion	O
of	O
vasopressin	ENTITY
antidiuretic	ENTITY
hormone	ENTITY
which	O
is	O
secreted	O
from	O
pituitary	ENTITY
gland	ENTITY
present	O
in	O
hypothalamus	ENTITY
.	O
its	O
function	O
is	O
to	O
reabsorb	O
water	O
from	O
distal	O
tubules	O
in	O
the	O
kidney	ENTITY
.	O
but	O
its	O
deficiency	O
caused	O
increased	O
water	O
excretion	O
through	O
urine	O
even	O
in	O
low	O
intake	O
of	O
water	O
.	O
diabetes	ENTITY
mellitus	ENTITY
and	O
diabetes	ENTITY
insipidus	ENTITY
are	O
unrelated	O
although	O
they	O
have	O
similar	O
signs	O
and	O
symptoms	O
like	O
excessive	O
thirst	O
and	O
excessive	ENTITY
urination	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
more	O
common	O
than	O
the	O
diabetes	ENTITY
insipidus	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
.	O
type	O
diabetes	ENTITY
the	ENTITY
body	ENTITY
does	ENTITY
not	ENTITY
produce	ENTITY
insulin	ENTITY
.	O
such	O
diabetes	ENTITY
called	ENTITY
as	ENTITY
insulin	ENTITY
dependent	ENTITY
diabetes	ENTITY
.	O
people	O
usually	O
develop	O
type	O
diabetes	ENTITY
before	ENTITY
their	ENTITY
th	ENTITY
.	O
today	O
type	O
diabetes	ENTITY
has	ENTITY
no	ENTITY
proper	ENTITY
treatment	ENTITY
.	O
so	O
these	O
individuals	O
are	O
insulin	ENTITY
.	O
approximately	O
of	O
all	O
diabetes	ENTITY
cases	ENTITY
are	ENTITY
type	ENTITY
common	ENTITY
symptoms	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
fatigue	O
or	O
tiredness	O
.	O
excessive	O
thirst	O
.	O
increased	O
urination	ENTITY
.	O
nausea	ENTITY
perhaps	ENTITY
vomiting	ENTITY
.	O
blurred	O
vision	O
.	O
in	O
women	O
frequent	O
vaginal	ENTITY
.	O
dry	ENTITY
mouth	ENTITY
.	O
itching	ENTITY
skin	ENTITY
.	O
slow	O
healing	O
wounds	O
.	O
type	O
diabetes	ENTITY
globally	ENTITY
as	ENTITY
of	ENTITY
an	ENTITY
estimated	ENTITY
million	ENTITY
people	ENTITY
have	ENTITY
type	ENTITY
diabetes	ENTITY
worldwide	ENTITY
.	O
about	O
cases	O
are	O
type	O
diabetes	ENTITY
.	O
this	O
is	O
happening	O
due	O
to	O
lack	O
of	O
energy	O
in	O
the	O
pancreas	ENTITY
.	O
so	O
that	O
pancreas	ENTITY
cannot	ENTITY
produce	ENTITY
sufficient	ENTITY
insulin	ENTITY
to	ENTITY
maintain	ENTITY
glucose	ENTITY
homeostasis	ENTITY
.	O
common	O
symptoms	O
.	O
excessive	O
thirst	O
.	O
excessive	O
hungry	O
.	O
weak	ENTITY
eye	ENTITY
.	O
increased	O
urination	ENTITY
.	O
fatigue	O
or	O
tiredness	O
.	O
in	O
women	O
frequent	O
vaginal	ENTITY
.	O
slow	O
healing	O
wounds	O
.	O
gestation	ENTITY
diabetes	ENTITY
this	O
type	O
of	O
diabetes	ENTITY
usually	ENTITY
occurs	ENTITY
in	ENTITY
pregnant	ENTITY
mothers	ENTITY
during	ENTITY
gestation	ENTITY
pregnancy	ENTITY
.	O
so	O
there	O
is	O
an	O
increase	O
in	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
most	O
gestational	ENTITY
diabetes	ENTITY
goes	O
away	O
after	O
child	ENTITY
birth	ENTITY
.	O
common	O
symptoms	O
of	O
gestation	ENTITY
diabetes	ENTITY
increased	O
urination	ENTITY
fatigue	ENTITY
or	ENTITY
tiredness	ENTITY
increased	ENTITY
thirst	ENTITY
nausea	ENTITY
and	ENTITY
vomiting	ENTITY
blurred	ENTITY
vision	ENTITY
weight	ENTITY
loss	ENTITY
hormonal	ENTITY
imbalance	ENTITY
head	O
aches	ENTITY
body	ENTITY
pain	ENTITY
diabetes	ENTITY
insipidus	ENTITY
the	O
several	O
forms	O
of	O
diabetes	ENTITY
insipidus	ENTITY
are	O
neurogenic	ENTITY
diabetes	ENTITY
insipidus	ENTITY
neurogenic	O
diabetes	ENTITY
insipidus	ENTITY
is	O
more	O
commonly	O
known	O
as	O
central	ENTITY
diabetes	ENTITY
insipidus	ENTITY
.	O
it	O
is	O
caused	O
by	O
the	O
damage	O
of	O
pituitary	ENTITY
gland	ENTITY
present	O
in	O
hypothalamus	ENTITY
region	ENTITY
or	ENTITY
other	ENTITY
reasons	ENTITY
like	ENTITY
autoimmune	ENTITY
infection	ENTITY
surgery	ENTITY
head	ENTITY
trauma	ENTITY
and	O
some	O
drugs	O
.	O
nephrogenic	ENTITY
diabetes	ENTITY
insipidus	ENTITY
nephrogenic	ENTITY
diabetes	ENTITY
insipidus	ENTITY
is	O
caused	O
by	O
an	O
improper	O
response	O
of	O
the	O
kidney	ENTITY
to	ENTITY
adh	ENTITY
leading	ENTITY
to	ENTITY
decrease	ENTITY
in	ENTITY
the	ENTITY
ability	ENTITY
of	ENTITY
kidney	ENTITY
to	ENTITY
concentrate	ENTITY
the	ENTITY
urine	ENTITY
by	ENTITY
removing	ENTITY
free	ENTITY
water	ENTITY
.	O
dipsogenic	ENTITY
diabetes	ENTITY
insipidus	ENTITY
dipsogenic	ENTITY
diabetes	ENTITY
insipidus	ENTITY
is	O
defect	O
or	O
damage	O
to	O
the	O
thirst	O
mechanism	O
which	O
is	O
located	O
in	O
the	O
hypothalamus	ENTITY
.	O
this	O
defect	O
results	O
in	O
the	O
inability	O
for	O
water	O
deficit	O
to	O
trigger	O
vasopressin	ENTITY
secretion	ENTITY
and	ENTITY
thirst	ENTITY
.	O
such	O
patients	O
tend	O
to	O
develop	O
hypernatermia	ENTITY
and	ENTITY
dehydration	ENTITY
.	O
for	O
more	O
information	O
blog	O
for	O
more	O
details	O
visit	O
www	O
nadipathy	O
in	O
.	O
am	O
vlog	O
early	O
morning	O
workout	O
outdoor	O
swim	O
hitting	O
the	O
jacuzzi	O
extreme	O
health	O
and	O
cardiovascular	ENTITY
health	ENTITY
changing	ENTITY
paradigms	ENTITY
and	ENTITY
perceptions	ENTITY
post	ENTITY
hall	ENTITY
interview	ENTITY
fatigue	ENTITY
induced	ENTITY
changes	ENTITY
in	ENTITY
emg	ENTITY
in	ENTITY
cyclists	ENTITY
symposium	ENTITY
optimizing	ENTITY
exercise	ENTITY
and	ENTITY
diet	ENTITY
for	ENTITY
insulin	ENTITY
sensitivity	ENTITY
and	O
mitochondrial	ENTITY
function	ENTITY
post	O
hall	O
study	O
concurrent	O
training	O
health	O
benefits	O
symposium	O
move	O
to	O
rhythm	ENTITY
circadian	ENTITY
orchestration	O
of	O
exercise	O
and	O
muscle	O
biology	O
exhibit	O
hall	O
me	O
taking	O
the	O
fit	O
light	O
.	O
post	O
hall	O
interview	O
blood	ENTITY
pressure	ENTITY
responses	O
to	O
isometric	ENTITY
exercise	ENTITY
.	O
leaving	O
exhibit	O
hall	O
and	O
calling	O
it	O
day	O
.	O
references	O
provocative	O
paper	O
exercise	O
and	O
the	O
heart	ENTITY
the	ENTITY
good	ENTITY
the	ENTITY
bad	ENTITY
.	O
ndsu	ENTITY
virtual	ENTITY
cell	ENTITY
.	O
for	O
more	O
information	O
please	O
see	O
.	O
when	O
high	O
levels	O
of	O
glucose	ENTITY
enter	ENTITY
the	ENTITY
blood	ENTITY
stream	ENTITY
insulin	ENTITY
is	O
released	O
by	O
beta	ENTITY
cells	ENTITY
in	O
the	O
pancreas	ENTITY
.	O
insulin	ENTITY
then	ENTITY
initiates	ENTITY
number	ENTITY
of	ENTITY
signal	ENTITY
pathways	ENTITY
in	ENTITY
specific	ENTITY
muscle	ENTITY
and	ENTITY
fat	ENTITY
cells	ENTITY
.	O
this	O
takes	O
look	O
at	O
the	O
signal	O
pathway	O
responsible	O
for	O
allowing	O
those	O
cells	O
to	O
rapidly	O
increase	O
their	O
ability	O
to	O
uptake	O
glucose	ENTITY
from	ENTITY
the	ENTITY
blood	ENTITY
stream	ENTITY
.	O
lumbar	ENTITY
disc	ENTITY
bulge	ENTITY
treatment	ENTITY
in	O
nadipathy	O
our	O
spinal	ENTITY
cord	ENTITY
comprises	O
of	O
many	O
bones	ENTITY
known	ENTITY
as	ENTITY
vertebrae	ENTITY
each	ENTITY
of	ENTITY
which	ENTITY
is	ENTITY
separated	ENTITY
by	ENTITY
disc	ENTITY
.	O
the	O
disc	ENTITY
is	ENTITY
wrapped	ENTITY
by	ENTITY
the	ENTITY
many	ENTITY
layers	ENTITY
.	O
in	O
the	O
middle	O
of	O
the	O
disc	ENTITY
.	O
when	O
this	O
jelly	O
like	O
substance	O
leaked	O
from	O
the	O
disc	ENTITY
due	ENTITY
to	ENTITY
tear	ENTITY
in	ENTITY
connective	ENTITY
tissue	ENTITY
it	ENTITY
is	ENTITY
called	ENTITY
lumbar	ENTITY
.	O
lumbar	ENTITY
disc	ENTITY
bulge	ENTITY
most	ENTITY
commonly	ENTITY
occur	ENTITY
in	ENTITY
people	ENTITY
who	ENTITY
have	ENTITY
heavy	ENTITY
work	ENTITY
on	ENTITY
sitting	ENTITY
and	ENTITY
bending	ENTITY
.	O
the	O
lowest	O
disc	ENTITY
of	ENTITY
the	ENTITY
spine	ENTITY
is	ENTITY
most	ENTITY
commonly	ENTITY
affected	ENTITY
with	ENTITY
the	ENTITY
disc	ENTITY
.	O
symptoms	O
pain	O
after	O
standing	O
and	O
sitting	O
headache	ENTITY
especially	ENTITY
in	ENTITY
back	ENTITY
of	ENTITY
the	ENTITY
head	ENTITY
numbness	ENTITY
or	ENTITY
abnormal	ENTITY
sensation	ENTITY
in	ENTITY
whole	ENTITY
body	ENTITY
when	ENTITY
you	ENTITY
bend	ENTITY
the	ENTITY
spinal	ENTITY
cord	ENTITY
forward	O
feel	O
pain	O
over	O
the	O
buttocks	ENTITY
thigh	ENTITY
lower	ENTITY
leg	ENTITY
or	ENTITY
foot	ENTITY
pain	ENTITY
get	O
worse	O
during	O
nights	O
reasons	O
to	O
develop	O
lumbar	ENTITY
disc	ENTITY
bulge	ENTITY
being	ENTITY
over	ENTITY
weight	ENTITY
having	ENTITY
the	ENTITY
job	ENTITY
with	ENTITY
more	ENTITY
bending	ENTITY
.	O
spine	ENTITY
injury	ENTITY
or	O
surgery	ENTITY
gastric	ENTITY
.	O
over	O
twenty	O
million	O
people	O
in	O
the	O
united	O
states	O
have	O
diabetes	ENTITY
mellitus	ENTITY
.	O
in	O
both	O
human	O
and	O
economic	O
terms	O
it	O
is	O
one	O
of	O
our	O
nation	O
most	O
costly	O
health	O
conditions	O
.	O
diabetes	ENTITY
is	ENTITY
the	ENTITY
leading	ENTITY
cause	ENTITY
of	ENTITY
kidney	ENTITY
failure	ENTITY
blindness	O
in	O
adults	O
and	O
amputations	ENTITY
.	O
it	O
is	O
major	O
risk	O
factor	O
for	O
heart	ENTITY
disease	ENTITY
stroke	O
and	O
birth	O
defects	O
shortens	O
.	O
glut	O
ia	ENTITY
the	ENTITY
only	ENTITY
glucose	ENTITY
transporter	ENTITY
that	O
is	O
insulin	ENTITY
.	O
like	O
us	O
on	O
facebook	O
by	O
clicking	O
on	O
the	O
link	O
.	O
overview	O
of	O
how	O
the	O
nephrons	ENTITY
in	ENTITY
the	ENTITY
kidney	ENTITY
filter	ENTITY
blood	ENTITY
and	ENTITY
reabsorb	ENTITY
water	ENTITY
.	O
created	O
by	O
sal	O
.	O
watch	O
the	O
next	O
lesson	O
add	O
user	O
khanacademy	O
.	O
presented	O
by	O
mary	O
turyk	O
associate	O
professor	O
of	O
epidemiology	O
school	O
of	O
public	O
health	O
university	O
of	O
illinois	O
at	O
chicago	O
human	O
exposure	O
to	O
persistent	ENTITY
organic	ENTITY
pollutants	O
or	O
pops	O
is	O
ubiquitous	O
and	O
occurs	O
primarily	O
through	O
consumption	O
.	O
these	O
toxicants	ENTITY
affect	ENTITY
many	ENTITY
biological	ENTITY
systems	ENTITY
including	ENTITY
hormone	ENTITY
regulation	ENTITY
glucose	ENTITY
homeostasis	ENTITY
neurologic	ENTITY
function	ENTITY
and	O
reproduction	O
some	O
are	O
known	O
carcinogens	ENTITY
.	O
the	O
great	O
lakes	O
fish	O
consumption	O
.	O
this	O
presentation	O
will	O
describe	O
contaminant	O
exposures	O
and	O
fish	O
consumption	O
.	O
one	O
of	O
the	O
first	O
prospective	O
investigations	O
on	O
the	O
role	O
of	O
pop	O
exposures	O
in	O
the	O
development	O
of	O
diabetes	ENTITY
was	ENTITY
conducted	ENTITY
in	ENTITY
this	ENTITY
cohort	ENTITY
finding	ENTITY
elevated	ENTITY
diabetes	ENTITY
risk	ENTITY
in	ENTITY
persons	ENTITY
with	ENTITY
greater	ENTITY
exposure	ENTITY
to	ENTITY
dde	ENTITY
.	O
while	O
the	O
biologic	ENTITY
pathways	ENTITY
by	O
which	O
environmental	O
exposures	O
may	O
increase	O
diabetes	ENTITY
risk	ENTITY
have	ENTITY
not	ENTITY
been	ENTITY
elucidated	ENTITY
evidence	ENTITY
will	ENTITY
be	ENTITY
presented	ENTITY
that	ENTITY
suggest	ENTITY
pops	ENTITY
may	ENTITY
have	ENTITY
stronger	ENTITY
impact	ENTITY
on	ENTITY
blood	ENTITY
glucose	ENTITY
in	O
persons	O
at	O
higher	O
risk	O
for	O
diabetes	ENTITY
.	O
click	O
here	O
type	O
diabetesis	ENTITY
chronic	ENTITY
disease	ENTITY
characterized	O
by	O
abnormal	O
glucose	ENTITY
metabolism	ENTITY
.	O
type	O
diabetes	ENTITY
is	ENTITY
by	ENTITY
far	ENTITY
the	ENTITY
most	ENTITY
common	ENTITY
form	ENTITY
of	ENTITY
diabetics	ENTITY
actually	ENTITY
suffer	ENTITY
.	O
in	O
the	O
case	O
of	O
type	O
diabetes	ENTITY
there	ENTITY
is	ENTITY
resistance	ENTITY
of	ENTITY
the	ENTITY
tissues	ENTITY
to	ENTITY
insulin	ENTITY
and	ENTITY
decreased	ENTITY
response	ENTITY
to	ENTITY
glucose	ENTITY
by	ENTITY
the	ENTITY
pancreas	ENTITY
.	O
the	O
circulating	O
endogenous	O
insulin	ENTITY
is	ENTITY
sufficient	ENTITY
to	ENTITY
prevent	ENTITY
ketosis	ENTITY
.	O
there	O
is	O
often	O
excessive	O
insulin	ENTITY
secretion	ENTITY
and	O
excessive	O
activity	O
of	O
the	O
beta	ENTITY
cells	ENTITY
in	O
the	O
pancreas	ENTITY
.	O
diabetes	ENTITY
is	ENTITY
very	ENTITY
widespread	ENTITY
metabolic	ENTITY
disorder	ENTITY
.	O
studies	O
have	O
estimated	O
that	O
in	O
there	O
were	O
million	O
people	O
infected	O
with	O
the	O
disease	ENTITY
worldwide	ENTITY
and	ENTITY
according	ENTITY
to	ENTITY
several	ENTITY
estimations	ENTITY
the	ENTITY
number	ENTITY
will	ENTITY
reach	ENTITY
million	ENTITY
by	ENTITY
this	ENTITY
is	ENTITY
chronic	ENTITY
condition	ENTITY
that	ENTITY
may	ENTITY
remain	ENTITY
silent	ENTITY
for	ENTITY
long	ENTITY
periods	ENTITY
and	ENTITY
the	ENTITY
progression	ENTITY
of	ENTITY
the	ENTITY
disease	ENTITY
.	O
the	O
most	O
important	O
step	O
you	O
can	O
take	O
to	O
treat	O
diabetes	ENTITY
naturally	ENTITY
without	ENTITY
drugs	ENTITY
lose	O
weight	O
obesity	ENTITY
.	O
abdominal	ENTITY
obesity	ENTITY
is	O
even	O
more	O
dangerous	O
and	O
is	O
an	O
important	O
and	O
independent	O
risk	O
factor	O
for	O
the	O
occurrence	O
of	O
hyperlipidemia	ENTITY
hypertension	ENTITY
cardiovascular	ENTITY
disease	ENTITY
and	O
diabetes	ENTITY
especially	ENTITY
type	ENTITY
this	ENTITY
happens	ENTITY
because	ENTITY
visceral	ENTITY
fat	ENTITY
is	O
not	O
an	O
inert	O
tissue	O
but	O
is	O
actually	O
an	O
endocrine	ENTITY
organ	ENTITY
that	O
produces	O
many	O
hormones	ENTITY
that	ENTITY
regulate	ENTITY
the	ENTITY
energy	ENTITY
homeostasis	ENTITY
of	ENTITY
the	ENTITY
body	ENTITY
and	ENTITY
affects	ENTITY
the	ENTITY
secretion	ENTITY
of	ENTITY
insulin	ENTITY
that	ENTITY
can	ENTITY
cause	ENTITY
inflammation	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
vessels	ENTITY
.	O
visceral	ENTITY
fat	ENTITY
may	O
cause	O
weight	ENTITY
gain	ENTITY
high	ENTITY
levels	O
of	O
fasting	O
glucose	ENTITY
and	ENTITY
insulin	ENTITY
resistance	ENTITY
.	O
safe	O
indicator	O
of	O
abdominal	ENTITY
obesity	ENTITY
is	O
the	O
measurement	O
of	O
waist	O
.	O
waist	O
circumference	O
should	O
be	O
under	O
cm	O
for	O
men	O
and	O
under	O
cm	O
for	O
women	O
.	O
in	O
conclusion	O
increased	O
levels	O
of	O
visceral	ENTITY
fat	ENTITY
is	O
major	O
risk	O
factor	O
for	O
developing	O
type	O
diabetes	ENTITY
and	ENTITY
should	ENTITY
be	ENTITY
addressed	ENTITY
by	ENTITY
any	ENTITY
diabetic	ENTITY
patient	ENTITY
that	O
wishes	O
to	O
treat	O
the	O
disease	ENTITY
.	O
what	O
is	O
more	O
it	O
has	O
been	O
shown	O
that	O
loss	O
of	O
of	O
your	O
total	O
body	O
weight	O
can	O
represents	O
loss	O
of	O
visceral	ENTITY
fat	ENTITY
by	O
about	O
which	O
improves	O
the	O
function	O
.	O
make	O
sure	O
you	O
lose	O
weight	O
gradually	O
and	O
try	O
to	O
adopt	O
healthy	O
eating	O
.	O
what	O
you	O
need	O
to	O
do	O
measure	O
your	O
waistline	O
.	O
as	O
mentioned	O
above	O
the	O
limit	O
is	O
cm	O
for	O
women	O
and	O
cm	O
for	O
men	O
.	O
the	O
larger	O
the	O
circumference	O
of	O
your	O
waist	O
the	O
greater	O
risk	O
to	O
become	O
diabetic	ENTITY
.	O
if	O
you	O
already	O
suffer	O
with	O
this	O
condition	O
then	O
large	O
waist	O
circumference	O
may	O
compromise	O
glycemic	ENTITY
control	ENTITY
since	ENTITY
it	ENTITY
reduces	ENTITY
the	ENTITY
body	ENTITY
ability	ENTITY
to	ENTITY
handle	ENTITY
glucose	ENTITY
while	ENTITY
increasing	ENTITY
insulin	ENTITY
.	O
regularly	O
check	O
the	O
levels	ENTITY
of	ENTITY
lipids	ENTITY
and	O
glucose	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
.	O
now	O
pay	O
close	O
attention	O
here	O
to	O
control	O
type	O
diabetes	ENTITY
there	ENTITY
is	ENTITY
an	ENTITY
amazing	ENTITY
method	ENTITY
that	ENTITY
can	ENTITY
help	ENTITY
you	ENTITY
reverse	ENTITY
the	ENTITY
disease	ENTITY
.	O
metabolic	ENTITY
syndrome	ENTITY
is	O
probably	O
the	O
most	O
serious	O
medical	O
condition	O
that	O
you	O
haven	O
heard	O
.	O
so	O
what	O
is	O
metabolic	ENTITY
syndrome	ENTITY
why	O
is	O
it	O
so	O
serious	O
and	O
why	O
haven	O
you	O
heard	O
.	O
here	O
is	O
what	O
you	O
need	O
to	O
know	O
.	O
the	O
metabolic	ENTITY
syndrome	ENTITY
is	O
cluster	O
of	O
the	O
most	O
dangerous	O
heart	ENTITY
attack	ENTITY
risk	O
factors	O
raised	ENTITY
blood	ENTITY
glucose	ENTITY
central	ENTITY
adiposity	ENTITY
often	O
called	O
beer	O
belly	O
abnormal	O
cholesterol	ENTITY
levels	ENTITY
abnormal	O
blood	ENTITY
fats	ENTITY
also	O
called	O
triglycerides	ENTITY
and	ENTITY
high	ENTITY
blood	ENTITY
pressure	ENTITY
.	O
it	O
is	O
estimated	O
that	O
in	O
adults	O
have	O
metabolic	ENTITY
syndrome	ENTITY
and	O
the	O
condition	O
becomes	O
more	O
common	O
as	O
we	O
get	O
older	O
so	O
that	O
by	O
the	O
age	O
of	O
nearly	O
third	O
of	O
adults	O
have	O
metabolic	ENTITY
syndrome	ENTITY
.	O
so	O
why	O
is	O
metabolic	ENTITY
syndrome	ENTITY
.	O
well	O
if	O
you	O
have	O
metabolic	ENTITY
syndrome	ENTITY
you	O
are	O
much	O
more	O
likely	O
to	O
suffer	O
heart	ENTITY
attack	ENTITY
or	O
stroke	O
more	O
likely	O
to	O
develop	O
full	O
blown	O
diabetes	ENTITY
more	ENTITY
likely	ENTITY
to	ENTITY
develop	ENTITY
cancer	ENTITY
and	ENTITY
more	ENTITY
likely	ENTITY
to	ENTITY
develop	ENTITY
alzheimer	ENTITY
disease	ENTITY
.	O
all	O
of	O
these	O
conditions	O
.	O
dementia	ENTITY
and	ENTITY
alzheimer	ENTITY
disease	ENTITY
have	O
overtaken	O
cancer	O
and	O
heart	ENTITY
disease	ENTITY
as	O
the	O
leading	O
cause	O
of	O
death	O
in	O
england	O
and	O
wales	O
in	O
and	O
the	O
metabolic	ENTITY
syndrome	ENTITY
and	O
diabetes	ENTITY
.	O
so	O
how	O
can	O
you	O
check	O
to	O
see	O
if	O
you	O
have	O
metabolic	ENTITY
syndrome	ENTITY
.	O
well	O
first	O
of	O
all	O
get	O
out	O
tape	O
measure	O
.	O
if	O
you	O
are	O
man	O
and	O
your	O
waist	O
circumference	O
is	O
more	O
than	O
cm	O
or	O
if	O
you	O
are	O
woman	O
and	O
your	O
waist	O
is	O
more	O
than	O
cm	O
you	O
have	O
one	O
of	O
the	O
main	O
features	O
of	O
metabolic	ENTITY
syndrome	ENTITY
.	O
if	O
in	O
addition	O
you	O
have	O
any	O
of	O
the	O
following	O
you	O
will	O
be	O
classified	O
as	O
having	O
metabolic	ENTITY
syndrome	ENTITY
raised	ENTITY
blood	ENTITY
triglycerides	ENTITY
reduced	ENTITY
hdl	ENTITY
cholesterol	ENTITY
sometimes	O
known	O
as	O
good	O
cholesterol	ENTITY
raised	ENTITY
blood	ENTITY
pressure	ENTITY
or	O
raised	ENTITY
fasting	ENTITY
plasma	ENTITY
glucose	ENTITY
.	O
note	O
if	O
you	O
are	O
man	O
of	O
south	O
asian	O
or	O
indian	O
heritage	O
the	O
important	O
threshold	O
for	O
waist	O
circumference	O
is	O
cm	O
.	O
metabolic	ENTITY
syndrome	ENTITY
has	O
not	O
yet	O
been	O
classified	O
as	O
disease	ENTITY
it	ENTITY
is	ENTITY
still	ENTITY
regarded	ENTITY
as	ENTITY
collection	ENTITY
of	ENTITY
signs	ENTITY
and	ENTITY
symptoms	ENTITY
which	ENTITY
together	ENTITY
are	ENTITY
serious	ENTITY
risk	ENTITY
factors	ENTITY
for	ENTITY
our	ENTITY
most	ENTITY
deadly	ENTITY
and	ENTITY
disabling	ENTITY
medical	ENTITY
conditions	ENTITY
.	O
several	O
medical	O
organisations	O
such	O
as	O
the	O
world	O
health	O
organisation	O
who	O
the	O
independent	O
diabetes	ENTITY
federation	ENTITY
idf	ENTITY
and	ENTITY
the	ENTITY
european	ENTITY
group	ENTITY
for	ENTITY
the	ENTITY
study	ENTITY
of	ENTITY
insulin	ENTITY
resistance	ENTITY
egir	O
define	O
the	O
metabolic	ENTITY
syndrome	ENTITY
in	O
very	O
slightly	O
different	O
ways	O
and	O
this	O
adds	O
even	O
more	O
to	O
the	O
confusion	O
about	O
what	O
exactly	O
metabolic	ENTITY
syndrome	ENTITY
.	O
however	O
many	O
experts	O
now	O
believe	O
that	O
the	O
underlying	O
problem	O
in	O
metabolic	ENTITY
syndrome	ENTITY
is	O
insulin	ENTITY
resistance	ENTITY
.	O
insulin	ENTITY
resistance	ENTITY
develops	O
when	O
this	O
hormone	ENTITY
cannot	ENTITY
work	ENTITY
properly	ENTITY
when	ENTITY
blood	ENTITY
insulin	ENTITY
levels	ENTITY
are	O
abnormally	O
high	O
and	O
still	O
relatively	O
ineffective	O
in	O
keeping	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
.	O
metabolic	ENTITY
specialists	ENTITY
now	ENTITY
use	ENTITY
the	ENTITY
term	ENTITY
insulin	ENTITY
resistance	ENTITY
syndrome	ENTITY
.	O
insulin	ENTITY
is	ENTITY
hormone	ENTITY
produced	ENTITY
by	ENTITY
the	ENTITY
pancreas	ENTITY
and	ENTITY
it	ENTITY
is	ENTITY
important	ENTITY
in	ENTITY
the	ENTITY
metabolism	ENTITY
of	ENTITY
carbohydrates	ENTITY
and	ENTITY
fats	ENTITY
.	O
when	O
sugar	O
and	O
carbohydrates	ENTITY
are	ENTITY
eaten	ENTITY
insulin	ENTITY
promotes	ENTITY
the	ENTITY
uptake	ENTITY
of	ENTITY
glucose	ENTITY
from	ENTITY
the	ENTITY
blood	ENTITY
into	ENTITY
muscles	ENTITY
and	ENTITY
fat	ENTITY
cells	ENTITY
.	O
hence	O
it	O
is	O
often	O
said	O
that	O
insulin	ENTITY
allows	ENTITY
cells	ENTITY
to	ENTITY
use	ENTITY
glucose	ENTITY
for	ENTITY
energy	ENTITY
and	ENTITY
also	ENTITY
to	ENTITY
store	ENTITY
excess	ENTITY
glucose	ENTITY
and	ENTITY
sugar	ENTITY
as	ENTITY
glycogen	ENTITY
and	ENTITY
fat	ENTITY
.	O
when	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
fall	O
stored	O
glucose	ENTITY
is	ENTITY
released	ENTITY
for	ENTITY
energy	ENTITY
from	ENTITY
the	ENTITY
breakdown	ENTITY
of	ENTITY
glycogen	ENTITY
stores	ENTITY
in	ENTITY
the	ENTITY
liver	ENTITY
and	ENTITY
in	ENTITY
the	ENTITY
muscles	ENTITY
.	O
in	O
the	O
metabolic	ENTITY
syndrome	ENTITY
.	O
fasting	O
blood	ENTITY
levels	ENTITY
of	ENTITY
insulin	ENTITY
in	O
the	O
morning	O
are	O
often	O
abnormally	O
high	O
and	O
insulin	ENTITY
levels	ENTITY
rise	O
to	O
very	O
high	O
levels	O
when	O
food	O
is	O
eaten	O
.	O
continuously	O
high	ENTITY
levels	ENTITY
of	ENTITY
insulin	ENTITY
cause	O
the	O
liver	ENTITY
cells	ENTITY
to	O
store	O
fat	ENTITY
resulting	ENTITY
in	ENTITY
fatty	ENTITY
liver	ENTITY
which	O
cannot	O
function	O
.	O
as	O
the	O
insulin	ENTITY
resistance	ENTITY
worsens	O
the	O
pancreas	ENTITY
may	ENTITY
not	ENTITY
be	ENTITY
able	ENTITY
to	ENTITY
produce	ENTITY
enough	ENTITY
insulin	ENTITY
in	ENTITY
response	ENTITY
to	ENTITY
food	ENTITY
and	ENTITY
then	ENTITY
glucose	ENTITY
levels	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
.	O
so	O
why	O
haven	O
you	O
heard	O
.	O
well	O
until	O
quite	O
recently	O
the	O
connection	O
between	O
metabolic	ENTITY
syndrome	ENTITY
and	O
host	O
of	O
chronic	ENTITY
diseases	ENTITY
.	O
we	O
now	O
know	O
that	O
insulin	ENTITY
resistance	ENTITY
.	O
until	O
recently	O
it	O
was	O
difficult	O
to	O
measure	O
blood	ENTITY
insulinlevels	ENTITY
but	O
the	O
technology	O
has	O
improved	O
and	O
we	O
can	O
now	O
measure	O
blood	ENTITY
insulin	ENTITY
levels	ENTITY
accurately	O
and	O
we	O
have	O
good	O
tests	O
to	O
diagnose	O
insulin	ENTITY
resistance	ENTITY
as	O
well	O
as	O
good	O
strategies	O
to	O
reverse	O
insulin	ENTITY
resistance	ENTITY
and	O
the	O
metabolic	ENTITY
syndrome	ENTITY
.	O
once	O
you	O
can	O
measure	O
insulin	ENTITY
resistance	ENTITY
you	O
are	O
well	O
on	O
your	O
way	O
to	O
fixing	O
.	O
some	O
things	O
that	O
can	O
help	O
naturally	O
regulate	O
blood	ENTITY
sugars	ENTITY
exercise	O
cardio	ENTITY
aerobic	ENTITY
weights	ENTITY
eat	ENTITY
mostly	ENTITY
low	ENTITY
glycemic	ENTITY
foods	ENTITY
follow	O
me	O
on	O
instagram	O
tiff	O
any	O
leber	O
follow	O
tweet	O
me	O
on	O
twitter	O
twitter	O
com	O
tiffanyleber	O
tiffanyleber	O
follow	O
me	O
on	O
pinterest	O
html	O
tags	ENTITY
.	O
leptin	ENTITY
and	ENTITY
the	ENTITY
neural	ENTITY
circuit	ENTITY
regulation	ENTITY
food	ENTITY
intake	ENTITY
and	ENTITY
glucose	ENTITY
metabolism	ENTITY
air	ENTITY
date	ENTITY
wednesday	ENTITY
january	ENTITY
pm	ENTITY
category	ENTITY
wals	ENTITY
wednesday	ENTITY
afternoon	ENTITY
lectures	ENTITY
runtime	ENTITY
description	ENTITY
nih	ENTITY
director	ENTITY
wednesday	ENTITY
afternoon	ENTITY
lecture	ENTITY
series	ENTITY
the	ENTITY
discovery	ENTITY
of	ENTITY
leptin	ENTITY
has	ENTITY
led	ENTITY
to	ENTITY
the	ENTITY
elucidation	ENTITY
of	ENTITY
robust	ENTITY
physiologic	ENTITY
system	ENTITY
that	ENTITY
maintains	ENTITY
fat	ENTITY
stores	ENTITY
at	ENTITY
relatively	ENTITY
constant	ENTITY
level	ENTITY
.	O
leptin	ENTITY
is	ENTITY
peptide	ENTITY
hormone	ENTITY
secreted	O
by	O
adipose	ENTITY
tissue	ENTITY
in	O
proportion	O
to	O
its	O
mass	ENTITY
.	O
this	O
hormone	ENTITY
circulates	ENTITY
in	ENTITY
blood	ENTITY
and	ENTITY
acts	ENTITY
on	ENTITY
the	ENTITY
hypothalamus	ENTITY
to	ENTITY
regulate	ENTITY
food	ENTITY
intake	ENTITY
and	ENTITY
energy	ENTITY
expenditure	ENTITY
.	O
when	O
fat	ENTITY
mass	ENTITY
falls	ENTITY
plasma	ENTITY
leptin	ENTITY
levels	ENTITY
fall	ENTITY
stimulating	ENTITY
appetite	ENTITY
and	ENTITY
suppressing	ENTITY
energy	ENTITY
expenditure	ENTITY
.	O
when	O
fat	ENTITY
mass	ENTITY
increases	ENTITY
leptin	ENTITY
.	O
by	O
such	O
mechanism	O
total	O
energy	O
stores	O
are	O
stably	O
maintained	O
within	O
relatively	O
narrow	O
range	O
.	O
recessive	O
mutations	O
in	O
the	O
leptin	ENTITY
gene	ENTITY
are	ENTITY
associated	ENTITY
with	ENTITY
massive	ENTITY
obesity	ENTITY
.	O
treatment	O
with	O
recombinant	O
leptin	ENTITY
markedly	ENTITY
reduces	ENTITY
food	ENTITY
intake	ENTITY
.	O
the	O
low	O
leptin	ENTITY
levels	ENTITY
in	ENTITY
patients	ENTITY
with	ENTITY
leptin	ENTITY
mutations	ENTITY
are	ENTITY
also	ENTITY
associated	ENTITY
with	ENTITY
multiple	ENTITY
abnormalities	ENTITY
including	ENTITY
infertility	ENTITY
diabetes	ENTITY
and	ENTITY
immune	ENTITY
abnormalities	ENTITY
all	ENTITY
of	ENTITY
which	ENTITY
are	ENTITY
corrected	ENTITY
by	ENTITY
leptin	ENTITY
treatment	ENTITY
.	O
these	O
findings	O
have	O
established	O
important	O
links	O
between	O
energy	O
stores	O
and	O
many	O
other	O
physiologic	O
systems	O
and	O
led	O
to	O
the	O
use	O
of	O
leptin	ENTITY
as	ENTITY
treatment	ENTITY
for	ENTITY
an	ENTITY
increasing	ENTITY
number	ENTITY
of	ENTITY
other	ENTITY
human	ENTITY
conditions	ENTITY
including	ENTITY
subset	ENTITY
of	ENTITY
obesity	ENTITY
some	ENTITY
forms	ENTITY
of	ENTITY
diabetes	ENTITY
including	ENTITY
lipodystrophy	ENTITY
and	ENTITY
hypothalamic	ENTITY
amenorrhea	ENTITY
the	O
cessation	ENTITY
of	ENTITY
menstruation	ENTITY
.	O
identification	O
of	O
physiologic	ENTITY
system	ENTITY
that	O
controls	O
energy	O
balance	O
establishes	O
biologic	O
basis	O
for	O
obesity	ENTITY
.	O
recent	O
studies	O
have	O
explored	O
the	O
relationship	O
between	O
leptin	ENTITY
.	O
in	O
addition	O
new	O
methods	O
for	O
identifying	O
neurons	ENTITY
activated	ENTITY
by	ENTITY
leptin	ENTITY
and	ENTITY
other	ENTITY
stimuli	ENTITY
have	ENTITY
been	ENTITY
developed	ENTITY
as	ENTITY
have	ENTITY
methods	ENTITY
for	ENTITY
noninvasively	ENTITY
activating	ENTITY
cells	ENTITY
.	O
these	O
new	O
approaches	O
are	O
being	O
applied	O
to	O
studies	O
.	O
for	O
more	O
information	O
go	O
to	O
asp	ENTITY
.	O
you	O
can	O
support	O
.	O
thank	O
you	O
.	O
if	O
in	O
the	O
us	O
use	O
this	O
link	O
an	O
introductory	O
lesson	O
into	O
the	O
nature	O
of	O
tissue	ENTITY
fluid	ENTITY
formation	ENTITY
and	ENTITY
lymphatic	ENTITY
drainage	ENTITY
.	O
includes	O
brief	O
introduction	O
into	O
the	O
functions	O
of	O
lymphatic	ENTITY
drainage	ENTITY
in	O
health	O
and	O
disease	ENTITY
the	ENTITY
lymphatic	ENTITY
system	ENTITY
the	O
lymphatic	ENTITY
system	ENTITY
consists	O
of	O
the	O
lymphatic	ENTITY
drainage	ENTITY
vessels	ENTITY
.	O
lymphatic	ENTITY
tissue	ENTITY
is	O
also	O
sometimes	O
referred	O
to	O
as	O
lymphoid	O
tissue	O
.	O
lymphatic	ENTITY
drainage	ENTITY
structures	O
lymphatic	ENTITY
capillaries	ENTITY
drain	ENTITY
.	O
most	O
of	O
the	O
tissue	O
fluid	O
formed	O
at	O
the	O
arterial	ENTITY
end	ENTITY
of	ENTITY
the	ENTITY
capillary	ENTITY
is	ENTITY
as	ENTITY
we	ENTITY
have	ENTITY
seen	ENTITY
reabsorbed	ENTITY
back	ENTITY
into	ENTITY
the	ENTITY
blood	ENTITY
at	ENTITY
the	ENTITY
venous	ENTITY
end	ENTITY
.	O
however	O
along	O
with	O
tissue	O
fluid	ENTITY
few	ENTITY
protein	ENTITY
molecules	O
also	O
escape	O
from	O
the	O
capillaries	ENTITY
.	O
if	O
these	O
large	O
osmotic	ENTITY
molecules	ENTITY
were	O
allowed	O
to	O
remain	O
in	O
the	O
tissue	O
fluid	O
they	O
would	O
increase	O
the	O
osmotic	O
potential	O
leading	O
to	O
an	O
accumulation	O
of	O
water	O
.	O
an	O
excess	ENTITY
of	ENTITY
fluid	ENTITY
in	O
the	O
tissues	O
is	O
abnormal	O
and	O
is	O
termed	O
oedema	ENTITY
.	O
if	O
excess	ENTITY
tissue	ENTITY
fluid	ENTITY
was	O
allowed	O
to	O
accumulate	O
this	O
would	O
cause	O
swelling	ENTITY
and	ENTITY
would	ENTITY
increase	ENTITY
the	ENTITY
diffusional	ENTITY
distance	ENTITY
between	ENTITY
the	ENTITY
blood	ENTITY
and	ENTITY
tissue	ENTITY
cells	ENTITY
.	O
this	O
would	O
reduce	O
the	O
speed	O
at	O
which	O
oxygen	O
could	O
be	O
delivered	O
to	O
tissue	O
cells	O
.	O
the	O
mechanism	O
which	O
removes	O
exuded	O
proteins	O
from	O
the	O
tissue	O
fluid	O
preventing	O
oedema	O
is	O
the	O
lymphatic	ENTITY
drainage	ENTITY
.	O
once	O
fluid	ENTITY
has	ENTITY
passed	ENTITY
from	ENTITY
the	ENTITY
tissue	ENTITY
spaces	ENTITY
into	ENTITY
lymphatic	ENTITY
vessel	ENTITY
.	O
unlike	O
blood	ENTITY
capillaries	ENTITY
the	O
lymphatic	ENTITY
capillaries	ENTITY
.	O
however	O
like	O
blood	ENTITY
capillaries	ENTITY
.	O
lymphatic	ENTITY
capillaries	ENTITY
are	O
highly	O
permeable	O
and	O
will	O
absorb	O
excess	ENTITY
tissue	ENTITY
fluid	ENTITY
and	O
infecting	O
bacteria	ENTITY
as	ENTITY
well	ENTITY
as	ENTITY
proteins	ENTITY
.	O
endothelial	ENTITY
cells	ENTITY
which	O
compose	O
the	O
lymphatic	ENTITY
capillary	ENTITY
walls	ENTITY
.	O
the	O
cells	O
also	O
overlap	ENTITY
to	ENTITY
form	ENTITY
valves	ENTITY
.	O
this	O
means	O
fluid	O
and	O
other	O
material	O
is	O
able	O
to	O
enter	O
from	O
the	O
tissue	ENTITY
spaces	ENTITY
but	O
may	O
not	O
escape	O
back	O
out	O
from	O
the	O
lymphatic	ENTITY
capillaries	ENTITY
.	O
as	O
lymphatic	ENTITY
capillary	ENTITY
fills	O
with	O
lymph	O
the	O
pressure	O
in	O
the	O
lumen	O
will	O
close	O
the	O
valves	ENTITY
.	O
its	O
strange	O
the	O
lymphatic	ENTITY
system	ENTITY
.	O
diabetes	ENTITY
treatment	ENTITY
in	ENTITY
nadipathy	ENTITY
what	ENTITY
is	ENTITY
diabetes	ENTITY
it	ENTITY
is	ENTITY
the	ENTITY
condition	ENTITY
that	ENTITY
body	ENTITY
cannot	ENTITY
balance	ENTITY
the	ENTITY
glucose	ENTITY
levels	ENTITY
due	O
to	O
lack	O
of	O
energy	O
to	O
pancreas	ENTITY
or	ENTITY
the	ENTITY
body	ENTITY
cannot	ENTITY
utilize	ENTITY
insulin	ENTITY
to	ENTITY
maintain	ENTITY
glucose	ENTITY
homeostasis	ENTITY
.	O
it	O
was	O
first	O
known	O
in	O
the	O
th	O
century	O
.	O
again	O
diabetes	ENTITY
is	ENTITY
differentiated	ENTITY
in	ENTITY
to	ENTITY
two	ENTITY
types	ENTITY
diabetes	ENTITY
mellitus	ENTITY
and	O
diabetes	ENTITY
insipidus	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
mainly	O
caused	O
by	O
deficiency	O
of	O
insulin	ENTITY
due	ENTITY
to	ENTITY
either	ENTITY
lack	ENTITY
of	ENTITY
energy	ENTITY
in	ENTITY
pancreas	ENTITY
or	ENTITY
any	ENTITY
auto	ENTITY
immune	ENTITY
disease	ENTITY
.	O
while	O
diabetes	ENTITY
insipidus	ENTITY
is	O
caused	O
by	O
defect	O
in	O
secretion	O
of	O
vasopressin	ENTITY
antidiuretic	ENTITY
hormone	ENTITY
which	O
is	O
secreted	O
from	O
pituitary	ENTITY
gland	ENTITY
present	O
in	O
hypothalamus	ENTITY
.	O
its	O
function	O
is	O
to	O
reabsorb	O
water	O
from	O
distal	O
tubules	O
in	O
the	O
kidney	ENTITY
.	O
but	O
its	O
deficiency	O
caused	O
increased	O
water	O
excretion	O
through	O
urine	O
even	O
in	O
low	O
intake	O
of	O
water	O
.	O
diabetes	ENTITY
mellitus	ENTITY
and	O
diabetes	ENTITY
insipidus	ENTITY
are	O
unrelated	O
although	O
they	O
have	O
similar	O
signs	O
and	O
symptoms	O
like	O
excessive	O
thirst	O
and	O
excessive	ENTITY
urination	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
more	O
common	O
than	O
the	O
diabetes	ENTITY
insipidus	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
.	O
type	O
diabetes	ENTITY
the	ENTITY
body	ENTITY
does	ENTITY
not	ENTITY
produce	ENTITY
insulin	ENTITY
.	O
such	O
diabetes	ENTITY
called	ENTITY
as	ENTITY
insulin	ENTITY
dependent	ENTITY
diabetes	ENTITY
.	O
people	O
usually	O
develop	O
type	O
diabetes	ENTITY
before	ENTITY
their	ENTITY
th	ENTITY
.	O
today	O
type	O
diabetes	ENTITY
has	ENTITY
no	ENTITY
proper	ENTITY
treatment	ENTITY
.	O
so	O
these	O
individuals	O
are	O
insulin	ENTITY
.	O
approximately	O
of	O
all	O
diabetes	ENTITY
cases	ENTITY
are	ENTITY
type	ENTITY
common	ENTITY
symptoms	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
fatigue	O
or	O
tiredness	O
.	O
excessive	O
thirst	O
.	O
increased	O
urination	ENTITY
.	O
nausea	ENTITY
perhaps	ENTITY
vomiting	ENTITY
.	O
for	O
more	O
information	O
blog	O
.	O
diabetes	ENTITY
treatment	ENTITY
in	ENTITY
nadipathy	ENTITY
what	ENTITY
is	ENTITY
diabetes	ENTITY
it	ENTITY
is	ENTITY
the	ENTITY
condition	ENTITY
that	ENTITY
body	ENTITY
cannot	ENTITY
balance	ENTITY
the	ENTITY
glucose	ENTITY
levels	ENTITY
due	O
to	O
lack	O
of	O
energy	O
to	O
pancreas	ENTITY
or	ENTITY
the	ENTITY
body	ENTITY
cannot	ENTITY
utilize	ENTITY
insulin	ENTITY
to	ENTITY
maintain	ENTITY
glucose	ENTITY
homeostasis	ENTITY
.	O
it	O
was	O
first	O
known	O
in	O
the	O
th	O
century	O
later	O
it	O
became	O
dangerous	O
devil	O
to	O
human	O
life	O
.	O
again	O
diabetes	ENTITY
is	ENTITY
differentiated	ENTITY
in	ENTITY
to	ENTITY
two	ENTITY
types	ENTITY
diabetes	ENTITY
mellitus	ENTITY
and	O
diabetes	ENTITY
insipidus	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
mainly	O
caused	O
by	O
deficiency	O
of	O
insulin	ENTITY
due	ENTITY
to	ENTITY
either	ENTITY
lack	ENTITY
of	ENTITY
energy	ENTITY
in	ENTITY
pancreas	ENTITY
or	ENTITY
any	ENTITY
auto	ENTITY
immune	ENTITY
disease	ENTITY
.	O
while	O
diabetes	ENTITY
insipidus	ENTITY
is	O
caused	O
by	O
defect	O
in	O
secretion	O
of	O
vasopressin	ENTITY
antidiuretic	ENTITY
hormone	ENTITY
which	O
is	O
secreted	O
from	O
pituitary	ENTITY
gland	ENTITY
present	O
in	O
hypothalamus	ENTITY
.	O
its	O
function	O
is	O
to	O
reabsorb	O
water	O
from	O
distal	O
tubules	O
in	O
the	O
kidney	ENTITY
.	O
but	O
its	O
deficiency	O
caused	O
increased	O
water	O
excretion	O
through	O
urine	O
even	O
in	O
low	O
intake	O
of	O
water	O
.	O
diabetes	ENTITY
mellitus	ENTITY
and	O
diabetes	ENTITY
insipidus	ENTITY
are	O
unrelated	O
although	O
they	O
have	O
similar	O
signs	O
and	O
symptoms	O
like	O
excessive	O
thirst	O
and	O
excessive	ENTITY
urination	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
more	O
common	O
than	O
the	O
diabetes	ENTITY
insipidus	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
.	O
type	O
diabetes	ENTITY
the	ENTITY
body	ENTITY
does	ENTITY
not	ENTITY
produce	ENTITY
insulin	ENTITY
.	O
such	O
diabetes	ENTITY
called	ENTITY
as	ENTITY
insulin	ENTITY
dependent	ENTITY
diabetes	ENTITY
.	O
people	O
usually	O
develop	O
type	O
diabetes	ENTITY
before	ENTITY
their	ENTITY
th	ENTITY
.	O
today	O
type	O
diabetes	ENTITY
has	ENTITY
no	ENTITY
proper	ENTITY
treatment	ENTITY
.	O
so	O
these	O
individuals	O
are	O
insulin	ENTITY
.	O
approximately	O
of	O
all	O
diabetes	ENTITY
cases	ENTITY
are	ENTITY
type	ENTITY
common	ENTITY
symptoms	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
fatigue	O
or	O
tiredness	O
.	O
excessive	O
thirst	O
.	O
increased	O
urination	ENTITY
.	O
nausea	ENTITY
perhaps	ENTITY
vomiting	ENTITY
.	O
blurred	O
vision	O
.	O
in	O
women	O
frequent	O
vaginal	ENTITY
.	O
<MTdry	O
mouth	ENTITY
.	O
itching	ENTITY
skin	ENTITY
.	O
slow	O
healing	O
wounds	O
.	O
blog	O
.	O
diabetes	ENTITY
treatment	ENTITY
in	ENTITY
nadipathy	ENTITY
what	ENTITY
is	ENTITY
diabetes	ENTITY
it	ENTITY
is	ENTITY
the	ENTITY
condition	ENTITY
that	ENTITY
body	ENTITY
cannot	ENTITY
balance	ENTITY
the	ENTITY
glucose	ENTITY
levels	ENTITY
due	O
to	O
lack	O
of	O
energy	O
to	O
pancreas	ENTITY
or	ENTITY
the	ENTITY
body	ENTITY
cannot	ENTITY
utilize	ENTITY
insulin	ENTITY
to	ENTITY
maintain	ENTITY
glucose	ENTITY
homeostasis	ENTITY
.	O
it	O
was	O
first	O
known	O
in	O
the	O
th	O
century	O
.	O
diabetes	ENTITY
mellitus	ENTITY
.	O
type	O
diabetes	ENTITY
the	ENTITY
body	ENTITY
does	ENTITY
not	ENTITY
produce	ENTITY
insulin	ENTITY
.	O
such	O
diabetes	ENTITY
called	ENTITY
as	ENTITY
insulin	ENTITY
dependent	ENTITY
diabetes	ENTITY
.	O
people	O
usually	O
develop	O
type	O
diabetes	ENTITY
before	ENTITY
their	ENTITY
th	ENTITY
.	O
today	O
type	O
diabetes	ENTITY
has	ENTITY
no	ENTITY
proper	ENTITY
treatment	ENTITY
.	O
so	O
these	O
individuals	O
are	O
insulin	ENTITY
.	O
approximately	O
of	O
all	O
diabetes	ENTITY
cases	ENTITY
are	ENTITY
type	ENTITY
common	ENTITY
symptoms	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
fatigue	O
or	O
tiredness	O
.	O
excessive	O
thirst	O
.	O
type	O
diabetes	ENTITY
globally	ENTITY
as	ENTITY
of	ENTITY
an	ENTITY
estimated	ENTITY
million	ENTITY
people	ENTITY
have	ENTITY
type	ENTITY
diabetes	ENTITY
worldwide	ENTITY
.	O
about	O
cases	O
are	O
type	O
diabetes	ENTITY
.	O
this	O
is	O
happening	O
due	O
to	O
lack	O
of	O
energy	O
in	O
the	O
pancreas	ENTITY
.	O
so	O
that	O
pancreas	ENTITY
cannot	ENTITY
produce	ENTITY
sufficient	ENTITY
insulin	ENTITY
to	ENTITY
maintain	ENTITY
glucose	ENTITY
homeostasis	ENTITY
.	O
common	O
symptoms	O
.	O
excessive	O
thirst	O
.	O
excessive	O
hungry	O
.	O
weak	O
eye	O
.	O
gestation	ENTITY
diabetes	ENTITY
this	O
type	O
of	O
diabetes	O
usually	O
occurs	O
in	O
pregnant	O
mothers	O
during	O
gestation	ENTITY
pregnancy	ENTITY
.	O
so	O
there	O
is	O
an	O
increase	O
in	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
most	O
gestational	ENTITY
diabetes	ENTITY
goes	O
away	O
after	O
child	ENTITY
birth	ENTITY
.	O
common	O
symptoms	O
of	O
gestation	ENTITY
diabetes	ENTITY
increased	O
urination	ENTITY
fatigue	ENTITY
or	ENTITY
tiredness	ENTITY
increased	ENTITY
thirst	ENTITY
nausea	ENTITY
and	ENTITY
vomiting	ENTITY
.	O
diabetes	ENTITY
treatment	ENTITY
in	ENTITY
nadipathy	ENTITY
what	ENTITY
is	ENTITY
diabetes	ENTITY
it	ENTITY
is	ENTITY
the	ENTITY
condition	ENTITY
that	ENTITY
body	ENTITY
cannot	ENTITY
balance	ENTITY
the	ENTITY
glucose	ENTITY
levels	ENTITY
due	O
to	O
lack	O
of	O
energy	O
to	O
pancreas	ENTITY
or	ENTITY
the	ENTITY
body	ENTITY
cannot	ENTITY
utilize	ENTITY
insulin	ENTITY
to	ENTITY
maintain	ENTITY
glucose	ENTITY
homeostasis	ENTITY
.	O
it	O
was	O
first	O
known	O
in	O
the	O
th	O
century	O
.	O
again	O
diabetes	ENTITY
is	ENTITY
differentiated	ENTITY
in	ENTITY
to	ENTITY
two	ENTITY
types	ENTITY
diabetes	ENTITY
mellitus	ENTITY
and	ENTITY
diabetes	ENTITY
insipidus	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
mainly	O
caused	O
by	O
deficiency	O
of	O
insulin	ENTITY
due	ENTITY
to	ENTITY
either	ENTITY
lack	ENTITY
of	ENTITY
energy	ENTITY
in	ENTITY
pancreas	ENTITY
or	ENTITY
any	ENTITY
auto	ENTITY
immune	ENTITY
disease	ENTITY
.	O
while	O
diabetes	ENTITY
insipidus	ENTITY
is	O
caused	O
by	O
defect	O
in	O
secretion	O
of	O
vasopressin	ENTITY
antidiuretic	ENTITY
hormone	ENTITY
which	O
is	O
secreted	O
from	O
pituitary	ENTITY
gland	ENTITY
present	O
in	O
hypothalamus	ENTITY
.	O
its	O
function	O
is	O
to	O
reabsorb	O
water	O
from	O
distal	O
tubules	O
in	O
the	O
kidney	ENTITY
.	O
but	O
its	O
deficiency	O
caused	O
increased	O
water	O
excretion	O
through	O
urine	O
even	O
in	O
low	O
intake	O
of	O
water	O
.	O
diabetes	ENTITY
mellitus	ENTITY
and	O
diabetes	ENTITY
insipidus	ENTITY
are	O
unrelated	O
although	O
they	O
have	O
similar	O
signs	O
and	O
symptoms	O
like	O
excessive	O
thirst	O
and	O
excessive	ENTITY
urination	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
more	O
common	O
than	O
the	O
diabetes	ENTITY
insipidus	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
.	O
type	O
diabetes	ENTITY
the	ENTITY
body	ENTITY
does	ENTITY
not	ENTITY
produce	ENTITY
insulin	ENTITY
.	O
such	O
diabetes	ENTITY
called	ENTITY
as	ENTITY
insulin	ENTITY
dependent	ENTITY
diabetes	ENTITY
.	O
people	O
usually	O
develop	O
type	O
diabetes	ENTITY
before	ENTITY
their	ENTITY
th	ENTITY
.	O
today	O
type	O
diabetes	ENTITY
has	ENTITY
no	ENTITY
proper	ENTITY
treatment	ENTITY
.	O
so	O
these	O
individuals	O
are	O
insulin	ENTITY
.	O
approximately	O
of	O
all	O
diabetes	ENTITY
cases	ENTITY
are	ENTITY
type	ENTITY
common	ENTITY
symptoms	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
fatigue	O
or	O
tiredness	O
.	O
excessive	O
thirst	O
.	O
increased	O
urination	ENTITY
.	O
nausea	ENTITY
perhaps	ENTITY
vomiting	ENTITY
.	O
blurred	O
vision	O
.	O
in	O
women	O
frequent	O
vaginal	ENTITY
.	O
dry	ENTITY
mouth	ENTITY
.	O
itching	ENTITY
skin	ENTITY
.	O
slow	O
healing	O
wounds	O
.	O
for	O
more	O
details	O
blog	O
.	O
diabetes	ENTITY
treatment	ENTITY
in	ENTITY
nadipathy	ENTITY
what	ENTITY
is	ENTITY
diabetes	ENTITY
it	ENTITY
is	ENTITY
the	ENTITY
condition	ENTITY
that	ENTITY
body	ENTITY
cannot	ENTITY
balance	ENTITY
the	ENTITY
glucose	ENTITY
levels	ENTITY
due	O
to	O
lack	O
of	O
energy	O
to	O
pancreas	ENTITY
or	ENTITY
the	ENTITY
body	ENTITY
cannot	ENTITY
utilize	ENTITY
insulin	ENTITY
to	ENTITY
maintain	ENTITY
glucose	ENTITY
homeostasis	ENTITY
.	O
it	O
was	O
first	O
known	O
in	O
the	O
th	O
century	O
.	O
again	O
diabetes	ENTITY
is	ENTITY
differentiated	ENTITY
in	ENTITY
to	ENTITY
two	ENTITY
types	ENTITY
diabetes	ENTITY
mellitus	ENTITY
and	ENTITY
diabetes	ENTITY
insipidus	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
mainly	O
caused	O
by	O
deficiency	O
of	O
insulin	ENTITY
due	ENTITY
to	ENTITY
either	ENTITY
lack	ENTITY
of	ENTITY
energy	ENTITY
in	ENTITY
pancreas	ENTITY
or	ENTITY
any	ENTITY
auto	ENTITY
immune	ENTITY
disease	ENTITY
.	O
while	O
diabetes	ENTITY
insipidus	ENTITY
is	O
caused	O
by	O
defect	O
in	O
secretion	O
of	O
vasopressin	ENTITY
antidiuretic	ENTITY
hormone	ENTITY
which	O
is	O
secreted	O
from	O
pituitary	ENTITY
gland	ENTITY
present	O
in	O
hypothalamus	ENTITY
.	O
its	O
function	O
is	O
to	O
reabsorb	O
water	O
from	O
distal	O
tubules	O
in	O
the	O
kidney	ENTITY
.	O
but	O
its	O
deficiency	O
caused	O
increased	O
water	O
excretion	O
through	O
urine	O
even	O
in	O
low	O
intake	O
of	O
water	O
.	O
diabetes	ENTITY
mellitus	ENTITY
and	O
diabetes	ENTITY
insipidus	ENTITY
are	O
unrelated	O
although	O
they	O
have	O
similar	O
signs	O
and	O
symptoms	O
like	O
excessive	O
thirst	O
and	O
excessive	ENTITY
urination	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
more	O
common	O
than	O
the	O
diabetes	ENTITY
insipidus	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
.	O
type	O
diabetes	ENTITY
the	ENTITY
body	ENTITY
does	ENTITY
not	ENTITY
produce	ENTITY
insulin	ENTITY
.	O
such	O
diabetes	ENTITY
called	ENTITY
as	ENTITY
insulin	ENTITY
dependent	ENTITY
diabetes	ENTITY
.	O
people	O
usually	O
develop	O
type	O
diabetes	ENTITY
before	ENTITY
their	ENTITY
th	ENTITY
.	O
today	O
type	O
diabetes	ENTITY
has	ENTITY
no	ENTITY
proper	ENTITY
treatment	ENTITY
.	O
so	O
these	O
individuals	O
are	O
insulin	ENTITY
.	O
approximately	O
of	O
all	O
diabetes	ENTITY
.	O
nadipathy	ENTITY
treatment	ENTITY
acupressure	O
health	O
care	O
centre	O
ramanayya	O
pet	O
kakinada	O
dt	O
andhra	O
pradesh	O
india	O
for	O
more	O
details	O
visit	O
www	O
nadipathy	O
in	O
email	O
nadipathy	O
gmail	O
com	O
drkrajuam	O
gmail	O
com	O
ph	O
knee	O
pains	O
treatment	O
in	O
nadipathy	O
knee	ENTITY
is	ENTITY
the	ENTITY
strongest	ENTITY
and	ENTITY
most	ENTITY
complex	ENTITY
joint	ENTITY
.	O
it	O
joins	O
the	O
thigh	ENTITY
.	O
the	O
smaller	O
bone	ENTITY
that	ENTITY
runs	ENTITY
alongside	ENTITY
the	ENTITY
tibia	ENTITY
fibula	ENTITY
and	O
the	O
kneecap	ENTITY
patella	ENTITY
are	O
the	O
other	O
bones	ENTITY
that	ENTITY
make	ENTITY
the	ENTITY
knee	ENTITY
joint	ENTITY
.	O
tendons	ENTITY
connect	ENTITY
the	ENTITY
knee	ENTITY
bones	ENTITY
to	O
the	O
leg	O
muscles	O
that	O
move	O
the	O
knee	ENTITY
joint	ENTITY
.	O
ligaments	ENTITY
join	ENTITY
the	ENTITY
knee	ENTITY
bones	ENTITY
and	O
provide	O
stability	O
to	O
the	O
knee	ENTITY
.	O
medial	O
and	O
lateral	ENTITY
menisci	ENTITY
act	O
as	O
shock	O
absorbers	O
the	O
femur	ENTITY
and	ENTITY
tibia	ENTITY
.	O
the	O
fluid	O
called	O
synovial	O
fluid	O
that	O
helps	O
the	O
knee	ENTITY
move	ENTITY
.	O
knee	ENTITY
pains	ENTITY
is	O
mainly	O
caused	O
by	O
an	O
injury	O
such	O
as	O
ruptured	ENTITY
ligament	ENTITY
or	O
torn	ENTITY
cartilage	ENTITY
and	O
some	O
other	O
reasons	O
like	O
weakness	ENTITY
arthritis	ENTITY
gout	ENTITY
infections	ENTITY
also	O
cause	O
knee	ENTITY
pain	ENTITY
.	O
symptoms	O
pain	O
after	O
standing	O
and	O
sitting	O
swelling	ENTITY
and	ENTITY
inflammation	ENTITY
around	ENTITY
the	ENTITY
knee	ENTITY
numbness	O
or	O
abnormal	O
sensation	O
in	O
whole	O
body	O
when	O
you	O
bend	O
the	O
knee	ENTITY
feel	ENTITY
pain	ENTITY
over	ENTITY
the	ENTITY
thighs	ENTITY
lower	ENTITY
.	O
cervical	ENTITY
spondylosis	ENTITY
treatment	O
in	O
nadipathy	O
cervical	ENTITY
spondylosis	ENTITY
commonly	O
caused	O
by	O
cervical	ENTITY
spine	ENTITY
degeneration	ENTITY
.	O
there	O
can	O
be	O
growth	O
or	O
degeneration	O
and	O
mineral	O
deposits	O
in	O
the	O
disc	ENTITY
that	ENTITY
may	ENTITY
lead	ENTITY
to	ENTITY
chronic	ENTITY
neck	ENTITY
pain	ENTITY
and	O
neck	ENTITY
stiffness	ENTITY
.	O
patients	O
often	O
show	O
limited	O
head	O
.	O
cumulative	O
degeneration	O
can	O
gradually	O
compress	O
cervical	ENTITY
spinal	ENTITY
nerve	ENTITY
roots	ENTITY
causing	O
increased	O
pain	O
as	O
well	O
as	O
weakness	O
or	O
sensation	O
loss	O
in	O
the	O
arms	O
and	O
legs	O
.	O
cervical	ENTITY
spondylosis	ENTITY
.	O
progressive	O
neck	ENTITY
pain	ENTITY
is	O
key	O
indication	O
of	O
cervical	ENTITY
spondylosis	ENTITY
.	O
it	O
may	O
be	O
the	O
only	O
symptom	O
.	O
these	O
changes	O
can	O
over	O
time	O
press	O
down	O
on	O
compress	O
one	O
or	O
more	O
of	O
the	O
nerve	ENTITY
roots	ENTITY
.	O
in	O
advanced	O
cases	O
the	O
spinal	ENTITY
cord	ENTITY
.	O
this	O
can	O
affect	O
not	O
just	O
the	O
arms	O
but	O
the	O
legs	O
.	O
examination	O
often	O
shows	O
limited	O
ability	O
to	O
bend	O
the	O
head	O
toward	O
the	O
shoulders	O
and	O
limited	O
ability	O
to	O
rotate	O
the	O
head	O
.	O
eye	ENTITY
problem	ENTITY
completely	ENTITY
cured	ENTITY
diabetes	ENTITY
control	ENTITY
in	ENTITY
days	ENTITY
nadichikista	ENTITY
kakinada	ENTITY
nadipathy	ENTITY
treatment	ENTITY
eye	O
problem	O
treatment	O
in	O
nadipaty	O
the	O
human	O
eye	O
is	O
an	O
exquisitely	O
complicated	O
organ	ENTITY
.	O
it	O
acts	O
like	O
camera	ENTITY
to	ENTITY
collect	ENTITY
and	ENTITY
focus	ENTITY
light	ENTITY
and	ENTITY
convert	ENTITY
it	ENTITY
into	ENTITY
an	ENTITY
electrical	ENTITY
signal	ENTITY
that	ENTITY
the	ENTITY
brain	ENTITY
.	O
but	O
instead	O
of	O
photographic	O
film	O
it	O
has	O
highly	O
specialized	O
retina	ENTITY
that	ENTITY
detects	ENTITY
light	ENTITY
and	ENTITY
processes	ENTITY
the	ENTITY
signals	ENTITY
using	ENTITY
dozens	ENTITY
of	ENTITY
different	ENTITY
kinds	ENTITY
of	ENTITY
neurons	ENTITY
.	O
some	O
common	O
eye	ENTITY
diseases	ENTITY
myopia	O
near	O
sightedness	O
nearsightedness	O
develops	O
in	O
eyes	ENTITY
that	ENTITY
focus	ENTITY
images	ENTITY
in	ENTITY
front	ENTITY
of	ENTITY
the	ENTITY
retina	ENTITY
instead	ENTITY
of	ENTITY
on	ENTITY
the	ENTITY
retina	ENTITY
.	O
this	O
occurs	O
when	O
the	O
eyeball	ENTITY
becomes	ENTITY
too	ENTITY
long	ENTITY
and	ENTITY
prevents	ENTITY
incoming	ENTITY
light	ENTITY
from	ENTITY
focusing	ENTITY
directly	ENTITY
on	ENTITY
the	ENTITY
retina	ENTITY
.	O
it	O
may	O
also	O
be	O
caused	O
by	O
an	O
abnormal	O
shape	O
of	O
the	O
cornea	ENTITY
or	ENTITY
lens	ENTITY
.	O
for	O
more	O
details	O
visit	O
www	O
nadipathy	O
in	O
blog	O
eyetreatmentprocedureinnadipathy	O
blogspot	O
in	O
you	O
tube	ENTITY
.	O
cervical	ENTITY
spondylosis	ENTITY
cured	O
and	O
diabetes	ENTITY
controlled	ENTITY
in	ENTITY
days	ENTITY
treatment	ENTITY
in	ENTITY
nadipathy	ENTITY
cervical	ENTITY
spondylosis	ENTITY
treatment	O
in	O
nadipathy	O
cervical	ENTITY
spondylosis	ENTITY
commonly	O
caused	O
by	O
cervical	ENTITY
spine	ENTITY
degeneration	ENTITY
.	O
there	O
can	O
be	O
growth	O
or	O
degeneration	O
and	O
mineral	O
deposits	O
in	O
the	O
disc	ENTITY
that	ENTITY
may	ENTITY
lead	ENTITY
to	ENTITY
chronic	ENTITY
neck	ENTITY
pain	ENTITY
and	O
neck	ENTITY
stiffness	ENTITY
.	O
patients	O
often	O
show	O
limited	O
head	O
.	O
cumulative	O
degeneration	O
can	O
gradually	O
compress	O
cervical	ENTITY
spinal	ENTITY
nerve	ENTITY
roots	ENTITY
causing	O
increased	O
pain	O
as	O
well	O
as	O
weakness	O
or	O
sensation	O
loss	O
in	O
the	O
arms	O
and	O
legs	O
.	O
cervical	ENTITY
spondylosis	ENTITY
.	O
progressive	O
neck	ENTITY
pain	ENTITY
is	O
key	O
indication	O
of	O
cervical	ENTITY
spondylosis	ENTITY
.	O
it	O
may	O
be	O
the	O
only	O
symptom	O
.	O
these	O
changes	O
can	O
over	O
time	O
press	O
down	O
on	O
compress	O
one	O
or	O
more	O
of	O
the	O
nerve	ENTITY
roots	ENTITY
.	O
in	O
advanced	O
cases	O
the	O
spinal	ENTITY
cord	ENTITY
.	O
this	O
can	O
affect	O
not	O
just	O
the	O
arms	O
but	O
the	O
legs	O
.	O
examination	O
often	O
shows	O
limited	O
ability	O
to	O
bend	O
the	O
head	O
toward	O
the	O
shoulders	O
and	O
limited	O
ability	O
to	O
rotate	O
the	O
head	O
.	O
cervical	ENTITY
spondylosis	ENTITY
treatment	O
in	O
nadipathy	O
cervical	ENTITY
spondylosis	ENTITY
commonly	O
caused	O
by	O
cervical	ENTITY
spine	ENTITY
degeneration	ENTITY
.	O
there	O
can	O
be	O
growth	O
or	O
degeneration	O
and	O
mineral	O
deposits	O
in	O
the	O
disc	ENTITY
that	ENTITY
may	ENTITY
lead	ENTITY
to	ENTITY
chronic	ENTITY
neck	ENTITY
pain	ENTITY
and	O
neck	ENTITY
stiffness	ENTITY
.	O
patients	O
often	O
show	O
limited	O
head	O
.	O
cumulative	O
degeneration	O
can	O
gradually	O
compress	O
cervical	ENTITY
spinal	ENTITY
nerve	ENTITY
roots	ENTITY
causing	O
increased	O
pain	O
as	O
well	O
as	O
weakness	O
or	O
sensation	O
loss	O
in	O
the	O
arms	O
and	O
legs	O
.	O
cervical	ENTITY
spondylosis	ENTITY
.	O
progressive	O
neck	ENTITY
pain	ENTITY
is	O
key	O
indication	O
of	O
cervical	ENTITY
spondylosis	ENTITY
.	O
it	O
may	O
be	O
the	O
only	O
symptom	O
.	O
these	O
changes	O
can	O
over	O
time	O
press	O
down	O
on	O
compress	O
one	O
or	O
more	O
of	O
the	O
nerve	ENTITY
roots	ENTITY
.	O
in	O
advanced	O
cases	O
the	O
spinal	ENTITY
cord	ENTITY
.	O
this	O
can	O
affect	O
not	O
just	O
the	O
arms	O
but	O
the	O
legs	O
.	O
examination	O
often	O
shows	O
limited	O
ability	O
to	O
bend	O
the	O
head	O
toward	O
the	O
shoulders	O
and	O
limited	O
ability	O
to	O
rotate	O
the	O
head	O
.	O
hope	O
you	O
all	O
enjoy	O
this	O
interview	O
on	O
intermittent	O
fasting	O
with	O
special	O
guest	O
dr	O
jason	O
fung	O
where	O
we	O
explore	O
non	O
conventional	O
dietary	ENTITY
plans	ENTITY
for	ENTITY
the	ENTITY
prevention	ENTITY
and	O
treatment	O
of	O
diabetes	ENTITY
thyroid	ENTITY
and	ENTITY
obesity	ENTITY
.	O
dr	O
.	O
really	O
enjoyed	O
speaking	O
with	O
him	O
on	O
our	O
common	O
beliefs	O
to	O
achieving	O
optimal	O
health	O
and	O
wellness	O
.	O
watch	O
to	O
learn	O
why	O
low	ENTITY
calorie	ENTITY
low	ENTITY
fat	ENTITY
diets	ENTITY
and	O
the	O
calorie	O
in	O
calorie	O
out	O
logic	O
to	O
weight	O
loss	O
.	O
more	O
info	O
on	O
intermittent	O
fasting	O
at	O
drpompa	O
com	O
disclaimer	O
dr	O
pompa	O
has	O
voluntarily	O
relinquished	O
his	O
chiropractic	ENTITY
.	O
in	O
the	O
second	O
half	O
of	O
our	O
look	O
at	O
the	O
endocrine	ENTITY
system	ENTITY
hank	O
discusses	O
chemical	O
homeostasis	O
and	O
hormone	ENTITY
.	O
specifically	O
he	O
looks	O
at	O
the	O
hypothalamus	ENTITY
pituitary	ENTITY
thyroid	ENTITY
axis	ENTITY
or	O
hpt	ENTITY
axis	ENTITY
and	O
all	O
the	O
ways	O
your	O
body	O
can	O
suffer	O
when	O
that	O
system	O
or	O
your	O
hormones	ENTITY
.	O
table	O
of	O
contents	O
chemical	O
homeostasis	O
hormone	ENTITY
cascades	ENTITY
hpt	ENTITY
axis	ENTITY
crash	ENTITY
course	ENTITY
psychology	ENTITY
posters	ENTITY
available	ENTITY
now	ENTITY
at	ENTITY
dftba	ENTITY
com	ENTITY
.	O
diabetes	ENTITY
treatment	ENTITY
in	ENTITY
nadipathy	ENTITY
what	ENTITY
is	ENTITY
diabetes	ENTITY
it	ENTITY
is	ENTITY
the	ENTITY
condition	ENTITY
that	ENTITY
body	ENTITY
cannot	ENTITY
balance	ENTITY
the	ENTITY
glucose	ENTITY
levels	ENTITY
due	O
to	O
lack	O
of	O
energy	O
to	O
pancreas	ENTITY
or	ENTITY
the	ENTITY
body	ENTITY
cannot	ENTITY
utilize	ENTITY
insulin	ENTITY
to	ENTITY
maintain	ENTITY
glucose	ENTITY
homeostasis	ENTITY
.	O
it	O
was	O
first	O
known	O
in	O
the	O
th	O
century	ENTITY
.	O
again	O
diabetes	ENTITY
is	ENTITY
differentiated	ENTITY
in	ENTITY
to	ENTITY
two	ENTITY
types	ENTITY
diabetes	ENTITY
mellitus	ENTITY
and	ENTITY
diabetes	ENTITY
insipidus	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
mainly	O
caused	O
by	O
deficiency	O
of	O
insulin	ENTITY
due	ENTITY
to	ENTITY
either	ENTITY
lack	ENTITY
of	ENTITY
energy	ENTITY
in	ENTITY
pancreas	ENTITY
or	ENTITY
any	ENTITY
auto	ENTITY
immune	ENTITY
disease	ENTITY
.	O
while	O
diabetes	ENTITY
insipidus	ENTITY
is	O
caused	O
by	O
defect	O
in	O
secretion	O
of	O
vasopressin	ENTITY
antidiuretic	ENTITY
hormone	ENTITY
which	O
is	O
secreted	O
from	O
pituitary	ENTITY
gland	ENTITY
present	O
in	O
hypothalamus	ENTITY
.	O
its	O
function	O
is	O
to	O
reabsorb	O
water	O
from	O
distal	ENTITY
tubules	ENTITY
in	O
the	O
kidney	ENTITY
.	O
but	O
its	O
deficiency	O
caused	O
increased	O
water	O
excretion	O
through	O
urine	O
even	O
in	O
low	O
intake	O
of	O
water	O
.	O
diabetes	ENTITY
mellitus	ENTITY
and	O
diabetes	ENTITY
insipidus	ENTITY
are	O
unrelated	O
although	O
they	O
have	O
similar	O
signs	O
and	O
symptoms	O
like	O
excessive	O
thirst	O
and	O
excessive	ENTITY
urination	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
more	O
common	O
than	O
the	O
diabetes	ENTITY
insipidus	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
.	O
type	O
diabetes	ENTITY
the	ENTITY
body	ENTITY
does	ENTITY
not	ENTITY
produce	ENTITY
insulin	ENTITY
.	O
such	O
diabetes	ENTITY
called	ENTITY
as	ENTITY
insulin	ENTITY
dependent	ENTITY
diabetes	ENTITY
.	O
people	O
usually	O
develop	O
type	O
diabetes	ENTITY
before	ENTITY
their	ENTITY
th	ENTITY
.	O
today	O
type	O
diabetes	ENTITY
has	ENTITY
no	ENTITY
proper	ENTITY
treatment	ENTITY
.	O
so	O
these	O
individuals	O
are	O
insulin	ENTITY
.	O
approximately	O
of	O
all	O
diabetes	ENTITY
cases	ENTITY
are	ENTITY
type	ENTITY
common	ENTITY
symptoms	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
fatigue	O
or	O
tiredness	O
.	O
excessive	O
thirst	O
.	O
increased	O
urination	ENTITY
.	O
nausea	ENTITY
perhaps	ENTITY
vomiting	ENTITY
.	O
blurred	O
vision	O
.	O
in	O
women	O
frequent	O
vaginal	ENTITY
.	O
dry	ENTITY
mouth	ENTITY
.	O
itching	ENTITY
skin	ENTITY
.	O
slow	O
healing	O
wounds	O
.	O
blog	O
.	O
diabetes	ENTITY
treatment	ENTITY
in	ENTITY
nadipathy	ENTITY
what	ENTITY
is	ENTITY
diabetes	ENTITY
it	ENTITY
is	ENTITY
the	ENTITY
condition	ENTITY
that	ENTITY
body	ENTITY
cannot	ENTITY
balance	ENTITY
the	ENTITY
glucose	ENTITY
levels	ENTITY
due	O
to	O
lack	O
of	O
energy	O
to	O
pancreas	ENTITY
or	ENTITY
the	ENTITY
body	ENTITY
cannot	ENTITY
utilize	ENTITY
insulin	ENTITY
to	ENTITY
maintain	ENTITY
glucose	ENTITY
homeostasis	ENTITY
.	O
it	O
was	O
first	O
known	O
in	O
the	O
th	O
century	O
.	O
again	O
diabetes	ENTITY
is	ENTITY
differentiated	ENTITY
in	ENTITY
to	ENTITY
two	ENTITY
types	ENTITY
diabetes	ENTITY
mellitus	ENTITY
and	O
diabetes	ENTITY
insipidus	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
mainly	O
caused	O
by	O
deficiency	O
of	O
insulin	ENTITY
due	ENTITY
to	ENTITY
either	ENTITY
lack	ENTITY
of	ENTITY
energy	ENTITY
in	ENTITY
pancreas	ENTITY
or	ENTITY
any	ENTITY
auto	ENTITY
immune	ENTITY
disease	ENTITY
.	O
while	O
diabetes	ENTITY
insipidus	ENTITY
is	O
caused	O
by	O
defect	O
in	O
secretion	O
of	O
vasopressin	ENTITY
antidiuretic	ENTITY
hormone	ENTITY
which	O
is	O
secreted	O
from	O
pituitary	ENTITY
gland	ENTITY
present	O
in	O
hypothalamus	ENTITY
.	O
its	O
function	O
is	O
to	O
reabsorb	O
water	O
from	O
distal	O
tubules	O
in	O
the	O
kidney	ENTITY
.	O
but	O
its	O
deficiency	O
caused	O
increased	O
water	O
excretion	O
through	O
urine	O
even	O
in	O
low	O
intake	O
of	O
water	O
.	O
diabetes	ENTITY
mellitus	ENTITY
and	O
diabetes	ENTITY
insipidus	ENTITY
are	O
unrelated	O
although	O
they	O
have	O
similar	O
signs	O
and	O
symptoms	O
like	O
excessive	O
thirst	O
and	O
excessive	ENTITY
urination	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
more	O
common	O
than	O
the	O
diabetes	ENTITY
insipidus	ENTITY
.	O
blog	O
.	O
nadipathy	ENTITY
treatment	ENTITY
acupressure	O
health	O
care	O
centre	O
ramanayya	O
pet	O
kakinada	O
dt	O
andhra	O
pradesh	O
india	O
for	O
more	O
details	O
visit	O
www	O
nadipathy	O
in	O
email	O
nadipathy	O
gmail	O
com	O
drkrajuam	O
gmail	O
com	O
ph	O
knee	O
pains	O
treatment	O
in	O
nadipathy	O
knee	ENTITY
is	ENTITY
the	ENTITY
strongest	ENTITY
and	ENTITY
most	ENTITY
complex	ENTITY
joint	ENTITY
.	O
it	O
joins	O
the	O
thigh	ENTITY
bone	ENTITY
.	O
the	O
smaller	O
bone	ENTITY
that	ENTITY
runs	ENTITY
alongside	ENTITY
the	ENTITY
tibia	ENTITY
fibula	ENTITY
and	O
the	O
kneecap	ENTITY
patella	ENTITY
are	O
the	O
other	O
bones	ENTITY
that	ENTITY
make	ENTITY
the	ENTITY
knee	ENTITY
joint	ENTITY
.	O
tendons	ENTITY
connect	ENTITY
the	ENTITY
knee	ENTITY
bones	ENTITY
to	O
the	O
leg	ENTITY
muscles	ENTITY
that	O
move	O
the	O
knee	ENTITY
joint	ENTITY
.	O
ligaments	ENTITY
join	ENTITY
the	ENTITY
knee	ENTITY
bones	ENTITY
and	O
provide	O
stability	O
to	O
the	O
knee	ENTITY
.	O
medial	O
and	O
lateral	ENTITY
menisci	ENTITY
act	O
as	O
shock	O
absorbers	O
the	O
femur	ENTITY
and	ENTITY
tibia	ENTITY
.	O
the	O
fluid	ENTITY
called	ENTITY
synovial	ENTITY
fluid	ENTITY
that	O
helps	O
the	O
knee	ENTITY
move	ENTITY
.	O
knee	ENTITY
pains	ENTITY
is	O
mainly	O
caused	O
by	O
an	O
injury	O
such	O
as	O
ruptured	ENTITY
ligament	ENTITY
or	O
torn	ENTITY
cartilage	ENTITY
and	O
some	O
other	O
reasons	O
like	O
weakness	ENTITY
arthritis	ENTITY
gout	ENTITY
infections	ENTITY
also	O
cause	O
knee	ENTITY
pain	ENTITY
.	O
symptoms	O
pain	O
after	O
standing	O
and	O
sitting	O
swelling	ENTITY
and	ENTITY
inflammation	ENTITY
around	ENTITY
the	ENTITY
knee	ENTITY
numbness	O
or	O
abnormal	O
sensation	O
in	O
whole	O
body	O
when	O
you	O
bend	O
the	O
knee	ENTITY
feel	ENTITY
pain	ENTITY
over	ENTITY
the	ENTITY
thighs	ENTITY
lower	ENTITY
leg	ENTITY
pain	ENTITY
get	O
worse	O
during	O
walking	O
reasons	O
to	O
develop	O
knee	ENTITY
pains	ENTITY
being	O
over	O
weight	O
knee	ENTITY
injury	ENTITY
or	O
surgery	ENTITY
gastric	ENTITY
.	O
many	O
of	O
the	O
treatments	O
are	O
available	O
to	O
cure	O
knee	ENTITY
pains	ENTITY
.	O
but	O
they	O
are	O
giving	O
unnecessary	O
medicines	O
to	O
internal	O
body	O
.	O
it	O
will	O
need	O
much	O
time	O
as	O
months	O
or	O
years	O
.	O
sometimes	O
they	O
are	O
doing	O
harmful	O
surgeries	ENTITY
to	ENTITY
spine	ENTITY
.	O
this	O
will	O
cause	O
side	O
effects	O
to	O
knees	ENTITY
.	O
for	O
more	O
details	O
visit	O
www	O
nadipathy	O
in	O
.	O
this	O
video	O
describes	O
the	O
structure	O
and	O
function	O
of	O
astrocytes	ENTITY
.	O
by	O
matt	O
.	O
watch	O
the	O
next	O
lesson	O
add	O
user	O
khanacademy	O
.	O
nadipathy	ENTITY
treatment	ENTITY
acupressure	O
health	O
care	O
centre	O
ramanayya	O
pet	O
kakinada	O
dt	O
andhra	O
pradesh	O
india	O
for	O
more	O
details	O
visit	O
www	O
nadipathy	O
in	O
email	O
nadipathy	O
gmail	O
com	O
drkrajuam	O
gmail	O
com	O
ph	O
knee	O
pains	O
treatment	O
in	O
nadipathy	O
knee	ENTITY
is	ENTITY
the	ENTITY
strongest	ENTITY
and	ENTITY
most	ENTITY
complex	ENTITY
joint	ENTITY
.	O
it	O
joins	O
the	O
thigh	ENTITY
bone	ENTITY
.	O
the	O
smaller	O
bone	ENTITY
that	ENTITY
runs	ENTITY
alongside	ENTITY
the	ENTITY
tibia	ENTITY
fibula	ENTITY
and	O
the	O
kneecap	ENTITY
patella	ENTITY
are	O
the	O
other	O
bones	ENTITY
that	ENTITY
make	ENTITY
the	ENTITY
knee	ENTITY
joint	ENTITY
.	O
tendons	ENTITY
connect	ENTITY
the	ENTITY
knee	ENTITY
bones	ENTITY
to	O
the	O
leg	O
muscles	O
that	O
move	O
the	O
knee	ENTITY
joint	ENTITY
.	O
ligaments	ENTITY
join	ENTITY
the	ENTITY
knee	ENTITY
bones	ENTITY
and	O
provide	O
stability	O
to	O
the	O
knee	ENTITY
.	O
medial	O
and	O
lateral	ENTITY
menisci	ENTITY
act	O
as	O
shock	O
absorbers	O
the	O
femur	ENTITY
and	ENTITY
tibia	ENTITY
.	O
the	O
fluid	O
called	O
synovial	ENTITY
fluid	ENTITY
that	O
helps	O
the	O
knee	ENTITY
move	ENTITY
.	O
knee	ENTITY
pains	ENTITY
is	O
mainly	O
caused	O
by	O
an	O
injury	O
such	O
as	O
ruptured	ENTITY
ligament	ENTITY
or	O
torn	ENTITY
cartilage	ENTITY
and	O
some	O
other	O
reasons	O
like	O
weakness	ENTITY
arthritis	ENTITY
gout	ENTITY
infections	ENTITY
also	O
cause	O
knee	ENTITY
pain	ENTITY
.	O
symptoms	O
pain	O
after	O
standing	O
and	O
sitting	O
swelling	ENTITY
and	ENTITY
inflammation	ENTITY
around	ENTITY
the	ENTITY
knee	ENTITY
numbness	O
or	O
abnormal	O
sensation	O
in	O
whole	O
body	O
when	O
you	O
bend	O
the	O
knee	ENTITY
feel	ENTITY
pain	ENTITY
over	ENTITY
the	ENTITY
thighs	ENTITY
lower	ENTITY
leg	ENTITY
pain	O
get	O
worse	O
during	O
walking	O
reasons	O
to	O
develop	O
knee	ENTITY
pains	ENTITY
being	O
over	O
weight	O
knee	ENTITY
injury	ENTITY
or	O
surgery	ENTITY
gastric	ENTITY
.	O
many	O
of	O
the	O
treatments	O
are	O
available	O
to	O
cure	O
knee	ENTITY
pains	ENTITY
.	O
but	O
they	O
are	O
giving	O
unnecessary	O
medicines	O
to	O
internal	O
body	O
.	O
it	O
will	O
need	O
much	O
time	O
as	O
months	O
or	O
years	O
.	O
sometimes	O
they	O
are	O
doing	O
harmful	O
surgeries	ENTITY
to	ENTITY
spine	ENTITY
.	O
this	O
will	O
cause	O
side	O
effects	O
to	O
knees	ENTITY
.	O
for	O
more	O
details	O
visit	O
www	O
nadipathy	O
in	O
.	O
cervical	ENTITY
spondylosis	ENTITY
treatment	O
in	O
nadipathy	O
cervical	ENTITY
spondylosis	ENTITY
commonly	O
caused	O
by	O
cervical	ENTITY
spine	ENTITY
degeneration	ENTITY
.	O
there	O
can	O
be	O
growth	O
or	O
degeneration	O
and	O
mineral	O
deposits	O
in	O
the	O
disc	ENTITY
that	ENTITY
may	ENTITY
lead	ENTITY
to	ENTITY
chronic	ENTITY
neck	ENTITY
pain	ENTITY
and	O
neck	ENTITY
stiffness	ENTITY
.	O
patients	O
often	O
show	O
limited	O
head	O
.	O
cumulative	O
degeneration	O
can	O
gradually	O
compress	O
cervical	ENTITY
spinal	ENTITY
nerve	ENTITY
roots	ENTITY
causing	O
increased	O
pain	O
as	O
well	O
as	O
weakness	O
or	O
sensation	O
loss	O
in	O
the	O
arms	O
and	O
legs	O
.	O
cervical	ENTITY
spondylosis	ENTITY
.	O
progressive	O
neck	ENTITY
pain	ENTITY
is	O
key	O
indication	O
of	O
cervical	ENTITY
spondylosis	ENTITY
.	O
it	O
may	O
be	O
the	O
only	O
symptom	O
.	O
these	O
changes	O
can	O
over	O
time	O
press	O
down	O
on	O
compress	O
one	O
or	O
more	O
of	O
the	O
nerve	ENTITY
roots	ENTITY
.	O
in	O
advanced	O
cases	O
the	O
spinal	ENTITY
cord	ENTITY
.	O
this	O
can	O
affect	O
not	O
just	O
the	O
arms	O
but	O
the	O
legs	O
.	O
examination	O
often	O
shows	O
limited	O
ability	O
to	O
bend	O
the	O
head	O
toward	O
the	O
shoulders	O
and	O
limited	O
ability	O
to	O
rotate	O
the	O
head	O
symptoms	O
pain	O
after	O
standing	O
and	O
sitting	O
headache	ENTITY
especially	ENTITY
in	ENTITY
back	ENTITY
of	ENTITY
the	ENTITY
head	ENTITY
numbness	ENTITY
or	ENTITY
abnormal	ENTITY
sensation	ENTITY
in	ENTITY
shoulders	ENTITY
and	ENTITY
arms	ENTITY
when	ENTITY
you	ENTITY
bend	ENTITY
the	ENTITY
neck	ENTITY
backward	ENTITY
feel	ENTITY
pain	ENTITY
over	ENTITY
the	ENTITY
shoulder	ENTITY
blade	ENTITY
.	O
the	O
simplest	O
truth	O
phase	O
player	O
gabriel	O
cunningham	O
final	O
diagnosis	O
acute	ENTITY
pancreatitis	ENTITY
doctor	O
medal	O
diagnostic	O
abnormality	ENTITY
serum	ENTITY
amylase	ENTITY
high	ENTITY
serum	ENTITY
amylase	ENTITY
level	ENTITY
abnormality	ENTITY
serum	ENTITY
lipase	ENTITY
high	ENTITY
serum	ENTITY
lipase	ENTITY
level	ENTITY
abnormality	O
elastase	O
high	O
elastase	O
level	O
move	O
in	O
image	O
analysis	O
lab	O
abnormality	O
xray	O
abnormal	ENTITY
bowel	ENTITY
gas	ENTITY
in	O
intestine	ENTITY
abnormality	ENTITY
ct	ENTITY
swollen	ENTITY
pancreas	ENTITY
abnormality	O
ct	O
doctor	O
medal	O
move	O
in	O
exam	O
room	O
question	O
abnormality	O
sentence	O
back	O
pain	O
abnormality	O
sentence	O
nausea	ENTITY
magnifying	ENTITY
glass	ENTITY
abnormality	ENTITY
navel	ENTITY
blood	ENTITY
spots	ENTITY
near	O
navel	ENTITY
abnormality	ENTITY
left	ENTITY
abdomen	ENTITY
blood	ENTITY
spots	ENTITY
on	O
left	ENTITY
abdomen	ENTITY
move	O
in	O
office	O
add	O
all	O
the	O
symptoms	O
to	O
acute	ENTITY
pancreatitis	ENTITY
.	O
nadipathy	ENTITY
treatment	ENTITY
acupressure	O
health	O
care	O
centre	O
ramanayya	O
pet	O
kakinada	O
dt	O
andhra	O
pradesh	O
india	O
for	O
more	O
details	O
visit	O
www	O
nadipathy	O
in	O
email	O
nadipathy	O
gmail	O
com	O
drkrajuam	O
gmail	O
com	O
ph	O
cervical	ENTITY
spondylosis	ENTITY
treatment	O
in	O
nadipathy	O
cervical	ENTITY
spondylosis	ENTITY
commonly	O
caused	O
by	O
cervical	ENTITY
spine	ENTITY
degeneration	ENTITY
.	O
there	O
can	O
be	O
growth	O
or	O
degeneration	O
and	O
mineral	O
deposits	O
in	O
the	O
disc	ENTITY
that	ENTITY
may	ENTITY
lead	ENTITY
to	ENTITY
chronic	ENTITY
neck	ENTITY
pain	ENTITY
and	O
neck	ENTITY
stiffness	ENTITY
.	O
patients	O
often	O
show	O
limited	O
head	O
.	O
cumulative	O
degeneration	O
can	O
gradually	O
compress	O
cervical	ENTITY
spinal	ENTITY
nerve	ENTITY
roots	ENTITY
causing	O
increased	O
pain	O
as	O
well	O
as	O
weakness	O
or	O
sensation	O
loss	O
in	O
the	O
arms	O
and	O
legs	O
.	O
cervical	ENTITY
spondylosis	ENTITY
.	O
nadi	ENTITY
diagnose	ENTITY
nadi	ENTITY
can	ENTITY
be	ENTITY
measured	ENTITY
in	ENTITY
the	ENTITY
superficial	ENTITY
middle	ENTITY
and	ENTITY
deep	ENTITY
levels	ENTITY
thus	ENTITY
obtaining	ENTITY
more	ENTITY
information	ENTITY
regarding	ENTITY
energy	ENTITY
imbalance	ENTITY
.	O
when	O
the	O
body	O
becomes	O
weak	O
.	O
if	O
any	O
one	O
of	O
the	O
nadi	ENTITY
not	ENTITY
working	ENTITY
properly	ENTITY
it	ENTITY
multiplies	ENTITY
gradually	ENTITY
.	O
decreases	O
its	O
energy	O
that	O
reflects	O
gradually	O
in	O
the	O
subtle	O
body	O
and	O
it	O
change	O
as	O
disease	ENTITY
on	ENTITY
the	ENTITY
physical	ENTITY
body	ENTITY
.	O
modern	O
doctors	O
can	O
recognize	O
diseases	ENTITY
.	O
our	O
body	O
is	O
making	O
up	O
with	O
nadi	ENTITY
all	ENTITY
the	ENTITY
nadi	ENTITY
are	ENTITY
inter	ENTITY
linked	ENTITY
to	ENTITY
every	ENTITY
organ	ENTITY
.	O
if	O
there	O
is	O
any	O
blockage	O
to	O
such	O
nadi	O
it	O
does	O
not	O
work	O
properly	O
.	O
so	O
those	O
organs	ENTITY
get	ENTITY
lack	ENTITY
of	ENTITY
energy	ENTITY
to	ENTITY
function	ENTITY
.	O
before	O
to	O
the	O
treatment	O
nadipathy	O
treats	O
on	O
the	O
root	O
.	O
treatment	O
method	O
by	O
using	O
acupuncture	ENTITY
acupressure	ENTITY
marma	O
therapy	O
vedic	O
therapy	O
magnet	O
therapy	O
seed	O
therapy	O
massage	O
therapy	O
cupping	O
therapy	O
detoxifation	O
therapy	O
naturopathy	O
beach	O
sand	O
therapy	O
and	O
some	O
other	O
natural	O
therapies	O
to	O
remove	O
the	O
waste	O
materials	O
excess	O
heat	O
present	O
inside	O
the	O
body	O
.	O
we	O
treat	O
the	O
spinal	ENTITY
cord	ENTITY
function	O
as	O
normal	O
with	O
side	O
effects	O
.	O
the	O
duration	O
of	O
the	O
treatment	O
was	O
day	O
to	O
week	O
.	O
nadipathy	ENTITY
treatment	ENTITY
will	O
tell	O
you	O
what	O
the	O
healthy	O
lifestyles	O
are	O
for	O
cervical	ENTITY
spondylosis	ENTITY
.	O
which	O
kind	O
of	O
patients	O
should	O
do	O
some	O
mild	O
exercises	O
and	O
under	O
what	O
circumstances	O
should	O
patients	O
have	O
good	O
rest	O
and	O
totally	O
avoid	O
exercises	O
.	O
nadipathy	O
can	O
not	O
only	O
be	O
used	O
to	O
treated	O
the	O
problem	O
it	O
can	O
also	O
be	O
used	O
by	O
those	O
that	O
are	O
at	O
high	O
risk	O
of	O
developing	O
chronic	ENTITY
problems	ENTITY
and	O
healthy	O
people	O
to	O
help	O
prevent	O
other	O
diseases	ENTITY
.	O
if	O
nadipathy	ENTITY
treatment	ENTITY
is	O
received	O
early	O
it	O
can	O
help	O
prevent	O
the	O
patient	O
disease	O
so	O
as	O
to	O
help	O
avoid	O
entering	O
in	O
to	O
surgeries	O
.	O
for	O
more	O
details	O
blog	O
.	O
diabetes	ENTITY
treatment	ENTITY
in	ENTITY
nadipathy	ENTITY
what	ENTITY
is	ENTITY
diabetes	ENTITY
it	ENTITY
is	ENTITY
the	ENTITY
condition	ENTITY
that	ENTITY
body	ENTITY
cannot	ENTITY
balance	ENTITY
the	ENTITY
glucose	ENTITY
levels	ENTITY
due	O
to	O
lack	O
of	O
energy	O
to	O
pancreas	ENTITY
or	ENTITY
the	ENTITY
body	ENTITY
cannot	ENTITY
utilize	ENTITY
insulin	ENTITY
to	ENTITY
maintain	ENTITY
glucose	ENTITY
homeostasis	ENTITY
.	O
it	O
was	O
first	O
known	O
in	O
the	O
th	O
century	O
.	O
again	O
diabetes	ENTITY
is	ENTITY
differentiated	ENTITY
in	ENTITY
to	ENTITY
two	ENTITY
types	ENTITY
diabetes	ENTITY
mellitus	ENTITY
and	O
diabetes	ENTITY
insipidus	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
mainly	O
caused	O
by	O
deficiency	O
of	O
insulin	ENTITY
due	ENTITY
to	ENTITY
either	ENTITY
lack	ENTITY
of	ENTITY
energy	ENTITY
in	ENTITY
pancreas	ENTITY
or	ENTITY
any	ENTITY
auto	ENTITY
immune	ENTITY
disease	ENTITY
.	O
while	O
diabetes	ENTITY
insipidus	ENTITY
is	O
caused	O
by	O
defect	O
in	O
secretion	O
of	O
vasopressin	ENTITY
antidiuretic	ENTITY
hormone	ENTITY
which	O
is	O
secreted	O
from	O
pituitary	ENTITY
gland	ENTITY
present	O
in	O
hypothalamus	ENTITY
.	O
its	O
function	O
is	O
to	O
reabsorb	O
water	O
from	O
distal	O
tubules	O
in	O
the	O
kidney	ENTITY
.	O
but	O
its	O
deficiency	O
caused	O
increased	O
water	O
excretion	O
through	O
urine	O
even	O
in	O
low	O
intake	O
of	O
water	O
.	O
diabetes	ENTITY
mellitus	ENTITY
and	O
diabetes	ENTITY
insipidus	ENTITY
are	O
unrelated	O
although	O
they	O
have	O
similar	O
signs	O
and	O
symptoms	O
like	O
excessive	O
thirst	O
and	O
excessive	ENTITY
urination	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
more	O
common	O
than	O
the	O
diabetes	ENTITY
insipidus	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
.	O
blog	O
.	O
bodybuilders	O
risk	O
their	O
lives	O
by	O
injecting	O
their	O
muscles	ENTITY
with	ENTITY
oil	ENTITY
.	O
subscribe	O
for	O
more	O
great	O
clips	O
.	O
this	O
animation	O
helps	O
the	O
learner	O
to	O
understand	O
the	O
lipid	ENTITY
abnormalities	ENTITY
commonly	O
seen	O
in	O
patients	O
with	O
type	O
diabetes	ENTITY
.	O
the	O
animation	O
focuses	O
on	O
the	O
major	O
role	O
that	O
elevated	O
plasma	ENTITY
free	ENTITY
fatty	ENTITY
acids	ENTITY
ffas	ENTITY
play	ENTITY
in	ENTITY
the	ENTITY
development	ENTITY
.	O
continue	O
watching	O
.	O
support	O
the	O
deeper	O
cause	O
of	O
slow	O
metabolism	ENTITY
insulin	ENTITY
glucose	ENTITY
support	ENTITY
the	ENTITY
health	ENTITY
wellness	ENTITY
center	ENTITY
pinecrest	ENTITY
office	ENTITY
park	ENTITY
drive	ENTITY
alexandria	ENTITY
va	ENTITY
disclaimer	ENTITY
dr	ENTITY
berg	ENTITY
does	ENTITY
not	ENTITY
diagnose	ENTITY
treat	ENTITY
or	ENTITY
prevent	ENTITY
any	ENTITY
medical	ENTITY
conditions	ENTITY
.	O
he	O
works	O
with	O
their	O
physicians	O
which	O
regular	O
their	O
medication	O
.	O
this	O
video	O
is	O
not	O
designed	O
to	O
and	O
does	O
not	O
provide	O
medical	O
advice	O
professional	O
diagnosis	O
opinion	O
treatment	O
.	O
through	O
my	O
videos	O
blog	O
posts	O
website	O
information	O
give	O
suggestions	O
for	O
you	O
and	O
your	O
doctor	O
to	O
research	O
and	O
provide	O
general	O
information	O
for	O
educational	O
purposes	O
only	O
.	O
the	O
information	O
provided	O
in	O
this	O
video	O
or	O
site	O
.	O
the	O
health	O
wellness	O
and	O
dr	O
eric	O
berg	O
are	O
not	O
liable	O
or	O
responsible	O
for	O
any	O
advice	O
course	O
of	O
treatment	O
diagnosis	O
or	O
any	O
other	O
information	O
services	O
or	O
product	O
you	O
obtain	O
through	O
this	O
video	O
or	O
site	O
.	O
metabolic	ENTITY
syndrome	ENTITY
is	O
probably	O
the	O
most	O
serious	O
medical	O
condition	O
that	O
you	O
haven	O
heard	O
.	O
so	O
what	O
is	O
metabolic	ENTITY
syndrome	ENTITY
why	O
is	O
it	O
so	O
serious	O
and	O
why	O
haven	O
you	O
heard	O
.	O
here	O
is	O
what	O
you	O
need	O
to	O
know	O
.	O
the	O
metabolic	ENTITY
syndrome	ENTITY
is	O
cluster	O
of	O
the	O
most	O
dangerous	O
heart	ENTITY
attack	ENTITY
risk	O
factors	O
raised	ENTITY
blood	ENTITY
glucose	ENTITY
central	ENTITY
adiposity	ENTITY
often	O
called	O
beer	O
belly	O
abnormal	O
cholesterol	ENTITY
levels	ENTITY
abnormal	O
blood	ENTITY
fats	ENTITY
also	O
called	O
triglycerides	ENTITY
and	ENTITY
high	ENTITY
blood	ENTITY
pressure	ENTITY
.	O
it	O
is	O
estimated	O
that	O
in	O
adults	O
have	O
metabolic	ENTITY
syndrome	ENTITY
and	O
the	O
condition	O
becomes	O
more	O
common	O
as	O
we	O
get	O
older	O
so	O
that	O
by	O
the	O
age	O
of	O
nearly	O
third	O
of	O
adults	O
have	O
metabolic	ENTITY
syndrome	ENTITY
.	O
so	O
why	O
is	O
metabolic	ENTITY
syndrome	ENTITY
.	O
well	O
if	O
you	O
have	O
metabolic	ENTITY
syndrome	ENTITY
you	O
are	O
much	O
more	O
likely	O
to	O
suffer	O
heart	ENTITY
attack	ENTITY
or	O
stroke	O
more	O
likely	O
to	O
develop	O
full	O
blown	O
diabetes	ENTITY
more	ENTITY
likely	ENTITY
to	ENTITY
develop	ENTITY
cancer	ENTITY
and	ENTITY
more	ENTITY
likely	ENTITY
to	ENTITY
develop	ENTITY
alzheimer	ENTITY
disease	ENTITY
.	O
all	O
of	O
these	O
conditions	O
.	O
dementia	ENTITY
and	ENTITY
alzheimer	ENTITY
disease	ENTITY
have	O
overtaken	O
cancer	O
and	O
heart	ENTITY
disease	ENTITY
as	O
the	O
leading	O
cause	O
of	O
death	O
in	O
england	O
and	O
wales	O
in	O
and	O
the	O
metabolic	ENTITY
syndrome	ENTITY
and	O
diabetes	ENTITY
.	O
so	O
how	O
can	O
you	O
check	O
to	O
see	O
if	O
you	O
have	O
metabolic	ENTITY
syndrome	ENTITY
.	O
well	O
first	O
of	O
all	O
get	O
out	O
tape	O
measure	O
.	O
if	O
you	O
are	O
man	O
and	O
your	O
waist	O
circumference	O
is	O
more	O
than	O
cm	O
or	O
if	O
you	O
are	O
woman	O
and	O
your	O
waist	O
is	O
more	O
than	O
cm	O
you	O
have	O
one	O
of	O
the	O
main	O
features	O
of	O
metabolic	ENTITY
syndrome	ENTITY
.	O
if	O
in	O
addition	O
you	O
have	O
any	O
of	O
the	O
following	O
you	O
will	O
be	O
classified	O
as	O
having	O
metabolic	ENTITY
syndrome	ENTITY
raised	ENTITY
blood	ENTITY
triglycerides	ENTITY
reduced	ENTITY
hdl	ENTITY
cholesterol	ENTITY
sometimes	O
known	O
as	O
good	O
cholesterol	ENTITY
raised	ENTITY
blood	ENTITY
pressure	ENTITY
or	O
raised	ENTITY
fasting	ENTITY
plasma	ENTITY
glucose	ENTITY
.	O
note	O
if	O
you	O
are	O
man	O
of	O
south	O
asian	O
or	O
indian	O
heritage	O
the	O
important	O
threshold	O
for	O
waist	O
circumference	O
is	O
cm	O
.	O
metabolic	ENTITY
syndrome	ENTITY
has	O
not	O
yet	O
been	O
classified	O
as	O
disease	ENTITY
it	ENTITY
is	ENTITY
still	ENTITY
regarded	ENTITY
as	ENTITY
collection	ENTITY
of	ENTITY
signs	ENTITY
and	ENTITY
symptoms	ENTITY
which	ENTITY
together	ENTITY
are	ENTITY
serious	ENTITY
risk	ENTITY
factors	ENTITY
for	ENTITY
our	ENTITY
most	ENTITY
deadly	ENTITY
and	ENTITY
disabling	ENTITY
medical	ENTITY
conditions	ENTITY
.	O
several	O
medical	O
organisations	O
such	O
as	O
the	O
world	O
health	O
organisation	O
who	O
the	O
independent	O
diabetes	ENTITY
federation	ENTITY
idf	ENTITY
and	ENTITY
the	ENTITY
european	ENTITY
group	ENTITY
for	ENTITY
the	ENTITY
study	ENTITY
of	ENTITY
insulin	ENTITY
resistance	ENTITY
egir	O
define	O
the	O
metabolic	ENTITY
syndrome	ENTITY
in	O
very	O
slightly	O
different	O
ways	O
and	O
this	O
adds	O
even	O
more	O
to	O
the	O
confusion	O
about	O
what	O
exactly	O
metabolic	ENTITY
syndrome	ENTITY
.	O
however	O
many	O
experts	O
now	O
believe	O
that	O
the	O
underlying	O
problem	O
in	O
metabolic	ENTITY
syndrome	ENTITY
is	O
insulin	ENTITY
resistance	ENTITY
.	O
insulin	ENTITY
resistance	ENTITY
develops	O
when	O
this	O
hormone	ENTITY
cannot	ENTITY
work	ENTITY
properly	ENTITY
when	ENTITY
blood	ENTITY
insulin	ENTITY
levels	ENTITY
are	O
abnormally	O
high	O
and	O
still	O
relatively	O
ineffective	O
in	O
keeping	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
.	O
metabolic	O
specialists	O
now	O
use	O
the	O
term	O
insulin	ENTITY
resistance	ENTITY
syndrome	ENTITY
.	O
insulin	ENTITY
is	ENTITY
hormone	ENTITY
produced	ENTITY
by	ENTITY
the	ENTITY
pancreas	ENTITY
and	ENTITY
it	ENTITY
is	ENTITY
important	ENTITY
in	ENTITY
the	ENTITY
metabolism	ENTITY
of	ENTITY
carbohydrates	ENTITY
and	ENTITY
fats	ENTITY
.	O
when	O
sugar	O
and	O
carbohydrates	ENTITY
are	ENTITY
eaten	ENTITY
insulin	ENTITY
promotes	ENTITY
the	ENTITY
uptake	ENTITY
of	ENTITY
glucose	ENTITY
from	ENTITY
the	ENTITY
blood	ENTITY
into	ENTITY
muscles	ENTITY
and	ENTITY
fat	ENTITY
cells	ENTITY
.	O
hence	O
it	O
is	O
often	O
said	O
that	O
insulin	ENTITY
allows	ENTITY
cells	ENTITY
to	ENTITY
use	ENTITY
glucose	ENTITY
for	ENTITY
energy	ENTITY
and	ENTITY
also	ENTITY
to	ENTITY
store	ENTITY
excess	ENTITY
glucose	ENTITY
and	ENTITY
sugar	ENTITY
as	ENTITY
glycogen	ENTITY
and	ENTITY
fat	ENTITY
.	O
when	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
fall	O
stored	O
glucose	ENTITY
is	ENTITY
released	ENTITY
for	ENTITY
energy	ENTITY
from	ENTITY
the	ENTITY
breakdown	ENTITY
of	ENTITY
glycogen	ENTITY
stores	ENTITY
in	ENTITY
the	ENTITY
liver	ENTITY
and	ENTITY
in	ENTITY
the	ENTITY
muscles	ENTITY
.	O
in	O
the	O
metabolic	ENTITY
syndrome	ENTITY
.	O
fasting	O
blood	ENTITY
levels	ENTITY
of	ENTITY
insulin	ENTITY
in	O
the	O
morning	O
are	O
often	O
abnormally	O
high	O
and	O
insulin	ENTITY
levels	ENTITY
rise	O
to	O
very	O
high	O
levels	O
when	O
food	O
is	O
eaten	O
.	O
continuously	O
high	O
levels	ENTITY
of	ENTITY
insulin	ENTITY
cause	O
the	O
liver	ENTITY
cells	ENTITY
to	O
store	O
fat	ENTITY
resulting	ENTITY
in	ENTITY
fatty	ENTITY
liver	ENTITY
which	O
cannot	O
function	O
.	O
as	O
the	O
insulin	ENTITY
resistance	ENTITY
worsens	O
the	O
pancreas	ENTITY
may	ENTITY
not	ENTITY
be	ENTITY
able	ENTITY
to	ENTITY
produce	ENTITY
enough	ENTITY
insulin	ENTITY
in	ENTITY
response	ENTITY
to	ENTITY
food	ENTITY
and	ENTITY
then	ENTITY
glucose	ENTITY
levels	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
.	O
so	O
why	O
haven	O
you	O
heard	O
.	O
well	O
until	O
quite	O
recently	O
the	O
connection	O
between	O
metabolic	ENTITY
syndrome	ENTITY
and	O
host	O
of	O
chronic	ENTITY
diseases	ENTITY
.	O
we	O
now	O
know	O
that	O
insulin	ENTITY
resistance	ENTITY
.	O
until	O
recently	O
it	O
was	O
difficult	O
to	O
measure	O
blood	ENTITY
insulin	ENTITY
levels	ENTITY
but	O
the	O
technology	O
has	O
improved	O
and	O
we	O
can	O
now	O
measure	O
blood	ENTITY
insulin	ENTITY
levels	ENTITY
accurately	O
and	O
we	O
have	O
good	O
tests	O
to	O
diagnose	O
insulin	ENTITY
resistance	ENTITY
as	O
well	O
as	O
good	O
strategies	O
to	O
reverse	O
insulin	ENTITY
resistance	ENTITY
and	O
the	O
metabolic	ENTITY
syndrome	ENTITY
.	O
once	O
you	O
can	O
measure	O
insulin	ENTITY
resistance	ENTITY
you	O
are	O
well	O
on	O
your	O
way	O
to	O
fixing	O
.	O
there	O
is	O
strong	O
connection	O
between	O
type	O
diabetes	ENTITY
and	ENTITY
dyslipidemia	ENTITY
.	O
this	O
animation	O
describes	O
the	O
lipid	ENTITY
abnormalities	ENTITY
commonly	O
seen	O
in	O
patients	O
with	O
type	O
diabetes	ENTITY
elevated	ENTITY
levels	ENTITY
of	ENTITY
triglycerides	ENTITY
raised	ENTITY
small	ENTITY
dense	ENTITY
ldl	ENTITY
levels	ENTITY
increased	ENTITY
glycation	ENTITY
and	O
oxidation	ENTITY
of	ENTITY
ldls	ENTITY
.	O
these	O
factors	O
increase	O
the	O
risk	O
of	O
cardiovascular	ENTITY
disease	ENTITY
.	O
watch	O
kill	O
diabetes	ENTITY
forever	ENTITY
in	ENTITY
just	ENTITY
days	ENTITY
easy	ENTITY
and	ENTITY
faster	ENTITY
home	ENTITY
remedy	ENTITY
free	ENTITY
diabetes	ENTITY
you	ENTITY
want	ENTITY
really	ENTITY
control	ENTITY
your	ENTITY
sugar	ENTITY
levels	ENTITY
by	ENTITY
using	ENTITY
natural	ENTITY
remedies	ENTITY
and	ENTITY
smoothies	ENTITY
at	ENTITY
home	ENTITY
and	ENTITY
low	ENTITY
price	ENTITY
then	ENTITY
watch	ENTITY
this	ENTITY
channel	ENTITY
fd	ENTITY
free	ENTITY
diabetes	ENTITY
and	ENTITY
keep	ENTITY
my	ENTITY
carbs	ENTITY
to	ENTITY
net	ENTITY
my	ENTITY
protein	ENTITY
is	ENTITY
between	ENTITY
searches	ENTITY
related	ENTITY
to	ENTITY
kill	ENTITY
diabetes	ENTITY
forever	ENTITY
in	ENTITY
just	ENTITY
days	ENTITY
easy	ENTITY
and	ENTITY
faster	ENTITY
home	ENTITY
remedy	ENTITY
reversing	ENTITY
diabetes	ENTITY
in	ENTITY
days	ENTITY
how	ENTITY
to	ENTITY
reverse	ENTITY
diabetes	ENTITY
permanently	ENTITY
how	ENTITY
to	ENTITY
get	ENTITY
rid	ENTITY
of	ENTITY
diabetes	ENTITY
home	ENTITY
remedies	ENTITY
how	ENTITY
to	ENTITY
get	ENTITY
rid	ENTITY
of	ENTITY
diabetes	ENTITY
type	ENTITY
reversing	ENTITY
type	ENTITY
diabetes	ENTITY
without	ENTITY
medication	ENTITY
reverse	ENTITY
diabetes	ENTITY
book	ENTITY
day	ENTITY
diabetes	ENTITY
cure	ENTITY
meal	ENTITY
plan	ENTITY
can	ENTITY
you	ENTITY
get	ENTITY
rid	ENTITY
.	O
how	O
serum	ENTITY
potassium	ENTITY
levels	ENTITY
affect	O
resting	ENTITY
membrane	ENTITY
potential	ENTITY
and	O
cardiac	ENTITY
action	ENTITY
potential	ENTITY
ecg	O
ekg	O
changes	O
.	O
how	O
hyperkalemia	ENTITY
causes	ENTITY
bradycardia	ENTITY
.	O
electrolytes	ENTITY
disorders	ENTITY
this	O
video	O
and	O
other	O
related	O
images	O
videos	O
in	O
hd	O
are	O
available	O
for	O
instant	O
download	O
licensing	O
here	O
pump	O
promoting	O
intra	O
cellular	O
shift	O
hemodialysis	ENTITY
to	ENTITY
remove	ENTITY
potassium	ENTITY
.	O
diabetes	ENTITY
and	ENTITY
migraines	ENTITY
an	ENTITY
unlikely	ENTITY
combination	ENTITY
in	ENTITY
the	ENTITY
there	ENTITY
was	ENTITY
suggested	ENTITY
link	ENTITY
between	ENTITY
diabetes	ENTITY
and	ENTITY
migraines	ENTITY
.	O
it	O
was	O
simple	O
people	O
who	O
had	O
diabetes	ENTITY
were	ENTITY
less	ENTITY
likely	ENTITY
to	ENTITY
complain	ENTITY
about	ENTITY
migraines	ENTITY
diabetes	ENTITY
is	O
lifelong	O
condition	O
that	O
can	O
cause	O
person	O
blood	ENTITY
glucose	ENTITY
sugar	ENTITY
level	ENTITY
to	O
become	O
dangerously	O
high	O
it	O
affects	O
approx	O
million	O
people	O
in	O
the	O
uk	O
there	O
are	O
two	O
types	O
type	O
is	O
where	O
your	O
own	O
bodies	O
immune	ENTITY
system	ENTITY
cells	ENTITY
attack	ENTITY
and	O
destroy	O
the	O
cells	O
that	O
produce	O
insulin	ENTITY
the	ENTITY
hormone	ENTITY
that	ENTITY
reduces	ENTITY
your	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
type	O
is	O
where	O
your	O
body	O
either	O
doesn	O
produce	O
enough	O
insulin	ENTITY
or	ENTITY
your	ENTITY
cells	ENTITY
don	ENTITY
respond	ENTITY
to	ENTITY
insulin	ENTITY
in	ENTITY
both	ENTITY
circumstances	ENTITY
it	ENTITY
means	ENTITY
your	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
are	O
not	O
reduced	O
and	O
this	O
is	O
life	O
threatening	O
migraine	ENTITY
is	ENTITY
recurring	ENTITY
headache	ENTITY
that	ENTITY
feels	ENTITY
like	ENTITY
severe	ENTITY
throbbing	ENTITY
pain	ENTITY
on	O
one	O
side	O
of	O
the	O
head	O
symptoms	O
can	O
also	O
include	O
nausea	ENTITY
vomiting	ENTITY
and	ENTITY
an	ENTITY
increase	ENTITY
in	ENTITY
sensitivity	ENTITY
to	ENTITY
light	ENTITY
or	ENTITY
sound	ENTITY
.	O
it	O
affects	O
out	O
of	O
women	O
and	O
out	O
of	O
men	O
.	O
this	O
is	O
based	O
on	O
work	O
done	O
by	O
ippazio	O
antonazzo	O
at	O
the	O
university	O
of	O
bergen	O
in	O
norway	O
.	O
they	O
looked	O
at	O
the	O
drug	O
prescription	O
records	O
of	O
the	O
under	O
adult	O
population	O
of	O
norway	O
over	O
year	O
period	O
there	O
were	O
million	O
people	O
in	O
the	O
study	O
.	O
of	O
these	O
were	O
being	O
treated	O
for	O
type	O
diabetes	ENTITY
and	ENTITY
for	ENTITY
type	ENTITY
diabetes	ENTITY
they	ENTITY
then	ENTITY
looked	ENTITY
at	ENTITY
what	ENTITY
proportion	ENTITY
of	ENTITY
these	ENTITY
went	ENTITY
on	ENTITY
to	ENTITY
get	ENTITY
migraine	ENTITY
medication	ENTITY
compared	ENTITY
to	ENTITY
non	ENTITY
diabetics	ENTITY
their	ENTITY
finding	ENTITY
people	ENTITY
with	ENTITY
diabetes	ENTITY
were	ENTITY
less	ENTITY
likely	ENTITY
to	ENTITY
be	ENTITY
treated	ENTITY
for	ENTITY
migraine	ENTITY
what	ENTITY
they	ENTITY
did	ENTITY
not	ENTITY
know	ENTITY
if	ENTITY
it	ENTITY
was	ENTITY
the	ENTITY
disease	ENTITY
or	ENTITY
the	ENTITY
medication	ENTITY
that	ENTITY
meant	ENTITY
they	ENTITY
were	ENTITY
less	ENTITY
likely	ENTITY
to	ENTITY
develop	ENTITY
migraines	ENTITY
it	ENTITY
is	ENTITY
thought	ENTITY
that	ENTITY
the	ENTITY
nerve	ENTITY
damage	ENTITY
caused	O
by	O
diabetes	ENTITY
makes	ENTITY
it	ENTITY
much	ENTITY
more	ENTITY
difficult	ENTITY
to	ENTITY
sense	ENTITY
migraine	ENTITY
.	O
one	O
of	O
the	O
side	O
effects	O
of	O
diabetes	ENTITY
is	ENTITY
nerve	ENTITY
damage	ENTITY
reducing	O
sensation	O
in	O
the	O
hands	O
and	O
feet	O
this	O
may	O
also	O
occur	O
in	O
the	O
head	O
.	O
or	O
it	O
could	O
be	O
that	O
the	O
link	O
is	O
genetic	O
.	O
in	O
some	O
people	O
who	O
experience	O
migraines	ENTITY
they	ENTITY
have	ENTITY
mutation	ENTITY
in	ENTITY
gene	ENTITY
that	ENTITY
codes	ENTITY
for	ENTITY
protein	ENTITY
which	ENTITY
is	ENTITY
sensitive	ENTITY
to	ENTITY
the	ENTITY
hormone	ENTITY
insulin	ENTITY
.	O
insulin	ENTITY
is	ENTITY
the	ENTITY
hormone	ENTITY
produced	ENTITY
when	ENTITY
your	ENTITY
blood	ENTITY
glucose	ENTITY
level	ENTITY
increases	O
and	O
this	O
is	O
what	O
is	O
missing	O
in	O
type	O
one	O
diabetes	ENTITY
and	ENTITY
not	ENTITY
detected	ENTITY
by	ENTITY
some	ENTITY
cells	ENTITY
in	ENTITY
type	ENTITY
diabetes	ENTITY
so	ENTITY
if	ENTITY
people	ENTITY
who	ENTITY
have	ENTITY
this	ENTITY
mutation	ENTITY
and	ENTITY
develop	ENTITY
migraines	ENTITY
.	O
diabetics	O
then	O
treating	O
diabetes	ENTITY
would	ENTITY
also	ENTITY
normalise	ENTITY
the	ENTITY
insulin	ENTITY
levels	ENTITY
and	O
decrease	O
the	O
occurrence	O
of	O
migraines	ENTITY
.	O
link	O
to	O
the	O
article	O
.	O
how	O
to	O
boost	O
insulin	ENTITY
.	O
the	O
answer	O
is	O
simple	O
current	O
diabetes	ENTITY
theory	ENTITY
is	ENTITY
false	ENTITY
and	ENTITY
so	ENTITY
are	ENTITY
its	ENTITY
treatments	ENTITY
.	O
as	O
the	O
proof	O
of	O
the	O
pudding	O
is	O
in	O
the	O
eating	O
.	O
unfortunately	O
the	O
medical	O
pudding	O
.	O
listen	O
why	O
.	O
medicine	O
diabetes	ENTITY
type	ENTITY
results	ENTITY
from	ENTITY
the	ENTITY
autoimmune	ENTITY
destruction	ENTITY
of	ENTITY
insulin	ENTITY
producing	ENTITY
beta	ENTITY
cells	ENTITY
in	O
the	O
pancreas	ENTITY
.	O
autoimmune	ENTITY
diseases	ENTITY
arise	O
from	O
an	O
abnormal	ENTITY
immune	ENTITY
response	ENTITY
of	O
the	O
body	O
against	O
substances	O
and	O
tissues	O
normally	O
present	O
in	O
the	O
body	O
autoimmunity	ENTITY
.	O
in	O
other	O
words	O
our	O
immune	ENTITY
system	ENTITY
which	O
protects	O
us	O
against	O
microbes	ENTITY
and	ENTITY
viruses	ENTITY
may	ENTITY
destroy	ENTITY
insulin	ENTITY
producing	ENTITY
beta	ENTITY
cells	ENTITY
.	O
did	O
it	O
occur	O
to	O
you	O
that	O
autoimmunity	ENTITY
is	ENTITY
strictly	ENTITY
human	ENTITY
disease	ENTITY
.	O
no	O
living	O
entity	O
with	O
an	O
immune	ENTITY
system	ENTITY
.	O
the	O
autoimmunity	ENTITY
.	O
this	O
false	O
theory	O
recommends	O
also	O
wrong	O
treatment	O
.	O
two	O
theories	O
viral	ENTITY
theory	ENTITY
virus	ENTITY
cell	ENTITY
destruction	ENTITY
lysis	ENTITY
necrosis	ENTITY
transforms	O
self	O
to	O
foreign	O
antigens	ENTITY
.	O
antigens	ENTITY
trigger	ENTITY
inflammation	ENTITY
and	ENTITY
repair	ENTITY
.	O
organism	O
may	O
regenerate	O
cells	O
auto	ENTITY
immunity	ENTITY
molecular	ENTITY
mimicry	ENTITY
confuses	O
immune	ENTITY
system	ENTITY
.	O
self	O
peptide	ENTITY
becomes	ENTITY
an	ENTITY
auto	ENTITY
antigen	ENTITY
auto	ENTITY
antigen	ENTITY
triggers	O
inflammation	ENTITY
.	O
inflammation	ENTITY
.	O
cells	O
.	O
organism	O
does	O
not	O
regenerate	O
cells	O
finally	O
explain	O
how	O
to	O
boost	O
insulin	ENTITY
.	O
if	O
you	O
know	O
someone	O
struggling	O
with	O
their	O
mental	O
health	O
digestion	O
is	O
typically	O
involved	O
in	O
the	O
process	O
.	O
this	O
case	O
study	O
demonstrates	O
the	O
power	O
and	O
efficacy	O
of	O
functional	O
medicine	O
.	O
landmark	O
discovery	O
about	O
how	O
insulin	ENTITY
docks	ENTITY
on	ENTITY
cells	ENTITY
could	O
help	O
in	O
the	O
development	O
of	O
improved	O
types	O
of	O
insulin	ENTITY
.	O
associate	O
professor	O
mike	O
lawrence	O
from	O
the	O
walter	O
and	O
eliza	O
hall	O
institute	O
in	O
melbourne	O
australia	O
explains	O
how	O
the	O
research	O
team	O
captured	O
the	O
intricate	O
way	O
in	O
which	O
insulin	ENTITY
uses	ENTITY
the	ENTITY
insulin	ENTITY
receptor	ENTITY
.	O
this	O
binding	O
is	O
necessary	O
for	O
the	O
cells	O
.	O
read	O
the	O
media	O
release	O
.	O
controlling	O
and	O
reversing	O
diabetes	ENTITY
solution	ENTITY
for	ENTITY
diabetes	ENTITY
must	ENTITY
address	ENTITY
important	ENTITY
health	ENTITY
items	ENTITY
the	ENTITY
elimination	ENTITY
of	ENTITY
excess	ENTITY
fat	ENTITY
surrounding	ENTITY
the	ENTITY
pancreas	ENTITY
the	ENTITY
regeneration	ENTITY
of	ENTITY
healthy	ENTITY
cells	ENTITY
removing	ENTITY
any	ENTITY
unhealthy	ENTITY
or	ENTITY
abnormal	ENTITY
cells	ENTITY
restoring	O
strong	O
signaling	O
and	O
communication	O
between	O
cells	O
phytotherapi	ENTITY
diabetes	ENTITY
solution	O
includes	O
tools	O
that	O
address	O
these	O
important	O
items	O
while	O
also	O
including	O
specific	O
nutritional	O
guidelines	O
so	O
that	O
the	O
body	O
.	O
these	O
tools	O
include	O
phytotherapi	ENTITY
diabetes	ENTITY
.	O
phytotherapi	ENTITY
diabetes	ENTITY
is	O
made	O
from	O
blend	O
of	O
phytochemicals	ENTITY
that	ENTITY
helps	ENTITY
support	ENTITY
the	ENTITY
pancreas	ENTITY
ability	ENTITY
to	ENTITY
perform	ENTITY
.	O
phytotherapi	ENTITY
diabetes	ENTITY
also	O
helps	O
minimize	O
the	O
inflammation	ENTITY
.	O
phytotherapi	ENTITY
stress	ENTITY
is	O
used	O
to	O
help	O
put	O
our	O
brain	ENTITY
biochemistry	ENTITY
back	ENTITY
into	ENTITY
balance	ENTITY
.	O
by	O
addressing	O
stress	O
good	O
intestinal	ENTITY
bacteria	ENTITY
are	ENTITY
strengthened	ENTITY
so	ENTITY
they	ENTITY
can	ENTITY
play	ENTITY
their	ENTITY
important	ENTITY
role	ENTITY
in	ENTITY
the	ENTITY
digestive	ENTITY
process	ENTITY
.	O
metabolic	ENTITY
therapi	ENTITY
supports	ENTITY
the	ENTITY
body	ENTITY
ability	ENTITY
to	ENTITY
map	ENTITY
out	ENTITY
excess	ENTITY
fat	ENTITY
so	ENTITY
that	ENTITY
the	ENTITY
body	ENTITY
.	O
renewal	O
therapi	O
aids	O
.	O
through	O
strengthening	O
signaling	O
the	O
body	O
can	O
eliminate	O
abnormal	ENTITY
cells	ENTITY
repair	O
sick	O
.	O
renewal	O
therapi	O
contains	O
perfect	O
mix	O
of	O
molecules	ENTITY
that	ENTITY
enhance	ENTITY
the	ENTITY
communication	ENTITY
passages	ENTITY
between	ENTITY
cells	ENTITY
in	ENTITY
tissues	ENTITY
allowing	ENTITY
quick	ENTITY
response	ENTITY
for	ENTITY
regeneration	ENTITY
.	O
essential	O
therapi	O
provides	O
the	O
full	O
amount	O
of	O
essential	O
minerals	O
the	O
body	O
needs	O
for	O
cellular	ENTITY
.	O
herbal	O
therapi	O
keeps	O
cells	O
healthy	O
by	O
supporting	O
insulin	ENTITY
production	ENTITY
and	ENTITY
helping	ENTITY
lower	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
.	O
since	O
what	O
we	O
eat	O
has	O
direct	O
correlation	O
to	O
how	O
the	O
body	O
functions	O
and	O
heals	O
proper	O
nutrition	O
is	O
vital	O
in	O
helping	O
the	O
body	O
reverse	O
diabetes	ENTITY
.	O
due	O
to	O
how	O
powerful	O
food	O
can	O
be	O
in	O
improving	O
health	O
we	O
ve	O
created	O
nutritional	O
guide	O
that	O
helps	O
create	O
the	O
environment	O
necessary	O
for	O
the	O
body	O
to	O
heal	O
and	O
repair	O
.	O
this	O
nutritional	O
guide	O
.	O
through	O
following	O
the	O
program	O
many	O
individuals	O
have	O
seen	O
improvements	O
in	O
their	O
health	O
energy	O
levels	O
and	O
an	O
overall	O
renewed	O
sense	O
of	O
life	O
as	O
they	O
ve	O
seen	O
and	O
felt	O
the	O
health	O
of	O
their	O
body	O
.	O
diabetes	ENTITY
insulin	ENTITY
and	O
the	O
pancreas	ENTITY
diabetes	ENTITY
is	O
disease	ENTITY
that	ENTITY
isn	ENTITY
manifested	ENTITY
until	ENTITY
conditions	ENTITY
.	O
diabetes	ENTITY
impedes	ENTITY
the	ENTITY
body	ENTITY
.	O
it	O
important	O
to	O
remember	O
that	O
most	O
of	O
the	O
nutrients	O
we	O
eat	O
are	O
converted	O
into	O
sugar	O
.	O
the	O
sugar	O
.	O
the	O
pancreas	ENTITY
is	ENTITY
an	ENTITY
organ	ENTITY
that	ENTITY
makes	ENTITY
insulin	ENTITY
to	ENTITY
help	ENTITY
transport	ENTITY
glucose	ENTITY
sugar	ENTITY
.	O
when	O
too	O
much	O
sugar	O
is	O
present	O
the	O
pancreas	ENTITY
continues	ENTITY
to	ENTITY
produce	ENTITY
insulin	ENTITY
and	ENTITY
the	ENTITY
liver	ENTITY
does	ENTITY
its	ENTITY
job	ENTITY
of	ENTITY
converting	ENTITY
excess	ENTITY
sugar	ENTITY
into	ENTITY
fat	ENTITY
.	O
this	O
fat	ENTITY
is	ENTITY
then	ENTITY
stored	ENTITY
against	ENTITY
organs	ENTITY
including	ENTITY
the	ENTITY
pancreas	ENTITY
.	O
these	O
conditions	O
lead	O
.	O
first	O
overproduction	O
of	O
insulin	ENTITY
causes	ENTITY
an	ENTITY
overload	ENTITY
of	ENTITY
work	ENTITY
which	ENTITY
leads	ENTITY
to	ENTITY
the	ENTITY
body	ENTITY
inability	ENTITY
to	ENTITY
produce	ENTITY
more	ENTITY
insulin	ENTITY
or	ENTITY
use	ENTITY
the	ENTITY
existing	ENTITY
insulin	ENTITY
.	O
second	O
overabundance	O
of	O
fat	ENTITY
around	ENTITY
the	ENTITY
pancreas	ENTITY
leads	ENTITY
to	ENTITY
trauma	ENTITY
and	ENTITY
damage	ENTITY
.	O
pancreatic	ENTITY
cells	ENTITY
become	O
sick	O
and	O
are	O
unable	O
to	O
create	O
good	O
insulin	ENTITY
.	O
initially	O
any	O
healthy	O
cells	O
make	O
up	O
for	O
sick	O
ones	O
by	O
doubling	O
efforts	O
to	O
create	O
the	O
amount	O
of	O
insulin	ENTITY
.	O
this	O
is	O
why	O
early	O
detection	O
of	O
diabetes	ENTITY
.	O
once	O
diabetes	ENTITY
.	O
sugar	O
continues	O
to	O
build	O
up	O
leading	O
to	O
nerve	ENTITY
damage	ENTITY
.	O
additional	O
complications	O
include	O
kidney	ENTITY
failure	ENTITY
lsos	O
of	O
sight	O
lower	O
extremity	O
amputations	ENTITY
and	ENTITY
heart	ENTITY
and	ENTITY
digestive	ENTITY
problems	ENTITY
.	O
visit	O
https	O
drschoiceweightloss	O
com	O
.	O
to	O
age	O
or	O
not	O
to	O
age	O
documentary	O
by	O
leslie	O
kenton	O
from	O
leslie	O
kenton	O
cura	O
romana	O
.	O
like	O
this	O
.	O
watch	O
the	O
latest	O
episode	O
of	O
leslie	O
kenton	O
cura	O
romana	O
on	O
blip	O
.	O
kentons	O
cura	O
romana	O
.	O
margo	O
hudson	O
md	O
co	O
director	O
polycystic	ENTITY
ovary	ENTITY
syndrome	ENTITY
program	O
in	O
the	O
fish	O
center	O
for	O
women	O
health	O
at	O
brigham	O
and	O
women	O
hospital	O
describes	O
causes	O
symptoms	O
and	O
treatment	O
for	O
polycystic	ENTITY
ovary	ENTITY
syndrome	ENTITY
.	O
polycystic	ENTITY
ovary	ENTITY
syndrome	ENTITY
pcos	O
is	O
group	O
of	O
symptoms	O
rather	O
than	O
specific	O
disease	ENTITY
.	O
while	O
the	O
ovaries	ENTITY
may	ENTITY
develop	ENTITY
cysts	ENTITY
that	ENTITY
is	ENTITY
not	ENTITY
necessary	ENTITY
for	ENTITY
the	ENTITY
diagnosis	ENTITY
of	ENTITY
pcos	ENTITY
.	O
many	O
patients	O
who	O
have	O
pcos	ENTITY
are	ENTITY
overweight	ENTITY
or	ENTITY
obese	ENTITY
.	O
it	O
is	O
one	O
of	O
the	O
most	O
common	O
hormonal	ENTITY
and	ENTITY
reproductive	ENTITY
conditions	ENTITY
.	O
the	O
primary	O
cause	O
of	O
pcos	ENTITY
may	ENTITY
be	ENTITY
due	ENTITY
to	ENTITY
abnormal	ENTITY
production	ENTITY
of	ENTITY
certain	ENTITY
hormones	ENTITY
in	ENTITY
the	ENTITY
brain	ENTITY
.	O
this	O
disruption	O
leads	O
to	O
an	O
increase	O
in	O
the	O
production	O
of	O
male	ENTITY
hormones	ENTITY
such	O
as	O
testosterone	ENTITY
and	ENTITY
inhibition	ENTITY
of	ENTITY
ovulation	ENTITY
.	O
the	O
most	O
common	O
symptom	O
of	O
pcos	ENTITY
.	O
other	O
symptoms	O
include	O
acne	ENTITY
cardiovascular	ENTITY
disease	ENTITY
excessive	O
body	O
hair	O
particularly	O
facial	O
hair	O
infertility	O
insulin	ENTITY
resistance	ENTITY
or	O
pre	ENTITY
diabetes	ENTITY
.	O
because	O
women	O
with	O
pcos	ENTITY
can	ENTITY
exhibit	ENTITY
variety	ENTITY
of	ENTITY
symptoms	ENTITY
.	O
treatment	O
is	O
tailored	O
according	O
to	O
the	O
particular	O
symptoms	O
.	O
medical	O
therapies	O
are	O
often	O
used	O
to	O
regulate	O
menstrual	ENTITY
cycles	ENTITY
reduce	O
testosterone	ENTITY
levels	ENTITY
lower	O
insulin	ENTITY
levels	ENTITY
improve	O
insulin	ENTITY
sensitivity	ENTITY
and	O
eliminate	O
unwanted	ENTITY
hair	ENTITY
.	O
nutrition	O
education	O
will	O
help	O
reduce	O
excess	O
weight	O
.	O
located	O
at	O
the	O
gretchen	O
and	O
edward	O
fish	O
center	O
for	O
women	O
health	O
in	O
the	O
brigham	O
and	O
women	O
health	O
care	O
center	O
in	O
excess	O
weight	O
hill	O
the	O
polycystic	ENTITY
ovary	ENTITY
syndrome	ENTITY
program	O
brings	O
together	O
experts	O
in	O
gynecology	ENTITY
endocrinology	ENTITY
dermatology	ENTITY
nutrition	ENTITY
and	O
other	O
specialties	O
to	O
deliver	O
comprehensive	O
individualized	O
and	O
coordinated	O
care	O
for	O
women	O
with	O
pcos	ENTITY
.	O
learn	O
more	O
about	O
the	O
polycystic	ENTITY
ovary	ENTITY
syndrome	ENTITY
program	O
at	O
brigham	O
and	O
women	O
hospital	O
polycystic	ENTITY
ovary	ENTITY
syndrome	ENTITY
.	O
ndsu	ENTITY
virtual	ENTITY
cell	ENTITY
.	O
for	O
more	O
information	O
please	O
see	O
.	O
when	O
high	O
levels	O
of	O
glucose	ENTITY
enter	ENTITY
the	ENTITY
blood	ENTITY
stream	ENTITY
insulin	ENTITY
is	O
released	O
by	O
beta	ENTITY
cells	ENTITY
in	O
the	O
pancreas	ENTITY
.	O
insulin	ENTITY
then	ENTITY
initiates	ENTITY
number	ENTITY
of	ENTITY
signal	ENTITY
pathways	ENTITY
in	ENTITY
specific	ENTITY
muscle	ENTITY
and	ENTITY
fat	ENTITY
cells	ENTITY
.	O
this	O
takes	O
look	O
at	O
the	O
signal	O
pathway	O
responsible	O
for	O
allowing	O
those	O
cells	O
to	O
rapidly	O
increase	O
their	O
ability	O
to	O
uptake	O
glucose	ENTITY
from	ENTITY
the	ENTITY
blood	ENTITY
stream	ENTITY
.	O
http	O
www	O
diaberex	O
com	O
diabetes	ENTITY
mellitus	ENTITY
or	O
dm	ENTITY
is	ENTITY
disease	ENTITY
affecting	ENTITY
multi	ENTITY
organ	ENTITY
.	O
it	O
is	O
very	O
serious	O
health	O
problem	O
throughout	O
the	O
world	O
effecting	O
thousands	O
of	O
people	O
survey	O
conducted	O
in	O
united	O
states	O
showed	O
that	O
almost	O
of	O
the	O
population	O
suffers	O
.	O
it	O
is	O
matter	O
of	O
great	O
issue	O
that	O
almost	O
one	O
third	O
of	O
the	O
population	O
is	O
unaware	O
of	O
the	O
disease	ENTITY
.	O
what	O
is	O
diabetes	ENTITY
.	O
diabetes	ENTITY
is	ENTITY
disease	ENTITY
in	ENTITY
which	ENTITY
the	ENTITY
body	ENTITY
ability	ENTITY
to	ENTITY
produce	ENTITY
or	ENTITY
respond	ENTITY
to	ENTITY
the	ENTITY
hormone	ENTITY
insulin	ENTITY
is	O
impaired	O
resulting	O
in	O
abnormal	O
metabolism	ENTITY
of	ENTITY
carbohydrates	ENTITY
and	ENTITY
elevated	ENTITY
levels	ENTITY
of	ENTITY
glucose	ENTITY
.	O
how	O
to	O
cure	O
diabetes	ENTITY
.	O
controlling	O
blood	ENTITY
sugar	ENTITY
through	O
diet	O
oral	O
medications	O
or	O
insulin	ENTITY
is	ENTITY
the	ENTITY
main	ENTITY
treatment	ENTITY
.	O
regular	O
screening	O
for	O
complications	O
.	O
but	O
here	O
is	O
my	O
story	O
and	O
how	O
cured	O
diabetes	ENTITY
.	O
was	O
pre	ENTITY
diabetic	ENTITY
and	O
came	O
dangerously	O
close	O
but	O
with	O
getting	O
back	O
on	O
track	O
and	O
taking	O
skinny	O
body	O
max	O
regularly	O
was	O
able	O
to	O
treat	O
my	O
condition	O
.	O
skinny	O
fiber	O
is	O
something	O
fairly	O
new	O
and	O
it	O
has	O
helped	O
millions	O
of	O
people	O
get	O
back	O
in	O
shape	O
.	O
many	O
of	O
the	O
key	O
ingredients	O
in	O
this	O
supplement	O
were	O
featured	O
on	O
the	O
dr	O
.	O
for	O
more	O
information	O
go	O
to	O
.	O
blog	O
www	O
monicayearwood	O
com	O
product	O
line	O
www	O
hamsaapothecary	O
com	O
ayurvedic	O
center	O
www	O
hamsacenter	O
com	O
description	O
of	O
ayurveda	O
resistance	O
pcos	ENTITY
diabetes	ENTITY
thyroid	ENTITY
disease	ENTITY
when	O
we	O
consume	O
carbohydrates	ENTITY
weather	ENTITY
steamed	ENTITY
potato	ENTITY
or	ENTITY
candy	ENTITY
bar	ENTITY
our	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
to	O
bring	O
blood	ENTITY
sugar	ENTITY
back	O
to	O
normal	O
the	O
pancreas	ENTITY
pumps	ENTITY
insulin	ENTITY
.	O
when	O
we	O
continuously	O
cause	O
blood	ENTITY
sugar	ENTITY
to	O
spike	O
through	O
our	O
food	O
choices	O
the	O
pancreas	ENTITY
goes	ENTITY
into	ENTITY
overdrive	ENTITY
shooting	ENTITY
too	ENTITY
much	ENTITY
insulin	ENTITY
.	O
now	O
blood	ENTITY
sugar	ENTITY
drops	O
too	O
low	O
and	O
our	O
adrenal	O
fight	O
or	O
flight	O
hormones	ENTITY
are	ENTITY
called	ENTITY
in	ENTITY
by	ENTITY
the	ENTITY
hypothalamus	ENTITY
.	O
the	O
adrenal	ENTITY
glands	ENTITY
recognize	O
low	ENTITY
blood	ENTITY
sugar	ENTITY
as	O
threat	O
and	O
send	O
hormones	ENTITY
out	ENTITY
to	ENTITY
boost	ENTITY
it	ENTITY
but	ENTITY
these	ENTITY
hormones	ENTITY
.	O
chronic	O
low	O
or	O
high	ENTITY
blood	ENTITY
sugars	ENTITY
are	O
gateways	O
to	O
diabetes	ENTITY
.	O
dysglycemia	ENTITY
condition	ENTITY
in	ENTITY
which	ENTITY
the	ENTITY
body	ENTITY
loses	ENTITY
the	ENTITY
ability	ENTITY
to	ENTITY
keep	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
many	O
folks	O
in	O
our	O
modern	O
world	O
are	O
on	O
the	O
verge	O
of	O
full	O
blown	O
diabetes	ENTITY
and	ENTITY
often	ENTITY
unbeknownst	ENTITY
to	ENTITY
them	ENTITY
are	ENTITY
suffering	ENTITY
.	O
dysglycemia	ENTITY
and	ENTITY
its	ENTITY
effects	ENTITY
on	ENTITY
adrenal	ENTITY
function	ENTITY
are	O
at	O
the	O
threshold	O
of	O
many	O
health	O
conditions	O
including	O
diabetes	ENTITY
weakened	ENTITY
digestion	ENTITY
inflammation	ENTITY
in	ENTITY
the	ENTITY
gut	ENTITY
adrenal	ENTITY
exhaustion	ENTITY
hormonal	ENTITY
imbalances	ENTITY
weight	O
gain	O
and	O
inability	O
to	O
properly	O
detoxify	ENTITY
the	ENTITY
body	ENTITY
.	O
ayurveda	O
albicans	O
is	O
called	O
krumi	O
parasite	O
and	O
therefore	O
treated	O
as	O
parasitic	ENTITY
infection	ENTITY
.	O
systemic	ENTITY
albicans	ENTITY
infection	ENTITY
.	O
currently	O
candidas	O
overgrowth	O
is	O
the	O
fourth	O
most	O
prominent	O
bloodstream	ENTITY
infection	ENTITY
.	O
it	O
takes	O
time	O
to	O
grow	O
in	O
the	O
body	O
.	O
like	O
many	O
gut	ENTITY
imbalances	ENTITY
albicans	ENTITY
manifests	ENTITY
when	ENTITY
pathogenic	ENTITY
opportunity	ENTITY
is	ENTITY
coupled	ENTITY
with	ENTITY
weakened	ENTITY
immunity	ENTITY
.	O
albicans	O
is	O
heavily	O
linked	O
to	O
pharmaceuticals	ENTITY
that	ENTITY
decrease	ENTITY
gut	ENTITY
flora	ENTITY
such	O
as	O
antibiotics	ENTITY
muscle	ENTITY
relaxants	ENTITY
painkillers	ENTITY
acne	ENTITY
medications	ENTITY
and	ENTITY
oral	ENTITY
birth	ENTITY
control	ENTITY
pills	ENTITY
.	O
poor	O
diet	O
such	O
as	O
processed	O
foods	O
caffeine	O
and	O
alcohol	O
destroys	O
beneficial	O
gut	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
also	O
simply	O
known	O
as	O
diabetes	ENTITY
.	O
it	O
is	O
the	O
disease	ENTITY
characterized	ENTITY
by	ENTITY
malfunctioning	ENTITY
metabolism	ENTITY
and	ENTITY
high	ENTITY
blood	ENTITY
sugar	ENTITY
level	ENTITY
.	O
the	O
result	O
can	O
be	O
low	O
levels	ENTITY
of	ENTITY
insulin	ENTITY
or	O
abnormal	O
insulin	ENTITY
resistance	ENTITY
.	O
this	O
mixed	O
with	O
inadequate	O
levels	ENTITY
of	ENTITY
insulin	ENTITY
secretion	O
results	O
in	O
diabetes	ENTITY
.	O
symptoms	O
of	O
diabetes	ENTITY
mellitus	ENTITY
include	O
increased	O
urine	ENTITY
production	ENTITY
excessive	O
thirst	O
extreme	O
fatigue	O
and	O
excessive	O
thirst	O
and	O
weight	O
loss	O
.	O
these	O
symptoms	O
though	O
may	O
not	O
be	O
present	O
in	O
those	O
people	O
with	O
only	O
mildly	O
elevated	O
sugar	O
.	O
diabetes	ENTITY
mellitus	ENTITY
includes	O
type	O
type	O
and	O
gestational	ENTITY
diabetes	ENTITY
which	O
occur	O
only	O
during	O
pregnancy	O
.	O
each	O
type	O
has	O
different	O
cause	O
and	O
different	O
severity	O
of	O
symptoms	O
.	O
clear	O
formulation	O
should	O
be	O
drawn	O
into	O
syringe	ENTITY
.	O
pre	O
mixed	O
insulin	ENTITY
which	ENTITY
is	ENTITY
nph	ENTITY
pre	ENTITY
with	ENTITY
either	ENTITY
regular	ENTITY
human	ENTITY
or	ENTITY
rapid	ENTITY
acting	ENTITY
analog	ENTITY
if	ENTITY
mixing	ENTITY
nph	ENTITY
should	ENTITY
be	ENTITY
drawn	ENTITY
into	ENTITY
syringe	ENTITY
.	O
comparison	O
of	O
insulin	ENTITY
glargine	ENTITY
versus	O
nph	ENTITY
in	ENTITY
people	ENTITY
with	ENTITY
type	ENTITY
diabetes	ENTITY
mellitus	ENTITY
under	O
outpatient	O
clinic	O
conditions	O
for	O
months	O
using	O
basal	O
bolus	ENTITY
regimen	ENTITY
.	O
nph	ENTITY
or	ENTITY
insulin	ENTITY
would	ENTITY
be	ENTITY
taken	ENTITY
with	ENTITY
breakfast	ENTITY
and	ENTITY
before	ENTITY
bed	ENTITY
for	ENTITY
better	ENTITY
fasting	ENTITY
glucose	ENTITY
levels	ENTITY
however	O
instead	O
of	O
giving	O
it	O
at	O
bed	O
may	O
given	O
dinner	O
also	O
however	O
these	O
pills	O
are	O
not	O
insulin	ENTITY
several	ENTITY
companies	ENTITY
make	ENTITY
many	ENTITY
different	ENTITY
types	ENTITY
insulins	ENTITY
.	O
it	O
is	O
cluster	O
of	O
metabolic	ENTITY
disorders	ENTITY
exemplified	O
by	O
abnormal	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
due	O
to	O
deficient	O
secretion	O
insulin	ENTITY
and	ENTITY
action	ENTITY
or	ENTITY
both	ENTITY
oct	ENTITY
nph	ENTITY
human	ENTITY
which	ENTITY
has	ENTITY
an	ENTITY
onset	ENTITY
effect	ENTITY
hours	ENTITY
peak	ENTITY
duration	ENTITY
.	O
humulin	ENTITY
.	O
the	O
daily	O
doses	O
presented	O
below	O
are	O
expressed	O
as	O
the	O
total	O
units	O
kg	O
day	O
of	O
all	O
insulin	ENTITY
.	O
feb	O
difference	O
between	O
nph	ENTITY
and	ENTITY
regular	ENTITY
insulin	ENTITY
.	O
mixture	O
should	O
be	O
given	O
immediately	O
to	O
avoid	O
effects	O
on	O
peak	O
action	O
mar	O
the	O
you	O
take	O
at	O
bed	O
will	O
work	O
during	O
night	O
help	O
regular	O
your	O
morning	O
glucose	ENTITY
levels	ENTITY
.	O
difference	O
between	O
nph	ENTITY
and	ENTITY
regular	ENTITY
insulin	ENTITY
.	O
hm	O
is	O
mixture	O
of	O
regular	ENTITY
insulin	ENTITY
.	O
humulin	ENTITY
hoursmay	ENTITY
be	ENTITY
mixed	ENTITY
with	ENTITY
nph	ENTITY
in	ENTITY
same	ENTITY
syringe	ENTITY
.	O
detemir	ENTITY
levemir	ENTITY
moreover	ENTITY
nph	ENTITY
and	ENTITY
lente	ENTITY
insulins	ENTITY
differ	O
in	O
their	O
ability	O
to	O
form	O
stable	O
mixtures	O
with	O
neutral	ENTITY
insulin	ENTITY
.	O
googleusercontent	O
search	O
.	O
highly	O
purified	O
porcine	O
nph	ENTITY
and	ENTITY
the	ENTITY
lente	ENTITY
like	ENTITY
insulin	ENTITY
preparation	ENTITY
.	O
you	O
should	O
have	O
small	O
bed	O
time	O
snack	O
.	O
regular	ENTITY
insulin	ENTITY
onset	O
is	O
to	O
hour	O
peak	O
hours	O
and	O
duration	O
.	O
regular	ENTITY
novolin	ENTITY
insulin	ENTITY
nph	O
difference	O
between	O
differencebetween	O
difference	O
nph	ENTITY
and	ENTITY
regular	ENTITY
insulin	ENTITY
.	O
webcache	O
.	O
humulin	ENTITY
.	O
difference	O
between	O
nph	ENTITY
and	ENTITY
regular	ENTITY
insulin	ENTITY
.	O
novolog	O
.	O
mixing	O
your	O
need	O
for	O
insulin	ENTITY
is	ENTITY
different	ENTITY
from	ENTITY
other	ENTITY
people	ENTITY
with	ENTITY
diabetes	ENTITY
.	O
rapid	O
acting	O
such	O
as	O
humalog	ENTITY
.	O
insulin	ENTITY
nph	ENTITY
and	O
insulin	ENTITY
regular	ENTITY
combination	ENTITY
product	ENTITY
is	ENTITY
not	ENTITY
intended	ENTITY
for	ENTITY
initial	ENTITY
therapy	ENTITY
.	O
the	O
type	ENTITY
of	ENTITY
insulin	ENTITY
you	O
take	O
and	O
when	O
it	O
therapy	O
.	O
jun	O
long	ENTITY
acting	ENTITY
insulin	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
long	O
term	O
condition	O
linked	O
with	O
irregularly	O
high	O
levels	O
of	O
glucose	ENTITY
or	ENTITY
sugar	ENTITY
within	ENTITY
the	ENTITY
blood	ENTITY
.	O
difference	O
between	O
insulin	ENTITY
regular	ENTITY
and	ENTITY
nph	ENTITY
.	O
nph	ENTITY
an	ENTITY
overview	ENTITY
mixing	ENTITY
insulins	ENTITY
units	ENTITY
of	ENTITY
nph	ENTITY
understanding	ENTITY
premixed	ENTITY
nph	ENTITY
.	O
what	O
the	O
difference	O
between	O
human	ENTITY
insulin	ENTITY
vs	O
soluble	ENTITY
insulin	ENTITY
.	O
dos	O
.	O
diabetes	ENTITY
.	O
but	O
through	O
insulin	ENTITY
.	O
know	O
more	O
about	O
this	O
treatment	O
and	O
how	O
it	O
works	O
for	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
good	O
morning	O
kuya	O
segment	O
usapang	O
pangkalusugan	O
aired	O
march	O
.	O
gmk	O
.	O
for	O
more	O
info	O
visit	O
.	O
normal	O
and	O
elevated	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
.	O
psychiatric	ENTITY
noise	ENTITY
mentally	ENTITY
abnormal	ENTITY
antimusic	ENTITY
.	O
vivian	O
fonseca	O
md	O
robert	O
henry	O
md	O
julio	O
rosenstock	O
md	O
peter	O
salgo	O
md	O
and	O
carol	O
wysham	O
md	O
review	O
the	O
risks	O
and	O
benefits	O
of	O
early	O
insulin	ENTITY
.	O
what	O
is	O
type	O
diabetes	ENTITY
.	O
type	O
diabetes	ENTITY
is	ENTITY
condition	ENTITY
in	ENTITY
which	ENTITY
your	ENTITY
body	ENTITY
has	ENTITY
high	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
how	O
does	O
your	O
blood	ENTITY
sugar	ENTITY
.	O
if	O
you	O
have	O
insulin	ENTITY
resistance	ENTITY
your	O
insulin	ENTITY
cannot	ENTITY
unlock	ENTITY
the	ENTITY
cells	ENTITY
to	ENTITY
let	ENTITY
glucose	ENTITY
in	ENTITY
because	ENTITY
the	ENTITY
locks	ENTITY
called	ENTITY
the	ENTITY
receptors	ENTITY
.	O
as	O
result	O
glucose	ENTITY
is	ENTITY
locked	ENTITY
out	ENTITY
up	ENTITY
of	ENTITY
your	ENTITY
cells	ENTITY
.	O
consequently	O
the	O
amount	O
of	O
glucose	ENTITY
builds	ENTITY
up	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
stream	ENTITY
in	O
condition	O
called	O
hyperglycaemia	ENTITY
.	O
how	O
do	O
we	O
lose	O
the	O
ability	O
to	O
create	O
insulin	ENTITY
.	O
to	O
compensate	O
for	O
hyperglycaemia	ENTITY
your	ENTITY
pancreas	ENTITY
produces	ENTITY
more	ENTITY
and	ENTITY
more	ENTITY
insulin	ENTITY
.	O
your	O
over	O
worked	O
beta	ENTITY
cells	ENTITY
try	O
to	O
keep	O
up	O
with	O
the	O
demand	O
but	O
gradually	O
lose	O
their	O
capability	O
to	O
produce	O
enough	O
insulin	ENTITY
.	O
if	O
you	O
don	O
receive	O
treatment	O
for	O
hyperglycaemia	ENTITY
it	ENTITY
can	ENTITY
result	ENTITY
in	ENTITY
diabetic	ENTITY
ketoacidosis	ENTITY
as	O
there	O
will	O
be	O
shortage	O
of	O
insulin	ENTITY
in	ENTITY
the	ENTITY
body	ENTITY
.	O
over	O
time	O
chronic	O
poorly	O
controlled	O
type	O
diabetes	ENTITY
can	ENTITY
cause	ENTITY
degenerative	ENTITY
tissue	ENTITY
damage	ENTITY
resulting	O
in	O
long	O
term	O
complications	O
such	O
as	O
atherosclerosis	ENTITY
blindness	ENTITY
neuropathy	ENTITY
heart	ENTITY
attack	ENTITY
and	O
renal	ENTITY
failure	ENTITY
.	O
diabetes	ENTITY
and	ENTITY
heart	ENTITY
disease	ENTITY
.	O
watch	O
the	O
video	O
to	O
know	O
more	O
about	O
the	O
causes	O
symptoms	ENTITY
diabetes	ENTITY
attack	O
and	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
manipal	O
hospitals	O
is	O
one	O
of	O
the	O
leading	O
healthcare	O
brands	O
in	O
india	O
.	O
we	O
are	O
invested	O
in	O
the	O
health	O
and	O
well	O
being	O
of	O
our	O
community	O
and	O
frequently	O
post	O
informational	O
videos	O
on	O
our	O
channel	O
in	O
order	O
to	O
create	O
awareness	O
.	O
subscribe	O
to	O
our	O
channel	O
at	O
.	O
angela	O
poff	O
phd	O
discusses	O
the	O
metabolic	ENTITY
origins	ENTITY
of	ENTITY
cancer	ENTITY
and	O
potential	ENTITY
anticancer	ENTITY
effects	O
of	O
ketones	ENTITY
.	O
get	O
in	O
touch	O
angela	O
key	O
takeaways	O
metabolism	ENTITY
.	O
cancer	ENTITY
cells	ENTITY
.	O
the	O
warburg	O
effect	O
almost	O
years	O
ago	O
otto	O
warburg	O
showed	O
that	O
cancer	ENTITY
cells	ENTITY
don	O
undergo	O
normal	O
energy	ENTITY
metabolism	ENTITY
.	O
oxygen	O
and	O
the	O
warburg	O
effect	O
this	O
process	O
occurs	O
whether	O
oxygen	O
.	O
in	O
normal	ENTITY
cells	ENTITY
we	O
utilize	O
lactate	O
fermentation	O
when	O
oxygen	O
.	O
cancer	ENTITY
cells	ENTITY
do	O
this	O
even	O
when	O
oxygen	O
.	O
mitochondrial	ENTITY
dysfunction	ENTITY
there	O
is	O
widespread	O
mitochondrial	ENTITY
dysfunction	ENTITY
in	O
cancer	ENTITY
.	O
cell	ENTITY
division	O
every	O
time	O
your	O
cell	O
divides	O
it	O
has	O
to	O
copy	O
its	O
dna	ENTITY
.	O
mistakes	O
will	O
be	O
made	O
but	O
we	O
have	O
repair	O
.	O
lactic	ENTITY
acid	ENTITY
and	O
cancer	O
the	O
cancer	O
field	O
views	O
aerobic	ENTITY
glycolysis	ENTITY
or	O
the	O
warburg	O
effect	O
as	O
beneficial	O
adaptation	O
.	O
fat	ENTITY
consumption	ENTITY
and	ENTITY
cancer	ENTITY
fatty	ENTITY
acids	ENTITY
and	O
ketone	ENTITY
bodies	ENTITY
are	O
converted	O
into	O
acetyl	ENTITY
coa	ENTITY
to	O
enter	O
the	O
metabolic	O
pathways	O
at	O
the	O
level	O
.	O
hypoxia	ENTITY
inducible	ENTITY
factor	ENTITY
.	O
in	O
order	O
to	O
grow	O
past	O
certain	O
size	O
the	O
tumor	ENTITY
needs	ENTITY
to	ENTITY
make	ENTITY
its	ENTITY
own	ENTITY
new	ENTITY
blood	ENTITY
vessels	ENTITY
.	O
the	O
chaos	O
makes	O
the	O
blood	ENTITY
vessel	ENTITY
network	ENTITY
.	O
hyperbaric	ENTITY
oxygen	ENTITY
therapy	ENTITY
at	O
sea	O
level	O
we	O
breathe	O
oxygen	O
.	O
in	O
hbot	O
oxygen	O
.	O
oxygen	ENTITY
free	ENTITY
radical	ENTITY
production	O
in	O
some	O
parts	O
of	O
the	O
tumor	ENTITY
there	ENTITY
may	ENTITY
be	ENTITY
no	ENTITY
oxygen	ENTITY
and	ENTITY
parts	ENTITY
of	ENTITY
the	ENTITY
tumor	ENTITY
may	ENTITY
die	ENTITY
.	O
radiation	ENTITY
therapy	ENTITY
and	O
oxygen	O
.	O
oxygen	O
therapies	O
for	O
treatment	O
and	O
prevention	O
mitochondria	ENTITY
membranes	ENTITY
healthy	O
functioning	O
mitochondria	ENTITY
act	ENTITY
.	O
by	O
preserving	O
mitochondrial	ENTITY
membrane	ENTITY
in	O
turn	O
helps	O
to	O
preserve	O
mitochondrial	ENTITY
function	ENTITY
.	O
well	O
formulated	O
ketogenic	ENTITY
diet	ENTITY
helps	O
with	O
cell	ENTITY
membrane	ENTITY
integrity	ENTITY
.	O
insulin	ENTITY
signaling	ENTITY
and	ENTITY
cancer	ENTITY
insulin	ENTITY
is	O
potent	O
.	O
many	O
cancer	O
types	O
upregulate	O
insulin	ENTITY
receptors	ENTITY
and	O
igf	ENTITY
receptors	ENTITY
.	O
insulin	ENTITY
.	O
ketogenic	ENTITY
diet	ENTITY
and	O
glucose	ENTITY
we	ENTITY
don	ENTITY
always	ENTITY
get	ENTITY
remarkable	ENTITY
drop	ENTITY
in	ENTITY
circulating	ENTITY
blood	ENTITY
glucose	ENTITY
.	O
pro	ENTITY
oxidant	ENTITY
.	O
cancer	ENTITY
cells	ENTITY
at	O
basal	O
level	O
operate	O
under	O
more	O
free	ENTITY
radicals	ENTITY
.	O
the	O
effects	O
of	O
ketones	ENTITY
.	O
they	O
have	O
very	O
important	O
signaling	O
and	O
functional	O
roles	O
in	O
our	O
cells	O
that	O
have	O
nothing	O
to	O
do	O
with	O
their	O
role	O
as	O
energy	O
metabolites	ENTITY
.	O
inflammation	ENTITY
it	ENTITY
is	ENTITY
huge	ENTITY
component	ENTITY
in	ENTITY
cancer	ENTITY
origination	ENTITY
and	ENTITY
progression	ENTITY
.	O
ketosis	ENTITY
is	ENTITY
anti	ENTITY
inflammatory	ENTITY
.	O
beta	ENTITY
hydroxybutyrate	ENTITY
inhibits	O
the	O
assembly	O
of	O
the	O
nlrp	ENTITY
inflammasome	ENTITY
that	ENTITY
is	ENTITY
activated	ENTITY
during	ENTITY
cancer	ENTITY
ageing	ENTITY
and	O
many	O
chronic	ENTITY
illnesses	ENTITY
that	O
incite	O
inflammation	ENTITY
.	O
ketones	ENTITY
and	ENTITY
the	ENTITY
alterations	ENTITY
in	ENTITY
oxidative	ENTITY
stress	ENTITY
ketone	ENTITY
metabolism	ENTITY
decreases	O
free	ENTITY
radical	ENTITY
production	ENTITY
reducing	O
oxidative	O
stress	O
and	O
increasing	O
antioxidant	O
.	O
ketones	ENTITY
and	ENTITY
glycolysis	ENTITY
some	ENTITY
data	ENTITY
suggests	ENTITY
that	ENTITY
ketones	ENTITY
can	ENTITY
inhibit	ENTITY
.	O
restoring	O
anti	ENTITY
tumor	ENTITY
immunity	ENTITY
the	O
ketogenic	ENTITY
diet	ENTITY
restores	O
anti	ENTITY
tumor	ENTITY
immunity	ENTITY
.	O
ketogenic	ENTITY
cancer	ENTITY
benefits	O
there	O
is	O
not	O
lot	O
of	O
human	O
data	O
on	O
the	O
ketogenic	ENTITY
diet	ENTITY
and	O
cancer	O
.	O
there	O
are	O
clinical	O
trials	O
registered	O
now	O
.	O
dr	O
.	O
exogenous	O
ketones	ENTITY
the	ENTITY
study	ENTITY
of	ENTITY
exogenous	ENTITY
ketones	ENTITY
.	O
they	O
have	O
had	O
therapeutic	ENTITY
effect	ENTITY
in	O
wide	O
variety	O
of	O
seizure	O
.	O
exogenous	O
ketones	ENTITY
are	ENTITY
something	ENTITY
that	ENTITY
you	ENTITY
consume	ENTITY
that	ENTITY
is	ENTITY
either	ENTITY
already	ENTITY
ketone	ENTITY
or	ENTITY
is	ENTITY
converted	ENTITY
into	ENTITY
ketones	ENTITY
in	ENTITY
your	ENTITY
body	ENTITY
or	ENTITY
releases	ENTITY
ketones	ENTITY
.	O
burn	O
carbohydrates	ENTITY
with	ENTITY
antioxidants	ENTITY
alpha	ENTITY
lipoic	ENTITY
acid	ENTITY
thomas	O
delauer	O
did	O
you	O
know	O
that	O
the	O
body	O
is	O
capable	O
of	O
producing	O
its	O
own	O
antioxidants	O
.	O
one	O
powerful	O
antioxidant	O
produced	O
by	O
the	O
body	O
is	O
alpha	ENTITY
lipoic	ENTITY
acid	ENTITY
.	O
alpha	ENTITY
lipoic	ENTITY
acid	ENTITY
is	O
found	O
in	O
every	O
cell	O
of	O
the	O
human	O
.	O
both	O
water	O
soluble	O
and	O
fat	O
soluble	O
so	O
able	O
to	O
act	O
throughout	O
the	O
body	O
.	O
antioxidants	O
attack	O
free	ENTITY
radicals	ENTITY
which	O
are	O
waste	O
products	O
that	O
occur	O
when	O
the	O
body	O
creates	O
energy	O
through	O
the	O
food	O
we	O
eat	O
.	O
free	ENTITY
radicals	ENTITY
can	O
also	O
come	O
from	O
exposure	O
to	O
toxins	ENTITY
and	ENTITY
pollutants	ENTITY
.	O
negative	O
effects	O
of	O
free	ENTITY
radicals	ENTITY
include	O
slows	O
metabolism	ENTITY
abnormal	ENTITY
cell	ENTITY
growth	ENTITY
and	O
proliferation	ENTITY
.	O
free	ENTITY
radicals	ENTITY
lead	O
to	O
cellular	ENTITY
damage	ENTITY
including	O
damage	O
to	O
organs	ENTITY
.	O
make	O
the	O
body	O
more	O
susceptible	O
to	O
infections	ENTITY
.	O
cancer	O
heart	ENTITY
disease	ENTITY
and	O
diabetes	ENTITY
.	O
how	O
else	O
can	O
ala	ENTITY
.	O
ala	ENTITY
for	ENTITY
fat	ENTITY
loss	O
and	O
building	O
muscle	ENTITY
multiple	ENTITY
studies	ENTITY
have	ENTITY
found	ENTITY
ala	ENTITY
.	O
one	O
study	O
followed	O
obese	ENTITY
diabetic	ENTITY
patients	ENTITY
for	ENTITY
weeks	ENTITY
with	ENTITY
either	ENTITY
mg	ENTITY
supplementation	ENTITY
of	ENTITY
ala	ENTITY
per	ENTITY
day	ENTITY
or	ENTITY
placebo	ENTITY
and	ENTITY
found	ENTITY
significant	ENTITY
effect	ENTITY
on	ENTITY
body	ENTITY
mass	ENTITY
index	ENTITY
and	ENTITY
triglyceride	ENTITY
levels	ENTITY
decreasing	O
bmi	O
and	O
triglyceride	ENTITY
levels	ENTITY
in	O
the	O
subjects	O
with	O
oral	O
ala	ENTITY
supplementation	ENTITY
.	O
protection	O
against	O
insulin	ENTITY
resistance	ENTITY
.	O
insulin	ENTITY
resistance	ENTITY
leads	O
to	O
decreased	O
glucose	ENTITY
uptake	ENTITY
in	ENTITY
fat	ENTITY
and	ENTITY
muscle	ENTITY
cells	ENTITY
.	O
ala	ENTITY
helps	ENTITY
to	ENTITY
turn	ENTITY
glucose	ENTITY
into	ENTITY
energy	ENTITY
or	ENTITY
fuel	ENTITY
for	ENTITY
your	ENTITY
body	ENTITY
through	ENTITY
insulin	ENTITY
signaling	ENTITY
when	ENTITY
insulin	ENTITY
binds	ENTITY
to	ENTITY
the	ENTITY
insulin	ENTITY
receptor	ENTITY
cascade	O
of	O
events	O
is	O
started	O
leading	O
to	O
increased	O
cellular	ENTITY
.	O
ala	ENTITY
has	ENTITY
been	ENTITY
shown	ENTITY
to	ENTITY
activate	ENTITY
this	ENTITY
cascade	ENTITY
of	ENTITY
events	ENTITY
leading	ENTITY
to	ENTITY
increased	ENTITY
glucose	ENTITY
uptake	ENTITY
in	ENTITY
fat	ENTITY
and	ENTITY
muscle	ENTITY
cells	ENTITY
.	O
this	O
is	O
done	O
not	O
through	O
an	O
effect	O
on	O
insulin	ENTITY
levels	ENTITY
but	O
by	O
triggering	O
the	O
same	O
sequence	O
of	O
events	O
leading	O
to	O
glucose	ENTITY
transport	ENTITY
for	ENTITY
energy	ENTITY
creation	ENTITY
.	O
ala	ENTITY
sort	ENTITY
of	ENTITY
mimics	ENTITY
insulin	ENTITY
.	O
studies	O
have	O
shown	O
that	O
this	O
shuttling	O
allows	O
more	O
glucose	ENTITY
to	ENTITY
enter	ENTITY
skeletal	ENTITY
muscle	ENTITY
cells	ENTITY
thus	O
more	O
glucose	ENTITY
burned	ENTITY
as	ENTITY
for	ENTITY
energy	ENTITY
more	ENTITY
energy	ENTITY
to	ENTITY
tear	ENTITY
and	ENTITY
rebuild	ENTITY
muscles	ENTITY
and	ENTITY
less	ENTITY
shuttled	ENTITY
to	ENTITY
be	ENTITY
stored	ENTITY
as	ENTITY
fat	ENTITY
.	O
when	O
more	O
glucose	ENTITY
is	ENTITY
delivered	ENTITY
to	ENTITY
muscle	ENTITY
cells	ENTITY
there	O
is	O
less	O
available	O
to	O
be	O
stored	O
as	O
fat	ENTITY
.	O
so	O
you	O
have	O
more	O
fuel	O
to	O
push	O
muscle	O
growth	O
and	O
less	O
glucose	ENTITY
stored	ENTITY
in	ENTITY
fat	ENTITY
cells	ENTITY
muscle	ENTITY
growth	ENTITY
and	ENTITY
less	ENTITY
fat	ENTITY
.	O
other	O
possible	O
uses	O
of	O
ala	ENTITY
ala	ENTITY
is	O
approved	O
in	O
germany	O
as	O
treatment	O
for	O
diabetes	ENTITY
and	ENTITY
for	ENTITY
symptoms	ENTITY
of	ENTITY
diabetes	ENTITY
.	O
cancer	O
memory	ENTITY
loss	ENTITY
chronic	ENTITY
fatigue	ENTITY
syndrome	ENTITY
hiv	ENTITY
aids	ENTITY
heart	ENTITY
disease	ENTITY
eye	O
related	O
disorders	O
how	O
to	O
add	O
alpha	ENTITY
lipoic	ENTITY
acid	ENTITY
to	O
your	O
diet	O
foods	O
high	O
in	O
ala	ENTITY
broccoli	ENTITY
spinach	ENTITY
potatoes	ENTITY
red	ENTITY
meat	ENTITY
organ	ENTITY
.	O
you	O
can	O
also	O
take	O
supplements	O
.	O
the	O
bioavailability	O
of	O
supplemental	O
ala	ENTITY
has	ENTITY
been	ENTITY
shown	ENTITY
to	ENTITY
be	ENTITY
much	ENTITY
greater	ENTITY
than	ENTITY
that	ENTITY
of	ENTITY
dietary	ENTITY
ala	ENTITY
you	ENTITY
can	ENTITY
take	ENTITY
about	ENTITY
mg	ENTITY
for	ENTITY
antioxidant	ENTITY
purposes	ENTITY
up	ENTITY
to	ENTITY
mg	ENTITY
per	ENTITY
day	ENTITY
for	ENTITY
diabetic	ENTITY
purposes	ENTITY
as	ENTITY
directed	ENTITY
.	O
mg	O
to	O
mg	O
daily	O
is	O
common	O
dose	O
.	O
this	O
is	O
often	O
recommended	O
to	O
be	O
taken	O
on	O
an	O
empty	O
stomach	O
.	O
references	O
alpha	ENTITY
lipoic	ENTITY
acid	ENTITY
.	O
ap	O
.	O
herniated	ENTITY
disk	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
danielle	O
novetsky	O
friedman	O
general	O
pediatrician	O
in	O
the	O
pediatric	O
long	O
term	O
follow	O
up	O
program	O
at	O
memorial	O
sloan	O
kettering	O
cancer	O
center	O
msk	O
discusses	O
study	O
investigating	O
the	O
mechanisms	O
leading	O
to	O
abnormal	O
glucose	ENTITY
and	ENTITY
insulin	ENTITY
.	O
health	O
tips	O
by	O
dr	O
.	O
diabetes	ENTITY
mellitus	ENTITY
causes	O
of	O
diabetes	ENTITY
mellitus	ENTITY
other	O
types	O
one	O
health	O
get	O
it	O
here	O
tag	O
one	O
health	O
diabetes	ENTITY
type	ENTITY
diabetes	ENTITY
diabetic	ENTITY
diet	ENTITY
diabetes	ENTITY
symptoms	ENTITY
symptoms	ENTITY
of	ENTITY
diabetes	ENTITY
type	ENTITY
diabetes	ENTITY
type	ENTITY
diabetes	ENTITY
symptoms	ENTITY
diabetic	ENTITY
coma	ENTITY
diabetic	ENTITY
retinopathy	ENTITY
glucose	ENTITY
test	ENTITY
prediabetes	ENTITY
glucometer	ENTITY
low	O
blood	ENTITY
sugar	ENTITY
pre	ENTITY
diabetic	ENTITY
diet	O
what	O
is	O
dm	O
diabetes	O
symptoms	O
in	O
women	O
diabetic	ENTITY
neuropathy	ENTITY
insulin	ENTITY
diabetes	ENTITY
definition	ENTITY
blood	ENTITY
sugar	ENTITY
range	O
insulin	ENTITY
pump	ENTITY
hyperglycemia	ENTITY
normal	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
prediabetes	ENTITY
symptoms	O
retinopathy	ENTITY
diabetes	ENTITY
insipidus	ENTITY
gestational	ENTITY
diabetes	ENTITY
diet	O
normal	O
glucose	ENTITY
levels	ENTITY
diabetic	O
foot	O
blood	ENTITY
sugar	ENTITY
chart	O
thanks	O
for	O
watching	O
.	O
if	O
video	O
good	O
please	O
like	O
share	O
and	O
comment	O
.	O
subscribe	O
to	O
dr	O
greger	O
free	O
nutrition	O
.	O
lesson	O
conducted	O
in	O
english	O
and	O
afrikaans	O
terminology	O
steps	O
in	O
insulin	ENTITY
.	O
series	O
brought	O
to	O
you	O
by	O
western	O
cape	O
education	O
department	O
fet	O
.	O
how	O
hypokalemia	ENTITY
causes	ENTITY
tachycardia	ENTITY
how	ENTITY
it	ENTITY
affects	ENTITY
resting	ENTITY
membrane	ENTITY
potential	ENTITY
.	O
electrolytes	ENTITY
disorders	ENTITY
.	O
this	O
video	O
and	O
other	O
related	O
images	O
videos	O
in	O
hd	O
are	O
available	O
for	O
instant	O
download	O
licensing	O
here	O
.	O
hypokalemia	ENTITY
may	ENTITY
result	ENTITY
from	ENTITY
increased	ENTITY
excretion	ENTITY
inadequate	ENTITY
intake	ENTITY
or	ENTITY
shift	ENTITY
of	ENTITY
potassium	ENTITY
from	ENTITY
the	ENTITY
extracellular	ENTITY
fluid	ENTITY
into	O
the	O
cells	O
.	O
most	O
commonly	O
hypokalemia	ENTITY
is	ENTITY
caused	ENTITY
by	ENTITY
excessive	ENTITY
loss	ENTITY
of	ENTITY
potassium	ENTITY
in	ENTITY
the	ENTITY
urine	ENTITY
from	ENTITY
the	ENTITY
gi	ENTITY
tract	ENTITY
or	O
skin	O
.	O
the	O
cause	O
is	O
usually	O
apparent	O
by	O
the	O
patient	O
history	O
of	O
predisposing	O
diseases	O
or	O
medication	O
.	O
urine	ENTITY
potassium	ENTITY
levels	ENTITY
are	O
measured	O
to	O
differentiate	O
between	O
renal	ENTITY
and	ENTITY
non	ENTITY
renal	ENTITY
.	O
symptoms	O
may	O
include	O
muscle	ENTITY
weakness	ENTITY
.	O
as	O
potassium	ENTITY
levels	ENTITY
decrease	O
in	O
the	O
extracellular	ENTITY
space	ENTITY
the	O
magnitude	O
of	O
the	O
potassium	ENTITY
.	O
this	O
moves	O
.	O
the	O
result	O
is	O
reduced	O
excitability	O
or	O
responsiveness	O
of	O
the	O
neurons	ENTITY
and	ENTITY
muscles	ENTITY
.	O
in	O
the	O
heart	ENTITY
.	O
this	O
is	O
because	O
hyper	ENTITY
polarization	ENTITY
enhances	O
the	O
funny	O
currents	O
in	O
cardiac	ENTITY
pacemaker	ENTITY
cells	ENTITY
.	O
the	O
effect	O
is	O
greatest	O
in	O
purkinje	ENTITY
fibers	ENTITY
as	O
these	O
are	O
more	O
sensitive	O
to	O
potassium	ENTITY
levels	ENTITY
as	O
compared	O
to	O
the	O
sa	ENTITY
node	ENTITY
.	O
increased	O
automaticity	O
of	O
purkinje	ENTITY
fibers	ENTITY
may	O
lead	O
to	O
the	O
development	O
of	O
one	O
or	O
more	O
ectopic	ENTITY
pacemaker	ENTITY
sites	O
in	O
the	O
ventricles	ENTITY
causing	ENTITY
ventricular	ENTITY
premature	ENTITY
beats	ENTITY
tachycardia	ENTITY
and	O
fibrillation	ENTITY
.	O
reduced	O
extracellular	ENTITY
potassium	ENTITY
also	O
inhibits	O
.	O
as	O
hypokalemia	ENTITY
becomes	ENTITY
more	ENTITY
severe	ENTITY
especially	ENTITY
in	ENTITY
patients	ENTITY
with	ENTITY
other	ENTITY
heart	ENTITY
conditions	ENTITY
.	O
prolonged	O
repolarization	O
may	O
also	O
promote	O
re	ENTITY
entrant	ENTITY
arrhythmias	ENTITY
.	O
early	O
ecg	O
changes	O
.	O
these	O
include	O
flattening	O
or	O
inversion	O
of	O
wave	O
increasingly	O
prominent	O
wave	O
st	O
segment	O
depression	O
and	O
prolonged	O
qu	O
interval	O
.	O
hypokalemia	ENTITY
induced	ENTITY
arrhythmias	ENTITY
require	ENTITY
immediate	ENTITY
potassium	ENTITY
replacement	ENTITY
.	O
oral	O
administration	O
.	O
if	O
potassium	ENTITY
infusion	ENTITY
is	ENTITY
indicated	ENTITY
continuous	ENTITY
cardiac	ENTITY
monitoring	ENTITY
and	O
hourly	O
serum	ENTITY
potassium	ENTITY
determinations	O
must	O
be	O
performed	O
to	O
avoid	O
hyperkalemia	ENTITY
complications	ENTITY
.	O
many	O
of	O
the	O
major	O
illnesses	O
that	O
face	O
us	O
today	O
have	O
their	O
origin	O
in	O
disturbances	O
in	O
our	O
metabolism	ENTITY
or	ENTITY
at	ENTITY
the	ENTITY
very	ENTITY
least	ENTITY
they	ENTITY
are	ENTITY
made	ENTITY
worse	ENTITY
by	ENTITY
metabolic	ENTITY
problems	ENTITY
.	O
illnesses	O
such	O
as	O
obesity	ENTITY
type	ENTITY
diabetes	ENTITY
high	ENTITY
blood	ENTITY
pressure	ENTITY
non	ENTITY
alcoholic	ENTITY
fatty	ENTITY
liver	ENTITY
neuropathy	ENTITY
some	ENTITY
mental	ENTITY
health	ENTITY
problems	ENTITY
some	O
cancers	O
the	O
old	O
theory	O
of	O
calories	O
in	O
calories	O
out	O
does	O
not	O
help	O
us	O
explain	O
our	O
current	O
obesity	ENTITY
.	O
the	O
old	O
advice	O
to	O
eat	O
less	O
and	O
exercise	O
more	O
fails	O
to	O
provide	O
healthy	O
sustained	O
weight	O
loss	O
.	O
and	O
traditional	O
advice	O
on	O
portion	O
control	O
weight	O
management	O
and	O
eating	O
starchy	ENTITY
carbohydrates	ENTITY
with	O
every	O
meal	O
often	O
does	O
not	O
help	O
type	O
diabetics	O
many	O
of	O
whom	O
see	O
their	O
illness	O
as	O
chronic	O
and	O
progressive	O
with	O
relentless	O
deterioration	O
towards	O
more	O
medication	O
and	O
eventually	O
the	O
prospect	O
of	O
insulin	ENTITY
injections	ENTITY
.	O
furthermore	O
despite	O
the	O
fact	O
that	O
most	O
of	O
us	O
are	O
eating	O
quantities	O
of	O
food	O
far	O
in	O
excess	O
of	O
our	O
energy	O
requirements	O
many	O
of	O
us	O
still	O
have	O
nutritional	ENTITY
deficiencies	ENTITY
such	O
as	O
vitamin	O
and	O
other	ENTITY
vitamins	ENTITY
minerals	ENTITY
such	O
as	O
magnesium	O
and	O
deficiencies	O
of	O
essential	O
fats	ENTITY
such	ENTITY
as	ENTITY
omega	ENTITY
the	ENTITY
melbury	ENTITY
metabolic	ENTITY
clinic	ENTITY
offers	O
an	O
assessment	O
of	O
the	O
common	O
metabolic	ENTITY
disturbances	ENTITY
glucose	ENTITY
metabolism	ENTITY
pre	ENTITY
diabetes	ENTITY
diabetes	ENTITY
insulin	ENTITY
resistance	ENTITY
abnormal	O
liver	ENTITY
function	ENTITY
vitamin	ENTITY
deficiency	ENTITY
magnesium	ENTITY
deficiency	ENTITY
omega	ENTITY
deficiency	ENTITY
level	ENTITY
of	ENTITY
inflammation	ENTITY
we	ENTITY
offer	ENTITY
patient	ENTITY
centred	ENTITY
individualised	ENTITY
assessments	ENTITY
to	ENTITY
help	ENTITY
you	ENTITY
on	ENTITY
correct	ENTITY
any	ENTITY
metabolic	ENTITY
disturbances	ENTITY
that	O
you	O
may	O
have	O
in	O
order	O
help	O
you	O
lose	O
weight	O
avoid	O
or	O
control	O
diabetes	ENTITY
and	ENTITY
to	ENTITY
reduce	ENTITY
or	ENTITY
eliminate	ENTITY
blood	ENTITY
pressure	ENTITY
medication	O
.	O
you	O
can	O
feel	O
better	O
and	O
function	O
better	O
once	O
your	O
metabolism	ENTITY
is	ENTITY
in	ENTITY
balance	ENTITY
.	O
igf	ENTITY
is	ENTITY
similar	ENTITY
to	ENTITY
insulin	ENTITY
igf	ENTITY
does	ENTITY
cell	ENTITY
multiplication	ENTITY
and	ENTITY
inhibits	ENTITY
.	O
igf	ENTITY
does	ENTITY
primary	ENTITY
.	O
benefits	O
skeletal	ENTITY
muscle	ENTITY
hypertrophy	ENTITY
prevents	ENTITY
muscle	ENTITY
loss	ENTITY
bone	ENTITY
development	ENTITY
fat	ENTITY
.	O
side	O
effects	O
organ	ENTITY
growth	ENTITY
.	O
dose	O
mcg	O
once	O
or	O
twice	O
day	O
after	O
workout	O
cycling	O
weeks	O
only	O
genuine	O
brand	O
increlex	ENTITY
mecasermin	ENTITY
us	O
presciption	O
drug	O
.	O
please	O
check	O
out	O
my	O
diabetes	ENTITY
and	ENTITY
blood	ENTITY
sugar	ENTITY
tips	O
.	O
playlist	O
.	O
wide	O
range	O
of	O
medical	O
topics	O
are	O
covered	O
ranging	O
from	O
treatment	O
for	O
infertility	ENTITY
diabetes	ENTITY
cancer	ENTITY
to	O
back	ENTITY
pain	ENTITY
spinal	ENTITY
problems	ENTITY
and	O
weight	O
loss	O
.	O
the	O
viewers	O
can	O
call	O
in	O
ask	O
doubts	O
and	O
seek	O
advice	O
.	O
my	O
name	O
is	O
barbara	O
grubbs	O
.	O
nurse	O
practitioner	O
and	O
want	O
to	O
help	O
you	O
reach	O
.	O
get	O
my	O
free	O
report	O
now	O
.	O
small	ENTITY
intestine	ENTITY
.	O
sj	O
gren	O
syndrome	ENTITY
sistyer	ENTITY
disease	ENTITY
to	ENTITY
lupus	ENTITY
.	O
the	O
hallmark	O
difference	O
is	O
that	O
the	O
body	O
heavily	O
attacks	O
glands	ENTITY
that	ENTITY
produce	ENTITY
tears	ENTITY
saliva	ENTITY
causing	O
dry	ENTITY
eyes	ENTITY
and	O
mouth	ENTITY
.	O
the	O
kidneys	ENTITY
.	O
hashimoto	ENTITY
disease	ENTITY
the	O
body	O
attacks	O
its	O
own	O
thyroid	ENTITY
.	O
type	O
diabetes	ENTITY
the	ENTITY
body	ENTITY
attacks	ENTITY
its	ENTITY
own	ENTITY
pancreas	ENTITY
and	ENTITY
destroys	ENTITY
cells	ENTITY
that	ENTITY
produce	ENTITY
insulin	ENTITY
.	O
multiple	ENTITY
sclerosis	ENTITY
the	O
body	O
attacks	O
its	O
own	O
healthy	O
nervous	ENTITY
system	ENTITY
.	O
please	O
share	O
this	O
with	O
others	O
to	O
help	O
spread	O
autoimmune	ENTITY
disease	ENTITY
.	O
how	O
diabetes	ENTITY
and	ENTITY
insulin	ENTITY
resistance	ENTITY
.	O
natural	O
healing	O
herbalist	O
and	O
herbs	ENTITY
have	ENTITY
written	ENTITY
about	ENTITY
these	ENTITY
disorders	ENTITY
.	O
in	O
this	O
article	O
will	O
bring	O
them	O
together	O
.	O
whenever	O
you	O
have	O
an	O
epidemic	O
on	O
the	O
scale	O
.	O
one	O
of	O
the	O
primary	O
influences	O
in	O
our	O
cancer	O
epidemic	O
is	O
insulin	ENTITY
resistance	ENTITY
diabetes	ENTITY
.	O
right	O
now	O
there	O
are	O
about	O
million	O
diabetics	O
in	O
the	O
however	O
there	O
are	O
about	O
million	O
people	O
with	O
insulin	ENTITY
resistance	ENTITY
.	O
insulin	ENTITY
resistance	ENTITY
is	O
the	O
pre	ENTITY
diabetic	ENTITY
condition	O
that	O
has	O
many	O
of	O
the	O
destructive	O
elements	O
.	O
what	O
this	O
adds	O
up	O
to	O
is	O
that	O
million	O
people	O
have	O
developed	O
one	O
of	O
the	O
main	O
foundations	O
that	O
cancer	O
can	O
build	O
on	O
.	O
when	O
patient	O
has	O
been	O
diagnosed	O
with	O
cancer	O
and	O
has	O
insulin	ENTITY
resistance	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
there	O
are	O
many	O
reasons	O
why	O
.	O
it	O
is	O
also	O
true	O
that	O
the	O
ramifications	O
of	O
insulin	ENTITY
resistance	ENTITY
type	ENTITY
diabetes	ENTITY
are	O
not	O
handled	O
with	O
enough	O
depth	O
in	O
both	O
the	O
diagnosis	O
and	O
treatment	ENTITY
of	ENTITY
cancer	ENTITY
.	O
insulin	ENTITY
resistance	ENTITY
diabetes	ENTITY
.	O
many	O
of	O
these	O
negative	O
changes	O
favor	O
.	O
cancer	O
is	O
an	O
opportunistic	O
disorder	O
.	O
once	O
it	O
has	O
developed	O
in	O
our	O
bodies	O
it	O
applies	O
everything	O
and	O
anything	O
it	O
can	O
to	O
further	O
its	O
ends	O
and	O
insulin	ENTITY
resistance	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
the	O
two	O
most	O
overt	O
areas	O
in	O
insulin	ENTITY
resistance	ENTITY
diabetes	ENTITY
that	O
feed	O
and	O
drive	O
cancer	O
are	O
sustained	O
elevated	ENTITY
blood	ENTITY
glucose	ENTITY
.	O
to	O
read	O
more	O
go	O
to	O
diabetes	ENTITY
and	ENTITY
insulin	ENTITY
.	O
the	O
most	O
common	O
disease	ENTITY
in	ENTITY
america	ENTITY
is	ENTITY
something	ENTITY
you	ENTITY
probably	ENTITY
never	ENTITY
heard	ENTITY
of	ENTITY
but	ENTITY
it	ENTITY
affects	ENTITY
million	ENTITY
americans	ENTITY
and	ENTITY
is	ENTITY
major	ENTITY
risk	ENTITY
factor	ENTITY
for	ENTITY
diabetes	ENTITY
heart	ENTITY
attacks	ENTITY
.	O
it	O
called	O
fatty	ENTITY
liver	ENTITY
and	O
it	O
caused	O
by	O
the	O
pounds	O
of	O
sugar	O
and	O
pounds	O
of	O
flour	O
in	O
our	O
diet	O
.	O
fatty	ENTITY
liver	ENTITY
creates	O
whole	O
cascade	O
of	O
issues	O
including	O
inflammation	ENTITY
insulin	ENTITY
resistance	ENTITY
pre	ENTITY
diabetes	ENTITY
and	O
diabetes	ENTITY
abnormal	ENTITY
cholesterol	ENTITY
high	ENTITY
blood	ENTITY
pressure	ENTITY
heart	ENTITY
attack	ENTITY
cancer	ENTITY
watch	O
this	O
week	O
edition	O
of	O
house	O
call	O
with	O
dr	O
hyman	O
to	O
learn	O
about	O
the	O
root	O
.	O
wishing	O
.	O
what	O
way	O
noni	O
helps	O
in	O
diabetes	ENTITY
.	O
the	O
miracle	O
of	O
xeronine	O
xeronine	O
the	O
alkaloid	ENTITY
of	ENTITY
noni	ENTITY
in	ENTITY
the	ENTITY
presence	ENTITY
of	ENTITY
insulin	ENTITY
activate	ENTITY
the	ENTITY
peripheral	ENTITY
cell	ENTITY
membrane	ENTITY
insulin	ENTITY
receptors	ENTITY
and	O
helps	O
for	O
the	O
normal	O
intracellular	ENTITY
absorption	ENTITY
of	O
glucose	ENTITY
as	ENTITY
well	ENTITY
as	ENTITY
corrects	ENTITY
the	ENTITY
intracellular	ENTITY
post	ENTITY
receptor	ENTITY
defect	ENTITY
of	ENTITY
the	ENTITY
action	ENTITY
of	ENTITY
insulin	ENTITY
for	O
carbohydrate	ENTITY
metabolism	ENTITY
and	O
thus	O
prevents	O
the	O
insulin	ENTITY
resistance	ENTITY
condition	ENTITY
in	ENTITY
diabetes	ENTITY
.	O
noni	O
the	O
cell	O
rejuvenator	O
noni	O
is	O
believed	O
to	O
fortify	O
and	O
maintain	O
the	O
cell	ENTITY
structure	ENTITY
this	O
can	O
be	O
accomplished	O
by	O
noni	O
acting	O
as	O
an	O
adaptogen	O
that	O
can	O
aid	O
sick	O
.	O
xeronine	O
and	O
other	O
nutraceuticals	O
present	O
in	O
noni	O
may	O
convert	O
the	O
abnormal	O
inactive	O
insulin	ENTITY
molecule	ENTITY
present	ENTITY
in	ENTITY
type	ENTITY
diabetes	ENTITY
mellitus	ENTITY
to	O
an	O
active	O
form	O
by	O
modifying	O
its	O
cell	O
rigidity	O
and	O
functional	O
level	O
to	O
maintain	O
its	O
normal	O
function	O
of	O
carbohydrate	ENTITY
metabolismin	ENTITY
our	O
body	O
.	O
noni	O
works	O
as	O
healthy	O
immune	ENTITY
system	ENTITY
promoter	ENTITY
one	O
of	O
the	O
nonis	O
effects	O
is	O
on	O
the	O
pancreas	ENTITY
and	ENTITY
immune	ENTITY
system	ENTITY
.	O
current	O
studies	O
have	O
revealed	O
that	O
noni	O
may	O
help	O
promote	O
healthy	O
immune	ENTITY
system	ENTITY
or	O
by	O
either	O
enhancing	O
an	O
already	O
functioning	O
system	O
.	O
noni	O
activating	O
our	O
body	O
immune	ENTITY
system	ENTITY
may	O
improve	O
the	O
non	O
functioning	O
beta	ENTITY
cells	ENTITY
of	ENTITY
the	ENTITY
pancreas	ENTITY
to	O
an	O
active	O
form	O
to	O
produce	O
the	O
normal	O
insulin	ENTITY
from	ENTITY
the	ENTITY
beta	ENTITY
cells	ENTITY
and	O
also	O
maintain	O
normal	O
insulin	ENTITY
level	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
to	O
the	O
response	O
of	O
the	O
carbohydrate	ENTITY
diet	ENTITY
.	O
low	ENTITY
glycemic	ENTITY
index	ENTITY
ratio	ENTITY
of	ENTITY
carbohydrates	ENTITY
to	O
fiber	O
in	O
noni	O
juice	O
helps	O
balance	O
blood	ENTITY
glucose	ENTITY
level	ENTITY
.	O
glycemic	ENTITY
index	ENTITY
refers	O
to	O
method	O
of	O
classification	O
by	O
which	O
number	O
is	O
assigned	O
to	O
foods	O
based	O
on	O
how	O
they	O
affect	O
blood	ENTITY
sugar	ENTITY
levels	ENTITY
.	O
foods	O
that	O
contain	O
the	O
same	O
amount	O
of	O
total	ENTITY
carbohydrate	ENTITY
.	O
for	O
example	O
kidney	O
beans	O
increase	O
blood	ENTITY
sugar	ENTITY
levels	ENTITY
more	O
significantly	O
than	O
soya	O
beans	O
because	O
of	O
its	O
higher	ENTITY
glycemic	ENTITY
.	O
noni	O
has	O
very	O
low	ENTITY
glycemic	ENTITY
index	ENTITY
and	O
hence	O
it	O
reduces	O
the	O
risk	O
of	O
chronic	O
conditions	O
of	O
diabetics	ENTITY
noni	ENTITY
might	ENTITY
have	ENTITY
the	ENTITY
role	ENTITY
by	ENTITY
modifying	ENTITY
our	ENTITY
body	ENTITY
immune	ENTITY
system	ENTITY
keeps	O
the	O
sensitivity	O
of	O
beta	ENTITY
cells	ENTITY
of	ENTITY
the	ENTITY
pancreas	ENTITY
intact	O
to	O
produce	O
an	O
adequate	O
amount	O
of	O
insulin	ENTITY
in	ENTITY
response	ENTITY
to	ENTITY
elevated	ENTITY
blood	ENTITY
glucose	ENTITY
level	ENTITY
by	O
keeping	O
and	O
maintaining	O
the	O
balance	O
of	O
release	O
of	O
the	O
neuro	O
endocrine	ENTITY
.	O
noni	O
may	O
help	O
the	O
diabetic	ENTITY
complications	ENTITY
like	O
care	O
of	O
diabetic	ENTITY
gangrene	ENTITY
by	O
its	O
powerful	O
healing	O
effects	O
and	O
also	O
helps	O
diabetic	ENTITY
poly	ENTITY
neuropathy	ENTITY
symptoms	O
by	O
providing	O
number	O
essential	O
micronutrients	O
vitamins	O
essential	O
minerals	O
and	O
amino	ENTITY
acids	ENTITY
.	O
noni	O
may	O
also	O
help	O
relieve	O
diabetic	ENTITY
complications	ENTITY
through	O
its	O
ability	O
to	O
stimulate	O
the	O
bodys	O
production	O
of	O
nitric	ENTITY
oxide	ENTITY
.	O
nitric	ENTITY
oxide	ENTITY
and	O
scopoletin	ENTITY
one	ENTITY
ingredient	ENTITY
in	ENTITY
noni	ENTITY
helps	ENTITY
also	ENTITY
reduce	ENTITY
the	ENTITY
diabetic	ENTITY
hypertension	ENTITY
.	O
both	O
may	O
also	O
be	O
important	O
factors	O
in	O
decreasing	O
symptoms	O
.	O
hence	O
it	O
is	O
the	O
gods	O
gift	O
to	O
the	O
human	O
society	O
.	O
blackstone	O
labs	O
how	O
to	O
build	O
muscle	O
fast	O
with	O
chosen	O
abnormal	O
brutal	O
ce	O
stack	O
by	O
blackstone	O
labs	O
.	O
you	O
decide	O
if	O
blackstone	O
labs	O
.	O
contact	O
me	O
at	O
my	O
email	O
blackstonelabsreview	O
gmail	O
com	O
if	O
you	O
would	O
like	O
to	O
get	O
blackstone	O
labs	O
.	O
just	O
say	O
send	O
me	O
blackstone	O
labs	O
.	O
my	O
name	O
is	O
eddie	O
and	O
test	O
many	O
different	O
products	O
and	O
give	O
my	O
honest	O
review	O
on	O
what	O
my	O
results	O
are	O
when	O
finally	O
get	O
done	O
testing	O
product	O
.	O
did	O
some	O
research	O
and	O
fell	O
in	O
love	O
with	O
what	O
blackstone	O
labs	O
.	O
so	O
because	O
of	O
this	O
have	O
decided	O
to	O
do	O
week	O
training	O
program	O
with	O
their	O
stack	O
called	O
elite	O
ice	O
.	O
the	O
st	O
weeks	O
will	O
involve	O
me	O
lower	O
calories	O
and	O
doing	O
heavy	O
compound	O
movements	O
to	O
burn	O
.	O
pj	O
braun	O
and	O
aaron	O
singerman	O
who	O
run	O
blackstone	O
labs	O
are	O
two	O
men	O
who	O
you	O
want	O
to	O
follow	O
because	O
they	O
are	O
on	O
the	O
path	O
.	O
truly	O
believe	O
in	O
these	O
two	O
guys	O
because	O
they	O
tell	O
it	O
like	O
it	O
is	O
with	O
truth	O
no	O
fluff	O
to	O
the	O
point	O
super	O
awesome	O
advice	O
that	O
proven	O
the	O
lead	O
you	O
on	O
the	O
right	O
path	O
.	O
will	O
be	O
doing	O
daily	O
reviews	O
on	O
blackstone	O
labs	O
.	O
this	O
company	O
gets	O
top	O
rating	O
in	O
my	O
book	O
because	O
they	O
will	O
soon	O
be	O
in	O
the	O
top	O
supplement	O
companies	O
.	O
just	O
watch	O
how	O
fast	O
this	O
company	O
will	O
reach	O
.	O
blackstone	O
labs	O
presents	O
new	O
products	O
like	O
epi	ENTITY
test	ENTITY
is	ENTITY
powdered	ENTITY
blend	ENTITY
of	ENTITY
epicatechins	ENTITY
aromastat	ENTITY
inhibitors	ENTITY
and	O
testosterone	ENTITY
.	O
great	O
for	O
making	O
lean	O
dry	O
gains	O
.	O
abnormal	O
transports	O
nordhea	O
the	O
precursor	O
to	O
norandrostenediol	O
to	O
your	O
body	O
.	O
not	O
only	O
is	O
it	O
good	O
for	O
joints	ENTITY
it	ENTITY
has	ENTITY
anabolic	ENTITY
ratio	ENTITY
making	ENTITY
it	ENTITY
times	ENTITY
more	ENTITY
anabolic	ENTITY
glycolog	ENTITY
an	O
insulin	ENTITY
.	O
eat	O
more	O
carbs	O
so	O
make	O
your	O
muscles	ENTITY
feel	ENTITY
fuller	ENTITY
and	ENTITY
pumped	ENTITY
.	O
and	O
shuttling	O
the	O
nutrients	O
where	O
they	O
need	O
to	O
go	O
without	O
storing	O
bodyfat	O
.	O
brutal	O
ce	O
dhea	O
blend	O
through	O
novel	O
step	O
conversion	O
system	O
brutal	O
ce	O
will	O
deliver	O
huge	O
load	O
of	O
testosterone	ENTITY
directly	ENTITY
to	ENTITY
your	ENTITY
bloodstream	ENTITY
.	O
the	O
muscle	O
boys	O
stack	O
includes	O
almost	O
all	O
of	O
blackstone	O
labs	O
products	O
in	O
big	O
package	O
.	O
chosen	O
makes	O
use	O
of	O
liposomal	ENTITY
.	O
this	O
prevents	O
the	O
liver	ENTITY
from	ENTITY
breaking	ENTITY
the	ENTITY
blend	ENTITY
down	ENTITY
delivering	ENTITY
testosterone	ENTITY
directly	ENTITY
to	ENTITY
your	ENTITY
bloodstream	ENTITY
.	O
the	O
elite	O
fire	O
ice	O
.	O
the	O
tighten	O
the	O
up	O
stack	O
take	O
this	O
stack	O
if	O
you	O
are	O
looking	O
to	O
get	O
ripped	O
.	O
natural	O
mass	O
stack	O
this	O
is	O
the	O
new	O
all	O
natural	O
stack	O
that	O
consists	O
of	O
epicat	ENTITY
anogenin	ENTITY
and	ENTITY
growth	ENTITY
.	O
its	O
safe	O
for	O
both	O
men	O
and	O
women	O
.	O
expect	O
lean	O
muscle	O
gains	O
loss	O
of	O
body	O
fat	O
and	O
increased	O
strength	O
the	O
natural	O
way	O
.	O
trojan	O
horse	O
non	O
stimulant	O
powdered	O
fat	ENTITY
burner	ENTITY
great	ENTITY
when	ENTITY
in	ENTITY
caloric	ENTITY
deficit	ENTITY
.	O
euphoria	O
legal	O
and	O
highly	O
effective	O
sedative	ENTITY
.	O
euphoria	O
is	O
the	O
all	O
natural	O
calorie	O
free	O
hangover	O
free	O
and	O
toxic	ENTITY
free	ENTITY
solution	ENTITY
.	O
dust	O
the	O
ultimate	O
pre	O
workout	O
energy	O
drink	O
for	O
insane	O
gains	O
in	O
the	O
gym	O
and	O
now	O
have	O
stronger	O
version	O
called	O
extreme	O
dust	O
.	O
also	O
want	O
to	O
thank	O
the	O
following	O
youtube	O
creators	O
for	O
inspiring	O
me	O
like	O
blackstone	O
labs	O
for	O
having	O
great	O
products	O
that	O
work	O
for	O
getting	O
in	O
shape	O
.	O
trial	O
nerror	O
for	O
doing	O
great	O
reviews	O
that	O
made	O
me	O
feel	O
even	O
more	O
cinfident	O
to	O
use	O
the	O
products	O
.	O
juggernautfitnesstv	O
for	O
creating	O
awesome	O
videos	O
about	O
the	O
company	O
to	O
reassure	O
me	O
.	O
newroids	O
for	O
explaining	O
blackstone	O
labs	O
.	O
eternalphysique	O
for	O
telling	O
it	O
like	O
it	O
is	O
about	O
the	O
products	O
.	O
tiger	O
fitness	O
for	O
convincing	O
me	O
that	O
getting	O
in	O
shape	O
is	O
the	O
best	O
thing	O
to	O
do	O
to	O
create	O
change	O
in	O
our	O
lives	O
.	O
suppz	O
com	O
for	O
doing	O
an	O
amazing	O
review	O
for	O
brutal	O
ce	O
that	O
made	O
me	O
order	O
the	O
elite	O
fire	O
and	O
ice	O
.	O
to	O
my	O
most	O
inspiring	O
person	O
here	O
on	O
youtube	O
mr	ENTITY
.	O
nick	O
wright	O
.	O
new	O
video	O
exposed	O
blackstone	O
labs	O
.	O
hypoglycemia	ENTITY
is	ENTITY
often	ENTITY
precursor	ENTITY
to	ENTITY
type	ENTITY
ii	ENTITY
diabetes	ENTITY
.	O
if	O
you	O
suffer	O
episodes	O
of	O
hypoglycemia	ENTITY
you	ENTITY
may	ENTITY
be	ENTITY
at	ENTITY
greater	ENTITY
risk	ENTITY
for	ENTITY
diabetes	ENTITY
.	O
it	O
is	O
good	O
idea	O
to	O
avoid	O
large	O
carbohydrate	ENTITY
.	O
both	O
the	O
types	O
of	O
carbs	O
and	O
the	O
amount	O
of	O
carbs	O
.	O
women	O
with	O
pcos	ENTITY
have	ENTITY
abnormal	ENTITY
insulin	ENTITY
regulation	ENTITY
where	ENTITY
there	ENTITY
is	ENTITY
often	ENTITY
delay	ENTITY
of	ENTITY
insulin	ENTITY
secretion	ENTITY
with	O
carbohydrate	ENTITY
load	ENTITY
then	ENTITY
insulin	ENTITY
secretion	ENTITY
continues	O
after	O
hormone	ENTITY
levels	ENTITY
fall	O
resulting	O
in	O
low	O
sugars	O
.	O
this	O
is	O
thought	O
to	O
be	O
due	O
to	O
an	O
abnormality	O
in	O
insulin	ENTITY
secreting	ENTITY
beta	ENTITY
cells	ENTITY
.	O
eventually	O
if	O
you	O
lose	O
enough	O
of	O
these	O
cells	O
you	O
are	O
at	O
risk	O
for	O
diabetes	ENTITY
.	O
on	O
this	O
episode	O
of	O
behind	O
the	O
muscle	O
the	O
guerrilla	O
chemist	O
discusses	O
the	O
latest	O
blackstone	O
labs	O
.	O
he	O
discusses	O
all	O
the	O
science	O
of	O
the	O
insulin	ENTITY
pathway	ENTITY
and	ENTITY
how	ENTITY
each	ENTITY
ingredient	ENTITY
plays	ENTITY
key	ENTITY
role	ENTITY
in	ENTITY
maximizing	ENTITY
insulin	ENTITY
use	ENTITY
for	ENTITY
building	ENTITY
muscle	ENTITY
and	ENTITY
or	ENTITY
controlling	ENTITY
insulin	ENTITY
.	O
so	O
sit	O
back	O
.	O
get	O
ripped	O
and	O
build	O
muscle	O
with	O
this	O
free	O
.	O
watch	O
full	O
version	O
.	O
this	O
animation	O
shows	O
the	O
regulation	O
of	O
insulin	ENTITY
secretion	ENTITY
in	O
beta	ENTITY
cell	ENTITY
.	O
glucose	ENTITY
is	ENTITY
transported	ENTITY
via	ENTITY
the	ENTITY
glucose	ENTITY
transporter	ENTITY
glut	O
into	O
the	O
cell	O
.	O
the	O
enzyme	ENTITY
glucokinase	ENTITY
converts	ENTITY
the	ENTITY
glucose	ENTITY
.	O
during	O
glycolysis	ENTITY
glucose	ENTITY
phosphate	ENTITY
is	O
metabolized	ENTITY
and	ENTITY
atp	ENTITY
as	ENTITY
well	ENTITY
as	ENTITY
pyruvate	ENTITY
.	O
the	O
pyruvate	ENTITY
is	ENTITY
transported	ENTITY
into	ENTITY
the	ENTITY
mitochondria	ENTITY
where	ENTITY
it	ENTITY
is	ENTITY
converted	ENTITY
to	ENTITY
acetyl	ENTITY
coa	ENTITY
.	O
during	O
the	O
citric	O
acid	O
cycle	O
more	O
atp	ENTITY
.	O
the	O
atp	ENTITY
.	O
the	O
elevated	O
concentration	O
of	O
atp	ENTITY
in	ENTITY
the	ENTITY
cell	ENTITY
leads	ENTITY
to	ENTITY
the	ENTITY
closing	ENTITY
of	ENTITY
the	ENTITY
potassium	ENTITY
channel	ENTITY
.	O
the	O
depolarization	O
triggers	O
the	O
opening	O
of	O
the	O
voltage	ENTITY
gated	ENTITY
calcium	ENTITY
channel	ENTITY
.	O
the	O
influx	O
of	O
ca	ENTITY
ions	ENTITY
as	ENTITY
well	ENTITY
as	ENTITY
their	ENTITY
triggered	ENTITY
release	ENTITY
from	ENTITY
the	ENTITY
endoplasmic	ENTITY
reticulum	ENTITY
leads	O
to	O
the	O
fusion	O
of	O
the	O
insulin	ENTITY
vesicles	ENTITY
with	O
the	O
cell	ENTITY
membrane	ENTITY
thereby	O
releasing	O
the	O
insulin	ENTITY
.	O
milwaukee	O
school	O
of	O
engineering	O
center	O
for	O
biomolecular	O
modeling	O
discusses	O
the	O
role	O
of	O
the	O
protein	O
insulin	ENTITY
in	ENTITY
the	ENTITY
regulation	ENTITY
of	ENTITY
glucose	ENTITY
in	ENTITY
the	ENTITY
bloodstream	ENTITY
.	O
may	O
as	O
the	O
glucose	ENTITY
level	ENTITY
in	O
the	O
blood	O
drops	O
to	O
normal	O
insulin	ENTITY
release	ENTITY
slows	ENTITY
or	ENTITY
the	ENTITY
blood	ENTITY
sugar	ENTITY
rise	O
caused	O
by	O
the	O
meal	O
peaks	O
about	O
half	O
an	O
hour	O
beta	ENTITY
cells	ENTITY
in	ENTITY
the	ENTITY
islets	ENTITY
of	ENTITY
langerhans	ENTITY
release	O
insulin	ENTITY
.	O
what	O
is	O
insulin	ENTITY
.	O
important	O
hormone	ENTITY
allows	ENTITY
your	ENTITY
body	ENTITY
to	ENTITY
use	ENTITY
sugar	ENTITY
insulin	ENTITY
secretion	ENTITY
and	O
type	O
diabetes	ENTITY
why	ENTITY
do	ENTITY
cells	ENTITY
fail	ENTITY
regulation	ENTITY
of	ENTITY
medscapedoes	ENTITY
caffeine	ENTITY
.	O
pancreas	ENTITY
.	O
the	O
second	O
phase	O
is	O
sustained	O
slow	O
release	O
of	O
newly	O
formed	O
vesicles	ENTITY
triggered	ENTITY
independently	ENTITY
sugar	ENTITY
peaking	ENTITY
in	ENTITY
to	ENTITY
hours	ENTITY
feb	ENTITY
this	ENTITY
rise	ENTITY
blood	ENTITY
glucose	ENTITY
causes	O
insulin	ENTITY
be	ENTITY
released	ENTITY
from	ENTITY
the	ENTITY
pancreas	ENTITY
.	O
however	O
once	O
the	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
return	O
to	O
normal	O
insulin	ENTITY
release	ENTITY
slows	ENTITY
down	ENTITY
is	ENTITY
secreted	ENTITY
in	ENTITY
primarily	ENTITY
response	ENTITY
elevated	ENTITY
concentrations	ENTITY
of	ENTITY
primary	ENTITY
triggers	ENTITY
for	ENTITY
exocytosis	ENTITY
containing	ENTITY
secretory	ENTITY
granules	ENTITY
keywords	O
cell	O
diabetes	ENTITY
glucose	ENTITY
hormones	ENTITY
secretion	O
able	O
adjust	O
production	O
immediate	O
environmental	O
by	O
jan	O
cells	O
which	O
are	O
nestled	O
inside	O
small	O
ball	O
shaped	O
charge	O
difference	O
called	O
depolarization	O
apr	ENTITY
after	ENTITY
you	ENTITY
eat	ENTITY
food	ENTITY
and	ENTITY
your	ENTITY
sugar	ENTITY
level	ENTITY
rises	ENTITY
cells	ENTITY
pancreas	ENTITY
known	O
as	O
beta	ENTITY
cells	ENTITY
signaled	O
into	O
may	O
rise	O
secretion	O
from	O
blue	O
within	O
pancreatic	ENTITY
islets	ENTITY
.	O
mar	O
although	O
insulin	ENTITY
and	ENTITY
peptide	ENTITY
are	ENTITY
co	ENTITY
released	ENTITY
from	ENTITY
cell	ENTITY
secretory	ENTITY
these	ENTITY
physiologic	ENTITY
and	ENTITY
pharmacologic	ENTITY
triggers	ENTITY
for	ENTITY
insulin	ENTITY
secretion	ENTITY
are	O
how	O
do	O
pancreatic	ENTITY
.	O
state	O
are	O
picked	O
up	O
by	O
this	O
protein	O
which	O
leads	O
to	O
the	O
electrical	O
signal	O
that	O
triggers	O
insulin	ENTITY
secretion	ENTITY
pancreatic	ENTITY
beta	ENTITY
cells	ENTITY
integrate	O
signals	O
from	O
several	O
metabolites	ENTITY
and	ENTITY
hormones	ENTITY
.	O
in	O
person	O
without	O
diabetes	ENTITY
rise	ENTITY
in	ENTITY
blood	ENTITY
amino	ENTITY
acid	ENTITY
concentration	ENTITY
the	O
result	O
of	O
protein	O
does	O
insulin	ENTITY
get	ENTITY
released	ENTITY
the	ENTITY
moment	ENTITY
you	ENTITY
start	ENTITY
chewing	ENTITY
on	ENTITY
glucose	ENTITY
.	O
type	O
diabetes	ENTITY
is	ENTITY
rise	ENTITY
in	ENTITY
free	ENTITY
cytosolic	ENTITY
ca	ENTITY
triggers	O
the	O
exocytosis	ENTITY
of	ENTITY
insulin	ENTITY
mar	ENTITY
contrary	ENTITY
to	ENTITY
what	ENTITY
many	ENTITY
believe	ENTITY
carbohydrates	ENTITY
that	ENTITY
is	ENTITY
sugar	ENTITY
and	ENTITY
starch	ENTITY
are	ENTITY
not	ENTITY
only	ENTITY
macronutrient	ENTITY
stimulates	ENTITY
release	ENTITY
insulin	ENTITY
jul	ENTITY
under	ENTITY
normal	ENTITY
circumstances	ENTITY
is	ENTITY
released	ENTITY
into	ENTITY
your	ENTITY
bloodstream	ENTITY
whenever	ENTITY
blood	ENTITY
glucose	ENTITY
level	ENTITY
rises	O
which	O
typically	O
occurs	O
from	O
beta	ENTITY
cells	ENTITY
pancreas	ENTITY
response	O
rising	O
dropping	O
then	O
switch	O
off	O
apr	ENTITY
so	ENTITY
you	ENTITY
eat	ENTITY
food	ENTITY
releases	ENTITY
.	O
proteins	O
in	O
food	O
and	O
other	O
hormones	ENTITY
produced	ENTITY
by	ENTITY
the	ENTITY
gut	ENTITY
response	ENTITY
to	ENTITY
also	ENTITY
stimulate	ENTITY
insulin	ENTITY
.	O
understanding	O
our	O
bodies	O
insulin	ENTITY
.	O
googleusercontent	O
search	O
.	O
insulin	ENTITY
lowers	ENTITY
blood	ENTITY
glucose	ENTITY
by	O
acting	O
on	O
target	O
beta	ENTITY
cell	ENTITY
dysfunction	ENTITY
in	O
type	O
diabetes	ENTITY
.	O
the	O
first	O
phase	O
release	O
.	O
how	O
insulin	ENTITY
really	ENTITY
works	ENTITY
it	ENTITY
causes	ENTITY
fat	ENTITY
storage	ENTITY
but	ENTITY
doesn	ENTITY
make	ENTITY
mechanism	ENTITY
of	ENTITY
how	ENTITY
is	ENTITY
released	ENTITY
from	ENTITY
pancreatic	ENTITY
beta	ENTITY
cells	ENTITY
secretion	O
in	O
response	O
to	O
diet	O
and	O
hormones	ENTITY
patrik	ENTITY
rorsman	ENTITY
diabetes	ENTITY
nuffield	ENTITY
reactome	ENTITY
amino	ENTITY
acids	ENTITY
stimulate	O
the	O
release	O
.	O
regulation	O
of	O
insulin	ENTITY
.	O
animated	O
chinwe	O
ntamere	O
voice	O
over	O
rebecca	O
yang	O
script	O
in	O
normal	O
person	O
beta	ENTITY
cells	ENTITY
within	ENTITY
the	ENTITY
pancreas	ENTITY
secrete	O
what	O
known	O
as	O
insulin	ENTITY
into	ENTITY
the	ENTITY
bloodstream	ENTITY
.	O
as	O
insulin	ENTITY
travels	ENTITY
within	ENTITY
the	ENTITY
bloodstream	ENTITY
it	ENTITY
binds	ENTITY
to	ENTITY
the	ENTITY
insulin	ENTITY
receptors	ENTITY
found	O
on	O
the	O
cells	O
.	O
as	O
insulin	ENTITY
and	ENTITY
insulin	ENTITY
receptor	ENTITY
bind	O
together	O
it	O
triggers	O
whole	O
series	O
of	O
events	O
known	O
as	O
cell	O
signaling	O
cascade	O
which	O
brings	O
up	O
the	O
glucose	ENTITY
transporters	ENTITY
.	O
and	O
now	O
glucose	ENTITY
can	ENTITY
enter	ENTITY
the	ENTITY
cells	ENTITY
.	O
this	O
brings	O
down	O
the	O
blood	ENTITY
glucose	ENTITY
level	ENTITY
.	O
however	O
in	O
type	O
diabetic	ENTITY
patient	ENTITY
like	O
jacob	O
there	O
problem	O
.	O
while	O
the	O
beta	ENTITY
cells	ENTITY
secrete	O
insulin	ENTITY
and	ENTITY
can	ENTITY
bind	ENTITY
to	ENTITY
the	ENTITY
insulin	ENTITY
receptors	ENTITY
the	O
series	O
of	O
cell	O
cascading	O
event	O
is	O
altered	O
so	O
that	O
the	O
glucose	ENTITY
transporters	ENTITY
.	O
without	O
the	O
glucose	ENTITY
transporters	ENTITY
glucose	ENTITY
cannot	ENTITY
enter	ENTITY
the	ENTITY
cells	ENTITY
and	ENTITY
the	ENTITY
blood	ENTITY
glucose	ENTITY
level	ENTITY
remains	O
high	O
which	O
is	O
known	O
as	O
hyperglycemia	ENTITY
.	O
ndsu	ENTITY
virtual	ENTITY
cell	ENTITY
.	O
for	O
more	O
information	O
please	O
see	O
.	O
when	O
high	O
levels	O
of	O
glucose	ENTITY
enter	ENTITY
the	ENTITY
blood	ENTITY
stream	ENTITY
insulin	ENTITY
is	O
released	O
by	O
beta	ENTITY
cells	ENTITY
in	O
the	O
pancreas	ENTITY
.	O
insulin	ENTITY
then	ENTITY
initiates	ENTITY
number	ENTITY
of	ENTITY
signal	ENTITY
pathways	ENTITY
in	ENTITY
specific	ENTITY
muscle	ENTITY
and	ENTITY
fat	ENTITY
cells	ENTITY
.	O
this	O
takes	O
look	O
at	O
the	O
signal	O
pathway	O
responsible	O
for	O
allowing	O
those	O
cells	O
to	O
rapidly	O
increase	O
their	O
ability	O
to	O
uptake	O
glucose	ENTITY
from	ENTITY
the	ENTITY
blood	ENTITY
stream	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
also	O
simply	O
known	O
as	O
diabetes	ENTITY
.	O
it	O
is	O
the	O
disease	ENTITY
characterized	ENTITY
by	ENTITY
malfunctioning	ENTITY
metabolism	ENTITY
and	ENTITY
high	ENTITY
blood	ENTITY
sugar	ENTITY
level	ENTITY
.	O
the	O
result	O
can	O
be	O
low	O
levels	ENTITY
of	ENTITY
insulin	ENTITY
or	O
abnormal	O
insulin	ENTITY
resistance	ENTITY
.	O
this	O
mixed	O
with	O
inadequate	O
levels	ENTITY
of	ENTITY
insulin	ENTITY
secretion	O
results	O
in	O
diabetes	ENTITY
.	O
symptoms	O
of	O
diabetes	ENTITY
mellitus	ENTITY
include	O
increased	O
urine	O
production	O
excessive	O
thirst	O
extreme	O
fatigue	O
and	O
excessive	O
thirst	O
and	O
weight	O
loss	O
.	O
these	O
symptoms	O
though	O
may	O
not	O
be	O
present	O
in	O
those	O
people	O
with	O
only	O
mildly	O
elevated	O
sugar	O
.	O
diabetes	ENTITY
mellitus	ENTITY
includes	O
type	O
type	O
and	O
gestational	ENTITY
diabetes	ENTITY
which	O
occur	O
only	O
during	O
pregnancy	O
.	O
each	O
type	O
has	O
different	O
cause	O
and	O
different	O
severity	O
of	O
symptoms	O
.	O
caffeine	O
and	O
glucose	ENTITY
homeostasis	ENTITY
during	O
rest	O
exercise	O
in	O
pathogenesis	O
.	O
how	O
does	O
diabetes	ENTITY
.	O
googleusercontent	O
search	O
.	O
people	O
with	O
type	O
diabetes	ENTITY
do	ENTITY
not	ENTITY
produce	ENTITY
insulin	ENTITY
due	ENTITY
to	ENTITY
auto	ENTITY
immune	ENTITY
most	ENTITY
cells	ENTITY
in	O
the	O
human	O
body	O
use	O
sugar	O
called	O
glucose	ENTITY
.	O
central	O
regulation	ENTITY
of	ENTITY
energy	ENTITY
homeostasis	ENTITY
glycolysis	ENTITY
in	ENTITY
the	ENTITY
control	ENTITY
blood	ENTITY
glucose	ENTITY
.	O
glucose	ENTITY
.	O
the	O
endocrine	ENTITY
system	ENTITY
and	O
diabetes	ENTITY
.	O
the	O
homeostatic	O
regulation	O
of	O
glucose	O
concentrations	O
.	O
how	O
does	O
diabetes	ENTITY
.	O
diabetes	ENTITY
.	O
diabetes	ENTITY
affects	ENTITY
homeostasis	ENTITY
by	ENTITY
throwing	ENTITY
off	ENTITY
and	ENTITY
creating	ENTITY
imbalances	ENTITY
.	O
gcse	O
science	O
revision	O
how	O
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
.	O
understanding	O
the	O
role	O
of	O
energy	O
homeostasis	O
in	O
diabetes	ENTITY
.	O
how	O
diabetes	ENTITY
.	O
diabetes	ENTITY
.	O
their	O
levels	O
of	O
physical	O
activity	O
and	O
their	O
diet	O
affect	O
the	O
amount	O
insulin	ENTITY
needed	ENTITY
endocrine	ENTITY
system	ENTITY
consists	O
number	O
different	O
glands	ENTITY
which	ENTITY
secrete	ENTITY
hormones	ENTITY
that	ENTITY
dictate	ENTITY
how	ENTITY
cells	ENTITY
.	O
processes	O
the	O
kidneys	ENTITY
maintain	ENTITY
homeostasis	ENTITY
in	ENTITY
body	ENTITY
by	ENTITY
regulating	ENTITY
amount	ENTITY
of	ENTITY
unfortunately	ENTITY
best	ENTITY
we	ENTITY
can	ENTITY
do	ENTITY
is	ENTITY
approximate	ENTITY
how	ENTITY
does	ENTITY
diabetes	ENTITY
.	O
metabolism	ENTITY
another	ENTITY
system	ENTITY
which	ENTITY
has	ENTITY
disrupted	ENTITY
from	ENTITY
water	ENTITY
regulation	ENTITY
disrupt	ENTITY
other	ENTITY
aspects	ENTITY
metabolism	ENTITY
.	O
pancreas	ENTITY
regulates	ENTITY
blood	ENTITY
glucose	ENTITY
knowing	O
how	O
diabetes	ENTITY
affects	ENTITY
your	ENTITY
body	ENTITY
can	ENTITY
help	ENTITY
you	ENTITY
look	ENTITY
after	ENTITY
and	ENTITY
prevent	ENTITY
diabetic	ENTITY
complications	ENTITY
from	O
developing	O
all	O
sorts	O
of	O
factors	O
affect	O
the	O
suitability	O
human	O
fluids	O
to	O
sustain	O
life	O
these	O
include	O
properties	O
like	O
temperature	O
salinity	O
.	O
oxygen	O
soothe	O
reaction	O
does	O
not	O
proceed	O
and	O
therefore	O
only	O
anaerobic	ENTITY
respiration	ENTITY
is	O
levels	ENTITY
of	ENTITY
blood	ENTITY
glucose	ENTITY
.	O
how	O
does	O
diabetes	ENTITY
.	O
diabetic	ENTITY
faq	ENTITY
.	O
commonly	O
seen	O
example	O
of	O
homeostatic	ENTITY
imbalance	ENTITY
is	O
diabetes	ENTITY
system	ENTITY
even	O
out	O
variations	O
experienced	O
by	O
body	O
water	O
potential	O
avoids	O
osmotic	ENTITY
problems	ENTITY
cellular	ENTITY
disruption	ENTITY
conc	ENTITY
ions	ENTITY
na	ENTITY
ca	ENTITY
mellitus	ENTITY
inability	ENTITY
control	ENTITY
blood	ENTITY
glucose	ENTITY
level	ENTITY
high	O
levels	O
in	O
the	O
case	O
concentration	O
regulated	O
variable	O
controlled	O
tissue	ENTITY
homeostasis	ENTITY
but	O
it	O
does	O
not	O
have	O
counterpart	O
at	O
or	O
while	O
all	O
three	O
plants	O
can	O
affect	O
value	O
variable	O
in	O
this	O
insulin	ENTITY
resistance	ENTITY
lipotoxicity	ENTITY
type	ENTITY
and	O
atherosclerosis	ENTITY
missing	ENTITY
links	ENTITY
homeostasis	ENTITY
during	ENTITY
rest	ENTITY
exercise	ENTITY
.	O
the	O
basic	O
restorative	O
hormone	ENTITY
in	ENTITY
the	ENTITY
body	ENTITY
is	ENTITY
insulin	ENTITY
secreted	ENTITY
by	ENTITY
pancreas	ENTITY
as	ENTITY
insulin	ENTITY
maintains	ENTITY
normal	ENTITY
amount	ENTITY
of	ENTITY
sugar	ENTITY
.	O
in	O
person	O
who	O
doesn	O
have	O
diabetes	ENTITY
the	ENTITY
body	ENTITY
has	ENTITY
number	ENTITY
of	ENTITY
hypoglycemia	ENTITY
unawareness	ENTITY
in	O
which	O
they	O
do	O
not	O
experience	O
or	O
healthy	O
individual	O
is	O
affected	O
by	O
keeps	O
blood	ENTITY
glucose	ENTITY
.	O
cells	ENTITY
disruption	ENTITY
of	ENTITY
secretory	ENTITY
function	ENTITY
adipocytes	ENTITY
and	O
an	O
impaired	ENTITY
diabetes	ENTITY
.	O
diabetes	ENTITY
what	ENTITY
factors	ENTITY
that	ENTITY
would	ENTITY
indicate	ENTITY
disruption	ENTITY
in	ENTITY
homeostasis	ENTITY
of	ENTITY
body	ENTITY
.	O
is	O
it	O
compulsory	O
to	O
have	O
medical	O
intervention	O
abnormally	O
high	ENTITY
levels	ENTITY
blood	ENTITY
glucose	ENTITY
.	O
blood	ENTITY
sugar	ENTITY
.	O
in	O
glucose	ENTITY
homeostasis	ENTITY
is	O
evidenced	O
by	O
the	O
fact	O
that	O
disruption	O
of	O
sensing	O
in	O
gk	O
overexpression	O
through	O
activation	O
glycolysis	ENTITY
but	ENTITY
does	ENTITY
not	ENTITY
cause	ENTITY
fatty	ENTITY
liver	ENTITY
body	O
depends	O
on	O
balance	O
between	O
type	O
diabetes	ENTITY
result	ENTITY
near	ENTITY
or	ENTITY
complete	ENTITY
lack	ENTITY
insulin	ENTITY
producing	ENTITY
cells	ENTITY
secretion	ENTITY
since	ENTITY
they	ENTITY
do	ENTITY
so	ENTITY
independent	ENTITY
fashion	ENTITY
insulin	ENTITY
as	ENTITY
used	ENTITY
diabetics	ENTITY
restorative	ENTITY
hormone	ENTITY
.	O
diabetes	ENTITY
is	ENTITY
group	ENTITY
of	ENTITY
metabolic	ENTITY
diseases	ENTITY
where	O
person	O
has	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
level	ENTITY
.	O
the	O
hormones	ENTITY
produced	ENTITY
by	ENTITY
the	ENTITY
endocrine	ENTITY
system	ENTITY
help	O
body	O
to	O
regulate	O
growth	O
sexual	ENTITY
function	ENTITY
mood	O
and	O
metabolism	ENTITY
.	O
how	O
does	O
homeostasis	O
affect	O
ph	ENTITY
level	ENTITY
.	O
diabetes	ENTITY
results	ENTITY
from	ENTITY
the	ENTITY
body	ENTITY
being	ENTITY
unable	ENTITY
to	ENTITY
maintain	ENTITY
blood	ENTITY
sugar	ENTITY
level	ENTITY
in	O
homeostatic	ENTITY
balance	ENTITY
learn	O
about	O
homeostasis	O
regulation	O
of	O
conditions	O
such	O
as	O
diabetes	ENTITY
is	ENTITY
condition	ENTITY
where	ENTITY
cannot	ENTITY
regulate	ENTITY
its	ENTITY
glucose	ENTITY
levels	ENTITY
.	O
in	O
type	ENTITY
ii	ENTITY
diabetes	ENTITY
insulin	ENTITY
secretion	ENTITY
is	O
not	O
reduced	O
however	O
there	O
reduced	O
sensitivity	O
if	O
that	O
balance	O
.	O
diabetes	ENTITY
.	O
how	O
does	O
diabetes	ENTITY
affect	ENTITY
the	ENTITY
body	ENTITY
.	O
your	O
first	O
answer	O
is	O
unfortunately	O
way	O
incorrect	O
.	O
the	O
brain	ENTITY
and	ENTITY
nervous	ENTITY
system	ENTITY
are	O
insulin	ENTITY
.	O
nervous	ENTITY
diabetes	ENTITY
affects	ENTITY
the	ENTITY
nervous	ENTITY
system	ENTITY
by	O
having	O
too	O
much	O
glucose	ENTITY
.	O
how	O
does	O
diabetes	ENTITY
.	O
original	O
video	O
by	O
novo	O
nordisk	O
html	O
.	O
victoza	O
liraglutide	O
is	O
glucagon	ENTITY
like	ENTITY
peptide	ENTITY
glp	ENTITY
receptor	ENTITY
agonist	ENTITY
indicated	O
as	O
an	O
adjunct	O
to	O
diet	O
and	O
exercise	O
to	O
improve	O
glycemic	ENTITY
control	ENTITY
in	O
adults	O
with	O
type	O
diabetes	ENTITY
mellitus	ENTITY
to	O
reduce	O
the	O
risk	O
of	O
major	O
adverse	ENTITY
cardiovascular	ENTITY
events	ENTITY
in	O
adults	O
with	O
type	O
diabetes	ENTITY
mellitus	ENTITY
and	O
established	O
cardiovascular	ENTITY
disease	ENTITY
.	O
liraglutide	O
is	O
an	O
analog	O
of	O
human	O
glp	ENTITY
and	ENTITY
acts	ENTITY
as	ENTITY
glp	ENTITY
.	O
the	O
peptide	ENTITY
precursor	ENTITY
of	ENTITY
liraglutide	ENTITY
produced	ENTITY
by	ENTITY
process	ENTITY
that	ENTITY
includes	ENTITY
expression	ENTITY
of	ENTITY
recombinant	ENTITY
dna	ENTITY
in	ENTITY
saccharomyces	ENTITY
cerevisiae	ENTITY
has	ENTITY
been	ENTITY
engineered	ENTITY
to	ENTITY
be	ENTITY
homologous	ENTITY
to	ENTITY
native	ENTITY
human	ENTITY
glp	ENTITY
by	ENTITY
substituting	ENTITY
arginine	ENTITY
for	ENTITY
lysine	ENTITY
at	O
position	O
liraglutide	O
is	O
made	O
by	O
attaching	O
fatty	ENTITY
acid	ENTITY
palmitic	ENTITY
acid	ENTITY
with	O
glutamic	ENTITY
acid	ENTITY
spacer	O
on	O
the	O
remaining	O
lysine	ENTITY
residue	ENTITY
at	ENTITY
position	ENTITY
of	ENTITY
the	ENTITY
peptide	ENTITY
.	O
liraglutide	O
is	O
an	O
acylated	O
human	O
glp	ENTITY
receptor	ENTITY
agonist	ENTITY
with	O
amino	ENTITY
acid	ENTITY
sequence	ENTITY
homology	ENTITY
to	O
endogenous	O
human	O
glp	ENTITY
.	O
glp	ENTITY
represents	ENTITY
less	ENTITY
than	ENTITY
of	ENTITY
total	ENTITY
circulating	ENTITY
endogenous	ENTITY
glp	ENTITY
like	ENTITY
glp	ENTITY
liraglutide	ENTITY
activates	ENTITY
the	ENTITY
glp	ENTITY
receptor	ENTITY
membrane	ENTITY
bound	ENTITY
cell	ENTITY
surface	O
receptor	O
coupled	O
to	O
adenylyl	ENTITY
cyclase	ENTITY
by	O
the	O
stimulatory	O
protein	O
.	O
liraglutide	O
increases	O
intracellular	ENTITY
cyclic	ENTITY
amp	ENTITY
camp	O
leading	O
to	O
insulin	ENTITY
release	ENTITY
in	ENTITY
the	ENTITY
presence	ENTITY
of	ENTITY
elevated	ENTITY
glucose	ENTITY
concentrations	ENTITY
.	O
this	O
insulin	ENTITY
secretion	ENTITY
subsides	O
as	O
blood	ENTITY
glucose	ENTITY
concentrations	O
decrease	O
and	O
approach	O
euglycemia	ENTITY
.	O
liraglutide	O
also	O
decreases	O
glucagon	ENTITY
secretion	ENTITY
in	ENTITY
glucose	ENTITY
.	O
the	O
mechanism	O
of	O
blood	ENTITY
glucose	ENTITY
.	O
pancreas	ENTITY
.	O
you	O
and	O
your	O
hormones	ENTITY
from	ENTITY
the	ENTITY
society	ENTITY
for	ENTITY
insulin	ENTITY
.	O
pancreas	ENTITY
functions	ENTITY
and	ENTITY
possible	ENTITY
problems	ENTITY
medical	ENTITY
news	ENTITY
today	ENTITY
pancreas	ENTITY
functions	ENTITY
anatomy	ENTITY
insulin	ENTITY
production	ENTITY
video	ENTITY
can	ENTITY
you	ENTITY
produce	ENTITY
too	ENTITY
much	ENTITY
insulin	ENTITY
.	O
gland	ENTITY
.	O
the	O
cells	O
which	O
produce	O
insulin	ENTITY
.	O
it	O
causes	O
permanent	O
damage	O
nov	ENTITY
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
are	ENTITY
hormones	ENTITY
that	ENTITY
help	ENTITY
regulate	ENTITY
the	ENTITY
blood	ENTITY
sugar	ENTITY
glucose	ENTITY
diabetes	ENTITY
mellitus	ENTITY
is	O
best	O
known	O
condition	O
problems	O
with	O
if	O
you	O
have	O
type	O
diabetes	ENTITY
your	ENTITY
pancreas	ENTITY
doesn	ENTITY
produce	ENTITY
when	ENTITY
levels	ENTITY
of	ENTITY
glucose	ENTITY
high	O
in	O
blood	ENTITY
cells	ENTITY
.	O
proteins	O
in	O
food	O
and	O
other	O
hormones	ENTITY
produced	ENTITY
by	ENTITY
the	ENTITY
gut	ENTITY
response	ENTITY
to	ENTITY
also	ENTITY
pancreas	ENTITY
detects	ENTITY
this	ENTITY
rise	ENTITY
blood	ENTITY
glucose	ENTITY
starts	O
secrete	O
insulin	ENTITY
.	O
uk	O
hypoglycemia	ENTITY
causes	ENTITY
mayo	ENTITY
clinic	ENTITY
.	O
glucagon	ENTITY
causes	ENTITY
glycogen	ENTITY
to	ENTITY
be	ENTITY
broken	ENTITY
down	ENTITY
into	ENTITY
glucose	ENTITY
in	ENTITY
the	ENTITY
liver	ENTITY
aug	ENTITY
tumors	ENTITY
of	ENTITY
pancreas	ENTITY
that	O
produce	O
too	O
much	O
insulin	ENTITY
are	ENTITY
called	ENTITY
high	ENTITY
blood	ENTITY
level	ENTITY
low	ENTITY
sugar	ENTITY
hypoglycemia	ENTITY
islets	ENTITY
langerhans	ENTITY
within	ENTITY
your	ENTITY
hormones	ENTITY
and	ENTITY
glucagon	ENTITY
.	O
high	ENTITY
levels	ENTITY
of	ENTITY
insulin	ENTITY
in	O
your	O
bloodstream	ENTITY
called	ENTITY
functioning	ENTITY
as	ENTITY
an	ENTITY
endocrine	ENTITY
gland	ENTITY
the	O
pancreas	ENTITY
secretes	ENTITY
hormones	ENTITY
beta	ENTITY
cells	ENTITY
produce	O
hormone	ENTITY
insulin	ENTITY
which	O
lowers	O
blood	ENTITY
glucose	ENTITY
may	O
our	O
bodies	O
release	O
right	O
before	O
and	O
during	O
eating	O
that	O
is	O
relatively	O
small	O
peptide	ENTITY
.	O
how	O
does	O
the	O
pancreas	ENTITY
.	O
national	O
library	O
of	O
medicine	O
.	O
the	O
pancreas	ENTITY
understanding	ENTITY
insulin	ENTITY
and	ENTITY
diabetes	ENTITY
.	O
insulin	ENTITY
helps	ENTITY
the	ENTITY
uptake	ENTITY
of	ENTITY
glucose	ENTITY
into	ENTITY
muscles	ENTITY
and	ENTITY
other	ENTITY
cells	ENTITY
this	ENTITY
causes	ENTITY
jun	ENTITY
in	ENTITY
type	ENTITY
diabetes	ENTITY
immune	ENTITY
system	ENTITY
erroneously	O
attacks	O
beta	ENTITY
cells	ENTITY
that	O
produce	O
insulin	ENTITY
your	ENTITY
pancreas	ENTITY
.	O
acute	ENTITY
chronic	ENTITY
pancreatitis	ENTITY
causes	O
signs	O
treatments	O
however	O
certain	O
health	O
conditions	O
can	O
cause	O
your	O
pancreas	ENTITY
to	ENTITY
produce	ENTITY
and	ENTITY
secrete	ENTITY
too	ENTITY
much	ENTITY
insulin	ENTITY
.	O
diabetes	ENTITY
and	ENTITY
your	ENTITY
pancreas	ENTITY
.	O
the	O
pancreas	ENTITY
releases	ENTITY
insulin	ENTITY
to	ENTITY
deal	ENTITY
with	ENTITY
elevated	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
it	O
causes	O
the	O
liver	ENTITY
cells	ENTITY
of	O
to	O
release	O
stored	O
sugar	O
and	O
convert	O
proteins	O
into	O
between	O
meals	O
pancreas	ENTITY
does	ENTITY
not	ENTITY
produce	ENTITY
insulin	ENTITY
this	ENTITY
allows	ENTITY
body	ENTITY
or	ENTITY
become	ENTITY
inefficient	ENTITY
do	ENTITY
make	ENTITY
enough	ENTITY
insulin	ENTITY
diabetes	ENTITY
rise	ENTITY
in	ENTITY
blood	ENTITY
.	O
these	O
cells	O
are	O
distributed	O
in	O
cluster	O
of	O
the	O
pancreas	ENTITY
jul	ENTITY
persistently	ENTITY
elevated	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
prompt	O
your	O
to	O
release	O
even	O
more	O
insulin	ENTITY
leading	ENTITY
abnormally	ENTITY
high	ENTITY
serum	ENTITY
insulin	ENTITY
nov	O
causes	O
hypoglycemia	ENTITY
occurs	ENTITY
when	ENTITY
sugar	ENTITY
enlargement	ENTITY
beta	ENTITY
that	ENTITY
produce	ENTITY
may	ENTITY
pancreatic	ENTITY
.	O
pancreas	ENTITY
and	ENTITY
insulin	ENTITY
.	O
regulation	O
of	O
pancreatic	ENTITY
hormones	ENTITY
will	O
cause	O
complications	O
related	O
dec	O
this	O
hormone	ENTITY
acts	ENTITY
as	ENTITY
an	ENTITY
antagonist	ENTITY
to	ENTITY
insulin	ENTITY
.	O
insulin	ENTITY
gets	ENTITY
released	ENTITY
into	ENTITY
the	ENTITY
bloodstream	ENTITY
where	ENTITY
it	ENTITY
causes	ENTITY
glucose	ENTITY
to	ENTITY
move	ENTITY
so	ENTITY
sugar	ENTITY
ingested	ENTITY
an	ENTITY
insulin	ENTITY
.	O
you	O
and	O
your	O
hormones	ENTITY
.	O
hypoglycemia	ENTITY
causes	ENTITY
symptoms	ENTITY
treatment	ENTITY
.	O
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
.	O
healthline	O
pancreas	ENTITY
information	ENTITY
at	ENTITY
patient	ENTITY
what	ENTITY
causes	ENTITY
the	ENTITY
pancrease	ENTITY
to	ENTITY
release	ENTITY
insulin	ENTITY
.	O
bodybuilding	O
.	O
this	O
is	O
primarily	O
the	O
cause	O
of	O
type	O
diabetes	ENTITY
.	O
at	O
first	O
may	O
thus	O
insulin	ENTITY
is	ENTITY
goldilocks	ENTITY
hormone	ENTITY
in	ENTITY
that	ENTITY
both	ENTITY
too	ENTITY
much	ENTITY
and	ENTITY
little	ENTITY
are	ENTITY
what	ENTITY
causes	ENTITY
the	ENTITY
deficiency	ENTITY
.	O
diabetes	ENTITY
causes	ENTITY
how	ENTITY
do	ENTITY
you	ENTITY
get	ENTITY
type	ENTITY
and	ENTITY
diabetes	ENTITY
.	O
if	O
type	O
diabetes	ENTITY
develops	ENTITY
over	ENTITY
number	ENTITY
of	ENTITY
years	ENTITY
the	ENTITY
extra	ENTITY
demands	ENTITY
on	ENTITY
pancreas	ENTITY
to	ENTITY
produce	ENTITY
insulin	ENTITY
can	ENTITY
lead	ENTITY
loss	ENTITY
producing	ENTITY
cells	ENTITY
known	ENTITY
as	ENTITY
pancreatic	ENTITY
beta	ENTITY
cells	ENTITY
they	O
wear	O
out	O
jun	O
people	O
with	O
low	O
don	O
get	O
enough	O
full	O
body	O
.	O
learn	O
more	O
about	O
how	O
lack	O
of	O
insulin	ENTITY
affects	ENTITY
the	ENTITY
body	ENTITY
in	ENTITY
this	ENTITY
article	ENTITY
several	ENTITY
common	ENTITY
medications	ENTITY
can	ENTITY
impair	ENTITY
body	ENTITY
use	ENTITY
insulin	ENTITY
causing	ENTITY
condition	ENTITY
known	ENTITY
as	ENTITY
secondary	ENTITY
diabetes	ENTITY
.	O
lack	O
of	O
insulin	ENTITY
harm	ENTITY
people	ENTITY
with	ENTITY
diabetes	ENTITY
.	O
sharecare	O
.	O
weight	O
loss	O
can	O
also	O
cut	O
down	O
on	O
insulin	O
resistance	O
sep	O
luckily	O
there	O
are	O
several	O
tell	O
tale	O
signs	O
or	O
clues	O
that	O
your	O
body	O
gives	O
you	O
and	O
symptoms	O
of	O
chronically	O
elevated	O
berberine	ENTITY
helps	ENTITY
to	ENTITY
improve	ENTITY
sensitivity	ENTITY
cholesterol	ENTITY
metabolism	ENTITY
assists	O
weight	O
nov	ENTITY
is	ENTITY
hormone	ENTITY
the	ENTITY
utilize	ENTITY
glucose	ENTITY
.	O
these	O
medications	O
include	O
treatments	O
for	O
one	O
action	O
of	O
insulin	ENTITY
is	ENTITY
to	ENTITY
cause	ENTITY
the	ENTITY
body	ENTITY
cells	ENTITY
particularly	ENTITY
muscle	ENTITY
and	O
fat	ENTITY
aerobic	ENTITY
exercise	ENTITY
without	ENTITY
weight	ENTITY
loss	ENTITY
increases	ENTITY
rate	ENTITY
at	ENTITY
which	ENTITY
glucose	ENTITY
an	ENTITY
essential	ENTITY
hormone	ENTITY
produced	ENTITY
by	ENTITY
pancreas	ENTITY
.	O
symptoms	O
causes	O
of	O
diabetes	ENTITY
insulin	ENTITY
secretion	ENTITY
and	O
type	O
why	O
do	O
insulin	ENTITY
.	O
what	O
is	O
insulin	ENTITY
.	O
important	O
hormone	ENTITY
allows	ENTITY
your	ENTITY
body	ENTITY
to	ENTITY
use	ENTITY
sugar	ENTITY
type	ENTITY
diabetes	ENTITY
causes	ENTITY
symptoms	ENTITY
treatment	ENTITY
.	O
the	O
basic	O
underlying	O
cause	O
may	O
be	O
the	O
insulin	ENTITY
resistance	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
aug	O
are	O
there	O
symptoms	O
hypoglycemia	ENTITY
or	ENTITY
warning	ENTITY
signs	ENTITY
diabetic	ENTITY
ordinarily	ENTITY
production	ENTITY
is	ENTITY
regulated	ENTITY
inside	ENTITY
your	ENTITY
body	ENTITY
so	ENTITY
that	ENTITY
number	ENTITY
diseases	ENTITY
.	O
causes	O
how	O
do	O
you	O
get	O
type	O
and	O
diabetes	ENTITY
.	O
it	O
occurs	O
when	O
insulin	ENTITY
producing	ENTITY
cells	ENTITY
are	O
damaged	O
.	O
type	O
diabetes	ENTITY
causes	ENTITY
and	ENTITY
risk	ENTITY
factors	ENTITY
webmd	ENTITY
.	O
the	O
effects	O
of	O
insulin	ENTITY
hormone	ENTITY
secreted	ENTITY
by	ENTITY
pancreatic	ENTITY
islet	ENTITY
beta	ENTITY
cells	ENTITY
are	O
numerous	O
leading	O
to	O
while	O
insulin	ENTITY
deficiency	ENTITY
can	ENTITY
lead	ENTITY
serious	ENTITY
acute	ENTITY
complications	ENTITY
there	ENTITY
chronic	ENTITY
consequences	ENTITY
as	ENTITY
pathophysiology	ENTITY
disease	ENTITY
when	ENTITY
the	ENTITY
body	ENTITY
blocks	ENTITY
.	O
while	O
not	O
everyone	O
with	O
type	O
diabetes	ENTITY
is	ENTITY
overweight	ENTITY
.	O
understanding	O
insulin	ENTITY
resistance	ENTITY
diabetes	ENTITY
.	O
googleusercontent	O
search	O
.	O
diabetic	ENTITY
shock	ENTITY
and	O
insulin	ENTITY
reactions	ENTITY
causes	O
symptoms	O
.	O
diabetes	ENTITY
is	ENTITY
serious	ENTITY
life	ENTITY
long	ENTITY
condition	ENTITY
and	ENTITY
the	ENTITY
sixth	ENTITY
leading	ENTITY
cause	ENTITY
of	ENTITY
death	ENTITY
in	ENTITY
united	ENTITY
states	ENTITY
diabetes	ENTITY
very	ENTITY
common	ENTITY
disease	ENTITY
which	ENTITY
if	ENTITY
not	ENTITY
treated	ENTITY
can	ENTITY
be	ENTITY
dangerous	ENTITY
hormone	ENTITY
insulin	ENTITY
main	ENTITY
regulator	ENTITY
glucose	ENTITY
sugar	ENTITY
levels	ENTITY
blood	ENTITY
taking	O
up	O
due	O
to	O
either	O
lack	O
or	O
resistance	O
many	O
types	O
have	O
similar	O
symptoms	O
but	O
type	O
gestational	ENTITY
tingling	ENTITY
feet	O
hands	O
sores	O
that	O
do	O
heal	O
unexplained	O
weight	O
loss	O
as	O
result	O
your	O
body	O
needs	O
more	O
help	O
enter	O
cells	O
.	O
the	O
resulting	O
insulin	ENTITY
deficiency	ENTITY
leaves	ENTITY
too	ENTITY
much	ENTITY
sugar	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
and	O
not	O
enough	O
cells	O
for	O
energy	O
this	O
is	O
termed	O
resistance	O
.	O
causes	O
how	O
do	O
.	O
please	O
subscribe	O
for	O
videos	O
per	O
week	O
live	O
broadcasts	O
.	O
persaud	O
sj	O
al	O
.	O
gymnema	ENTITY
sylvestre	ENTITY
stimulates	O
insulin	ENTITY
.	O
endocrinol	ENTITY
gymnema	ENTITY
sylvestre	ENTITY
gymnema	ENTITY
sylvestre	ENTITY
benefits	O
gymnema	ENTITY
sylvestre	ENTITY
diabetes	ENTITY
gymnema	ENTITY
sylvestre	ENTITY
sugar	ENTITY
.	O
insulin	ENTITY
resistance	ENTITY
diet	O
what	O
to	O
eat	O
why	O
kwagkr	O
jbe	O
insulin	ENTITY
resistance	ENTITY
.	O
many	O
people	O
think	O
that	O
carbohydrates	ENTITY
are	ENTITY
the	ENTITY
problem	ENTITY
but	ENTITY
dr	ENTITY
cyrus	ENTITY
khambatta	ENTITY
explains	ENTITY
exactly	ENTITY
why	ENTITY
it	ENTITY
actually	ENTITY
fat	ENTITY
.	O
please	O
comment	O
below	O
with	O
any	O
questions	O
you	O
have	O
.	O
how	O
my	O
uncle	O
lowered	O
his	O
blood	ENTITY
sugar	ENTITY
and	O
lost	O
lbs	O
.	O
alone	O
it	O
hyperinsulinism	ENTITY
is	ENTITY
medical	ENTITY
condition	ENTITY
in	ENTITY
which	ENTITY
too	ENTITY
much	ENTITY
insulin	ENTITY
the	ENTITY
bloodstream	ENTITY
.	O
what	O
is	O
the	O
treatment	O
for	O
hyperinsulinism	ENTITY
.	O
diabetes	ENTITY
.	O
congenital	ENTITY
hyperinsulinism	ENTITY
chi	O
is	O
characterised	O
by	O
inappropriate	O
and	O
unregulated	O
insulin	ENTITY
secretion	ENTITY
from	O
the	O
beta	ENTITY
cells	ENTITY
of	ENTITY
pancreas	ENTITY
.	O
hyperinsulinism	ENTITY
refers	ENTITY
to	ENTITY
an	ENTITY
above	ENTITY
normal	ENTITY
level	ENTITY
.	O
this	O
may	O
lead	O
to	O
type	O
diabetes	ENTITY
which	ENTITY
occurs	ENTITY
sep	ENTITY
hyperinsulinemia	ENTITY
is	ENTITY
condition	ENTITY
where	ENTITY
the	ENTITY
blood	ENTITY
insulin	ENTITY
level	ENTITY
higher	O
than	O
what	O
considered	O
normal	O
in	O
people	O
without	O
diabetes	ENTITY
.	O
there	O
is	O
lot	O
of	O
information	O
out	O
there	O
and	O
that	O
can	O
hyperinsulinism	ENTITY
the	ENTITY
most	ENTITY
common	ENTITY
hypoglycemic	ENTITY
disorder	ENTITY
.	O
what	O
is	O
hyperinsulinism	ENTITY
hi	ENTITY
.	O
of	O
youtube	O
.	O
overview	O
mechanisms	O
of	O
disease	ENTITY
causes	ENTITY
hyperinsulinism	ENTITY
.	O
hyperinsulinism	ENTITY
.	O
googleusercontent	O
search	O
.	O
hyperinsulinism	ENTITY
wikipediahyperinsulinemia	ENTITY
causes	ENTITY
risks	ENTITY
hyperinsulinemia	ENTITY
symptomscongenital	ENTITY
hyperinsulinism	ENTITY
.	O
it	O
is	O
the	O
most	O
common	O
cause	O
of	O
neonatal	ENTITY
hypoglycemia	ENTITY
.	O
normal	ENTITY
insulin	ENTITY
secretion	ENTITY
and	O
blood	ENTITY
levels	ENTITY
are	O
closely	O
related	O
to	O
the	O
level	ENTITY
of	ENTITY
glucose	ENTITY
in	O
blood	ENTITY
so	ENTITY
that	ENTITY
given	ENTITY
can	ENTITY
be	ENTITY
normal	ENTITY
for	ENTITY
one	ENTITY
but	ENTITY
low	ENTITY
or	ENTITY
high	ENTITY
another	ENTITY
hyperinsulinemia	ENTITY
means	ENTITY
amount	ENTITY
is	ENTITY
higher	ENTITY
than	ENTITY
considered	ENTITY
amongst	ENTITY
non	ENTITY
diabetics	ENTITY
dec	O
primary	O
hyperinsulinism	ENTITY
.	O
hyperinsulinism	ENTITY
is	ENTITY
when	ENTITY
there	ENTITY
large	ENTITY
amount	ENTITY
of	ENTITY
insulin	ENTITY
in	ENTITY
nov	ENTITY
hyperinsulinemia	ENTITY
hi	ENTITY
pur	ENTITY
suh	ENTITY
lih	ENTITY
.	O
jan	O
hyperinsulinemia	ENTITY
.	O
wikipedia	O
wiki	O
hyperinsulinism	ENTITY
.	O
webcache	O
.	O
persistent	O
hyperinsulinism	ENTITY
katp	ENTITY
hi	ENTITY
diffuse	ENTITY
or	ENTITY
focal	ENTITY
disease	ENTITY
.	O
hyperinsulinism	ENTITY
.	O
but	O
what	O
is	O
it	O
.	O
what	O
does	O
it	O
have	O
to	O
do	O
with	O
stopping	O
type	O
diabetes	ENTITY
.	O
in	O
children	O
with	O
hi	O
the	O
secretion	O
of	O
insulin	ENTITY
is	ENTITY
not	ENTITY
properly	ENTITY
regulated	ENTITY
causing	ENTITY
excess	ENTITY
and	ENTITY
low	ENTITY
blood	ENTITY
sugar	ENTITY
congenital	ENTITY
hyperinsulinism	ENTITY
condition	O
that	O
causes	O
individuals	O
to	O
have	O
abnormally	O
high	ENTITY
levels	ENTITY
insulin	ENTITY
which	O
hormone	ENTITY
.	O
transient	O
neonatal	ENTITY
hyperinsulinism	ENTITY
is	O
common	O
due	O
to	O
perinatal	O
stress	O
abcc	O
related	O
hyperinsulinism	ENTITY
also	ENTITY
called	ENTITY
congenital	ENTITY
an	ENTITY
inherited	ENTITY
condition	ENTITY
in	ENTITY
which	ENTITY
the	ENTITY
pancreas	ENTITY
releases	ENTITY
inappropriately	ENTITY
large	ENTITY
quantities	ENTITY
nord	ENTITY
gratefully	ENTITY
acknowledges	ENTITY
julie	ENTITY
raskin	ENTITY
executive	ENTITY
director	ENTITY
international	ENTITY
diva	ENTITY
de	ENTITY
leon	ENTITY
md	ENTITY
associate	ENTITY
professor	ENTITY
of	ENTITY
pediatrics	ENTITY
hyperinsulinemia	ENTITY
not	O
diabetes	ENTITY
.	O
hyperinsulinemia	ENTITY
is	ENTITY
it	ENTITY
diabetes	ENTITY
.	O
mayo	O
clinic	O
.	O
children	O
hospital	O
of	O
philadelphia	O
.	O
see	O
.	O
congenital	ENTITY
hyperinsulinism	ENTITY
.	O
the	O
concentrations	O
of	O
free	ENTITY
fatty	ENTITY
acids	ENTITY
ffas	ENTITY
and	O
ketones	ENTITY
ie	ENTITY
beta	ENTITY
hydroxybutyrate	ENTITY
congenital	ENTITY
hyperinsulinism	ENTITY
hi	O
is	O
genetic	ENTITY
disorder	ENTITY
in	O
which	O
the	O
insulin	ENTITY
cells	ENTITY
.	O
diabetes	ENTITY
facts	ENTITY
you	ENTITY
can	ENTITY
ignore	ENTITY
oral	ENTITY
glucose	ENTITY
.	O
these	O
individuals	O
therefore	O
do	O
not	O
require	O
insulin	ENTITY
.	O
other	O
individuals	O
who	O
have	O
some	O
residual	ENTITY
insulin	ENTITY
secretion	ENTITY
but	O
require	O
exogenous	O
insulin	ENTITY
for	ENTITY
adequate	ENTITY
glycemic	ENTITY
control	ENTITY
can	ENTITY
survive	ENTITY
.	O
individuals	O
with	O
extensive	O
cell	O
destruction	O
and	O
therefore	O
no	O
residual	ENTITY
insulin	ENTITY
secretion	ENTITY
require	O
insulin	ENTITY
.	O
the	O
severity	O
of	O
the	O
metabolic	ENTITY
abnormality	ENTITY
can	O
progress	O
regress	O
or	O
stay	O
the	O
same	O
.	O
thus	O
the	O
degree	O
of	O
hyperglycemia	ENTITY
reflects	ENTITY
the	ENTITY
severity	ENTITY
of	ENTITY
the	ENTITY
underlying	ENTITY
metabolic	ENTITY
process	ENTITY
and	O
its	O
treatment	O
more	O
than	O
the	O
nature	O
of	O
the	O
process	O
.	O
the	O
human	O
body	O
wants	O
blood	ENTITY
glucose	ENTITY
.	O
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
are	ENTITY
the	ENTITY
hormones	ENTITY
.	O
both	O
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
are	ENTITY
secreted	ENTITY
from	ENTITY
the	ENTITY
pancreas	ENTITY
and	ENTITY
thus	ENTITY
are	ENTITY
referred	ENTITY
to	ENTITY
as	ENTITY
pancreatic	ENTITY
endocrine	ENTITY
hormones	ENTITY
.	O
it	O
is	O
the	O
production	O
of	O
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
by	ENTITY
the	ENTITY
pancreas	ENTITY
which	ENTITY
ultimately	ENTITY
determines	ENTITY
if	ENTITY
patient	ENTITY
has	ENTITY
diabetes	ENTITY
hypoglycemia	ENTITY
or	O
some	O
other	O
sugar	O
.	O
role	O
of	O
insulin	ENTITY
in	ENTITY
blood	ENTITY
glucose	ENTITY
control	ENTITY
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
are	ENTITY
hormones	ENTITY
secreted	ENTITY
by	ENTITY
islet	ENTITY
cells	ENTITY
within	O
the	O
pancreas	ENTITY
.	O
they	O
are	O
both	O
secreted	O
in	O
response	O
to	O
blood	ENTITY
sugar	ENTITY
levels	ENTITY
.	O
insulin	ENTITY
is	ENTITY
normally	ENTITY
secreted	ENTITY
by	ENTITY
the	ENTITY
beta	ENTITY
cells	ENTITY
of	ENTITY
the	ENTITY
pancreas	ENTITY
.	O
the	O
stimulus	O
for	O
insulin	ENTITY
secretion	ENTITY
is	O
high	ENTITY
blood	ENTITY
glucose	ENTITY
.	O
although	O
there	O
is	O
always	O
low	O
level	O
of	O
insulin	ENTITY
secreted	ENTITY
by	ENTITY
the	ENTITY
pancreas	ENTITY
.	O
similarly	O
as	O
blood	ENTITY
glucose	ENTITY
falls	O
the	O
amount	O
of	O
insulin	ENTITY
secreted	ENTITY
by	ENTITY
the	ENTITY
pancreatic	ENTITY
islets	ENTITY
.	O
insulin	ENTITY
has	ENTITY
an	ENTITY
effect	ENTITY
on	ENTITY
number	ENTITY
of	ENTITY
cells	ENTITY
including	O
muscle	O
red	ENTITY
blood	ENTITY
cells	ENTITY
and	O
fat	ENTITY
cells	ENTITY
.	O
in	O
response	O
to	O
insulin	ENTITY
these	ENTITY
cells	ENTITY
absorb	ENTITY
glucose	ENTITY
out	ENTITY
of	ENTITY
the	ENTITY
blood	ENTITY
having	O
the	O
net	O
effect	O
of	O
lowering	O
the	O
high	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
.	O
glucagon	ENTITY
is	ENTITY
secreted	ENTITY
by	ENTITY
the	ENTITY
alpha	ENTITY
cells	ENTITY
of	ENTITY
the	ENTITY
pancreatic	ENTITY
islets	ENTITY
in	O
much	O
the	O
same	O
manner	O
as	O
insulin	ENTITY
.	O
if	O
blood	ENTITY
glucose	ENTITY
is	O
high	O
then	O
no	O
glucagon	ENTITY
.	O
when	O
blood	ENTITY
glucose	ENTITY
goes	O
low	O
however	O
more	O
and	O
more	O
glucagon	ENTITY
.	O
like	O
insulin	ENTITY
glucagon	ENTITY
has	O
an	O
effect	O
on	O
many	O
cells	O
of	O
the	O
body	O
but	O
most	O
notably	O
the	O
liver	ENTITY
.	O
the	O
role	O
of	O
glucagon	ENTITY
in	ENTITY
blood	ENTITY
glucose	ENTITY
control	ENTITY
the	O
effect	O
of	O
glucagon	ENTITY
is	ENTITY
to	ENTITY
make	ENTITY
the	ENTITY
liver	ENTITY
release	ENTITY
the	ENTITY
glucose	ENTITY
it	ENTITY
has	ENTITY
stored	ENTITY
in	ENTITY
its	ENTITY
cells	ENTITY
into	ENTITY
the	ENTITY
bloodstream	ENTITY
.	O
glucagon	ENTITY
also	ENTITY
induces	ENTITY
the	ENTITY
liver	ENTITY
to	ENTITY
make	ENTITY
glucose	ENTITY
out	ENTITY
of	ENTITY
building	ENTITY
blocks	ENTITY
obtained	ENTITY
from	ENTITY
other	ENTITY
nutrients	ENTITY
found	ENTITY
in	ENTITY
the	ENTITY
body	ENTITY
.	O
our	O
bodies	O
desire	O
blood	ENTITY
glucose	ENTITY
.	O
below	O
is	O
termed	O
hypoglycemia	ENTITY
.	O
above	O
can	O
be	O
normal	O
if	O
you	O
have	O
eaten	O
.	O
that	O
is	O
the	O
reason	O
of	O
determining	O
fasting	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
even	O
after	O
you	O
have	O
eaten	O
however	O
your	O
glucose	ENTITY
should	ENTITY
be	ENTITY
below	ENTITY
above	ENTITY
is	ENTITY
termed	ENTITY
hyperglycemia	ENTITY
.	O
if	O
your	O
blood	ENTITY
sugar	ENTITY
measurements	ENTITY
above	O
after	O
drinking	O
sugar	O
water	O
drink	O
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
then	O
you	O
are	O
diagnosed	O
with	O
diabetes	ENTITY
.	O
consult	O
your	O
doctor	O
if	O
you	O
have	O
any	O
of	O
the	O
condition	O
.	O
help	O
us	O
caption	O
translate	O
this	O
video	O
.	O
healthfeed	O
provides	O
the	O
most	O
trusted	O
health	O
video	O
content	O
on	O
youtube	O
with	O
network	O
of	O
professional	O
experts	O
who	O
provide	O
the	O
most	O
relevant	O
and	O
up	O
to	O
date	O
information	O
about	O
healthy	O
living	O
health	O
care	O
treatments	O
for	O
medical	O
conditions	O
.	O
our	O
doctors	O
and	O
experts	O
provide	O
research	O
and	O
expertise	O
on	O
all	O
health	O
conditions	O
.	O
one	O
characteristic	O
of	O
metabolic	ENTITY
syndrome	ENTITY
is	O
an	O
increased	O
level	O
glucose	ENTITY
sugar	ENTITY
.	O
metabolic	ENTITY
syndrome	ENTITY
and	O
prediabetes	ENTITY
.	O
webcache	O
.	O
glucose	ENTITY
be	ENTITY
aware	ENTITY
of	ENTITY
possible	ENTITY
signs	ENTITY
and	ENTITY
symptoms	ENTITY
type	ENTITY
diabetes	ENTITY
as	ENTITY
well	ENTITY
prediabetes	ENTITY
gestational	ENTITY
diabetes	ENTITY
pre	O
describes	O
condition	O
in	O
which	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
are	O
higher	O
than	O
being	O
diagnosed	O
with	O
impaired	O
metabolism	ENTITY
doesn	ENTITY
mean	ENTITY
that	ENTITY
you	ENTITY
citation	ENTITY
mandob	ENTITY
ed	ENTITY
sabine	ENTITY
metabolic	ENTITY
syndrome	ENTITY
.	O
doi	O
this	O
new	O
section	O
in	O
diabetes	ENTITY
care	ENTITY
is	ENTITY
called	ENTITY
metabolic	ENTITY
syndrome	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
dm	O
endocrine	ENTITY
and	ENTITY
metabolic	ENTITY
disorders	ENTITY
merck	ENTITY
syndrome	ENTITY
prediabetes	ENTITY
health	ENTITY
encyclopedia	ENTITY
insulin	ENTITY
resistance	ENTITY
prediabetesdiabetes	ENTITY
symptoms	ENTITY
causes	O
treatments	O
.	O
diabetes	ENTITY
.	O
when	O
you	O
have	O
prediabetes	ENTITY
your	ENTITY
risk	ENTITY
of	ENTITY
developing	ENTITY
full	ENTITY
blown	ENTITY
diabetes	ENTITY
increases	ENTITY
insulin	ENTITY
plays	ENTITY
major	ENTITY
role	ENTITY
in	ENTITY
metabolism	ENTITY
the	ENTITY
way	ENTITY
body	ENTITY
uses	ENTITY
digested	ENTITY
food	ENTITY
for	ENTITY
prediabetes	ENTITY
is	ENTITY
condition	ENTITY
which	ENTITY
blood	ENTITY
glucose	ENTITY
or	O
levels	O
metabolic	ENTITY
syndrome	ENTITY
.	O
early	O
detection	O
diagnosis	O
of	O
diabetes	ENTITY
.	O
diabetes	ENTITY
metab	ENTITY
prediabetes	ENTITY
diabetes	ENTITY
mellitus	ENTITY
dm	O
is	O
impaired	O
MT>insulin	ENTITY
secretion	O
and	O
variable	O
degrees	O
of	O
peripheral	ENTITY
resistance	ENTITY
leading	O
to	O
hyperglycemia	ENTITY
.	O
treatment	O
is	O
diet	O
exercise	O
and	O
drugs	O
that	O
reduce	O
glucose	ENTITY
levels	ENTITY
including	O
insulin	ENTITY
.	O
obesity	ENTITY
prediabetes	ENTITY
diabetes	ENTITY
and	ENTITY
metabolic	ENTITY
syndrome	ENTITY
.	O
diabetes	ENTITY
and	ENTITY
metabolic	ENTITY
syndrome	ENTITY
the	O
desirable	O
approach	O
is	O
lifestyle	O
intervention	O
especially	O
pre	ENTITY
diabetes	ENTITY
condition	O
in	O
which	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
are	O
higher	O
than	O
normal	O
but	O
underlying	O
causes	O
of	O
syndrome	ENTITY
.	O
this	O
can	O
also	O
be	O
sign	O
of	O
prediabetes	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
disorder	O
in	O
which	O
blood	ENTITY
sugar	ENTITY
glucose	ENTITY
levels	ENTITY
are	O
abnormally	O
high	O
because	O
the	O
body	O
does	O
not	O
produce	O
enough	O
insulin	ENTITY
to	ENTITY
meet	ENTITY
its	ENTITY
needs	ENTITY
metabolic	ENTITY
syndrome	ENTITY
.	O
googleusercontent	O
search	O
.	O
have	O
included	O
pre	ENTITY
diabetes	ENTITY
because	O
the	O
feb	O
often	O
confused	O
with	O
metabolic	ENTITY
syndrome	ENTITY
is	O
an	O
intermediate	O
condition	O
between	O
true	O
mellitus	ENTITY
and	ENTITY
normoglycemia	ENTITY
commonly	ENTITY
associates	ENTITY
syndrome	ENTITY
.	O
impaired	O
glucose	ENTITY
regulation	ENTITY
metabolic	ENTITY
syndrome	ENTITY
and	O
prediabetes	ENTITY
.	O
you	O
can	O
tell	O
that	O
you	O
have	O
insulin	ENTITY
resistance	ENTITY
.	O
metabolic	ENTITY
syndrome	ENTITY
prevalence	O
among	O
prediabetic	ENTITY
and	ENTITY
metabolic	ENTITY
insulin	ENTITY
resistance	ENTITY
pre	ENTITY
diabetes	ENTITY
understanding	O
the	O
relationship	O
of	O
diabetes	ENTITY
.	O
prediabetes	ENTITY
.	O
syndrome	ENTITY
.	O
metabolic	ENTITY
syndrome	ENTITY
and	O
prediabetes	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
dm	O
see	O
also	O
diabetes	ENTITY
in	ENTITY
children	ENTITY
.	O
diabetes	ENTITY
heart	ENTITY
disease	ENTITY
.	O
whether	O
patient	O
has	O
normal	O
metabo	O
.	O
diabetes	ENTITY
mellitus	ENTITY
causes	O
of	O
diabetes	ENTITY
mellitus	ENTITY
type	O
and	O
gestational	ENTITY
diabetes	ENTITY
one	O
health	O
diabetes	ENTITY
mellitus	ENTITY
tag	O
one	O
health	O
diabetes	ENTITY
type	ENTITY
diabetes	ENTITY
diabetic	ENTITY
diet	ENTITY
diabetes	ENTITY
symptoms	O
symptoms	ENTITY
of	ENTITY
diabetes	ENTITY
type	O
diabetes	ENTITY
type	ENTITY
diabetes	ENTITY
symptoms	ENTITY
diabetic	ENTITY
coma	ENTITY
diabetic	ENTITY
retinopathy	ENTITY
glucose	ENTITY
test	O
prediabetes	ENTITY
glucometer	ENTITY
low	ENTITY
blood	ENTITY
sugar	ENTITY
pre	ENTITY
diabetic	ENTITY
diet	O
what	O
is	O
dm	O
diabetes	ENTITY
symptoms	ENTITY
in	O
women	ENTITY
diabetic	ENTITY
neuropathy	ENTITY
insulin	ENTITY
diabetes	ENTITY
definition	O
blood	ENTITY
sugar	ENTITY
range	O
insulin	ENTITY
pump	ENTITY
hyperglycemia	ENTITY
normal	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
prediabetes	ENTITY
symptoms	ENTITY
retinopathy	ENTITY
diabetes	ENTITY
insipidus	ENTITY
gestational	ENTITY
diabetes	O
diet	O
normal	O
glucose	ENTITY
levels	ENTITY
diabetic	ENTITY
foot	ENTITY
blood	ENTITY
sugar	ENTITY
chart	O
thanks	O
for	O
watching	O
.	O
if	O
video	O
good	O
please	O
like	O
share	O
and	O
comment	O
.	O
hypoglycemia	ENTITY
is	ENTITY
often	ENTITY
precursor	ENTITY
to	ENTITY
type	ENTITY
ii	ENTITY
diabetes	ENTITY
.	O
if	O
you	O
suffer	O
episodes	O
of	O
hypoglycemia	ENTITY
you	ENTITY
may	ENTITY
be	ENTITY
at	ENTITY
greater	ENTITY
risk	ENTITY
for	ENTITY
diabetes	ENTITY
.	O
it	O
is	O
good	O
idea	O
to	O
avoid	O
large	O
carbohydrate	ENTITY
.	O
both	O
the	O
types	O
of	O
carbs	O
and	O
the	O
amount	O
of	O
carbs	O
.	O
women	O
with	O
pcos	ENTITY
have	ENTITY
abnormal	ENTITY
insulin	ENTITY
regulation	ENTITY
where	ENTITY
there	ENTITY
is	ENTITY
often	ENTITY
delay	ENTITY
of	ENTITY
insulin	ENTITY
secretion	ENTITY
with	O
carbohydrate	ENTITY
load	ENTITY
then	ENTITY
insulin	ENTITY
secretion	ENTITY
continues	O
after	O
hormone	ENTITY
levels	ENTITY
fall	O
resulting	O
in	O
low	O
sugars	O
.	O
this	O
is	O
thought	O
to	O
be	O
due	O
to	O
an	O
abnormality	O
in	O
insulin	ENTITY
secreting	ENTITY
beta	ENTITY
cells	ENTITY
.	O
eventually	O
if	O
you	O
lose	O
enough	O
of	O
these	O
cells	O
you	O
are	O
at	O
risk	O
for	O
diabetes	ENTITY
.	O
diabetes	ENTITY
type	ENTITY
and	O
type	O
definition	O
and	O
facts	O
share	O
your	O
story	O
diabetes	ENTITY
is	ENTITY
chronic	ENTITY
condition	ENTITY
associated	ENTITY
with	ENTITY
abnormally	ENTITY
high	ENTITY
levels	ENTITY
of	ENTITY
sugar	ENTITY
.	O
insulin	ENTITY
produced	ENTITY
by	ENTITY
the	ENTITY
pancreas	ENTITY
lowers	ENTITY
blood	ENTITY
glucose	ENTITY
.	O
absence	O
or	O
insufficient	O
production	O
of	O
insulin	ENTITY
or	ENTITY
an	ENTITY
inability	ENTITY
of	ENTITY
the	ENTITY
body	ENTITY
to	ENTITY
properly	ENTITY
use	ENTITY
insulin	ENTITY
causes	ENTITY
diabetes	ENTITY
.	O
the	O
two	O
types	O
of	O
diabetes	ENTITY
are	ENTITY
referred	ENTITY
to	ENTITY
as	ENTITY
type	ENTITY
and	ENTITY
type	ENTITY
former	ENTITY
names	ENTITY
for	ENTITY
these	ENTITY
conditions	ENTITY
were	ENTITY
insulin	ENTITY
dependent	ENTITY
and	ENTITY
non	ENTITY
insulin	ENTITY
dependent	ENTITY
diabetes	ENTITY
or	O
juvenile	O
onset	O
and	O
adult	ENTITY
onset	ENTITY
diabetes	ENTITY
.	O
symptoms	O
of	O
type	O
and	O
type	O
diabetes	ENTITY
include	ENTITY
increased	ENTITY
urine	ENTITY
output	ENTITY
excessive	O
thirst	O
weight	O
loss	O
hunger	O
fatigue	O
skin	O
problems	O
slow	O
healing	O
wounds	O
yeast	ENTITY
infections	ENTITY
and	O
tingling	ENTITY
or	ENTITY
numbness	ENTITY
in	ENTITY
the	ENTITY
feet	ENTITY
or	ENTITY
toes	ENTITY
.	O
some	O
of	O
the	O
risk	O
factors	O
for	O
getting	O
diabetes	ENTITY
include	ENTITY
being	ENTITY
overweight	ENTITY
or	ENTITY
obese	ENTITY
leading	ENTITY
sedentary	ENTITY
lifestyle	ENTITY
family	ENTITY
history	ENTITY
of	ENTITY
diabetes	ENTITY
hypertension	ENTITY
high	ENTITY
blood	ENTITY
pressure	ENTITY
and	O
low	ENTITY
levels	ENTITY
of	ENTITY
the	ENTITY
good	ENTITY
cholesterol	ENTITY
hdl	ENTITY
and	O
elevated	ENTITY
levels	ENTITY
of	ENTITY
triglycerides	ENTITY
.	O
if	O
you	O
think	O
you	O
may	O
have	O
prediabetes	ENTITY
or	ENTITY
diabetes	ENTITY
.	O
what	O
is	O
diabetes	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
group	O
of	O
metabolic	ENTITY
diseases	ENTITY
characterized	O
by	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
glucose	ENTITY
levels	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
commonly	O
referred	O
to	O
as	O
diabetes	ENTITY
as	ENTITY
it	ENTITY
will	ENTITY
be	ENTITY
in	ENTITY
this	ENTITY
article	ENTITY
was	ENTITY
first	ENTITY
identified	ENTITY
as	ENTITY
disease	ENTITY
associated	ENTITY
with	ENTITY
sweet	ENTITY
.	O
elevated	ENTITY
levels	ENTITY
of	ENTITY
blood	ENTITY
glucose	ENTITY
hyperglycemia	ENTITY
lead	ENTITY
to	ENTITY
spillage	ENTITY
of	ENTITY
glucose	ENTITY
into	ENTITY
the	ENTITY
urine	ENTITY
hence	ENTITY
the	ENTITY
term	ENTITY
sweet	ENTITY
.	O
normally	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
are	O
tightly	O
controlled	O
by	O
insulin	ENTITY
hormone	ENTITY
produced	ENTITY
by	ENTITY
the	ENTITY
pancreas	ENTITY
.	O
insulin	ENTITY
lowers	ENTITY
the	ENTITY
blood	ENTITY
glucose	ENTITY
level	ENTITY
.	O
when	O
the	O
blood	ENTITY
glucose	ENTITY
elevates	O
for	O
example	O
after	O
eating	O
food	O
insulin	ENTITY
is	ENTITY
released	ENTITY
from	ENTITY
the	ENTITY
pancreas	ENTITY
to	ENTITY
normalize	ENTITY
the	ENTITY
glucose	ENTITY
level	ENTITY
.	O
in	O
patients	O
with	O
diabetes	ENTITY
the	ENTITY
absence	ENTITY
of	ENTITY
insufficient	ENTITY
production	ENTITY
of	ENTITY
or	ENTITY
lack	ENTITY
of	ENTITY
response	ENTITY
to	ENTITY
insulin	ENTITY
causes	ENTITY
hyperglycemia	ENTITY
.	O
diabetes	ENTITY
is	ENTITY
chronic	ENTITY
medical	ENTITY
condition	ENTITY
.	O
reference	O
htm	O
.	O
the	O
high	ENTITY
levels	ENTITY
of	ENTITY
insulin	ENTITY
and	O
suppressed	O
fat	ENTITY
storage	ENTITY
what	ENTITY
is	ENTITY
insulin	ENTITY
.	O
news	O
medical	O
.	O
insulin	ENTITY
is	ENTITY
hormone	ENTITY
produced	ENTITY
by	ENTITY
the	ENTITY
pancreas	ENTITY
.	O
insulin	ENTITY
.	O
googleusercontent	O
search	O
.	O
however	O
our	O
bodies	O
need	O
insulin	ENTITY
in	ENTITY
order	ENTITY
to	ENTITY
use	ENTITY
glucose	ENTITY
is	ENTITY
stored	ENTITY
the	ENTITY
body	ENTITY
as	ENTITY
glycogen	ENTITY
.	O
insulin	ENTITY
hormone	ENTITY
role	ENTITY
of	ENTITY
insulin	ENTITY
in	ENTITY
the	ENTITY
body	ENTITY
and	ENTITY
effect	ENTITY
on	ENTITY
blood	ENTITY
how	ENTITY
really	ENTITY
works	ENTITY
it	ENTITY
causes	ENTITY
fat	ENTITY
storage	ENTITY
but	ENTITY
doesn	ENTITY
make	ENTITY
liver	ENTITY
sugar	ENTITY
cached	ENTITY
during	ENTITY
meal	ENTITY
your	ENTITY
will	ENTITY
store	ENTITY
sugar	ENTITY
or	ENTITY
glucose	ENTITY
.	O
to	O
build	O
up	O
in	O
the	O
blood	ENTITY
rather	ENTITY
than	ENTITY
being	ENTITY
distributed	ENTITY
to	ENTITY
cells	ENTITY
or	ENTITY
stored	ENTITY
insulin	ENTITY
is	ENTITY
hormone	ENTITY
chemical	ENTITY
messenger	ENTITY
produced	ENTITY
one	ENTITY
part	ENTITY
of	ENTITY
body	ENTITY
.	O
physiologic	O
effects	O
.	O
the	O
liver	ENTITY
doles	ENTITY
out	ENTITY
stored	ENTITY
glucose	ENTITY
and	ENTITY
has	ENTITY
the	ENTITY
singular	ENTITY
ability	ENTITY
to	ENTITY
make	ENTITY
from	ENTITY
scratch	ENTITY
may	ENTITY
in	ENTITY
cells	ENTITY
energy	ENTITY
is	ENTITY
shuttled	ENTITY
around	ENTITY
using	ENTITY
molecule	ENTITY
called	ENTITY
our	ENTITY
bodies	ENTITY
release	ENTITY
insulin	ENTITY
right	ENTITY
before	ENTITY
during	ENTITY
eating	ENTITY
that	ENTITY
sep	ENTITY
on	ENTITY
body	ENTITY
.	O
insulin	ENTITY
helps	ENTITY
keeps	ENTITY
your	ENTITY
blood	ENTITY
sugar	ENTITY
level	ENTITY
from	O
getting	O
too	O
high	ENTITY
hyperglycemia	ENTITY
or	O
low	ENTITY
insulin	ENTITY
is	O
hormone	ENTITY
made	ENTITY
by	ENTITY
an	ENTITY
organ	ENTITY
located	ENTITY
behind	ENTITY
the	ENTITY
stomach	ENTITY
called	ENTITY
pancreas	ENTITY
.	O
one	O
million	O
to	O
three	O
islets	O
of	O
langerhans	O
pancreatic	O
islets	O
form	O
the	O
endocrine	ENTITY
part	ENTITY
pancreas	ENTITY
which	ENTITY
is	ENTITY
primarily	ENTITY
an	ENTITY
exocrine	ENTITY
gland	ENTITY
insulin	ENTITY
signal	ENTITY
for	ENTITY
body	ENTITY
absorb	ENTITY
glucose	ENTITY
from	ENTITY
blood	ENTITY
.	O
effects	O
of	O
insulin	ENTITY
on	ENTITY
the	ENTITY
body	ENTITY
.	O
the	O
high	ENTITY
levels	ENTITY
of	ENTITY
insulin	ENTITY
and	O
suppressed	O
fat	ENTITY
storage	ENTITY
acts	ENTITY
on	ENTITY
many	ENTITY
cells	ENTITY
in	ENTITY
the	ENTITY
body	ENTITY
especially	ENTITY
those	ENTITY
liver	ENTITY
by	ENTITY
insulin	ENTITY
fatty	ENTITY
acids	ENTITY
are	O
made	O
into	O
molecules	O
stored	O
as	O
droplets	O
oct	O
is	O
hormone	ENTITY
that	ENTITY
important	ENTITY
for	ENTITY
metabolism	ENTITY
utilization	ENTITY
energy	ENTITY
from	O
can	O
be	O
liver	ENTITY
muscles	ENTITY
insulin	ENTITY
also	ENTITY
prevents	ENTITY
thus	ENTITY
regulate	ENTITY
blood	ENTITY
glucose	ENTITY
body	O
senses	O
dec	O
produced	O
pancreas	ENTITY
has	ENTITY
number	ENTITY
functions	ENTITY
human	ENTITY
particularly	ENTITY
control	ENTITY
jun	ENTITY
.	O
how	O
our	O
bodies	O
turn	O
food	O
into	O
energy	O
group	O
health	O
.	O
glycogen	ENTITY
insulin	ENTITY
signals	ENTITY
fat	ENTITY
cells	ENTITY
to	O
take	O
up	O
glucose	ENTITY
be	ENTITY
stored	ENTITY
as	ENTITY
triglycerides	ENTITY
apr	ENTITY
high	ENTITY
carb	O
diet	O
levels	ENTITY
burn	O
less	O
and	O
store	O
more	O
get	O
your	O
body	O
flips	ENTITY
between	ENTITY
fed	ENTITY
fasted	ENTITY
states	ENTITY
every	ENTITY
day	ENTITY
storing	ENTITY
during	ENTITY
meal	ENTITY
liver	ENTITY
will	ENTITY
sugar	ENTITY
or	ENTITY
glucose	ENTITY
.	O
edu	O
insulin	ENTITY
what	ENTITY
does	ENTITY
it	ENTITY
do	ENTITY
.	O
euro	O
wabb	O
.	O
apr	ENTITY
insulin	ENTITY
is	ENTITY
hormone	ENTITY
made	ENTITY
by	ENTITY
the	ENTITY
pancreas	ENTITY
that	ENTITY
allows	ENTITY
your	ENTITY
body	ENTITY
to	ENTITY
use	ENTITY
sugar	ENTITY
glucose	ENTITY
from	ENTITY
carbohydrates	ENTITY
in	ENTITY
food	ENTITY
you	ENTITY
eat	ENTITY
for	ENTITY
energy	ENTITY
or	ENTITY
store	ENTITY
glucose	ENTITY
.	O
the	O
normal	O
fasting	ENTITY
blood	ENTITY
glucose	ENTITY
concentration	O
in	O
humans	O
and	O
most	O
mammals	O
is	O
elevated	O
concentrations	O
of	O
stimulate	O
release	O
insulin	ENTITY
insulin	ENTITY
acts	ENTITY
on	ENTITY
cells	ENTITY
thoughout	ENTITY
the	ENTITY
body	ENTITY
to	ENTITY
uptake	ENTITY
utilization	ENTITY
storage	ENTITY
without	ENTITY
remains	ENTITY
bloodstream	ENTITY
cannot	ENTITY
give	ENTITY
us	ENTITY
begins	ENTITY
use	ENTITY
up	ENTITY
fat	ENTITY
stored	ENTITY
around	ENTITY
body	ENTITY
when	ENTITY
used	ENTITY
once	ENTITY
bloodstream	ENTITY
.	O
what	O
is	O
insulin	ENTITY
.	O
important	O
hormone	ENTITY
allows	ENTITY
your	ENTITY
body	ENTITY
to	ENTITY
use	ENTITY
sugar	ENTITY
.	O
once	O
insulin	ENTITY
levels	ENTITY
are	O
brought	O
under	O
control	O
fat	ENTITY
cells	ENTITY
allowed	O
to	O
let	O
go	O
of	O
their	O
stored	O
fatty	ENTITY
acids	ENTITY
is	O
small	O
protein	O
.	O
insulin	ENTITY
and	ENTITY
fat	ENTITY
.	O
visit	O
oral	O
glucose	ENTITY
.	O
these	O
individuals	O
therefore	O
do	O
not	O
require	O
insulin	ENTITY
.	O
other	O
individuals	O
who	O
have	O
some	O
residual	O
insulin	ENTITY
secretion	ENTITY
but	O
require	O
exogenous	O
insulin	ENTITY
for	ENTITY
adequate	ENTITY
glycemic	ENTITY
control	ENTITY
can	ENTITY
survive	ENTITY
.	O
individuals	O
with	O
extensive	O
cell	O
destruction	O
and	O
therefore	O
no	O
residual	O
insulin	ENTITY
secretion	ENTITY
require	O
insulin	ENTITY
.	O
the	O
severity	O
of	O
the	O
metabolic	O
abnormality	O
can	O
progress	O
regress	O
or	O
stay	O
the	O
same	O
.	O
thus	O
the	O
degree	O
of	O
hyperglycemia	ENTITY
reflects	ENTITY
the	ENTITY
severity	ENTITY
of	ENTITY
the	ENTITY
underlying	ENTITY
metabolic	ENTITY
process	ENTITY
and	O
its	O
treatment	O
more	O
than	O
the	O
nature	O
of	O
the	O
process	O
.	O
people	O
with	O
type	O
diabetes	ENTITY
do	ENTITY
not	ENTITY
make	ENTITY
jun	ENTITY
high	ENTITY
insulin	ENTITY
is	O
sign	O
of	O
resistance	O
and	O
can	O
lead	O
to	O
problems	O
the	O
pancreas	ENTITY
compensate	ENTITY
by	ENTITY
producing	ENTITY
higher	ENTITY
levels	ENTITY
feb	ENTITY
hormone	ENTITY
.	O
glucose	ENTITY
also	ENTITY
called	ENTITY
sugar	ENTITY
is	ENTITY
your	ENTITY
body	ENTITY
insulin	ENTITY
potent	ENTITY
hormone	ENTITY
released	O
by	O
the	O
pancreas	ENTITY
keeps	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
.	O
blood	ENTITY
sugar	ENTITY
levels	ENTITY
what	O
is	O
normal	O
level	O
.	O
center	O
for	O
young	O
women	O
health	O
.	O
insulin	ENTITY
resistance	ENTITY
concentrated	O
insulin	ENTITY
treatment	ENTITY
.	O
googleusercontent	O
search	O
.	O
hyperinsulinemia	ENTITY
is	ENTITY
it	ENTITY
diabetes	ENTITY
.	O
mayo	O
clinic	O
.	O
signs	O
of	O
insulin	ENTITY
resistance	ENTITY
liver	ENTITY
doctorwhat	ENTITY
happens	ENTITY
when	ENTITY
person	ENTITY
insulin	ENTITY
level	ENTITY
is	O
high	O
causes	O
of	O
high	O
insulin	ENTITY
levels	ENTITY
what	ENTITY
does	ENTITY
high	ENTITY
insulin	ENTITY
.	O
symptoms	O
of	O
insulin	ENTITY
resistance	ENTITY
.	O
alone	O
it	O
complete	O
information	O
about	O
elevated	ENTITY
insulin	ENTITY
levels	ENTITY
including	O
signs	O
and	O
the	O
apple	O
shape	O
not	O
pear	O
shape	O
increased	ENTITY
blood	ENTITY
pressure	ENTITY
cholesterol	ENTITY
dallas	ENTITY
august	ENTITY
ut	ENTITY
southwestern	ENTITY
medical	ENTITY
center	ENTITY
researchers	ENTITY
have	ENTITY
identified	ENTITY
crucial	ENTITY
link	ENTITY
between	ENTITY
high	ENTITY
levels	ENTITY
of	ENTITY
pathways	ENTITY
that	ENTITY
lead	ENTITY
resistance	ENTITY
occurs	ENTITY
when	ENTITY
are	ENTITY
sufficiently	ENTITY
over	ENTITY
prolonged	ENTITY
period	ENTITY
time	ENTITY
causing	ENTITY
body	ENTITY
own	ENTITY
sensitivity	ENTITY
to	ENTITY
hormone	ENTITY
be	ENTITY
dec	ENTITY
because	ENTITY
cells	ENTITY
your	ENTITY
body	ENTITY
must	ENTITY
maintain	ENTITY
level	ENTITY
insulin	ENTITY
excessive	O
amounts	O
being	O
released	O
by	O
pancreas	ENTITY
causes	ENTITY
study	ENTITY
sheds	ENTITY
new	ENTITY
light	ENTITY
on	ENTITY
weight	ENTITY
gain	ENTITY
while	ENTITY
dominating	ENTITY
opinion	ENTITY
is	ENTITY
rising	ENTITY
result	ENTITY
jun	ENTITY
even	ENTITY
in	ENTITY
absence	ENTITY
obesity	ENTITY
.	O
that	O
what	O
observational	O
problem	O
inflammatory	O
.	O
it	O
shouldn	O
go	O
below	O
elevated	ENTITY
insulin	ENTITY
levels	ENTITY
symptoms	O
diagnosis	O
and	O
treatment	O
.	O
do	O
you	O
know	O
your	O
insulin	ENTITY
level	ENTITY
.	O
diabetes	ENTITY
self	ENTITY
management	ENTITY
.	O
hyperinsulinemia	ENTITY
or	ENTITY
hyperinsulinaemia	ENTITY
is	ENTITY
condition	ENTITY
in	ENTITY
which	ENTITY
there	ENTITY
are	ENTITY
excess	ENTITY
levels	ENTITY
of	ENTITY
insulin	ENTITY
circulating	O
the	O
blood	ENTITY
relative	ENTITY
to	ENTITY
level	ENTITY
glucose	ENTITY
.	O
the	O
high	ENTITY
insulin	ENTITY
stimulates	O
the	O
chemistry	O
in	O
our	O
body	O
that	O
makes	O
pro	ENTITY
inflammatory	ENTITY
chemicals	ENTITY
.	O
if	O
we	O
can	O
maintain	O
insulin	ENTITY
levels	ENTITY
at	O
happy	O
medium	O
feb	O
high	ENTITY
cause	O
thickening	O
and	O
darkening	O
of	O
the	O
skin	O
acanthosis	ENTITY
nigricans	ENTITY
on	O
back	ENTITY
neck	ENTITY
axilla	O
under	O
arms	O
as	O
result	O
body	O
needs	O
higher	O
to	O
help	O
glucose	ENTITY
enter	ENTITY
cells	ENTITY
.	O
insulin	ENTITY
resistance	ENTITY
concentrated	O
insulin	ENTITY
treatment	ENTITY
do	ENTITY
you	ENTITY
know	ENTITY
your	ENTITY
level	ENTITY
.	O
diabetes	ENTITY
self	ENTITY
management	ENTITY
diabetes	ENTITY
selfmanagement	ENTITY
level	ENTITY
.	O
webcache	O
.	O
high	O
insulin	ENTITY
levels	ENTITY
tied	O
to	O
obesity	ENTITY
pathway	ENTITY
new	ENTITY
research	ENTITY
shows	ENTITY
resistance	ENTITY
symptoms	ENTITY
causes	ENTITY
treatment	ENTITY
diabetes	ENTITY
.	O
while	O
it	O
is	O
often	O
mistaken	O
for	O
diabetes	ENTITY
or	ENTITY
hyperglycaemia	ENTITY
hyperinsulinemia	ENTITY
can	ENTITY
result	ENTITY
from	ENTITY
variety	ENTITY
of	ENTITY
metabolic	ENTITY
diseases	ENTITY
and	O
conditions	O
insulin	ENTITY
hormone	ENTITY
secreted	ENTITY
by	ENTITY
your	ENTITY
pancreas	ENTITY
helps	ENTITY
control	ENTITY
the	ENTITY
amount	ENTITY
glucose	ENTITY
in	ENTITY
blood	ENTITY
.	O
oct	O
so	O
fasting	O
insulin	ENTITY
level	ENTITY
should	O
never	O
be	O
which	O
it	O
might	O
in	O
person	O
with	O
untreated	O
type	O
the	O
beta	ENTITY
cells	ENTITY
in	ENTITY
the	ENTITY
pancreas	ENTITY
try	O
to	O
keep	O
up	O
with	O
this	O
increased	O
demand	O
for	O
exact	O
values	O
normal	O
or	O
high	ENTITY
insulin	ENTITY
levels	ENTITY
vary	O
according	O
laboratory	O
and	O
type	O
of	O
test	O
performed	O
nov	O
hyperinsulinemia	ENTITY
hi	ENTITY
pur	ENTITY
suh	ENTITY
lih	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
causes	O
of	O
diabetes	ENTITY
mellitus	ENTITY
other	O
types	O
one	O
health	O
get	O
it	O
here	O
tag	O
one	O
health	ENTITY
diabetes	ENTITY
type	O
diabetes	ENTITY
diabetic	ENTITY
diet	ENTITY
diabetes	ENTITY
symptoms	O
symptoms	ENTITY
of	ENTITY
diabetes	ENTITY
type	O
diabetes	ENTITY
type	ENTITY
diabetes	ENTITY
symptoms	ENTITY
diabetic	ENTITY
coma	ENTITY
diabetic	ENTITY
retinopathy	ENTITY
glucose	ENTITY
test	ENTITY
prediabetes	ENTITY
glucometer	ENTITY
low	ENTITY
blood	ENTITY
sugar	ENTITY
pre	ENTITY
diabetic	ENTITY
diet	ENTITY
what	O
is	O
dm	O
diabetes	ENTITY
symptoms	ENTITY
in	ENTITY
women	ENTITY
diabetic	ENTITY
neuropathy	ENTITY
insulin	ENTITY
diabetes	ENTITY
definition	O
blood	ENTITY
sugar	ENTITY
range	ENTITY
insulin	ENTITY
pump	O
hyperglycemia	ENTITY
normal	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
prediabetes	ENTITY
symptoms	ENTITY
retinopathy	ENTITY
diabetes	ENTITY
insipidus	ENTITY
gestational	ENTITY
diabetes	ENTITY
diet	O
normal	O
glucose	ENTITY
levels	ENTITY
diabetic	ENTITY
foot	ENTITY
blood	ENTITY
sugar	ENTITY
chart	O
thanks	O
for	O
watching	O
.	O
if	O
video	O
good	O
please	O
like	O
share	O
and	O
comment	O
.	O
when	O
you	O
eat	O
certain	O
types	O
of	O
foods	O
your	O
body	O
must	O
release	O
more	O
insulin	ENTITY
and	ENTITY
high	ENTITY
levels	ENTITY
trigger	ENTITY
insulin	ENTITY
is	ENTITY
hormone	ENTITY
produced	ENTITY
by	ENTITY
the	ENTITY
pancreas	ENTITY
.	O
here	O
are	O
things	O
you	O
can	O
do	O
to	O
lower	O
your	O
insulin	ENTITY
levels	ENTITY
.	O
insulin	ENTITY
and	ENTITY
weight	ENTITY
loss	ENTITY
how	ENTITY
to	ENTITY
control	ENTITY
lower	ENTITY
insulin	ENTITY
resistance	ENTITY
lowering	O
level	O
is	O
the	O
key	O
longer	O
life	O
dr	O
.	O
avoid	O
sedentary	O
behavior	O
an	O
insulin	ENTITY
resistance	ENTITY
diet	O
helps	O
you	O
lose	O
excess	O
weight	O
and	O
regulate	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
in	O
order	O
to	O
reduce	O
your	O
risk	O
of	O
developing	O
here	O
are	O
some	O
ways	O
that	O
help	O
insulin	ENTITY
could	ENTITY
eating	ENTITY
blueberries	ENTITY
get	ENTITY
rid	ENTITY
.	O
take	O
vitamin	O
ways	O
to	O
improve	O
your	O
insulin	ENTITY
sensitivity	ENTITY
insulin	ENTITY
resistance	ENTITY
.	O
add	O
pistachios	O
to	O
your	O
dietget	O
active	O
.	O
another	O
group	O
of	O
type	O
diabetics	ENTITY
has	ENTITY
common	ENTITY
story	ENTITY
was	ENTITY
never	ENTITY
fat	ENTITY
until	ENTITY
after	ENTITY
my	ENTITY
doctor	ENTITY
started	ENTITY
me	ENTITY
on	ENTITY
insulin	ENTITY
.	O
another	O
group	O
of	O
type	O
diabetics	ENTITY
has	ENTITY
common	ENTITY
story	ENTITY
was	ENTITY
never	ENTITY
fat	ENTITY
until	ENTITY
after	ENTITY
my	ENTITY
doctor	ENTITY
started	ENTITY
me	ENTITY
on	ENTITY
insulin	ENTITY
.	O
usually	O
these	O
how	O
to	O
lose	O
weight	O
by	O
controlling	O
insulin	ENTITY
.	O
more	O
proof	O
that	O
eating	O
right	O
to	O
lower	O
your	O
insulin	ENTITY
level	ENTITY
is	O
the	O
primary	O
factor	O
that	O
can	O
increase	O
your	O
lifespan	O
insulin	ENTITY
is	ENTITY
hormone	ENTITY
that	ENTITY
has	ENTITY
huge	ENTITY
effect	ENTITY
on	ENTITY
both	ENTITY
muscle	ENTITY
building	ENTITY
and	ENTITY
fat	ENTITY
loss	ENTITY
learn	ENTITY
how	ENTITY
to	ENTITY
keep	ENTITY
your	ENTITY
insulin	ENTITY
levels	ENTITY
low	O
in	O
three	O
simple	O
insulin	ENTITY
levels	ENTITY
are	O
much	O
higher	O
when	O
you	O
eat	O
lot	O
of	O
carbohydrates	ENTITY
and	ENTITY
lower	ENTITY
on	ENTITY
low	ENTITY
carb	ENTITY
diet	ENTITY
.	O
food	O
order	O
has	O
significant	O
impact	O
on	O
glucose	ENTITY
and	ENTITY
insulin	ENTITY
levels	ENTITY
sensitivity	O
why	O
you	O
can	O
blast	O
that	O
fat	ENTITY
.	O
how	O
to	O
lose	O
weight	O
by	O
controlling	O
insulin	ENTITY
.	O
it	O
secreted	O
in	O
small	O
amounts	O
throughout	O
the	O
day	O
and	O
larger	O
after	O
meals	O
these	O
nine	O
foods	O
will	O
help	O
you	O
lower	O
your	O
blood	ENTITY
pressure	ENTITY
.	O
ways	O
to	O
lower	O
your	O
insulin	ENTITY
levels	ENTITY
.	O
the	O
insulin	ENTITY
resistance	ENTITY
diet	O
protocol	O
to	O
help	O
prevent	O
diabetes	ENTITY
dr	ENTITY
seven	ENTITY
easy	ENTITY
tips	ENTITY
reduce	ENTITY
and	ENTITY
lose	ENTITY
belly	ENTITY
fat	ENTITY
.	O
metabolism	ENTITY
of	ENTITY
both	ENTITY
glucose	ENTITY
and	ENTITY
cholesterol	ENTITY
reducing	ENTITY
blood	ENTITY
sugar	ENTITY
insulin	ENTITY
levels	ENTITY
metabolic	ENTITY
syndrome	ENTITY
leading	O
cause	O
weight	ENTITY
gain	ENTITY
obesity	ENTITY
occurs	O
when	O
the	O
body	O
.	O
having	O
high	ENTITY
levels	ENTITY
of	ENTITY
insulin	ENTITY
can	O
promote	O
fat	ENTITY
storage	ENTITY
and	ENTITY
make	ENTITY
weight	ENTITY
loss	ENTITY
.	O
ways	O
to	O
improve	O
your	O
insulin	ENTITY
sensitivity	ENTITY
insulin	ENTITY
resistance	ENTITY
.	O
high	ENTITY
insulin	ENTITY
be	O
preventing	O
you	O
from	O
losing	O
weight	O
liver	ENTITY
how	ENTITY
to	ENTITY
avoid	ENTITY
resistance	ENTITY
.	O
exercise	O
also	O
ve	O
checked	O
my	O
insulin	ENTITY
levels	ENTITY
twice	O
and	O
both	O
times	O
they	O
were	O
lower	O
.	O
stay	O
away	O
from	O
refined	O
carbs	O
.	O
usually	O
these	O
using	O
diet	O
to	O
manage	O
insulin	ENTITY
levels	ENTITY
low	O
carb	O
or	O
come	O
up	O
with	O
your	O
own	O
specific	O
plan	O
help	O
left	O
untreated	O
how	O
can	O
you	O
naturally	O
lower	O
high	ENTITY
insulin	ENTITY
.	O
what	O
are	O
normal	O
are	O
levels	O
the	O
same	O
as	O
blood	ENTITY
glucose	ENTITY
.	O
lower	O
your	O
insulin	ENTITY
levels	ENTITY
.	O
the	O
figure	O
above	O
from	O
boden	O
et	O
.	O
nine	O
things	O
that	O
improve	O
insulin	ENTITY
sensitivity	ENTITY
accelerate	O
fat	ENTITY
loss	ENTITY
prediabetes	ENTITY
resistance	ENTITY
causes	ENTITY
of	ENTITY
low	ENTITY
in	ENTITY
people	ENTITY
who	ENTITY
eat	ENTITY
normal	ENTITY
levels	ENTITY
the	ENTITY
ketogenic	ENTITY
diet	ENTITY
and	O
how	O
to	O
lower	ENTITY
fasting	ENTITY
physiology	ENTITY
part	O
ii	ENTITY
.	O
is	O
one	O
insulin	ENTITY
sensitivity	ENTITY
so	O
important	O
for	O
fat	ENTITY
loss	ENTITY
because	ENTITY
when	ENTITY
you	ENTITY
are	ENTITY
which	ENTITY
reason	ENTITY
that	ENTITY
high	ENTITY
levels	ENTITY
associated	ENTITY
with	ENTITY
obesity	ENTITY
.	O
the	O
thin	O
clients	O
that	O
checked	O
also	O
had	O
low	O
insulin	ENTITY
allows	ENTITY
cells	ENTITY
in	ENTITY
the	ENTITY
body	ENTITY
absorb	ENTITY
glucose	ENTITY
ultimately	ENTITY
lowering	ENTITY
levels	ENTITY
of	ENTITY
glucose	ENTITY
blood	ENTITY
.	O
it	O
is	O
quite	O
simple	O
you	O
can	O
help	O
lower	O
your	O
insulin	ENTITY
levels	ENTITY
naturally	O
by	O
eating	O
fewer	O
starches	O
and	O
sugars	O
more	O
foods	O
that	O
are	O
high	O
in	O
fiber	O
low	O
refined	O
protein	O
vegetables	O
before	O
carbohydrates	ENTITY
leads	ENTITY
to	ENTITY
post	ENTITY
meal	ENTITY
glucose	ENTITY
obese	ENTITY
patients	ENTITY
with	ENTITY
type	ENTITY
diabetes	ENTITY
despite	ENTITY
some	ENTITY
people	ENTITY
having	ENTITY
level	ENTITY
slower	ENTITY
response	ENTITY
who	ENTITY
better	ENTITY
adapted	ENTITY
carbs	ENTITY
their	ENTITY
diet	ENTITY
there	ENTITY
still	ENTITY
she	ENTITY
would	ENTITY
cut	ENTITY
the	ENTITY
fat	ENTITY
out	ENTITY
of	ENTITY
her	ENTITY
diet	ENTITY
drastically	O
reduce	O
portion	O
sizes	O
but	O
blood	ENTITY
fatty	ENTITY
liver	ENTITY
go	O
hand	O
body	O
has	O
release	O
keep	O
all	O
balanced	O
functioning	O
well	O
will	O
never	O
be	O
able	O
hot	O
flashes	O
lose	O
sure	O
we	O
re	O
not	O
burning	O
any	O
when	O
elevated	O
once	O
our	O
participants	O
dhea	ENTITY
didn	ENTITY
get	ENTITY
benefits	ENTITY
medications	ENTITY
resistance	ENTITY
include	ENTITY
biguanides	ENTITY
increased	ENTITY
physical	ENTITY
activity	ENTITY
whereas	ENTITY
pharmacotherapy	ENTITY
.	O
this	O
was	O
first	O
noted	O
decades	O
ago	O
and	O
widely	O
accepted	O
as	O
true	O
.	O
how	O
to	O
reduce	O
insulin	ENTITY
for	ENTITY
weight	ENTITY
loss	ENTITY
ways	ENTITY
lower	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
googleusercontent	O
search	O
.	O
lower	O
your	O
insulin	ENTITY
levels	ENTITY
healthline	O
ways	O
to	O
lower	O
healthline	O
nutrition	O
.	O
webcache	O
.	O
follow	O
low	O
carb	O
dietwatch	O
portion	O
sizes	O
.	O
yes	O
low	O
carb	O
diet	O
greatly	O
lowers	O
your	O
insulin	ENTITY
.	O
foods	O
that	O
lower	O
blood	ENTITY
sugar	ENTITY
four	O
steps	O
to	O
reducing	O
insulin	ENTITY
levels	ENTITY
methods	O
ways	O
your	O
and	O
lose	O
weightanother	O
group	O
of	O
type	ENTITY
diabetics	ENTITY
has	O
common	O
story	O
was	O
never	O
fat	ENTITY
.	O
after	O
meal	O
is	O
consumed	O
bloodglucose	ENTITY
levels	ENTITY
and	O
very	O
low	O
carb	O
diet	O
can	O
actually	O
cause	O
insulin	ENTITY
resistance	ENTITY
as	O
part	O
of	O
the	O
paleo	O
reduces	O
carbs	O
to	O
an	O
sensitizing	O
level	O
almost	O
automatically	O
even	O
it	O
both	O
hero	O
foe	O
you	O
need	O
stay	O
at	O
fit	O
weight	O
so	O
follow	O
this	O
guide	O
we	O
ll	O
show	O
how	O
lower	O
.	O
endurance	O
training	O
improves	O
insulin	ENTITY
sensitivity	ENTITY
.	O
new	O
video	O
red	O
alert	O
proof	O
they	O
will	O
start	O
ww	O
.	O
what	O
is	O
chromium	ENTITY
picolinate	ENTITY
chromium	O
is	O
trace	ENTITY
mineral	ENTITY
naturally	O
found	O
in	O
wholegrain	O
foods	O
eggs	O
and	O
meat	O
chromium	ENTITY
picolinate	ENTITY
benefit	O
chromium	O
contributes	O
to	O
normal	ENTITY
macronutrient	ENTITY
metabolism	ENTITY
.	O
who	O
is	O
chromium	ENTITY
picolinate	ENTITY
.	O
chromium	ENTITY
picolinate	ENTITY
is	O
recommended	O
for	O
anyone	O
wanting	O
to	O
enhance	O
glucose	ENTITY
metabolism	ENTITY
therefore	O
it	O
is	O
particularly	O
important	O
for	O
those	O
involved	O
in	O
sports	O
which	O
predominantly	O
require	O
glucose	ENTITY
as	ENTITY
an	ENTITY
energy	ENTITY
source	ENTITY
hromium	ENTITY
helps	ENTITY
metabolize	ENTITY
carbohydrates	ENTITY
.	O
it	O
monitors	O
blood	ENTITY
sugar	ENTITY
levels	ENTITY
and	O
helps	O
stabilize	O
blood	ENTITY
sugar	ENTITY
.	O
it	O
can	O
also	O
prevent	O
hypertension	ENTITY
or	ENTITY
high	ENTITY
blood	ENTITY
pressure	ENTITY
.	O
although	O
trials	O
are	O
still	O
being	O
conducted	O
chromium	ENTITY
compounds	ENTITY
are	O
considered	O
helpful	O
in	O
preventing	O
memory	O
loss	O
and	O
in	O
treating	O
alzheimer	ENTITY
disease	ENTITY
chromium	O
supplements	O
are	O
easily	O
available	O
in	O
stores	O
and	O
come	O
in	O
the	O
form	O
of	O
chromium	ENTITY
picolinate	ENTITY
chromium	ENTITY
nictitate	ENTITY
high	ENTITY
chromium	ENTITY
yeast	ENTITY
or	O
chromium	ENTITY
citrate	ENTITY
.	O
part	O
of	O
essential	O
health	O
and	O
nutrition	O
.	O
there	O
are	O
several	O
other	O
chromium	ENTITY
.	O
regular	O
intake	O
of	O
chromium	ENTITY
as	ENTITY
health	ENTITY
supplement	ENTITY
reduces	ENTITY
the	ENTITY
risk	ENTITY
of	ENTITY
heart	ENTITY
disease	ENTITY
.	O
it	O
raises	O
heart	O
rate	O
while	O
aso	O
having	O
the	O
ability	O
to	O
ward	O
off	O
infections	ENTITY
.	O
additionally	O
it	O
reduces	O
hunger	O
which	O
aids	O
in	O
weight	O
loss	O
.	O
thorne	O
research	O
chromium	ENTITY
picolinate	ENTITY
dietary	O
supplement	O
to	O
aid	O
metabolism	ENTITY
of	ENTITY
carbs	ENTITY
and	ENTITY
sugar	ENTITY
vegetarian	ENTITY
capsules	ENTITY
this	ENTITY
very	ENTITY
popular	ENTITY
form	ENTITY
of	ENTITY
chromium	ENTITY
.	O
chromium	ENTITY
is	ENTITY
an	ENTITY
essential	ENTITY
nutrient	ENTITY
for	ENTITY
human	ENTITY
life	ENTITY
and	ENTITY
is	ENTITY
widely	ENTITY
distributed	ENTITY
in	ENTITY
small	ENTITY
quantities	ENTITY
in	ENTITY
food	ENTITY
however	ENTITY
the	ENTITY
refining	ENTITY
of	ENTITY
flour	ENTITY
and	ENTITY
sugar	ENTITY
has	ENTITY
depleted	ENTITY
chromium	ENTITY
.	O
metabolic	ENTITY
stress	ENTITY
strenuous	O
exercise	O
and	O
pregnancy	O
can	O
all	O
increase	O
chromium	ENTITY
.	O
studies	O
suggest	O
adequate	O
chromium	O
intake	O
supports	O
already	O
normal	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
insulin	ENTITY
sensitivity	ENTITY
and	O
sperm	ENTITY
.	O
chromium	ENTITY
in	ENTITY
the	ENTITY
form	ENTITY
of	ENTITY
picolinate	ENTITY
has	O
been	O
widely	O
studied	O
for	O
support	O
of	O
blood	ENTITY
sugar	ENTITY
.	O
decreases	O
in	O
carbohydrate	ENTITY
cravings	ENTITY
.	O
other	O
studies	O
have	O
shown	O
chromium	ENTITY
picolinate	ENTITY
can	O
increase	O
lean	O
body	O
mass	O
in	O
obese	ENTITY
.	O
picolinic	ENTITY
acid	ENTITY
is	O
natural	O
mineral	ENTITY
chelator	ENTITY
produced	O
in	O
the	O
body	O
.	O
it	O
is	O
produced	O
from	O
the	O
amino	ENTITY
acid	ENTITY
tryptophan	ENTITY
in	O
the	O
liver	ENTITY
and	ENTITY
kidneys	ENTITY
and	ENTITY
is	ENTITY
transported	ENTITY
to	ENTITY
the	ENTITY
pancreas	ENTITY
.	O
during	O
digestion	O
it	O
is	O
secreted	O
from	O
the	O
pancreas	ENTITY
into	ENTITY
the	ENTITY
small	ENTITY
intestine	ENTITY
where	O
it	O
binds	O
to	O
minerals	O
.	O
chromium	ENTITY
picolinate	ENTITY
dosage	O
for	O
weight	O
loss	O
chromium	ENTITY
picolinate	ENTITY
supplementation	O
may	O
lead	O
to	O
an	O
increase	O
in	O
weight	O
loss	O
.	O
participants	O
taking	O
supplemental	O
chromium	ENTITY
in	ENTITY
the	ENTITY
studies	ENTITY
.	O
another	O
review	O
article	O
published	O
in	O
the	O
cochrane	O
database	O
of	O
systematic	O
reviews	O
the	O
same	O
year	O
didn	O
find	O
enough	O
evidence	O
to	O
show	O
whether	O
the	O
use	O
of	O
chromium	ENTITY
picolinate	ENTITY
was	O
safe	O
or	O
effective	O
and	O
noted	O
that	O
the	O
existing	O
studies	O
diabetes	ENTITY
is	ENTITY
chronic	ENTITY
condition	ENTITY
associated	ENTITY
with	ENTITY
abnormally	ENTITY
high	ENTITY
levels	ENTITY
of	ENTITY
sugar	ENTITY
.	O
insulin	ENTITY
produced	ENTITY
by	ENTITY
the	ENTITY
pancreas	ENTITY
lowers	ENTITY
blood	ENTITY
glucose	ENTITY
.	O
absence	O
or	O
insufficient	O
production	O
of	O
insulin	ENTITY
or	ENTITY
an	ENTITY
inability	ENTITY
of	ENTITY
the	ENTITY
body	ENTITY
to	ENTITY
properly	ENTITY
use	ENTITY
insulin	ENTITY
causes	ENTITY
diabetes	ENTITY
the	ENTITY
two	ENTITY
types	ENTITY
of	ENTITY
diabetes	ENTITY
are	ENTITY
referred	ENTITY
to	ENTITY
as	ENTITY
type	ENTITY
and	ENTITY
type	ENTITY
former	ENTITY
names	ENTITY
for	ENTITY
these	ENTITY
conditions	ENTITY
were	ENTITY
insulin	ENTITY
dependent	ENTITY
and	ENTITY
non	ENTITY
insulin	ENTITY
dependent	ENTITY
diabetes	ENTITY
or	O
juvenile	O
onset	O
and	O
adult	ENTITY
onset	ENTITY
diabetes	ENTITY
.	O
diabetes	ENTITY
treatment	ENTITY
depends	ENTITY
on	ENTITY
the	ENTITY
type	ENTITY
and	ENTITY
severity	ENTITY
of	ENTITY
the	ENTITY
diabetes	ENTITY
.	O
type	O
diabetes	ENTITY
is	ENTITY
treated	ENTITY
with	ENTITY
insulin	ENTITY
exercise	ENTITY
and	ENTITY
diabetic	ENTITY
diet	ENTITY
.	O
type	O
diabetes	ENTITY
is	ENTITY
first	ENTITY
treated	ENTITY
with	ENTITY
weight	ENTITY
reduction	ENTITY
type	ENTITY
diabetic	ENTITY
diet	ENTITY
and	ENTITY
exercise	ENTITY
.	O
when	O
these	O
measures	O
fail	O
to	O
control	O
the	O
elevated	ENTITY
blood	ENTITY
sugars	ENTITY
oral	O
medications	O
.	O
if	O
oral	O
medications	O
are	O
still	O
insufficient	O
insulin	ENTITY
and	ENTITY
other	ENTITY
injectable	ENTITY
medications	ENTITY
are	ENTITY
considered	ENTITY
type	ENTITY
diabetes	ENTITY
cannot	ENTITY
be	ENTITY
prevented	ENTITY
however	ENTITY
type	ENTITY
diabetes	ENTITY
may	ENTITY
be	ENTITY
prevented	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
is	O
group	O
of	O
metabolic	ENTITY
diseases	ENTITY
characterized	O
by	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
glucose	ENTITY
levels	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
commonly	O
referred	O
to	O
as	O
diabetes	ENTITY
as	ENTITY
it	ENTITY
will	ENTITY
be	ENTITY
in	ENTITY
this	ENTITY
article	ENTITY
was	ENTITY
first	ENTITY
identified	ENTITY
as	ENTITY
disease	ENTITY
associated	ENTITY
with	ENTITY
sweet	ENTITY
.	O
elevated	ENTITY
levels	ENTITY
of	ENTITY
blood	ENTITY
glucose	ENTITY
hyperglycemia	ENTITY
lead	ENTITY
to	ENTITY
spillage	ENTITY
of	ENTITY
glucose	ENTITY
into	ENTITY
the	ENTITY
urine	ENTITY
hence	ENTITY
the	ENTITY
term	ENTITY
sweet	ENTITY
.	O
diabetes	ENTITY
is	ENTITY
chronic	ENTITY
disorder	ENTITY
occurs	O
when	O
pancreas	ENTITY
does	ENTITY
not	ENTITY
secrete	ENTITY
enough	ENTITY
insulin	ENTITY
or	ENTITY
cells	ENTITY
become	ENTITY
resisitant	ENTITY
to	ENTITY
insulin	ENTITY
which	ENTITY
leads	ENTITY
to	ENTITY
elevated	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
diabetic	ENTITY
patients	ENTITY
should	O
watch	O
over	O
what	O
they	O
eat	O
in	O
order	O
to	O
keep	O
their	O
blood	ENTITY
sugar	ENTITY
levels	ENTITY
.	O
the	O
patients	O
should	O
primarily	O
consume	O
vegetables	O
containing	O
anti	O
oxidants	O
minerals	O
and	O
vitamins	O
that	O
are	O
vital	O
for	O
the	O
body	O
.	O
it	O
is	O
better	O
to	O
avoid	O
those	O
vegetables	O
containing	O
excess	O
of	O
carbohydrates	ENTITY
protein	ENTITY
and	O
fat	ENTITY
.	O
in	O
that	O
case	O
four	O
to	O
five	O
serving	O
of	O
vegetables	O
would	O
also	O
not	O
harm	O
the	O
body	O
.	O
vegetables	O
can	O
be	O
eaten	O
.	O
they	O
can	O
be	O
baked	O
grilled	O
or	O
micro	O
.	O
you	O
can	O
add	O
variety	O
to	O
it	O
by	O
making	O
delicious	O
salads	O
with	O
various	O
sauces	O
vegetables	O
give	O
the	O
required	O
fiber	O
content	O
to	O
the	O
human	O
body	O
.	O
they	O
promote	O
the	O
health	O
and	O
help	O
you	O
to	O
prevent	O
many	O
diseases	ENTITY
.	O
vegetables	O
reduce	O
the	O
risk	O
of	O
getting	O
affected	O
by	O
chronic	ENTITY
disorders	ENTITY
stroke	O
coronary	ENTITY
heart	ENTITY
diseases	ENTITY
and	O
cancers	ENTITY
in	ENTITY
the	ENTITY
lungs	ENTITY
and	O
digestive	ENTITY
tract	ENTITY
.	O
vegetables	O
also	O
increase	O
the	O
mineral	O
density	O
in	O
the	O
bones	ENTITY
and	ENTITY
lower	ENTITY
the	ENTITY
bone	ENTITY
.	O
disclaimer	O
the	O
information	O
provided	O
by	O
diet	O
.	O
before	O
starting	O
new	O
diet	O
.	O
if	O
you	O
have	O
medical	O
problem	O
promptly	O
contact	O
your	O
health	O
care	O
provider	O
.	O
youtube	O
channel	O
.	O
hypoglycemia	ENTITY
means	ENTITY
low	ENTITY
blood	ENTITY
glucose	ENTITY
an	O
untreated	O
diabetic	ENTITY
suffers	ENTITY
primarily	ENTITY
from	ENTITY
lack	ENTITY
of	ENTITY
insulin	ENTITY
to	ENTITY
let	ENTITY
nourishment	ENTITY
into	ENTITY
make	ENTITY
sugar	ENTITY
levels	ENTITY
high	ENTITY
by	ENTITY
comparison	ENTITY
which	ENTITY
makes	ENTITY
hypertonic	ENTITY
sterols	ENTITY
and	O
cholestanol	ENTITY
reflecting	ENTITY
cholesterol	ENTITY
absorption	ENTITY
efficiency	O
with	O
sensitivity	O
measured	O
the	O
hyper	ENTITY
.	O
when	O
person	O
has	O
hyperinsulinemia	ENTITY
they	ENTITY
have	ENTITY
problem	ENTITY
controlling	ENTITY
blood	ENTITY
sugar	ENTITY
meaning	O
that	O
the	O
pancreas	ENTITY
to	ENTITY
secrete	ENTITY
larger	ENTITY
amounts	ENTITY
of	ENTITY
insulin	ENTITY
keep	ENTITY
sugar	ENTITY
at	ENTITY
normal	ENTITY
level	ENTITY
hyperinsulinemia	ENTITY
or	ENTITY
hyperinsulinaemia	ENTITY
is	ENTITY
condition	ENTITY
in	ENTITY
which	ENTITY
there	ENTITY
are	ENTITY
excess	ENTITY
levels	ENTITY
circulating	ENTITY
relative	ENTITY
glucose	ENTITY
.	O
people	O
close	O
to	O
you	O
know	O
what	O
your	O
hypo	ENTITY
symptoms	ENTITY
are	ENTITY
and	ENTITY
how	ENTITY
treat	ENTITY
or	ENTITY
hyper	ENTITY
aug	ENTITY
hyperinsulemia	ENTITY
means	ENTITY
having	ENTITY
too	ENTITY
much	ENTITY
insulin	ENTITY
.	O
hyper	ENTITY
insulinemia	ENTITY
causes	O
risks	O
hyperinsulinemia	ENTITY
symptoms	ENTITY
diabetes	ENTITY
.	O
elevated	ENTITY
insulin	ENTITY
levels	ENTITY
symptoms	O
diagnosis	O
and	O
treatment	O
.	O
alone	O
it	O
jul	O
complete	O
information	O
aboutelevated	ENTITY
insulin	ENTITY
levels	ENTITY
including	O
signs	O
and	O
symptomscontributing	O
risk	O
factors	O
some	O
other	O
diabetes	ENTITY
.	O
insulin	ENTITY
resistance	ENTITY
hyperinsulinemia	ENTITY
and	ENTITY
hypertension	ENTITY
causes	ENTITY
hyperinsulinism	ENTITY
hypoglycemia	ENTITY
diabetic	ENTITY
.	O
causes	O
of	O
insulin	ENTITY
resistance	ENTITY
and	O
hyperinsulinism	ENTITY
.	O
hyperinsulinemia	ENTITY
hyperinsulinemia	ENTITY
causes	ENTITY
risks	ENTITY
symptoms	ENTITY
.	O
hyperinsulinemia	ENTITY
is	ENTITY
common	ENTITY
condition	ENTITY
in	ENTITY
type	ENTITY
diabetes	ENTITY
with	ENTITY
underlying	ENTITY
the	ENTITY
insulin	ENTITY
level	ENTITY
bloodstream	ENTITY
then	ENTITY
rapidly	ENTITY
rises	ENTITY
to	ENTITY
damaging	ENTITY
levels	ENTITY
and	ENTITY
together	ENTITY
resulting	ENTITY
elevated	ENTITY
hypertriglyceridemia	ENTITY
vs	ENTITY
hyperlemia	ENTITY
jun	ENTITY
main	ENTITY
reason	ENTITY
for	ENTITY
hyperinsulinism	ENTITY
or	ENTITY
excessive	ENTITY
release	ENTITY
of	ENTITY
abnormalities	ENTITY
particularly	ENTITY
thyroid	ENTITY
gland	ENTITY
hypo	ENTITY
and	O
hyper	ENTITY
mar	ENTITY
hormone	ENTITY
that	ENTITY
released	ENTITY
response	ENTITY
glucose	ENTITY
.	O
html	O
url	O
.	O
webcache	O
.	O
hyperinsulinemia	ENTITY
is	ENTITY
it	ENTITY
diabetes	ENTITY
.	O
mayo	O
clinic	O
.	O
hypos	O
and	O
hypers	O
diabetes	ENTITY
.	O
hyperinsulinemia	ENTITY
symptoms	ENTITY
diagnosis	ENTITY
treatments	ENTITY
and	ENTITY
causes	ENTITY
hyperinsulinemia	ENTITY
healing	ENTITY
.	O
while	O
it	O
is	O
often	O
mistaken	O
for	O
diabetes	ENTITY
or	ENTITY
hyperglycaemia	ENTITY
hyperinsulinemia	ENTITY
can	ENTITY
result	ENTITY
from	ENTITY
variety	ENTITY
of	ENTITY
metabolic	ENTITY
diseases	ENTITY
and	O
conditions	O
sep	O
condition	O
where	O
the	O
blood	ENTITY
insulin	ENTITY
.	O
congenital	ENTITY
hyperinsulinism	ENTITY
chi	O
is	O
characterised	O
by	O
inappropriate	O
and	O
unregulated	O
insulin	ENTITY
secretion	ENTITY
from	ENTITY
the	ENTITY
beta	ENTITY
cells	ENTITY
of	ENTITY
pancreas	ENTITY
hypoglycemia	ENTITY
hypoglycemia	ENTITY
or	ENTITY
an	ENTITY
reaction	ENTITY
can	ENTITY
happen	ENTITY
if	ENTITY
you	ENTITY
are	ENTITY
taking	ENTITY
oral	ENTITY
medications	ENTITY
.	O
people	O
with	O
type	O
diabetesno	ENTITY
longer	ENTITY
make	ENTITY
insulin	ENTITY
to	ENTITY
help	ENTITY
their	ENTITY
bodies	ENTITY
nov	ENTITY
.	O
hyperinsulinism	ENTITY
diet	ENTITY
cached	ENTITY
similar	ENTITY
mar	ENTITY
insulin	ENTITY
is	ENTITY
hormone	ENTITY
that	ENTITY
released	ENTITY
in	ENTITY
response	ENTITY
to	ENTITY
glucose	ENTITY
or	ENTITY
sugar	ENTITY
the	ENTITY
blood	ENTITY
stream	ENTITY
making	O
major	O
part	O
of	O
treatment	O
.	O
explained	O
by	O
the	O
january	O
gene	ENTITY
reveiw	ENTITY
hyperinsulinism	ENTITY
does	ENTITY
not	ENTITY
usually	ENTITY
present	ENTITY
itself	ENTITY
with	ENTITY
signs	ENTITY
or	ENTITY
symptoms	ENTITY
until	ENTITY
low	ENTITY
blood	ENTITY
sugar	ENTITY
occurs	O
apr	ENTITY
hyperglycemia	ENTITY
.	O
explained	O
by	O
the	O
ja	O
.	O
peptide	ENTITY
peptide	ENTITY
byproduct	O
of	O
insulin	ENTITY
production	ENTITY
usually	ENTITY
by	ENTITY
the	ENTITY
pancreas	ENTITY
.	O
the	O
level	O
of	O
peptide	ENTITY
is	ENTITY
gauge	ENTITY
of	ENTITY
how	ENTITY
much	ENTITY
insulin	ENTITY
is	ENTITY
being	ENTITY
produced	ENTITY
in	ENTITY
the	ENTITY
body	ENTITY
.	O
peptide	ENTITY
is	ENTITY
made	ENTITY
up	ENTITY
of	ENTITY
chemical	ENTITY
compounds	ENTITY
called	ENTITY
amino	ENTITY
acids	ENTITY
.	O
when	O
the	O
pancreas	ENTITY
produces	ENTITY
insulin	ENTITY
it	ENTITY
releases	ENTITY
peptide	ENTITY
into	ENTITY
the	ENTITY
bloodstream	ENTITY
in	ENTITY
the	ENTITY
same	ENTITY
way	ENTITY
that	ENTITY
the	ENTITY
production	ENTITY
of	ENTITY
heat	ENTITY
from	ENTITY
burning	ENTITY
coal	ENTITY
or	ENTITY
wood	ENTITY
releases	ENTITY
smoke	ENTITY
.	O
the	O
amount	O
of	O
peptide	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
can	O
indicate	O
the	O
presence	O
.	O
for	O
example	O
abnormally	O
low	O
amounts	O
of	O
peptide	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
suggest	O
the	O
insulin	ENTITY
production	ENTITY
is	ENTITY
too	ENTITY
low	ENTITY
or	ENTITY
absent	ENTITY
because	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
also	ENTITY
known	ENTITY
as	ENTITY
juvenile	ENTITY
or	ENTITY
insulin	ENTITY
dependent	ENTITY
diabetes	ENTITY
.	O
abnormally	O
high	O
amounts	O
of	O
peptide	ENTITY
warn	ENTITY
of	ENTITY
the	ENTITY
possible	ENTITY
presence	ENTITY
of	ENTITY
tumor	ENTITY
called	ENTITY
an	ENTITY
insulinoma	ENTITY
that	ENTITY
secretes	ENTITY
insulin	ENTITY
.	O
normal	O
levels	O
of	O
peptide	ENTITY
.	O
however	O
in	O
person	O
with	O
diabetes	ENTITY
normal	ENTITY
level	ENTITY
of	ENTITY
peptide	ENTITY
indicates	ENTITY
the	ENTITY
body	ENTITY
is	ENTITY
making	ENTITY
plenty	ENTITY
of	ENTITY
insulin	ENTITY
but	ENTITY
the	ENTITY
body	ENTITY
.	O
this	O
is	O
the	O
hallmark	O
of	O
type	O
diabetes	ENTITY
adult	ENTITY
insulin	ENTITY
resistant	ENTITY
.	O
peptide	ENTITY
therefore	ENTITY
plays	ENTITY
crucial	ENTITY
diagnostic	ENTITY
role	ENTITY
as	ENTITY
regards	ENTITY
insulin	ENTITY
.	O
insulin	ENTITY
is	ENTITY
hormone	ENTITY
that	ENTITY
regulates	ENTITY
the	ENTITY
body	ENTITY
use	ENTITY
of	ENTITY
glucose	ENTITY
.	O
muscle	ENTITY
cells	ENTITY
and	O
other	O
types	O
of	O
cells	O
need	O
glucose	ENTITY
.	O
the	O
body	O
manufactures	O
glucose	ENTITY
.	O
it	O
is	O
the	O
job	O
of	O
insulin	ENTITY
to	ENTITY
deliver	ENTITY
glucose	ENTITY
.	O
there	O
it	O
knocks	O
on	O
the	O
front	O
door	O
and	O
places	O
the	O
glucose	ENTITY
.	O
the	O
occupant	O
then	O
uses	O
the	O
glucose	ENTITY
to	ENTITY
help	ENTITY
its	ENTITY
master	ENTITY
the	ENTITY
body	ENTITY
walk	ENTITY
run	ENTITY
throw	ENTITY
lift	ENTITY
.	O
football	O
players	O
mountain	O
climbers	O
and	O
lumberjacks	O
all	O
thrive	O
.	O
insulin	ENTITY
also	ENTITY
prevents	ENTITY
glucose	ENTITY
overload	ENTITY
in	ENTITY
the	ENTITY
bloodstream	ENTITY
by	ENTITY
lowering	ENTITY
the	ENTITY
level	ENTITY
of	ENTITY
blood	ENTITY
glucose	ENTITY
.	O
insulin	ENTITY
is	ENTITY
released	ENTITY
by	ENTITY
cells	ENTITY
in	ENTITY
the	ENTITY
pancreas	ENTITY
called	ENTITY
the	ENTITY
islets	ENTITY
of	ENTITY
langerhans	ENTITY
.	O
how	O
to	O
pronounce	O
peptide	ENTITY
definition	ENTITY
of	ENTITY
peptide	ENTITY
audio	ENTITY
dictionary	ENTITY
how	ENTITY
to	ENTITY
say	ENTITY
peptide	ENTITY
what	ENTITY
is	ENTITY
the	ENTITY
meaning	ENTITY
of	ENTITY
peptide	ENTITY
pronounce	ENTITY
peptide	ENTITY
.	O
subscribe	O
for	O
videos	O
per	O
week	O
.	O
youtube	O
channel	O
diminished	O
tissue	ENTITY
responses	ENTITY
to	ENTITY
insulin	ENTITY
at	ENTITY
one	ENTITY
or	ENTITY
more	ENTITY
points	ENTITY
in	ENTITY
the	ENTITY
complex	ENTITY
pathways	ENTITY
of	ENTITY
hormone	ENTITY
.	O
impairment	O
of	O
insulin	ENTITY
secretion	ENTITY
and	O
defects	O
in	O
insulin	ENTITY
action	ENTITY
frequently	ENTITY
coexist	ENTITY
in	ENTITY
the	ENTITY
same	ENTITY
patient	ENTITY
and	ENTITY
it	ENTITY
is	ENTITY
often	ENTITY
unclear	ENTITY
which	ENTITY
abnormality	ENTITY
if	ENTITY
either	ENTITY
alone	ENTITY
is	ENTITY
the	ENTITY
primary	ENTITY
cause	ENTITY
of	ENTITY
the	ENTITY
hyperglycemia	ENTITY
.	O
symptoms	O
of	O
marked	O
hyperglycemia	ENTITY
include	ENTITY
polyuria	ENTITY
.	O
impairment	O
of	O
growth	O
and	O
susceptibility	O
to	O
certain	O
infections	ENTITY
may	ENTITY
also	ENTITY
accompany	ENTITY
chronic	ENTITY
hyperglycemia	ENTITY
.	O
acute	O
life	O
threatening	O
consequences	O
of	O
uncontrolled	O
diabetes	ENTITY
are	ENTITY
hyperglycemia	ENTITY
with	ENTITY
ketoacidosis	ENTITY
or	ENTITY
the	ENTITY
nonketotic	ENTITY
hyperosmolar	ENTITY
syndrome	ENTITY
.	O
long	O
term	O
complications	O
of	O
diabetes	ENTITY
include	ENTITY
retinopathy	ENTITY
with	ENTITY
potential	ENTITY
loss	ENTITY
of	ENTITY
vision	ENTITY
nephropathy	ENTITY
leading	ENTITY
to	ENTITY
renal	ENTITY
failure	ENTITY
peripheral	O
neuropathy	ENTITY
with	ENTITY
risk	ENTITY
of	ENTITY
foot	ENTITY
ulcers	ENTITY
amputations	ENTITY
and	O
charcot	ENTITY
joints	ENTITY
and	O
autonomic	ENTITY
neuropathy	ENTITY
causing	O
gastrointestinal	ENTITY
genitourinary	ENTITY
and	O
cardiovascular	ENTITY
symptoms	ENTITY
and	O
sexual	ENTITY
dysfunction	ENTITY
.	O
patients	O
with	O
diabetes	ENTITY
have	ENTITY
an	ENTITY
increased	ENTITY
incidence	ENTITY
of	ENTITY
atherosclerotic	ENTITY
cardiovascular	ENTITY
peripheral	ENTITY
arterial	ENTITY
and	ENTITY
cerebrovascular	ENTITY
disease	ENTITY
.	O
hypertension	ENTITY
and	ENTITY
abnormalities	ENTITY
of	ENTITY
lipoprotein	ENTITY
metabolism	ENTITY
are	O
often	O
found	O
in	O
people	O
with	O
diabetes	ENTITY
.	O
what	O
is	O
insulinoma	ENTITY
.	O
what	O
does	O
insulinoma	ENTITY
mean	ENTITY
.	O
insulinoma	ENTITY
meaning	ENTITY
insulinoma	ENTITY
pronunciation	ENTITY
insulinoma	ENTITY
definition	ENTITY
insulinoma	ENTITY
explanation	ENTITY
how	ENTITY
to	ENTITY
pronounce	ENTITY
insulinoma	ENTITY
.	O
source	O
wikipedia	O
org	O
article	O
adapted	O
under	O
or	O
less	O
and	O
reversibility	O
of	O
symptoms	O
with	O
administration	O
of	O
glucose	ENTITY
.	O
the	O
definitive	O
management	O
is	O
surgical	O
removal	O
.	O
this	O
may	O
involve	O
removing	O
part	ENTITY
of	ENTITY
the	ENTITY
pancreas	ENTITY
as	O
well	O
whipple	O
procedure	O
and	O
distal	ENTITY
pancreatectomy	ENTITY
.	O
medications	O
such	O
as	O
diazoxide	ENTITY
and	ENTITY
somatostatin	ENTITY
can	ENTITY
be	ENTITY
used	ENTITY
to	ENTITY
block	ENTITY
the	ENTITY
release	ENTITY
of	ENTITY
insulin	ENTITY
for	ENTITY
patients	ENTITY
who	ENTITY
are	ENTITY
not	ENTITY
surgical	ENTITY
.	O
streptozotocin	ENTITY
is	ENTITY
used	ENTITY
in	ENTITY
islet	ENTITY
cell	ENTITY
carcinomas	ENTITY
which	ENTITY
produce	ENTITY
excessive	ENTITY
insulin	ENTITY
.	O
combination	ENTITY
chemotherapy	ENTITY
is	O
used	O
either	O
doxorubicin	ENTITY
streptozotocin	ENTITY
or	O
fluorouracil	ENTITY
streptotozocin	ENTITY
in	ENTITY
patients	ENTITY
where	ENTITY
doxorubicin	ENTITY
.	O
in	O
metastasizing	ENTITY
tumours	ENTITY
with	ENTITY
intrahepatic	ENTITY
growth	ENTITY
hepatic	ENTITY
arterial	ENTITY
occlusion	ENTITY
or	O
embolization	ENTITY
.	O
most	O
patients	O
with	O
benign	ENTITY
insulinomas	ENTITY
can	O
be	O
cured	O
with	O
surgery	O
.	O
persistent	ENTITY
or	ENTITY
recurrent	ENTITY
hypoglycemia	ENTITY
after	O
surgery	O
.	O
about	O
two	O
percent	O
of	O
patients	O
develop	O
diabetes	ENTITY
mellitus	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
or	O
simply	O
diabetes	ENTITY
is	ENTITY
group	ENTITY
of	ENTITY
metabolic	ENTITY
diseases	ENTITY
in	O
which	O
person	O
has	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
either	O
because	O
the	O
pancreas	ENTITY
does	ENTITY
not	ENTITY
produce	ENTITY
enough	ENTITY
insulin	ENTITY
or	ENTITY
because	ENTITY
cells	ENTITY
do	ENTITY
not	ENTITY
respond	ENTITY
to	ENTITY
the	ENTITY
insulin	ENTITY
.	O
this	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
produces	O
the	O
classical	O
symptoms	O
of	O
polyuria	ENTITY
frequent	ENTITY
urination	ENTITY
polydipsia	ENTITY
increased	O
thirst	O
and	O
polyphagia	ENTITY
increased	ENTITY
hunger	ENTITY
.	O
there	O
are	O
three	O
main	O
types	O
of	O
diabetes	ENTITY
mellitus	ENTITY
dm	ENTITY
.	O
type	O
dm	ENTITY
results	ENTITY
from	ENTITY
the	ENTITY
body	ENTITY
failure	ENTITY
to	ENTITY
produce	ENTITY
insulin	ENTITY
and	ENTITY
currently	ENTITY
requires	ENTITY
the	ENTITY
person	ENTITY
to	ENTITY
inject	ENTITY
insulin	ENTITY
or	ENTITY
wear	ENTITY
an	ENTITY
insulin	ENTITY
pump	ENTITY
.	O
this	O
form	O
was	O
previously	O
referred	O
to	O
as	O
insulin	ENTITY
dependent	ENTITY
diabetes	ENTITY
mellitus	ENTITY
iddm	O
or	O
juvenile	ENTITY
diabetes	ENTITY
.	O
type	O
dm	ENTITY
results	ENTITY
from	ENTITY
insulin	ENTITY
resistance	ENTITY
condition	O
in	O
which	O
cells	O
fail	O
to	O
use	O
insulin	ENTITY
properly	ENTITY
sometimes	ENTITY
combined	ENTITY
with	ENTITY
an	ENTITY
absolute	ENTITY
insulin	ENTITY
.	O
this	O
form	O
was	O
previously	O
referred	O
to	O
as	O
non	ENTITY
insulin	ENTITY
dependent	ENTITY
diabetes	ENTITY
mellitus	ENTITY
niddm	ENTITY
or	ENTITY
adult	ENTITY
onset	ENTITY
diabetes	ENTITY
.	O
the	O
third	O
main	O
form	O
gestational	ENTITY
diabetes	ENTITY
occurs	O
when	O
pregnant	O
women	O
without	O
previous	O
diagnosis	O
of	O
diabetes	ENTITY
develop	ENTITY
high	ENTITY
blood	ENTITY
glucose	ENTITY
level	ENTITY
.	O
it	O
may	O
precede	O
development	O
of	O
type	O
dm	O
.	O
other	O
forms	O
of	O
diabetes	ENTITY
mellitus	ENTITY
include	O
congenital	ENTITY
diabetes	ENTITY
which	O
is	O
due	O
to	O
genetic	O
defects	O
of	O
insulin	ENTITY
secretion	ENTITY
cystic	ENTITY
fibrosis	ENTITY
related	O
diabetes	ENTITY
steroid	ENTITY
diabetes	ENTITY
induced	O
by	O
high	O
doses	O
of	O
glucocorticoids	ENTITY
and	ENTITY
several	ENTITY
forms	ENTITY
of	ENTITY
monogenic	ENTITY
diabetes	ENTITY
.	O
untreated	O
diabetes	ENTITY
can	ENTITY
cause	ENTITY
many	ENTITY
complications	ENTITY
.	O
acute	O
complications	O
include	O
diabetic	ENTITY
ketoacidosis	ENTITY
and	O
nonketotic	ENTITY
hyperosmolar	ENTITY
coma	ENTITY
.	O
serious	O
long	O
term	O
complications	O
include	O
cardiovascular	ENTITY
disease	ENTITY
chronic	ENTITY
renal	ENTITY
failure	ENTITY
and	O
diabetic	ENTITY
retinopathy	ENTITY
.	O
adequate	O
treatment	O
of	O
diabetes	ENTITY
is	ENTITY
thus	ENTITY
important	ENTITY
as	ENTITY
well	ENTITY
as	ENTITY
blood	ENTITY
pressure	ENTITY
control	O
and	O
lifestyle	O
factors	O
such	O
as	O
stopping	O
.	O
all	O
forms	O
of	O
diabetes	ENTITY
have	ENTITY
been	ENTITY
treatable	ENTITY
since	ENTITY
insulin	ENTITY
.	O
insulin	ENTITY
and	ENTITY
some	ENTITY
oral	ENTITY
medications	ENTITY
can	ENTITY
cause	ENTITY
hypoglycemia	ENTITY
.	O
both	O
types	O
and	O
are	O
chronic	O
conditions	O
.	O
pancreas	ENTITY
transplants	ENTITY
have	O
been	O
tried	O
with	O
limited	O
success	O
in	O
type	O
dm	ENTITY
gastric	ENTITY
bypass	ENTITY
surgery	ENTITY
has	ENTITY
been	ENTITY
successful	ENTITY
in	ENTITY
many	ENTITY
with	ENTITY
morbid	ENTITY
obesity	ENTITY
and	O
type	O
dm	ENTITY
.	O
gestational	ENTITY
diabetes	ENTITY
usually	O
resolves	O
after	O
delivery	O
.	O
type	O
diabetes	ENTITY
is	ENTITY
partly	ENTITY
inherited	ENTITY
and	ENTITY
then	ENTITY
triggered	ENTITY
by	ENTITY
certain	ENTITY
infections	ENTITY
with	ENTITY
some	ENTITY
evidence	ENTITY
pointing	ENTITY
at	ENTITY
coxsackie	ENTITY
virus	ENTITY
.	O
genetic	ENTITY
element	ENTITY
in	O
individual	O
susceptibility	O
to	O
some	O
of	O
these	O
triggers	O
has	O
been	O
traced	O
to	O
particular	O
hla	ENTITY
genotypes	ENTITY
the	ENTITY
genetic	ENTITY
self	ENTITY
identifiers	ENTITY
relied	ENTITY
upon	ENTITY
by	ENTITY
the	ENTITY
immune	ENTITY
system	ENTITY
.	O
however	O
even	O
in	O
those	O
who	O
have	O
inherited	O
the	O
susceptibility	O
type	O
dm	ENTITY
.	O
the	O
onset	O
of	O
type	O
diabetes	ENTITY
is	ENTITY
unrelated	ENTITY
to	ENTITY
lifestyle	ENTITY
.	O
type	O
diabetes	ENTITY
is	ENTITY
due	ENTITY
primarily	ENTITY
to	ENTITY
lifestyle	ENTITY
factors	ENTITY
and	ENTITY
genetics	ENTITY
hypertension	ENTITY
htn	O
or	O
high	ENTITY
blood	ENTITY
pressure	ENTITY
sometimes	O
called	O
arterial	ENTITY
hypertension	ENTITY
is	O
chronic	O
medical	O
condition	O
.	O
this	O
requires	O
the	O
heart	ENTITY
to	ENTITY
work	ENTITY
harder	ENTITY
than	ENTITY
normal	ENTITY
to	ENTITY
circulate	ENTITY
blood	ENTITY
through	ENTITY
the	ENTITY
blood	ENTITY
vessels	ENTITY
.	O
blood	ENTITY
pressure	ENTITY
is	O
summarised	O
by	O
two	O
measurements	O
systolic	O
and	O
diastolic	O
which	O
depend	O
.	O
normal	O
blood	ENTITY
pressure	ENTITY
at	O
rest	O
is	O
within	O
the	O
range	O
of	O
mmhg	ENTITY
systolic	ENTITY
top	ENTITY
reading	ENTITY
and	ENTITY
mmhg	ENTITY
diastolic	ENTITY
bottom	ENTITY
reading	ENTITY
.	O
high	ENTITY
blood	ENTITY
pressure	ENTITY
.	O
hypertension	ENTITY
is	ENTITY
classified	ENTITY
as	ENTITY
either	ENTITY
primary	ENTITY
essential	ENTITY
hypertension	ENTITY
or	O
secondary	ENTITY
hypertension	ENTITY
about	O
of	O
cases	O
are	O
categorized	O
as	O
primary	ENTITY
hypertension	ENTITY
which	O
means	O
high	ENTITY
blood	ENTITY
pressure	ENTITY
.	O
the	O
remaining	O
of	O
cases	O
secondary	ENTITY
hypertension	ENTITY
are	O
caused	O
by	O
other	O
conditions	O
that	O
affect	O
the	O
kidneys	ENTITY
arteries	ENTITY
heart	O
or	O
endocrine	ENTITY
system	ENTITY
.	O
win	O
an	O
acronym	O
for	O
what	O
is	O
new	O
is	O
comprehensive	O
multimedia	O
services	O
package	O
for	O
maximum	O
news	O
distribution	O
across	O
several	O
media	O
channels	O
via	O
win	O
tv	O
exclusively	O
dedicated	O
.	O
reduced	O
chronic	ENTITY
kidney	ENTITY
disease	ENTITY
.	O
follow	O
this	O
healthy	O
diet	O
tips	O
to	O
reduce	O
kidney	ENTITY
pain	ENTITY
kidney	ENTITY
stones	ENTITY
eliminated	O
kidney	ENTITY
failure	ENTITY
.	O
cardiovascular	ENTITY
complications	ENTITY
of	O
diabetic	ENTITY
kidney	ENTITY
disease	ENTITY
diabetic	ENTITY
nephropathy	ENTITY
is	O
the	O
most	O
common	O
cause	O
of	O
chronic	ENTITY
kidney	ENTITY
disease	ENTITY
.	O
patients	O
with	O
diabetic	ENTITY
kidney	ENTITY
disease	ENTITY
have	O
exceptionally	O
high	O
rates	O
of	O
cardiovascular	ENTITY
morbidity	ENTITY
.	O
in	O
fact	O
the	O
excess	O
mortality	O
among	O
patients	O
with	O
diabetes	ENTITY
appears	ENTITY
to	ENTITY
be	ENTITY
largely	ENTITY
limited	ENTITY
to	ENTITY
the	ENTITY
subgroup	ENTITY
with	ENTITY
kidney	ENTITY
disease	ENTITY
and	O
explained	O
by	O
their	O
high	O
burden	O
of	O
cardiovascular	ENTITY
disease	ENTITY
.	O
the	O
mechanisms	O
underlying	O
the	O
strong	O
association	O
between	O
diabetic	ENTITY
kidney	ENTITY
disease	ENTITY
and	O
various	O
forms	O
of	O
cardiovascular	ENTITY
disease	ENTITY
.	O
traditional	O
risk	O
factors	O
for	O
cardiovascular	ENTITY
disease	ENTITY
although	O
prevalent	O
among	O
those	O
with	O
diabetes	ENTITY
.	O
despite	O
their	O
susceptibility	O
to	O
cardiovascular	ENTITY
disease>	ENTITY
patients	O
with	O
chronic	ENTITY
kidney	ENTITY
disease	ENTITY
.	O
moreover	O
as	O
patients	O
with	O
chronic	ENTITY
kidney	ENTITY
disease	ENTITY
have	O
commonly	O
been	O
excluded	O
from	O
major	O
cardiovascular	ENTITY
trials	ENTITY
the	ENTITY
evidence	ENTITY
for	ENTITY
potential	ENTITY
treatments	ENTITY
.	O
currently	O
mainstays	O
of	O
treatment	O
for	O
diabetic	ENTITY
kidney	ENTITY
disease	ENTITY
include	O
blockade	O
of	O
the	O
renin	ENTITY
angiotensin	ENTITY
aldosterone	ENTITY
system	ENTITY
and	O
control	O
of	O
hypertension	ENTITY
hyperglycemia	ENTITY
and	ENTITY
dyslipidemia	ENTITY
.	O
increased	O
awareness	O
of	O
the	O
vulnerability	O
of	O
this	O
patient	O
population	O
and	O
more	O
timely	O
interventions	O
are	O
likely	O
to	O
improve	O
outcomes	O
while	O
large	O
evidence	O
gaps	O
are	O
filled	O
with	O
newer	O
.	O
keywords	O
coronary	ENTITY
artery	ENTITY
disease	ENTITY
diabetes	ENTITY
mellitus	ENTITY
chronic	ENTITY
kidney	ENTITY
disease	ENTITY
end	ENTITY
stage	ENTITY
renal	ENTITY
disease	ENTITY
patients	O
with	O
chronic	ENTITY
kidney	ENTITY
disease	ENTITY
could	O
be	O
at	O
risk	O
of	O
type	O
diabetes	ENTITY
new	ENTITY
research	ENTITY
shows	ENTITY
that	ENTITY
chronic	ENTITY
kidney	ENTITY
disease	ENTITY
shares	O
link	O
to	O
the	O
development	O
.	O
the	O
findings	O
were	O
made	O
by	O
scientists	O
at	O
the	O
university	O
of	O
montreal	O
hospital	O
research	O
centre	O
who	O
believe	O
that	O
should	O
their	O
findings	O
be	O
confirmed	O
in	O
further	O
studies	O
patients	O
with	O
chronic	ENTITY
kidney	ENTITY
disease	ENTITY
might	O
require	O
antioxidants	O
.	O
chronic	ENTITY
kidney	ENTITY
disease	ENTITY
occurs	O
when	O
patients	O
suffer	O
loss	ENTITY
of	ENTITY
kidney	ENTITY
function	ENTITY
and	O
can	O
no	O
longer	O
eliminate	O
toxins	ENTITY
.	O
patients	O
have	O
to	O
either	O
undergo	O
kidney	ENTITY
transplantation	ENTITY
or	O
dialysis	ENTITY
to	ENTITY
get	ENTITY
rid	ENTITY
.	O
in	O
new	O
observations	O
of	O
mice	O
and	O
human	O
samples	O
of	O
chronic	ENTITY
kidney	ENTITY
disease	ENTITY
montreal	O
researchers	O
found	O
that	O
around	O
half	O
had	O
elevated	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
.	O
when	O
they	O
investigated	O
further	O
they	O
also	O
noted	O
that	O
the	O
samples	O
had	O
impaired	O
insulin	ENTITY
secretion	ENTITY
from	O
pancreatic	ENTITY
beta	ENTITY
cells	ENTITY
.	O
type	O
diabetes	ENTITY
is	ENTITY
known	ENTITY
cause	ENTITY
of	ENTITY
chronic	ENTITY
kidney	ENTITY
disease	ENTITY
and	O
lead	O
researcher	O
dr	O
.	O
we	O
identified	O
molecular	ENTITY
mechanisms	ENTITY
that	O
may	O
be	O
responsible	O
for	O
increased	O
blood	ENTITY
glucose	ENTITY
levels	O
in	O
patients	O
with	O
non	ENTITY
diabetic	ENTITY
chronic	ENTITY
kidney	ENTITY
disease	ENTITY
.	O
our	O
observations	O
in	O
mice	O
and	O
in	O
human	O
samples	O
show	O
that	O
the	O
disease	ENTITY
can	ENTITY
cause	ENTITY
secondary	ENTITY
diabetes	ENTITY
.	O
poitout	O
team	O
believe	O
that	O
when	O
the	O
kidneys	ENTITY
fail	ENTITY
waste	ENTITY
product	ENTITY
called	ENTITY
urea	ENTITY
.	O
this	O
is	O
normally	O
filtered	O
by	O
the	O
kidneys	ENTITY
and	ENTITY
excreted	ENTITY
in	ENTITY
urine	ENTITY
but	ENTITY
not	ENTITY
in	ENTITY
patients	ENTITY
with	ENTITY
chronic	ENTITY
kidney	ENTITY
disease	ENTITY
.	O
in	O
patients	O
with	O
chronic	ENTITY
renal	ENTITY
failure	ENTITY
the	O
kidneys	ENTITY
are	ENTITY
no	ENTITY
longer	ENTITY
able	ENTITY
to	ENTITY
eliminate	ENTITY
toxins	ENTITY
.	O
urea	ENTITY
.	O
this	O
study	O
demonstrates	O
that	O
urea	ENTITY
is	ENTITY
directly	ENTITY
responsible	ENTITY
for	ENTITY
impaired	ENTITY
insulin	ENTITY
secretion	ENTITY
in	O
chronic	ENTITY
kidney	ENTITY
disease	ENTITY
.	O
the	O
study	O
team	O
now	O
plan	O
to	O
conduct	O
further	O
studies	O
to	O
validate	O
these	O
findings	O
in	O
humans	O
which	O
could	O
lead	O
to	O
new	O
treatment	O
approaches	O
to	O
protect	O
beta	ENTITY
cells	ENTITY
in	O
people	O
with	O
kidney	ENTITY
disease	ENTITY
.	O
the	O
findings	O
appear	O
in	O
the	O
journal	O
of	O
clinical	O
investigation	O
.	O
can	O
glipizide	O
.	O
sitagliptin	ENTITY
is	ENTITY
as	ENTITY
effective	ENTITY
as	ENTITY
glipizide	ENTITY
at	ENTITY
lowering	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
in	O
patients	O
with	O
type	O
diabetes	ENTITY
and	ENTITY
chronic	ENTITY
kidney	ENTITY
disease	ENTITY
.	O
sitagliptin	ENTITY
is	ENTITY
less	ENTITY
likely	ENTITY
than	ENTITY
glipizide	ENTITY
to	ENTITY
cause	ENTITY
dangerously	ENTITY
low	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
.	O
patients	O
on	O
sitagliptin	ENTITY
tend	ENTITY
to	ENTITY
lose	ENTITY
weight	ENTITY
while	ENTITY
those	ENTITY
on	ENTITY
glipizide	ENTITY
.	O
can	O
dialysis	ENTITY
cure	ENTITY
diabetes	ENTITY
.	O
no	O
diet	O
or	O
treatment	O
can	O
reverse	O
the	O
damage	O
done	O
to	O
the	O
kidneys	ENTITY
.	O
the	O
diabetic	ENTITY
dialysis	ENTITY
diet	ENTITY
will	O
keep	O
you	O
healthy	O
by	O
managing	O
your	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
and	O
lessening	O
the	O
chances	O
of	O
other	O
complications	O
resulting	O
from	O
diabetes	ENTITY
and	ENTITY
kidney	ENTITY
disease	ENTITY
.	O
how	O
do	O
you	O
keep	O
your	O
kidneys	ENTITY
.	O
what	O
can	O
you	O
do	O
for	O
your	O
kidneys	ENTITY
.	O
keep	O
fit	O
.	O
keep	O
regular	O
control	O
of	O
your	O
blood	ENTITY
sugar	ENTITY
.	O
monitor	O
your	O
blood	ENTITY
pressure	ENTITY
.	O
eat	O
.	O
maintain	O
healthy	O
fluid	O
intake	O
.	O
do	O
not	O
smoke	O
.	O
do	O
not	O
take	O
over	O
the	O
counter	ENTITY
pills	ENTITY
.	O
high	ENTITY
cortisol	ENTITY
has	O
number	O
of	O
negative	O
impacts	O
on	O
the	O
body	O
.	O
here	O
are	O
just	O
few	O
.	O
exercise	O
the	O
ultimate	O
challenge	O
in	O
blood	ENTITY
sugar	ENTITY
control	O
how	O
many	O
factors	O
actually	O
affect	O
glucose	ENTITY
.	O
diabetes	ENTITY
and	ENTITY
exercise	ENTITY
.	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
so	O
`today	O
.	O
diabetes	ENTITY
.	O
webcache	O
.	O
the	O
best	O
kind	O
of	O
exercise	O
to	O
control	O
your	O
blood	ENTITY
sugar	ENTITY
managing	O
sugars	ENTITY
during	O
and	O
activity	O
.	O
ve	O
noticed	O
this	O
tested	O
my	O
blood	ENTITY
sugar	ENTITY
at	O
pm	O
today	O
it	O
was	O
why	O
does	O
exercise	O
sometimes	O
raise	O
blood	ENTITY
sugar	ENTITY
.	O
exercise	O
can	O
trigger	O
the	O
body	O
to	O
release	O
stress	O
hormones	ENTITY
like	ENTITY
adrenaline	ENTITY
which	ENTITY
stimulates	ENTITY
the	ENTITY
liver	ENTITY
to	ENTITY
release	ENTITY
glucose	ENTITY
or	ENTITY
cortisol	ENTITY
which	ENTITY
makes	ENTITY
you	ENTITY
more	ENTITY
resistant	ENTITY
to	ENTITY
insulin	ENTITY
.	O
blood	ENTITY
glucose	ENTITY
sugar	ENTITY
.	O
mysugr	O
.	O
sometimes	O
if	O
insulin	ENTITY
levels	ENTITY
are	O
high	O
before	O
you	O
exercise	O
they	O
can	O
stay	O
you	O
re	O
not	O
hi	ENTITY
am	ENTITY
puzzled	ENTITY
by	ENTITY
my	ENTITY
bs	ENTITY
after	ENTITY
certain	ENTITY
intensity	ENTITY
exercises	ENTITY
.	O
dealing	O
with	O
unexplained	O
blood	ENTITY
sugar	ENTITY
.	O
dietitian	O
start	O
to	O
exercise	O
and	O
ur	ENTITY
sugars	ENTITY
are	ENTITY
already	ENTITY
little	ENTITY
high	ENTITY
it	ENTITY
can	ENTITY
make	ENTITY
them	ENTITY
why	ENTITY
is	ENTITY
that	ENTITY
sometimes	ENTITY
my	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
.	O
yes	O
exercise	O
can	O
help	O
you	O
improve	O
your	O
blood	ENTITY
sugar	ENTITY
control	ENTITY
boost	O
overall	O
if	O
when	O
have	O
high	O
level	O
of	O
ketones	ENTITY
risk	ENTITY
it	ENTITY
is	ENTITY
healthy	ENTITY
for	ENTITY
to	ENTITY
rise	ENTITY
during	ENTITY
because	ENTITY
the	ENTITY
muscles	ENTITY
body	ENTITY
will	O
adjust	O
after	O
exercising	O
and	O
bring	O
levels	O
prevent	O
low	O
sugar	O
one	O
reduce	O
insulin	ENTITY
increase	ENTITY
usual	ENTITY
based	ENTITY
on	ENTITY
food	ENTITY
level	ENTITY
then	ENTITY
multiply	ENTITY
dose	ENTITY
how	ENTITY
many	ENTITY
different	ENTITY
factors	ENTITY
affect	ENTITY
glucose	ENTITY
.	O
the	O
impact	O
brief	O
intensity	O
glucose	ENTITY
.	O
exercise	O
and	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
.	O
our	O
blood	ENTITY
sugar	ENTITY
response	O
will	O
also	O
depend	O
on	O
our	O
level	O
of	O
physical	O
fitness	O
and	O
personal	O
exertion	O
exercise	O
is	O
stressor	O
meaning	O
that	O
in	O
the	O
short	O
term	O
exercising	O
raise	O
glucose	ENTITY
levels	ENTITY
.	O
however	O
the	O
blood	ENTITY
sugar	ENTITY
level	ENTITY
although	O
sometimes	O
can	O
temporarily	O
rise	O
with	O
exercise	O
.	O
exercise	O
can	O
only	O
lower	O
glucose	ENTITY
when	ENTITY
there	ENTITY
is	ENTITY
enough	ENTITY
insulin	ENTITY
available	ENTITY
in	ENTITY
the	ENTITY
impact	ENTITY
of	ENTITY
brief	ENTITY
high	ENTITY
intensity	ENTITY
exercise	ENTITY
on	ENTITY
blood	ENTITY
levels	ENTITY
suggest	O
that	O
physical	O
activity	O
reduce	O
risk	O
type	O
diabetes	ENTITY
by	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
.	O
why	O
some	O
types	O
of	O
exercise	O
can	O
make	O
your	O
blood	ENTITY
sugar	ENTITY
increase	ENTITY
control	ENTITY
during	O
and	O
after	O
beyond	O
type	O
diabetes	ENTITY
and	ENTITY
exercise	ENTITY
when	ENTITY
to	ENTITY
monitor	ENTITY
your	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
basically	O
stimulated	O
by	O
the	O
demand	O
from	O
low	O
insulin	ENTITY
coupled	ENTITY
with	ENTITY
physical	ENTITY
activity	ENTITY
stimulates	ENTITY
secretion	ENTITY
of	ENTITY
trigger	ENTITY
liver	ENTITY
to	ENTITY
release	ENTITY
glucose	ENTITY
into	ENTITY
blood	ENTITY
thereby	O
increasing	O
prevent	O
problem	O
bg	O
should	O
be	O
checked	O
before	O
exercise	O
and	O
if	O
level	O
exceeds	O
more	O
intense	O
is	O
greater	O
blood	ENTITY
can	ENTITY
rise	ENTITY
most	ENTITY
commonly	ENTITY
your	ENTITY
is	ENTITY
too	ENTITY
high	ENTITY
when	ENTITY
you	ENTITY
levels	ENTITY
are	ENTITY
likely	ENTITY
sharply	ENTITY
after	ENTITY
affect	ENTITY
has	ENTITY
on	ENTITY
will	ENTITY
vary	ENTITY
checking	ENTITY
often	ENTITY
help	ENTITY
going	ENTITY
or	ENTITY
it	ENTITY
good	ENTITY
for	ENTITY
glucose	ENTITY
.	O
blood	ENTITY
glucose	ENTITY
and	O
exercise	O
.	O
blood	ENTITY
glucose	ENTITY
sugar	ENTITY
levels	ENTITY
why	O
does	O
my	O
sugar	O
go	O
up	O
after	O
exercise	O
.	O
why	O
exercise	O
increase	O
blood	ENTITY
glucose	ENTITY
.	O
diabetes	ENTITY
.	O
know	O
that	O
overall	O
exercise	O
is	O
supposed	O
to	O
lower	O
blood	ENTITY
sugar	ENTITY
levels	ENTITY
.	O
higher	O
intensity	O
so	O
having	O
soda	O
will	O
cause	O
faster	O
rise	O
in	O
your	O
blood	ENTITY
sugar	ENTITY
levels	ENTITY
than	O
exercise	O
can	O
have	O
big	O
effect	O
on	O
because	O
when	O
you	O
high	O
for	O
long	O
time	O
it	O
damage	O
the	O
vessels	ENTITY
that	ENTITY
supply	ENTITY
finding	ENTITY
of	ENTITY
increased	ENTITY
exercise	ENTITY
muscles	ENTITY
take	ENTITY
up	ENTITY
glucose	ENTITY
sugar	ENTITY
much	O
faster	O
resulting	O
studies	O
shown	O
interval	O
training	O
help	O
people	O
burn	ENTITY
more	ENTITY
fat	ENTITY
and	O
increase	O
fitness	O
even	O
after	O
just	O
or	O
minutes	O
helps	O
body	O
.	O
diabetes	ENTITY
.	O
it	O
is	O
not	O
usually	O
dangerous	O
to	O
exercise	O
with	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
level	ENTITY
as	O
long	O
as	O
you	O
are	O
spilling	O
ketones	ENTITY
but	ENTITY
performance	ENTITY
will	ENTITY
be	ENTITY
influenced	ENTITY
by	ENTITY
even	ENTITY
controlling	ENTITY
your	ENTITY
glucose	ENTITY
.	O
the	O
impact	O
of	O
brief	O
high	O
intensity	O
exercise	O
on	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
.	O
diabetes	ENTITY
.	O
effect	O
of	O
exercise	O
on	O
fasting	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
.	O
blood	ENTITY
sugar	ENTITY
increasing	O
with	O
workout	O
usms	O
forum	O
us	O
masters	O
swimming	O
.	O
insulin	ENTITY
secretion	ENTITY
and	O
increases	O
glycogen	ENTITY
breakdown	ENTITY
into	ENTITY
glucose	ENTITY
.	O
generally	O
low	O
intensity	O
exercise	O
will	O
decrease	O
blood	ENTITY
sugar	ENTITY
.	O
this	O
is	O
because	O
your	O
body	O
does	O
not	O
recognize	O
the	O
glucose	ENTITY
in	ENTITY
blood	ENTITY
and	O
calls	O
for	O
have	O
you	O
ever	O
wondered	O
why	O
blood	ENTITY
sugar	ENTITY
falls	O
during	O
certain	O
types	O
of	O
exercise	O
whilst	O
roaring	ENTITY
to	ENTITY
sky	ENTITY
high	ENTITY
levels	ENTITY
after	ENTITY
other	ENTITY
so	ENTITY
if	ENTITY
iob	ENTITY
.	O
intense	O
exercise	O
can	O
increase	O
blood	ENTITY
sugar	ENTITY
levels	ENTITY
.	O
important	O
if	O
you	O
already	O
have	O
blocked	ENTITY
arteries	ENTITY
or	O
high	ENTITY
blood	ENTITY
pressure	ENTITY
your	O
sugar	O
is	O
when	O
begin	O
to	O
exercise	O
.	O
blood	ENTITY
glucose	ENTITY
sugar	ENTITY
levels	ENTITY
.	O
provo	O
utah	O
researchers	O
have	O
found	O
compounds	O
in	O
chocolate	O
that	O
could	O
help	O
prevent	O
and	O
treat	O
.	O
beta	ENTITY
cells	ENTITY
inside	ENTITY
the	ENTITY
islet	ENTITY
of	O
langerhans	ENTITY
in	ENTITY
the	ENTITY
pancreas	ENTITY
are	ENTITY
responsible	ENTITY
for	ENTITY
secreting	ENTITY
insulin	ENTITY
the	ENTITY
hormone	ENTITY
that	ENTITY
regulates	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
.	O
in	O
someone	O
suffering	O
from	O
type	O
diabetes	ENTITY
the	ENTITY
beta	ENTITY
cells	ENTITY
malfunction	O
and	O
produce	O
insufficient	O
levels	ENTITY
of	ENTITY
insulin	ENTITY
.	O
researchers	O
at	O
brigham	O
young	O
university	O
have	O
discovered	O
that	O
compounds	O
found	O
naturally	O
in	O
cocoa	O
called	O
epicatechin	ENTITY
monomers	ENTITY
are	ENTITY
able	ENTITY
to	ENTITY
increase	ENTITY
the	ENTITY
ability	ENTITY
of	ENTITY
beta	ENTITY
cells	ENTITY
to	O
secrete	O
insulin	ENTITY
.	O
the	O
team	O
said	O
the	O
compound	O
successfully	O
helped	O
mice	O
on	O
high	ENTITY
fat	ENTITY
diet	ENTITY
to	O
cope	O
with	O
elevated	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
as	O
well	O
as	O
decrease	O
the	O
extent	O
of	O
their	O
obesity	ENTITY
.	O
what	O
happens	O
is	O
it	O
protecting	O
the	O
cells	O
.	O
the	O
epicatechin	ENTITY
monomers	ENTITY
are	ENTITY
making	ENTITY
the	ENTITY
mitochondria	ENTITY
in	ENTITY
the	ENTITY
beta	ENTITY
cells	ENTITY
stronger	O
which	O
produces	O
more	O
atp	ENTITY
cell	ENTITY
energy	ENTITY
source	ENTITY
which	ENTITY
then	ENTITY
results	ENTITY
in	ENTITY
more	ENTITY
insulin	ENTITY
.	O
the	O
team	O
are	O
looking	O
for	O
ways	O
to	O
extract	O
the	O
compound	O
out	O
of	O
cocoa	O
in	O
order	O
to	O
make	O
treatment	O
for	O
current	O
diabetes	ENTITY
patients	ENTITY
and	ENTITY
advised	ENTITY
people	ENTITY
not	ENTITY
to	ENTITY
stock	ENTITY
up	ENTITY
on	ENTITY
chocolate	ENTITY
.	O
you	O
probably	O
have	O
to	O
eat	O
lot	O
of	O
cocoa	O
and	O
you	O
probably	O
don	O
want	O
it	O
to	O
have	O
lot	O
of	O
sugar	O
.	O
it	O
the	O
compound	O
in	O
cocoa	O
.	O
the	O
study	O
was	O
published	O
in	O
the	O
journal	O
of	O
nutritional	O
biochemistry	O
.	O
go	O
to	O
.	O
how	O
the	O
liver	ENTITY
affects	ENTITY
insulin	ENTITY
and	ENTITY
vice	ENTITY
versa	ENTITY
part	ENTITY
carbohydrate	ENTITY
how	ENTITY
sugar	ENTITY
messes	ENTITY
up	ENTITY
your	ENTITY
gives	ENTITY
you	ENTITY
diabetes	ENTITY
.	O
at	O
night	O
while	O
we	O
are	O
when	O
the	O
liver	ENTITY
is	ENTITY
maximally	ENTITY
full	ENTITY
excess	ENTITY
sugar	ENTITY
converted	ENTITY
by	ENTITY
into	ENTITY
fatty	ENTITY
to	ENTITY
fat	ENTITY
in	ENTITY
liver	ENTITY
feedback	ENTITY
mechanism	ENTITY
that	ENTITY
tells	ENTITY
body	ENTITY
stop	ENTITY
producing	ENTITY
here	ENTITY
list	ENTITY
of	ENTITY
carbohydrates	ENTITY
do	ENTITY
not	ENTITY
trigger	ENTITY
such	ENTITY
strong	ENTITY
insulin	ENTITY
response	ENTITY
pancreas	ENTITY
located	ENTITY
behind	ENTITY
and	ENTITY
stomach	ENTITY
.	O
in	O
people	O
with	O
diabetes	ENTITY
however	ENTITY
the	ENTITY
liver	ENTITY
doesn	ENTITY
process	ENTITY
and	ENTITY
produce	ENTITY
glucose	ENTITY
normally	ENTITY
adding	ENTITY
to	ENTITY
challenge	ENTITY
of	ENTITY
blood	ENTITY
why	ENTITY
does	ENTITY
cell	ENTITY
store	ENTITY
excess	ENTITY
as	ENTITY
glycogen	ENTITY
.	O
liver	ENTITY
sugar	ENTITY
.	O
it	O
the	O
liver	ENTITY
dumps	ENTITY
that	ENTITY
do	ENTITY
me	ENTITY
if	ENTITY
body	ENTITY
can	ENTITY
produce	ENTITY
its	ENTITY
own	ENTITY
glucose	ENTITY
or	ENTITY
does	ENTITY
all	ENTITY
glucose	ENTITY
come	ENTITY
comes	ENTITY
during	ENTITY
stress	ENTITY
is	ENTITY
often	ENTITY
coming	ENTITY
from	ENTITY
your	ENTITY
glut	ENTITY
also	ENTITY
mediates	ENTITY
release	ENTITY
liver	ENTITY
however	ENTITY
deletion	ENTITY
of	ENTITY
not	ENTITY
affect	ENTITY
hepatic	ENTITY
production	ENTITY
in	ENTITY
fasted	ENTITY
state	ENTITY
suggesting	ENTITY
insulin	ENTITY
physiology	ENTITY
and	ENTITY
metabolism	ENTITY
.	O
liver	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
the	O
liver	ENTITY
stores	ENTITY
glucose	ENTITY
.	O
learn	O
why	O
this	O
happens	O
how	O
to	O
manage	O
blood	ENTITY
sugar	ENTITY
.	O
hypoglycemia	ENTITY
low	ENTITY
blood	ENTITY
sugar	ENTITY
causes	O
symptoms	O
treatment	O
hypoglycemia	ENTITY
.	O
why	O
diabetics	O
over	O
produce	O
sugar	ENTITY
in	ENTITY
the	ENTITY
liver	ENTITY
defeat	ENTITY
diabetes	ENTITY
and	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
.	O
how	O
is	O
glucose	ENTITY
stored	ENTITY
in	ENTITY
the	ENTITY
liver	ENTITY
.	O
quora	O
.	O
gluconeogenesis	ENTITY
and	ENTITY
glycogenolysis	ENTITY
within	ENTITY
hepatic	ENTITY
cells	ENTITY
produce	O
glucose	ENTITY
when	ENTITY
metabolically	ENTITY
most	ENTITY
glycogen	ENTITY
is	ENTITY
stored	ENTITY
in	ENTITY
the	ENTITY
liver	ENTITY
.	O
why	O
does	O
this	O
happen	O
.	O
to	O
understand	O
how	O
blood	ENTITY
some	ENTITY
of	ENTITY
glucose	ENTITY
goes	ENTITY
to	ENTITY
the	ENTITY
liver	ENTITY
.	O
googleusercontent	O
search	O
.	O
this	O
low	ENTITY
blood	ENTITY
sugar	ENTITY
signals	O
the	O
liver	ENTITY
to	ENTITY
produce	ENTITY
glucose	ENTITY
and	ENTITY
with	ENTITY
help	ENTITY
of	ENTITY
vitamin	ENTITY
produces	ENTITY
proteins	ENTITY
that	ENTITY
are	ENTITY
after	ENTITY
meal	ENTITY
removes	ENTITY
from	ENTITY
supplied	ENTITY
by	ENTITY
portal	ENTITY
vein	ENTITY
.	O
diabetes	ENTITY
.	O
glucose	ENTITY
insulin	ENTITY
pancreas	ENTITY
function	O
diabetes	ENTITY
basics	ENTITY
does	ENTITY
glucagon	ENTITY
.	O
although	O
secondly	O
stops	O
the	O
liver	ENTITY
from	ENTITY
consuming	ENTITY
some	ENTITY
glucose	ENTITY
.	O
insulin	ENTITY
is	ENTITY
produced	ENTITY
by	ENTITY
the	ENTITY
cells	ENTITY
of	ENTITY
pancreas	ENTITY
in	ENTITY
response	ENTITY
to	ENTITY
elevated	ENTITY
blood	ENTITY
glucose	ENTITY
there	O
lot	O
evidence	O
that	O
excess	O
sugar	ENTITY
diet	ENTITY
.	O
the	O
liver	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
why	O
blood	ENTITY
sugar	ENTITY
levels	ENTITY
rise	O
overnight	O
how	O
makes	O
you	O
fat	ENTITY
greenfield	ENTITY
fitness	ENTITY
systems	ENTITY
.	O
livestrong	O
how	O
does	O
the	O
liver	ENTITY
.	O
national	O
library	O
of	O
medicine	O
pubmed	O
regulation	O
glucose	ENTITY
.	O
can	O
the	O
body	O
produce	O
its	O
own	O
glucose	ENTITY
.	O
key	O
protein	O
causing	O
excess	O
liver	ENTITY
production	ENTITY
of	ENTITY
glucose	ENTITY
in	ENTITY
diabetes	ENTITY
.	O
the	O
high	ENTITY
levels	ENTITY
of	ENTITY
insulin	ENTITY
and	O
suppressed	O
glucagon	ENTITY
during	ENTITY
meal	ENTITY
promote	ENTITY
the	ENTITY
storage	ENTITY
glucose	ENTITY
as	ENTITY
glycogen	ENTITY
when	ENTITY
drop	ENTITY
production	ENTITY
falls	ENTITY
.	O
during	O
meal	O
your	O
liver	ENTITY
will	ENTITY
store	ENTITY
sugar	ENTITY
or	ENTITY
glucose	ENTITY
as	ENTITY
glycogen	ENTITY
for	ENTITY
later	ENTITY
time	ENTITY
when	ENTITY
body	ENTITY
.	O
healing	O
leaky	O
livers	ENTITY
.	O
in	O
addition	O
if	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
get	O
too	O
low	O
the	O
pancreas	ENTITY
secretes	ENTITY
glucagon	ENTITY
to	ENTITY
stimulate	ENTITY
release	ENTITY
of	ENTITY
from	ENTITY
liver	ENTITY
.	O
bbc	O
gcse	O
bitesize	O
controlling	O
blood	ENTITY
sugar	ENTITY
levels	ENTITY
.	O
suppress	O
blood	ENTITY
sugar	ENTITY
without	O
drugs	O
page	O
what	O
is	O
insulin	ENTITY
.	O
important	O
hormone	ENTITY
allows	ENTITY
your	ENTITY
body	ENTITY
to	ENTITY
use	ENTITY
liver	ENTITY
disease	ENTITY
and	O
diabetes	ENTITY
mellitus	ENTITY
.	O
this	O
has	O
to	O
do	O
with	O
how	O
sugar	O
affects	O
liver	ENTITY
too	ENTITY
low	ENTITY
insulin	ENTITY
not	ENTITY
secreted	ENTITY
into	ENTITY
the	ENTITY
blood	ENTITY
does	ENTITY
convert	ENTITY
glucose	ENTITY
glucosewhich	ENTITY
enters	ENTITY
bloodtoo	ENTITY
much	ENTITY
yet	ENTITY
type	ENTITY
ii	ENTITY
diabetes	ENTITY
can	O
be	O
caused	O
by	O
excess	O
production	O
of	O
internally	O
as	O
in	O
gluconeogenesis	ENTITY
helps	ENTITY
keeps	ENTITY
your	ENTITY
blood	ENTITY
level	ENTITY
from	O
getting	O
high	O
store	O
and	O
releases	O
it	O
when	O
productionif	O
body	O
produce	O
enough	O
or	O
cells	O
this	O
central	O
role	O
for	O
homeostasis	O
offers	O
clue	O
therefore	O
is	O
possible	O
that	O
plays	O
more	O
significant	O
than	O
peripheral	O
phosphate	ENTITY
final	ENTITY
step	ENTITY
via	ENTITY
information	ENTITY
about	ENTITY
glucose	ENTITY
insulin	ENTITY
pancreas	ENTITY
function	ENTITY
temporarily	ENTITY
shuts	ENTITY
down	ENTITY
its	ENTITY
body	ENTITY
ability	ENTITY
glycogen	ENTITY
limited	ENTITY
any	ENTITY
what	ENTITY
glucagon	ENTITY
.	O
although	O
secondly	O
stops	O
consuming	O
some	O
.	O
in	O
type	O
diabetes	ENTITY
the	ENTITY
body	ENTITY
does	ENTITY
not	ENTITY
produce	ENTITY
insulin	ENTITY
blocking	ENTITY
protein	ENTITY
markedly	ENTITY
reduced	ENTITY
liver	ENTITY
production	ENTITY
of	ENTITY
glucose	ENTITY
although	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
within	O
two	O
weeks	O
of	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
drop	O
when	O
you	O
re	O
not	O
eating	O
such	O
as	O
during	O
sleep	O
.	O
the	O
liver	ENTITY
role	ENTITY
how	ENTITY
it	ENTITY
processes	ENTITY
fats	ENTITY
and	ENTITY
carbs	ENTITY
diabetes	ENTITY
.	O
finally	O
glucagon	ENTITY
works	ENTITY
in	ENTITY
process	ENTITY
known	ENTITY
as	ENTITY
gluconeogenesis	ENTITY
which	ENTITY
is	ENTITY
the	ENTITY
production	ENTITY
of	ENTITY
glucose	ENTITY
.	O
the	O
liver	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
within	O
two	O
weeks	O
of	O
insulin	ENTITY
is	ENTITY
produced	ENTITY
in	ENTITY
response	ENTITY
to	ENTITY
an	ENTITY
increase	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
how	O
much	O
the	O
body	O
secretes	O
cells	O
simply	O
do	O
not	O
respond	O
when	O
drop	O
production	O
falls	O
.	O
in	O
this	O
review	O
we	O
focus	O
on	O
the	O
if	O
all	O
had	O
to	O
do	O
was	O
control	O
my	O
fasting	O
and	O
postprandial	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
edu	ENTITY
types	ENTITY
of	ENTITY
sugar	ENTITY
the	ENTITY
liver	ENTITY
.	O
webcache	O
.	O
pitt	O
team	O
identifies	O
key	O
protein	O
causing	O
excess	O
liver	ENTITY
.	O
htm	O
the	O
body	O
produces	O
insulin	ENTITY
but	ENTITY
the	ENTITY
cells	ENTITY
in	ENTITY
the	ENTITY
body	ENTITY
become	ENTITY
resistant	ENTITY
to	ENTITY
insulin	ENTITY
and	ENTITY
are	ENTITY
unable	ENTITY
to	ENTITY
use	ENTITY
it	ENTITY
as	ENTITY
effectively	ENTITY
leading	ENTITY
to	ENTITY
hyperglycemia	ENTITY
.	O
if	O
undetected	O
this	O
can	O
indicate	O
wider	O
health	O
problems	O
such	O
as	O
high	ENTITY
blood	ENTITY
pressure	ENTITY
and	O
cholesterol	ENTITY
levels	ENTITY
.	O
what	O
causes	O
insulin	ENTITY
resistance	ENTITY
it	O
is	O
well	O
known	O
that	O
insulin	ENTITY
resistance	ENTITY
commonly	O
coexists	O
with	O
obesity	ENTITY
.	O
elevated	ENTITY
levels	ENTITY
of	ENTITY
free	ENTITY
fatty	ENTITY
acids	ENTITY
and	O
triglycerides	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
stream	ENTITY
and	ENTITY
tissues	ENTITY
have	O
been	O
found	O
to	O
contribute	O
to	O
diminished	O
insulin	ENTITY
.	O
these	O
are	O
correlated	O
with	O
excess	O
body	ENTITY
fat	ENTITY
.	O
primarily	O
cause	O
by	O
dieting	O
choice	O
sedentary	O
lifestyle	O
and	O
smoking	O
have	O
also	O
been	O
linked	O
to	O
the	O
causes	O
of	O
insulin	ENTITY
sensitivity	ENTITY
.	O
signs	O
of	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
may	O
be	O
warning	O
sign	O
that	O
the	O
body	O
is	O
developing	O
an	O
insulin	ENTITY
sensitivity	ENTITY
.	O
additional	O
signs	O
include	O
sleepiness	O
after	O
meals	O
increased	O
blood	ENTITY
pressure	ENTITY
as	O
well	O
as	O
weight	O
gain	O
fat	ENTITY
.	O
how	O
to	O
manage	O
it	O
there	O
are	O
three	O
ways	O
to	O
manage	O
insulin	ENTITY
resistance	ENTITY
.	O
the	O
most	O
important	O
is	O
in	O
person	O
diet	O
.	O
diet	O
to	O
keep	O
your	O
insulin	ENTITY
resistance	ENTITY
from	O
increasing	O
always	O
eat	O
.	O
breakfast	O
provides	O
kickstart	O
to	O
your	O
metabolism	ENTITY
that	ENTITY
plays	ENTITY
crucial	ENTITY
role	ENTITY
in	ENTITY
helping	ENTITY
your	ENTITY
body	ENTITY
properly	ENTITY
process	ENTITY
insulin	ENTITY
.	O
grabbing	O
quick	O
snack	O
instead	O
of	O
balanced	O
meal	O
will	O
make	O
it	O
hard	O
to	O
keep	O
your	O
blood	ENTITY
sugar	ENTITY
levels	ENTITY
.	O
to	O
reduce	O
your	O
body	O
insulin	ENTITY
resistance	ENTITY
.	O
whole	O
grain	O
rye	O
is	O
rich	O
in	O
fiber	O
and	O
has	O
been	O
shown	O
to	O
naturally	O
increase	O
your	O
body	O
insulin	ENTITY
.	O
this	O
is	O
directly	O
linked	O
to	O
lower	O
insulin	ENTITY
resistance	ENTITY
and	O
helps	O
to	O
increase	O
your	O
body	O
sensitivity	O
to	O
insulin	ENTITY
.	O
try	O
eating	O
rye	O
pasta	O
with	O
food	O
rich	O
in	O
lycopene	ENTITY
.	O
exercise	O
start	O
an	O
appropriate	O
exercise	O
regime	O
.	O
choose	O
something	O
that	O
is	O
customized	O
for	O
current	O
fitness	O
levels	O
.	O
any	O
exercise	O
will	O
vastly	O
improve	O
overall	O
nutrition	O
.	O
you	O
may	O
be	O
able	O
lose	O
the	O
fat	ENTITY
that	ENTITY
causes	ENTITY
insulin	ENTITY
resistance	ENTITY
but	O
it	O
will	O
always	O
be	O
there	O
waiting	O
for	O
you	O
to	O
give	O
it	O
foothold	O
to	O
take	O
your	O
body	O
back	O
.	O
stay	O
on	O
track	O
with	O
your	O
diet	O
changes	O
and	O
increase	O
in	O
exercise	O
.	O
supplements	O
there	O
are	O
variety	O
of	O
supplements	O
available	O
to	O
help	O
with	O
insulin	ENTITY
resistance	ENTITY
.	O
cinnamomum	O
cassia	O
potent	O
extract	O
harvested	O
from	O
indonesian	O
cinnamon	O
bark	O
that	O
has	O
been	O
shown	O
to	O
effectively	O
assist	O
in	O
managing	O
blood	ENTITY
sugar	ENTITY
it	O
is	O
pure	O
does	O
not	O
undergo	O
any	O
irradiation	O
whatsoever	O
and	O
is	O
concentrated	O
.	O
also	O
rare	O
plant	ENTITY
alkaloid	ENTITY
called	O
berberine	ENTITY
which	ENTITY
has	ENTITY
been	ENTITY
used	ENTITY
for	ENTITY
centuries	ENTITY
.	O
berberine	ENTITY
works	ENTITY
slightly	ENTITY
differently	ENTITY
by	ENTITY
improving	ENTITY
the	ENTITY
signaling	ENTITY
between	ENTITY
insulin	ENTITY
and	ENTITY
its	ENTITY
associated	ENTITY
receptors	ENTITY
while	ENTITY
also	ENTITY
increasing	ENTITY
glucose	ENTITY
uptake	ENTITY
by	ENTITY
skeletal	ENTITY
muscle	ENTITY
not	O
fat	ENTITY
.	O
look	O
for	O
foods	O
or	O
supplements	O
that	O
contain	O
both	O
to	O
reverse	O
insulin	ENTITY
resistance	ENTITY
.	O
beta	ENTITY
cell	ENTITY
.	O
functions	O
of	O
erk	ENTITY
in	ENTITY
pancreatic	ENTITY
beta	ENTITY
cells	ENTITY
air	O
date	O
wednesday	O
may	O
pm	O
time	O
displayed	O
is	O
eastern	O
time	O
washington	O
dc	O
local	O
category	O
wednesday	O
afternoon	O
lectures	O
description	O
diabetes	ENTITY
mellitus	ENTITY
.	O
obesity	ENTITY
insulin	ENTITY
resistance	ENTITY
and	O
metabolic	ENTITY
abnormalities	ENTITY
in	O
liver	ENTITY
adipose	ENTITY
.	O
most	O
of	O
the	O
gene	O
loci	O
recently	O
found	O
associated	O
with	O
type	O
diabetes	ENTITY
however	ENTITY
encode	ENTITY
proteins	ENTITY
that	ENTITY
enable	ENTITY
insulin	ENTITY
.	O
nutrients	O
and	O
hormones	ENTITY
regulate	ENTITY
not	ENTITY
only	ENTITY
insulin	ENTITY
secretion	ENTITY
but	O
also	O
the	O
capacity	O
of	O
cells	O
to	O
continue	O
to	O
produce	O
insulin	ENTITY
.	O
during	O
the	O
onset	O
of	O
diabetes	ENTITY
pancreatic	ENTITY
beta	ENTITY
cells	ENTITY
become	O
unable	O
to	O
produce	O
sufficient	O
insulin	ENTITY
.	O
among	O
important	O
nutrient	O
sensing	O
pathways	O
are	O
the	O
mitogen	ENTITY
activated	ENTITY
protein	ENTITY
kinases	ENTITY
erk	O
these	O
protein	ENTITY
kinases	ENTITY
are	O
essential	O
for	O
nutrient	O
stimulated	O
insulin	ENTITY
gene	ENTITY
transcription	ENTITY
and	ENTITY
also	ENTITY
contribute	ENTITY
to	ENTITY
reduced	ENTITY
nutrient	ENTITY
induced	ENTITY
insulin	ENTITY
gene	ENTITY
transcription	ENTITY
following	ENTITY
long	ENTITY
term	ENTITY
hyperglycemia	ENTITY
and	ENTITY
hyperglycemia	ENTITY
combined	ENTITY
with	ENTITY
proinflammatory	ENTITY
cytokines	ENTITY
.	O
the	O
core	O
erk	O
cascade	O
kinases	ENTITY
are	ENTITY
associated	ENTITY
with	ENTITY
the	ENTITY
insulin	ENTITY
gene	ENTITY
and	O
we	O
are	O
examining	O
how	O
they	O
act	O
on	O
the	O
insulin	ENTITY
gene	ENTITY
promoter	ENTITY
.	O
we	O
are	O
also	O
examining	O
molecular	ENTITY
mechanisms	ENTITY
of	O
action	O
.	O
these	O
molecules	O
stimulate	O
insulin	ENTITY
production	ENTITY
by	ENTITY
cells	ENTITY
improve	O
oral	ENTITY
glucose	ENTITY
tolerance	ENTITY
of	O
mice	O
and	O
restore	O
insulin	ENTITY
production	ENTITY
by	ENTITY
human	ENTITY
islets	ENTITY
in	ENTITY
long	ENTITY
term	ENTITY
culture	ENTITY
.	O
we	O
have	O
identified	O
number	O
of	O
changes	O
that	O
take	O
place	ENTITY
in	ENTITY
cells	ENTITY
treated	O
with	O
these	O
drugs	O
including	O
epigenetic	ENTITY
alterations	ENTITY
and	ENTITY
changes	ENTITY
in	ENTITY
concentrations	ENTITY
of	ENTITY
key	ENTITY
transcription	ENTITY
factors	ENTITY
.	O
these	O
small	ENTITY
molecules	ENTITY
may	O
offer	O
promise	O
for	O
future	O
diabetic	ENTITY
therapies	ENTITY
.	O
the	O
nih	O
wednesday	O
afternoon	O
lecture	O
series	O
includes	O
weekly	O
scientific	O
talks	O
by	O
some	O
of	O
the	O
top	O
researchers	O
in	O
the	O
biomedical	O
sciences	O
worldwide	O
.	O
for	O
more	O
information	O
visit	O
the	O
nih	O
director	O
wednesday	O
afternoon	O
lecture	O
series	O
author	O
melanie	O
cobb	O
ph	O
university	O
of	O
texas	O
southwestern	O
medical	O
center	O
runtime	O
permanent	O
link	O
asp	ENTITY
.	O
subscribe	O
for	O
the	O
more	O
videos	O
.	O
diabetes	ENTITY
it	ENTITY
is	ENTITY
metabolic	ENTITY
disorder	ENTITY
in	O
which	O
the	O
person	O
has	O
high	ENTITY
blood	ENTITY
glucose	ENTITY
level	ENTITY
because	O
of	O
insulin	ENTITY
production	ENTITY
is	ENTITY
inadequate	ENTITY
or	ENTITY
the	ENTITY
body	ENTITY
cell	ENTITY
do	ENTITY
not	ENTITY
respond	ENTITY
to	ENTITY
insulin	ENTITY
.	O
diabetes	ENTITY
is	ENTITY
long	ENTITY
term	ENTITY
condition	ENTITY
.	O
insulin	ENTITY
insulin	ENTITY
is	ENTITY
produced	ENTITY
by	ENTITY
beta	ENTITY
cells	ENTITY
of	ENTITY
the	ENTITY
pancreas	ENTITY
.	O
insulin	ENTITY
regulates	ENTITY
the	ENTITY
metabolism	ENTITY
of	ENTITY
carbohydrates	ENTITY
fats	ENTITY
and	ENTITY
protein	ENTITY
.	O
it	O
promotes	O
absorption	O
of	O
glucose	ENTITY
from	ENTITY
the	ENTITY
blood	ENTITY
into	ENTITY
fat	ENTITY
liver	ENTITY
and	O
skeletal	ENTITY
muscle	ENTITY
cells	ENTITY
which	O
converted	O
into	O
glycogen	ENTITY
.	O
type	O
type	O
diabetes	ENTITY
in	ENTITY
type	ENTITY
diabetes	ENTITY
beta	ENTITY
cells	ENTITY
are	O
destroyed	O
by	O
an	O
autoimmune	ENTITY
reaction	ENTITY
.	O
it	O
is	O
characterized	O
by	O
abnormally	O
high	ENTITY
blood	ENTITY
glucose	ENTITY
concentration	O
.	O
type	O
diabetes	ENTITY
type	ENTITY
diabetes	ENTITY
characterized	ENTITY
by	ENTITY
high	ENTITY
rates	ENTITY
of	ENTITY
glucagon	ENTITY
secretion	ENTITY
into	O
the	O
blood	ENTITY
which	ENTITY
is	ENTITY
unresponsive	ENTITY
to	ENTITY
the	ENTITY
concentration	ENTITY
of	ENTITY
glucose	ENTITY
into	O
the	O
blood	ENTITY
glucose	ENTITY
.	O
in	O
this	O
diabetes	ENTITY
insulin	ENTITY
is	O
secreted	O
into	O
the	O
blood	ENTITY
in	ENTITY
response	ENTITY
to	ENTITY
blood	ENTITY
glucose	ENTITY
.	O
gestational	ENTITY
diabetes	ENTITY
it	O
means	O
some	O
mothers	O
start	O
developing	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
level	ENTITY
.	O
symptoms	O
of	O
diabetes	ENTITY
increased	ENTITY
urination	ENTITY
increased	ENTITY
urination	ENTITY
is	ENTITY
also	ENTITY
called	ENTITY
polyuria	ENTITY
which	ENTITY
is	ENTITY
major	ENTITY
symptom	ENTITY
of	ENTITY
diabetes	ENTITY
.	O
in	O
diabetes	ENTITY
.	O
so	O
kidneys	ENTITY
work	ENTITY
overtime	ENTITY
to	ENTITY
filter	ENTITY
and	ENTITY
absorb	ENTITY
excess	ENTITY
sugar	ENTITY
.	O
excess	O
sugar	O
.	O
diabetic	ENTITY
patient	ENTITY
experience	ENTITY
disturb	ENTITY
sleep	ENTITY
.	O
excessive	O
thrust	O
it	O
is	O
also	O
called	O
polydipsia	ENTITY
.	O
excessive	O
thrust	O
accompanied	O
by	O
excessive	ENTITY
dryness	ENTITY
of	ENTITY
mouth	ENTITY
.	O
in	O
diabetes	ENTITY
kidney	ENTITY
loses	ENTITY
the	ENTITY
ability	ENTITY
to	ENTITY
pull	ENTITY
out	ENTITY
glucose	ENTITY
from	ENTITY
the	ENTITY
water	ENTITY
.	O
hence	O
osmotic	O
pressure	O
creates	O
which	O
causes	O
thrust	O
.	O
it	O
is	O
pressure	O
that	O
builds	O
up	O
between	O
liquid	O
with	O
high	O
concentration	O
of	O
solute	O
and	O
liquid	O
.	O
weight	O
loss	O
in	O
diabetic	ENTITY
patient	ENTITY
insulin	ENTITY
hormone	ENTITY
is	O
not	O
getting	O
glucose	ENTITY
.	O
body	O
starts	O
burning	ENTITY
of	ENTITY
fat	ENTITY
and	O
muscle	ENTITY
cell	ENTITY
as	O
source	O
of	O
fuel	O
which	O
causes	O
weight	O
loss	O
.	O
hunger	O
increases	O
appetite	O
.	O
when	O
we	O
eat	O
food	O
the	O
body	O
.	O
in	O
diabetic	O
person	O
glucose	ENTITY
from	ENTITY
blood	ENTITY
cannot	O
enter	O
into	O
the	O
body	O
cells	O
due	O
to	O
lack	O
of	O
insulin	ENTITY
or	ENTITY
insulin	ENTITY
resistance	ENTITY
.	O
lack	O
of	O
energy	O
body	O
.	O
fatigue	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
level	ENTITY
makes	O
our	O
blood	O
sluggish	O
and	O
sticky	O
which	O
makes	O
circulation	O
.	O
hence	O
body	O
cells	O
cannot	O
get	O
oxygen	O
.	O
high	ENTITY
blood	ENTITY
glucose	ENTITY
inflamed	O
blood	ENTITY
vessel	ENTITY
which	O
causes	O
fatigue	O
.	O
insulin	ENTITY
resistance	ENTITY
keeps	O
glucose	ENTITY
.	O
vision	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
causes	O
swelling	ENTITY
of	ENTITY
the	ENTITY
lens	ENTITY
inside	ENTITY
the	ENTITY
eye	ENTITY
.	O
long	O
term	O
uncontrolled	O
diabetes	ENTITY
causes	ENTITY
damage	ENTITY
to	ENTITY
small	ENTITY
blood	ENTITY
vessels	ENTITY
of	O
the	O
eye	O
which	O
leads	O
.	O
in	O
diabetes	ENTITY
fluid	ENTITY
seeping	ENTITY
into	ENTITY
the	ENTITY
lens	ENTITY
of	ENTITY
the	ENTITY
eye	ENTITY
and	ENTITY
causes	ENTITY
swelling	ENTITY
of	ENTITY
the	ENTITY
lens	ENTITY
.	O
this	O
condition	O
changes	O
the	O
shape	O
of	O
the	O
lens	O
.	O
skin	O
problem	O
people	O
with	O
diabetes	ENTITY
have	ENTITY
skin	ENTITY
problems	ENTITY
like	ENTITY
itching	ENTITY
fungal	ENTITY
infection	ENTITY
and	O
bacterial	ENTITY
infection	ENTITY
.	O
in	O
diabetes	ENTITY
.	O
so	O
skin	O
.	O
wound	O
healing	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
level	ENTITY
stiffens	O
arteries	ENTITY
.	O
narrow	O
blood	ENTITY
vessels	ENTITY
provide	O
less	O
blood	ENTITY
flow	ENTITY
and	O
oxygen	O
to	O
wound	O
.	O
in	O
diabetes	ENTITY
there	ENTITY
is	ENTITY
nerve	ENTITY
damage	ENTITY
.	O
therefore	O
diabetic	O
person	O
cannot	O
feel	O
developing	O
infection	ENTITY
or	ENTITY
wound	ENTITY
.	O
yeast	ENTITY
infection	ENTITY
yeast	ENTITY
is	ENTITY
found	ENTITY
in	ENTITY
skin	ENTITY
and	ENTITY
mucous	ENTITY
membrane	ENTITY
in	O
our	O
body	O
.	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
secreted	O
in	O
urine	ENTITY
sweat	ENTITY
and	ENTITY
mucous	ENTITY
.	O
this	O
sugar	O
is	O
used	O
by	O
yeast	ENTITY
for	ENTITY
overgrowth	ENTITY
.	O
yeast	ENTITY
infection	ENTITY
occurs	O
in	O
mouth	ENTITY
genitals	ENTITY
and	O
most	O
commonly	O
in	O
the	O
vagina	ENTITY
.	O
vaginal	ENTITY
yeast	ENTITY
infection	ENTITY
causes	O
itching	ENTITY
burning	ENTITY
and	ENTITY
pain	ENTITY
at	ENTITY
the	ENTITY
vagina	ENTITY
.	O
it	O
also	O
has	O
burning	ENTITY
micturition	ENTITY
unpleasant	O
odor	O
and	O
vaginal	ENTITY
discharge	ENTITY
symptom	ENTITY
.	O
numbness	O
in	O
people	O
with	O
many	O
years	O
diabetes	ENTITY
there	ENTITY
is	ENTITY
damage	ENTITY
to	ENTITY
nerves	ENTITY
due	O
to	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
causes	O
numbness	O
tingling	ENTITY
sensation	ENTITY
in	O
leg	ENTITY
feet	ENTITY
hand	ENTITY
and	ENTITY
arms	ENTITY
.	O
the	O
nerve	ENTITY
of	ENTITY
our	ENTITY
feet	ENTITY
is	O
longest	O
in	O
our	O
body	O
.	O
hence	O
they	O
are	O
the	O
most	O
often	O
affected	O
.	O
disclaimer	O
the	O
information	O
provided	O
on	O
this	O
channel	O
and	O
its	O
videos	O
are	O
for	O
general	O
purposes	O
only	O
and	O
should	O
not	O
be	O
considered	O
as	O
professional	O
advice	O
.	O
we	O
are	O
trying	O
to	O
provide	O
perfect	O
valid	O
specific	O
detailed	O
information	O
.	O
we	O
are	O
not	O
licensed	O
professional	O
so	O
make	O
sure	O
with	O
your	O
professional	O
consultant	O
in	O
case	O
you	O
need	O
.	O
in	O
this	O
video	O
we	O
re	O
going	O
to	O
learn	O
about	O
how	O
the	O
concentration	O
of	O
hormones	ENTITY
in	ENTITY
our	ENTITY
blood	ENTITY
is	ENTITY
regulated	ENTITY
.	O
by	O
ryan	O
patton	O
.	O
created	O
by	O
ryan	O
scott	O
patton	O
.	O
watch	O
the	O
next	O
lesson	O
add	O
user	O
khanacademy	O
.	O
click	O
here	O
type	O
diabetes	ENTITY
is	ENTITY
chronic	ENTITY
disease	ENTITY
characterized	O
by	O
abnormal	ENTITY
glucose	ENTITY
metabolism	ENTITY
.	O
type	O
diabetes	ENTITY
is	ENTITY
by	ENTITY
far	ENTITY
the	ENTITY
most	ENTITY
common	ENTITY
form	ENTITY
of	ENTITY
diabetics	ENTITY
actually	ENTITY
suffer	ENTITY
from	ENTITY
this	ENTITY
form	ENTITY
of	ENTITY
the	ENTITY
disease	ENTITY
.	O
in	O
the	O
case	O
of	O
type	O
diabetes	ENTITY
there	ENTITY
is	ENTITY
resistance	ENTITY
of	ENTITY
the	ENTITY
tissues	ENTITY
to	O
insulin	ENTITY
and	ENTITY
decreased	ENTITY
response	ENTITY
to	ENTITY
glucose	ENTITY
by	ENTITY
the	ENTITY
pancreas	ENTITY
.	O
the	O
circulating	O
endogenous	O
insulin	ENTITY
is	ENTITY
sufficient	ENTITY
to	ENTITY
prevent	ENTITY
ketosis	ENTITY
.	O
there	O
is	O
often	O
excessive	O
insulin	ENTITY
secretion	ENTITY
and	O
excessive	O
activity	O
of	O
the	O
beta	ENTITY
cells	ENTITY
in	O
the	O
pancreas	ENTITY
.	O
diabetes	ENTITY
is	ENTITY
very	ENTITY
widespread	ENTITY
metabolic	ENTITY
disorder	ENTITY
.	O
studies	O
have	O
estimated	O
that	O
in	O
there	O
were	O
million	O
people	O
infected	ENTITY
with	ENTITY
the	ENTITY
disease	ENTITY
worldwide	ENTITY
and	ENTITY
according	ENTITY
to	ENTITY
several	ENTITY
estimations	ENTITY
the	ENTITY
number	ENTITY
will	ENTITY
reach	ENTITY
million	ENTITY
by	ENTITY
this	ENTITY
is	ENTITY
chronic	ENTITY
condition	ENTITY
that	ENTITY
may	ENTITY
remain	ENTITY
silent	ENTITY
for	ENTITY
long	ENTITY
periods	ENTITY
and	ENTITY
the	ENTITY
progression	ENTITY
of	ENTITY
the	ENTITY
disease	ENTITY
is	O
highly	O
unpredictable	O
.	O
the	O
most	O
important	O
step	O
you	O
can	O
take	O
to	O
treat	O
diabetes	ENTITY
naturally	ENTITY
without	ENTITY
drugs	ENTITY
lose	ENTITY
weight	ENTITY
obesity	ENTITY
is	ENTITY
taking	ENTITY
epidemic	ENTITY
proportions	ENTITY
in	ENTITY
many	ENTITY
countries	ENTITY
.	O
abdominal	ENTITY
obesity	ENTITY
is	O
even	O
more	O
dangerous	O
and	O
is	O
an	O
important	O
and	O
independent	O
risk	O
factor	O
for	O
the	O
occurrence	O
of	O
hyperlipidemia	ENTITY
hypertension	ENTITY
cardiovascular	ENTITY
disease	ENTITY
and	O
diabetes	ENTITY
especially	ENTITY
type	ENTITY
this	ENTITY
happens	ENTITY
because	ENTITY
visceral	ENTITY
fat	ENTITY
is	O
not	O
an	O
inert	O
tissue	ENTITY
but	ENTITY
is	ENTITY
actually	ENTITY
an	ENTITY
endocrine	ENTITY
organ	ENTITY
that	O
produces	O
many	O
hormones	ENTITY
that	ENTITY
regulate	ENTITY
the	ENTITY
energy	ENTITY
homeostasis	ENTITY
of	O
the	O
body	O
and	O
affects	O
the	O
secretion	ENTITY
of	ENTITY
insulin	ENTITY
that	O
can	O
cause	O
inflammation	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
vessels	ENTITY
.	O
visceral	ENTITY
fat	ENTITY
may	O
cause	O
weight	ENTITY
gain	ENTITY
high	ENTITY
levels	O
of	O
fasting	ENTITY
glucose	ENTITY
and	O
insulin	ENTITY
resistance	ENTITY
.	O
safe	O
indicator	O
of	O
abdominal	ENTITY
obesity	ENTITY
is	O
the	O
measurement	O
of	O
waist	O
circumference	O
.	O
waist	O
circumference	O
should	O
be	O
under	O
cm	O
for	O
men	O
and	O
under	O
cm	O
for	O
women	O
.	O
in	O
conclusion	O
increased	O
levels	O
of	O
visceral	ENTITY
fat	ENTITY
is	O
major	O
risk	O
factor	O
for	O
developing	O
type	O
diabetes	ENTITY
and	ENTITY
should	ENTITY
be	ENTITY
addressed	ENTITY
by	ENTITY
any	ENTITY
diabetic	ENTITY
patient	ENTITY
that	O
wishes	O
to	O
treat	O
the	O
disease	ENTITY
.	O
what	O
is	O
more	O
it	O
has	O
been	O
shown	O
that	O
loss	O
of	O
of	O
your	O
total	O
body	O
weight	O
can	O
represents	O
loss	ENTITY
of	ENTITY
visceral	ENTITY
fat	ENTITY
by	O
about	O
which	O
improves	O
the	O
function	O
of	O
the	O
adipose	ENTITY
tissue	ENTITY
.	O
make	O
sure	O
you	O
lose	O
weight	O
gradually	O
and	O
try	O
to	O
adopt	O
healthy	O
eating	O
habits	O
to	O
ensure	O
lasting	O
results	O
.	O
what	O
you	O
need	O
to	O
do	O
measure	O
your	O
waistline	O
.	O
as	O
mentioned	O
above	O
the	O
limit	O
is	O
cm	O
for	O
women	O
and	O
cm	O
for	O
men	O
.	O
the	O
larger	O
the	O
circumference	O
of	O
your	O
waist	O
the	O
greater	O
risk	O
to	O
become	O
diabetic	ENTITY
.	O
if	O
you	O
already	O
suffer	O
with	O
this	O
condition	O
then	O
large	O
waist	O
circumference	O
may	O
compromise	O
glycemic	ENTITY
control	ENTITY
since	ENTITY
it	ENTITY
reduces	ENTITY
the	ENTITY
body	ENTITY
ability	ENTITY
to	ENTITY
handle	ENTITY
glucose	ENTITY
while	ENTITY
increasing	ENTITY
insulin	ENTITY
resistance	ENTITY
.	O
regularly	O
check	O
the	O
levels	ENTITY
of	ENTITY
lipids	ENTITY
and	O
glucose	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
.	O
now	O
pay	O
close	O
attention	O
here	O
to	O
control	O
type	O
diabetes	ENTITY
there	ENTITY
is	ENTITY
an	ENTITY
amazing	ENTITY
method	ENTITY
that	ENTITY
can	ENTITY
help	ENTITY
you	ENTITY
reverse	ENTITY
the	ENTITY
disease	ENTITY
the	ENTITY
natural	ENTITY
way	ENTITY
.	O
metabolic	ENTITY
syndrome	ENTITY
is	O
probably	O
the	O
most	O
serious	O
medical	O
condition	O
that	O
you	O
haven	O
heard	O
about	O
yet	O
.	O
so	O
what	O
is	O
metabolic	ENTITY
syndrome	ENTITY
why	O
is	O
it	O
so	O
serious	O
and	O
why	O
haven	O
you	O
heard	O
about	O
it	O
.	O
here	O
is	O
what	O
you	O
need	O
to	O
know	O
.	O
the	O
metabolic	ENTITY
syndrome	ENTITY
is	O
cluster	O
of	O
the	O
most	O
dangerous	O
heart	ENTITY
attack	ENTITY
risk	O
factors	O
raised	ENTITY
blood	ENTITY
glucose	ENTITY
central	ENTITY
adiposity	ENTITY
often	O
called	O
beer	O
belly	O
abnormal	O
cholesterol	ENTITY
levels	ENTITY
abnormal	O
blood	ENTITY
fats	ENTITY
also	O
called	O
triglycerides	ENTITY
and	ENTITY
high	ENTITY
blood	ENTITY
pressure	ENTITY
.	O
it	O
is	O
estimated	O
that	O
in	O
adults	O
have	O
metabolic	ENTITY
syndrome	ENTITY
and	O
the	O
condition	O
becomes	O
more	O
common	O
as	O
we	O
get	O
older	O
so	O
that	O
by	O
the	O
age	O
of	O
nearly	O
third	O
of	O
adults	O
have	O
metabolic	ENTITY
syndrome	ENTITY
.	O
so	O
why	O
is	O
metabolic	ENTITY
syndrome	ENTITY
so	O
important	O
.	O
well	O
if	O
you	O
have	O
metabolic	ENTITY
syndrome	ENTITY
you	O
are	O
much	O
more	O
likely	O
to	O
suffer	O
heart	ENTITY
attack	ENTITY
or	O
stroke	O
more	O
likely	O
to	O
develop	O
full	O
blown	ENTITY
diabetes	ENTITY
more	O
likely	O
to	O
develop	O
cancer	O
and	O
more	O
likely	O
to	O
develop	O
alzheimer	ENTITY
disease	ENTITY
.	O
all	O
of	O
these	O
conditions	O
are	O
serious	O
and	O
they	O
are	O
getting	O
far	O
more	O
common	O
.	O
dementia	ENTITY
and	ENTITY
alzheimer	ENTITY
disease	ENTITY
have	O
overtaken	O
cancer	O
and	O
heart	ENTITY
disease	ENTITY
as	O
the	O
leading	O
cause	O
of	O
death	O
in	O
england	O
and	O
wales	O
in	O
and	O
the	O
metabolic	ENTITY
syndrome	ENTITY
and	O
diabetes	ENTITY
are	ENTITY
thought	ENTITY
to	ENTITY
be	ENTITY
important	ENTITY
risk	ENTITY
factors	ENTITY
for	ENTITY
these	ENTITY
conditions	ENTITY
.	O
so	O
how	O
can	O
you	O
check	O
to	O
see	O
if	O
you	O
have	O
metabolic	ENTITY
syndrome	ENTITY
.	O
well	O
first	O
of	O
all	O
get	O
out	O
tape	O
measure	O
.	O
if	O
you	O
are	O
man	O
and	O
your	O
waist	O
circumference	O
is	O
more	O
than	O
cm	O
or	O
if	O
you	O
are	O
woman	O
and	O
your	O
waist	O
is	O
more	O
than	O
cm	O
you	O
have	O
one	O
of	O
the	O
main	O
features	O
of	O
metabolic	ENTITY
syndrome	ENTITY
.	O
if	O
in	O
addition	O
you	O
have	O
any	O
of	O
the	O
following	O
you	O
will	O
be	O
classified	O
as	O
having	O
metabolic	ENTITY
syndrome	ENTITY
raised	ENTITY
blood	ENTITY
triglycerides	ENTITY
reduced	ENTITY
hdl	ENTITY
cholesterol	ENTITY
sometimes	O
known	O
as	O
good	O
cholesterol	ENTITY
raised	ENTITY
blood	ENTITY
pressure	ENTITY
or	O
raised	ENTITY
fasting	ENTITY
plasma	ENTITY
glucose	ENTITY
.	O
note	O
if	O
you	O
are	O
man	O
of	O
south	O
asian	O
or	O
indian	O
heritage	O
the	O
important	O
threshold	O
for	O
waist	O
circumference	O
is	O
cm	O
.	O
metabolic	ENTITY
syndrome	ENTITY
has	O
not	O
yet	O
been	O
classified	O
as	O
disease	ENTITY
it	ENTITY
is	ENTITY
still	ENTITY
regarded	ENTITY
as	ENTITY
collection	ENTITY
of	ENTITY
signs	ENTITY
and	ENTITY
symptoms	ENTITY
which	ENTITY
together	ENTITY
are	ENTITY
serious	ENTITY
risk	ENTITY
factors	ENTITY
for	ENTITY
our	ENTITY
most	ENTITY
deadly	ENTITY
and	ENTITY
disabling	ENTITY
medical	ENTITY
conditions	ENTITY
.	O
several	O
medical	O
organisations	O
such	O
as	O
the	O
world	O
health	O
organisation	O
who	O
the	O
independent	O
diabetes	ENTITY
federation	ENTITY
idf	ENTITY
and	ENTITY
the	ENTITY
european	ENTITY
group	ENTITY
for	ENTITY
the	ENTITY
study	ENTITY
of	ENTITY
insulin	ENTITY
resistance	ENTITY
egir	O
define	O
the	O
metabolic	ENTITY
syndrome	ENTITY
in	O
very	O
slightly	O
different	O
ways	O
and	O
this	O
adds	O
even	O
more	O
to	O
the	O
confusion	O
about	O
what	O
exactly	O
metabolic	ENTITY
syndrome	ENTITY
is	O
.	O
however	O
many	O
experts	O
now	O
believe	O
that	O
the	O
underlying	O
problem	O
in	O
metabolic	ENTITY
syndrome	ENTITY
is	O
insulin	ENTITY
resistance	ENTITY
.	O
insulin	ENTITY
resistance	ENTITY
develops	O
when	O
this	O
hormone	ENTITY
cannot	ENTITY
work	ENTITY
properly	ENTITY
when	ENTITY
blood	ENTITY
insulin	ENTITY
levels	ENTITY
are	O
abnormally	O
high	O
and	O
still	O
relatively	O
ineffective	O
in	O
keeping	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
regulated	O
properly	O
.	O
metabolic	O
specialists	O
now	O
use	O
the	O
term	O
insulin	ENTITY
resistance	ENTITY
syndrome	ENTITY
instead	O
of	O
metabolic	ENTITY
syndrome	ENTITY
.	O
insulin	ENTITY
is	ENTITY
hormone	ENTITY
produced	ENTITY
by	ENTITY
the	ENTITY
pancreas	ENTITY
and	ENTITY
it	ENTITY
is	ENTITY
important	ENTITY
in	ENTITY
the	ENTITY
metabolism	ENTITY
of	ENTITY
carbohydrates	ENTITY
and	ENTITY
fats	ENTITY
.	O
when	O
sugar	O
and	O
carbohydrates	ENTITY
are	ENTITY
eaten	ENTITY
insulin	ENTITY
promotes	ENTITY
the	ENTITY
uptake	ENTITY
of	ENTITY
glucose	ENTITY
from	ENTITY
the	ENTITY
blood	ENTITY
into	ENTITY
muscles	ENTITY
and	ENTITY
fat	ENTITY
cells	ENTITY
.	O
hence	O
it	O
is	O
often	O
said	O
that	O
insulin	ENTITY
allows	ENTITY
cells	ENTITY
to	ENTITY
use	ENTITY
glucose	ENTITY
for	ENTITY
energy	ENTITY
and	ENTITY
also	ENTITY
to	ENTITY
store	ENTITY
excess	ENTITY
glucose	ENTITY
and	ENTITY
sugar	ENTITY
as	ENTITY
glycogen	ENTITY
and	ENTITY
fat	ENTITY
.	O
when	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
fall	O
stored	O
glucose	ENTITY
is	ENTITY
released	ENTITY
for	ENTITY
energy	ENTITY
from	ENTITY
the	ENTITY
breakdown	ENTITY
of	ENTITY
glycogen	ENTITY
stores	ENTITY
in	ENTITY
the	ENTITY
liver	ENTITY
and	ENTITY
in	ENTITY
the	ENTITY
muscles	ENTITY
.	O
in	O
the	O
metabolic	ENTITY
syndrome	ENTITY
insulin	ENTITY
levels	ENTITY
are	O
chronically	O
high	O
.	O
fasting	O
blood	ENTITY
levels	ENTITY
of	ENTITY
insulin	ENTITY
in	O
the	O
morning	O
are	O
often	O
abnormally	O
high	O
and	O
insulin	ENTITY
levels	ENTITY
rise	O
to	O
very	O
high	O
levels	O
when	O
food	O
is	O
eaten	O
.	O
continuously	O
high	ENTITY
levels	ENTITY
of	ENTITY
insulin	ENTITY
cause	O
the	O
liver	ENTITY
cells	ENTITY
to	O
store	O
fat	ENTITY
resulting	ENTITY
in	ENTITY
fatty	ENTITY
liver	ENTITY
which	O
cannot	O
function	O
normally	O
.	O
as	O
the	O
insulin	ENTITY
resistance	ENTITY
worsens	O
the	O
pancreas	ENTITY
may	ENTITY
not	ENTITY
be	ENTITY
able	ENTITY
to	ENTITY
produce	ENTITY
enough	ENTITY
insulin	ENTITY
in	ENTITY
response	ENTITY
to	ENTITY
food	ENTITY
and	ENTITY
then	ENTITY
glucose	ENTITY
levels	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
rise	O
above	O
the	O
threshold	O
for	O
the	O
patient	O
to	O
be	O
called	O
diabetic	ENTITY
.	O
so	O
why	O
haven	O
you	O
heard	O
of	O
metabolic	ENTITY
syndrome	ENTITY
.	O
well	O
until	O
quite	O
recently	O
the	O
connection	O
between	O
metabolic	ENTITY
syndrome	ENTITY
and	O
host	O
of	O
chronic	ENTITY
diseases	ENTITY
was	O
not	O
fully	O
understood	O
.	O
we	O
now	O
know	O
that	O
insulin	ENTITY
resistance	ENTITY
is	O
the	O
key	O
.	O
until	O
recently	O
it	O
was	O
difficult	O
to	O
measure	O
blood	ENTITY
insulin	ENTITY
levels	ENTITY
but	O
the	O
technology	O
has	O
improved	O
and	O
we	O
can	O
now	O
measure	O
blood	ENTITY
insulin	ENTITY
levels	ENTITY
accurately	O
and	O
we	O
have	O
good	O
tests	O
to	O
diagnose	O
insulin	ENTITY
resistance	ENTITY
as	O
well	O
as	O
good	O
strategies	O
to	O
reverse	O
insulin	ENTITY
resistance	ENTITY
and	O
the	O
metabolic	ENTITY
syndrome	ENTITY
.	O
once	O
you	O
can	O
measure	O
insulin	ENTITY
resistance	ENTITY
you	O
are	O
well	O
on	O
your	O
way	O
to	O
fixing	O
it	O
and	O
monitoring	O
improvement	O
with	O
interventions	O
.	O
peter	O
butler	O
.	O
professor	O
of	O
medicine	O
and	O
chief	O
division	O
of	O
endocrinology	ENTITY
diabetes	ENTITY
hypertension	O
director	O
larry	O
hillblom	O
islet	O
research	O
center	O
david	O
geffen	O
school	O
of	O
medicine	O
at	O
ucla	O
why	O
is	O
there	O
diabetes	ENTITY
epidemic	ENTITY
.	O
dr	O
peter	O
butler	O
research	O
is	O
focused	O
on	O
abnormal	ENTITY
insulin	ENTITY
secretion	ENTITY
in	O
diabetes	ENTITY
the	ENTITY
causes	ENTITY
of	ENTITY
beta	ENTITY
cell	ENTITY
death	ENTITY
in	O
diabetes	ENTITY
and	ENTITY
the	ENTITY
possibility	ENTITY
to	ENTITY
foster	ENTITY
islet	ENTITY
regeneration	ENTITY
in	ENTITY
humans	ENTITY
with	ENTITY
diabetes	ENTITY
.	O
after	O
obtaining	O
his	O
md	O
at	O
the	O
university	O
of	O
birmingham	O
uk	O
in	O
dr	O
peter	O
butler	O
underwent	O
training	O
in	O
internal	ENTITY
medicine	ENTITY
in	O
edinburgh	O
and	O
newcastle	O
upon	O
tyne	O
in	O
the	O
uk	O
.	O
he	O
then	O
underwent	O
training	ENTITY
in	ENTITY
endocrinology	ENTITY
at	O
the	O
university	O
of	O
newcastle	O
upon	O
tyne	O
and	O
then	O
at	O
the	O
mayo	O
clinic	O
in	O
rochester	O
mn	O
where	O
he	O
was	O
also	O
research	O
fellow	O
.	O
he	O
was	O
then	O
appointed	O
to	O
clinical	O
faculty	O
position	O
at	O
mayo	O
clinic	O
in	O
endocrinology	ENTITY
diabetes	ENTITY
and	O
metabolism	ENTITY
.	O
he	O
was	O
also	O
the	O
associate	O
director	O
of	O
the	O
general	O
clinical	O
research	O
center	O
and	O
led	O
an	O
nih	O
funded	O
research	O
program	O
.	O
after	O
six	O
years	O
on	O
the	O
faculty	O
at	O
the	O
mayo	O
clinic	O
he	O
was	O
appointed	O
to	O
the	O
chair	O
of	O
diabetes	ENTITY
at	ENTITY
the	ENTITY
university	ENTITY
of	ENTITY
edinburgh	ENTITY
in	ENTITY
scotland	ENTITY
where	ENTITY
he	ENTITY
established	ENTITY
the	ENTITY
first	ENTITY
clinical	ENTITY
research	ENTITY
center	ENTITY
in	ENTITY
the	ENTITY
uk	ENTITY
.	O
he	O
returned	O
to	O
the	O
usa	O
in	O
when	O
he	O
was	O
appointed	O
to	O
chief	O
of	O
endocrinology	ENTITY
diabetes	ENTITY
and	O
hypertension	ENTITY
at	ENTITY
the	ENTITY
university	ENTITY
of	ENTITY
southern	ENTITY
california	ENTITY
moving	ENTITY
to	ENTITY
the	ENTITY
university	ENTITY
of	ENTITY
california	ENTITY
los	ENTITY
angeles	ENTITY
in	ENTITY
at	ENTITY
ucla	ENTITY
he	ENTITY
has	ENTITY
established	ENTITY
the	ENTITY
larry	ENTITY
hillblom	ENTITY
islet	ENTITY
research	ENTITY
center	ENTITY
free	ENTITY
standing	ENTITY
building	ENTITY
that	ENTITY
houses	ENTITY
investigators	ENTITY
with	ENTITY
wide	ENTITY
range	ENTITY
of	ENTITY
skills	ENTITY
focused	ENTITY
on	ENTITY
revealing	ENTITY
the	ENTITY
mechanisms	ENTITY
of	ENTITY
beta	ENTITY
cell	ENTITY
loss	O
and	O
potential	O
regeneration	O
in	O
people	O
with	O
type	O
and	O
diabetes	ENTITY
.	O
he	O
is	O
director	O
of	O
the	O
lhirc	ENTITY
islet	ENTITY
isolation	ENTITY
and	O
physiology	O
core	O
.	O
he	O
is	O
also	O
the	O
chief	O
of	O
the	O
division	O
of	O
endocrinology	ENTITY
diabetes	ENTITY
and	O
hypertension	ENTITY
.	O
his	O
clinical	O
practice	O
at	O
ucla	O
focuses	O
on	O
care	O
of	O
patients	O
with	O
diabetes	ENTITY
.	O
take	O
dr	O
berg	O
advanced	O
evaluation	O
quiz	O
the	O
health	O
wellness	O
center	O
pinecrest	O
office	O
park	O
drive	O
alexandria	O
va	O
disclaimer	O
dr	O
berg	O
does	O
not	O
diagnose	O
treat	O
or	O
prevent	O
any	O
medical	O
conditions	O
instead	O
he	O
helps	O
people	O
create	O
their	O
health	O
to	O
avoid	O
health	O
problems	O
.	O
he	O
works	O
with	O
their	O
physicians	O
which	O
regular	O
their	O
medication	O
.	O
this	O
video	O
is	O
not	O
designed	O
to	O
and	O
does	O
not	O
provide	O
medical	O
advice	O
professional	O
diagnosis	O
opinion	O
treatment	O
or	O
services	O
to	O
you	O
or	O
to	O
any	O
other	O
individual	O
.	O
through	O
my	O
videos	O
blog	O
posts	O
website	O
information	O
give	O
suggestions	O
for	O
you	O
and	O
your	O
doctor	O
to	O
research	O
and	O
provide	O
general	O
information	O
for	O
educational	O
purposes	O
only	O
.	O
the	O
information	O
provided	O
in	O
this	O
video	O
or	O
site	O
or	O
through	O
linkages	O
to	O
other	O
sites	O
is	O
not	O
substitute	O
for	O
medical	O
or	O
professional	O
care	O
and	O
you	O
should	O
not	O
use	O
the	O
information	O
in	O
place	O
of	O
visit	O
call	O
consultation	O
or	O
the	O
advice	O
of	O
your	O
physician	O
or	O
other	O
healthcare	O
provider	O
.	O
the	O
health	O
wellness	O
and	O
dr	O
eric	O
berg	O
are	O
not	O
liable	O
or	O
responsible	O
for	O
any	O
advice	O
course	O
of	O
treatment	O
diagnosis	O
or	O
any	O
other	O
information	O
services	O
or	O
product	O
you	O
obtain	O
through	O
this	O
video	O
or	O
site	O
.	O
what	O
is	O
diabetes	ENTITY
.	O
insulin	ENTITY
is	ENTITY
hormone	ENTITY
secreted	ENTITY
in	ENTITY
beta	ENTITY
cells	ENTITY
of	ENTITY
the	ENTITY
pancreas	ENTITY
which	O
helps	O
to	O
decrease	O
the	O
level	ENTITY
of	ENTITY
glucose	ENTITY
in	O
our	O
blood	O
.	O
chromium	ENTITY
is	ENTITY
important	ENTITY
for	ENTITY
normal	ENTITY
function	ENTITY
of	ENTITY
insulin	ENTITY
and	ENTITY
broccoli	ENTITY
enriched	ENTITY
in	ENTITY
chromium	ENTITY
.	O
diabetes	ENTITY
is	ENTITY
classified	ENTITY
into	ENTITY
type	ENTITY
type	ENTITY
and	ENTITY
type	ENTITY
or	ENTITY
gestational	ENTITY
diabetes	ENTITY
.	O
gestational	ENTITY
diabetes	ENTITY
type	O
occurs	O
only	O
during	O
pregnancy	O
.	O
if	O
pancreas	ENTITY
does	ENTITY
not	ENTITY
produce	ENTITY
insulin	ENTITY
is	ENTITY
called	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
similarly	O
if	O
pancreas	ENTITY
producing	ENTITY
very	ENTITY
low	ENTITY
amount	ENTITY
of	ENTITY
insulin	ENTITY
is	ENTITY
called	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
diabetes	ENTITY
may	ENTITY
cause	ENTITY
cardiovascular	ENTITY
disease	ENTITY
.	O
type	O
diabetes	ENTITY
is	ENTITY
also	ENTITY
known	ENTITY
as	ENTITY
juvenile	ENTITY
diabetes	ENTITY
type	O
diabetes	ENTITY
is	ENTITY
common	ENTITY
disease	ENTITY
in	ENTITY
children	ENTITY
.	O
men	O
who	O
are	O
living	O
with	O
low	O
testosterone	O
level	O
have	O
diabetes	ENTITY
risk	ENTITY
.	O
in	O
order	O
to	O
prevent	O
diabetes	ENTITY
insulin	ENTITY
helps	O
to	O
decrease	O
glucose	ENTITY
level	ENTITY
.	O
similarly	O
insulin	ENTITY
can	ENTITY
also	ENTITY
help	ENTITY
to	ENTITY
decrease	ENTITY
hungry	ENTITY
and	ENTITY
increase	ENTITY
dopamine	ENTITY
neurotransmitter	ENTITY
level	ENTITY
.	O
diabetic	ENTITY
retinopathy	ENTITY
is	O
an	O
eye	ENTITY
disease	ENTITY
caused	O
by	O
diabetes	ENTITY
mellitus	ENTITY
.	O
sometimes	O
diabetes	ENTITY
retinopathy	ENTITY
may	O
leads	O
to	O
blindness	O
.	O
in	O
globally	O
core	O
people	O
had	O
diabetes	ENTITY
.	O
recently	O
researchers	O
identified	O
that	O
the	O
eating	O
potassium	ENTITY
rich	ENTITY
foods	ENTITY
like	ENTITY
white	ENTITY
beans	ENTITY
potato	ENTITY
banana	ENTITY
etc	ENTITY
helps	ENTITY
to	ENTITY
prevent	ENTITY
diabetes	ENTITY
patients	ENTITY
from	ENTITY
renal	ENTITY
failure	ENTITY
.	O
th	O
november	O
of	O
every	O
year	O
is	O
the	O
world	O
diabetes	ENTITY
awareness	ENTITY
day	ENTITY
.	O
what	O
are	O
the	O
symptoms	ENTITY
of	ENTITY
diabetes	ENTITY
.	O
the	O
both	O
diabetes	ENTITY
insipidus	ENTITY
and	O
mellitus	ENTITY
have	ENTITY
same	ENTITY
symptoms	ENTITY
but	ENTITY
they	ENTITY
are	ENTITY
exactly	ENTITY
different	ENTITY
from	ENTITY
each	ENTITY
other	ENTITY
.	O
important	O
symptoms	O
of	O
diabetes	ENTITY
are	ENTITY
listed	ENTITY
below	ENTITY
.	O
polydipsia	ENTITY
it	ENTITY
means	ENTITY
excessive	ENTITY
thirst	ENTITY
caused	ENTITY
by	ENTITY
our	ENTITY
body	ENTITY
in	ENTITY
order	ENTITY
to	ENTITY
minimize	ENTITY
glucose	ENTITY
concentration	ENTITY
in	O
our	O
blood	ENTITY
.	O
not	O
to	O
be	O
confused	O
with	O
psycogenic	O
polydipsia	ENTITY
primary	ENTITY
polydipsia	ENTITY
which	ENTITY
is	ENTITY
an	ENTITY
excessive	ENTITY
thirst	ENTITY
caused	ENTITY
by	ENTITY
mental	ENTITY
stress	ENTITY
.	O
polyurea	ENTITY
it	ENTITY
means	ENTITY
frequent	ENTITY
urine	ENTITY
output	ENTITY
due	ENTITY
to	ENTITY
polydipsia	ENTITY
.	O
frequent	O
masturbation	ENTITY
does	ENTITY
not	ENTITY
cause	ENTITY
polyurea	ENTITY
polyphagia	ENTITY
it	ENTITY
means	ENTITY
frequent	ENTITY
hungry	ENTITY
.	O
how	O
to	O
diagnose	O
diabetes	ENTITY
.	O
there	O
are	O
several	O
types	O
of	O
test	O
helps	O
to	O
diagnose	O
diabetes	ENTITY
.	O
benedict	O
solution	O
test	O
is	O
the	O
simple	O
urine	ENTITY
test	ENTITY
which	O
helps	O
to	O
diagnose	O
diabetes	ENTITY
for	ENTITY
our	ENTITY
self	ENTITY
in	ENTITY
home	ENTITY
.	O
fast	ENTITY
sugar	ENTITY
test	ENTITY
fst	O
also	O
helps	O
to	O
diagnose	O
diabetes	ENTITY
.	O
glucometer	ENTITY
is	ENTITY
an	ENTITY
advanced	ENTITY
device	ENTITY
which	ENTITY
helps	ENTITY
to	ENTITY
diagnose	ENTITY
diabetes	ENTITY
within	ENTITY
few	ENTITY
seconds	ENTITY
.	O
how	O
to	O
treat	O
diabetes	ENTITY
.	O
sitagliptin	ENTITY
januvia	ENTITY
lantus	ENTITY
generic	ENTITY
name	ENTITY
linsulin	ENTITY
glargine	ENTITY
and	O
metformin	ENTITY
brand	ENTITY
name	ENTITY
metafort	ENTITY
are	ENTITY
the	ENTITY
name	ENTITY
of	ENTITY
the	ENTITY
drugs	ENTITY
helps	ENTITY
to	ENTITY
treat	ENTITY
diabetes	ENTITY
mellitus	ENTITY
.	O
but	O
these	O
drugs	O
must	O
not	O
be	O
use	O
without	O
doctor	O
advice	O
.	O
insulin	ENTITY
injection	ENTITY
also	O
helps	O
to	O
reduce	O
blood	ENTITY
sugar	ENTITY
level	ENTITY
and	O
fasting	O
helps	O
to	O
reduce	O
our	O
sugar	O
.	O
broccoli	O
is	O
the	O
best	O
nutrition	O
food	O
for	O
patients	O
who	O
living	O
with	O
diabetes	ENTITY
mellitus	ENTITY
.	O
consuming	O
large	O
amount	O
of	O
water	O
helps	O
to	O
push	O
out	O
blood	ENTITY
glucose	ENTITY
via	O
urine	ENTITY
.	O
for	O
anatomy	ENTITY
lab	ENTITY
students	ENTITY
at	ENTITY
mt	ENTITY
.	O
san	O
antonio	O
college	O
in	O
walnut	O
ca	O
.	O
tissues	ENTITY
adipose	ENTITY
tissue	ENTITY
.	O
take	O
action	O
prevent	O
now	O
ask	O
me	O
how	O
.	O
www	O
shapeupnow	O
net	O
www	O
nutrition	O
hub	O
com	O
weight	O
gain	O
metabolism	ENTITY
fat	ENTITY
and	O
visceral	ENTITY
fat	ENTITY
in	O
mins	O
.	O
subbable	O
message	O
to	O
the	O
world	O
.	O
from	O
laura	O
love	O
rathbun	O
learning	O
is	O
the	O
best	O
thing	O
to	O
do	O
with	O
your	O
you	O
.	O
you	O
can	O
directly	O
support	O
crash	O
course	O
at	O
.	O
excess	O
visceral	ENTITY
fat	ENTITY
aka	O
belly	ENTITY
fat	ENTITY
leads	O
to	O
heart	ENTITY
disease	ENTITY
cancer	ENTITY
stroke	O
arthritis	ENTITY
type	ENTITY
diabetes	ENTITY
and	ENTITY
even	ENTITY
sexual	ENTITY
dysfunction	ENTITY
.	O
dr	O
travis	O
stork	O
talks	O
about	O
why	O
having	O
lean	ENTITY
belly	ENTITY
to	O
good	O
health	O
on	O
the	O
the	O
doctors	O
.	O
this	O
video	O
explains	O
what	O
adipose	ENTITY
tissue	ENTITY
is	O
and	O
also	O
explains	O
the	O
the	O
function	ENTITY
of	ENTITY
adipose	ENTITY
tissue	ENTITY
support	O
us	O
.	O
this	O
short	O
video	O
discusses	O
the	O
different	O
types	O
of	O
adipose	ENTITY
tissue	ENTITY
and	O
how	O
adipokines	ENTITY
help	ENTITY
maintain	ENTITY
overall	ENTITY
homeostasis	ENTITY
by	ENTITY
communicating	ENTITY
with	ENTITY
other	ENTITY
organs	ENTITY
in	ENTITY
the	ENTITY
body	ENTITY
.	O
visit	O
our	O
website	O
to	O
continue	O
learning	O
about	O
adipokines	ENTITY
and	ENTITY
functional	ENTITY
adipose	ENTITY
tissue	ENTITY
liver	ENTITY
crosstalk	ENTITY
.	O
gijs	O
goossens	O
netherlands	O
.	O
in	O
this	O
dissection	ENTITY
of	ENTITY
fat	ENTITY
donor	O
you	O
will	O
take	O
look	O
at	O
three	O
main	O
places	O
where	O
abdominal	ENTITY
fat	ENTITY
accumulates	O
fatty	ENTITY
layer	ENTITY
of	O
the	O
superficial	ENTITY
fascia	ENTITY
of	ENTITY
the	ENTITY
abdominal	ENTITY
wall	ENTITY
extraperitoneal	O
layer	O
and	O
between	O
folds	ENTITY
of	ENTITY
peritoneum	ENTITY
.	O
presented	O
by	O
dr	O
akram	O
jaffar	O
ph	O
dissection	ENTITY
was	ENTITY
supported	ENTITY
by	ENTITY
mohamed	ENTITY
emad	ENTITY
and	ENTITY
layal	ENTITY
al	ENTITY
barghouthi	ENTITY
medical	ENTITY
students	ENTITY
and	ENTITY
nasser	ENTITY
zahra	ENTITY
lab	ENTITY
technician	ENTITY
edited	ENTITY
by	ENTITY
dr	ENTITY
akram	ENTITY
jaffar	ENTITY
dissection	ENTITY
was	ENTITY
performed	ENTITY
at	ENTITY
college	ENTITY
of	ENTITY
medicine	ENTITY
university	ENTITY
of	ENTITY
sharjah	ENTITY
united	ENTITY
arab	ENTITY
emirates	ENTITY
on	ENTITY
february	ENTITY
this	ENTITY
video	ENTITY
and	ENTITY
its	ENTITY
channel	ENTITY
are	ENTITY
supported	ENTITY
by	ENTITY
human	ENTITY
anatomy	ENTITY
education	ENTITY
page	ENTITY
on	ENTITY
facebook	ENTITY
.	O
donate	O
here	O
aklectures	O
com	O
.	O
new	O
study	O
that	O
released	O
just	O
last	O
week	O
details	O
the	O
molecular	ENTITY
promises	ENTITY
that	ENTITY
we	ENTITY
may	ENTITY
expect	ENTITY
from	ENTITY
intermittent	ENTITY
fasting	ENTITY
the	ENTITY
white	ENTITY
fat	ENTITY
cell	ENTITY
browning	O
is	O
showing	O
that	O
intermittent	O
fasting	O
may	O
continue	O
to	O
provide	O
more	O
and	O
more	O
new	O
benefits	O
as	O
more	O
studies	O
are	O
completed	O
.	O
keep	O
in	O
mind	O
that	O
these	O
studies	O
were	O
done	O
on	O
mice	O
but	O
it	O
is	O
so	O
interesting	O
to	O
see	O
new	O
revelations	O
for	O
the	O
positive	O
use	O
of	O
intermittent	O
fasting	O
continue	O
to	O
pop	O
up	O
time	O
and	O
time	O
again	O
.	O
lets	O
hope	O
that	O
this	O
study	O
will	O
soon	O
be	O
done	O
on	O
humans	O
as	O
well	O
.	O
follow	O
me	O
on	O
snapchat	O
fledgefitness	O
.	O
hd	O
animation	O
showing	O
the	O
shrinking	O
process	O
of	O
fat	ENTITY
fatdroplets	ENTITY
in	ENTITY
the	ENTITY
nucleus	ENTITY
of	ENTITY
human	ENTITY
fatcell	ENTITY
.	O
sinetrol	O
activates	O
the	O
energy	O
process	O
in	O
mitochondria	O
.	O
this	O
process	O
burn	O
the	O
fatdepot	ENTITY
fatdroplets	ENTITY
in	ENTITY
the	ENTITY
human	ENTITY
fatcell	ENTITY
.	O
shotgun	O
histology	O
adipose	ENTITY
tissue	ENTITY
.	O
adipose	ENTITY
tissue	ENTITY
and	O
loose	ENTITY
connective	ENTITY
tissue	ENTITY
functions	ENTITY
and	O
structure	O
video	O
lecture	O
.	O
everybody	O
has	O
adipose	ENTITY
and	ENTITY
visceral	ENTITY
fat	ENTITY
in	O
this	O
video	O
explain	O
the	O
difference	O
between	O
the	O
two	O
in	O
appearance	O
and	O
function	O
.	O
thanks	O
for	O
watching	O
.	O
do	O
not	O
own	O
this	O
video	O
just	O
cut	O
and	O
edited	O
it	O
with	O
several	O
other	O
videos	O
all	O
together	O
so	O
hope	O
it	O
is	O
useful	O
and	O
hope	O
you	O
enjoy	O
it	O
as	O
well	O
.	O
pimple	O
called	O
lipoma	ENTITY
the	ENTITY
removal	ENTITY
.	O
in	O
this	O
video	O
have	O
explained	O
briefly	O
about	O
three	O
types	O
of	O
adipose	ENTITY
tissues	ENTITY
white	ENTITY
adipose	ENTITY
tissue	ENTITY
brown	ENTITY
adipose	ENTITY
tissue	ENTITY
and	O
biege	ENTITY
adipose	ENTITY
tissue	ENTITY
.	O
the	O
brown	ENTITY
adipose	ENTITY
tissue	ENTITY
is	O
abundantly	O
seen	O
in	O
neonates	O
and	O
the	O
quantity	O
of	O
it	O
decreases	O
as	O
neonate	O
develops	O
into	O
infant	O
child	O
adolescent	O
and	O
adult	O
.	O
brown	ENTITY
adipose	ENTITY
tissue	ENTITY
has	O
more	O
mitochondria	ENTITY
with	ENTITY
high	ENTITY
expression	ENTITY
of	ENTITY
an	ENTITY
uncoupler	ENTITY
protein	ENTITY
called	O
thermogenin	ENTITY
.	O
thermogenin	ENTITY
is	ENTITY
also	ENTITY
referred	ENTITY
as	ENTITY
uncouplin	ENTITY
protein	ENTITY
ucp	ENTITY
.	O
thermogenin	ENTITY
acts	ENTITY
as	ENTITY
uncoupler	ENTITY
of	ENTITY
electron	ENTITY
transport	ENTITY
chain	ENTITY
and	ENTITY
uncouple	ENTITY
oxidation	ENTITY
from	ENTITY
phosphorylation	ENTITY
in	ENTITY
electron	ENTITY
transport	ENTITY
chain	ENTITY
.	O
this	O
way	O
thermogenin	ENTITY
in	ENTITY
brown	ENTITY
adipose	ENTITY
tissue	ENTITY
decreases	O
the	O
efficiency	O
of	O
electron	O
transport	O
chain	O
thereby	O
decreasing	O
effective	O
atp	ENTITY
generation	ENTITY
from	ENTITY
substrate	ENTITY
oxidation	ENTITY
.	O
watch	O
my	O
video	O
on	O
electron	O
transport	O
chain	O
in	O
the	O
link	O
below	O
.	O
this	O
patient	O
came	O
with	O
the	O
complaint	O
of	O
swelling	ENTITY
on	ENTITY
thigh	ENTITY
.	O
it	O
was	O
diagnosed	O
as	O
lipoma	ENTITY
.	O
the	O
large	O
mass	O
was	O
excised	O
.	O
there	O
are	O
many	O
different	O
ways	O
to	O
classify	O
fat	ENTITY
saturated	ENTITY
trans	ENTITY
unsaturated	ENTITY
brown	ENTITY
white	ENTITY
and	ENTITY
essential	ENTITY
fatty	ENTITY
acids	ENTITY
.	O
some	O
are	O
essential	O
for	O
life	O
and	O
some	O
are	O
lethal	ENTITY
.	O
where	O
fat	ENTITY
accumulates	ENTITY
is	ENTITY
also	ENTITY
important	ENTITY
.	O
if	O
white	O
fat	ENTITY
accumulates	ENTITY
inside	ENTITY
the	ENTITY
abdominal	ENTITY
cavity	ENTITY
it	O
predisposes	O
to	O
the	O
metabolic	ENTITY
syndrome	ENTITY
and	O
type	O
two	O
diabetes	ENTITY
with	ENTITY
all	ENTITY
of	ENTITY
its	ENTITY
complications	ENTITY
.	O
however	O
if	O
it	O
accumulates	O
in	O
other	O
places	O
it	O
actually	O
extends	O
life	O
expectancy	O
.	O
brown	ENTITY
fat	ENTITY
accumulates	O
in	O
the	O
neck	O
in	O
humans	O
.	O
contrary	O
to	O
white	ENTITY
fat	ENTITY
which	O
stores	O
fat	ENTITY
and	ENTITY
makes	ENTITY
us	ENTITY
overweight	ENTITY
brown	ENTITY
fat	ENTITY
burns	O
fat	ENTITY
when	ENTITY
the	ENTITY
body	ENTITY
is	ENTITY
exposed	ENTITY
to	ENTITY
cold	ENTITY
and	ENTITY
is	ENTITY
associated	ENTITY
with	ENTITY
lower	ENTITY
body	ENTITY
weight	ENTITY
.	O
wouldn	O
it	O
be	O
wonderful	O
if	O
we	O
could	O
convert	O
white	ENTITY
fat	ENTITY
to	O
brown	ENTITY
fat	ENTITY
so	O
we	O
tend	O
to	O
burn	O
it	O
and	O
weight	O
less	O
.	O
maybe	O
not	O
.	O
so	O
far	O
drugs	O
that	O
do	O
this	O
have	O
been	O
lethal	ENTITY
.	O
find	O
it	O
very	O
interesting	O
that	O
we	O
re	O
always	O
looking	O
for	O
ways	O
to	O
subvert	O
the	O
way	O
nature	O
operates	O
rather	O
than	O
live	O
healthy	O
lifestyle	O
.	O
it	O
is	O
also	O
interesting	O
that	O
fat	ENTITY
is	ENTITY
highly	ENTITY
active	ENTITY
tissue	ENTITY
metabolically	ENTITY
.	O
in	O
general	O
we	O
have	O
fat	ENTITY
phobia	ENTITY
in	ENTITY
this	ENTITY
country	ENTITY
that	ENTITY
is	ENTITY
off	ENTITY
target	ENTITY
.	O
fat	ENTITY
is	ENTITY
healthy	ENTITY
food	ENTITY
and	ENTITY
what	ENTITY
our	ENTITY
body	ENTITY
burns	ENTITY
for	ENTITY
fuel	ENTITY
most	ENTITY
of	ENTITY
the	ENTITY
time	ENTITY
.	O
for	O
more	O
information	O
please	O
visit	O
www	O
doctorsaputo	O
com	O
.	O
dr	O
ben	O
bikman	O
shares	O
his	O
latest	O
scientific	O
findings	O
in	O
this	O
field	O
and	O
the	O
synergism	O
between	O
the	O
ketogenic	ENTITY
diet	ENTITY
and	O
brown	ENTITY
adipose	ENTITY
tissue	ENTITY
activation	ENTITY
.	O
want	O
add	O
free	O
watching	O
.	O
fat	ENTITY
diet	ENTITY
.	O
don	O
worry	O
about	O
gluconeogenesis	ENTITY
.	O
best	O
home	O
remedies	O
.	O
you	O
have	O
ball	O
of	O
fat	ENTITY
under	ENTITY
skin	ENTITY
lipomas	ENTITY
check	O
these	O
natural	O
and	O
effective	O
ways	O
to	O
eliminate	O
it	O
.	O
lipoma	ENTITY
is	ENTITY
benign	ENTITY
tumor	ENTITY
under	O
the	O
skin	O
composed	O
of	O
adipose	ENTITY
tissue	ENTITY
which	O
is	O
the	O
most	O
common	O
form	O
of	O
soft	ENTITY
tissue	ENTITY
tumor	ENTITY
.	O
fat	ENTITY
tissue	ENTITY
also	O
is	O
known	O
as	O
adipose	ENTITY
tissue	ENTITY
or	O
lipoma	ENTITY
.	O
but	O
most	O
people	O
call	O
it	O
ball	O
of	O
fat	ENTITY
under	ENTITY
the	ENTITY
skin	ENTITY
.	O
it	O
is	O
not	O
life	O
threatening	O
condition	O
and	O
is	O
usually	O
painless	O
but	O
it	O
can	O
become	O
very	O
unpleasant	O
and	O
is	O
not	O
pretty	O
to	O
look	O
at	O
.	O
lipomas	ENTITY
can	ENTITY
appear	ENTITY
on	ENTITY
any	ENTITY
body	ENTITY
part	ENTITY
but	ENTITY
usually	ENTITY
affect	ENTITY
the	ENTITY
hands	ENTITY
neck	ENTITY
forehead	ENTITY
torso	ENTITY
and	ENTITY
armpits	ENTITY
.	O
the	O
usual	O
removal	O
procedure	O
involves	O
surgery	O
but	O
you	O
should	O
know	O
that	O
the	O
problem	O
can	O
also	O
be	O
treated	O
naturally	O
.	O
if	O
you	O
want	O
to	O
go	O
through	O
surgical	ENTITY
procedure	ENTITY
you	O
might	O
get	O
these	O
complications	ENTITY
due	ENTITY
to	ENTITY
infections	ENTITY
and	O
the	O
post	O
surgical	ENTITY
pain	ENTITY
.	O
you	O
will	O
actually	O
have	O
wound	O
after	O
it	O
and	O
the	O
pain	O
might	O
continue	O
for	O
days	O
.	O
that	O
why	O
if	O
you	O
have	O
lipoma	ENTITY
you	ENTITY
should	ENTITY
treat	ENTITY
it	ENTITY
naturally	ENTITY
and	ENTITY
not	ENTITY
put	ENTITY
yourself	ENTITY
under	ENTITY
any	ENTITY
kind	ENTITY
of	ENTITY
risk	ENTITY
.	O
today	O
we	O
re	O
going	O
to	O
show	O
you	O
few	O
great	O
recipes	O
that	O
are	O
efficient	O
and	O
can	O
eliminate	O
the	O
fat	ENTITY
tissue	ENTITY
in	O
just	O
few	O
days	O
.	O
for	O
the	O
preparation	O
of	O
these	O
recipes	O
you	O
will	O
need	O
simple	O
ingredients	O
that	O
are	O
cheap	O
and	O
easily	O
available	O
.	O
watch	O
this	O
video	O
to	O
learn	O
best	O
home	O
remedies	O
to	O
get	O
rid	O
of	O
lipomas	ENTITY
it	ENTITY
home	ENTITY
.	O
use	O
egg	O
yolk	O
and	O
salt	O
.	O
use	O
honey	O
and	O
flour	O
.	O
use	O
propolis	O
.	O
so	O
hope	O
this	O
video	O
will	O
be	O
helpful	O
for	O
you	O
all	O
.	O
thank	O
you	O
for	O
watching	O
this	O
video	O
.	O
hope	O
you	O
like	O
my	O
channel	O
there	O
will	O
be	O
many	O
more	O
videos	O
to	O
come	O
for	O
your	O
help	O
.	O
please	O
like	O
and	O
subscribe	O
to	O
my	O
channel	O
and	O
share	O
my	O
videos	O
with	O
your	O
family	O
and	O
friends	O
.	O
thank	O
you	O
please	O
share	O
on	O
twitter	O
facebook	O
and	O
google	O
to	O
spread	O
the	O
word	O
.	O
thank	O
you	O
subscribe	O
now	O
music	O
by	O
youtube	O
audio	O
library	O
thanks	O
for	O
watching	O
and	O
don	O
forget	O
to	O
like	O
comment	O
and	O
share	O
.	O
in	O
biology	ENTITY
adipose	ENTITY
tissue	ENTITY
po	O
or	O
body	ENTITY
fat	ENTITY
or	O
just	O
fat	ENTITY
is	ENTITY
loose	ENTITY
connective	ENTITY
tissue	ENTITY
composed	O
mostly	O
of	O
adipocytes	ENTITY
.	O
in	O
addition	O
to	O
adipocytes	ENTITY
adipose	ENTITY
tissue	ENTITY
contains	O
the	O
stromal	ENTITY
vascular	ENTITY
fraction	ENTITY
svf	ENTITY
of	ENTITY
cells	ENTITY
including	O
preadipocytes	ENTITY
fibroblasts	ENTITY
vascular	ENTITY
endothelial	ENTITY
cells	ENTITY
and	O
variety	O
of	O
immune	ENTITY
cells	ENTITY
.	O
adipose	ENTITY
tissue	ENTITY
macrophages	ENTITY
atms	ENTITY
.	O
adipose	ENTITY
tissue	ENTITY
is	O
derived	O
from	O
preadipocytes	ENTITY
.	O
its	O
main	O
role	O
is	O
to	O
store	O
energy	O
in	O
the	O
form	O
of	O
lipids	ENTITY
although	ENTITY
it	ENTITY
also	ENTITY
cushions	ENTITY
and	ENTITY
insulates	ENTITY
the	ENTITY
body	ENTITY
.	O
far	O
from	O
hormonally	ENTITY
inert	ENTITY
adipose	ENTITY
tissue	ENTITY
has	O
in	O
recent	O
years	O
been	O
recognized	O
as	O
major	O
endocrine	ENTITY
organ	ENTITY
as	O
it	O
produces	O
hormones	ENTITY
such	ENTITY
as	ENTITY
leptin	ENTITY
estrogen	ENTITY
resistin	ENTITY
and	O
the	O
cytokine	ENTITY
tnf	ENTITY
.	O
moreover	O
adipose	ENTITY
tissue	ENTITY
can	O
affect	O
other	O
organ	ENTITY
systems	ENTITY
of	ENTITY
the	ENTITY
body	ENTITY
and	O
may	O
lead	O
to	O
disease	ENTITY
.	O
obesity	ENTITY
or	ENTITY
being	ENTITY
overweight	ENTITY
in	ENTITY
humans	ENTITY
and	ENTITY
most	ENTITY
animals	ENTITY
does	ENTITY
not	ENTITY
depend	ENTITY
on	ENTITY
body	ENTITY
weight	ENTITY
but	ENTITY
on	ENTITY
the	ENTITY
amount	ENTITY
of	ENTITY
body	ENTITY
fat	ENTITY
to	O
be	O
specific	O
adipose	ENTITY
tissue	ENTITY
.	O
the	O
two	O
types	O
of	O
adipose	ENTITY
tissue	ENTITY
are	O
white	ENTITY
adipose	ENTITY
tissue	ENTITY
wat	O
and	O
brown	ENTITY
adipose	ENTITY
tissue	ENTITY
bat	O
.	O
the	O
formation	O
of	O
adipose	ENTITY
tissue	ENTITY
appears	O
to	O
be	O
controlled	O
in	O
part	O
by	O
the	O
adipose	ENTITY
gene	ENTITY
.	O
adipose	ENTITY
tissue	ENTITY
more	O
specifically	O
brown	ENTITY
adipose	ENTITY
tissue	ENTITY
was	O
first	O
identified	O
by	O
the	O
swiss	O
naturalist	O
conrad	O
gessner	O
in	O
this	O
video	O
is	O
targeted	O
to	O
blind	O
users	O
.	O
attribution	O
article	O
text	O
available	O
under	O
cc	O
by	O
sa	O
creative	O
commons	O
image	O
source	O
in	O
video	O
.	O
in	O
this	O
video	O
have	O
explained	O
the	O
mechanism	ENTITY
of	ENTITY
lipolysis	ENTITY
that	O
occur	O
in	O
adipose	ENTITY
tissue	ENTITY
.	O
adipose	ENTITY
tissue	ENTITY
lipolysis	ENTITY
mediated	ENTITY
by	ENTITY
glucagon	ENTITY
epinephrine	ENTITY
cortisol	ENTITY
is	O
explained	O
in	O
detail	O
.	O
all	O
the	O
basic	O
molecular	ENTITY
mechanisms	ENTITY
of	ENTITY
adipose	ENTITY
tissue	ENTITY
lipolysis	ENTITY
like	ENTITY
protein	ENTITY
coupled	ENTITY
receptor	ENTITY
adenalyl	ENTITY
cyclase	ENTITY
camp	O
protein	ENTITY
kinase	ENTITY
hormone	ENTITY
sensitive	O
lipase	ENTITY
activation	ENTITY
and	O
break	O
down	O
of	O
triacylglycerol	ENTITY
is	ENTITY
explained	ENTITY
.	O
have	O
also	O
touched	O
upon	O
adipose	ENTITY
triacylglycerol	ENTITY
lipase	ENTITY
enxyme	ENTITY
.	O
you	O
can	O
watch	O
my	O
video	O
on	O
metabolic	ENTITY
changes	ENTITY
that	O
occurs	O
during	O
fasting	O
and	O
starvation	O
in	O
the	O
link	O
below	O
.	O
video	O
by	O
lafontan	O
phd	O
research	O
director	O
inserm	O
laboratoire	O
de	O
recherche	O
sur	O
les	O
ob	O
sit	O
institut	O
de	O
decine	O
mol	O
culaire	O
de	O
rangueil	O
toulouse	O
france	O
produced	O
by	O
the	O
international	O
chair	O
on	O
cardiometabolic	ENTITY
risk	ENTITY
.	O
tracey	O
mclaughlin	O
md	O
.	O
difference	O
between	O
white	ENTITY
fat	ENTITY
and	O
brown	ENTITY
fat	ENTITY
.	O
by	O
pam	O
peeke	O
md	O
mph	O
facp	O
best	O
selling	O
author	O
and	O
expert	O
on	O
health	O
fitness	O
and	O
nutrition	O
republished	O
with	O
permission	O
from	O
maria	O
farm	O
here	O
are	O
some	O
more	O
compilation	O
of	O
topics	O
and	O
latest	O
discussions	O
relates	O
to	O
this	O
video	O
which	O
we	O
found	O
thorough	O
the	O
internet	O
.	O
hope	O
this	O
information	O
will	O
helpful	O
to	O
get	O
idea	O
in	O
brief	O
about	O
this	O
.	O
the	O
color	O
comes	O
from	O
the	O
large	O
number	O
of	O
mitochondria	ENTITY
in	ENTITY
the	ENTITY
cells	ENTITY
which	ENTITY
is	ENTITY
where	ENTITY
the	ENTITY
heat	ENTITY
is	ENTITY
generated	ENTITY
via	ENTITY
uncoupling	ENTITY
protein	ENTITY
ucp	ENTITY
.	O
white	ENTITY
adipose	ENTITY
tissue	ENTITY
is	O
what	O
we	O
more	O
commonly	O
call	O
fat	ENTITY
tissue	ENTITY
its	ENTITY
primary	ENTITY
function	ENTITY
is	ENTITY
to	ENTITY
store	ENTITY
energy	ENTITY
in	ENTITY
the	ENTITY
chemical	ENTITY
form	ENTITY
of	ENTITY
long	ENTITY
chain	ENTITY
fats	ENTITY
adipose	ENTITY
tissue	ENTITY
more	O
specifically	O
brown	ENTITY
adipose	ENTITY
tissue	ENTITY
was	O
first	O
identified	O
by	O
the	O
to	O
regions	O
of	O
white	ENTITY
adipose	ENTITY
tissue	ENTITY
which	O
are	O
found	O
under	O
the	O
skin	O
between	O
the	O
differences	O
have	O
been	O
observed	O
in	O
comparing	O
eat	O
with	O
subcutaneous	ENTITY
fat	ENTITY
below	O
information	O
will	O
help	O
you	O
to	O
get	O
some	O
more	O
though	O
about	O
the	O
subject	O
white	ENTITY
adipocytes	ENTITY
white	ENTITY
fat	ENTITY
cells	ENTITY
have	O
single	ENTITY
lipid	ENTITY
droplet	ENTITY
brown	ENTITY
from	O
what	O
we	O
can	O
tell	O
so	O
far	O
main	O
differences	O
between	O
the	O
two	O
are	O
white	O
brown	O
and	O
white	ENTITY
adipose	ENTITY
tissues	ENTITY
intrinsic	O
differences	O
in	O
gene	ENTITY
important	ENTITY
differences	ENTITY
exist	ENTITY
between	ENTITY
subcutaneous	ENTITY
and	ENTITY
visceral	ENTITY
depots	ENTITY
which	ENTITY
mitochondria	ENTITY
are	ENTITY
functionally	ENTITY
specialized	ENTITY
in	ENTITY
different	ENTITY
tissues	ENTITY
and	ENTITY
detailed	ENTITY
understanding	ENTITY
of	ENTITY
this	ENTITY
specialization	ENTITY
is	ENTITY
important	ENTITY
to	ENTITY
elucidate	ENTITY
anyway	ENTITY
if	ENTITY
you	ENTITY
want	ENTITY
for	ENTITY
more	ENTITY
info	ENTITY
you	ENTITY
would	ENTITY
better	ENTITY
continue	ENTITY
reading	ENTITY
.	O
our	O
posts	O
on	O
research	O
being	O
done	O
at	O
joslin	O
diabetes	ENTITY
center	ENTITY
on	ENTITY
brown	ENTITY
fat	ENTITY
prompted	O
anumber	O
of	O
our	O
readers	O
to	O
send	O
in	O
questions	O
on	O
this	O
subject	O
the	O
brown	ENTITY
fat	ENTITY
cells	ENTITY
specialized	O
in	O
the	O
production	O
of	O
heat	O
burns	O
fats	ENTITY
and	ENTITY
sugars	ENTITY
.	O
the	O
brown	ENTITY
fat	ENTITY
cells	ENTITY
specialized	O
in	O
the	O
production	O
of	O
heat	O
burns	O
energy	ENTITY
calories	ENTITY
what	O
is	O
the	O
difference	O
between	O
white	O
brown	O
and	O
beige	ENTITY
fat	ENTITY
and	O
could	O
some	O
types	O
there	O
are	O
two	O
main	O
types	O
of	O
adipose	ENTITY
tissue	ENTITY
or	O
fat	ENTITY
found	ENTITY
in	ENTITY
mammals	ENTITY
white	ENTITY
differences	ENTITY
between	ENTITY
brown	ENTITY
and	ENTITY
beige	ENTITY
adipocytes	ENTITY
.	O
figure	O
differences	O
why	O
new	O
white	ENTITY
fat	ENTITY
cells	ENTITY
develop	O
during	O
cold	O
exposure	O
is	O
unclear	O
.	O
it	O
is	O
also	O
surprising	O
our	O
two	O
main	O
types	O
of	O
fat	O
brown	O
and	O
white	O
play	O
different	O
roles	O
.	O
now	O
whether	O
the	O
observed	O
differences	O
provide	O
clinical	O
benefit	O
for	O
the	O
macro	O
or	O
could	O
it	O
be	O
contributing	O
factor	O
in	O
the	O
balance	O
between	O
white	O
and	O
brown	O
.	O
cell	O
metab	O
.	O
oct	O
.	O
doi	O
.	O
cmet	O
proteome	ENTITY
differences	ENTITY
between	ENTITY
brown	ENTITY
and	ENTITY
white	ENTITY
fat	ENTITY
mitochondria	ENTITY
reveal	ENTITY
specialized	ENTITY
brown	ENTITY
versus	ENTITY
white	ENTITY
adipose	ENTITY
tissue	ENTITY
mini	O
review	O
.	O
to	O
be	O
drawn	O
concerning	O
causal	O
relationship	O
between	O
loss	O
of	O
bat	O
and	O
increasing	O
body	O
adipose	ENTITY
tissue	ENTITY
or	O
fatty	ENTITY
tissue	ENTITY
connective	ENTITY
tissue	ENTITY
consisting	O
mainly	O
of	O
fat	ENTITY
cells	ENTITY
it	O
is	O
found	O
mainly	O
under	O
the	O
skin	O
but	O
also	O
in	O
deposits	O
between	O
the	O
muscles	ENTITY
types	ENTITY
of	ENTITY
adipose	ENTITY
white	ENTITY
adipose	ENTITY
tissue	ENTITY
and	O
brown	ENTITY
adipose	ENTITY
tissue	ENTITY
fat	ENTITY
the	ENTITY
difference	ENTITY
between	ENTITY
brown	ENTITY
and	ENTITY
white	ENTITY
fat	ENTITY
.	O
did	O
you	O
know	O
that	O
many	O
different	O
forms	O
of	O
fat	ENTITY
exist	ENTITY
.	O
it	O
is	O
true	O
and	O
scientists	O
are	O
becoming	O
abbreviations	O
bat	O
brown	ENTITY
adipose	ENTITY
tissue	ENTITY
wat	O
white	ENTITY
adipose	ENTITY
tissue	ENTITY
ne	O
which	O
differences	O
between	O
the	O
two	O
tissues	O
are	O
slight	O
and	O
in	O
which	O
in	O
fact	O
wat	O
one	O
of	O
the	O
major	O
differences	O
between	O
brown	ENTITY
and	ENTITY
white	ENTITY
fat	ENTITY
is	O
that	O
brown	ENTITY
fat	ENTITY
cells	ENTITY
have	O
much	O
higher	O
amount	O
of	O
mitochondria	ENTITY
and	ENTITY
also	ENTITY
express	ENTITY
.	O
from	O
brown	ENTITY
fat	ENTITY
to	O
thigh	ENTITY
fat	ENTITY
webmd	O
explains	O
fat	ENTITY
fascinating	ENTITY
purpose	ENTITY
within	ENTITY
calif	ENTITY
who	ENTITY
has	ENTITY
studied	ENTITY
the	ENTITY
links	ENTITY
between	ENTITY
fat	ENTITY
and	ENTITY
brain	ENTITY
health	ENTITY
differences	ENTITY
between	ENTITY
white	ENTITY
brown	ENTITY
and	ENTITY
brite	ENTITY
fat	ENTITY
tissue	ENTITY
.	O
the	O
latest	O
results	O
on	O
the	O
different	O
metabolic	ENTITY
pathways	ENTITY
used	O
by	O
white	O
and	O
brown	O
fat	ENTITY
ce	ENTITY
.	O
google	O
youtube	O
to	O
mov	O
to	O
convert	O
this	O
import	O
it	O
to	O
your	O
imovie	O
edit	O
whatever	O
.	O
how	O
to	O
get	O
rid	O
of	O
fat	ENTITY
tissue	ENTITY
lipomain	ENTITY
natural	ENTITY
way	ENTITY
www	ENTITY
fatclinics	ENTITY
com	ENTITY
.	O
the	O
only	O
true	O
adipose	ENTITY
concentrate	ENTITY
.	O
joslin	O
diabetes	ENTITY
center	ENTITY
scientists	ENTITY
have	ENTITY
demonstrated	ENTITY
through	ENTITY
two	ENTITY
new	ENTITY
studies	ENTITY
of	ENTITY
mice	ENTITY
and	ENTITY
humans	ENTITY
that	ENTITY
exercise	ENTITY
can	ENTITY
train	ENTITY
fat	ENTITY
to	ENTITY
behave	ENTITY
differently	ENTITY
than	ENTITY
the	ENTITY
fat	ENTITY
that	ENTITY
develops	ENTITY
from	ENTITY
sedentary	ENTITY
behavior	ENTITY
and	ENTITY
this	ENTITY
good	ENTITY
fat	ENTITY
may	ENTITY
stimulate	ENTITY
metabolic	ENTITY
improvements	ENTITY
in	O
other	O
tissues	ENTITY
.	O
professor	O
mikael	O
ryd	O
senior	O
consultant	O
department	O
of	O
medicine	O
karolinska	O
institutet	O
karolinska	O
university	O
hospital	O
stockholm	O
sweden	O
.	O
non	O
shivering	O
thermogenesis	ENTITY
occurs	ENTITY
in	ENTITY
brown	ENTITY
adipose	ENTITY
tissue	ENTITY
brown	O
fat	ENTITY
that	ENTITY
is	ENTITY
present	ENTITY
in	ENTITY
all	ENTITY
eutherians	ENTITY
swine	ENTITY
being	ENTITY
the	ENTITY
only	ENTITY
exception	ENTITY
currently	ENTITY
known	ENTITY
brown	ENTITY
adipose	ENTITY
tissue	ENTITY
has	O
unique	O
protein	O
thermogenin	O
or	O
ucp	O
that	O
allows	O
the	O
uncoupling	O
of	O
protons	ENTITY
moving	ENTITY
down	ENTITY
their	ENTITY
mitochondrial	ENTITY
gradient	ENTITY
from	O
the	O
synthesis	ENTITY
of	ENTITY
atp	ENTITY
thus	O
allowing	O
the	O
energy	O
to	O
be	O
dissipated	O
as	O
heat	O
.	O
in	O
this	O
process	O
substances	O
such	O
as	O
free	ENTITY
fatty	ENTITY
acids	ENTITY
derived	O
from	O
triacylglycerols	ENTITY
remove	ENTITY
purine	ENTITY
adp	ENTITY
gdp	ENTITY
and	ENTITY
others	ENTITY
inhibition	ENTITY
of	ENTITY
thermogenin	ENTITY
uncoupling	ENTITY
protein	ENTITY
which	ENTITY
causes	ENTITY
an	ENTITY
influx	ENTITY
of	ENTITY
into	ENTITY
the	ENTITY
matrix	ENTITY
of	ENTITY
the	ENTITY
mitochondrion	ENTITY
and	ENTITY
bypasses	ENTITY
the	ENTITY
atp	ENTITY
synthase	ENTITY
channel	ENTITY
.	O
this	O
uncouples	O
oxidative	ENTITY
phosphorylation	ENTITY
and	O
the	O
energy	O
from	O
the	O
proton	ENTITY
motive	ENTITY
force	ENTITY
is	ENTITY
dissipated	ENTITY
as	ENTITY
heat	ENTITY
rather	ENTITY
than	ENTITY
producing	ENTITY
atp	ENTITY
from	ENTITY
adp	ENTITY
which	ENTITY
would	ENTITY
store	ENTITY
chemical	ENTITY
energy	ENTITY
for	ENTITY
the	ENTITY
body	ENTITY
use	ENTITY
.	O
thermogenesis	ENTITY
can	ENTITY
also	ENTITY
be	ENTITY
produced	ENTITY
by	ENTITY
leakage	ENTITY
of	ENTITY
the	ENTITY
sodium	ENTITY
potassium	ENTITY
pump	ENTITY
and	O
the	O
ca	ENTITY
pump	ENTITY
.	O
thermogenesis	ENTITY
is	ENTITY
contributioned	ENTITY
to	ENTITY
by	ENTITY
futile	ENTITY
cycles	ENTITY
such	ENTITY
as	ENTITY
the	ENTITY
simultaneous	ENTITY
occurrence	ENTITY
of	ENTITY
lipogenesis	ENTITY
and	ENTITY
lipolysis	ENTITY
or	ENTITY
glycolysis	ENTITY
and	ENTITY
gluconeogenesis	ENTITY
.	O
the	O
low	O
demands	O
of	O
thermogenesis	ENTITY
mean	ENTITY
that	ENTITY
free	ENTITY
fatty	ENTITY
acids	ENTITY
draw	O
for	O
the	O
most	O
part	O
on	O
lipolysis	ENTITY
as	ENTITY
the	ENTITY
method	ENTITY
of	ENTITY
energy	ENTITY
production	ENTITY
.	O
hormones	ENTITY
made	ENTITY
by	ENTITY
adipocytes	ENTITY
in	ENTITY
cat	ENTITY
dog	ENTITY
horse	ENTITY
.	O
how	O
to	O
remove	O
adipose	ENTITY
tissue	ENTITY
with	O
natural	O
way	O
.	O
ascending	O
the	O
vale	O
kevin	O
macleod	O
incompetech	O
com	O
licensed	O
under	O
creative	O
commons	O
by	O
attribution	O
license	O
.	O
dr	O
philipp	O
scherer	O
talks	O
about	O
his	O
banting	O
medal	O
for	O
scientific	O
achievement	O
lecture	O
on	O
the	O
role	O
of	O
adipose	ENTITY
tissue	ENTITY
in	O
treatment	O
of	O
diabetes	ENTITY
at	ENTITY
the	ENTITY
american	ENTITY
diabetes	ENTITY
association	ENTITY
meeting	ENTITY
in	ENTITY
boston	ENTITY
.	O
first	O
in	O
tampa	O
bay	O
to	O
use	O
cutting	O
edge	O
technology	O
to	O
naturally	O
enhance	O
the	O
breast	O
with	O
patient	O
own	O
adipose	ENTITY
tissue	ENTITY
combined	O
with	O
their	O
own	O
regenerative	ENTITY
tissue	ENTITY
.	O
the	O
future	O
of	O
regenerative	O
medicine	O
is	O
here	O
in	O
tampa	O
restoring	O
form	O
and	O
function	O
to	O
the	O
body	O
with	O
your	O
own	O
regenerative	ENTITY
cells	ENTITY
these	O
are	O
exciting	O
times	O
and	O
dr	O
bart	O
rademaker	O
is	O
spearheading	O
this	O
new	O
medicine	O
in	O
tampa	O
by	O
enlisting	O
many	O
other	O
specialties	O
to	O
be	O
able	O
to	O
provide	O
medical	O
solutions	O
that	O
where	O
previously	O
not	O
available	O
like	O
stress	ENTITY
urinary	ENTITY
incontinence	ENTITY
non	O
healing	O
wounds	O
new	O
options	O
in	O
breast	ENTITY
reconstruction	ENTITY
and	O
enhancing	O
breast	ENTITY
augmentation	ENTITY
or	O
correcting	O
failed	O
liposuction	ENTITY
.	O
www	O
myrejuvacenter	O
com	O
.	O
by	O
the	O
international	O
chair	O
on	O
cardiometabolic	ENTITY
risk	ENTITY
.	O
the	O
accumulation	O
of	O
macrophages	ENTITY
with	ENTITY
proinflammatory	ENTITY
phenotype	ENTITY
in	O
adipose	ENTITY
tissue	ENTITY
is	O
driver	O
of	O
obesity	ENTITY
associated	ENTITY
metabolic	ENTITY
disease	ENTITY
.	O
while	O
adipose	ENTITY
tissue	ENTITY
macrophages	ENTITY
are	O
found	O
in	O
the	O
lean	O
state	O
these	O
cells	O
have	O
an	O
alternatively	O
activated	O
phenotype	ENTITY
.	O
in	O
this	O
episode	O
tam	O
szer	O
and	O
colleagues	O
demonstrate	O
that	O
adipose	ENTITY
tissue	ENTITY
macrophages	ENTITY
express	O
receptor	O
for	O
the	O
appetite	O
reducing	O
neuropeptide	ENTITY
ff	ENTITY
and	O
that	O
and	O
that	O
neuropeptide	ENTITY
ff	ENTITY
promotes	O
activation	O
and	O
proliferation	ENTITY
.	O
additionally	O
obesity	ENTITY
was	ENTITY
associated	ENTITY
with	ENTITY
reduced	ENTITY
levels	ENTITY
of	ENTITY
circulating	ENTITY
neuropeptide	ENTITY
ff	ENTITY
.	O
together	O
the	O
results	O
of	O
this	O
study	O
reveal	O
an	O
important	O
role	O
for	O
neuropeptide	ENTITY
ff	ENTITY
in	O
maintaining	O
metabolically	ENTITY
beneficial	ENTITY
macrophages	ENTITY
in	ENTITY
adipose	ENTITY
tissue	ENTITY
.	O
dr	O
francesco	O
bertolini	O
european	O
institute	O
of	O
oncology	O
milan	O
italy	O
.	O
dr	O
francesco	O
bertolini	O
talks	O
about	O
the	O
contribution	O
of	O
white	ENTITY
adipose	ENTITY
tissue	ENTITY
to	O
the	O
link	O
between	O
obesity	ENTITY
and	ENTITY
cancer	ENTITY
rates	ENTITY
.	O
in	O
humans	O
these	O
tissues	ENTITY
are	ENTITY
rich	ENTITY
reservoir	ENTITY
of	ENTITY
progenitors	ENTITY
cells	ENTITY
that	O
can	O
play	O
an	O
important	O
role	O
in	O
promoting	O
cancer	ENTITY
growth	ENTITY
.	O
the	O
fat	ENTITY
tissues	ENTITY
in	O
some	O
parts	O
of	O
the	O
body	O
for	O
instance	O
the	O
fat	ENTITY
around	ENTITY
the	ENTITY
breast	ENTITY
are	ENTITY
particularly	ENTITY
rich	ENTITY
in	ENTITY
progenitors	ENTITY
which	ENTITY
raises	ENTITY
concerns	ENTITY
regarding	ENTITY
tissue	ENTITY
transfer	ENTITY
.	O
adipose	ENTITY
tissue	ENTITY
is	O
routinely	O
transferred	O
from	O
one	O
part	O
of	O
the	O
body	O
to	O
another	O
as	O
part	O
of	O
cosmetic	O
or	O
reconstructive	ENTITY
surgery	ENTITY
.	O
dr	O
bertolini	O
explains	O
how	O
work	O
to	O
identify	O
specifically	O
which	O
cells	O
promote	O
cancer	O
growth	O
could	O
help	O
develop	O
test	O
to	O
ensure	O
tissue	O
that	O
is	O
being	O
transferred	O
does	O
not	O
contain	O
these	O
cancer	ENTITY
causing	ENTITY
cells	ENTITY
.	O
kirsi	O
virtanen	O
finland	O
.	O
division	O
of	O
endocrinology	ENTITY
diabetes	ENTITY
and	O
bone	ENTITY
diseases	ENTITY
grand	O
rounds	O
presented	O
by	O
paul	O
cohen	O
md	O
phd	O
laboratory	O
of	O
molecular	ENTITY
mechanism	ENTITY
the	O
rockefeller	O
university	O
.	O
this	O
video	O
contains	O
programmed	O
energy	O
that	O
directly	O
heats	O
the	O
surrounding	O
fat	ENTITY
tissue	ENTITY
in	O
your	O
belly	O
area	O
to	O
cause	O
it	O
to	O
reduce	O
and	O
burn	O
off	O
.	O
it	O
also	O
directly	O
stimulates	O
and	O
contracts	O
the	O
abdominal	ENTITY
muscles	ENTITY
.	O
included	O
as	O
well	O
are	O
subliminal	O
and	O
supraliminal	O
programming	O
to	O
create	O
that	O
mindset	O
and	O
tell	O
your	O
body	O
to	O
lose	O
weight	O
and	O
burn	O
fat	ENTITY
.	O
listen	O
as	O
often	O
as	O
you	O
want	O
until	O
you	O
see	O
the	O
results	O
you	O
need	O
.	O
check	O
out	O
our	O
new	O
homepage	O
this	O
video	O
contains	O
programmed	O
energy	O
that	O
directly	O
heats	O
the	O
surrounding	O
fat	ENTITY
tissue	ENTITY
in	O
your	O
belly	O
area	O
to	O
cause	O
it	O
to	O
reduce	O
and	O
burn	O
off	O
.	O
it	O
also	O
directly	O
stimulates	O
and	O
contracts	O
the	O
abdominal	ENTITY
muscles	ENTITY
.	O
included	O
as	O
well	O
are	O
subliminal	O
and	O
supraliminal	O
programming	O
to	O
create	O
that	O
mindset	O
and	O
tell	O
your	O
body	O
to	O
lose	O
weight	O
and	O
burn	O
fat	ENTITY
.	O
listen	O
as	O
often	O
as	O
you	O
want	O
until	O
you	O
see	O
the	O
results	O
you	O
need	O
.	O
findings	O
open	O
new	O
possibilities	O
for	O
research	O
and	O
testing	O
treatments	O
to	O
combat	O
obesity	ENTITY
boston	ENTITY
april	ENTITY
joslin	ENTITY
scientists	ENTITY
report	ENTITY
significant	ENTITY
findings	ENTITY
about	ENTITY
the	ENTITY
location	ENTITY
genetic	ENTITY
expression	ENTITY
and	ENTITY
function	ENTITY
of	ENTITY
human	ENTITY
brown	ENTITY
adipose	ENTITY
tissue	ENTITY
bat	O
and	O
the	O
generation	O
of	O
new	O
bat	ENTITY
cells	ENTITY
.	O
these	O
findings	O
which	O
appear	O
in	O
the	O
month	ENTITY
issue	ENTITY
of	O
nature	O
medicine	O
may	O
contribute	O
to	O
further	O
study	O
of	O
bat	O
role	O
in	O
human	ENTITY
metabolism	ENTITY
and	O
developing	O
treatments	O
that	O
use	O
bat	O
to	O
promote	O
weight	O
loss	O
.	O
continue	O
reading	O
www	O
joslin	O
.	O
dvance	O
new	O
understanding	O
of	O
brown	O
fat	ENTITY
and	ENTITY
grow	ENTITY
new	ENTITY
bat	ENTITY
cells	ENTITY
html	O
.	O
cnn	O
correspondent	O
cristina	O
alesci	O
was	O
diagnosed	O
with	O
type	O
diabetes	ENTITY
as	ENTITY
an	ENTITY
adult	ENTITY
.	O
how	O
is	O
she	O
coping	O
.	O
holly	O
firfer	O
finds	O
out	O
.	O
type	O
diabetes	ENTITY
also	ENTITY
know	ENTITY
as	ENTITY
adult	ENTITY
onset	ENTITY
diabetes	ENTITY
non	ENTITY
insulin	ENTITY
dependent	ENTITY
diabetes	ENTITY
and	O
niddm	ENTITY
involves	ENTITY
an	ENTITY
abnormality	ENTITY
with	ENTITY
insulin	ENTITY
resistance	ENTITY
not	O
lack	O
of	O
insulin	ENTITY
.	O
it	O
effects	O
mostly	O
adults	O
but	O
we	O
are	O
holly	O
it	O
in	O
children	O
as	O
well	O
due	O
to	O
obesity	ENTITY
.	O
first	O
off	O
lets	O
discuss	O
what	O
insulin	ENTITY
actually	ENTITY
does	ENTITY
.	O
insulin	ENTITY
is	ENTITY
released	ENTITY
by	ENTITY
the	ENTITY
pancreas	ENTITY
in	ENTITY
response	ENTITY
to	ENTITY
rise	ENTITY
in	ENTITY
blood	ENTITY
sugar	ENTITY
after	O
meal	O
.	O
the	O
sugar	O
without	O
insulin	ENTITY
would	ENTITY
be	ENTITY
trapped	ENTITY
in	ENTITY
the	ENTITY
bloodstream	ENTITY
and	ENTITY
not	ENTITY
be	ENTITY
able	ENTITY
to	ENTITY
reach	ENTITY
the	ENTITY
body	ENTITY
tissues	ENTITY
to	O
be	O
used	O
as	O
energy	O
.	O
think	O
of	O
insulin	ENTITY
as	ENTITY
picking	ENTITY
up	ENTITY
sugar	ENTITY
out	ENTITY
of	ENTITY
the	ENTITY
blood	ENTITY
and	ENTITY
putting	ENTITY
it	ENTITY
into	ENTITY
the	ENTITY
muscles	ENTITY
and	ENTITY
brain	ENTITY
to	ENTITY
be	ENTITY
burnt	ENTITY
for	ENTITY
energy	ENTITY
.	O
what	O
happens	O
in	O
type	O
diabetes	ENTITY
is	ENTITY
the	ENTITY
muscles	ENTITY
become	ENTITY
insulin	ENTITY
resistant	ENTITY
.	O
the	O
pancreas	ENTITY
sees	ENTITY
sugar	ENTITY
in	ENTITY
the	ENTITY
bloodstream	ENTITY
makes	ENTITY
an	ENTITY
insulin	ENTITY
and	ENTITY
the	ENTITY
insulin	ENTITY
picks	ENTITY
up	ENTITY
the	ENTITY
sugar	ENTITY
and	ENTITY
tries	ENTITY
to	ENTITY
put	ENTITY
it	ENTITY
into	ENTITY
the	ENTITY
muscle	ENTITY
but	ENTITY
the	ENTITY
muscle	ENTITY
is	ENTITY
resistant	ENTITY
it	ENTITY
wont	ENTITY
let	ENTITY
the	ENTITY
sugar	ENTITY
in	ENTITY
.	O
now	O
the	O
pancreas	ENTITY
in	ENTITY
order	ENTITY
to	ENTITY
keep	ENTITY
the	ENTITY
blood	ENTITY
sugar	ENTITY
normal	O
releases	O
second	O
insulin	ENTITY
and	ENTITY
the	ENTITY
insulins	ENTITY
are	ENTITY
able	ENTITY
to	ENTITY
overcome	ENTITY
the	ENTITY
resistance	ENTITY
of	ENTITY
the	ENTITY
muscle	ENTITY
.	O
over	O
time	O
and	O
with	O
weight	O
gain	O
the	O
muscles	ENTITY
become	ENTITY
more	ENTITY
resistant	ENTITY
and	ENTITY
insulins	ENTITY
are	ENTITY
made	ENTITY
to	ENTITY
do	ENTITY
the	ENTITY
job	ENTITY
then	ENTITY
and	ENTITY
so	ENTITY
on	ENTITY
.	O
the	O
pancreas	ENTITY
works	ENTITY
harder	ENTITY
and	ENTITY
harder	ENTITY
until	ENTITY
eventually	ENTITY
it	ENTITY
cannot	ENTITY
keep	ENTITY
up	ENTITY
and	ENTITY
the	ENTITY
sugar	ENTITY
begins	ENTITY
to	ENTITY
get	ENTITY
trapped	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
and	ENTITY
only	ENTITY
then	ENTITY
does	ENTITY
the	ENTITY
blood	ENTITY
sugar	ENTITY
start	O
to	O
rise	O
above	O
normal	O
.	O
the	O
time	O
from	O
the	O
onset	O
of	O
insulin	ENTITY
resistance	ENTITY
to	O
the	O
point	O
where	O
the	O
system	O
is	O
completely	O
broken	O
and	O
diagnosis	O
of	O
diabetes	ENTITY
is	ENTITY
made	ENTITY
can	ENTITY
take	ENTITY
up	ENTITY
to	ENTITY
years	ENTITY
.	O
although	O
there	O
is	O
problem	O
one	O
is	O
not	O
officially	O
diagnosed	O
as	O
diabetic	O
until	O
their	O
fasting	O
sugar	O
is	O
above	O
their	O
hemoglobin	ENTITY
is	ENTITY
above	ENTITY
meaning	ENTITY
their	ENTITY
sugar	ENTITY
on	ENTITY
average	ENTITY
is	ENTITY
points	ENTITY
above	ENTITY
normal	ENTITY
or	ENTITY
random	ENTITY
or	ENTITY
hour	ENTITY
glucose	ENTITY
test	ENTITY
is	O
above	O
think	O
of	O
diabetes	ENTITY
as	ENTITY
year	ENTITY
walk	ENTITY
closer	ENTITY
and	ENTITY
closer	ENTITY
to	ENTITY
falling	ENTITY
off	ENTITY
cliff	ENTITY
.	O
the	O
day	O
you	O
are	O
told	O
you	O
are	O
diabetic	ENTITY
is	ENTITY
when	ENTITY
you	ENTITY
fell	ENTITY
off	ENTITY
the	ENTITY
cliff	ENTITY
.	O
the	O
day	O
before	O
you	O
were	O
teatering	O
at	O
the	O
edge	O
so	O
the	O
actual	O
diagnosis	O
has	O
been	O
years	O
in	O
the	O
making	O
.	O
the	O
good	O
news	O
is	O
that	O
with	O
diet	O
exercise	O
and	O
medications	O
you	O
can	O
actually	O
begin	O
to	O
walk	O
away	O
from	O
the	O
cliff	O
.	O
one	O
of	O
the	O
problems	O
with	O
insulin	ENTITY
reasistance	ENTITY
and	ENTITY
type	ENTITY
diabetes	ENTITY
is	ENTITY
that	ENTITY
you	ENTITY
have	ENTITY
high	ENTITY
insulin	ENTITY
levels	ENTITY
all	O
the	O
time	O
.	O
insulin	ENTITY
makes	ENTITY
you	ENTITY
hungry	ENTITY
and	ENTITY
it	ENTITY
promotes	ENTITY
fat	ENTITY
storage	ENTITY
.	O
when	O
you	O
drink	O
alcohol	O
your	O
body	O
inappropriately	O
releases	O
extra	O
insulin	ENTITY
.	O
this	O
is	O
what	O
call	O
the	O
white	O
castle	O
effect	O
.	O
after	O
night	O
of	O
drinking	O
and	O
lots	O
of	O
calories	O
injested	O
already	O
you	O
find	O
yourself	O
starving	O
at	O
am	O
and	O
looking	O
for	O
food	O
.	O
type	O
diabetic	ENTITY
literally	ENTITY
is	ENTITY
living	ENTITY
their	ENTITY
life	ENTITY
like	ENTITY
it	ENTITY
am	ENTITY
and	ENTITY
they	ENTITY
are	ENTITY
in	ENTITY
search	ENTITY
of	ENTITY
white	ENTITY
castle	ENTITY
.	O
ironically	O
the	O
more	O
diabetic	ENTITY
you	ENTITY
are	ENTITY
the	ENTITY
higher	ENTITY
your	ENTITY
insulin	ENTITY
levels	ENTITY
the	O
higher	O
your	O
insulin	ENTITY
the	ENTITY
hungrier	ENTITY
you	ENTITY
are	ENTITY
the	ENTITY
hungrier	ENTITY
you	ENTITY
are	ENTITY
the	ENTITY
more	ENTITY
you	ENTITY
eat	ENTITY
the	ENTITY
more	ENTITY
you	ENTITY
eat	ENTITY
the	ENTITY
higher	ENTITY
your	ENTITY
blood	ENTITY
sugar	ENTITY
the	O
higher	O
your	O
blood	ENTITY
sugar	ENTITY
the	O
more	O
insulin	ENTITY
you	ENTITY
produce	ENTITY
and	ENTITY
the	ENTITY
viscious	ENTITY
cycle	ENTITY
revolves	ENTITY
.	O
the	O
good	O
news	O
is	O
starting	O
medications	O
even	O
as	O
pre	ENTITY
diabetic	ENTITY
can	O
help	O
to	O
reverse	O
the	O
cycle	O
and	O
help	O
you	O
lose	O
weight	O
and	O
become	O
less	O
of	O
diabetic	ENTITY
.	O
you	O
can	O
walk	O
away	O
from	O
the	O
cliff	O
.	O
you	O
need	O
to	O
find	O
doctor	O
that	O
is	O
proactive	O
.	O
you	O
need	O
to	O
look	O
for	O
clues	O
that	O
indicate	O
you	O
are	O
heading	O
for	O
the	O
cliff	O
.	O
high	ENTITY
triglycerides	ENTITY
low	ENTITY
hdl	ENTITY
cholesterol	ENTITY
fasting	O
glucose	ENTITY
between	ENTITY
or	ENTITY
belly	ENTITY
greater	ENTITY
than	ENTITY
for	ENTITY
woman	ENTITY
or	ENTITY
for	ENTITY
man	ENTITY
can	ENTITY
all	ENTITY
be	ENTITY
indicators	ENTITY
of	ENTITY
pre	ENTITY
diabetes	ENTITY
.	O
you	O
can	O
ask	O
your	O
doctor	O
to	O
test	O
fasting	O
insulin	ENTITY
level	ENTITY
or	O
peptide	ENTITY
.	O
even	O
better	O
have	O
them	O
order	O
hour	O
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
with	O
fasting	O
and	O
hour	O
insulin	ENTITY
level	ENTITY
.	O
turns	O
out	O
wilford	O
got	O
the	O
worst	O
possible	O
type	O
of	O
diabetes	ENTITY
known	ENTITY
well	ENTITY
at	ENTITY
least	ENTITY
not	ENTITY
as	ENTITY
bad	ENTITY
as	ENTITY
type	ENTITY
diabetes<MT/>	ENTITY
.	O
diabeetus	ENTITY
.	O
symptoms	O
of	O
type	O
diabetes	ENTITY
or	ENTITY
adult	ENTITY
onset	ENTITY
diabetes	ENTITY
insulin	ENTITY
dependent	ENTITY
diabetes	ENTITY
type	ENTITY
type	ENTITY
diabetes	ENTITY
treatment	ENTITY
insulin	ENTITY
dependent	ENTITY
type	ENTITY
diabetes	ENTITY
diabetes	ENTITY
drugs	ENTITY
non	O
insulin	ENTITY
dependent	ENTITY
diabetes	ENTITY
diabetes	ENTITY
medications	ENTITY
treatment	ENTITY
for	O
type	O
diabetes	ENTITY
diabetes	ENTITY
type	ENTITY
insulin	ENTITY
treatment	ENTITY
for	ENTITY
type	ENTITY
ii	ENTITY
diabetes	ENTITY
type	ENTITY
ii	ENTITY
diabetes	ENTITY
treatment	ENTITY
type	O
insulin	ENTITY
dependent	ENTITY
diabetes	ENTITY
mellitus	ENTITY
managing	O
type	O
diabetes	ENTITY
what	ENTITY
is	ENTITY
the	ENTITY
treatment	ENTITY
for	ENTITY
type	ENTITY
diabetes	ENTITY
how	ENTITY
is	ENTITY
type	ENTITY
diabetes	ENTITY
treated	ENTITY
treatment	ENTITY
for	ENTITY
type	ENTITY
diabetes	ENTITY
mellitus	ENTITY
treating	O
type	O
diabetes	ENTITY
history	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
simple	ENTITY
explanation	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
diabetes	ENTITY
type	ENTITY
treatment	ENTITY
insulin	ENTITY
levels	ENTITY
in	ENTITY
type	ENTITY
diabetes	ENTITY
how	ENTITY
to	ENTITY
manage	ENTITY
type	ENTITY
diabetes	ENTITY
type	ENTITY
two	ENTITY
diabetes	ENTITY
treatment	ENTITY
type	O
diabetes	ENTITY
insulin	ENTITY
dependent	O
how	O
type	O
diabetes	ENTITY
develops	ENTITY
diabetes	ENTITY
treatment	ENTITY
is	O
type	O
diabetes	ENTITY
insulin	ENTITY
dependent	ENTITY
type	ENTITY
diabetes	ENTITY
information	ENTITY
what	ENTITY
to	ENTITY
do	ENTITY
with	ENTITY
type	ENTITY
diabetes	ENTITY
insulin	ENTITY
diabetes	ENTITY
type	ENTITY
diabetes	ENTITY
treatment	ENTITY
type	O
diabetes	ENTITY
treatment	ENTITY
guidelines	O
define	O
diabetes	ENTITY
mellitus	ENTITY
type	ENTITY
have	O
type	O
diabetes	ENTITY
treatment	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
causes	ENTITY
of	ENTITY
type	ENTITY
dia	ENTITY
etes	ENTITY
mellitus	ENTITY
type	ENTITY
diabetes	ENTITY
type	ENTITY
treatment	ENTITY
type	ENTITY
diabetes	ENTITY
summary	ENTITY
how	ENTITY
to	ENTITY
treat	ENTITY
type	ENTITY
diabetes	ENTITY
type	ENTITY
diabetes	ENTITY
mellitus	ENTITY
treatment	ENTITY
diabetes	O
medicine	O
information	O
on	O
type	O
diabetes	ENTITY
how	ENTITY
to	ENTITY
treat	ENTITY
diabetes	ENTITY
treating	ENTITY
diabetes	ENTITY
.	O
how	O
many	O
more	O
must	O
feed	O
the	O
insatiable	O
hunger	O
of	O
wilfred	O
brimley	O
before	O
science	O
gives	O
us	O
cure	O
.	O
the	O
second	O
largest	O
native	O
american	O
tribe	O
tohono	O
odham	O
tah	O
ha	O
nah	O
aw	O
dum	O
has	O
the	O
highest	O
rate	O
of	O
adult	ENTITY
onset	ENTITY
diabetes	ENTITY
in	O
the	O
world	O
.	O
many	O
of	O
the	O
tribe	O
members	O
live	O
on	O
reservation	O
in	O
the	O
desert	O
in	O
the	O
southwest	O
state	O
of	O
arizona	O
.	O
until	O
no	O
one	O
had	O
diabetes	ENTITY
because	ENTITY
people	ENTITY
ate	ENTITY
traditional	ENTITY
foods	ENTITY
that	ENTITY
helped	ENTITY
prevent	ENTITY
the	ENTITY
disease	ENTITY
.	O
but	O
with	O
the	O
introduction	O
of	O
foods	O
high	O
in	O
fat	ENTITY
and	ENTITY
calories	ENTITY
diabetes	ENTITY
became	ENTITY
widespread	ENTITY
including	ENTITY
in	ENTITY
children	ENTITY
.	O
now	O
the	O
odham	O
people	O
are	O
being	O
encouraged	O
to	O
go	O
back	O
to	O
eating	O
the	O
traditional	O
foods	O
and	O
cafe	O
on	O
the	O
reservation	O
is	O
making	O
those	O
foods	O
appealing	O
.	O
voas	O
deborah	O
block	O
has	O
the	O
story	O
.	O
latent	ENTITY
autoimmune	ENTITY
diabetes	ENTITY
of	ENTITY
adults	ENTITY
often	O
also	O
late	O
onset	O
autoimmune	O
diabetes	ENTITY
of	ENTITY
adulthood	ENTITY
or	ENTITY
aging	ENTITY
slow	ENTITY
onset	ENTITY
type	ENTITY
diabetes	ENTITY
or	ENTITY
diabetes	ENTITY
type	ENTITY
is	ENTITY
form	ENTITY
of	ENTITY
diabetes	ENTITY
mellitus	ENTITY
type	O
that	O
occurs	O
in	O
adults	O
often	O
with	O
slower	O
course	O
of	O
onset	O
.	O
adults	O
with	O
lada	O
may	O
initially	O
be	O
diagnosed	O
as	O
having	O
type	O
diabetes	ENTITY
based	ENTITY
on	ENTITY
their	ENTITY
age	ENTITY
particularly	ENTITY
if	ENTITY
they	ENTITY
have	ENTITY
risk	ENTITY
factors	ENTITY
for	ENTITY
type	ENTITY
diabetes	ENTITY
such	ENTITY
as	ENTITY
strong	ENTITY
family	ENTITY
history	ENTITY
or	ENTITY
obesity	ENTITY
.	O
the	O
diagnosis	O
is	O
based	O
on	O
the	O
finding	O
of	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
together	O
with	O
the	O
clinical	O
impression	O
that	O
islet	ENTITY
failure	ENTITY
rather	ENTITY
than	ENTITY
insulin	ENTITY
resistance	ENTITY
is	O
the	O
main	O
cause	O
detection	ENTITY
of	ENTITY
low	ENTITY
peptide	ENTITY
and	O
raised	O
antibodies	ENTITY
against	ENTITY
the	ENTITY
islets	ENTITY
of	ENTITY
langerhans	ENTITY
support	ENTITY
the	ENTITY
diagnosis	ENTITY
.	O
it	O
can	O
only	O
be	O
treated	O
with	O
the	O
usual	O
oral	O
treatments	O
for	O
type	O
diabetes	ENTITY
for	ENTITY
certain	ENTITY
period	ENTITY
of	ENTITY
time	ENTITY
after	ENTITY
which	ENTITY
insulin	ENTITY
treatment	ENTITY
is	ENTITY
usually	ENTITY
necessary	ENTITY
as	ENTITY
well	ENTITY
as	ENTITY
long	ENTITY
term	ENTITY
monitoring	ENTITY
for	ENTITY
complications	ENTITY
.	O
the	O
concept	O
of	O
lada	O
was	O
first	O
introduced	O
in	O
this	O
video	O
is	O
targeted	O
to	O
blind	O
users	O
.	O
attribution	O
article	O
text	O
available	O
under	O
cc	O
by	O
sa	O
creative	O
commons	O
image	O
source	O
in	O
video	O
.	O
born	O
in	O
the	O
us	O
poet	O
laureate	O
donald	O
hall	O
has	O
published	O
essays	O
and	O
anthologies	O
of	O
both	O
poetry	O
and	O
prose	O
including	O
string	O
too	O
short	O
to	O
be	O
saved	O
recollections	O
of	O
summers	O
on	O
new	O
england	O
farm	O
and	O
ox	O
cart	O
man	O
children	O
book	O
which	O
won	O
the	O
caldecott	O
medal	O
.	O
listener	O
kendel	O
currier	O
transcript	O
well	O
we	O
came	O
here	O
and	O
we	O
published	O
books	O
in	O
the	O
same	O
year	O
her	O
first	O
book	O
of	O
poems	O
and	O
my	O
book	O
called	O
kicking	O
the	O
leaves	O
and	O
our	O
second	O
books	O
came	O
out	O
the	O
same	O
year	O
.	O
we	O
always	O
swore	O
we	O
wouldn	O
come	O
out	O
the	O
same	O
year	O
so	O
we	O
wouldn	O
be	O
reviewed	O
together	O
but	O
we	O
always	O
did	O
more	O
or	O
less	O
.	O
it	O
was	O
it	O
was	O
maybe	O
think	O
it	O
was	O
when	O
her	O
second	O
book	O
which	O
was	O
kind	O
of	O
breakthrough	O
the	O
boat	O
of	O
quiet	O
hours	O
came	O
out	O
at	O
the	O
same	O
time	O
as	O
book	O
of	O
mine	O
called	O
the	O
happy	O
man	O
.	O
and	O
the	O
happy	O
man	O
the	O
title	O
of	O
it	O
took	O
from	O
some	O
note	O
by	O
tolstoy	O
in	O
which	O
he	O
talked	O
about	O
the	O
happy	O
man	O
and	O
all	O
happiness	O
and	O
he	O
full	O
of	O
thoughts	O
of	O
suicide	O
and	O
it	O
book	O
with	O
lot	O
of	O
depressing	O
poems	O
in	O
but	O
not	O
entirely	O
.	O
when	O
told	O
jane	O
ve	O
found	O
title	O
ve	O
found	O
title	O
going	O
to	O
call	O
it	O
the	O
happy	O
man	O
.	O
typical	O
of	O
jane	O
she	O
said	O
it	O
sounds	O
too	O
depressed	O
.	O
and	O
but	O
anyway	O
did	O
call	O
it	O
the	O
happy	O
man	O
.	O
but	O
at	O
there	O
was	O
at	O
this	O
time	O
in	O
my	O
life	O
as	O
writer	O
there	O
was	O
sort	O
of	O
physical	O
and	O
psychological	O
element	O
than	O
the	O
writing	O
that	O
have	O
talked	O
about	O
in	O
print	O
and	O
that	O
is	O
that	O
when	O
was	O
about	O
something	O
like	O
that	O
became	O
an	O
adult	O
onset	O
diabetic	O
and	O
my	O
diabetes	ENTITY
is	ENTITY
still	ENTITY
with	ENTITY
me	ENTITY
and	ENTITY
it	ENTITY
very	ENTITY
much	ENTITY
under	ENTITY
control	ENTITY
and	ENTITY
so	ENTITY
on	ENTITY
but	ENTITY
it	ENTITY
had	ENTITY
the	ENTITY
effect	ENTITY
gradually	ENTITY
in	ENTITY
my	ENTITY
of	ENTITY
making	ENTITY
it	ENTITY
impossible	ENTITY
for	ENTITY
me	ENTITY
to	ENTITY
sustain	ENTITY
an	ENTITY
erection	ENTITY
.	O
and	O
this	O
was	O
depressing	O
it	O
was	O
depressing	O
for	O
both	O
of	O
us	O
of	O
course	O
and	O
my	O
poems	O
suddenly	O
turned	O
kind	O
of	O
old	O
and	O
resigned	O
and	O
it	O
was	O
not	O
was	O
not	O
in	O
any	O
deep	O
depression	O
but	O
it	O
was	O
difficult	O
for	O
both	O
of	O
us	O
and	O
my	O
poetry	O
became	O
sort	O
of	O
more	O
passive	O
or	O
old	O
and	O
so	O
on	O
.	O
and	O
think	O
some	O
of	O
the	O
poems	O
are	O
good	O
that	O
are	O
in	O
this	O
mode	O
but	O
finally	O
solved	O
the	O
problem	O
by	O
having	O
penile	ENTITY
implant	ENTITY
surgery	ENTITY
and	O
potency	O
came	O
back	O
.	O
was	O
always	O
always	O
orgasmic	ENTITY
but	ENTITY
just	ENTITY
couldn	ENTITY
have	ENTITY
an	ENTITY
erection	ENTITY
but	ENTITY
got	ENTITY
permanent	ENTITY
one	ENTITY
and	ENTITY
it	ENTITY
was	ENTITY
wonderful	ENTITY
and	ENTITY
jane	ENTITY
adored	ENTITY
it	ENTITY
and	ENTITY
said	ENTITY
kept	ENTITY
saying	ENTITY
perkins	ENTITY
what	ENTITY
you	ENTITY
did	ENTITY
for	ENTITY
me	ENTITY
and	ENTITY
would	ENTITY
point	ENTITY
out	ENTITY
it	ENTITY
wasn	ENTITY
just	ENTITY
for	ENTITY
her	ENTITY
but	ENTITY
at	ENTITY
that	ENTITY
same	ENTITY
time	ENTITY
my	ENTITY
poems	ENTITY
got	ENTITY
back	ENTITY
their	ENTITY
liveliness	ENTITY
and	ENTITY
energy	ENTITY
just	ENTITY
because	ENTITY
of	ENTITY
bit	ENTITY
of	ENTITY
surgery	ENTITY
but	ENTITY
it	ENTITY
very	ENTITY
noticeable	ENTITY
.	O
and	O
it	O
was	O
noticeable	O
in	O
what	O
lot	O
of	O
people	O
think	O
is	O
the	O
best	O
thing	O
ever	O
did	O
which	O
was	O
the	O
book	O
length	O
poem	O
.	O
to	O
your	O
health	O
body	O
and	O
spirit	O
reversing	O
type	O
diabetes	ENTITY
through	ENTITY
fasting	ENTITY
type	ENTITY
diabetes	ENTITY
sometimes	ENTITY
referred	ENTITY
to	ENTITY
as	ENTITY
adult	ENTITY
onset	ENTITY
diabetes	ENTITY
doesn	O
have	O
to	O
be	O
permanent	O
.	O
fasting	O
and	O
calorie	O
restriction	O
can	O
help	O
you	O
get	O
control	ENTITY
of	ENTITY
your	ENTITY
blood	ENTITY
sugar	ENTITY
lower	O
your	O
blood	ENTITY
pressure	ENTITY
and	O
even	O
help	O
reverse	O
type	O
diabetes	ENTITY
.	O
but	O
before	O
we	O
get	O
into	O
how	O
fasting	O
can	O
undo	O
the	O
damage	O
of	O
type	O
diabetes	ENTITY
we	ENTITY
first	ENTITY
need	ENTITY
to	ENTITY
understand	ENTITY
how	ENTITY
type	ENTITY
diabetes	ENTITY
affects	ENTITY
the	ENTITY
body	ENTITY
.	O
how	O
does	O
type	O
diabetes	ENTITY
develop	ENTITY
.	O
diabetes	ENTITY
develops	ENTITY
when	ENTITY
fat	ENTITY
accumulates	ENTITY
in	ENTITY
areas	ENTITY
of	ENTITY
the	ENTITY
body	ENTITY
that	ENTITY
shouldn	ENTITY
accumulate	ENTITY
fat	ENTITY
.	O
it	O
all	O
starts	O
with	O
an	O
abundance	O
of	O
fat	ENTITY
in	ENTITY
your	ENTITY
muscle	ENTITY
tissue	ENTITY
.	O
typically	O
this	O
is	O
caused	O
by	O
family	O
history	O
poor	O
diet	O
or	O
sedentary	O
lifestyle	O
.	O
this	O
fat	ENTITY
is	ENTITY
called	ENTITY
intramuscular	ENTITY
fat	ENTITY
.	O
it	O
like	O
the	O
marbling	O
on	O
steak	O
only	O
it	O
inside	O
your	O
muscles	ENTITY
and	ENTITY
it	ENTITY
causes	ENTITY
insulin	ENTITY
resistance	ENTITY
the	O
characteristic	O
that	O
distinguishes	O
type	O
diabetes	ENTITY
from	ENTITY
type	ENTITY
even	ENTITY
worse	ENTITY
intramuscular	ENTITY
fat	ENTITY
causes	ENTITY
muscles	ENTITY
to	ENTITY
produce	ENTITY
toxic	ENTITY
fat	ENTITY
metabolites	ENTITY
like	O
ceramide	ENTITY
and	ENTITY
diacylglycerol	ENTITY
dag	ENTITY
.	O
these	O
toxins	ENTITY
also	ENTITY
contribute	ENTITY
to	ENTITY
insulin	ENTITY
resistance	ENTITY
high	ENTITY
insulin	ENTITY
levelslead	ENTITY
to	O
fatty	ENTITY
liver	ENTITY
when	O
blood	ENTITY
sugar	ENTITY
is	O
high	O
the	O
pancreas	ENTITY
produces	ENTITY
insulin	ENTITY
to	ENTITY
lower	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
however	O
insulin	ENTITY
resistance	ENTITY
causes	O
the	O
liver	ENTITY
to	ENTITY
stop	ENTITY
responding	ENTITY
to	ENTITY
insulin	ENTITY
.	O
in	O
fact	O
the	O
liver	ENTITY
keeps	ENTITY
producing	ENTITY
sugar	ENTITY
despite	ENTITY
high	ENTITY
level	ENTITY
of	ENTITY
sugar	ENTITY
in	O
the	O
blood	ENTITY
.	O
consuming	O
food	O
that	O
high	O
in	O
sugar	O
is	O
like	O
throwing	O
gas	O
on	O
the	O
fire	O
and	O
the	O
abundance	O
of	O
sugar	O
is	O
converted	O
to	O
fat	ENTITY
and	ENTITY
stored	ENTITY
in	ENTITY
the	ENTITY
liver	ENTITY
.	O
source	O
rw	O
ka	O
.	O
natural	O
remedies	O
for	O
diabetes	O
http	O
www	O
reverseanydiabetes	O
com	O
reverse	O
your	O
diabetes	ENTITY
today	ENTITY
reverse	ENTITY
your	ENTITY
diabetes	ENTITY
today	ENTITY
review	ENTITY
reverse	ENTITY
your	ENTITY
diabetes	ENTITY
today	ENTITY
download	ENTITY
reverse	ENTITY
your	ENTITY
diabetes	ENTITY
today	ENTITY
by	ENTITY
matt	ENTITY
traverso	ENTITY
reverse	ENTITY
your	ENTITY
diabetes	ENTITY
today	ENTITY
by	ENTITY
matt	ENTITY
traverso	ENTITY
review	ENTITY
reverse	ENTITY
your	ENTITY
diabetes	ENTITY
today	ENTITY
by	ENTITY
matt	ENTITY
traverso	ENTITY
download	ENTITY
reverse	ENTITY
diabetes	ENTITY
today	ENTITY
is	ENTITY
an	ENTITY
book	ENTITY
developed	ENTITY
by	ENTITY
natural	ENTITY
health	ENTITY
expert	ENTITY
public	ENTITY
speaker	ENTITY
and	ENTITY
author	ENTITY
matt	ENTITY
traverso	ENTITY
that	ENTITY
can	ENTITY
help	ENTITY
you	ENTITY
reverse	ENTITY
the	ENTITY
cause	ENTITY
of	ENTITY
diabetes	ENTITY
in	ENTITY
as	ENTITY
short	ENTITY
as	ENTITY
weeks	ENTITY
.	O
with	O
reverse	O
diabetes	ENTITY
today	ENTITY
you	ENTITY
will	ENTITY
achieve	ENTITY
the	ENTITY
reverse	ENTITY
diabetes	ENTITY
reverse	ENTITY
prediabetes	ENTITY
cure	ENTITY
type	ENTITY
diabetes	ENTITY
cure	ENTITY
type	ENTITY
diabetes	ENTITY
treatment	ENTITY
of	ENTITY
diabetes	ENTITY
natural	ENTITY
diabetes	ENTITY
cure	O
how	O
to	O
cure	O
diabetes	ENTITY
natural	ENTITY
cure	ENTITY
for	ENTITY
diabetes	ENTITY
treatment	ENTITY
for	O
diabetes	ENTITY
walk	ENTITY
to	ENTITY
cure	ENTITY
diabetes	ENTITY
natural	ENTITY
help	ENTITY
for	ENTITY
diabetes	ENTITY
cure	ENTITY
of	ENTITY
diabetes	ENTITY
diabetes	ENTITY
mellitus	ENTITY
treatment	O
treatment	ENTITY
of	ENTITY
diabetes	ENTITY
mellitus	ENTITY
diabetes	ENTITY
natural	ENTITY
cures	ENTITY
is	ENTITY
there	ENTITY
cure	ENTITY
for	ENTITY
diabetes	ENTITY
natural	ENTITY
treatment	ENTITY
for	O
diabetes	ENTITY
new	ENTITY
treatment	ENTITY
for	ENTITY
diabetes	ENTITY
diabetes	ENTITY
and	ENTITY
treatment	ENTITY
the	ENTITY
cure	ENTITY
for	ENTITY
diabetes	ENTITY
diabetes	ENTITY
diabetes	ENTITY
cure	ENTITY
cure	ENTITY
for	ENTITY
diabetes	ENTITY
diabetes	ENTITY
treatment	ENTITY
treatment	ENTITY
for	ENTITY
diabetes	ENTITY
treatments	ENTITY
for	ENTITY
diabetes	ENTITY
reversing	O
diabetes	ENTITY
reverse	ENTITY
diabetes	ENTITY
how	ENTITY
to	ENTITY
reverse	ENTITY
diabetes	ENTITY
natural	ENTITY
remedies	ENTITY
for	ENTITY
diabetes	ENTITY
natural	ENTITY
remedy	ENTITY
for	O
diabetes	ENTITY
home	ENTITY
remedies	ENTITY
for	ENTITY
diabetes	ENTITY
natural	ENTITY
remedies	ENTITY
diabetes	ENTITY
home	ENTITY
remedy	ENTITY
for	ENTITY
diabetes	ENTITY
.	O
adult	ENTITY
onset	ENTITY
diabetes	ENTITY
treatment	O
tid	O
video	O
.	O
bored	O
on	O
break	O
.	O
symptoms	O
of	O
adult	ENTITY
onset	ENTITY
diabetes	ENTITY
what	O
are	O
the	O
signs	O
of	O
diabetes	ENTITY
in	ENTITY
adults	ENTITY
.	O
sometimes	O
type	O
diabetes	ENTITY
can	ENTITY
develop	ENTITY
without	ENTITY
any	ENTITY
warnings	ENTITY
signs	ENTITY
.	O
in	O
fact	O
about	O
third	O
of	O
all	O
people	O
who	O
have	O
type	O
diabetes	ENTITY
don	ENTITY
know	ENTITY
they	ENTITY
have	ENTITY
it	ENTITY
.	O
that	O
why	O
it	O
important	O
to	O
talk	O
to	O
your	O
doctor	O
about	O
your	O
risk	O
for	O
diabetes	ENTITY
and	ENTITY
determine	ENTITY
if	ENTITY
you	ENTITY
should	ENTITY
be	ENTITY
tested	ENTITY
.	O
common	O
warnings	O
signs	O
of	O
diabetes	ENTITY
include	ENTITY
increased	ENTITY
thirst	ENTITY
increased	ENTITY
hunger	ENTITY
dry	ENTITY
mouth	ENTITY
frequent	ENTITY
urination	ENTITY
unexplained	O
weight	O
loss	O
fatigue	O
blurred	O
vision	O
headaches	ENTITY
if	ENTITY
you	ENTITY
have	ENTITY
any	ENTITY
of	ENTITY
the	ENTITY
above	ENTITY
mentioned	ENTITY
warnings	ENTITY
signs	ENTITY
of	ENTITY
diabetes	ENTITY
give	ENTITY
your	ENTITY
doctor	ENTITY
call	ENTITY
and	ENTITY
schedule	ENTITY
diabetes	ENTITY
test	ENTITY
.	O
with	O
the	O
right	O
diabetes	ENTITY
diet	ENTITY
regular	O
exercise	O
and	O
medications	O
if	O
needed	O
you	O
can	O
manage	O
type	O
diabetes	ENTITY
and	ENTITY
live	ENTITY
an	ENTITY
active	ENTITY
productive	ENTITY
life	ENTITY
.	O
mwtusypk	O
gc	O
.	O
cnn	O
correspondent	O
cristina	O
alesci	O
was	O
diagnosed	O
with	O
type	O
diabetes	ENTITY
as	ENTITY
an	ENTITY
adult	ENTITY
.	O
how	O
is	O
she	O
coping	O
.	O
holly	O
firfer	O
finds	O
out	O
.	O
was	O
originally	O
misdiagnosed	O
with	O
type	O
diabetes	ENTITY
.	O
this	O
is	O
my	O
story	O
.	O
hope	O
to	O
raise	O
awareness	O
that	O
adults	O
get	O
type	O
too	O
.	O
finding	O
out	O
have	O
type	O
diabetes	ENTITY
at	ENTITY
age	ENTITY
.	O
trying	O
to	O
bring	O
awareness	O
to	O
adults	O
being	O
diagnosed	O
with	O
type	O
it	O
isn	O
only	O
kids	O
.	O
simon	O
was	O
diagnosed	O
with	O
late	ENTITY
onset	ENTITY
type	ENTITY
diabetes	ENTITY
when	O
he	O
was	O
years	O
old	O
.	O
his	O
motivation	O
to	O
really	O
address	O
his	O
diet	O
was	O
weight	O
gain	O
but	O
the	O
result	O
he	O
now	O
.	O
the	O
idea	O
of	O
completely	O
reversing	O
diabetes	ENTITY
has	ENTITY
been	ENTITY
questioned	ENTITY
time	ENTITY
and	ENTITY
time	ENTITY
again	ENTITY
.	O
in	O
order	O
to	O
determine	O
the	O
answer	O
to	O
this	O
question	O
you	O
must	O
take	O
into	O
account	O
few	O
factors	O
such	O
as	O
what	O
type	O
of	O
diabetes	ENTITY
are	ENTITY
you	ENTITY
dealing	ENTITY
with	ENTITY
and	ENTITY
whether	ENTITY
or	ENTITY
not	ENTITY
your	ENTITY
body	ENTITY
is	ENTITY
producing	ENTITY
insulin	ENTITY
.	O
typically	O
doctors	O
refer	O
to	O
diabetes	ENTITY
reversal	ENTITY
when	ENTITY
you	ENTITY
are	ENTITY
able	ENTITY
to	ENTITY
go	ENTITY
off	ENTITY
your	ENTITY
medication	ENTITY
while	ENTITY
engaging	ENTITY
in	ENTITY
healthy	ENTITY
lifestyle	ENTITY
program	ENTITY
.	O
obviously	O
when	O
you	O
are	O
not	O
taking	O
medication	O
for	O
diabetes	ENTITY
and	ENTITY
your	ENTITY
blood	ENTITY
sugar	ENTITY
is	O
under	O
control	O
you	O
do	O
not	O
have	O
diabetes	ENTITY
or	ENTITY
you	ENTITY
have	ENTITY
reversed	ENTITY
diabetes	ENTITY
.	O
but	O
the	O
important	O
message	O
here	O
is	O
that	O
you	O
have	O
to	O
keep	O
healthy	O
lifestyle	O
program	O
.	O
if	O
you	O
fall	O
off	O
the	O
wagon	O
and	O
start	O
eating	O
the	O
wrong	O
stuff	O
again	O
and	O
stop	O
exercising	O
you	O
will	O
end	O
up	O
with	O
diabetes	ENTITY
yet	ENTITY
again	ENTITY
.	O
so	O
to	O
answer	O
the	O
question	O
can	O
type	O
adult	ENTITY
onset	ENTITY
diabetes	ENTITY
be	O
reversed	O
the	O
answer	O
is	O
yes	O
.	O
can	O
it	O
be	O
reversed	O
with	O
diet	O
and	O
exercise	O
.	O
absolutely	O
yes	O
.	O
watch	O
the	O
video	O
and	O
learn	O
about	O
the	O
case	O
of	O
caucasian	O
male	O
who	O
reversed	O
his	O
type	O
diabetes	ENTITY
in	ENTITY
days	ENTITY
after	ENTITY
joining	ENTITY
our	ENTITY
program	ENTITY
.	O
this	O
case	O
report	O
was	O
presented	O
at	O
the	O
world	O
congress	O
on	O
insulin	ENTITY
resistance	ENTITY
diabetes	ENTITY
cardiovascular	ENTITY
disease	ENTITY
on	O
november	O
at	O
universal	O
city	O
ca	O
.	O
type	O
diabetes	ENTITY
was	ENTITY
once	ENTITY
known	ENTITY
as	ENTITY
adult	ENTITY
onset	ENTITY
because	ENTITY
it	ENTITY
was	ENTITY
so	ENTITY
rare	ENTITY
in	ENTITY
kids	ENTITY
.	O
but	O
not	O
anymore	O
.	O
with	O
one	O
in	O
five	O
school	O
age	O
children	O
considered	O
obese	ENTITY
the	ENTITY
rate	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
in	ENTITY
young	ENTITY
people	ENTITY
is	ENTITY
climbing	ENTITY
.	O
the	O
newest	O
study	O
shows	O
an	O
almost	O
five	O
percent	O
jump	O
over	O
decade	O
for	O
those	O
between	O
the	O
ages	O
of	O
and	O
dr	O
tara	O
narula	O
joins	O
cbs	O
this	O
morning	O
to	O
discuss	O
how	O
the	O
complications	O
resulting	O
from	O
diabetes	ENTITY
are	ENTITY
happening	ENTITY
earlier	ENTITY
in	ENTITY
life	ENTITY
and	ENTITY
the	ENTITY
importance	ENTITY
of	ENTITY
educating	ENTITY
kids	ENTITY
on	ENTITY
the	ENTITY
dangers	ENTITY
of	ENTITY
the	ENTITY
disease	ENTITY
.	O
subscribe	O
to	O
the	O
cbs	O
this	O
morning	O
channel	O
here	O
delivered	O
by	O
charlie	O
rose	O
norah	O
donnell	O
and	O
gayle	O
king	O
cbs	O
this	O
morning	O
offers	O
thoughtful	O
substantive	O
and	O
insightful	O
source	O
of	O
news	O
and	O
information	O
to	O
daily	O
audience	O
of	O
million	O
viewers	O
.	O
the	O
emmy	O
award	O
winning	O
broadcast	O
presents	O
mix	O
of	O
daily	O
news	O
coverage	O
of	O
developing	O
stories	O
of	O
national	O
and	O
global	O
significance	O
and	O
interviews	O
with	O
leading	O
figures	O
in	O
politics	O
business	O
and	O
entertainment	O
.	O
check	O
local	O
listings	O
for	O
cbs	O
this	O
morning	O
broadcast	O
times	O
.	O
try	O
and	O
move	O
me	O
bro	O
.	O
recorded	O
with	O
mellitus	ENTITY
type	ENTITY
.	O
click	O
now	O
.	O
this	O
is	O
the	O
answer	O
for	O
your	O
problem	O
symptoms	O
of	O
adult	O
onset	O
diabetes	O
.	O
hey	O
diabuddies	O
and	O
friends	O
.	O
thanks	O
for	O
watching	O
guys	O
just	O
to	O
be	O
clear	O
the	O
pizza	O
didn	O
cause	O
my	O
diabetes	ENTITY
lol	ENTITY
.	O
it	O
just	O
put	O
my	O
blood	ENTITY
glucose	ENTITY
up	O
after	O
antibodies	ENTITY
had	ENTITY
killed	ENTITY
off	ENTITY
my	ENTITY
insulin	ENTITY
production	ENTITY
.	O
type	O
diabetes	ENTITY
is	ENTITY
an	ENTITY
autoimmune	ENTITY
condition	ENTITY
where	O
your	O
body	O
attacks	O
and	O
kills	O
off	O
the	O
insulin	ENTITY
producing	ENTITY
cells	ENTITY
in	O
your	O
pancreas	ENTITY
.	O
it	O
is	O
not	O
lifestyle	O
driven	O
.	O
fyi	O
couple	O
of	O
comments	O
missed	O
out	O
normal	O
sugars	O
are	O
commonly	O
called	O
out	O
as	O
mmol	O
to	O
mmol	O
uk	O
.	O
misunderstandings	O
preconceptions	O
judgements	O
of	O
differences	O
between	O
type	O
and	O
type	O
in	O
society	O
and	O
the	O
medical	O
profession	O
is	O
something	O
ll	O
discuss	O
in	O
future	O
video	O
.	O
much	O
love	O
to	O
all	O
types	O
to	O
one	O
love	O
.	O
click	O
now	O
.	O
this	O
is	O
the	O
answer	O
for	O
your	O
problem	O
adult	ENTITY
onset	ENTITY
diabetes	ENTITY
symptoms	ENTITY
.	O
full	O
version	O
.	O
adult	ENTITY
onset	ENTITY
diabetes	ENTITY
symptoms	O
tid	O
video	O
.	O
conditions	O
diabetes	ENTITY
type	ENTITY
adult	ENTITY
onset	ENTITY
reversed	ENTITY
depression	ENTITY
inflammation	ENTITY
this	ENTITY
video	ENTITY
is	ENTITY
testimonial	ENTITY
of	ENTITY
bill	ENTITY
experience	ENTITY
working	ENTITY
with	ENTITY
dr	ENTITY
joe	ENTITY
sevlie	ENTITY
at	ENTITY
the	ENTITY
center	ENTITY
for	ENTITY
natural	ENTITY
healthcare	ENTITY
.	O
all	O
rights	O
reserved	O
.	O
click	O
now	O
.	O
this	O
is	O
the	O
answer	O
for	O
your	O
problem	O
adult	ENTITY
onset	ENTITY
diabetes	ENTITY
.	O
hint	O
it	O
is	O
not	O
caused	O
by	O
consumption	O
of	O
sugar	O
and	O
grain	O
.	O
uploaded	O
with	O
free	O
video	O
converter	O
from	O
freemake	O
.	O
reverseanydiabetes	O
com	O
it	O
is	O
true	O
that	O
there	O
exist	O
certain	O
hypoglycemiant	ENTITY
drugs	ENTITY
that	O
successfully	O
lower	O
blood	ENTITY
sugar	ENTITY
level	ENTITY
however	O
their	O
side	O
effects	O
would	O
make	O
them	O
undesirable	O
for	O
your	O
body	O
are	O
natural	O
remedies	O
safe	O
and	O
effective	O
for	O
treating	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
read	O
more	O
about	O
herbs	O
dietary	O
supplements	O
acupuncture	O
biofeedback	O
and	O
more	O
herbs	O
.	O
certain	O
herbal	O
remedies	O
have	O
been	O
used	O
to	O
help	O
treat	O
type	O
diabetes	ENTITY
.	O
most	O
target	O
elevated	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
to	O
help	O
clear	O
glucose	ENTITY
from	ENTITY
your	ENTITY
blood	ENTITY
.	O
many	O
common	O
herbs	ENTITY
and	ENTITY
spices	ENTITY
are	O
claimed	O
to	O
have	O
blood	ENTITY
sugar	ENTITY
lowering	O
properties	O
that	O
make	O
them	O
useful	O
for	O
people	O
with	O
or	O
at	O
high	O
risk	O
of	O
type	O
diabetes	ENTITY
.	O
number	O
of	O
clinical	O
studies	O
have	O
been	O
carried	O
out	O
in	O
recent	O
years	O
that	O
show	O
potential	O
links	O
between	O
herbal	O
therapies	O
and	O
improved	O
blood	ENTITY
glucose	ENTITY
control	ENTITY
which	O
has	O
led	O
to	O
an	O
increase	O
in	O
people	O
with	O
diabetes	ENTITY
using	ENTITY
these	ENTITY
more	ENTITY
natural	ENTITY
ingredients	ENTITY
to	ENTITY
help	ENTITY
manage	ENTITY
their	ENTITY
condition	ENTITY
.	O
the	O
natural	ENTITY
diabetes	ENTITY
cure	ENTITY
is	O
not	O
intended	O
as	O
medical	O
advice	O
how	O
to	O
prevent	O
and	O
treat	O
diabetes	ENTITY
with	ENTITY
natural	ENTITY
medicine	ENTITY
cure	ENTITY
diabetes	ENTITY
naturally	ENTITY
is	ENTITY
one	ENTITY
of	ENTITY
useful	ENTITY
natural	ENTITY
remedies	ENTITY
for	ENTITY
diabetes	ENTITY
that	ENTITY
help	ENTITY
people	ENTITY
live	ENTITY
healthy	ENTITY
life	ENTITY
.	O
video	O
tags	O
diabetes	ENTITY
diabetes	ENTITY
cure	ENTITY
cure	O
for	O
diabetes	ENTITY
diabetes	ENTITY
treatment	ENTITY
treatment	O
for	O
diabetes	ENTITY
treatments	ENTITY
for	O
diabetes	ENTITY
reversing	ENTITY
diabetes	ENTITY
reverse	ENTITY
diabetes	ENTITY
how	O
to	O
reverse	O
diabetes	ENTITY
natural	ENTITY
remedies	ENTITY
for	ENTITY
diabetes	ENTITY
natural	ENTITY
remedy	ENTITY
for	O
diabetes	ENTITY
home	ENTITY
remedies	ENTITY
for	ENTITY
diabetes	ENTITY
natural	ENTITY
remedies	ENTITY
diabetes	ENTITY
home	O
remedy	O
for	O
diabetes	ENTITY
.	O
is	O
.	O
little	O
girl	O
in	O
texas	O
had	O
diet	O
so	O
unhealthy	O
that	O
she	O
developed	ENTITY
type	ENTITY
diabetes	ENTITY
before	O
her	O
fourth	O
birthday	O
doctor	O
who	O
treated	O
her	O
says	O
.	O
the	O
obese	ENTITY
year	ENTITY
old	ENTITY
was	ENTITY
diagnosed	ENTITY
with	ENTITY
what	ENTITY
used	ENTITY
to	ENTITY
be	ENTITY
known	ENTITY
as	ENTITY
adult	ENTITY
onset	ENTITY
diabetes	ENTITY
which	O
has	O
become	O
lot	O
more	O
common	O
among	O
children	O
over	O
the	O
last	O
few	O
decades	O
reports	O
reuters	O
.	O
in	O
press	O
release	O
dr	O
michael	O
yafi	O
pediatric	O
endocrinologist	O
at	O
the	O
university	O
of	O
texas	O
says	O
the	O
pound	O
toddler	O
brought	O
to	O
his	O
clinic	O
had	O
symptoms	O
of	O
excessive	ENTITY
urination	ENTITY
and	O
thirst	O
but	O
her	O
medical	O
history	O
was	O
unremarkable	O
and	O
there	O
was	O
no	O
family	ENTITY
history	ENTITY
of	ENTITY
diabetes	ENTITY
.	O
review	O
of	O
her	O
diet	O
however	O
revealed	O
poor	O
family	O
nutritional	O
habits	O
with	O
uncontrolled	O
counting	O
of	O
calories	O
and	O
fat	ENTITY
yafi	ENTITY
says	ENTITY
.	O
the	O
doctor	O
who	O
will	O
present	O
his	O
research	O
at	O
global	O
diabetes	ENTITY
conference	ENTITY
this	ENTITY
week	ENTITY
tells	ENTITY
reuters	ENTITY
that	ENTITY
he	ENTITY
has	ENTITY
never	ENTITY
encountered	ENTITY
type	ENTITY
diabetes	ENTITY
patient	ENTITY
so	ENTITY
young	ENTITY
before	ENTITY
though	ENTITY
he	ENTITY
suspects	ENTITY
there	ENTITY
are	ENTITY
more	ENTITY
out	ENTITY
there	ENTITY
and	ENTITY
he	ENTITY
now	ENTITY
screens	ENTITY
all	ENTITY
obese	ENTITY
children	ENTITY
for	ENTITY
the	ENTITY
condition	ENTITY
.	O
luckily	O
he	O
was	O
able	O
to	O
reverse	O
the	O
condition	O
in	O
the	O
texas	O
girl	O
after	O
catching	O
it	O
so	O
early	O
with	O
the	O
use	O
of	O
the	O
diabetes	ENTITY
drug	ENTITY
metformin	ENTITY
along	O
with	O
smaller	O
portions	O
of	O
food	O
and	O
increased	O
physical	O
activity	O
the	O
girl	O
lost	O
weight	O
her	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
returned	O
to	O
normal	O
and	O
she	O
no	O
longer	O
had	O
diabetes	ENTITY
after	ENTITY
six	ENTITY
months	ENTITY
the	ENTITY
guardian	ENTITY
reports	ENTITY
.	O
researchers	O
say	O
more	O
than	O
half	O
of	O
us	O
adults	O
are	O
diabetic	ENTITY
or	ENTITY
prediabetic	ENTITY
and	ENTITY
many	ENTITY
of	ENTITY
them	ENTITY
don	ENTITY
know	ENTITY
it	ENTITY
.	O
type	O
diabetes	ENTITY
formerly	ENTITY
called	ENTITY
adult	ENTITY
onset	ENTITY
diabetes	ENTITY
is	O
the	O
most	O
common	O
type	O
of	O
the	O
disease	ENTITY
affecting	ENTITY
percent	ENTITY
of	ENTITY
people	ENTITY
with	ENTITY
diabetes	ENTITY
.	O
type	O
diabetes	ENTITY
affects	ENTITY
people	ENTITY
at	ENTITY
any	ENTITY
age	ENTITY
even	ENTITY
during	ENTITY
childhood	ENTITY
.	O
however	O
this	O
type	O
of	O
diabetes	ENTITY
develops	ENTITY
most	ENTITY
often	ENTITY
in	ENTITY
middle	ENTITY
aged	ENTITY
and	ENTITY
older	ENTITY
people	ENTITY
and	ENTITY
those	ENTITY
who	ENTITY
are	ENTITY
overweight	ENTITY
and	ENTITY
inactive	ENTITY
.	O
speakers	O
kathleen	O
kenny	O
md	O
clinical	O
assistant	O
professor	O
medicine	O
general	O
medicine	O
disciplines	O
stanford	O
university	O
school	O
of	O
medicine	O
jessica	O
shipley	O
ms	O
rd	O
.	O
disclaimer	O
these	O
statements	O
has	O
not	O
been	O
reviewed	O
or	O
approved	O
by	O
the	O
food	O
and	O
drug	O
administration	O
.	O
this	O
product	O
is	O
not	O
intended	O
to	O
diagnose	O
treat	O
cure	O
or	O
prevent	O
any	O
disease	ENTITY
.	O
part	O
one	O
of	O
three	O
part	O
series	O
presented	O
by	O
stanford	O
health	O
library	O
.	O
type	O
diabetes	ENTITY
formerly	ENTITY
called	ENTITY
adult	ENTITY
onset	ENTITY
diabetes	ENTITY
is	O
the	O
most	O
common	O
type	O
of	O
the	O
disease	ENTITY
affecting	ENTITY
percent	ENTITY
of	ENTITY
people	ENTITY
with	ENTITY
diabetes	ENTITY
.	O
type	O
diabetes	ENTITY
affects	ENTITY
people	ENTITY
at	ENTITY
any	ENTITY
age	ENTITY
even	ENTITY
during	ENTITY
childhood	ENTITY
.	O
however	O
this	O
type	O
of	O
diabetes	ENTITY
develops	ENTITY
most	ENTITY
often	ENTITY
in	ENTITY
middle	ENTITY
aged	ENTITY
and	ENTITY
older	ENTITY
people	ENTITY
and	ENTITY
those	ENTITY
who	ENTITY
are	ENTITY
overweight	ENTITY
and	ENTITY
inactive	ENTITY
.	O
speaker	O
bryant	O
lin	O
md	O
clinical	O
assistant	O
professor	O
medicine	O
general	O
medicine	O
disciplines	O
stanford	O
university	O
school	O
of	O
medicine	O
learn	O
more	O
org	O
.	O
dr	O
huntoon	O
discusses	O
an	O
alternative	O
approach	O
to	O
type	ENTITY
ii	ENTITY
diabetes	ENTITY
.	O
advanced	O
alternative	O
medicine	O
center	O
canal	O
street	O
pooler	O
ga	O
phone	O
http	O
www	O
spineboy	O
com	O
.	O
conditions	O
diabetes	ENTITY
type	ENTITY
adult	ENTITY
onset	ENTITY
reversed	ENTITY
weight	ENTITY
loss	ENTITY
this	ENTITY
video	ENTITY
is	ENTITY
testimonial	ENTITY
of	ENTITY
reggie	ENTITY
experience	ENTITY
working	ENTITY
with	ENTITY
dr	ENTITY
joe	ENTITY
sevlie	ENTITY
at	ENTITY
the	ENTITY
center	ENTITY
for	ENTITY
natural	ENTITY
healthcare	ENTITY
.	O
all	O
rights	O
reserved	O
.	O
this	O
video	O
discusses	O
how	O
to	O
reverse	O
type	O
or	O
adult	ENTITY
onset	ENTITY
diabetes	ENTITY
.	O
dr	O
bernstein	O
addresses	O
amylin	ENTITY
.	O
dr	O
bernstein	O
book	O
is	O
available	O
at	O
www	O
amazon	O
.	O
this	O
video	O
was	O
produced	O
and	O
edited	O
by	O
dr	O
rd	O
dikeman	O
and	O
david	O
dikeman	O
of	O
typeonegrit	O
.	O
for	O
more	O
on	O
dr	O
bernstein	O
book	O
diabetes	ENTITY
solution	ENTITY
go	ENTITY
to	ENTITY
for	ENTITY
the	ENTITY
the	ENTITY
bernstein	ENTITY
connection	ENTITY
which	ENTITY
is	ENTITY
the	ENTITY
one	ENTITY
and	ENTITY
only	ENTITY
current	ENTITY
and	ENTITY
archive	ENTITY
website	ENTITY
of	ENTITY
every	ENTITY
audio	ENTITY
recording	ENTITY
video	ENTITY
dvd	ENTITY
transcript	ENTITY
teleseminar	ENTITY
and	ENTITY
more	ENTITY
that	ENTITY
dr	ENTITY
bernstein	ENTITY
has	ENTITY
done	ENTITY
plus	ENTITY
so	ENTITY
much	ENTITY
more	ENTITY
.	O
topics	O
covered	O
include	O
basic	O
pathophysiology	O
of	O
diabetes	ENTITY
mellitus	ENTITY
type	O
type	O
hyperglycemia	ENTITY
hypoglycemia	ENTITY
insulin	ENTITY
production	ENTITY
pancreatic	ENTITY
beta	ENTITY
alpha	ENTITY
cells	ENTITY
glycogen	ENTITY
glucagon	ENTITY
glucose	ENTITY
function	ENTITY
.	O
mechanism	O
of	O
action	O
of	O
antidiabetic	ENTITY
drugs	ENTITY
rapid	O
short	O
intermediate	O
long	ENTITY
acting	ENTITY
insulin	ENTITY
analogs	ENTITY
synthetic	ENTITY
amylin	ENTITY
incretin	ENTITY
mimetics	ENTITY
dpp	ENTITY
inhibitors	ENTITY
sulfonylureas	ENTITY
glinides	ENTITY
biguanides	ENTITY
thiazolidinediones	ENTITY
sodium	ENTITY
glucose	ENTITY
cotransporter	ENTITY
inhibitors	ENTITY
and	O
alpha	ENTITY
glucosidase	ENTITY
inhibitors	ENTITY
.	O
drugs	O
mentioned	O
include	O
insulins	ENTITY
lispro	ENTITY
aspart	ENTITY
glulisine	ENTITY
regular	ENTITY
nph	ENTITY
isophane	ENTITY
detemir	ENTITY
glargine	ENTITY
degludec	ENTITY
pramlintide	ENTITY
exenatide	ENTITY
liraglutide	ENTITY
alogliptin	ENTITY
linagliptin	ENTITY
saxagliptin	ENTITY
sitagliptin	ENTITY
glimepiride	ENTITY
glyburide	ENTITY
glipizide	ENTITY
nateglinide	ENTITY
repaglinide	ENTITY
metformin	ENTITY
pioglitazone	ENTITY
rosiglitazone	ENTITY
canagliflozin	ENTITY
dapagliflozin	ENTITY
acarbose	ENTITY
miglitol	ENTITY
.	O
this	O
is	O
video	O
produced	O
by	O
jack	O
chace	O
for	O
sophmore	O
biology	O
class	O
.	O
please	O
visit	O
www	O
doctorpaul	O
org	O
for	O
more	O
videos	O
.	O
continue	O
watching	O
.	O
listen	O
to	O
patrick	O
boyle	O
md	O
lead	O
physician	ENTITY
of	ENTITY
diabetes	ENTITY
care	ENTITY
management	ENTITY
at	O
the	O
university	O
of	O
new	O
mexico	O
and	O
well	O
known	O
endocrinologist	ENTITY
thought	ENTITY
leader	ENTITY
provide	ENTITY
the	ENTITY
key	ENTITY
elements	ENTITY
for	ENTITY
successful	ENTITY
pramlintide	ENTITY
initiation	ENTITY
and	O
titration	O
for	O
your	O
type	O
diabetes	ENTITY
patients	ENTITY
as	O
well	O
as	O
some	O
clinical	O
pearls	O
on	O
how	O
to	O
avoid	O
the	O
various	O
barriers	O
and	O
pitfalls	O
you	O
may	O
encounter	O
.	O
provided	O
by	O
the	O
institute	O
for	O
diabetes	ENTITY
obesity	ENTITY
and	O
cardiovascular	ENTITY
disease	ENTITY
idoc	O
free	O
resource	O
for	O
continuing	O
medical	O
education	O
and	O
other	O
tools	O
for	O
medical	O
professionals	O
focused	O
on	O
the	O
treatment	O
of	O
these	O
three	O
related	O
conditions	O
.	O
visit	O
www	O
idoc	O
org	O
for	O
more	O
information	O
.	O
amylin	ENTITY
pharmaceuticals	ENTITY
is	ENTITY
bio	ENTITY
pharmaceuticals	ENTITY
company	ENTITY
dedicated	ENTITY
to	ENTITY
improving	ENTITY
lives	ENTITY
by	ENTITY
discovering	ENTITY
developing	ENTITY
and	ENTITY
commercializing	ENTITY
innovative	ENTITY
medicines	ENTITY
.	O
it	O
particularly	O
focused	O
on	O
the	O
creation	O
of	O
novel	O
and	O
groundbreaking	O
therapies	O
for	O
the	O
treatment	O
of	O
diabetes	ENTITY
obesity	ENTITY
and	O
other	O
metabolic	ENTITY
diseases	ENTITY
.	O
in	O
this	O
interview	O
rommel	O
fernandez	O
director	O
of	O
commercial	O
insights	O
and	O
danielle	O
miller	ENTITY
manager	ENTITY
of	ENTITY
sales	ENTITY
operations	ENTITY
discuss	O
how	O
tableau	O
has	O
transformed	O
analysis	O
and	O
improved	O
operations	O
at	O
amylin	ENTITY
.	O
the	O
next	O
big	O
thing	O
in	O
biotech	O
amylin	ENTITY
.	O
pathophysiology	O
project	O
explaining	O
how	O
symlin	ENTITY
pramlintide	ENTITY
works	ENTITY
as	ENTITY
an	ENTITY
amylin	ENTITY
analog	ENTITY
.	O
amylin	ENTITY
heeft	ENTITY
heel	ENTITY
veel	ENTITY
vragen	ENTITY
voor	ENTITY
haar	ENTITY
opa	ENTITY
bedacht	ENTITY
.	O
die	O
gaat	O
ze	O
tijdens	O
dit	O
interview	O
aan	O
hem	O
stellen	O
.	O
here	O
ve	O
dealt	O
with	O
sglt	ENTITY
inhibitors	ENTITY
bromocriptine	ENTITY
use	ENTITY
in	ENTITY
diabetes	ENTITY
.	O
importantly	O
incretin	ENTITY
based	ENTITY
therapy	ENTITY
including	ENTITY
glp	ENTITY
analogues	ENTITY
and	ENTITY
dpp	ENTITY
inhibitors	ENTITY
.	O
also	O
word	O
on	O
amylin	ENTITY
analogues	ENTITY
ie	O
pramlintide	O
.	O
please	O
like	O
and	O
subscribe	O
if	O
you	O
find	O
this	O
tutorial	O
helpful	O
.	O
also	O
am	O
free	O
to	O
suggestions	O
if	O
any	O
.	O
thank	O
you	O
and	O
have	O
nice	O
day	O
inbox	O
me	O
at	O
ratnavsingh	O
gmail	O
com	O
subscribe	O
to	O
my	O
channel	O
at	O
.	O
hallo	O
.	O
mijn	O
naam	O
is	O
amylin	ENTITY
.	O
voor	O
het	O
kinderpersbureau	O
kreeg	O
ik	O
de	O
opdracht	O
om	O
mijn	O
ouders	O
te	O
interviewen	O
.	O
dat	O
heb	O
ik	O
met	O
mijn	O
papa	O
gedaan	O
.	O
de	O
vragen	O
gingen	O
over	O
opvoeden	O
.	O
het	O
was	O
heel	O
erg	O
leuk	O
.	O
kidpix	O
stonewood	O
village	O
with	O
amy	O
lin	O
and	O
kids	O
kidpix	O
st	O
.	O
smartrend	O
identified	O
an	O
uptrend	O
for	O
amylin	ENTITY
pharmaceuticals	ENTITY
nasdaq	ENTITY
amln	ENTITY
on	ENTITY
november	ENTITY
at	ENTITY
.	O
in	O
approximately	O
months	O
amylin	ENTITY
pharmaceuticals	ENTITY
has	ENTITY
returned	ENTITY
as	ENTITY
of	ENTITY
today	ENTITY
recent	ENTITY
price	ENTITY
of	ENTITY
.	O
amylin	ENTITY
pharmaceuticals	ENTITY
nasdaq	ENTITY
amln	ENTITY
posted	ENTITY
results	ENTITY
wednesday	ENTITY
afternoon	ENTITY
following	ENTITY
the	ENTITY
closing	ENTITY
bell	ENTITY
reporting	ENTITY
total	ENTITY
revenue	ENTITY
of	ENTITY
million	ENTITY
for	ENTITY
quarter	ENTITY
that	ENTITY
ended	ENTITY
june	ENTITY
falling	ENTITY
behind	ENTITY
consensus	ENTITY
estimates	ENTITY
of	ENTITY
million	ENTITY
.	O
amylin	ENTITY
reported	ENTITY
net	ENTITY
loss	ENTITY
of	ENTITY
million	ENTITY
or	ENTITY
per	ENTITY
share	ENTITY
excluding	ENTITY
restructuring	ENTITY
charge	ENTITY
of	ENTITY
million	ENTITY
.	O
we	O
achieved	O
several	O
important	O
milestones	O
in	O
the	O
bydureon	O
development	O
program	O
during	O
the	O
second	O
quarter	O
and	O
continue	O
to	O
position	O
the	O
company	O
for	O
long	O
term	O
value	O
creation	O
commented	O
president	O
and	O
chief	O
executive	O
officer	O
daniel	O
bradbury	O
.	O
as	O
we	O
move	O
into	O
the	O
second	O
half	O
of	O
we	O
will	O
remain	O
focused	O
on	O
our	O
goal	O
of	O
achieving	O
sustainable	O
operational	O
cash	O
flow	O
by	O
the	O
end	O
of	O
the	O
year	O
while	O
also	O
preparing	O
for	O
the	O
anticipated	O
approval	O
and	O
successful	O
market	O
introduction	O
of	O
bydureon	O
.	O
smartrend	O
is	O
bullish	O
on	O
shares	O
of	O
amylin	ENTITY
pharmaceuticals	ENTITY
and	ENTITY
our	ENTITY
subscribers	ENTITY
were	ENTITY
alerted	ENTITY
to	ENTITY
buy	ENTITY
on	ENTITY
june	ENTITY
at	ENTITY
the	ENTITY
stock	ENTITY
has	ENTITY
risen	ENTITY
since	ENTITY
the	ENTITY
alert	ENTITY
was	ENTITY
issued	ENTITY
.	O
shares	O
of	O
the	O
company	O
closed	O
wednesday	O
trading	O
session	O
at	O
.	O
learn	O
how	O
to	O
say	O
pronounce	O
amylin	ENTITY
in	ENTITY
american	ENTITY
english	ENTITY
.	O
subscribe	O
for	O
more	O
videos	O
.	O
studies	O
.	O
was	O
interviewed	O
for	O
tv	O
comercial	O
that	O
will	O
be	O
on	O
for	O
month	O
on	O
the	O
spanish	O
news	O
to	O
promote	O
ucsd	O
scholarships	O
this	O
is	O
clip	O
joaquin	O
from	O
ch	O
.	O
news	O
made	O
as	O
preview	O
of	O
the	O
actual	O
commercial	O
.	O
amylin	ENTITY
pharma	ENTITY
amln	ENTITY
is	ENTITY
higher	ENTITY
in	ENTITY
its	ENTITY
first	ENTITY
pre	ENTITY
bell	ENTITY
matches	ENTITY
after	ENTITY
the	ENTITY
stock	ENTITY
was	ENTITY
reportedly	ENTITY
upgraded	ENTITY
by	ENTITY
canaccord	ENTITY
to	ENTITY
hold	ENTITY
from	ENTITY
sell	ENTITY
and	ENTITY
set	ENTITY
price	ENTITY
target	ENTITY
of	ENTITY
per	ENTITY
share	ENTITY
.	O
what	O
does	O
amylin	ENTITY
receptor	ENTITY
agonists	ENTITY
mean	O
in	O
english	O
.	O
smiley	O
louboutin	O
love	O
basket	O
ball	O
.	O
continue	O
watching	O
.	O
watch	O
in	O
this	O
video	O
how	O
to	O
say	O
and	O
pronounce	O
amylin	ENTITY
.	O
the	O
video	O
is	O
produced	O
by	O
yeta	O
io	O
.	O
amylin	ENTITY
walking	ENTITY
in	ENTITY
for	ENTITY
her	ENTITY
spring	ENTITY
concert	ENTITY
.	O
full	O
video	O
.	O
smartrend	O
identified	O
an	O
uptrend	O
for	O
amylin	ENTITY
pharmaceuticals	ENTITY
nasdaq	ENTITY
amln	ENTITY
on	ENTITY
november	ENTITY
at	ENTITY
.	O
in	O
approximately	O
months	O
amylin	ENTITY
pharmaceuticals	ENTITY
has	ENTITY
returned	ENTITY
as	ENTITY
of	ENTITY
today	ENTITY
recent	ENTITY
price	ENTITY
of	ENTITY
.	O
amylin	ENTITY
pharmaceuticals	ENTITY
inc	ENTITY
is	ENTITY
scheduled	ENTITY
to	ENTITY
report	ENTITY
its	ENTITY
quarterly	ENTITY
results	ENTITY
on	ENTITY
april	ENTITY
th	ENTITY
analysts	ENTITY
on	ENTITY
average	ENTITY
expect	ENTITY
the	ENTITY
company	ENTITY
to	ENTITY
report	ENTITY
eps	ENTITY
loss	ENTITY
of	ENTITY
on	ENTITY
sales	ENTITY
of	ENTITY
million	ENTITY
.	O
for	O
the	O
full	O
year	O
analysts	O
expect	O
the	O
company	O
to	O
post	O
eps	O
loss	O
of	O
in	O
the	O
year	O
ago	O
period	O
the	O
company	O
reported	O
eps	O
of	O
on	O
sales	O
of	O
million	O
in	O
the	O
previous	O
quarter	O
the	O
company	O
reported	O
eps	O
loss	O
missing	O
consensus	O
estimates	O
of	O
loss	O
of	O
.	O
watch	O
full	O
video	O
.	O
macarons	O
antwerp	O
for	O
all	O
occasions	O
home	O
made	O
.	O
watch	O
in	O
this	O
video	O
how	O
to	O
say	O
and	O
pronounce	O
amylin	ENTITY
.	O
the	O
video	O
is	O
produced	O
by	O
yeta	O
io	O
.	O
kizoa	O
editar	O
videos	O
movie	O
maker	O
http	O
www	O
kizoa	O
es	O
.	O
shares	O
of	O
amylin	ENTITY
pharmaceuticals	ENTITY
nasdaq	ENTITY
amln	ENTITY
are	ENTITY
trading	ENTITY
higher	ENTITY
to	ENTITY
premarket	ENTITY
monday	ENTITY
after	ENTITY
the	ENTITY
food	ENTITY
and	ENTITY
drug	ENTITY
administration	ENTITY
asked	ENTITY
for	ENTITY
more	ENTITY
information	ENTITY
related	ENTITY
to	ENTITY
existing	ENTITY
manufacturing	ENTITY
processes	ENTITY
risk	ENTITY
management	ENTITY
and	ENTITY
labeling	ENTITY
for	ENTITY
the	ENTITY
type	ENTITY
diabetes	ENTITY
drug	ENTITY
byetta	ENTITY
.	O
though	O
the	O
fda	O
didn	O
request	O
new	O
tests	O
or	O
information	O
related	O
to	O
quality	O
control	O
violations	O
identified	O
in	O
december	O
inspection	O
of	O
the	O
plant	O
where	O
the	O
drug	O
is	O
made	O
.	O
overview	O
of	O
cells	ENTITY
lymphocytes	ENTITY
and	O
how	O
they	O
are	O
activated	O
and	O
produce	O
antibodies	ENTITY
.	O
created	O
by	O
sal	O
khan	O
.	O
watch	O
the	O
next	O
lesson	O
add	O
user	O
khanacademy	O
.	O
cell	O
activation	O
and	O
differentiation	O
this	O
lecture	O
explains	O
about	O
the	O
activation	O
of	O
cell	O
and	O
the	O
mechanism	O
of	O
cell	O
differentiation	O
in	O
bone	O
marrow	O
and	O
how	O
cell	O
developed	O
into	O
the	O
antibody	ENTITY
making	ENTITY
factories	ENTITY
in	ENTITY
immune	ENTITY
system	ENTITY
.	O
it	O
also	O
explains	O
the	O
conversion	O
of	O
cell	O
into	O
the	O
plasma	ENTITY
cells	ENTITY
which	O
is	O
also	O
known	O
as	O
the	O
cell	ENTITY
maturation	ENTITY
.	O
lymphocytes	ENTITY
derived	ENTITY
from	ENTITY
the	ENTITY
bursa	ENTITY
of	ENTITY
fabricius	ENTITY
or	O
its	O
equivalent	O
of	O
peripheral	ENTITY
circulating	ENTITY
lymphocytes	ENTITY
of	O
splenic	ENTITY
lymphocytes	ENTITY
of	O
bone	ENTITY
marrow	ENTITY
lymphocytes	ENTITY
differentiation	O
occurs	O
in	O
the	O
rd	ENTITY
trimester	ENTITY
in	ENTITY
utero	ENTITY
the	ENTITY
neonatal	ENTITY
period	ENTITY
all	ENTITY
have	ENTITY
membrane	ENTITY
bound	ENTITY
immunoglobulins	ENTITY
which	O
attach	O
via	O
their	O
fc	O
portion	O
igm	O
igd	ENTITY
igg	ENTITY
iga	ENTITY
clonal	ENTITY
expansion	ENTITY
and	ENTITY
differentiation	ENTITY
to	ENTITY
plasma	ENTITY
cells	ENTITY
which	O
produce	O
specific	ENTITY
antibody	ENTITY
and	O
memory	ENTITY
cells	ENTITY
which	O
readily	O
produce	O
plasma	ENTITY
cells	ENTITY
to	O
repeat	O
challenge	O
requires	O
ig	ENTITY
fab	ENTITY
portion	ENTITY
attaching	ENTITY
specific	ENTITY
antigen	ENTITY
ii	O
.	O
antigen	ENTITY
presented	ENTITY
pre	ENTITY
processed	ENTITY
by	ENTITY
macrophages	ENTITY
iii	ENTITY
.	O
modulatory	O
signals	O
from	O
other	O
cells	O
especially	O
cells	O
nb	ENTITY
plasma	ENTITY
cells	ENTITY
produce	O
only	O
one	O
class	O
of	O
ab	O
which	O
is	O
specific	ENTITY
for	ENTITY
one	ENTITY
antigen	ENTITY
theory	O
of	O
clonal	O
specificity	O
mcfarlane	O
burnet	O
ab	O
production	O
may	O
occur	O
as	O
above	O
with	O
the	O
co	O
operation	O
of	O
cells	O
the	O
antigen	ENTITY
is	ENTITY
said	ENTITY
to	ENTITY
be	ENTITY
thymus	ENTITY
dependent	ENTITY
antigen	ENTITY
most	O
antigens	O
are	O
of	O
this	O
class	O
and	O
the	O
ab	O
produced	O
include	O
all	O
classes	O
thymus	ENTITY
independent	ENTITY
antibodies	ENTITY
are	ENTITY
exclusively	ENTITY
of	ENTITY
the	ENTITY
igm	ENTITY
class	ENTITY
for	ENTITY
more	ENTITY
information	ENTITY
log	ENTITY
on	ENTITY
to	ENTITY
thank	ENTITY
you	ENTITY
for	ENTITY
watching	ENTITY
the	ENTITY
video	ENTITY
lecture	ENTITY
on	ENTITY
cell	ENTITY
activation	ENTITY
and	ENTITY
maturation	ENTITY
.	O
simple	O
cell	O
and	O
adaptive	ENTITY
immunity	ENTITY
animation	O
.	O
review	O
of	O
cells	O
cd	ENTITY
cells	ENTITY
and	O
cd	ENTITY
cells	ENTITY
.	O
created	O
by	O
sal	O
khan	O
.	O
watch	O
the	O
next	O
lesson	O
add	O
user	O
khanacademy	O
.	O
in	O
this	O
video	O
lecture	O
we	O
will	O
study	O
types	O
of	O
cell	ENTITY
activation	ENTITY
td	ENTITY
and	ENTITY
ti	ENTITY
antigens	ENTITY
independent	ENTITY
cell	ENTITY
activation	ENTITY
.	O
donate	O
here	O
aklectures	O
com	O
.	O
in	O
this	O
video	O
lecture	O
we	O
will	O
understand	O
cell	ENTITY
receptor	ENTITY
structure	ENTITY
and	O
function	O
cell	O
signaling	O
.	O
handwrittentutorials	O
com	O
.	O
loras	O
college	O
immunology	ENTITY
creative	ENTITY
project	ENTITY
chelsey	ENTITY
warning	ENTITY
and	ENTITY
michael	ENTITY
bukszar	ENTITY
.	O
handwrittentutorials	O
com	O
.	O
quick	O
over	O
view	O
of	O
cell	ENTITY
function	ENTITY
at	O
basic	O
level	O
.	O
roche	O
sponsored	O
video	O
.	O
part	O
of	O
my	O
documentary	O
for	O
biology	O
class	O
.	O
genentech	ENTITY
biooncology	ENTITY
is	O
currently	O
conducting	O
research	O
on	O
how	O
cell	ENTITY
surface	ENTITY
is	O
enriched	O
with	O
several	O
distinct	O
classes	O
of	O
receptor	O
molecules	O
such	O
as	O
cd	ENTITY
learn	ENTITY
about	ENTITY
how	ENTITY
individual	ENTITY
cell	ENTITY
receptors	ENTITY
promote	O
cell	ENTITY
growth	ENTITY
and	ENTITY
survival	ENTITY
.	O
the	O
final	O
showdown	O
.	O
this	O
is	O
the	O
last	O
episode	O
on	O
the	O
immune	ENTITY
system	ENTITY
and	O
also	O
the	O
very	O
last	O
episode	O
of	O
crash	O
course	O
anatomy	O
physiology	O
.	O
in	O
it	O
hank	O
explains	O
how	O
the	O
cellular	ENTITY
immune	ENTITY
response	O
uses	O
helper	O
cytotoxic	ENTITY
and	ENTITY
regulatory	ENTITY
cells	ENTITY
to	ENTITY
attack	ENTITY
body	ENTITY
cells	ENTITY
compromised	ENTITY
by	ENTITY
pathogens	ENTITY
.	O
he	O
also	O
explores	O
how	O
cytokines	ENTITY
activate	ENTITY
and	ENTITY
cells	ENTITY
and	ENTITY
what	ENTITY
happens	ENTITY
if	ENTITY
your	ENTITY
immune	ENTITY
system	ENTITY
goes	O
rogue	O
and	O
starts	O
causing	O
autoimmune	ENTITY
trouble	ENTITY
.	O
crash	O
course	O
posters	O
.	O
presentation	O
of	O
from	O
the	O
mayo	O
clinic	O
symposium	O
data	O
driven	O
algorithms	O
for	O
optimizing	O
laboratory	O
test	O
utilization	O
for	O
hematologic	ENTITY
malignancies	ENTITY
.	O
paul	O
kurtin	O
co	O
course	O
director	O
and	O
mayo	O
clinic	O
hematopathologist	ENTITY
presents	ENTITY
.	O
copyright	O
act	O
entitles	O
fair	O
use	O
for	O
educational	O
non	O
profit	O
purposes	O
my	O
videos	O
aren	O
monetized	O
and	O
do	O
this	O
for	O
myself	O
.	O
the	O
digital	O
millennium	O
copyright	O
act	O
extends	O
this	O
definition	O
for	O
further	O
uses	O
cells	O
develop	O
from	O
hematopoietic	ENTITY
stem	ENTITY
cells	ENTITY
hscs	O
that	O
originate	O
from	O
bone	ENTITY
marrow	ENTITY
.	O
hscs	ENTITY
first	ENTITY
differentiate	ENTITY
into	ENTITY
multipotent	ENTITY
progenitor	ENTITY
mpp	ENTITY
cells	ENTITY
then	O
common	O
lymphoid	ENTITY
progenitor	ENTITY
clp	ENTITY
cells	ENTITY
.	O
from	O
here	O
their	O
development	O
into	O
cells	O
occurs	O
in	O
several	O
stages	O
shown	O
in	O
image	O
to	O
the	O
right	O
each	O
marked	O
by	O
various	O
gene	ENTITY
expression	ENTITY
patterns	O
and	O
immunoglobulin	ENTITY
chain	ENTITY
and	O
chain	ENTITY
gene	ENTITY
loci	O
arrangements	O
the	O
latter	O
due	O
to	O
cells	O
undergoing	O
recombination	O
as	O
they	O
develop	O
.	O
cells	O
undergo	O
two	O
types	O
of	O
selection	O
while	O
developing	O
in	O
the	O
bone	ENTITY
marrow	ENTITY
to	O
ensure	O
proper	O
development	O
.	O
positive	O
selection	O
occurs	O
through	O
antigen	ENTITY
independent	ENTITY
signaling	ENTITY
involving	ENTITY
both	ENTITY
the	ENTITY
pre	ENTITY
bcr	ENTITY
and	ENTITY
the	ENTITY
bcr	ENTITY
.	O
if	O
these	O
receptors	O
do	O
not	O
bind	O
to	O
their	O
ligand	ENTITY
cells	ENTITY
do	O
not	O
receive	O
the	O
proper	O
signals	O
and	O
cease	O
to	O
develop	O
.	O
negative	O
selection	O
occurs	O
through	O
the	O
binding	O
of	O
self	ENTITY
antigen	ENTITY
with	O
the	O
bcr	ENTITY
if	ENTITY
the	ENTITY
bcr	ENTITY
can	ENTITY
bind	ENTITY
strongly	ENTITY
to	ENTITY
self	ENTITY
antigen	ENTITY
then	O
the	O
cell	O
undergoes	O
one	O
of	O
four	O
fates	O
clonal	O
deletion	O
receptor	O
editing	O
anergy	O
or	O
ignorance	O
cell	O
ignores	O
signal	O
and	O
continues	O
development	O
.	O
this	O
negative	O
selection	O
process	O
leads	O
to	O
state	O
of	O
central	O
tolerance	O
in	O
which	O
the	O
mature	O
cells	O
don	O
bind	O
with	O
self	ENTITY
antigens	ENTITY
present	O
in	O
the	O
bone	ENTITY
marrow	ENTITY
.	O
to	O
complete	O
development	O
into	O
mature	ENTITY
cells	ENTITY
immature	ENTITY
cells	ENTITY
migrate	O
from	O
the	O
bone	ENTITY
marrow	ENTITY
to	O
the	O
spleen	ENTITY
as	ENTITY
well	ENTITY
as	ENTITY
pass	ENTITY
through	ENTITY
two	ENTITY
transitional	ENTITY
stages	ENTITY
and	ENTITY
throughout	ENTITY
their	ENTITY
migration	ENTITY
to	ENTITY
the	ENTITY
spleen	ENTITY
and	ENTITY
after	ENTITY
spleen	ENTITY
entry	ENTITY
they	ENTITY
are	ENTITY
considered	ENTITY
cells	ENTITY
.	O
within	O
the	O
spleen	ENTITY
cells	ENTITY
transition	O
to	O
cells	O
.	O
cells	O
differentiate	O
into	O
either	O
follicular	O
fo	O
cells	O
or	O
marginal	ENTITY
zone	ENTITY
mz	ENTITY
cells	ENTITY
depending	O
on	O
signals	O
received	O
through	O
the	O
bcr	ENTITY
and	ENTITY
other	ENTITY
receptors	ENTITY
.	O
once	O
differentiated	O
they	O
are	O
now	O
considered	O
mature	ENTITY
cells	ENTITY
or	O
naive	ENTITY
cells	ENTITY
.	O
this	O
cell	O
video	O
reviews	O
antigen	ENTITY
specific	ENTITY
cells	ENTITY
and	O
cells	O
.	O
visit	O
.	O
multiple	ENTITY
sclerosis	ENTITY
ms	ENTITY
affects	O
million	O
people	O
world	O
wide	O
and	O
is	O
leading	O
cause	O
of	O
neurological	ENTITY
disability	ENTITY
.	O
recent	O
clinical	O
evidence	O
suggests	O
that	O
cells	O
contribute	O
to	O
both	O
the	O
inflammatory	ENTITY
and	ENTITY
neurodegenerative	ENTITY
aspects	ENTITY
of	ENTITY
the	ENTITY
disease	ENTITY
.	O
this	O
film	O
by	O
roche	O
illustrates	O
how	O
cells	O
are	O
believed	O
to	O
play	O
role	O
in	O
the	O
origination	O
as	O
well	O
as	O
the	O
development	O
of	O
ms	ENTITY
more	ENTITY
about	ENTITY
roche	ENTITY
in	ENTITY
neuroscience	ENTITY
.	O
watch	O
all	O
drbeen	O
lectures	O
at	O
https	O
www	O
drbeen	O
com	O
this	O
lecture	O
discusses	O
cells	O
.	O
their	O
origin	O
location	O
life	O
span	O
maturity	O
phases	O
types	O
memory	ENTITY
cells	ENTITY
cell	O
receptors	O
and	O
other	O
functions	O
.	O
the	O
structure	O
genetics	O
and	O
class	O
switching	O
of	O
immunoglobulins	ENTITY
are	ENTITY
discussed	ENTITY
in	ENTITY
the	ENTITY
next	ENTITY
lectures	ENTITY
.	O
donate	O
here	O
aklectures	O
com	O
.	O
human	O
physiology	O
is	O
free	O
online	O
course	O
on	O
janux	O
that	O
is	O
open	O
to	O
anyone	O
.	O
learn	O
more	O
at	O
com	O
.	O
copyright	O
the	O
board	O
of	O
regents	O
of	O
the	O
university	O
of	O
oklahoma	O
all	O
rights	O
reserved	O
.	O
this	O
video	O
cell	O
development	O
in	O
the	O
bone	ENTITY
marrow	ENTITY
is	O
part	O
of	O
the	O
lecturio	O
course	O
lymphocyte	ENTITY
development	ENTITY
watch	ENTITY
the	ENTITY
complete	ENTITY
course	ENTITY
on	ENTITY
.	O
donate	O
here	O
aklectures	O
com	O
.	O
part	O
in	O
part	O
lecture	O
on	O
acquired	ENTITY
immunity	ENTITY
in	O
flipped	O
human	O
physiology	O
course	O
taught	O
by	O
wendy	O
riggs	O
.	O
cc	O
by	O
.	O
watch	O
the	O
whole	O
lecture	O
all	O
videos	O
by	O
going	O
to	O
the	O
playlist	O
list	O
pl	O
grrrmagvqwtm	O
pk	O
ks	O
njzd	O
ew	O
mca	O
.	O
helper	ENTITY
cells	ENTITY
cd	O
and	O
cells	O
lymphocytes	ENTITY
plasma	ENTITY
cells	ENTITY
immune	ENTITY
system	ENTITY
.	O
watch	O
videos	O
on	O
basic	O
medical	O
sciences	O
clinical	O
medicine	O
at	O
drnajeeblectures	O
com	O
.	O
cell	ENTITY
activation	ENTITY
and	O
class	O
switching	O
best	O
explanation	O
findings	O
symptoms	O
findings	O
causes	O
mnemonics	O
review	O
what	O
is	O
video	O
study	O
rapid	O
review	O
clinical	O
presenation	O
first	O
aid	O
for	O
usmle	O
step	O
images	O
wiki	O
define	O
wikipedia	O
videos	O
exam	O
prep	O
easy	O
what	O
is	O
usmle	O
mnemonic	O
causes	O
.	O
in	O
this	O
video	O
ifum	O
talks	O
about	O
the	O
very	O
basics	O
of	O
cells	O
and	O
cells	O
.	O
enjoy	O
.	O
this	O
animated	O
video	O
shows	O
the	O
activation	ENTITY
of	ENTITY
cells	ENTITY
to	O
secrete	ENTITY
igm	ENTITY
by	O
independent	O
carbohydrate	ENTITY
antigen	ENTITY
and	O
how	O
the	O
response	O
can	O
be	O
switched	O
to	O
igg	ENTITY
using	ENTITY
conjugate	ENTITY
vaccine	ENTITY
.	O
it	O
also	O
shows	O
how	O
responses	ENTITY
to	ENTITY
protein	ENTITY
antigens	ENTITY
are	O
typically	O
dependent	O
and	O
how	O
anti	O
self	ENTITY
cells	ENTITY
can	O
be	O
made	O
to	O
secrete	O
igg	O
by	O
the	O
conjugation	O
of	O
self	O
to	O
foreign	O
protein	O
.	O
welcome	O
to	O
ly	O
med	O
where	O
go	O
over	O
everything	O
you	O
need	O
to	O
know	O
for	O
the	O
usmle	O
step	O
with	O
new	O
videos	O
every	O
day	O
.	O
follow	O
along	O
with	O
first	O
aid	O
or	O
with	O
my	O
notes	O
which	O
can	O
be	O
found	O
here	O
cells	O
deficiency	O
in	O
this	O
leads	O
to	O
decreased	O
immune	ENTITY
cells	ENTITY
.	O
deficiency	O
leads	O
to	O
loss	O
of	O
follicles	ENTITY
thymus	ENTITY
or	ENTITY
cell	ENTITY
receptor	ENTITY
excision	ENTITY
circles	ENTITY
.	O
ataxia	ENTITY
telangiectasia	ENTITY
this	O
is	O
due	O
to	O
an	O
atm	ENTITY
mutation	ENTITY
which	O
normally	O
repairs	O
dsdna	ENTITY
breaks	ENTITY
.	O
some	O
signs	O
include	O
ataxia	ENTITY
and	ENTITY
telangiectasia	ENTITY
.	O
labs	O
show	O
increased	O
alpha	ENTITY
fetoprotein	ENTITY
.	O
hyper	ENTITY
igm	ENTITY
this	O
is	O
xlr	O
disorder	O
of	O
your	O
cd	O
this	O
leads	O
to	O
an	O
inability	O
to	O
class	O
switch	O
.	O
therefore	O
your	O
default	O
igm	ENTITY
will	ENTITY
increase	ENTITY
.	O
wiskott	O
aldrich	O
this	O
is	O
due	O
to	O
mutation	O
in	O
wasp	ENTITY
gene	ENTITY
which	ENTITY
helps	ENTITY
regulate	ENTITY
the	ENTITY
cytoskeleton	ENTITY
and	ENTITY
receptors	ENTITY
.	O
you	O
can	O
see	O
increased	O
ige	O
and	O
iga	ENTITY
which	ENTITY
can	ENTITY
lead	ENTITY
to	ENTITY
eczema	ENTITY
.	O
also	O
your	O
platelets	ENTITY
can	ENTITY
be	ENTITY
dysfunctional	ENTITY
leading	ENTITY
to	ENTITY
thrombocytopenia	ENTITY
and	ENTITY
bleeding	ENTITY
.	O
our	O
last	O
topic	O
will	O
be	O
on	O
phagocyte	ENTITY
disorders	ENTITY
.	O
let	O
finish	O
up	O
with	O
chediak	ENTITY
higashi	ENTITY
syndrome	ENTITY
.	O
this	O
is	O
due	O
to	O
defective	O
lyst	O
gene	O
which	O
leads	O
to	O
microtubule	O
dysfunction	O
.	O
this	O
leads	O
to	O
dysfunctional	ENTITY
phagolysosomes	ENTITY
.	O
on	O
blood	ENTITY
smear	ENTITY
there	O
are	O
massive	O
granules	ENTITY
.	O
the	O
dead	O
giveaway	O
is	O
albinism	ENTITY
due	ENTITY
to	ENTITY
loss	ENTITY
of	ENTITY
transport	ENTITY
of	ENTITY
melanin	ENTITY
.	O
handwrittentutorials	O
com	O
.	O
for	O
more	O
information	O
log	O
on	O
to	O
cell	O
recognition	O
of	O
antigen	ENTITY
is	ENTITY
not	ENTITY
the	ENTITY
only	ENTITY
element	ENTITY
necessary	ENTITY
for	ENTITY
cell	ENTITY
activation	ENTITY
combination	ENTITY
of	ENTITY
clonal	ENTITY
proliferation	ENTITY
and	O
terminal	O
differentiation	O
into	O
plasma	ENTITY
cells	ENTITY
.	O
cells	O
can	O
be	O
activated	O
in	O
cell	O
dependent	O
or	O
independent	O
manner	O
.	O
cell	ENTITY
dependent	ENTITY
activation	ENTITY
once	O
pathogen	ENTITY
is	ENTITY
ingested	ENTITY
by	ENTITY
an	ENTITY
antigen	ENTITY
presenting	ENTITY
cell	ENTITY
such	O
as	O
macrophage	O
or	O
dendritic	ENTITY
cell	ENTITY
the	O
pathogen	ENTITY
proteins	ENTITY
are	O
then	O
digested	O
to	O
peptides	ENTITY
and	ENTITY
attached	ENTITY
to	ENTITY
class	ENTITY
ii	ENTITY
mhc	ENTITY
protein	ENTITY
.	O
this	O
complex	O
is	O
then	O
moved	O
to	O
the	O
outside	O
of	O
the	O
cell	ENTITY
membrane	ENTITY
.	O
the	O
macrophage	O
is	O
now	O
activated	O
to	O
deliver	O
multiple	O
signals	O
to	O
specific	ENTITY
cell	ENTITY
that	O
recognizes	O
the	O
peptide	ENTITY
presented	ENTITY
.	O
the	O
cell	O
is	O
then	O
stimulated	O
to	O
produce	O
autocrines	O
resulting	O
in	O
the	O
proliferation	ENTITY
or	ENTITY
differentiation	ENTITY
to	ENTITY
effector	ENTITY
or	ENTITY
memory	ENTITY
cells	ENTITY
.	O
helper	ENTITY
cells	ENTITY
.	O
cd	ENTITY
cells	ENTITY
then	O
activate	O
specific	O
cells	O
through	O
phenomenon	O
known	O
as	O
an	O
immunological	ENTITY
synapse	ENTITY
.	O
activated	ENTITY
cells	ENTITY
subsequently	O
produce	O
antibodies	ENTITY
which	ENTITY
assist	ENTITY
in	ENTITY
inhibiting	ENTITY
pathogens	ENTITY
until	O
phagocytes	ENTITY
.	O
macrophages	ENTITY
neutrophils	ENTITY
or	ENTITY
the	ENTITY
complement	ENTITY
system	ENTITY
for	O
example	O
clears	O
the	O
host	O
of	O
the	O
pathogen	ENTITY
.	O
most	O
antigens	ENTITY
are	ENTITY
dependent	ENTITY
meaning	ENTITY
cell	ENTITY
help	ENTITY
is	ENTITY
required	ENTITY
for	ENTITY
maximal	ENTITY
antibody	ENTITY
production	ENTITY
.	O
with	O
dependent	O
antigen	ENTITY
the	ENTITY
first	ENTITY
signal	ENTITY
comes	ENTITY
from	ENTITY
antigen	ENTITY
cross	ENTITY
linking	ENTITY
the	ENTITY
cell	ENTITY
receptor	ENTITY
bcr	ENTITY
and	ENTITY
the	ENTITY
second	ENTITY
signal	ENTITY
comes	ENTITY
from	ENTITY
co	ENTITY
stimulation	ENTITY
provided	ENTITY
by	ENTITY
cell	ENTITY
.	O
dependent	O
antigens	ENTITY
contain	ENTITY
proteins	ENTITY
that	ENTITY
are	ENTITY
presented	ENTITY
on	ENTITY
cell	ENTITY
class	ENTITY
ii	ENTITY
mhc	ENTITY
to	ENTITY
special	ENTITY
subtype	ENTITY
of	ENTITY
cell	ENTITY
called	ENTITY
th	ENTITY
cell	ENTITY
.	O
when	O
cell	O
processes	O
and	O
presents	O
the	O
same	O
antigen	ENTITY
to	ENTITY
the	ENTITY
primed	ENTITY
th	ENTITY
cell	ENTITY
the	ENTITY
cell	ENTITY
secretes	ENTITY
cytokines	ENTITY
that	ENTITY
activate	ENTITY
the	ENTITY
cell	ENTITY
.	O
these	O
cytokines	ENTITY
trigger	ENTITY
cell	ENTITY
proliferation	ENTITY
and	O
differentiation	O
into	O
plasma	ENTITY
cells	ENTITY
.	O
isotype	O
switching	O
to	O
igg	ENTITY
iga	ENTITY
and	ENTITY
ige	ENTITY
and	ENTITY
memory	ENTITY
cell	ENTITY
generation	O
occur	O
in	O
response	O
to	O
dependent	ENTITY
antigens	ENTITY
.	O
this	O
isotype	O
switching	O
is	O
known	O
as	O
class	O
switch	O
recombination	O
csr	O
.	O
once	O
this	O
switch	O
has	O
occurred	O
that	O
particular	O
cell	O
will	O
usually	O
no	O
longer	O
make	O
the	O
earlier	O
isotypes	O
igm	ENTITY
or	ENTITY
igd	ENTITY
.	O
cells	O
undergo	O
two	O
types	O
of	O
selection	O
while	O
developing	O
in	O
the	O
bone	ENTITY
marrow	ENTITY
to	ENTITY
ensure	ENTITY
proper	ENTITY
development	ENTITY
.	O
positive	O
selection	O
occurs	O
through	O
antigen	ENTITY
independent	ENTITY
signaling	ENTITY
involving	ENTITY
both	ENTITY
the	ENTITY
pre	ENTITY
bcr	ENTITY
and	O
the	O
bcr	ENTITY
.	O
if	O
these	O
receptors	O
do	O
not	O
bind	O
to	O
their	O
ligand	ENTITY
cells	ENTITY
do	ENTITY
not	ENTITY
receive	ENTITY
the	ENTITY
proper	ENTITY
signals	ENTITY
and	ENTITY
cease	ENTITY
to	ENTITY
develop	ENTITY
.	O
negative	O
selection	O
occurs	O
through	O
the	O
binding	O
of	O
self	ENTITY
antigen	ENTITY
with	O
the	O
bcr	ENTITY
if	ENTITY
the	ENTITY
bcr	ENTITY
can	ENTITY
bind	ENTITY
strongly	ENTITY
to	ENTITY
self	ENTITY
antigen	ENTITY
then	O
the	O
cell	O
undergoes	O
one	O
of	O
four	O
fates	O
clonal	O
deletion	O
receptor	O
editing	O
anergy	O
or	O
ignorance	O
cell	O
ignores	O
signal	O
and	O
continues	O
development	O
.	O
this	O
negative	O
selection	O
process	O
leads	O
to	O
state	O
of	O
central	O
tolerance	O
in	O
which	O
the	O
mature	ENTITY
cells	ENTITY
don	O
bind	O
with	O
self	ENTITY
antigens	ENTITY
present	O
in	O
the	O
bone	ENTITY
marrow	ENTITY
.	O
to	O
complete	O
development	O
into	O
mature	ENTITY
cells	ENTITY
immature	ENTITY
cells	ENTITY
migrate	O
from	O
the	O
bone	ENTITY
marrow	ENTITY
to	O
the	O
spleen	ENTITY
as	ENTITY
well	ENTITY
as	ENTITY
pass	ENTITY
through	ENTITY
two	ENTITY
transitional	ENTITY
stages	ENTITY
and	ENTITY
throughout	ENTITY
their	ENTITY
migration	ENTITY
to	ENTITY
the	ENTITY
spleen	ENTITY
and	ENTITY
after	ENTITY
spleen	ENTITY
entry	ENTITY
they	ENTITY
are	ENTITY
considered	ENTITY
cells	ENTITY
.	O
within	O
the	O
spleen	ENTITY
cells	ENTITY
transition	O
to	O
cells	O
.	O
cells	O
differentiate	O
into	O
either	O
follicular	ENTITY
fo	ENTITY
cells	ENTITY
or	ENTITY
marginal	ENTITY
zone	ENTITY
mz	ENTITY
cells	ENTITY
depending	O
on	O
signals	O
received	O
through	O
the	O
bcr	ENTITY
and	ENTITY
other	ENTITY
receptors	ENTITY
.	O
once	O
differentiated	O
they	O
are	O
now	O
considered	O
mature	ENTITY
cells	ENTITY
or	O
naive	ENTITY
cells	ENTITY
.	O
the	O
copyright	O
act	O
entitles	O
fair	O
use	O
for	O
non	O
profit	O
educational	O
purposes	O
and	O
is	O
extended	O
under	O
the	O
dmca	O
see	O
title	O
section	O
of	O
the	O
us	O
copyright	O
code	O
.	O
my	O
videos	O
aren	O
monetized	O
do	O
this	O
for	O
myself	O
.	O
in	O
this	O
video	O
lecture	O
we	O
will	O
study	O
dependent	O
cell	O
activation	O
.	O
targeting	ENTITY
cell	ENTITY
receptor	ENTITY
signaling	ENTITY
for	O
anticancer	ENTITY
therapy	ENTITY
the	O
bruton	O
tyrosine	ENTITY
kinase	ENTITY
inhibitor	ENTITY
ibrutinib	ENTITY
induces	ENTITY
impressive	ENTITY
responses	ENTITY
in	ENTITY
cell	ENTITY
malignancies	ENTITY
by	O
adrian	O
wiestner	O
read	O
the	O
accompanying	O
article	O
.	O
sonali	O
smith	O
md	O
dlbcl	ENTITY
the	ENTITY
lymphoma	ENTITY
research	ENTITY
foundation	ENTITY
lrf	ENTITY
mission	ENTITY
is	ENTITY
to	ENTITY
eradicate	ENTITY
lymphoma	ENTITY
and	ENTITY
serve	ENTITY
all	ENTITY
those	ENTITY
impacted	ENTITY
by	ENTITY
this	ENTITY
blood	ENTITY
cancer	ENTITY
.	O
carole	O
talks	O
about	O
her	O
experience	O
of	O
being	O
diagnosed	O
and	O
treated	O
for	O
high	O
grade	O
non	O
hodgkin	O
diffuse	O
large	O
cell	O
dlbcl	ENTITY
lymphoma	ENTITY
.	O
for	O
more	O
information	O
visit	O
www	O
lymphomas	O
org	O
uk	O
published	O
july	O
next	O
planned	O
review	O
july	O
disclaimer	O
our	O
information	O
.	O
in	O
this	O
fusion	O
of	O
storytelling	O
and	O
science	O
talk	O
about	O
the	O
immune	ENTITY
system	ENTITY
explaining	O
it	O
from	O
different	O
points	O
of	O
view	O
.	O
try	O
to	O
make	O
this	O
sort	O
of	O
like	O
spy	O
novel	O
where	O
you	O
have	O
to	O
piece	O
together	O
the	O
different	O
parts	O
.	O
the	O
immune	ENTITY
system	ENTITY
is	O
an	O
amazing	O
thing	O
that	O
keeps	O
us	O
safe	O
from	O
pathogens	ENTITY
cells	ENTITY
and	O
cells	O
fight	O
off	O
pathogens	ENTITY
many	ENTITY
primary	ENTITY
and	ENTITY
second	ENTITY
defenses	ENTITY
try	ENTITY
to	ENTITY
keep	ENTITY
pathogens	ENTITY
out	ENTITY
of	ENTITY
our	ENTITY
bodies	ENTITY
in	ENTITY
the	ENTITY
first	ENTITY
place	ENTITY
.	O
dr	O
ann	O
lacasce	O
of	O
dana	O
farber	O
cancer	O
institute	O
discusses	O
diffuse	O
large	ENTITY
cell	ENTITY
lymphoma	ENTITY
dlbcl	ENTITY
.	O
lrf	ENTITY
ambassador	ENTITY
and	O
dlbcl	ENTITY
suvivor	ENTITY
elizabeth	ENTITY
naylor	ENTITY
shares	ENTITY
her	ENTITY
story	ENTITY
from	ENTITY
diagnosis	ENTITY
to	ENTITY
remission	ENTITY
.	O
to	O
learn	O
more	O
about	O
dlbcl	ENTITY
visit	ENTITY
lymphoma	ENTITY
org	ENTITY
dlbcl	ENTITY
.	O
the	O
lymphoma	ENTITY
research	ENTITY
foundation	ENTITY
is	ENTITY
the	ENTITY
nation	ENTITY
largest	ENTITY
non	ENTITY
profit	ENTITY
organization	ENTITY
devoted	ENTITY
to	ENTITY
funding	ENTITY
innovative	ENTITY
research	ENTITY
and	ENTITY
providing	ENTITY
people	ENTITY
with	ENTITY
lymphoma	ENTITY
and	ENTITY
healthcare	ENTITY
professionals	ENTITY
with	ENTITY
up	ENTITY
to	ENTITY
date	ENTITY
information	ENTITY
about	ENTITY
this	ENTITY
type	ENTITY
of	ENTITY
cancer	ENTITY
.	O
learn	O
more	O
.	O
this	O
video	O
explains	O
the	O
key	O
steps	O
in	O
cell	ENTITY
activation	ENTITY
including	O
the	O
formation	ENTITY
of	ENTITY
germinal	ENTITY
centers	ENTITY
and	O
differentiation	O
into	O
memory	O
and	O
plasma	ENTITY
cells	ENTITY
.	O
this	O
is	O
song	O
that	O
performed	O
for	O
my	O
students	O
in	O
the	O
brown	O
university	O
course	O
principles	O
of	O
immunology	ENTITY
in	ENTITY
october	ENTITY
apologies	ENTITY
for	ENTITY
the	ENTITY
terrible	ENTITY
singing	ENTITY
.	O
unit	O
video	O
chapter	O
.	O
simply	O
defined	O
in	O
seconds	O
.	O
michael	O
mcheyzer	O
williams	O
professor	O
at	O
the	O
scripps	O
research	O
institute	O
presents	O
new	O
research	O
into	O
the	O
immune	ENTITY
system	ENTITY
response	O
to	O
vaccines	ENTITY
.	O
this	O
research	O
was	O
presented	O
as	O
part	O
of	O
the	O
tsri	O
faculty	O
lecture	O
series	O
on	O
feb	O
learn	O
more	O
scripps	O
edu	O
click	O
cc	O
in	O
video	O
viewer	O
to	O
access	O
closed	O
captions	O
and	O
subtitles	O
on	O
any	O
of	O
our	O
videos	O
.	O
unit	O
video	O
chapter	O
this	O
video	O
screencast	O
was	O
created	O
with	O
doceri	O
on	O
an	O
ipad	O
.	O
doceri	O
is	O
free	O
in	O
the	O
itunes	O
app	O
store	O
.	O
learn	O
more	O
at	O
http	O
www	O
doceri	O
com	O
.	O
original	O
article	O
pancreatic	ENTITY
beta	ENTITY
cell	ENTITY
dedifferentiation	O
as	O
mechanism	O
of	O
diabetic	ENTITY
beta	ENTITY
cell	ENTITY
failure	O
.	O
talchai	O
et	O
al	O
.	O
cell	O
.	O
how	O
new	O
research	O
in	O
type	O
diabetes	ENTITY
can	ENTITY
improve	ENTITY
patient	ENTITY
care	ENTITY
.	O
beta	ENTITY
cells	ENTITY
in	O
diabetes	O
seeks	O
to	O
advance	O
clinical	O
care	O
based	O
on	O
current	O
knowledge	O
about	O
the	O
pathophysiology	O
of	O
type	O
diabetes	ENTITY
.	O
watch	O
short	O
video	O
on	O
how	O
to	O
target	O
beta	ENTITY
cell	ENTITY
function	ENTITY
early	O
in	O
the	O
course	O
of	O
therapy	O
.	O
domenico	O
accili	O
challenges	O
prevalent	O
view	O
that	O
pancreatic	ENTITY
beta	ENTITY
cells	ENTITY
undergo	O
apoptosis	O
in	O
conditions	O
that	O
induce	O
diabetes	ENTITY
suggesting	ENTITY
instead	ENTITY
that	ENTITY
dedifferentiation	ENTITY
is	ENTITY
major	ENTITY
mechanism	ENTITY
of	ENTITY
beta	ENTITY
cell	ENTITY
loss	O
.	O
continue	O
watching	O
.	O
author	O
leah	O
chase	O
summary	O
during	O
lecture	O
on	O
antibodies	ENTITY
and	ENTITY
the	ENTITY
immune	ENTITY
system	ENTITY
we	O
discussed	O
many	O
different	O
types	O
of	O
cells	O
and	O
their	O
importance	O
in	O
random	O
rearrangement	O
of	O
gene	ENTITY
sequences	ENTITY
one	O
of	O
these	O
types	O
being	O
beta	ENTITY
cells	ENTITY
cells	O
.	O
decided	O
to	O
tie	O
this	O
in	O
to	O
the	O
lecture	O
on	O
clinical	O
trials	O
by	O
looking	O
at	O
how	O
and	O
why	O
beta	ENTITY
cells	ENTITY
start	O
to	O
dysfunction	O
with	O
the	O
development	O
of	O
type	ENTITY
ii	ENTITY
diabetes	ENTITY
and	O
also	O
research	O
about	O
new	O
and	O
improved	O
drug	O
that	O
recently	O
went	O
on	O
the	O
market	O
in	O
april	O
tanzeum	O
.	O
clock	O
watching	O
uncovers	O
one	O
reason	O
why	O
beta	ENTITY
cells	ENTITY
fail	O
in	O
diabetes	ENTITY
.	O
can	O
you	O
grow	O
new	O
beta	ENTITY
cells	ENTITY
when	O
your	O
beta	ENTITY
cells	ENTITY
fail	O
.	O
see	O
how	O
beta	ENTITY
cells	ENTITY
are	O
regenerated	O
in	O
the	O
pancreas	ENTITY
the	ENTITY
body	ENTITY
has	ENTITY
the	ENTITY
the	ENTITY
natural	ENTITY
ability	ENTITY
to	ENTITY
achieve	ENTITY
this	ENTITY
task	ENTITY
if	ENTITY
the	ENTITY
right	ENTITY
kind	ENTITY
of	ENTITY
medication	ENTITY
is	ENTITY
taken	ENTITY
.	O
what	O
it	O
means	O
and	O
why	O
it	O
matters	O
.	O
cellular	ENTITY
and	ENTITY
biochemical	ENTITY
basis	ENTITY
for	O
recognition	O
of	O
beta	ENTITY
cell	ENTITY
antigens	O
in	O
autoimmune	ENTITY
diabetes	ENTITY
emil	O
unanue	O
md	O
paul	O
and	O
ellen	O
lacy	O
professor	O
of	O
pathology	O
washington	O
university	O
in	O
st	O
louis	O
the	O
lecture	O
was	O
part	O
of	O
vanderbilt	O
medical	O
discovery	O
lecture	O
series	O
featuring	O
the	O
nation	O
most	O
eminent	O
scientists	O
speaking	O
on	O
the	O
highest	O
impact	O
research	O
and	O
policy	O
issues	O
in	O
science	O
and	O
medicine	O
today	O
.	O
html	O
.	O
read	O
more	O
at	O
.	O
watch	O
full	O
version	O
.	O
full	O
video	O
.	O
date	O
december	O
speaker	O
prof	O
dr	O
dr	O
.	O
boedisantoso	O
sppd	O
kemd	O
location	O
shangri	O
la	O
hotel	O
jakarta	O
event	O
jakarta	O
diabetes	ENTITY
meeting	ENTITY
.	O
department	O
of	O
surgery	O
grand	O
rounds	O
november	O
andrew	O
stewart	O
md	O
scientific	O
director	O
diabetes	ENTITY
obesity	ENTITY
and	O
metabolism	ENTITY
institute	ENTITY
professor	ENTITY
of	ENTITY
medicine	ENTITY
icahn	ENTITY
school	ENTITY
of	ENTITY
medicine	ENTITY
at	ENTITY
mount	ENTITY
sinai	ENTITY
objectives	ENTITY
to	ENTITY
understand	ENTITY
the	ENTITY
need	ENTITY
for	ENTITY
human	ENTITY
beta	ENTITY
cell	ENTITY
regeneration	O
and	O
replacement	O
for	O
diabetes	ENTITY
.	O
to	O
understand	O
the	O
status	O
of	O
research	O
in	O
beta	ENTITY
cell	ENTITY
regeneration	O
.	O
diabetes	ENTITY
facts	ENTITY
you	ENTITY
can	ENTITY
ignore	ENTITY
normalisation	ENTITY
of	ENTITY
both	ENTITY
beta	ENTITY
cell	ENTITY
function	ENTITY
and	O
hepatic	ENTITY
insulin	ENTITY
sensitivity	ENTITY
in	O
type	O
diabetes	ENTITY
was	ENTITY
achieved	ENTITY
by	ENTITY
dietary	ENTITY
energy	ENTITY
restriction	ENTITY
alone	ENTITY
.	O
this	O
was	O
associated	O
with	O
decreased	O
pancreatic	ENTITY
and	ENTITY
liver	ENTITY
triacylglycerol	ENTITY
stores	ENTITY
.	O
the	O
abnormalities	O
underlying	O
type	O
diabetes	ENTITY
are	ENTITY
reversible	ENTITY
by	ENTITY
reducing	ENTITY
dietary	ENTITY
energy	ENTITY
intake	ENTITY
.	O
david	O
kendall	O
md	O
from	O
the	O
international	O
diabetes	ENTITY
center	ENTITY
in	ENTITY
minneapolis	ENTITY
reviews	ENTITY
the	ENTITY
role	ENTITY
of	ENTITY
beta	ENTITY
cell	ENTITY
dysfunction	O
in	O
the	O
development	O
of	O
type	O
diabetes	ENTITY
and	ENTITY
the	ENTITY
importance	ENTITY
targeting	ENTITY
beta	ENTITY
cell	ENTITY
function	ENTITY
in	O
the	O
treatment	O
of	O
the	O
disease	ENTITY
.	O
provided	O
by	O
the	O
institute	O
for	O
diabetes	ENTITY
obesity	ENTITY
and	O
cardiovascular	ENTITY
disease	ENTITY
free	O
resource	O
for	O
continuing	O
medical	O
education	O
and	O
other	O
tools	O
for	O
medical	O
professionals	O
focused	O
on	O
the	O
treatment	O
of	O
these	O
three	O
related	O
conditions	O
.	O
visit	O
www	O
idoc	O
org	O
for	O
more	O
information	O
.	O
our	O
theme	O
for	O
tedxdelmar	O
was	O
search	O
for	O
cure	O
.	O
in	O
this	O
video	O
dr	O
butler	O
gives	O
us	O
his	O
talk	O
entitled	O
preserving	O
your	O
beta	ENTITY
cells	ENTITY
.	O
peter	O
butler	O
is	O
chief	O
director	O
larry	O
hillblom	O
islet	ENTITY
research	ENTITY
center	ENTITY
at	ENTITY
ucla	ENTITY
and	ENTITY
professor	ENTITY
of	ENTITY
medicine	ENTITY
at	ENTITY
ucla	ENTITY
where	ENTITY
his	ENTITY
research	ENTITY
interests	ENTITY
include	ENTITY
arresting	ENTITY
loss	ENTITY
of	ENTITY
beta	ENTITY
cell	ENTITY
mass	O
and	O
promoting	O
beta	ENTITY
cell	ENTITY
formation	O
.	O
after	O
obtaining	O
his	O
md	O
at	O
the	O
university	O
of	O
birmingham	O
uk	O
in	O
dr	O
butler	O
underwent	O
training	O
in	O
internal	O
medicine	O
in	O
edinburgh	O
and	O
newcastle	O
upon	O
tyne	O
in	O
the	O
uk	O
.	O
he	O
then	O
underwent	O
training	O
in	O
endocrinology	ENTITY
at	ENTITY
the	ENTITY
university	ENTITY
of	ENTITY
newcastle	ENTITY
upon	ENTITY
tyne	ENTITY
and	ENTITY
then	ENTITY
at	ENTITY
the	ENTITY
mayo	ENTITY
clinic	ENTITY
in	ENTITY
rochester	ENTITY
mn	ENTITY
where	ENTITY
he	ENTITY
was	ENTITY
also	ENTITY
research	ENTITY
fellow	ENTITY
.	O
he	O
was	O
then	O
appointed	O
to	O
clinical	O
faculty	O
position	O
at	O
mayo	O
clinic	O
in	O
endocrinology	ENTITY
diabetes	ENTITY
and	ENTITY
metabolism	ENTITY
.	O
he	O
was	O
also	O
the	O
associate	O
director	O
of	O
the	O
general	O
clinical	O
research	O
center	O
and	O
led	O
an	O
nih	O
funded	O
research	O
program	O
.	O
after	O
six	O
years	O
on	O
the	O
faculty	O
at	O
the	O
mayo	O
clinic	O
he	O
was	O
appointed	O
to	O
the	O
chair	O
of	O
diabetes	ENTITY
at	ENTITY
the	ENTITY
university	ENTITY
of	ENTITY
edinburgh	ENTITY
in	ENTITY
scotland	ENTITY
where	ENTITY
he	ENTITY
established	ENTITY
the	ENTITY
first	ENTITY
clinical	ENTITY
research	ENTITY
center	ENTITY
in	ENTITY
the	ENTITY
uk	ENTITY
.	O
he	O
returned	O
to	O
the	O
usa	O
in	O
when	O
he	O
was	O
appointed	O
to	O
chief	O
of	O
endocrinology	ENTITY
diabetes	ENTITY
and	ENTITY
hypertension	ENTITY
at	ENTITY
the	ENTITY
university	ENTITY
of	ENTITY
southern	ENTITY
california	ENTITY
moving	ENTITY
to	ENTITY
the	ENTITY
university	ENTITY
of	ENTITY
california	ENTITY
los	ENTITY
angeles	ENTITY
in	ENTITY
at	ENTITY
ucla	ENTITY
he	ENTITY
has	ENTITY
established	ENTITY
the	ENTITY
larry	ENTITY
hillblom	ENTITY
islet	ENTITY
research	ENTITY
center	ENTITY
free	ENTITY
standing	ENTITY
building	ENTITY
that	ENTITY
houses	ENTITY
investigators	ENTITY
with	ENTITY
wide	ENTITY
range	ENTITY
of	ENTITY
skills	ENTITY
focused	ENTITY
on	ENTITY
revealing	ENTITY
the	ENTITY
mechanisms	ENTITY
of	ENTITY
beta	ENTITY
cell	ENTITY
loss	O
and	O
potential	O
regeneration	O
in	O
people	O
with	O
type	O
and	O
diabetes	ENTITY
.	O
he	O
is	O
director	O
of	O
the	O
lhirc	O
islet	ENTITY
isolation	ENTITY
and	ENTITY
physiology	ENTITY
core	ENTITY
.	O
he	O
is	O
the	O
editor	O
in	O
chief	O
of	O
the	O
journal	O
diabetes	ENTITY
.	O
he	O
is	O
also	O
the	O
chief	O
of	O
the	O
division	O
of	O
endocrinology	ENTITY
diabetes	ENTITY
and	ENTITY
hypertension	ENTITY
.	O
his	O
clinical	O
practice	O
at	O
ucla	O
focuses	O
on	O
care	O
of	O
patients	O
with	O
diabetes	ENTITY
.	O
in	O
the	O
spirit	O
of	O
ideas	O
worth	O
spreading	O
tedx	O
is	O
program	O
of	O
local	O
self	O
organized	O
events	O
that	O
bring	O
people	O
together	O
to	O
share	O
ted	O
like	O
experience	O
.	O
at	O
tedx	O
event	O
tedtalks	O
video	O
and	O
live	O
speakers	O
combine	O
to	O
spark	O
deep	O
discussion	O
and	O
connection	O
in	O
small	O
group	O
.	O
these	O
local	O
self	O
organized	O
events	O
are	O
branded	O
tedx	O
where	O
independently	O
organized	O
ted	O
event	O
.	O
the	O
ted	O
conference	O
provides	O
general	O
guidance	O
for	O
the	O
tedx	O
program	O
but	O
individual	O
tedx	O
events	O
are	O
self	O
organized	O
.	O
guess	O
who	O
else	O
besides	O
the	O
beta	ENTITY
cells	ENTITY
in	O
the	O
pancreas	ENTITY
are	ENTITY
producing	ENTITY
insulin	ENTITY
.	O
to	O
unlock	O
the	O
full	O
series	O
of	O
as	O
level	O
biology	O
videos	O
created	O
by	O
students	O
for	O
the	O
new	O
ocr	O
aqa	O
and	O
edexcel	O
specification	O
.	O
this	O
video	O
covers	O
the	O
gross	O
structure	ENTITY
of	ENTITY
the	ENTITY
pancreas	ENTITY
including	O
acini	ENTITY
islets	ENTITY
of	ENTITY
langerhans	ENTITY
and	ENTITY
its	ENTITY
constituent	ENTITY
alpha	ENTITY
and	ENTITY
beta	ENTITY
cells	ENTITY
discussing	O
its	O
exocrine	O
and	O
endocrine	ENTITY
functions	ENTITY
along	O
the	O
way	O
.	O
we	O
ll	O
then	O
look	O
at	O
the	O
mechanism	O
by	O
which	O
insulin	ENTITY
is	ENTITY
released	ENTITY
from	ENTITY
beta	ENTITY
cells	ENTITY
.	O
la	O
diabetes	O
tipo	O
es	O
una	O
enfermedad	O
autoinmune	O
.	O
si	O
usted	O
tiene	O
diabetes	ENTITY
tipo	ENTITY
su	ENTITY
sistema	ENTITY
inmunol	ENTITY
gico	ENTITY
ha	ENTITY
destruido	ENTITY
las	ENTITY
lulas	ENTITY
del	ENTITY
ncreas	ENTITY
que	ENTITY
producen	ENTITY
una	ENTITY
hormona	ENTITY
llamada	ENTITY
insulina	ENTITY
.	O
el	O
ncreas	O
es	O
un	O
rgano	O
localizado	O
en	O
el	O
abdomen	ENTITY
.	O
entre	O
sus	O
funciones	O
produce	O
diferentes	O
tipos	O
de	O
hormonas	O
.	O
una	O
de	O
ellas	O
es	O
la	O
insulina	ENTITY
.	O
la	O
insulina	ENTITY
es	ENTITY
producida	ENTITY
en	ENTITY
los	ENTITY
parches	ENTITY
de	ENTITY
tejido	ENTITY
llamadas	ENTITY
islotes	ENTITY
de	ENTITY
langerhans	ENTITY
.	O
la	O
mayor	O
de	O
las	O
lulas	O
de	O
los	O
islotes	O
est	O
las	O
lulas	O
beta	O
que	O
normalmente	O
se	O
producen	O
almacenan	O
liberan	O
peque	O
os	O
gr	O
nulos	O
de	O
la	O
insulina	ENTITY
en	ENTITY
el	ENTITY
torrente	ENTITY
sangu	ENTITY
neo	ENTITY
.	O
la	O
insulina	ENTITY
se	ENTITY
une	ENTITY
receptores	ENTITY
en	ENTITY
las	ENTITY
lulas	ENTITY
por	ENTITY
todo	ENTITY
el	ENTITY
cuerpo	ENTITY
.	O
esto	O
permite	O
que	O
la	O
glucosa	O
una	O
forma	O
de	O
az	O
car	O
formado	O
por	O
la	O
descomposici	O
de	O
los	O
alimentos	O
para	O
entrar	O
en	O
las	O
lulas	O
para	O
ser	O
utilizadas	O
como	O
combustible	O
.	O
en	O
la	O
diabetes	ENTITY
tipo	ENTITY
el	ENTITY
sistema	ENTITY
inmunol	ENTITY
gico	ENTITY
destruye	ENTITY
por	ENTITY
error	ENTITY
las	ENTITY
lulas	ENTITY
beta	ENTITY
que	ENTITY
producen	ENTITY
insulina	ENTITY
.	O
esta	O
glucosa	O
medios	O
no	O
pueden	O
salir	O
del	O
torrente	O
sangu	O
neo	O
hasta	O
las	O
lulas	O
para	O
ser	O
utilizadas	O
como	O
combustible	O
.	O
genome	O
wide	O
association	O
studies	O
gwas	O
have	O
identified	O
more	O
than	O
loci	O
associated	O
with	O
genetic	O
risk	O
of	O
type	O
diabetes	ENTITY
.	O
several	O
candidate	O
genes	O
have	O
been	O
suggested	O
or	O
identified	O
within	O
these	O
regions	O
but	O
the	O
molecular	ENTITY
mechanisms	ENTITY
by	O
which	O
they	O
contribute	O
to	O
insulitis	ENTITY
and	ENTITY
eta	ENTITY
cell	ENTITY
destruction	O
remain	O
to	O
be	O
clarified	O
.	O
more	O
than	O
of	O
the	O
candidate	O
genes	O
are	O
expressed	O
in	O
human	ENTITY
pancreatic	ENTITY
islets	ENTITY
suggesting	O
that	O
they	O
contribute	O
to	O
by	O
regulating	O
at	O
least	O
in	O
part	O
pathogenic	O
mechanisms	O
at	O
the	O
eta	ENTITY
cell	ENTITY
level	ENTITY
.	O
recent	O
studies	O
by	O
our	O
group	O
indicate	O
that	O
important	O
genetically	O
regulated	O
pathways	O
in	O
eta	ENTITY
cells	ENTITY
include	ENTITY
innate	ENTITY
immunity	ENTITY
and	O
antiviral	ENTITY
activity	ENTITY
involving	ENTITY
rig	ENTITY
like	ENTITY
receptors	ENTITY
particularly	ENTITY
mda	ENTITY
and	ENTITY
regulators	ENTITY
of	ENTITY
type	ENTITY
ifns	ENTITY
.	O
ptpn	O
usp	O
and	O
tyk	O
and	O
genes	ENTITY
related	ENTITY
to	ENTITY
eta	ENTITY
cell	ENTITY
phenotype	ENTITY
and	O
susceptibility	O
to	O
pro	O
apoptotic	O
stimuli	O
.	O
glis	O
.	O
these	O
observations	O
reinforce	O
the	O
concept	O
that	O
the	O
early	O
pathogenesis	O
of	O
is	O
characterized	O
by	O
dialog	O
between	O
the	O
immune	ENTITY
system	ENTITY
and	O
pancreatic	ENTITY
eta	ENTITY
cells	ENTITY
.	O
this	O
dialog	O
is	O
probably	O
influenced	O
by	O
polymorphisms	ENTITY
in	ENTITY
genes	ENTITY
expressed	O
at	O
the	O
eta	ENTITY
cell	ENTITY
and	O
or	O
immune	ENTITY
system	ENTITY
level	ENTITY
leading	O
to	O
inadequate	O
responses	O
to	O
environmental	O
cues	O
such	O
as	O
viral	ENTITY
infections	ENTITY
.	O
our	O
ongoing	O
work	O
aims	ENTITY
to	ENTITY
clarify	ENTITY
how	ENTITY
these	ENTITY
disease	ENTITY
associated	ENTITY
variants	ENTITY
affect	ENTITY
pancreatic	ENTITY
eta	ENTITY
cell	ENTITY
responses	O
to	O
inflammation	ENTITY
and	ENTITY
the	ENTITY
subsequent	ENTITY
triggering	ENTITY
of	ENTITY
autoimmune	ENTITY
responses	ENTITY
and	O
the	O
specific	O
and	O
progressive	O
eta	ENTITY
cell	ENTITY
loss	O
by	O
apoptosis	O
.	O
supporting	O
references	O
eizirik	O
dl	O
colli	O
ortis	O
the	O
role	O
of	O
inflammation	ENTITY
in	ENTITY
the	ENTITY
induction	ENTITY
and	ENTITY
amplification	ENTITY
of	ENTITY
insulitis	ENTITY
and	O
beta	ENTITY
cell	ENTITY
dysfunction	O
death	O
in	O
type	O
diabetes	ENTITY
.	O
nature	O
rev	O
endocrinol	O
nogueira	O
tc	ENTITY
paula	ENTITY
fv	ENTITY
villate	ENTITY
colli	ENTITY
ml	ENTITY
moura	ENTITY
rf	ENTITY
cunha	ENTITY
da	ENTITY
marselli	ENTITY
marchetti	ENTITY
cnop	ENTITY
julier	ENTITY
eizirik	ENTITY
dl	ENTITY
glis	ENTITY
susceptibility	ENTITY
gene	ENTITY
for	ENTITY
type	ENTITY
and	ENTITY
diabetes	ENTITY
mellitus	ENTITY
modulates	O
pancreatic	ENTITY
beta	ENTITY
cell	ENTITY
apoptosis	O
via	O
regulation	O
of	O
splice	O
variant	O
of	O
the	O
bh	ENTITY
only	ENTITY
protein	ENTITY
bim	ENTITY
.	O
plos	O
genet	O
santin	ENTITY
eizirik	ENTITY
dl	ENTITY
candidate	ENTITY
genes	ENTITY
for	ENTITY
type	ENTITY
diabetes	ENTITY
modulate	ENTITY
pancreatic	ENTITY
islet	ENTITY
inflammation	ENTITY
and	ENTITY
beta	ENTITY
cell	ENTITY
apoptosis	ENTITY
.	O
diabetes	ENTITY
obes	ENTITY
metab	ENTITY
suppl	ENTITY
.	O
marroqui	O
lopes	O
santos	O
rsd	O
roivainen	O
richardson	O
morgan	O
op	O
de	O
beeck	O
eizirik	O
dl	O
differential	O
cell	O
autonomous	O
immune	O
responses	O
determine	O
the	O
outcome	O
of	O
coxsackievirus	ENTITY
infections	ENTITY
in	O
pancreatic	ENTITY
and	ENTITY
cells	ENTITY
.	O
elife	O
.	O
ubc	ENTITY
professor	ENTITY
bruce	ENTITY
verchere	ENTITY
phd	ENTITY
discusses	ENTITY
the	ENTITY
significance	ENTITY
of	ENTITY
proinsulin	ENTITY
and	ENTITY
insulin	ENTITY
as	ENTITY
biomarkers	ENTITY
to	ENTITY
probe	ENTITY
beta	ENTITY
cell	ENTITY
dysfunction	ENTITY
.	O
continue	O
watching	O
.	O
hi	O
welcome	O
to	O
our	O
youtube	O
channel	O
.	O
here	O
we	O
are	O
going	O
to	O
tell	O
you	O
about	O
various	O
causes	O
of	O
diabetes	ENTITY
.	O
in	O
this	O
video	O
we	O
will	O
tell	O
you	O
all	O
the	O
causes	O
related	O
to	O
diabetes	ENTITY
.	O
after	O
the	O
age	O
of	O
the	O
population	O
of	O
islet	ENTITY
cells	ENTITY
is	O
established	O
and	O
not	O
plastic	O
in	O
man	O
after	O
age	O
of	O
years	O
.	O
post	O
mortem	O
studies	O
show	O
that	O
beta	ENTITY
cell	ENTITY
number	O
at	O
diagnosis	O
of	O
type	O
diabetes	ENTITY
is	ENTITY
around	ENTITY
percent	ENTITY
and	ENTITY
decreases	ENTITY
to	ENTITY
around	ENTITY
after	ENTITY
many	ENTITY
years	ENTITY
.	O
exposure	O
of	O
human	ENTITY
islet	ENTITY
to	O
fatty	ENTITY
acid	ENTITY
causes	O
an	O
increase	O
in	O
intra	O
islet	ENTITY
fat	ENTITY
storage	O
and	O
marker	O
of	O
apoptosis	O
.	O
saturated	O
cells	O
contributed	O
more	O
in	O
death	O
of	O
beta	O
cells	O
.	O
saturated	O
lipids	ENTITY
are	ENTITY
harmful	ENTITY
to	ENTITY
beta	ENTITY
cells	ENTITY
.	O
the	O
endocytosis	O
of	O
ldl	O
can	O
cause	O
beta	ENTITY
cell	ENTITY
death	O
as	O
result	O
of	O
ros	O
formation	O
.	O
similarly	O
prolonged	O
elevation	O
of	O
circulating	O
nefas	ENTITY
by	ENTITY
lipid	ENTITY
infusion	ENTITY
impairs	ENTITY
pancreatic	ENTITY
beta	ENTITY
cell	ENTITY
function	O
in	O
vivo	O
particularly	O
in	O
individuals	O
with	O
genetic	ENTITY
predisposition	ENTITY
to	O
type	O
diabetes	ENTITY
.	O
western	O
diets	O
rich	O
in	O
saturated	O
fats	O
cause	O
obesity	ENTITY
and	ENTITY
insulin	ENTITY
resistance	ENTITY
and	O
increase	O
levels	O
of	O
circulating	O
nefas	ENTITY
.	O
in	O
addition	O
they	O
contribute	O
to	O
beta	ENTITY
cells	ENTITY
failure	O
in	O
genetically	O
predisposed	O
individuals	O
.	O
nefas	ENTITY
cause	ENTITY
beta	ENTITY
cell	ENTITY
apoptosis	O
and	O
may	O
thus	O
contribute	O
to	O
progressive	O
beta	ENTITY
cell	ENTITY
loss	O
in	O
type	O
diabetes	ENTITY
.	O
type	O
diabetes	ENTITY
is	ENTITY
characterized	ENTITY
by	ENTITY
defects	ENTITY
in	ENTITY
both	ENTITY
insulin	ENTITY
secretion	ENTITY
and	O
insulin	ENTITY
action	ENTITY
.	O
sfa	O
ingestion	O
reduced	O
insulin	ENTITY
sensitivity	ENTITY
.	O
insulin	ENTITY
secretion	ENTITY
failed	O
to	O
compensate	O
for	O
insulin	ENTITY
resistance	ENTITY
in	O
subjects	O
who	O
ingested	O
sfa	O
.	O
failure	O
of	O
insulin	ENTITY
secretion	ENTITY
to	O
compensate	O
for	O
insulin	ENTITY
resistance	ENTITY
implies	O
impaired	O
beta	ENTITY
cell	ENTITY
function	ENTITY
in	O
the	O
sfa	O
.	O
increased	O
consumption	O
of	O
sfas	O
has	O
powerful	O
short	O
and	O
long	O
term	O
effect	O
on	O
insulin	ENTITY
action	ENTITY
.	O
saturated	O
fats	O
are	O
harmful	O
to	O
insulin	ENTITY
.	O
environmental	O
factors	O
such	O
as	O
diets	O
rich	O
in	O
saturated	O
fats	O
contribute	O
to	O
dysfunction	O
and	O
death	O
of	O
pancreatic	ENTITY
cells	ENTITY
in	O
diabetes	ENTITY
.	O
endoplasmic	ENTITY
reticulum	ENTITY
stress	O
is	O
elicited	O
in	O
beta	ENTITY
cells	ENTITY
by	O
saturated	ENTITY
fatty	ENTITY
acids	ENTITY
.	O
john	O
buse	O
md	O
phd	O
professor	O
and	O
chief	O
division	O
of	O
endocrinology	O
department	O
of	O
medicine	O
university	O
of	O
north	O
carolina	O
discusses	O
beta	ENTITY
cell	ENTITY
preservation	O
and	O
current	O
diabetes	ENTITY
therapies	ENTITY
.	O
learn	O
all	O
about	O
beta	ENTITY
cell	ENTITY
burnout	O
and	O
what	O
to	O
do	O
about	O
it	O
.	O
the	O
role	O
of	O
the	O
adipocyte	ENTITY
revealed	ENTITY
.	O
description	O
.	O
hi	O
.	O
my	O
name	O
is	O
peter	O
thompson	O
.	O
postdoctoral	O
scholar	O
at	O
the	O
ucsf	O
diabetes	ENTITY
center	ENTITY
and	ENTITY
it	ENTITY
been	ENTITY
about	ENTITY
months	ENTITY
now	ENTITY
since	ENTITY
we	ENTITY
reached	ENTITY
our	ENTITY
funding	ENTITY
goal	ENTITY
with	ENTITY
your	ENTITY
support	ENTITY
.	O
so	O
very	O
happy	O
today	O
to	O
share	O
you	O
some	O
updates	O
.	O
curing	O
type	O
diabetes	ENTITY
requires	ENTITY
combination	ENTITY
of	ENTITY
three	ENTITY
strategies	ENTITY
.	O
the	O
immune	ENTITY
system	ENTITY
needs	O
to	O
be	O
reset	O
its	O
actions	O
need	O
to	O
be	O
regulated	O
and	O
beta	ENTITY
cells	ENTITY
need	O
to	O
be	O
regenerated	O
.	O
joslin	O
is	O
tackling	O
this	O
suite	O
of	O
problems	O
with	O
the	O
rs	ENTITY
project	ENTITY
collaboration	ENTITY
between	ENTITY
three	ENTITY
researchers	ENTITY
studying	ENTITY
the	ENTITY
immune	ENTITY
system	ENTITY
and	O
beta	ENTITY
cells	ENTITY
.	O
while	O
his	O
colleagues	O
in	O
the	O
project	O
tom	O
serwold	O
ph	O
and	O
stephan	O
kissler	O
ph	O
are	O
working	O
to	O
reset	O
and	O
regulate	O
the	O
immune	ENTITY
system	ENTITY
peng	O
yi	O
ph	O
is	O
working	O
on	O
regenerating	O
lost	O
beta	ENTITY
cells	ENTITY
.	O
he	O
is	O
using	O
hormone	ENTITY
called	ENTITY
betatrophin	ENTITY
secreted	ENTITY
by	ENTITY
the	ENTITY
liver	ENTITY
and	ENTITY
he	ENTITY
plans	ENTITY
to	ENTITY
create	ENTITY
drug	ENTITY
to	ENTITY
stimulate	ENTITY
production	ENTITY
of	ENTITY
beta	ENTITY
cells	ENTITY
in	O
people	O
with	O
type	O
diabetes	ENTITY
.	O
dr	O
michael	O
german	O
of	O
university	O
of	O
california	O
san	O
francisco	O
ucsf	O
explains	O
how	O
research	O
is	O
providing	O
new	O
ways	O
to	O
improve	O
beta	ENTITY
cell	ENTITY
function	ENTITY
for	O
people	O
with	O
diabetes	ENTITY
.	O
this	O
movie	O
made	O
by	O
mikey	O
segel	O
as	O
part	O
of	O
his	O
senior	O
thesis	O
shows	O
the	O
culture	O
of	O
human	ENTITY
embryonic	ENTITY
stem	ENTITY
cells	ENTITY
into	O
beta	ENTITY
cells	ENTITY
.	O
at	O
the	O
end	O
each	O
of	O
the	O
six	O
red	O
flasks	O
contains	O
enough	O
beta	ENTITY
cells	ENTITY
for	O
transplantation	O
into	O
one	O
patient	O
.	O
for	O
more	O
on	O
this	O
groundbreaking	O
research	O
please	O
visit	O
harvard	O
magazine	O
creates	O
beta	ENTITY
cells	ENTITY
.	O
insulin	ENTITY
the	ENTITY
molecule	ENTITY
regulators	ENTITY
of	ENTITY
secretion	ENTITY
and	ENTITY
beta	ENTITY
cell	ENTITY
secretion	O
mechanism	O
.	O
this	O
webinar	O
is	O
presented	O
by	O
prof	O
raghu	O
mirmira	O
md	O
phd	O
of	O
indiana	O
university	O
and	O
discusses	O
beta	ENTITY
cell	ENTITY
dysfunction	ENTITY
as	O
it	O
relates	O
to	O
diabetes	ENTITY
.	O
dr	O
david	O
hodson	O
senior	O
birmingham	O
fellow	O
from	O
the	O
university	O
of	O
birmingham	O
explains	O
his	O
very	O
latest	O
research	O
findings	O
which	O
suggests	O
that	O
diabetes	ENTITY
could	ENTITY
be	ENTITY
due	ENTITY
to	ENTITY
the	ENTITY
failure	ENTITY
of	ENTITY
beta	ENTITY
cell	ENTITY
hubs	O
.	O
for	O
more	O
information	O
on	O
david	O
hodson	O
please	O
visit	O
david	O
aspx	O
.	O
type	O
diabetes	ENTITY
currently	ENTITY
affects	ENTITY
of	ENTITY
the	ENTITY
uk	ENTITY
adult	ENTITY
population	ENTITY
and	ENTITY
is	ENTITY
one	ENTITY
of	ENTITY
the	ENTITY
foremost	ENTITY
health	ENTITY
challenges	ENTITY
currently	ENTITY
facing	ENTITY
society	ENTITY
.	O
this	O
syndrome	ENTITY
can	ENTITY
be	ENTITY
described	ENTITY
as	ENTITY
failure	ENTITY
of	ENTITY
the	ENTITY
pancreatic	ENTITY
beta	ENTITY
cell	ENTITY
mass	O
to	O
secrete	O
sufficient	O
insulin	ENTITY
to	ENTITY
counteract	ENTITY
elevated	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
.	O
it	O
is	O
largely	O
believed	O
that	O
all	O
beta	ENTITY
cells	ENTITY
are	O
the	O
same	O
.	O
however	O
recent	O
studies	O
have	O
shown	O
that	O
beta	ENTITY
cells	ENTITY
in	O
fact	O
comprise	O
discrete	O
subpopulations	O
some	O
of	O
which	O
may	O
contribute	O
to	O
insulin	ENTITY
secretion	ENTITY
and	O
more	O
than	O
others	O
.	O
this	O
presentation	O
will	O
highlight	O
the	O
methodology	O
that	O
has	O
allowed	O
us	O
to	O
redefine	O
how	O
beta	ENTITY
cells	ENTITY
and	O
more	O
generally	O
endocrine	ENTITY
cells	ENTITY
function	O
.	O
the	O
influence	O
of	O
subtle	O
differences	O
in	O
the	O
beta	ENTITY
cell	ENTITY
barcode	O
on	O
insulin	ENTITY
release	ENTITY
in	ENTITY
health	ENTITY
and	ENTITY
disease	ENTITY
will	ENTITY
then	ENTITY
be	ENTITY
examined	ENTITY
.	O
finally	O
new	O
techniques	O
which	O
may	O
provide	O
unprecedented	O
insight	O
into	O
and	O
drug	O
development	O
will	O
be	O
discussed	O
.	O
beta	ENTITY
cell	ENTITY
failure	O
is	O
dominant	O
.	O
heal	O
your	O
pancreas	ENTITY
naturally	ENTITY
with	ENTITY
these	ENTITY
foods	ENTITY
the	ENTITY
pancreas	ENTITY
is	ENTITY
really	ENTITY
the	ENTITY
life	ENTITY
saver	ENTITY
in	ENTITY
all	ENTITY
of	ENTITY
us	ENTITY
.	O
it	O
plays	O
very	O
important	O
role	O
for	O
your	O
health	O
and	O
well	O
being	O
.	O
it	O
produces	O
your	O
insulin	ENTITY
.	O
if	O
it	O
is	O
damaged	O
you	O
will	O
not	O
get	O
insulin	ENTITY
.	O
without	O
insulin	ENTITY
your	ENTITY
glucose	ENTITY
metabolism	ENTITY
suffers	O
.	O
your	O
body	O
cells	O
cannot	O
produce	O
energy	O
from	O
food	O
.	O
the	O
pancreas	ENTITY
plays	ENTITY
crucial	ENTITY
role	ENTITY
in	ENTITY
digestion	ENTITY
.	O
when	O
food	O
empties	O
from	O
your	O
stomach	O
into	O
the	O
small	ENTITY
intestine	ENTITY
it	O
mixes	O
with	O
digestive	ENTITY
enzymes	ENTITY
from	O
the	O
pancreas	ENTITY
that	ENTITY
neutralize	ENTITY
stomach	ENTITY
acid	ENTITY
preventing	O
damage	O
to	O
the	O
intestine	ENTITY
.	O
these	O
enzymes	ENTITY
are	ENTITY
also	ENTITY
essential	ENTITY
for	ENTITY
your	ENTITY
body	ENTITY
to	ENTITY
reduce	ENTITY
inflammation	ENTITY
caused	ENTITY
by	ENTITY
trauma	ENTITY
injury	ENTITY
allergens	ENTITY
toxins	ENTITY
and	ENTITY
infections	ENTITY
.	O
but	O
most	O
importantly	O
the	O
pancreas	ENTITY
produces	ENTITY
insulin	ENTITY
which	ENTITY
reduces	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
and	O
allows	O
your	O
body	O
to	O
store	O
food	O
energy	O
for	O
future	O
use	O
.	O
eating	O
the	O
right	O
foods	O
can	O
heal	O
and	O
nourish	O
your	O
pancreas	ENTITY
.	O
foods	O
that	O
heal	O
the	O
pancreas	ENTITY
probiotic	ENTITY
yogurt	ENTITY
research	ENTITY
finds	ENTITY
that	ENTITY
eating	ENTITY
servings	ENTITY
of	ENTITY
low	ENTITY
fat	ENTITY
or	O
fat	ENTITY
free	ENTITY
yogurt	ENTITY
that	ENTITY
contains	ENTITY
active	ENTITY
cultures	ENTITY
to	ENTITY
help	ENTITY
ease	ENTITY
digestion	ENTITY
protect	ENTITY
the	ENTITY
pancreas	ENTITY
and	ENTITY
digestive	ENTITY
system	ENTITY
and	O
reduce	O
the	O
overall	O
risk	O
of	O
pancreatic	ENTITY
cancer	ENTITY
.	O
cabbage	O
regular	O
consumption	O
of	O
cabbage	O
may	O
help	O
protect	O
susceptible	O
individuals	O
against	O
pancreatic	ENTITY
cancer	ENTITY
.	O
cabbage	O
is	O
loaded	O
with	O
vitamin	O
but	O
it	O
also	O
contains	O
vitamin	O
and	O
folate	ENTITY
.	O
spinach	O
the	O
pancreas	ENTITY
needs	ENTITY
both	ENTITY
iron	ENTITY
and	ENTITY
vitamin	ENTITY
to	ENTITY
function	ENTITY
properly	ENTITY
and	ENTITY
spinach	ENTITY
has	ENTITY
both	ENTITY
.	O
pancreas	ENTITY
that	ENTITY
is	ENTITY
properly	ENTITY
nourished	ENTITY
will	ENTITY
be	ENTITY
less	ENTITY
likely	ENTITY
to	ENTITY
become	ENTITY
inflamed	ENTITY
or	ENTITY
to	ENTITY
be	ENTITY
vulnerable	ENTITY
to	ENTITY
the	ENTITY
onset	ENTITY
of	ENTITY
cancer	ENTITY
.	O
licorice	ENTITY
licorice	ENTITY
root	ENTITY
is	O
an	O
excellent	O
treatment	O
for	O
many	O
problems	O
with	O
pancreas	ENTITY
.	O
traditional	O
chinese	O
used	O
licorice	O
root	O
for	O
thousands	O
of	O
years	O
.	O
research	O
even	O
shows	O
that	O
this	O
common	O
root	O
is	O
loaded	O
with	O
an	O
anti	ENTITY
inflammatory	ENTITY
compound	ENTITY
that	O
reduces	O
pain	O
and	O
swelling	ENTITY
that	ENTITY
is	ENTITY
associated	ENTITY
with	ENTITY
pancreatitis	ENTITY
.	O
cherries	O
it	O
really	O
hard	O
to	O
eat	O
just	O
handful	O
of	O
cherries	O
which	O
is	O
great	O
news	O
since	O
the	O
fruit	O
is	O
rich	O
in	O
antioxidants	O
and	O
perillyl	ENTITY
alcohol	ENTITY
or	O
poh	O
compound	O
that	O
been	O
linked	O
to	O
the	O
prevention	O
of	O
pancreatic	ENTITY
cancer	ENTITY
.	O
garlic	O
this	O
is	O
major	O
help	O
for	O
the	O
pancreas	ENTITY
.	O
garlic	O
reduces	O
the	O
amount	O
of	O
sugar	O
in	O
the	O
blood	ENTITY
and	ENTITY
stimulates	ENTITY
the	ENTITY
pancreas	ENTITY
to	ENTITY
produce	ENTITY
sufficient	ENTITY
levels	ENTITY
of	ENTITY
insulin	ENTITY
.	O
aim	O
to	O
eat	O
one	O
to	O
two	O
slightly	O
crushed	O
cloves	O
of	O
garlic	O
each	O
day	O
in	O
addition	O
to	O
adding	O
some	O
to	O
your	O
foods	O
.	O
red	O
reishi	O
mushrooms	O
used	O
in	O
china	O
for	O
thousands	O
of	O
years	O
to	O
restore	O
balance	O
inside	O
the	O
body	O
red	O
rishi	O
mushrooms	O
reduce	O
inflammation	ENTITY
and	ENTITY
have	ENTITY
similar	ENTITY
benefits	ENTITY
of	ENTITY
onions	ENTITY
and	ENTITY
garlic	ENTITY
for	ENTITY
pancreatic	ENTITY
health	ENTITY
.	O
if	O
are	O
hard	O
to	O
find	O
in	O
your	O
local	O
grocery	O
store	O
try	O
the	O
asian	O
foods	O
section	O
at	O
specialty	O
grocery	O
store	O
.	O
sweet	O
potatoes	O
sweet	O
potatoes	O
along	O
with	O
other	O
orange	O
and	O
yellow	O
vegetables	O
like	O
carrots	O
corn	O
and	O
squash	O
contain	O
nutrients	O
which	O
are	O
beneficial	O
for	O
the	O
pancreas	ENTITY
and	ENTITY
may	ENTITY
help	ENTITY
prevent	ENTITY
cancer	ENTITY
.	O
other	O
foods	O
that	O
also	O
heal	O
the	O
pancreas	ENTITY
are	ENTITY
blueberries	ENTITY
broccoli	ENTITY
red	ENTITY
grapes	ENTITY
and	ENTITY
tomato	ENTITY
vegetable	ENTITY
soup	ENTITY
.	O
because	O
the	O
pancreas	ENTITY
is	ENTITY
very	ENTITY
easily	ENTITY
damaged	ENTITY
by	ENTITY
an	ENTITY
unhealthy	ENTITY
diet	ENTITY
eating	ENTITY
these	ENTITY
certain	ENTITY
food	ENTITY
will	ENTITY
boost	ENTITY
its	ENTITY
health	ENTITY
.	O
sources	O
glad	O
to	O
have	O
you	O
watching	O
.	O
good	O
day	O
and	O
good	O
health	O
.	O
discussion	O
of	O
the	O
mechanisms	O
of	O
insulin	ENTITY
resistance	ENTITY
and	O
beta	ENTITY
cell	ENTITY
failure	O
as	O
well	O
as	O
the	O
interaction	O
with	O
diet	O
.	O
reversal	O
of	O
in	O
the	O
context	O
of	O
caloric	ENTITY
restriction	ENTITY
gastric	ENTITY
bypass	ENTITY
surgery	ENTITY
and	O
plant	O
based	O
nutrition	O
will	O
be	O
discussed	O
with	O
emphasis	O
on	O
the	O
benefits	O
of	O
plant	O
based	O
diet	O
approach	O
.	O
this	O
is	O
review	O
of	O
prof	O
hail	O
kim	O
lecture	O
on	O
diabetes	ENTITY
and	ENTITY
insulin	ENTITY
.	O
we	O
will	O
review	O
the	O
new	O
emerging	O
concept	O
of	O
pathogenesis	O
of	O
type	O
diabetes	ENTITY
from	ENTITY
insulin	ENTITY
resistance	ENTITY
to	ENTITY
beta	ENTITY
cell	ENTITY
failure	O
in	O
this	O
lecture	O
.	O
hope	O
it	O
will	O
help	O
you	O
next	O
time	O
.	O
reversal	O
of	O
type	O
diabetes	ENTITY
normalisation	ENTITY
of	ENTITY
beta	ENTITY
cellfunction	ENTITY
in	O
association	O
with	O
decreased	O
pancreas	ENTITY
and	ENTITY
liver	ENTITY
triacylglycerol	ENTITY
abstractaims	ENTITY
hypothesis	ENTITY
type	ENTITY
diabetes	ENTITY
is	ENTITY
regarded	ENTITY
as	ENTITY
inevitably	ENTITY
progressive	ENTITY
with	ENTITY
irreversible	ENTITY
beta	ENTITY
cell	ENTITY
failure	O
.	O
the	O
hypothesis	O
was	O
tested	O
that	O
both	O
beta	ENTITY
cell	ENTITY
failure	O
and	O
insulin	ENTITY
resistance	ENTITY
can	O
be	O
reversed	O
by	O
dietary	O
restriction	O
of	O
energy	O
intake	O
.	O
check	O
out	O
the	O
following	O
links	O
below	O
.	O
over	O
medical	O
questions	O
email	O
contact	O
minuteschool	O
com	O
.	O
for	O
more	O
information	O
active	O
technology	O
solutions	O
pvt	O
ltd	O
.	O
is	O
an	O
educational	O
digital	O
content	O
provider	O
for	O
we	O
also	O
customise	O
the	O
content	O
as	O
per	O
your	O
requirement	O
for	O
companies	O
platform	O
providers	O
colleges	O
etc	O
.	O
active	O
driving	O
force	O
the	O
joy	O
of	O
happy	O
learning	O
is	O
what	O
makes	O
difference	O
from	O
other	O
digital	O
content	O
providers	O
.	O
we	O
consider	O
student	O
needs	O
lecturer	O
needs	O
and	O
college	O
needs	O
in	O
designing	O
the	O
animated	O
video	O
lectures	O
.	O
we	O
are	O
carrying	O
huge	O
digital	O
library	O
ready	O
to	O
use	O
.	O
human	O
endocrine	ENTITY
system	ENTITY
pancreas	ENTITY
pancreas	ENTITY
is	ENTITY
mixed	ENTITY
gland	ENTITY
portion	ENTITY
of	ENTITY
pancreas	ENTITY
acts	ENTITY
like	ENTITY
exocrine	ENTITY
gland	ENTITY
and	O
another	O
portion	O
acts	O
like	O
an	O
endocrine	ENTITY
gland	ENTITY
.	O
the	O
cells	ENTITY
of	ENTITY
endocrine	ENTITY
pancreas	ENTITY
are	O
called	O
islets	ENTITY
of	ENTITY
langerhangs	ENTITY
representing	ENTITY
to	ENTITY
of	ENTITY
pancreatic	ENTITY
tissue	ENTITY
.	O
they	O
secrete	O
hormones	ENTITY
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
insulin	ENTITY
the	ENTITY
hormone	ENTITY
is	ENTITY
produced	ENTITY
by	ENTITY
cells	ENTITY
of	ENTITY
islet	ENTITY
of	O
langerhangs	O
.	O
it	O
is	O
peptide	ENTITY
hormone	ENTITY
which	O
plays	O
major	O
role	O
in	O
the	O
regulation	O
of	O
glucose	ENTITY
homeostasis	ENTITY
.	O
insulin	ENTITY
promotes	ENTITY
the	ENTITY
conversion	ENTITY
of	ENTITY
glucose	ENTITY
to	ENTITY
glycogen	ENTITY
in	ENTITY
liver	ENTITY
and	O
muscle	O
that	O
is	O
stored	O
in	O
these	O
tissue	O
for	O
future	O
use	O
.	O
insulin	ENTITY
is	ENTITY
liberated	ENTITY
when	ENTITY
the	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
are	O
high	O
usually	O
when	O
food	O
is	O
digested	O
and	O
absorbed	O
.	O
if	O
sufficient	O
insulin	ENTITY
is	ENTITY
not	ENTITY
produced	ENTITY
glucose	ENTITY
level	ENTITY
in	ENTITY
blood	ENTITY
increases	O
and	O
it	O
is	O
excreted	O
through	O
urine	ENTITY
.	O
this	O
is	O
called	O
diabetes	ENTITY
mellitus	ENTITY
.	O
diabetes	ENTITY
is	ENTITY
identified	ENTITY
by	ENTITY
the	ENTITY
presence	ENTITY
of	ENTITY
sugar	ENTITY
in	ENTITY
urine	ENTITY
.	O
diabetic	ENTITY
patients	ENTITY
take	O
insulin	ENTITY
injections	ENTITY
regularly	O
.	O
insulin	ENTITY
also	ENTITY
affects	ENTITY
the	ENTITY
metabolism	ENTITY
of	ENTITY
fats	ENTITY
and	O
proteins	O
.	O
unattended	O
diabetis	O
results	O
in	O
wasting	O
of	O
body	O
tissue	O
reduced	O
healing	O
power	O
ketone	ENTITY
bodies	ENTITY
blurred	O
vision	O
and	O
kidney	ENTITY
problems	ENTITY
.	O
they	O
may	O
end	O
up	O
with	O
gangrene	ENTITY
and	ENTITY
coma	ENTITY
glucagon	ENTITY
is	ENTITY
peptide	ENTITY
hormone	ENTITY
secreted	O
by	O
cells	ENTITY
of	ENTITY
islets	ENTITY
of	ENTITY
langerhans	ENTITY
.	O
glucagon	ENTITY
acts	ENTITY
on	ENTITY
liver	ENTITY
cells	ENTITY
and	O
stimulates	O
glyconeolysis	ENTITY
resulting	ENTITY
in	ENTITY
an	ENTITY
increased	ENTITY
blood	ENTITY
sugar	ENTITY
hyperglycemia	ENTITY
.	O
this	O
hormone	ENTITY
stimulates	ENTITY
the	ENTITY
process	ENTITY
of	ENTITY
gluconeogenesis	ENTITY
which	ENTITY
also	ENTITY
contributes	ENTITY
to	ENTITY
hyperglycemia	ENTITY
.	O
glucagon	ENTITY
reduces	ENTITY
the	ENTITY
cellular	ENTITY
glucose	ENTITY
uptake	O
and	O
utilization	O
.	O
thus	O
glucagon	ENTITY
is	ENTITY
hyperglycemic	ENTITY
hormone	ENTITY
.	O
donate	O
here	O
aklectures	O
com	O
.	O
people	O
with	O
type	O
diabetes	ENTITY
may	ENTITY
develop	ENTITY
complications	ENTITY
from	ENTITY
long	ENTITY
term	ENTITY
use	ENTITY
of	ENTITY
insulin	ENTITY
and	ENTITY
develop	ENTITY
hypoglycemia	ENTITY
or	ENTITY
severe	ENTITY
low	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
now	O
researchers	O
have	O
developed	O
therapy	O
that	O
may	O
help	O
protect	O
type	O
diabetics	ENTITY
from	ENTITY
this	ENTITY
life	ENTITY
threatening	ENTITY
condition	ENTITY
.	O
alpha	O
and	O
beta	ENTITY
cells	ENTITY
are	O
involved	O
in	O
healthy	O
functioning	O
of	O
your	O
pancreas	ENTITY
and	ENTITY
in	ENTITY
regulating	ENTITY
insulin	ENTITY
levels	ENTITY
.	O
based	O
on	O
ocr	O
level	O
knowledge	O
.	O
here	O
try	O
to	O
explain	O
the	O
process	O
of	O
insulin	ENTITY
secretion	ENTITY
as	O
quickly	O
and	O
concisely	O
as	O
possible	O
.	O
this	O
is	O
based	O
on	O
the	O
ocr	O
scheme	O
of	O
work	O
and	O
is	O
designed	O
to	O
either	O
get	O
you	O
started	O
or	O
to	O
help	O
you	O
revise	O
.	O
fastest	O
explanation	O
of	O
beta	ENTITY
cell	ENTITY
function	ENTITY
in	O
the	O
islets	O
of	O
langerhans	O
.	O
this	O
whole	O
process	O
takes	O
place	O
in	O
the	O
pancreas	ENTITY
which	ENTITY
is	ENTITY
an	ENTITY
interesting	ENTITY
organ	ENTITY
as	ENTITY
it	ENTITY
serves	ENTITY
endocrine	ENTITY
and	ENTITY
exocrine	ENTITY
functions	ENTITY
.	O
exocrine	ENTITY
cells	ENTITY
secrete	O
proteins	O
usually	O
enzymes	ENTITY
into	ENTITY
ducts	ENTITY
.	O
endocrine	ENTITY
cells	ENTITY
secrete	O
hormones	ENTITY
directly	ENTITY
into	ENTITY
the	ENTITY
blood	ENTITY
.	O
demonstration	O
on	O
how	O
to	O
isolate	ENTITY
mouse	ENTITY
iselts	ENTITY
.	O
greg	O
szot	O
.	O
created	O
by	O
raja	O
narayan	O
.	O
watch	O
the	O
next	O
lesson	O
add	O
user	O
khanacademy	O
.	O
to	O
unlock	O
the	O
full	O
series	O
of	O
as	O
level	O
biology	O
videos	O
created	O
by	O
students	O
for	O
the	O
new	O
ocr	O
aqa	O
and	O
edexcel	O
specification	O
.	O
this	O
video	O
covers	O
the	O
gross	O
structure	ENTITY
of	ENTITY
the	ENTITY
pancreas	ENTITY
including	O
acini	ENTITY
islets	ENTITY
of	ENTITY
langerhans	ENTITY
and	ENTITY
its	ENTITY
constituent	ENTITY
alpha	ENTITY
and	ENTITY
beta	ENTITY
cells	ENTITY
discussing	O
its	O
exocrine	O
and	O
endocrine	ENTITY
functions	ENTITY
along	O
the	O
way	O
.	O
we	O
ll	O
then	O
look	O
at	O
the	O
mechanism	O
by	O
which	O
insulin	ENTITY
is	ENTITY
released	ENTITY
from	ENTITY
beta	ENTITY
cells	ENTITY
.	O
insulin	ENTITY
is	ENTITY
the	ENTITY
principal	ENTITY
hormone	ENTITY
that	ENTITY
regulates	ENTITY
the	ENTITY
uptake	ENTITY
of	ENTITY
glucose	ENTITY
from	ENTITY
the	ENTITY
blood	ENTITY
into	ENTITY
most	ENTITY
cells	ENTITY
of	O
the	O
body	O
especially	O
liver	ENTITY
muscle	ENTITY
and	O
adipose	ENTITY
tissue	ENTITY
.	O
therefore	O
deficiency	O
of	O
insulin	ENTITY
or	ENTITY
the	ENTITY
insensitivity	ENTITY
of	ENTITY
its	ENTITY
receptors	ENTITY
plays	ENTITY
central	ENTITY
role	ENTITY
in	ENTITY
all	ENTITY
forms	ENTITY
of	ENTITY
diabetes	ENTITY
mellitus	ENTITY
.	O
the	O
body	O
obtains	O
glucose	ENTITY
from	ENTITY
three	ENTITY
main	ENTITY
places	ENTITY
the	ENTITY
intestinal	ENTITY
absorption	ENTITY
of	ENTITY
food	ENTITY
the	ENTITY
breakdown	ENTITY
of	ENTITY
glycogen	ENTITY
the	ENTITY
storage	ENTITY
form	ENTITY
of	ENTITY
glucose	ENTITY
found	ENTITY
in	ENTITY
the	ENTITY
liver	ENTITY
and	ENTITY
gluconeogenesis	ENTITY
the	ENTITY
generation	ENTITY
of	ENTITY
glucose	ENTITY
from	ENTITY
non	ENTITY
carbohydrate	ENTITY
substrates	ENTITY
in	ENTITY
the	ENTITY
body	ENTITY
.	O
insulin	ENTITY
plays	ENTITY
critical	ENTITY
role	ENTITY
in	ENTITY
balancing	ENTITY
glucose	ENTITY
levels	ENTITY
in	O
the	O
body	O
.	O
insulin	ENTITY
can	ENTITY
inhibit	ENTITY
the	ENTITY
breakdown	ENTITY
of	ENTITY
glycogen	ENTITY
or	ENTITY
the	ENTITY
process	ENTITY
of	ENTITY
gluconeogenesis	ENTITY
it	ENTITY
can	ENTITY
stimulate	ENTITY
the	ENTITY
transport	ENTITY
of	ENTITY
glucose	ENTITY
into	ENTITY
fat	ENTITY
and	ENTITY
muscle	ENTITY
cells	ENTITY
and	O
it	O
can	O
stimulate	O
the	O
storage	O
of	O
glucose	ENTITY
in	ENTITY
the	ENTITY
form	ENTITY
of	ENTITY
glycogen	ENTITY
.	O
insulin	ENTITY
is	ENTITY
released	ENTITY
into	ENTITY
the	ENTITY
blood	ENTITY
by	ENTITY
beta	ENTITY
cells	ENTITY
cells	O
found	O
in	O
the	O
islets	O
of	O
langerhans	O
in	O
the	O
pancreas	ENTITY
in	ENTITY
response	ENTITY
to	ENTITY
rising	ENTITY
levels	ENTITY
of	ENTITY
blood	ENTITY
glucose	ENTITY
typically	O
after	O
eating	O
.	O
insulin	ENTITY
is	ENTITY
used	ENTITY
by	ENTITY
about	ENTITY
two	ENTITY
thirds	ENTITY
of	ENTITY
the	ENTITY
body	ENTITY
cells	ENTITY
to	ENTITY
absorb	ENTITY
glucose	ENTITY
from	ENTITY
the	ENTITY
blood	ENTITY
for	O
use	O
as	O
fuel	O
for	O
conversion	O
to	O
other	O
needed	O
molecules	O
or	O
for	O
storage	O
.	O
lower	O
glucose	ENTITY
levels	ENTITY
result	O
in	O
decreased	O
insulin	ENTITY
release	ENTITY
from	ENTITY
the	ENTITY
beta	ENTITY
cells	ENTITY
and	O
in	O
the	O
breakdown	O
of	O
glycogen	ENTITY
to	ENTITY
glucose	ENTITY
.	O
this	O
process	O
is	O
mainly	O
controlled	O
by	O
the	O
hormone	ENTITY
glucagon	ENTITY
which	ENTITY
acts	ENTITY
in	ENTITY
the	ENTITY
opposite	ENTITY
manner	ENTITY
to	ENTITY
insulin	ENTITY
.	O
if	O
the	O
amount	O
of	O
insulin	ENTITY
available	ENTITY
is	ENTITY
insufficient	ENTITY
if	ENTITY
cells	ENTITY
respond	ENTITY
poorly	ENTITY
to	ENTITY
the	ENTITY
effects	ENTITY
of	ENTITY
insulin	ENTITY
insulin	ENTITY
insensitivity	ENTITY
or	O
insulin	ENTITY
resistance	ENTITY
or	O
if	O
the	O
insulin	ENTITY
itself	ENTITY
is	ENTITY
defective	ENTITY
then	ENTITY
glucose	ENTITY
will	ENTITY
not	ENTITY
be	ENTITY
absorbed	ENTITY
properly	ENTITY
by	ENTITY
the	ENTITY
body	ENTITY
cells	ENTITY
that	O
require	O
it	O
and	O
it	O
will	O
not	O
be	O
stored	O
appropriately	O
in	O
the	O
liver	ENTITY
and	ENTITY
muscles	ENTITY
.	O
the	O
net	O
effect	O
is	O
persistently	O
high	ENTITY
levels	ENTITY
of	ENTITY
blood	ENTITY
glucose	ENTITY
poor	ENTITY
protein	ENTITY
synthesis	ENTITY
and	O
other	O
metabolic	ENTITY
derangements	ENTITY
such	O
as	O
acidosis	ENTITY
.	O
when	O
the	O
glucose	ENTITY
concentration	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
remains	O
high	O
over	O
time	O
the	O
kidneys	ENTITY
will	ENTITY
reach	ENTITY
threshold	ENTITY
of	ENTITY
reabsorption	ENTITY
and	ENTITY
glucose	ENTITY
will	ENTITY
be	ENTITY
excreted	ENTITY
in	ENTITY
the	ENTITY
urine	ENTITY
glycosuria	ENTITY
this	O
increases	O
the	O
osmotic	ENTITY
pressure	ENTITY
of	ENTITY
the	ENTITY
urine	ENTITY
and	O
inhibits	O
reabsorption	O
of	O
water	O
by	O
the	O
kidney	ENTITY
resulting	ENTITY
in	ENTITY
increased	ENTITY
urine	ENTITY
production	ENTITY
polyuria	ENTITY
and	ENTITY
increased	ENTITY
fluid	ENTITY
loss	ENTITY
.	O
lost	O
blood	ENTITY
volume	ENTITY
will	O
be	O
replaced	O
osmotically	O
from	O
water	O
held	O
in	O
body	O
cells	O
and	O
other	O
body	ENTITY
compartments	ENTITY
causing	O
dehydration	ENTITY
and	ENTITY
increased	ENTITY
thirst	ENTITY
polydipsia	ENTITY
.	O
source	O
wikipedia	O
.	O
the	O
pancreas	ENTITY
the	ENTITY
pancreas	ENTITY
is	ENTITY
shown	ENTITY
here	ENTITY
with	ENTITY
the	ENTITY
foreground	ENTITY
highly	ENTITY
magnified	ENTITY
to	ENTITY
reveal	ENTITY
its	ENTITY
inner	ENTITY
anatomy	ENTITY
.	O
ninety	O
nine	O
percent	O
of	O
pancreatic	ENTITY
tissue	ENTITY
is	O
composed	O
of	O
acinar	ENTITY
glands	ENTITY
which	O
secrete	O
an	O
alkaline	O
digestive	O
juice	O
into	O
the	O
duodenum	O
via	O
the	O
pancreatic	ENTITY
duct	ENTITY
to	O
help	O
digest	O
food	O
.	O
the	O
endocrine	ENTITY
areas	ENTITY
of	ENTITY
the	ENTITY
pancreas	ENTITY
known	O
as	O
the	O
islets	O
of	O
langerhans	O
are	O
composed	O
of	O
two	O
major	O
types	O
of	O
cell	O
.	O
the	O
alpha	ENTITY
cells	ENTITY
secrete	O
the	O
hormone	ENTITY
glucagon	ENTITY
and	ENTITY
the	ENTITY
beta	ENTITY
cells	ENTITY
secrete	O
insulin	ENTITY
into	ENTITY
the	ENTITY
bloodstream	ENTITY
.	O
these	O
hormones	ENTITY
work	ENTITY
in	ENTITY
opposition	ENTITY
to	ENTITY
control	ENTITY
the	ENTITY
blood	ENTITY
glucose	ENTITY
level	ENTITY
.	O
insulin	ENTITY
promotes	ENTITY
the	ENTITY
uptake	ENTITY
and	ENTITY
usage	ENTITY
of	ENTITY
glucose	ENTITY
in	ENTITY
the	ENTITY
tissues	ENTITY
particularly	ENTITY
skeletal	ENTITY
muscle	ENTITY
and	O
fat	ENTITY
and	ENTITY
reduces	ENTITY
glucose	ENTITY
production	ENTITY
in	O
the	O
liver	ENTITY
.	O
glucagon	ENTITY
has	ENTITY
an	ENTITY
anti	ENTITY
insulin	ENTITY
effect	ENTITY
in	O
the	O
liver	ENTITY
increasing	ENTITY
glucose	ENTITY
release	ENTITY
.	O
the	O
anatomy	ENTITY
of	ENTITY
the	ENTITY
pancreas	ENTITY
also	ENTITY
includes	ENTITY
the	ENTITY
ampulla	ENTITY
of	ENTITY
the	ENTITY
common	ENTITY
bile	ENTITY
duct	ENTITY
the	O
pancreatic	ENTITY
duct	ENTITY
which	O
carries	O
digestive	ENTITY
juice	ENTITY
containing	ENTITY
enzymes	ENTITY
to	O
the	O
duodenum	O
the	O
acini	ENTITY
the	ENTITY
exocrine	ENTITY
portions	ENTITY
of	ENTITY
the	ENTITY
pancreas	ENTITY
which	O
secrete	O
digestive	O
juice	O
into	O
the	O
pancreas	O
the	O
splenic	ENTITY
arteries	ENTITY
which	O
conduct	O
oxygenated	O
blood	ENTITY
into	ENTITY
the	ENTITY
pancreas	ENTITY
and	ENTITY
the	ENTITY
mesenteric	ENTITY
veins	ENTITY
which	O
carry	O
deoxygenated	ENTITY
blood	ENTITY
containing	ENTITY
insulin	ENTITY
and	O
glucagon	ENTITY
away	ENTITY
from	ENTITY
the	ENTITY
pancreas	ENTITY
.	O
developed	O
at	O
loughborough	O
university	O
in	O
partnership	O
with	O
the	O
institute	O
of	O
cellular	ENTITY
medicine	ENTITY
at	ENTITY
newcastle	ENTITY
university	ENTITY
the	ENTITY
technology	ENTITY
will	ENTITY
provide	ENTITY
optimal	ENTITY
storage	ENTITY
and	ENTITY
transportation	ENTITY
conditions	ENTITY
for	ENTITY
donated	ENTITY
cells	ENTITY
as	ENTITY
well	ENTITY
as	ENTITY
automated	ENTITY
delivery	ENTITY
.	O
original	O
article	O
pancreatic	ENTITY
beta	ENTITY
cell	ENTITY
dedifferentiation	O
as	O
mechanism	ENTITY
of	ENTITY
diabetic	ENTITY
beta	ENTITY
cell	ENTITY
failure	O
.	O
talchai	O
et	O
al	O
.	O
cell	O
.	O
how	O
pancreatic	ENTITY
beta	ENTITY
cells	ENTITY
release	O
insulin	ENTITY
.	O
three	O
important	O
transporters	O
on	O
the	O
pancreatic	ENTITY
beta	ENTITY
cell	ENTITY
that	O
participate	O
in	O
the	O
regulation	O
of	O
insulin	ENTITY
secretion	ENTITY
glut	ENTITY
glucose	ENTITY
transporter	ENTITY
potassium	ENTITY
channel	ENTITY
voltage	O
gated	O
calcium	O
channel	O
.	O
the	O
glut	ENTITY
transporter	ENTITY
has	O
high	O
km	O
value	O
and	O
therefore	O
sensitive	O
only	O
when	O
there	O
high	O
level	O
of	O
glucose	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
.	O
when	O
the	O
glucose	ENTITY
concentration	ENTITY
in	O
the	O
blood	ENTITY
is	ENTITY
high	ENTITY
glut	ENTITY
transporter	ENTITY
on	O
the	O
beta	ENTITY
cells	ENTITY
opens	O
up	O
and	O
facilitated	O
the	O
uptake	O
of	O
glucose	ENTITY
from	ENTITY
the	ENTITY
blood	ENTITY
into	ENTITY
the	ENTITY
beta	ENTITY
cells	ENTITY
.	O
inside	O
the	O
beta	ENTITY
cells	ENTITY
glucose	ENTITY
will	O
undergoes	O
glycolysis	ENTITY
and	ENTITY
increase	ENTITY
the	ENTITY
production	ENTITY
of	ENTITY
atp	ENTITY
inside	ENTITY
the	ENTITY
beta	ENTITY
cell	ENTITY
.	O
increase	O
level	O
of	O
atp	ENTITY
inside	ENTITY
the	ENTITY
cell	ENTITY
causes	ENTITY
the	ENTITY
potassium	ENTITY
channel	ENTITY
to	O
closes	O
.	O
normally	O
the	O
potassium	ENTITY
channel	ENTITY
in	O
the	O
beta	ENTITY
cells	ENTITY
pumps	ENTITY
potassium	ENTITY
from	ENTITY
inside	ENTITY
the	ENTITY
cell	ENTITY
out	ENTITY
to	ENTITY
the	ENTITY
extracellular	ENTITY
compartment	ENTITY
.	O
because	O
increases	O
in	O
atp	ENTITY
closes	ENTITY
the	ENTITY
potassium	ENTITY
pump	ENTITY
potassium	ENTITY
will	ENTITY
build	ENTITY
up	ENTITY
inside	ENTITY
the	ENTITY
cell	ENTITY
.	O
the	O
build	O
up	O
of	O
positive	O
charge	O
potassium	ENTITY
causes	ENTITY
the	ENTITY
membrane	ENTITY
to	ENTITY
depolarize	ENTITY
becomes	ENTITY
less	ENTITY
negative	ENTITY
this	ENTITY
depolarization	ENTITY
opens	ENTITY
up	ENTITY
the	ENTITY
voltage	ENTITY
gated	ENTITY
calcium	ENTITY
channel	ENTITY
.	O
once	O
the	O
voltage	ENTITY
gated	ENTITY
calcium	ENTITY
channel	ENTITY
opens	O
calcium	ENTITY
rushs	ENTITY
into	ENTITY
the	ENTITY
beta	ENTITY
cell	ENTITY
.	O
increase	O
intracellular	O
calcium	ENTITY
serves	ENTITY
as	ENTITY
second	ENTITY
messenger	ENTITY
to	ENTITY
stimulate	ENTITY
the	ENTITY
release	ENTITY
of	ENTITY
insulin	ENTITY
from	ENTITY
the	ENTITY
beta	ENTITY
cell	ENTITY
.	O
clinical	O
correlation	O
sulfonylureas	ENTITY
mechanism	ENTITY
of	ENTITY
action	ENTITY
function	ENTITY
similar	ENTITY
to	ENTITY
an	ENTITY
increase	ENTITY
in	ENTITY
atp	ENTITY
within	ENTITY
the	ENTITY
pancreatic	ENTITY
beta	ENTITY
cells	ENTITY
in	O
causes	O
the	O
potassium	ENTITY
channel	ENTITY
to	O
close	O
increase	O
intracellular	ENTITY
potassium	ENTITY
concentration	O
depolarization	O
of	O
the	O
plasma	ENTITY
membrane	ENTITY
this	O
opens	O
the	O
voltage	ENTITY
gated	ENTITY
calcium	ENTITY
channel	ENTITY
increase	O
in	O
the	O
influx	ENTITY
of	ENTITY
calcium	ENTITY
into	O
the	O
cell	O
calcium	ENTITY
then	ENTITY
acts	ENTITY
as	ENTITY
second	ENTITY
messenger	ENTITY
that	ENTITY
will	ENTITY
stimulate	ENTITY
the	ENTITY
release	ENTITY
of	ENTITY
insulin	ENTITY
from	ENTITY
the	ENTITY
pancreatic	ENTITY
beta	ENTITY
cells	ENTITY
.	O
neonatal	ENTITY
diabetes	ENTITY
there	O
is	O
mutation	O
in	O
the	O
kcnj	O
gene	O
this	O
gene	O
encodes	O
for	O
the	O
subunit	O
of	O
the	O
potassium	ENTITY
channel	ENTITY
.	O
the	O
mutation	O
keeps	O
the	O
channel	ENTITY
opens	ENTITY
therefore	ENTITY
more	ENTITY
potassium	ENTITY
is	ENTITY
efflux	ENTITY
from	ENTITY
the	ENTITY
cell	ENTITY
and	ENTITY
unable	ENTITY
to	ENTITY
accumulate	ENTITY
within	ENTITY
the	ENTITY
beta	ENTITY
pancreatic	ENTITY
cells	ENTITY
.	O
beta	ENTITY
pancreatic	ENTITY
cell	ENTITY
does	O
not	O
depolarize	O
and	O
does	O
not	O
stimulate	O
voltage	ENTITY
gated	ENTITY
calcium	ENTITY
channel	ENTITY
to	O
open	O
therefore	O
it	O
disrupt	O
the	O
release	O
of	O
insulin	ENTITY
from	ENTITY
pancreas	ENTITY
.	O
tried	O
my	O
best	O
to	O
explain	O
these	O
concepts	O
to	O
the	O
best	O
of	O
my	O
knowledge	O
and	O
made	O
it	O
as	O
simple	O
as	O
possible	O
.	O
hope	O
that	O
you	O
might	O
find	O
them	O
helpful	O
while	O
you	O
are	O
reviewing	O
your	O
materials	O
for	O
your	O
steps	O
.	O
good	O
luck	O
to	O
you	O
all	O
.	O
disclaimer	O
the	O
author	O
disclaims	O
any	O
liability	O
loss	O
injury	O
or	O
damage	O
incurred	O
as	O
consequence	O
directly	O
or	O
indirectly	O
of	O
the	O
use	O
and	O
application	O
of	O
any	O
of	O
the	O
content	O
and	O
material	O
contained	O
in	O
this	O
video	O
.	O
although	O
the	O
information	O
in	O
this	O
video	O
has	O
been	O
carefully	O
reviewed	O
for	O
correctness	O
the	O
author	O
cannot	O
accept	O
any	O
responsibility	O
for	O
any	O
errors	O
or	O
omissions	O
that	O
may	O
be	O
made	O
.	O
the	O
author	O
makes	O
no	O
warranty	O
.	O
express	O
or	O
implied	O
.	O
as	O
to	O
the	O
completeness	O
currency	O
or	O
accuracy	O
of	O
the	O
contents	O
of	O
this	O
video	O
.	O
the	O
information	O
contained	O
in	O
this	O
video	O
should	O
not	O
be	O
construed	O
as	O
specific	O
instructions	O
for	O
individual	O
patients	O
manufacturer	O
product	O
information	O
and	O
package	O
inserts	O
should	O
be	O
reviewed	O
for	O
current	O
information	O
.	O
including	O
contraindications	O
.	O
dosages	O
.	O
and	O
precautions	O
.	O
usmleaid	O
this	O
is	O
video	O
is	O
made	O
and	O
uploaded	O
exclusively	O
for	O
usmleaid	O
any	O
reuploading	O
is	O
prohibited	O
and	O
will	O
be	O
reported	O
to	O
youtube	O
as	O
copyright	O
infringement	O
.	O
get	O
the	O
new	O
endocrine	ENTITY
app	ENTITY
with	ENTITY
videos	ENTITY
on	ENTITY
the	ENTITY
go	ENTITY
for	ENTITY
apple	ENTITY
and	ENTITY
andoird	ENTITY
devices	ENTITY
.	O
itunes	O
hladhghjcg	O
feature	O
youtu	O
be	O
or	O
search	O
for	O
endocrine	ENTITY
or	ENTITY
profroofs	ENTITY
or	ENTITY
john	ENTITY
roufaiel	ENTITY
in	ENTITY
the	ENTITY
medical	ENTITY
category	ENTITY
.	O
this	O
video	O
briefly	O
describes	O
the	O
endocrine	ENTITY
portion	ENTITY
of	ENTITY
the	ENTITY
pancreas	ENTITY
.	O
it	O
describes	O
that	O
the	O
pancreas	ENTITY
regulates	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
and	O
the	O
roles	O
of	O
the	O
hormones	ENTITY
of	ENTITY
the	ENTITY
alpha	ENTITY
beta	ENTITY
and	ENTITY
delta	ENTITY
cells	ENTITY
of	ENTITY
the	ENTITY
islet	ENTITY
of	ENTITY
langerhans	ENTITY
.	O
find	O
my	O
website	O
at	O
www	O
profroofs	O
com	O
or	O
email	O
me	O
at	O
profroofs	O
gmail	O
com	O
.	O
insulin	ENTITY
the	ENTITY
molecule	ENTITY
regulators	ENTITY
of	ENTITY
secretion	ENTITY
and	ENTITY
beta	ENTITY
cell	ENTITY
secretion	O
mechanism	O
.	O
this	O
video	O
shows	O
the	O
procedure	ENTITY
of	ENTITY
islet	ENTITY
cell	ENTITY
transplantation	ENTITY
for	O
the	O
treatment	O
of	O
diabetes	ENTITY
.	O
the	O
purified	O
islet	ENTITY
cells	ENTITY
are	O
infused	O
into	O
the	O
portal	ENTITY
vein	ENTITY
via	O
percutaneous	ENTITY
approach	ENTITY
under	ENTITY
local	ENTITY
anaesthetic	ENTITY
.	O
the	O
endocrine	ENTITY
pancreas	ENTITY
hormones	ENTITY
such	ENTITY
as	ENTITY
insulin	ENTITY
glucagon	ENTITY
and	O
somatostain	ENTITY
physiology	ENTITY
and	ENTITY
pathophysiology	ENTITY
explained	ENTITY
for	ENTITY
usmle	ENTITY
step	ENTITY
is	ENTITY
made	ENTITY
up	ENTITY
of	ENTITY
types	ENTITY
of	ENTITY
cells	ENTITY
.	O
alpha	ENTITY
cells	ENTITY
secrete	O
glucagon	ENTITY
beta	ENTITY
cells	ENTITY
secrete	O
insulin	ENTITY
and	ENTITY
delta	ENTITY
cells	ENTITY
secrete	O
somatostatin	ENTITY
.	O
insulin	ENTITY
generally	ENTITY
speaking	ENTITY
insulin	ENTITY
is	ENTITY
designed	ENTITY
for	ENTITY
energy	ENTITY
abundance	ENTITY
.	O
so	O
your	O
body	O
prefers	O
to	O
use	O
glucose	ENTITY
rather	ENTITY
than	ENTITY
fats	ENTITY
for	ENTITY
energy	ENTITY
.	O
the	O
body	O
will	O
use	O
ch	ENTITY
instead	ENTITY
of	ENTITY
fat	ENTITY
and	ENTITY
glycogen	ENTITY
.	O
and	O
use	O
amino	ENTITY
acids	ENTITY
for	ENTITY
protein	ENTITY
synthesis	ENTITY
.	O
glucose	ENTITY
muscle	ENTITY
will	ENTITY
have	ENTITY
increase	ENTITY
uptake	ENTITY
to	ENTITY
make	ENTITY
glycogen	ENTITY
in	ENTITY
the	ENTITY
muscle	ENTITY
.	O
in	O
the	O
liver	ENTITY
it	ENTITY
will	ENTITY
be	ENTITY
used	ENTITY
for	ENTITY
uptake	ENTITY
to	ENTITY
use	ENTITY
for	ENTITY
glycogen	ENTITY
and	ENTITY
fat	ENTITY
.	O
brain	ENTITY
will	ENTITY
only	ENTITY
use	ENTITY
glucose	ENTITY
and	ENTITY
this	ENTITY
is	ENTITY
independent	ENTITY
of	ENTITY
insulin	ENTITY
.	O
fat	ENTITY
increase	ENTITY
fat	ENTITY
storage	ENTITY
.	O
increase	O
citrate	ENTITY
and	ENTITY
isocitrate	ENTITY
.	O
increase	O
acetylcoa	ENTITY
carboxylase	ENTITY
.	O
this	O
increase	O
malonyl	ENTITY
coa	ENTITY
which	O
will	O
increase	O
fat	ENTITY
synthesis	ENTITY
.	O
this	O
will	O
increase	O
lipoprotein	ENTITY
lilpase	ENTITY
and	O
decrease	O
lipase	ENTITY
.	O
in	O
deficiency	O
you	O
prefer	O
fats	ENTITY
so	ENTITY
you	ENTITY
increase	ENTITY
lipoprotein	ENTITY
lipase	ENTITY
which	O
increase	O
free	ENTITY
fatty	ENTITY
acids	ENTITY
.	O
this	O
will	O
become	O
phospholipids	ENTITY
and	ENTITY
cholesterol	ENTITY
leading	ENTITY
to	ENTITY
heart	ENTITY
disease	ENTITY
.	O
when	O
there	O
is	O
free	ENTITY
fatty	ENTITY
acids	ENTITY
without	O
insulin	ENTITY
this	ENTITY
will	ENTITY
increase	ENTITY
ketone	ENTITY
bodies	ENTITY
acetoacetic	ENTITY
acid	ENTITY
and	O
hydroxyacetate	ENTITY
.	O
protein	O
increase	O
synthesis	O
and	O
storage	O
of	O
protein	O
.	O
increase	O
aa	O
and	O
increase	O
protein	ENTITY
synthesis	ENTITY
.	O
in	O
deficiency	O
there	O
is	O
increase	O
serum	O
aa	O
and	O
increase	O
urea	ENTITY
in	ENTITY
urine	ENTITY
.	O
it	O
also	O
increase	O
effect	O
on	O
growth	ENTITY
hormone	ENTITY
.	O
mechanism	O
of	O
action	O
of	O
beta	ENTITY
cell	ENTITY
when	O
glucose	ENTITY
comes	ENTITY
in	ENTITY
this	ENTITY
increases	ENTITY
atp	ENTITY
and	ENTITY
blocks	ENTITY
potassium	ENTITY
channel	ENTITY
.	O
this	O
depolarizes	O
and	O
causes	O
opening	O
of	O
calcium	ENTITY
channel	ENTITY
.	O
regulated	O
by	O
glucose	ENTITY
amino	ENTITY
acids	ENTITY
and	ENTITY
git	ENTITY
hormones	ENTITY
.	O
glucagon	ENTITY
this	ENTITY
hormone	ENTITY
is	ENTITY
expressed	ENTITY
when	ENTITY
glucose	ENTITY
is	ENTITY
low	ENTITY
.	O
therefore	O
it	O
will	O
increase	O
gluconeogenesis	ENTITY
by	ENTITY
converting	ENTITY
amino	ENTITY
acids	ENTITY
into	O
glucose	ENTITY
and	ENTITY
converted	ENTITY
fats	ENTITY
into	ENTITY
glucose	ENTITY
.	O
increase	O
camp	ENTITY
which	ENTITY
will	ENTITY
increase	ENTITY
phorphokinase	ENTITY
which	ENTITY
will	ENTITY
increase	ENTITY
phorphorylase	ENTITY
and	ENTITY
increase	ENTITY
glucose	ENTITY
phosphate	ENTITY
.	O
only	O
small	O
amount	O
of	O
glucose	ENTITY
is	ENTITY
necessary	ENTITY
to	ENTITY
have	ENTITY
greater	ENTITY
effects	ENTITY
because	ENTITY
of	ENTITY
amplification	ENTITY
.	O
at	O
really	O
high	O
concentrations	O
it	O
can	O
increase	O
heart	O
contraction	O
increase	O
blood	ENTITY
flow	ENTITY
to	O
organs	O
increase	O
bile	O
secretion	O
an	O
block	O
gastric	ENTITY
acid	ENTITY
.	O
somatostatin	ENTITY
regulated	ENTITY
by	ENTITY
high	ENTITY
glucose	ENTITY
amino	ENTITY
acids	ENTITY
fatty	ENTITY
acids	ENTITY
and	O
git	O
hormones	ENTITY
.	O
effects	O
of	O
somatostatin	ENTITY
decrease	ENTITY
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
.	O
decreases	O
motility	O
of	O
duodenum	ENTITY
stomach	ENTITY
and	O
gallbladder	ENTITY
.	O
decreases	O
secretion	O
and	O
absorption	O
in	O
git	O
.	O
understanding	O
how	O
beta	ENTITY
cells	ENTITY
first	O
form	O
in	O
the	O
developing	O
embryo	ENTITY
is	ENTITY
providing	ENTITY
scientists	ENTITY
with	ENTITY
the	ENTITY
know	ENTITY
how	ENTITY
to	ENTITY
make	ENTITY
these	ENTITY
cells	ENTITY
in	ENTITY
the	ENTITY
lab	ENTITY
.	O
one	O
page	O
summary	O
of	O
the	O
endocrine	ENTITY
functions	ENTITY
of	O
the	O
pancreas	ENTITY
you	ENTITY
can	ENTITY
support	ENTITY
the	ENTITY
work	ENTITY
of	ENTITY
campbellteaching	ENTITY
at	ENTITY
no	ENTITY
cost	ENTITY
whatsoever	ENTITY
to	ENTITY
yourself	ENTITY
if	ENTITY
you	ENTITY
use	ENTITY
the	ENTITY
link	ENTITY
below	ENTITY
as	ENTITY
your	ENTITY
bookmark	ENTITY
to	ENTITY
access	ENTITY
amazon	ENTITY
.	O
thank	O
you	O
.	O
if	O
in	O
the	O
us	O
use	O
this	O
link	O
.	O
how	O
new	O
research	O
in	O
type	O
diabetes	ENTITY
can	ENTITY
improve	ENTITY
patient	ENTITY
care	ENTITY
.	O
beta	ENTITY
cells	ENTITY
in	O
diabetes	ENTITY
seeks	ENTITY
to	ENTITY
advance	ENTITY
clinical	ENTITY
care	ENTITY
based	ENTITY
on	ENTITY
current	ENTITY
knowledge	ENTITY
about	ENTITY
the	ENTITY
pathophysiology	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
watch	O
short	O
video	O
on	O
how	O
to	O
target	O
beta	ENTITY
cell	ENTITY
function	ENTITY
early	O
in	O
the	O
course	O
of	O
therapy	O
.	O
in	O
this	O
lesson	O
you	O
will	O
learn	O
how	O
these	O
hormones	ENTITY
regulate	ENTITY
as	ENTITY
the	ENTITY
food	ENTITY
is	ENTITY
digested	ENTITY
and	ENTITY
nutrient	ENTITY
levels	ENTITY
in	ENTITY
blood	ENTITY
rise	ENTITY
pancreas	ENTITY
produces	ENTITY
insulin	ENTITY
to	ENTITY
help	ENTITY
body	ENTITY
store	ENTITY
glucose	ENTITY
energy	ENTITY
away	ENTITY
.	O
pancreas	ENTITY
and	ENTITY
insulin	ENTITY
mydr	ENTITY
.	O
hormone	ENTITY
producing	ENTITY
an	ENTITY
alternative	ENTITY
source	ENTITY
of	ENTITY
beta	ENTITY
cells	ENTITY
such	O
insulin	ENTITY
producing	ENTITY
cells	ENTITY
derived	O
from	O
adult	ENTITY
stem	ENTITY
or	ENTITY
progenitor	ENTITY
may	O
enzymes	ENTITY
digestive	ENTITY
juices	ENTITY
are	ENTITY
secreted	ENTITY
by	ENTITY
the	ENTITY
pancreas	ENTITY
into	ENTITY
also	ENTITY
produces	ENTITY
and	ENTITY
secretes	ENTITY
it	ENTITY
is	ENTITY
produced	ENTITY
in	ENTITY
.	O
the	O
pancreas	ENTITY
detects	ENTITY
this	ENTITY
rise	ENTITY
in	ENTITY
blood	ENTITY
glucose	ENTITY
and	O
starts	O
to	O
secrete	O
insulin	ENTITY
dec	ENTITY
the	ENTITY
is	ENTITY
located	ENTITY
upper	ENTITY
abdomen	ENTITY
behind	O
stomach	O
.	O
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
how	ENTITY
do	ENTITY
they	ENTITY
work	ENTITY
.	O
healthline	O
.	O
functioning	O
as	O
an	O
endocrine	ENTITY
gland	ENTITY
the	O
pancreas	ENTITY
secretes	ENTITY
hormones	ENTITY
insulin	ENTITY
.	O
facts	O
about	O
diabetes	ENTITY
and	ENTITY
insulin	ENTITY
nobelprize	ENTITY
.	O
the	O
insulin	ENTITY
tells	ENTITY
cells	ENTITY
throughout	ENTITY
your	ENTITY
body	ENTITY
to	ENTITY
take	ENTITY
in	ENTITY
glucose	ENTITY
from	ENTITY
may	ENTITY
it	ENTITY
can	ENTITY
also	ENTITY
mean	ENTITY
that	ENTITY
pancreas	ENTITY
is	ENTITY
still	ENTITY
producing	ENTITY
insulin	ENTITY
but	ENTITY
it	ENTITY
just	ENTITY
not	ENTITY
enough	ENTITY
accomplish	ENTITY
the	ENTITY
job	ENTITY
.	O
it	O
regulates	O
the	O
metabolism	ENTITY
of	ENTITY
carbohydrates	ENTITY
fats	ENTITY
and	O
protein	ENTITY
by	ENTITY
promoting	ENTITY
beta	ENTITY
cells	ENTITY
are	O
type	O
cell	O
found	O
in	O
pancreatic	ENTITY
islets	ENTITY
pancreas	ENTITY
.	O
these	O
two	O
glucagon	ENTITY
and	ENTITY
insulin	ENTITY
are	ENTITY
the	ENTITY
primary	ENTITY
hormones	ENTITY
both	ENTITY
produced	ENTITY
by	ENTITY
pancreas	ENTITY
that	ENTITY
stimulate	ENTITY
or	ENTITY
depress	ENTITY
level	ENTITY
of	ENTITY
sugar	ENTITY
glucose	ENTITY
in	ENTITY
blood	ENTITY
pancreas	ENTITY
mydr	O
.	O
to	O
be	O
more	O
specific	O
it	O
produced	O
by	O
the	O
beta	ENTITY
cells	ENTITY
in	O
islets	ENTITY
of	ENTITY
langerhans	ENTITY
pancreas	ENTITY
.	O
the	O
pancreatic	ENTITY
islets	ENTITY
or	O
of	O
langerhans	O
are	O
the	O
regions	O
pancreas	ENTITY
that	ENTITY
contain	ENTITY
its	ENTITY
endocrine	ENTITY
pancreas	ENTITY
functions	O
anatomy	ENTITY
insulin	ENTITY
production	ENTITY
video	ENTITY
you	ENTITY
your	ENTITY
hormones	ENTITY
glucose	ENTITY
pancreas	ENTITY
function	ENTITY
diabetes	ENTITY
basics	ENTITY
wikipediapancreatic	ENTITY
islets	ENTITY
wikipedia	ENTITY
.	O
it	O
plays	O
these	O
islet	ENTITY
cells	ENTITY
produce	O
insulin	ENTITY
glucagon	ENTITY
and	ENTITY
other	ENTITY
hormones	ENTITY
as	ENTITY
more	ENTITY
beta	ENTITY
get	ENTITY
killed	ENTITY
off	ENTITY
the	ENTITY
pancreas	ENTITY
struggles	ENTITY
to	ENTITY
enough	ENTITY
insulin	ENTITY
keep	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
down	ENTITY
symptoms	O
of	O
diabetes	ENTITY
begin	ENTITY
is	ENTITY
synthesized	ENTITY
in	ENTITY
significant	ENTITY
quantities	ENTITY
only	ENTITY
.	O
when	O
we	O
eat	O
glucose	ENTITY
levels	ENTITY
nov	O
this	O
increase	O
in	O
blood	O
signals	O
your	O
pancreas	ENTITY
to	ENTITY
produce	ENTITY
insulin	ENTITY
.	O
how	O
does	O
the	O
pancreas	ENTITY
work	ENTITY
.	O
national	O
library	O
of	O
medicine	O
and	O
diabetes	ENTITY
role	ENTITY
insulin	ENTITY
.	O
what	O
is	O
insulin	ENTITY
.	O
important	O
hormone	ENTITY
allows	ENTITY
your	ENTITY
body	ENTITY
to	ENTITY
use	ENTITY
sugar	ENTITY
pancreas	ENTITY
and	ENTITY
insulin	ENTITY
mydr	ENTITY
.	O
insulin	ENTITY
synthesis	ENTITY
and	ENTITY
secretion	ENTITY
vivo	ENTITY
.	O
an	O
overview	O
of	O
the	O
pancreas	ENTITY
understanding	ENTITY
insulin	ENTITY
and	ENTITY
diabetes	ENTITY
endocrineweb	ENTITY
endocrinology	ENTITY
url	ENTITY
.	O
webcache	O
.	O
pancreas	O
functions	O
and	O
possible	O
problems	O
medical	O
news	O
today	O
.	O
after	O
you	O
eat	O
meal	O
any	O
carbohydrates	ENTITY
you	ENTITY
ve	ENTITY
eaten	ENTITY
are	ENTITY
broken	ENTITY
down	ENTITY
into	ENTITY
glucose	ENTITY
and	ENTITY
passed	ENTITY
the	ENTITY
bloodstream	ENTITY
.	O
diabetes	ENTITY
and	ENTITY
your	ENTITY
pancreas	ENTITY
what	ENTITY
you	ENTITY
should	ENTITY
know	ENTITY
healthlinethe	ENTITY
endocrine	ENTITY
the	ENTITY
its	ENTITY
role	ENTITY
in	ENTITY
sugar	ENTITY
metabolism	ENTITY
.	O
insulin	ENTITY
is	ENTITY
produced	ENTITY
by	ENTITY
the	ENTITY
beta	ENTITY
cells	ENTITY
of	ENTITY
pancreas	ENTITY
its	O
endocrine	ENTITY
function	ENTITY
involves	O
secretion	O
insulin	ENTITY
produced	ENTITY
cells	ENTITY
and	O
glucagon	ENTITY
alpha	ENTITY
within	ENTITY
pancreatic	ENTITY
islets	ENTITY
.	O
most	O
of	O
the	O
time	O
type	O
diabetes	ENTITY
nucleic	ENTITY
acids	ENTITY
in	O
food	O
.	O
between	O
meals	O
apr	ENTITY
diabetes	ENTITY
information	ENTITY
about	ENTITY
glucose	ENTITY
insulin	ENTITY
and	O
pancreas	ENTITY
function	ENTITY
in	ENTITY
the	ENTITY
liver	ENTITY
temporarily	ENTITY
shuts	ENTITY
down	ENTITY
its	ENTITY
production	ENTITY
of	ENTITY
insulin	ENTITY
is	ENTITY
peptide	ENTITY
hormone	ENTITY
produced	O
by	O
beta	ENTITY
cells	ENTITY
pancreatic	ENTITY
islets	ENTITY
.	O
the	O
insulin	ENTITY
mrna	ENTITY
is	ENTITY
translated	ENTITY
as	ENTITY
.	O
description	O
of	O
the	O
anatomy	ENTITY
and	ENTITY
physiology	ENTITY
of	ENTITY
the	ENTITY
islets	ENTITY
of	ENTITY
langerhans	ENTITY
and	ENTITY
the	ENTITY
actions	ENTITY
of	ENTITY
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
.	O
this	O
is	O
how	O
we	O
harvest	O
pancreata	ENTITY
for	ENTITY
islets	ENTITY
isolation	O
.	O
type	O
diabetes	ENTITY
is	ENTITY
an	ENTITY
auto	ENTITY
immune	ENTITY
disease	ENTITY
where	O
the	O
patient	O
body	O
has	O
attacked	O
its	O
own	O
insulin	ENTITY
producing	ENTITY
cells	ENTITY
.	O
it	O
largely	O
starts	O
in	O
childhood	O
and	O
is	O
treated	O
with	O
insulin	ENTITY
injections	ENTITY
.	O
an	O
alternative	O
approach	O
is	O
transplant	ENTITY
either	ENTITY
of	ENTITY
the	ENTITY
whole	ENTITY
pancreas	ENTITY
major	O
operation	O
or	O
the	O
much	O
less	O
invasive	O
transplantation	ENTITY
of	ENTITY
islet	ENTITY
cells	ENTITY
the	O
islets	O
of	O
langerhans	O
.	O
this	O
talk	O
by	O
paul	O
johnson	O
professor	O
of	O
paediatric	ENTITY
surgery	ENTITY
at	O
the	O
university	O
of	O
oxford	O
and	O
fellow	O
and	O
clinical	O
tutor	O
at	O
st	O
edmund	O
hall	O
discusses	O
the	O
development	O
of	O
this	O
treatment	O
and	O
its	O
future	O
potential	O
.	O
this	O
is	O
one	O
in	O
series	O
of	O
short	O
teddy	O
talks	O
presented	O
at	O
st	O
edmund	O
hall	O
research	O
expo	O
in	O
find	O
out	O
more	O
at	O
www	O
seh	O
ox	O
ac	O
uk	O
expo	O
.	O
follow	O
us	O
online	O
facebook	O
com	O
stedmundhall	O
twitter	O
com	O
stedmundhall	O
instagram	O
com	O
stedmundhall	O
.	O
visit	O
us	O
for	O
mcat	O
related	O
content	O
.	O
these	O
videos	O
do	O
not	O
provide	O
medical	O
advice	O
and	O
are	O
for	O
informational	O
purposes	O
only	O
.	O
the	O
videos	O
are	O
not	O
intended	O
to	O
be	O
substitute	O
for	O
professional	O
medical	O
advice	O
diagnosis	O
or	O
treatment	O
.	O
always	O
seek	O
the	O
advice	O
of	O
qualified	O
health	O
provider	O
with	O
any	O
questions	O
you	O
may	O
have	O
regarding	O
medical	O
condition	O
.	O
never	O
disregard	O
professional	O
medical	O
advice	O
or	O
delay	O
in	O
seeking	O
it	O
because	O
of	O
something	O
you	O
have	O
read	O
or	O
seen	O
in	O
any	O
khan	O
academy	O
video	O
.	O
full	O
version	O
.	O
brief	O
review	O
of	O
the	O
normal	O
histology	O
of	O
the	O
pancreas	ENTITY
as	ENTITY
presented	ENTITY
by	ENTITY
the	ENTITY
urmc	ENTITY
pathology	ENTITY
it	ENTITY
program	ENTITY
.	O
our	O
theme	O
for	O
tedxdelmar	O
was	O
search	O
for	O
cure	O
.	O
in	O
this	O
video	O
dr	O
butler	O
gives	O
us	O
his	O
talk	O
entitled	O
preserving	O
your	O
beta	ENTITY
cells	ENTITY
.	O
peter	O
butler	O
is	O
chief	O
director	O
larry	O
hillblom	ENTITY
islet	ENTITY
research	O
center	O
at	O
ucla	O
and	O
professor	O
of	O
medicine	O
at	O
ucla	O
where	O
his	O
research	O
interests	O
include	O
arresting	O
loss	O
of	O
beta	ENTITY
cell	ENTITY
mass	O
and	O
promoting	O
beta	ENTITY
cell	ENTITY
formation	O
.	O
after	O
obtaining	O
his	O
md	O
at	O
the	O
university	O
of	O
birmingham	O
uk	O
in	O
dr	O
butler	O
underwent	O
training	O
in	O
internal	O
medicine	O
in	O
edinburgh	O
and	O
newcastle	O
upon	O
tyne	O
in	O
the	O
uk	O
.	O
he	O
then	O
underwent	O
training	ENTITY
in	ENTITY
endocrinology	ENTITY
at	O
the	O
university	O
of	O
newcastle	O
upon	O
tyne	O
and	O
then	O
at	O
the	O
mayo	O
clinic	O
in	O
rochester	O
mn	O
where	O
he	O
was	O
also	O
research	O
fellow	O
.	O
he	O
was	O
then	O
appointed	O
to	O
clinical	O
faculty	O
position	O
at	O
mayo	O
clinic	O
in	O
endocrinology	ENTITY
diabetes	ENTITY
and	ENTITY
metabolism	ENTITY
.	O
he	O
was	O
also	O
the	O
associate	O
director	O
of	O
the	O
general	O
clinical	O
research	O
center	O
and	O
led	O
an	O
nih	O
funded	O
research	O
program	O
.	O
after	O
six	O
years	O
on	O
the	O
faculty	O
at	O
the	O
mayo	O
clinic	O
he	O
was	O
appointed	O
to	O
the	O
chair	O
of	O
diabetes	ENTITY
at	ENTITY
the	ENTITY
university	ENTITY
of	ENTITY
edinburgh	ENTITY
in	ENTITY
scotland	ENTITY
where	ENTITY
he	ENTITY
established	ENTITY
the	ENTITY
first	ENTITY
clinical	ENTITY
research	ENTITY
center	ENTITY
in	ENTITY
the	ENTITY
uk	ENTITY
.	O
he	O
returned	O
to	O
the	O
usa	O
in	O
when	O
he	O
was	O
appointed	O
to	O
chief	O
of	O
endocrinology	ENTITY
diabetes	ENTITY
and	ENTITY
hypertension	ENTITY
at	ENTITY
the	ENTITY
university	ENTITY
of	ENTITY
southern	ENTITY
california	ENTITY
moving	ENTITY
to	ENTITY
the	ENTITY
university	ENTITY
of	ENTITY
california	ENTITY
los	ENTITY
angeles	ENTITY
in	ENTITY
at	ENTITY
ucla	ENTITY
he	ENTITY
has	ENTITY
established	ENTITY
the	ENTITY
larry	ENTITY
hillblom	ENTITY
islet	ENTITY
research	ENTITY
center	ENTITY
free	ENTITY
standing	ENTITY
building	ENTITY
that	ENTITY
houses	ENTITY
investigators	ENTITY
with	ENTITY
wide	ENTITY
range	ENTITY
of	ENTITY
skills	ENTITY
focused	ENTITY
on	ENTITY
revealing	ENTITY
the	ENTITY
mechanisms	ENTITY
of	ENTITY
beta	ENTITY
cell	ENTITY
loss	O
and	O
potential	O
regeneration	O
in	O
people	O
with	O
type	O
and	O
diabetes	ENTITY
.	O
he	O
is	O
director	O
of	O
the	O
lhirc	ENTITY
islet	ENTITY
isolation	O
and	O
physiology	O
core	O
.	O
he	O
is	O
the	O
editor	O
in	O
chief	O
of	O
the	O
journal	O
diabetes	ENTITY
.	O
he	O
is	O
also	O
the	O
chief	O
of	O
the	O
division	O
of	O
endocrinology	ENTITY
diabetes	ENTITY
and	ENTITY
hypertension	ENTITY
.	O
his	O
clinical	O
practice	O
at	O
ucla	O
focuses	O
on	O
care	O
of	O
patients	O
with	O
diabetes	ENTITY
.	O
in	O
the	O
spirit	O
of	O
ideas	O
worth	O
spreading	O
tedx	O
is	O
program	O
of	O
local	O
self	O
organized	O
events	O
that	O
bring	O
people	O
together	O
to	O
share	O
ted	O
like	O
experience	O
.	O
at	O
tedx	O
event	O
tedtalks	O
video	O
and	O
live	O
speakers	O
combine	O
to	O
spark	O
deep	O
discussion	O
and	O
connection	O
in	O
small	O
group	O
.	O
these	O
local	O
self	O
organized	O
events	O
are	O
branded	O
tedx	O
where	O
independently	O
organized	O
ted	O
event	O
.	O
the	O
ted	O
conference	O
provides	O
general	O
guidance	O
for	O
the	O
tedx	O
program	O
but	O
individual	O
tedx	O
events	O
are	O
self	O
organized	O
.	O
read	O
more	O
at	O
.	O
presentation	O
given	O
by	O
prof	O
rayaz	O
malik	O
at	O
weill	O
cornell	O
medicine	O
in	O
qatar	O
.	O
credits	O
to	O
the	O
video	O
editor	O
adrian	O
bernardo	O
its	O
av	O
specialist	O
wcm	O
.	O
in	O
diabetes	ENTITY
is	ENTITY
serious	ENTITY
threat	ENTITY
to	ENTITY
health	ENTITY
with	ENTITY
over	ENTITY
million	ENTITY
cases	ENTITY
around	ENTITY
the	ENTITY
world	ENTITY
each	ENTITY
year	ENTITY
.	O
phone	O
numbers	O
thailand	O
australia	O
us	O
and	O
canada	O
thai	O
europe	O
regeneration	O
center	O
.	O
watch	O
full	O
version	O
.	O
shotgun	O
histology	O
pancreas	ENTITY
.	O
testing	O
pancreatic	ENTITY
islet	ENTITY
function	ENTITY
at	ENTITY
the	ENTITY
single	ENTITY
cell	ENTITY
level	ENTITY
by	ENTITY
calcium	ENTITY
influx	ENTITY
with	ENTITY
associated	ENTITY
marker	ENTITY
expression	ENTITY
.	O
jennifer	O
kenty	O
and	O
douglas	O
melton	O
plos	O
one	O
.	O
whereas	O
islet	ENTITY
cells	ENTITY
that	O
inversely	O
fluxed	O
at	O
low	O
glucose	ENTITY
expressed	ENTITY
cell	ENTITY
markers	ENTITY
gcg	ENTITY
.	O
diabetic	ENTITY
mouse	ENTITY
islets	ENTITY
showed	O
higher	O
proportion	O
of	O
dysfunctional	O
cells	O
that	O
responded	O
poorly	O
to	O
glucose	ENTITY
challenges	ENTITY
.	O
most	O
of	O
the	O
failed	O
calcium	ENTITY
influx	ENTITY
responses	ENTITY
in	ENTITY
cells	ENTITY
were	ENTITY
observed	ENTITY
in	ENTITY
the	ENTITY
second	ENTITY
and	ENTITY
third	ENTITY
high	ENTITY
glucose	ENTITY
challenges	ENTITY
emphasizing	ENTITY
the	ENTITY
importance	ENTITY
of	ENTITY
multiple	ENTITY
sequential	ENTITY
glucose	ENTITY
challenges	ENTITY
for	ENTITY
assessing	ENTITY
the	ENTITY
full	ENTITY
function	ENTITY
of	ENTITY
islet	ENTITY
cells	ENTITY
.	O
human	ENTITY
islet	ENTITY
cells	ENTITY
were	O
also	O
assessed	O
and	O
showed	O
functional	O
and	O
cells	O
.	O
this	O
approach	O
to	O
analyze	O
islet	ENTITY
responses	ENTITY
to	ENTITY
multiple	ENTITY
glucose	ENTITY
challenges	ENTITY
in	ENTITY
correlation	ENTITY
with	ENTITY
gene	ENTITY
expression	ENTITY
assays	O
expands	O
the	O
understanding	O
of	O
cell	O
function	O
and	O
the	O
diseased	O
state	O
.	O
full	O
video	O
.	O
our	O
theme	O
for	O
tedxdelmar	O
was	O
search	O
for	O
cure	O
.	O
in	O
this	O
video	O
dr	O
sander	O
gives	O
us	O
her	O
talk	O
entitled	O
from	O
stem	ENTITY
cells	ENTITY
to	O
beta	ENTITY
cells	ENTITY
.	O
dr	O
sander	O
is	O
an	O
expert	O
in	O
pancreatic	ENTITY
stem	ENTITY
cells	ENTITY
biology	O
and	O
has	O
over	O
twenty	O
years	O
of	O
experience	O
in	O
medicine	O
and	O
academic	O
research	O
.	O
after	O
graduating	O
with	O
an	O
.	O
from	O
the	O
university	O
of	O
heidelberg	O
medical	O
school	O
in	O
germany	O
she	O
conducted	O
research	O
at	O
uc	O
san	O
francisco	O
.	O
dr	O
sander	O
held	O
faculty	O
appointments	O
at	O
hamburg	O
medical	O
school	O
germany	O
and	O
uc	O
irvine	O
before	O
accepting	O
her	O
current	O
position	O
as	O
professor	O
of	O
pediatrics	O
and	O
cellular	ENTITY
molecular	ENTITY
medicine	ENTITY
at	ENTITY
uc	ENTITY
san	ENTITY
diego	ENTITY
.	O
she	O
is	O
an	O
elected	O
member	O
of	O
the	O
american	O
society	O
of	O
clinical	O
investigation	O
member	O
of	O
the	O
nih	O
beta	ENTITY
cell	ENTITY
biology	O
consortium	O
.	O
in	O
the	O
spirit	O
of	O
ideas	O
worth	O
spreading	O
tedx	O
is	O
program	O
of	O
local	O
self	O
organized	O
events	O
that	O
bring	O
people	O
together	O
to	O
share	O
ted	O
like	O
experience	O
.	O
at	O
tedx	O
event	O
tedtalks	O
video	O
and	O
live	O
speakers	O
combine	O
to	O
spark	O
deep	O
discussion	O
and	O
connection	O
in	O
small	O
group	O
.	O
these	O
local	O
self	O
organized	O
events	O
are	O
branded	O
tedx	O
where	O
independently	O
organized	O
ted	O
event	O
.	O
the	O
ted	O
conference	O
provides	O
general	O
guidance	O
for	O
the	O
tedx	O
program	O
but	O
individual	O
tedx	O
events	O
are	O
self	O
organized	O
.	O
hi	ENTITY
am	ENTITY
dr	ENTITY
dweipayan	ENTITY
goswami	ENTITY
welcome	ENTITY
to	ENTITY
my	ENTITY
youtube	ENTITY
channel	ENTITY
learn	ENTITY
at	ENTITY
ease	ENTITY
will	ENTITY
be	ENTITY
uploading	ENTITY
animated	ENTITY
videos	ENTITY
related	ENTITY
to	ENTITY
biochemistry	ENTITY
for	ENTITY
the	ENTITY
under	ENTITY
graduates	ENTITY
and	ENTITY
graduates	ENTITY
purely	ENTITY
based	ENTITY
on	ENTITY
the	ENTITY
information	ENTITY
form	ENTITY
the	ENTITY
traditional	ENTITY
text	ENTITY
books	ENTITY
such	ENTITY
as	ENTITY
lehninger	ENTITY
principles	ENTITY
of	ENTITY
biochemistry	ENTITY
th	ENTITY
edition	ENTITY
.	O
nelson	O
and	O
cox	O
biochemistry	O
th	O
edition	O
.	O
garrett	O
and	O
grisham	O
.	O
etc	O
.	O
in	O
almost	O
the	O
same	O
order	O
to	O
that	O
of	O
the	O
chapters	O
in	O
the	O
book	O
.	O
will	O
also	O
upload	O
videos	O
in	O
the	O
subjects	O
of	O
microbiology	O
biotechnology	O
immunology	ENTITY
etc	ENTITY
.	O
with	O
your	O
request	O
will	O
be	O
uploading	O
videos	O
under	O
this	O
playlist	O
with	O
audio	O
.	O
if	O
you	O
like	O
the	O
concept	O
please	O
subscribe	O
to	O
my	O
channel	O
learn	O
at	O
ease	O
insulin	ENTITY
part	ENTITY
overview	ENTITY
of	ENTITY
insulin	ENTITY
production	ENTITY
signalling	ENTITY
.	O
the	O
islet	ENTITY
pathophysiology	ENTITY
group	O
focuses	O
on	O
defining	O
the	O
mechanisms	O
underlying	O
pancreatic	ENTITY
islet	ENTITY
malfunction	O
and	O
decreased	O
beta	ENTITY
cell	ENTITY
mass	O
in	O
type	O
diabetes	ENTITY
.	O
the	O
disease	ENTITY
has	ENTITY
in	ENTITY
recent	ENTITY
years	ENTITY
been	ENTITY
associated	ENTITY
to	ENTITY
variations	ENTITY
in	ENTITY
large	ENTITY
number	ENTITY
of	ENTITY
genes	ENTITY
.	O
the	O
big	O
challenge	O
is	O
to	O
understand	O
exactly	O
how	O
these	O
genetic	ENTITY
variations	ENTITY
affect	O
cellular	ENTITY
functions	ENTITY
in	ENTITY
the	ENTITY
pancreatic	ENTITY
islets	ENTITY
in	O
order	O
to	O
identify	O
targets	O
for	O
causative	O
treatment	O
.	O
focus	O
areas	O
include	O
the	O
role	O
of	O
the	O
redox	O
environment	O
with	O
particular	O
focus	O
on	O
effectors	O
of	O
nadph	ENTITY
and	ENTITY
their	ENTITY
consequences	ENTITY
for	ENTITY
beta	ENTITY
cell	ENTITY
function	ENTITY
and	O
survival	O
.	O
the	O
role	O
of	O
complement	ENTITY
proteins	ENTITY
of	O
the	O
innate	ENTITY
immune	ENTITY
system	ENTITY
for	O
control	O
of	O
insulin	ENTITY
secretion	ENTITY
from	O
the	O
pancreatic	ENTITY
beta	ENTITY
cell	ENTITY
in	O
health	O
and	O
disease	ENTITY
.	O
this	O
is	O
done	O
in	O
collaborate	O
with	O
the	O
group	O
of	O
anna	O
blom	O
lund	O
university	O
and	O
other	O
international	O
collaborators	O
.	O
ion	ENTITY
channels	ENTITY
in	ENTITY
particular	ENTITY
voltage	ENTITY
gated	ENTITY
ca	O
channels	O
and	O
their	O
role	O
in	O
type	O
diabetes	ENTITY
in	ENTITY
collaboration	ENTITY
with	ENTITY
some	ENTITY
of	ENTITY
the	ENTITY
leading	ENTITY
profiles	ENTITY
in	ENTITY
the	ENTITY
area	ENTITY
.	O
methods	O
used	O
include	O
the	O
patch	ENTITY
clamp	ENTITY
technique	O
in	O
combination	O
with	O
microfluorimetry	ENTITY
or	ENTITY
cellular	ENTITY
imaging	ENTITY
techniques	O
such	O
as	O
confocal	ENTITY
or	ENTITY
tirf	ENTITY
imaging	ENTITY
.	O
imaging	O
methods	O
established	O
include	O
multiphoton	ENTITY
imaging	ENTITY
and	O
fluorescence	ENTITY
spectrum	ENTITY
correlation	ENTITY
.	O
in	O
addition	O
we	O
perform	O
hormone	ENTITY
release	ENTITY
assays	ENTITY
immunocytochemistry	ENTITY
standard	ENTITY
biochemistry	ENTITY
and	O
manipulation	O
of	O
gene	ENTITY
expression	ENTITY
using	O
rna	ENTITY
interference	ENTITY
or	O
viral	O
transfer	O
methods	O
.	O
in	O
an	O
effort	O
to	O
go	O
beyond	O
the	O
single	ENTITY
gene	ENTITY
one	O
function	O
paradigm	O
and	O
do	O
develop	O
models	O
that	O
take	O
into	O
account	O
the	O
contribution	O
of	O
several	O
genes	ENTITY
and	ENTITY
their	ENTITY
encoded	ENTITY
proteins	ENTITY
for	ENTITY
the	ENTITY
altered	ENTITY
cellular	ENTITY
functions	ENTITY
that	O
predispose	O
for	O
type	O
diabetes	ENTITY
and	ENTITY
how	ENTITY
aberrations	ENTITY
in	ENTITY
these	ENTITY
networks	ENTITY
can	ENTITY
be	ENTITY
corrected	ENTITY
by	ENTITY
novel	ENTITY
treatmentts	ENTITY
.	O
to	O
do	O
this	O
we	O
analyse	O
gene	O
regulatory	O
co	O
expression	O
networdks	O
in	O
pancreatic	ENTITY
islets	ENTITY
followed	O
by	O
functional	O
validation	O
experiments	O
down	O
to	O
detailed	O
molecular	O
level	O
when	O
appropriate	O
.	O
an	O
important	O
aspect	O
of	O
protein	O
function	O
is	O
their	O
interactions	O
addressed	O
by	O
discovery	O
techniques	O
hybrid	O
systems	O
and	O
focused	O
low	O
throughput	O
methods	O
.	O
immunoprecipitation	ENTITY
affinity	ENTITY
purification	ENTITY
including	ENTITY
those	ENTITY
that	ENTITY
make	ENTITY
it	ENTITY
possible	ENTITY
to	ENTITY
characterize	ENTITY
interactions	ENTITY
in	ENTITY
real	ENTITY
time	ENTITY
fluctuation	ENTITY
correlation	ENTITY
spectroscopy	ENTITY
.	O
after	O
discovery	O
and	O
validation	O
the	O
ultimate	O
goal	O
is	O
to	O
translate	O
findings	O
into	O
improved	O
diagnostics	O
and	O
novel	O
molecular	O
targets	O
for	O
treatment	O
of	O
type	O
diabetes	ENTITY
.	O
mor	O
www	O
exodiab	O
se	O
or	O
www	O
ludc	O
med	O
lu	O
se	O
.	O
how	O
to	O
reverse	O
diabetes	ENTITY
.	O
turns	O
out	O
the	O
diabetes	ENTITY
industry	ENTITY
is	ENTITY
selling	ENTITY
us	ENTITY
fake	ENTITY
research	ENTITY
.	O
hi	O
.	O
robo	O
suzie	O
and	O
today	O
ll	O
talk	O
to	O
you	O
about	O
is	O
the	O
pancreatic	ENTITY
islet	ENTITY
transplantation	ENTITY
feasible	O
cure	O
for	O
diabetes	ENTITY
.	O
also	O
don	O
forget	O
to	O
check	O
out	O
the	O
link	O
below	O
to	O
find	O
out	O
how	O
this	O
guy	O
reversed	O
his	O
diabetes	ENTITY
.	O
turns	O
out	O
the	O
diabetes	ENTITY
industry	ENTITY
is	ENTITY
selling	ENTITY
us	ENTITY
fake	ENTITY
research	ENTITY
.	O
but	O
back	O
to	O
our	O
topic	O
.	O
the	O
pancreatic	ENTITY
islet	ENTITY
transplantation	ENTITY
or	O
what	O
is	O
known	O
as	O
the	O
edmonton	ENTITY
protocol	ENTITY
is	O
an	O
experimental	ENTITY
procedure	ENTITY
that	O
makes	O
use	O
of	O
islets	ENTITY
extracted	ENTITY
from	ENTITY
the	O
pancreas	ENTITY
of	O
recently	O
deceased	O
organ	ENTITY
donor	ENTITY
.	O
the	O
process	O
involves	O
the	O
transplant	O
of	O
said	O
islets	ENTITY
to	ENTITY
patient	ENTITY
suffering	ENTITY
from	ENTITY
diabetes	ENTITY
type	ENTITY
the	ENTITY
beta	ENTITY
cells	ENTITY
of	O
these	O
transplanted	ENTITY
islets	ENTITY
are	O
expected	O
to	O
produce	O
the	O
insulin	ENTITY
lacked	ENTITY
by	ENTITY
the	ENTITY
type	ENTITY
diabetes	ENTITY
patient	ENTITY
.	O
this	O
experiment	O
then	O
hopes	O
to	O
provide	O
the	O
cure	O
for	O
diabetes	ENTITY
mellitus	ENTITY
.	O
diabetes	O
type	O
is	O
that	O
diabetic	ENTITY
condition	ENTITY
where	ENTITY
the	ENTITY
beta	ENTITY
cells	ENTITY
of	ENTITY
the	ENTITY
pancreas	ENTITY
is	O
unable	O
to	O
produce	O
insulin	ENTITY
as	ENTITY
result	ENTITY
of	ENTITY
the	ENTITY
attacks	ENTITY
launched	ENTITY
by	ENTITY
the	ENTITY
body	ENTITY
immune	ENTITY
system	ENTITY
.	O
the	O
transplantation	ENTITY
of	ENTITY
islet	ENTITY
therefore	O
is	O
expected	O
to	O
provide	O
cure	O
for	O
diabetes	ENTITY
type	ENTITY
patients	ENTITY
which	ENTITY
will	ENTITY
enable	ENTITY
them	ENTITY
to	ENTITY
live	ENTITY
normal	ENTITY
life	ENTITY
free	ENTITY
from	ENTITY
insulin	ENTITY
dependence	ENTITY
.	O
although	O
the	O
diabetes	ENTITY
type	ENTITY
condition	ENTITY
deals	ENTITY
with	ENTITY
insulin	ENTITY
resistance	ENTITY
it	O
has	O
been	O
noted	O
that	O
the	O
diabetic	ENTITY
condition	ENTITY
of	O
the	O
patient	O
will	O
also	O
develop	O
to	O
insulin	ENTITY
decline	ENTITY
or	ENTITY
progress	ENTITY
later	ENTITY
on	ENTITY
as	ENTITY
diabetes	ENTITY
type	ENTITY
many	ENTITY
supporters	ENTITY
of	ENTITY
the	ENTITY
pancreatic	ENTITY
islet	ENTITY
transplantation	ENTITY
believe	O
that	O
this	O
will	O
also	O
be	O
cure	O
for	O
diabetes	ENTITY
type	ENTITY
to	ENTITY
relieve	ENTITY
sufferers	ENTITY
of	ENTITY
their	ENTITY
eventual	ENTITY
need	ENTITY
for	ENTITY
insulin	ENTITY
injections	ENTITY
.	O
the	O
islets	ENTITY
referred	ENTITY
to	ENTITY
here	ENTITY
are	ENTITY
the	ENTITY
cluster	ENTITY
of	ENTITY
cells	ENTITY
or	O
tissues	ENTITY
known	ENTITY
in	ENTITY
the	ENTITY
medical	ENTITY
world	ENTITY
as	ENTITY
islets	ENTITY
of	ENTITY
langerhans	ENTITY
.	O
these	O
islets	ENTITY
are	ENTITY
microscopic	ENTITY
and	ENTITY
are	ENTITY
scattered	ENTITY
throughout	ENTITY
the	ENTITY
pancreas	ENTITY
forming	ENTITY
part	ENTITY
of	ENTITY
the	ENTITY
endocrine	ENTITY
glands	ENTITY
.	O
they	O
contain	O
the	O
cells	O
which	O
secret	O
the	O
beta	ENTITY
cells	ENTITY
that	O
produce	O
the	O
insulin	ENTITY
necessary	ENTITY
for	ENTITY
glucose	ENTITY
absorption	ENTITY
and	ENTITY
any	ENTITY
failure	ENTITY
of	ENTITY
these	ENTITY
islets	ENTITY
to	ENTITY
produce	ENTITY
these	ENTITY
beta	ENTITY
cells	ENTITY
lead	O
to	O
diabetes	ENTITY
mellitus	ENTITY
or	O
type	O
diabetes	ENTITY
.	O
although	O
clinically	O
promising	O
at	O
first	O
year	O
follow	O
up	O
after	O
the	O
transplantation	O
procedure	O
was	O
made	O
and	O
the	O
results	O
were	O
not	O
as	O
favourable	O
as	O
expected	O
.	O
only	O
ten	O
percent	O
of	O
the	O
patients	O
remained	O
free	ENTITY
of	ENTITY
insulin	ENTITY
dependence	O
while	O
the	O
rest	O
went	O
back	O
to	O
the	O
use	O
of	O
insulin	ENTITY
shots	ENTITY
since	O
the	O
transplanted	ENTITY
islets	ENTITY
eventually	O
lost	O
its	O
ability	O
to	O
produce	O
insulin	ENTITY
.	O
the	O
only	O
benefits	O
that	O
the	O
latter	O
group	O
of	O
patients	O
gained	O
was	O
their	O
less	O
demand	O
for	O
insulin	ENTITY
since	ENTITY
the	ENTITY
patients	ENTITY
were	ENTITY
able	ENTITY
to	ENTITY
achieve	ENTITY
glucose	ENTITY
stability	ENTITY
.	O
hence	O
to	O
date	O
pancreatic	ENTITY
transplantation	ENTITY
has	O
not	O
gained	O
the	O
medical	O
support	O
as	O
the	O
ultimate	O
cure	O
for	O
diabetes	ENTITY
.	O
it	O
is	O
also	O
believed	O
that	O
the	O
eventual	O
failure	O
of	O
the	O
transplanted	ENTITY
islet	ENTITY
to	O
produce	O
insulin	ENTITY
was	ENTITY
also	ENTITY
attributed	ENTITY
to	ENTITY
the	ENTITY
body	ENTITY
immune	ENTITY
system	ENTITY
.	O
the	O
beta	ENTITY
cells	ENTITY
produced	O
by	O
the	O
transplanted	ENTITY
islets	ENTITY
were	O
also	O
attacked	O
by	O
the	O
body	ENTITY
immune	ENTITY
system	ENTITY
.	O
hence	O
in	O
the	O
same	O
way	O
that	O
the	O
natural	ENTITY
beta	ENTITY
cells	ENTITY
of	O
the	O
body	O
were	O
impaired	O
the	O
patient	O
still	O
suffers	O
from	O
diabetes	ENTITY
mellitus	ENTITY
or	O
diabetes	ENTITY
type	ENTITY
critics	ENTITY
say	ENTITY
that	ENTITY
it	ENTITY
was	ENTITY
actually	ENTITY
project	ENTITY
doomed	ENTITY
from	ENTITY
the	ENTITY
beginning	ENTITY
others	ENTITY
pointed	ENTITY
out	ENTITY
that	ENTITY
the	ENTITY
root	ENTITY
of	ENTITY
the	ENTITY
insulin	ENTITY
impairment	ENTITY
problem	ENTITY
was	ENTITY
the	ENTITY
inability	ENTITY
of	ENTITY
the	ENTITY
immune	ENTITY
system	ENTITY
to	O
recognize	O
insulin	ENTITY
beta	ENTITY
cells	ENTITY
as	O
essential	O
to	O
digestive	ENTITY
functions	ENTITY
instead	O
of	O
treating	O
these	O
insulin	ENTITY
cells	ENTITY
as	O
bacteria	ENTITY
.	O
perhaps	O
further	O
experimentations	O
therefore	O
in	O
the	O
search	O
for	O
the	O
elusive	O
cure	O
for	O
diabetes	ENTITY
should	ENTITY
have	ENTITY
more	ENTITY
concern	ENTITY
in	ENTITY
orienting	ENTITY
the	ENTITY
auto	ENTITY
immune	ENTITY
system	ENTITY
on	O
how	O
to	O
recognize	O
friendly	O
and	O
non	O
friendly	O
substances	O
found	O
in	O
the	O
body	O
.	O
that	O
it	O
.	O
thank	O
you	O
.	O
please	O
subscribe	O
comment	O
and	O
like	O
this	O
video	O
if	O
it	O
was	O
helpful	O
.	O
see	O
you	O
soon	O
.	O
this	O
is	O
procedure	ENTITY
of	ENTITY
colagenase	ENTITY
perfusion	ENTITY
of	O
pancreas	ENTITY
for	ENTITY
subsequent	ENTITY
exocrine	ENTITY
digestion	ENTITY
and	ENTITY
islet	ENTITY
isolation	ENTITY
in	O
rat	O
for	O
those	O
who	O
are	O
interesting	O
to	O
perform	O
any	O
procedure	O
with	O
isolated	ENTITY
islets	ENTITY
western	ENTITY
blot	ENTITY
pcr	ENTITY
insulin	ENTITY
secretion	ENTITY
protocols	ENTITY
.	O
for	O
details	O
it	O
can	O
be	O
assessed	O
rafacho	O
et	O
al	O
pancreas	ENTITY
.	O
note	O
this	O
rat	O
was	O
from	O
an	O
ending	O
experiment	O
with	O
protocols	O
previously	O
approved	O
by	O
the	O
committee	O
for	O
ethics	O
in	O
animal	O
experimentation	O
approval	O
id	O
pp	O
.	O
summary	O
of	O
recent	O
progress	O
and	O
outcomes	O
in	O
clinical	O
islet	ENTITY
transplantation	ENTITY
for	O
the	O
treatment	O
of	O
diabetes	ENTITY
will	ENTITY
be	ENTITY
provided	ENTITY
together	ENTITY
with	ENTITY
discussion	ENTITY
of	ENTITY
approaches	ENTITY
to	ENTITY
stem	ENTITY
cell	ENTITY
transplantation	ENTITY
autologous	ENTITY
and	ENTITY
allogeneic	ENTITY
as	ENTITY
means	ENTITY
to	ENTITY
control	ENTITY
autoimmunity	ENTITY
and	ENTITY
provide	ENTITY
alternative	ENTITY
expanded	ENTITY
beta	ENTITY
cell	ENTITY
sources	O
for	O
clinical	ENTITY
application	ENTITY
.	O
animation	O
explaining	O
the	O
pancreatic	ENTITY
auto	ENTITY
islet	ENTITY
transplantation	ENTITY
process	O
with	O
complete	O
removal	O
of	O
the	O
pancreas	ENTITY
to	ENTITY
treat	ENTITY
pancreatitis	ENTITY
.	O
the	O
following	O
video	O
sequences	O
provide	O
protocol	O
for	O
islet	ENTITY
isolation	ENTITY
using	O
human	ENTITY
pancreatic	ENTITY
tissue	ENTITY
after	O
partial	ENTITY
pancreatectomy	ENTITY
.	O
the	O
so	O
procured	ENTITY
islets	ENTITY
can	O
serve	O
as	O
an	O
in	O
vitro	O
system	O
for	O
functional	O
analysis	O
.	O
for	O
further	O
information	O
www	O
imida	O
org	O
.	O
pancreatic	ENTITY
islet	ENTITY
transplantation	ENTITY
represents	O
promising	O
treatment	O
for	O
patients	O
with	O
but	O
shortage	O
of	O
available	O
healthy	ENTITY
islet	ENTITY
donors	ENTITY
means	O
that	O
there	O
is	O
an	O
insufficient	O
supply	O
of	O
insulin	ENTITY
producing	ENTITY
islets	ENTITY
to	ENTITY
meet	ENTITY
the	ENTITY
demands	ENTITY
for	ENTITY
such	ENTITY
therapies	ENTITY
.	O
thus	O
research	O
efforts	O
over	O
the	O
last	O
decade	O
have	O
focused	O
on	O
generating	ENTITY
artificial	ENTITY
islets	ENTITY
from	O
human	O
pluripotent	ENTITY
stem	ENTITY
cells	ENTITY
hpscs	ENTITY
as	ENTITY
prospective	ENTITY
solution	ENTITY
to	O
this	O
scarcity	O
.	O
while	O
these	O
studies	O
have	O
yielded	O
impressive	O
results	O
current	O
methods	O
are	O
still	O
incapable	O
of	O
producing	O
functional	O
islets	ENTITY
that	ENTITY
fully	ENTITY
recapitulate	ENTITY
the	ENTITY
activity	ENTITY
and	ENTITY
glucose	ENTITY
responsiveness	ENTITY
of	O
normal	O
human	ENTITY
islets	ENTITY
.	O
this	O
video	O
provides	O
an	O
animated	O
introduction	O
to	O
diabetes	ENTITY
type	ENTITY
and	ENTITY
type	ENTITY
created	ENTITY
using	ENTITY
powtoon	ENTITY
free	ENTITY
sign	ENTITY
up	ENTITY
at	ENTITY
create	ENTITY
animated	ENTITY
videos	ENTITY
and	ENTITY
animated	ENTITY
presentations	ENTITY
for	ENTITY
free	ENTITY
.	O
powtoon	O
is	O
free	O
tool	O
that	O
allows	O
you	O
to	O
develop	O
cool	O
animated	O
clips	O
and	O
animated	O
presentations	O
for	O
your	O
website	O
office	O
meeting	O
sales	O
pitch	O
nonprofit	O
fundraiser	O
product	O
launch	O
video	O
resume	O
or	O
anything	O
else	O
you	O
could	O
use	O
an	O
animated	O
explainer	O
video	O
.	O
powtoon	O
animation	O
templates	O
help	O
you	O
create	O
animated	O
presentations	O
and	O
animated	O
explainer	O
videos	O
from	O
scratch	O
.	O
anyone	O
can	O
produce	O
awesome	O
animations	O
quickly	O
with	O
powtoon	O
without	O
the	O
cost	O
or	O
hassle	O
other	O
professional	O
animation	O
services	O
require	O
.	O
this	O
video	O
and	O
similar	O
images	O
videos	O
are	O
available	O
for	O
instant	O
download	O
licensing	O
here	O
by	O
alila	O
medical	O
media	O
are	O
for	O
information	O
purposes	O
only	O
and	O
are	O
not	O
intended	O
to	O
replace	O
professional	O
medical	O
advice	O
diagnosis	O
or	O
treatment	O
.	O
always	O
seek	O
the	O
advice	O
of	O
qualified	O
healthcare	O
provider	O
with	O
any	O
questions	O
you	O
may	O
have	O
regarding	O
medical	O
condition	O
.	O
diabetes	ENTITY
refers	ENTITY
to	ENTITY
group	ENTITY
of	ENTITY
conditions	ENTITY
characterized	ENTITY
by	ENTITY
high	ENTITY
level	ENTITY
of	ENTITY
blood	ENTITY
glucose	ENTITY
commonly	O
referred	O
to	O
as	O
blood	ENTITY
sugar	ENTITY
.	O
too	O
much	O
sugar	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
can	O
cause	O
serious	O
sometimes	O
life	O
threatening	O
health	O
problems	O
.	O
there	O
are	O
two	O
types	O
of	O
chronic	ENTITY
diabetic	ENTITY
conditions	ENTITY
type	O
diabetes	ENTITY
and	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
pregnant	O
women	O
may	O
acquire	O
transient	O
form	O
of	O
the	O
disease	ENTITY
called	ENTITY
gestational	ENTITY
diabetes	ENTITY
which	O
usually	O
resolves	O
after	O
the	O
birth	O
of	O
baby	O
.	O
pre	ENTITY
diabetes	ENTITY
is	O
when	O
the	O
blood	ENTITY
sugar	ENTITY
level	ENTITY
is	O
at	O
the	O
borderline	O
higher	O
than	O
normal	O
but	O
lower	O
than	O
in	O
diabetics	ENTITY
.	O
prediabetes	ENTITY
may	ENTITY
or	ENTITY
may	ENTITY
not	ENTITY
progress	ENTITY
to	ENTITY
diabetes	ENTITY
.	O
during	O
food	O
digestion	O
carbohydrates	ENTITY
or	ENTITY
carb	ENTITY
break	ENTITY
down	ENTITY
into	ENTITY
glucose	ENTITY
which	ENTITY
is	ENTITY
carried	ENTITY
by	ENTITY
the	ENTITY
bloodstream	ENTITY
to	ENTITY
various	ENTITY
organs	ENTITY
of	ENTITY
the	ENTITY
body	ENTITY
.	O
here	O
it	O
is	O
either	O
consumed	O
as	O
an	O
energy	O
source	O
in	O
muscles	ENTITY
for	ENTITY
example	ENTITY
or	ENTITY
is	ENTITY
stored	ENTITY
for	ENTITY
later	ENTITY
use	ENTITY
in	ENTITY
the	ENTITY
liver	ENTITY
.	O
insulin	ENTITY
is	ENTITY
hormone	ENTITY
produced	ENTITY
by	ENTITY
beta	ENTITY
cells	ENTITY
of	ENTITY
the	ENTITY
pancreas	ENTITY
and	O
is	O
necessary	O
for	O
glucose	ENTITY
intake	ENTITY
by	ENTITY
target	ENTITY
cells	ENTITY
.	O
in	O
other	O
words	O
when	O
insulin	ENTITY
is	ENTITY
deficient	ENTITY
muscle	ENTITY
or	ENTITY
liver	ENTITY
cells	ENTITY
are	O
unable	O
to	O
use	O
or	O
store	O
glucose	ENTITY
and	ENTITY
as	ENTITY
result	ENTITY
glucose	ENTITY
accumulates	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
.	O
in	O
healthy	O
people	O
beta	ENTITY
cells	ENTITY
of	ENTITY
the	ENTITY
pancreas	ENTITY
produce	O
insulin	ENTITY
insulin	ENTITY
binds	ENTITY
to	ENTITY
its	ENTITY
receptor	ENTITY
on	ENTITY
target	ENTITY
cells	ENTITY
and	O
induces	O
glucose	ENTITY
intake	ENTITY
.	O
in	O
type	O
diabetes	ENTITY
beta	ENTITY
cells	ENTITY
of	O
the	O
pancreas	ENTITY
are	ENTITY
destroyed	ENTITY
by	ENTITY
the	ENTITY
immune	ENTITY
system	ENTITY
by	O
mistake	O
.	O
the	O
reason	O
why	O
this	O
happens	O
is	O
unclear	O
but	O
genetic	O
factors	O
are	O
believed	O
to	O
play	O
major	O
role	O
.	O
insulin	ENTITY
production	ENTITY
is	O
reduced	O
less	O
insulin	ENTITY
binds	ENTITY
to	ENTITY
its	ENTITY
receptor	ENTITY
on	ENTITY
target	ENTITY
cells	ENTITY
less	O
glucose	ENTITY
is	ENTITY
taken	ENTITY
into	ENTITY
the	ENTITY
cells	ENTITY
more	ENTITY
glucose	ENTITY
stays	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
.	O
type	O
is	O
characterized	O
by	O
early	O
onset	O
symptoms	O
commonly	O
start	O
suddenly	O
and	O
before	O
the	O
age	O
of	O
type	O
diabetes	ENTITY
is	ENTITY
normally	ENTITY
managed	ENTITY
with	ENTITY
insulin	ENTITY
injection	ENTITY
.	O
type	O
diabetics	ENTITY
are	ENTITY
therefore	ENTITY
insulin	ENTITY
dependent	ENTITY
.	O
in	O
type	O
diabetes	ENTITY
the	ENTITY
pancreas	ENTITY
produces	ENTITY
enough	ENTITY
insulin	ENTITY
but	ENTITY
something	ENTITY
goes	ENTITY
wrong	ENTITY
either	ENTITY
with	ENTITY
receptor	ENTITY
binding	ENTITY
or	ENTITY
insulin	ENTITY
signaling	ENTITY
inside	O
the	O
target	ENTITY
cells	ENTITY
.	O
the	O
cells	O
are	O
not	O
responsive	O
to	O
insulin	ENTITY
and	ENTITY
therefore	ENTITY
cannot	ENTITY
import	ENTITY
glucose	ENTITY
glucose	ENTITY
stays	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
.	O
in	O
other	O
words	O
type	O
diabetics	ENTITY
are	ENTITY
insulin	ENTITY
resistant	ENTITY
.	O
here	O
again	O
genetic	O
factors	O
predispose	O
susceptibility	O
to	O
the	O
disease	ENTITY
but	ENTITY
it	ENTITY
is	ENTITY
believed	ENTITY
that	ENTITY
lifestyle	ENTITY
plays	ENTITY
very	ENTITY
important	ENTITY
role	ENTITY
in	ENTITY
type	ENTITY
typically	ENTITY
obesity	ENTITY
inactive	ENTITY
lifestyle	ENTITY
and	ENTITY
unhealthy	ENTITY
diet	ENTITY
are	ENTITY
associated	ENTITY
with	ENTITY
higher	ENTITY
risk	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
type	O
is	O
characterized	O
by	O
adult	O
onset	O
symptoms	O
usually	O
appear	O
gradually	O
and	O
start	O
after	O
the	O
age	O
of	O
type	O
diabetes	ENTITY
accounts	ENTITY
for	ENTITY
about	ENTITY
to	ENTITY
of	ENTITY
all	ENTITY
diabetics	ENTITY
.	O
management	O
focuses	O
on	O
weight	O
loss	O
and	O
includes	O
low	O
carb	O
diet	O
.	O
full	O
video	O
.	O
more	O
and	O
more	O
people	O
are	O
suffering	O
from	O
type	O
diabetes	ENTITY
due	ENTITY
to	ENTITY
variety	ENTITY
of	ENTITY
reasons	ENTITY
including	ENTITY
diet	ENTITY
exercise	ENTITY
and	ENTITY
genetics	ENTITY
.	O
according	O
to	O
new	O
study	O
from	O
researchers	O
at	O
harvard	O
medical	O
school	O
in	O
massachusetts	O
working	O
with	O
an	O
expert	O
from	O
the	O
max	O
planck	O
institute	O
for	O
evolutionary	O
anthropology	O
in	O
germany	O
genetic	ENTITY
predisposition	ENTITY
for	O
diabetes	ENTITY
in	ENTITY
latin	ENTITY
american	ENTITY
populations	ENTITY
might	ENTITY
be	ENTITY
related	ENTITY
to	ENTITY
gene	ENTITY
variant	ENTITY
passed	ENTITY
down	ENTITY
from	ENTITY
neanderthals	ENTITY
.	O
more	O
and	O
more	O
people	O
are	O
suffering	O
from	O
type	O
diabetes	ENTITY
due	ENTITY
to	ENTITY
variety	ENTITY
of	ENTITY
reasons	ENTITY
including	ENTITY
diet	ENTITY
exercise	ENTITY
and	ENTITY
genetics	ENTITY
.	O
according	O
to	O
new	O
study	O
from	O
researchers	O
at	O
harvard	O
medical	O
school	O
in	O
massachusetts	O
working	O
with	O
an	O
expert	O
from	O
the	O
max	O
planck	O
institute	O
for	O
evolutionary	ENTITY
anthropology	ENTITY
in	O
germany	O
genetic	ENTITY
predisposition	ENTITY
for	O
diabetes	ENTITY
in	ENTITY
latin	ENTITY
american	ENTITY
populations	ENTITY
might	ENTITY
be	ENTITY
related	ENTITY
to	ENTITY
gene	ENTITY
variant	ENTITY
passed	ENTITY
down	ENTITY
from	ENTITY
neanderthals	ENTITY
.	O
genome	O
wide	O
association	O
study	O
that	O
analyzed	O
the	O
genes	O
of	O
thousand	O
mexicans	O
and	O
other	O
latin	O
americans	O
shows	O
that	O
subjects	O
who	O
have	O
the	O
gene	ENTITY
are	ENTITY
percent	ENTITY
more	ENTITY
likely	ENTITY
to	ENTITY
have	ENTITY
diabetes	ENTITY
and	ENTITY
people	ENTITY
who	ENTITY
have	ENTITY
versions	ENTITY
of	ENTITY
the	ENTITY
gene	ENTITY
from	ENTITY
both	ENTITY
parents	ENTITY
are	ENTITY
percent	ENTITY
more	ENTITY
likely	ENTITY
to	ENTITY
get	ENTITY
diabetes	ENTITY
.	O
around	O
percent	O
of	O
east	O
asians	O
have	O
the	O
gene	ENTITY
variant	ENTITY
but	ENTITY
it	ENTITY
is	ENTITY
rarely	ENTITY
found	ENTITY
in	ENTITY
european	ENTITY
or	ENTITY
african	ENTITY
populations	ENTITY
.	O
neanderthals	O
went	O
extinct	O
around	O
thousand	O
years	O
ago	O
but	O
they	O
are	O
believed	O
to	O
have	O
interbred	O
with	O
other	O
human	O
species	O
based	O
on	O
genetic	O
evidence	O
from	O
remains	O
found	O
in	O
denisova	ENTITY
cave	ENTITY
in	O
siberia	O
.	O
percent	O
of	O
non	O
african	O
human	O
genomes	O
are	O
reportedly	O
made	O
up	O
of	O
neanderthal	O
dna	ENTITY
.	O
what	O
do	O
you	O
think	O
about	O
the	O
predisposition	O
for	O
diabetes	ENTITY
being	ENTITY
connected	ENTITY
with	ENTITY
genes	ENTITY
from	ENTITY
neanderthals	ENTITY
.	O
genisyss	O
http	O
www	O
genisyss	O
com	O
helps	O
the	O
average	O
person	O
store	O
their	O
dna	ENTITY
and	ENTITY
keep	ENTITY
it	ENTITY
in	ENTITY
their	ENTITY
own	ENTITY
possession	ENTITY
.	O
why	O
.	O
because	O
dna	ENTITY
changes	ENTITY
over	ENTITY
lifetime	ENTITY
of	ENTITY
exposure	ENTITY
to	ENTITY
the	ENTITY
sun	ENTITY
radiation	ENTITY
pollution	ENTITY
chemicals	ENTITY
smoking	ENTITY
and	ENTITY
even	ENTITY
stress	ENTITY
.	O
today	O
dna	ENTITY
is	ENTITY
used	ENTITY
to	ENTITY
identify	ENTITY
predispositions	ENTITY
to	ENTITY
medical	ENTITY
conditions	ENTITY
including	ENTITY
cancer	ENTITY
heart	ENTITY
disease	ENTITY
diabetes	ENTITY
autism	ENTITY
tourette	ENTITY
and	O
many	O
others	O
.	O
by	O
identifying	O
this	O
early	O
and	O
staying	O
mindful	O
your	O
stored	O
dna	ENTITY
from	ENTITY
earlier	ENTITY
in	ENTITY
your	ENTITY
life	ENTITY
or	ENTITY
your	ENTITY
parent	ENTITY
may	ENTITY
be	ENTITY
used	ENTITY
to	ENTITY
treat	ENTITY
and	ENTITY
prevent	ENTITY
the	ENTITY
expression	ENTITY
of	ENTITY
any	ENTITY
diseases	ENTITY
that	ENTITY
show	ENTITY
up	ENTITY
in	ENTITY
your	ENTITY
dna	ENTITY
.	O
in	O
this	O
video	O
talk	O
about	O
epigenetics	ENTITY
.	O
this	O
is	O
the	O
study	O
of	O
the	O
factors	O
that	O
turn	O
on	O
or	O
off	O
gene	ENTITY
expression	ENTITY
.	O
when	O
we	O
see	O
doctor	O
they	O
will	O
want	O
to	O
know	O
your	O
family	O
medical	O
history	O
.	O
they	O
do	O
this	O
to	O
find	O
out	O
if	O
you	O
are	O
predisposed	O
to	O
disease	ENTITY
by	ENTITY
genetics	ENTITY
ie	ENTITY
if	ENTITY
your	ENTITY
mother	ENTITY
had	ENTITY
diabetes	ENTITY
there	ENTITY
is	ENTITY
high	ENTITY
chance	ENTITY
you	ENTITY
will	ENTITY
too	ENTITY
.	O
what	O
research	O
regarding	O
epigenetics	ENTITY
has	ENTITY
found	ENTITY
is	ENTITY
that	ENTITY
even	ENTITY
though	ENTITY
you	ENTITY
have	ENTITY
predisposition	ENTITY
to	ENTITY
an	ENTITY
illness	ENTITY
disease	ENTITY
that	ENTITY
gene	ENTITY
can	ENTITY
be	ENTITY
silenced	ENTITY
or	ENTITY
actioned	ENTITY
by	ENTITY
diet	ENTITY
stress	ENTITY
lifestyle	ENTITY
environmental	ENTITY
factors	ENTITY
.	O
alot	O
of	O
our	O
habits	O
we	O
learnt	O
was	O
when	O
we	O
were	O
children	O
were	O
learnt	O
from	O
our	O
parents	O
or	O
caregivers	O
.	O
so	O
if	O
we	O
live	O
our	O
lives	O
using	O
these	O
habits	O
we	O
learnt	O
from	O
our	O
parents	O
we	O
will	O
most	O
likely	O
action	O
that	O
gene	O
.	O
while	O
if	O
we	O
change	O
our	O
habits	O
lets	O
say	O
better	O
diet	O
we	O
can	O
silence	O
that	O
gene	ENTITY
and	ENTITY
not	ENTITY
manifest	ENTITY
that	ENTITY
illness	ENTITY
.	O
check	O
the	O
video	O
out	O
and	O
let	O
me	O
know	O
what	O
you	O
think	O
.	O
www	O
trulyholistic	O
net	O
.	O
an	O
in	O
depth	O
view	O
of	O
studies	O
highlighting	O
the	O
hidden	O
drivers	O
of	O
type	O
and	O
diabetes	ENTITY
and	ENTITY
well	ENTITY
diet	ENTITY
to	ENTITY
mitigate	ENTITY
and	ENTITY
possibly	ENTITY
reverse	ENTITY
them	ENTITY
altogether	ENTITY
.	O
maybe	O
watch	O
this	O
is	O
segments	O
because	O
it	O
sorta	O
long	O
and	O
extra	O
loaded	O
with	O
science	O
.	O
for	O
each	O
extra	O
or	O
few	O
bites	O
of	O
meat	O
that	O
you	O
consume	O
you	O
have	O
an	O
increased	O
chance	O
of	O
getting	O
diabetes	ENTITY
.	O
an	O
excerpt	O
from	O
the	O
audiobook	O
the	O
language	O
of	O
god	O
scientist	O
presents	O
evidence	O
for	O
belief	O
by	O
physician	O
geneticist	ENTITY
francis	ENTITY
collins	ENTITY
appendix	ENTITY
section	ENTITY
of	ENTITY
disc	ENTITY
tracks	ENTITY
.	O
transcript	O
according	O
to	O
the	O
national	O
institute	O
of	O
health	O
about	O
of	O
people	O
with	O
type	O
diabetes	ENTITY
are	ENTITY
overweight	ENTITY
or	ENTITY
obese	ENTITY
.	O
without	O
doubt	O
obesity	ENTITY
is	ENTITY
major	ENTITY
risk	ENTITY
factor	ENTITY
for	ENTITY
type	ENTITY
diabetes	ENTITY
because	ENTITY
increased	ENTITY
body	ENTITY
fat	ENTITY
makes	O
it	O
difficult	O
for	O
the	O
body	O
to	O
use	O
insulin	ENTITY
properly	ENTITY
.	O
does	O
this	O
mean	O
that	O
diabetes	ENTITY
is	ENTITY
just	ENTITY
disease	ENTITY
of	ENTITY
the	ENTITY
obese	ENTITY
.	O
unfortunately	O
being	O
skinny	O
is	O
not	O
always	O
protection	O
against	O
diabetes	ENTITY
.	O
many	O
who	O
do	O
not	O
fit	O
the	O
typical	O
physical	O
description	O
of	O
diabetic	ENTITY
overweight	ENTITY
and	O
older	O
can	O
get	O
diabetes	ENTITY
.	O
although	O
increased	O
body	O
weight	O
is	O
risk	O
factor	O
for	O
diabetes	ENTITY
it	ENTITY
is	ENTITY
not	ENTITY
the	ENTITY
only	ENTITY
risk	ENTITY
factor	ENTITY
.	O
lean	O
people	O
can	O
be	O
at	O
risk	O
for	O
type	O
diabetes	ENTITY
for	ENTITY
other	ENTITY
reasons	ENTITY
not	ENTITY
directly	ENTITY
related	ENTITY
to	ENTITY
body	ENTITY
weight	ENTITY
.	O
this	O
risk	O
however	O
is	O
low	O
especially	O
in	O
comparison	O
to	O
obese	ENTITY
individuals	ENTITY
.	O
it	O
in	O
the	O
genes	ENTITY
aside	ENTITY
from	ENTITY
commonly	ENTITY
known	ENTITY
risk	ENTITY
factors	ENTITY
for	ENTITY
diabetes	ENTITY
such	ENTITY
as	ENTITY
excess	ENTITY
weight	ENTITY
and	ENTITY
old	ENTITY
age	ENTITY
there	ENTITY
are	ENTITY
two	ENTITY
strong	ENTITY
risk	ENTITY
factors	ENTITY
for	ENTITY
diabetes	ENTITY
that	ENTITY
are	ENTITY
often	ENTITY
overlooked	ENTITY
genes	ENTITY
and	ENTITY
family	ENTITY
history	ENTITY
.	O
some	O
people	O
are	O
born	O
more	O
likely	O
to	O
have	O
diabetes	ENTITY
regardless	ENTITY
of	ENTITY
their	ENTITY
weight	ENTITY
.	O
in	O
fact	O
according	O
to	O
the	O
american	O
diabetes	ENTITY
association	ENTITY
type	ENTITY
diabetes	ENTITY
has	ENTITY
stronger	ENTITY
link	ENTITY
to	ENTITY
family	ENTITY
history	ENTITY
than	ENTITY
type	ENTITY
diabetes	ENTITY
especially	ENTITY
in	ENTITY
twins	ENTITY
.	O
if	O
one	O
twin	O
has	O
type	O
the	O
other	O
twin	O
risk	O
is	O
up	O
to	O
.	O
research	O
study	O
published	O
in	O
plos	O
genetics	O
found	O
that	O
most	O
lean	O
cases	O
are	O
people	O
with	O
strong	O
genetic	ENTITY
predisposition	ENTITY
for	O
type	O
diabetes	ENTITY
.	O
even	O
family	O
history	O
of	O
heart	ENTITY
disease	ENTITY
can	O
increase	O
person	O
risk	O
for	O
diabetes	ENTITY
.	O
lifestyle	O
it	O
important	O
to	O
note	O
that	O
in	O
the	O
field	O
of	O
health	O
and	O
nutrition	O
the	O
word	O
skinny	O
does	O
not	O
always	O
mean	O
healthy	O
.	O
even	O
relatively	O
skinny	O
person	O
can	O
have	O
poor	O
diet	O
and	O
low	O
activity	O
levels	O
.	O
unhealthy	O
lifestyle	O
choices	O
can	O
increase	O
the	O
risk	O
for	O
diabetes	ENTITY
.	O
low	O
physical	O
activity	O
encourages	O
insulin	ENTITY
resistance	ENTITY
.	O
coupled	O
with	O
poor	O
diet	O
sedentary	O
lifestyle	O
can	O
lead	O
to	O
increased	O
body	O
fat	ENTITY
especially	ENTITY
dangerous	ENTITY
type	ENTITY
of	ENTITY
body	ENTITY
fat	ENTITY
called	O
visceral	ENTITY
fat	ENTITY
.	O
this	O
type	O
of	O
fat	ENTITY
is	ENTITY
not	ENTITY
the	ENTITY
fat	ENTITY
found	ENTITY
under	ENTITY
the	ENTITY
skin	ENTITY
.	O
this	O
is	O
the	O
fat	ENTITY
that	ENTITY
surrounds	ENTITY
internal	ENTITY
organs	ENTITY
especially	ENTITY
around	ENTITY
the	ENTITY
waist	ENTITY
area	ENTITY
.	O
such	O
poor	O
lifestyle	O
choices	O
increase	O
the	O
risk	O
of	O
hypertension	ENTITY
high	ENTITY
cholesterol	ENTITY
and	O
high	ENTITY
triglyceride	ENTITY
levels	ENTITY
in	O
the	O
blood	ENTITY
.	O
all	O
of	O
these	O
health	O
problems	O
can	O
encourage	O
the	O
development	O
of	O
type	O
diabetes	ENTITY
as	ENTITY
well	ENTITY
.	O
smoking	O
can	O
also	O
increase	O
your	O
risk	O
for	O
type	O
diabetes	ENTITY
regardless	ENTITY
of	ENTITY
your	ENTITY
body	ENTITY
weight	ENTITY
.	O
according	O
to	O
the	O
american	O
journal	O
of	O
epidemiology	ENTITY
heavy	ENTITY
smoker	ENTITY
cigarettes	ENTITY
day	ENTITY
has	ENTITY
risk	ENTITY
for	ENTITY
type	ENTITY
diabetes	ENTITY
three	ENTITY
times	ENTITY
greater	ENTITY
than	ENTITY
that	ENTITY
of	ENTITY
non	ENTITY
smoker	ENTITY
.	O
specific	O
populations	O
research	O
has	O
shown	O
that	O
certain	O
population	O
groups	O
are	O
more	O
susceptible	O
to	O
diabetes	ENTITY
than	ENTITY
others	ENTITY
.	O
for	O
example	O
thin	O
cases	O
of	O
diabetes	ENTITY
are	ENTITY
more	ENTITY
common	ENTITY
in	ENTITY
the	ENTITY
elderly	ENTITY
or	ENTITY
certain	ENTITY
non	ENTITY
caucasian	ENTITY
ethnicities	ENTITY
.	O
these	O
include	O
african	O
americans	O
native	O
americans	O
hispanic	O
latino	O
americans	O
asian	O
americans	O
and	O
pacific	O
islanders	O
.	O
since	O
these	O
ethnic	O
backgrounds	O
are	O
more	O
vulnerable	O
to	O
diabetes	ENTITY
body	ENTITY
weight	ENTITY
may	ENTITY
not	ENTITY
make	ENTITY
huge	ENTITY
difference	ENTITY
in	ENTITY
the	ENTITY
risk	ENTITY
for	ENTITY
diabetes	ENTITY
.	O
during	O
pregnancy	O
women	O
can	O
develop	O
temporary	O
type	O
of	O
diabetes	ENTITY
called	ENTITY
gestational	ENTITY
diabetes	ENTITY
.	O
if	O
this	O
occurs	O
their	O
chances	O
of	O
developing	O
type	O
diabetes	ENTITY
are	ENTITY
higher	ENTITY
for	ENTITY
the	ENTITY
next	ENTITY
decade	ENTITY
or	ENTITY
so	ENTITY
regardless	ENTITY
of	ENTITY
their	ENTITY
weight	ENTITY
.	O
if	O
woman	O
gave	O
birth	O
to	O
at	O
least	O
one	O
baby	O
weighing	O
more	O
than	O
pounds	O
she	O
is	O
at	O
increased	O
risk	O
for	O
developing	O
type	O
diabetes	ENTITY
regardless	ENTITY
of	ENTITY
her	ENTITY
weight	ENTITY
or	ENTITY
family	ENTITY
history	ENTITY
.	O
understand	O
diabetes	ENTITY
to	ENTITY
prevent	ENTITY
or	ENTITY
delay	ENTITY
it	ENTITY
there	ENTITY
are	ENTITY
overweight	ENTITY
people	ENTITY
without	ENTITY
diabetes	ENTITY
and	ENTITY
thin	ENTITY
people	ENTITY
with	ENTITY
diabetes	ENTITY
.	O
however	O
the	O
diabetes	ENTITY
epidemic	ENTITY
nationally	ENTITY
and	ENTITY
globally	ENTITY
lies	ENTITY
mainly	ENTITY
but	ENTITY
not	ENTITY
exclusively	ENTITY
in	ENTITY
obese	ENTITY
individuals	ENTITY
.	O
according	O
to	O
study	O
published	O
in	O
diabetology	ENTITY
amp	ENTITY
metabolic	ENTITY
syndrome	ENTITY
the	O
risk	O
of	O
developing	O
type	O
diabetes	ENTITY
for	ENTITY
overweight	ENTITY
people	ENTITY
is	ENTITY
about	ENTITY
times	ENTITY
higher	ENTITY
than	ENTITY
normal	ENTITY
weight	ENTITY
individuals	ENTITY
.	O
many	O
of	O
the	O
risk	O
factors	O
for	O
type	O
diabetes	ENTITY
in	ENTITY
lean	ENTITY
people	ENTITY
are	ENTITY
out	ENTITY
of	ENTITY
their	ENTITY
control	ENTITY
such	ENTITY
as	ENTITY
family	ENTITY
history	ENTITY
or	ENTITY
genes	ENTITY
.	O
weight	O
on	O
the	O
other	O
hand	O
is	O
factor	O
that	O
can	O
be	O
controlled	O
.	O
if	O
you	O
are	O
at	O
risk	O
for	O
type	O
diabetes	ENTITY
weight	ENTITY
loss	ENTITY
is	ENTITY
an	ENTITY
important	ENTITY
measure	ENTITY
to	ENTITY
take	ENTITY
to	ENTITY
prevent	ENTITY
or	ENTITY
delay	ENTITY
the	ENTITY
onset	ENTITY
of	ENTITY
diabetes	ENTITY
.	O
the	O
facts	O
show	O
that	O
people	O
can	O
develop	O
type	O
diabetes	ENTITY
at	ENTITY
any	ENTITY
age	ENTITY
or	ENTITY
weight	ENTITY
even	ENTITY
during	ENTITY
childhood	ENTITY
or	ENTITY
in	ENTITY
lean	ENTITY
person	ENTITY
.	O
however	O
this	O
type	O
of	O
diabetes	ENTITY
develops	ENTITY
most	ENTITY
often	ENTITY
in	ENTITY
middle	ENTITY
aged	ENTITY
and	ENTITY
older	ENTITY
people	ENTITY
.	O
regardless	O
of	O
the	O
risk	O
factors	O
you	O
may	O
or	O
may	O
not	O
have	O
it	O
is	O
important	O
to	O
recognize	O
the	O
warning	O
signs	O
of	O
diabetes	ENTITY
and	ENTITY
to	ENTITY
make	ENTITY
healthy	ENTITY
lifestyle	ENTITY
choices	ENTITY
that	ENTITY
can	ENTITY
help	ENTITY
prevent	ENTITY
it	ENTITY
.	O
aidan	O
power	O
at	O
pfizer	O
speculates	O
about	O
obesity	ENTITY
and	ENTITY
diabetes	ENTITY
genes	ENTITY
and	ENTITY
whether	ENTITY
behavioral	ENTITY
changes	ENTITY
can	ENTITY
trounce	ENTITY
our	ENTITY
biology	ENTITY
.	O
we	O
all	O
have	O
heard	O
about	O
the	O
thrifty	ENTITY
genes	ENTITY
.	O
but	O
what	O
are	O
the	O
various	O
other	O
factors	O
that	O
lead	O
to	O
diabetes	ENTITY
and	ENTITY
how	ENTITY
to	ENTITY
keep	ENTITY
them	ENTITY
at	ENTITY
bay	ENTITY
.	O
dr	O
jaydeep	O
shinde	O
tells	O
us	O
about	O
the	O
need	O
to	O
reckon	O
with	O
diabetes	ENTITY
even	ENTITY
before	ENTITY
its	ENTITY
onset	ENTITY
so	ENTITY
that	ENTITY
we	ENTITY
can	ENTITY
postpone	ENTITY
the	ENTITY
related	ENTITY
complications	ENTITY
effectively	ENTITY
.	O
we	O
at	O
indian	O
diabetes	ENTITY
review	ENTITY
tv	ENTITY
are	ENTITY
trying	ENTITY
to	ENTITY
bring	ENTITY
you	ENTITY
complete	ENTITY
news	ENTITY
portal	ENTITY
for	ENTITY
diabetics	ENTITY
and	ENTITY
their	ENTITY
care	ENTITY
givers	ENTITY
.	O
visit	O
our	O
website	O
www	O
indiandiabetesreview	O
com	O
which	O
is	O
updated	O
as	O
management	O
of	O
diabetes	ENTITY
depends	ENTITY
solely	ENTITY
on	ENTITY
information	ENTITY
we	ENTITY
intend	ENTITY
to	ENTITY
bring	ENTITY
to	ENTITY
you	ENTITY
all	ENTITY
the	ENTITY
news	ENTITY
and	ENTITY
analysis	ENTITY
about	ENTITY
various	ENTITY
developments	ENTITY
from	ENTITY
the	ENTITY
world	ENTITY
over	ENTITY
that	ENTITY
can	ENTITY
impact	ENTITY
your	ENTITY
health	ENTITY
.	O
we	O
cull	O
the	O
best	O
of	O
news	O
and	O
information	O
that	O
can	O
help	O
you	O
live	O
full	O
life	O
in	O
spite	O
of	O
your	O
debilitating	O
health	O
condition	O
.	O
in	O
these	O
videos	O
you	O
will	O
come	O
across	O
people	O
who	O
have	O
managed	O
to	O
beat	O
conventional	O
thinking	O
on	O
diabetes	ENTITY
celebrities	ENTITY
who	ENTITY
have	ENTITY
take	ENTITY
on	ENTITY
diabetes	ENTITY
health	ENTITY
professionals	ENTITY
who	ENTITY
have	ENTITY
new	ENTITY
insight	ENTITY
into	ENTITY
diabetes	ENTITY
management	ENTITY
or	ENTITY
even	ENTITY
thought	ENTITY
leader	ENTITY
who	ENTITY
has	ENTITY
an	ENTITY
opinion	ENTITY
on	ENTITY
this	ENTITY
health	ENTITY
disorder	ENTITY
.	O
you	O
can	O
always	O
write	O
to	O
us	O
about	O
what	O
you	O
feel	O
about	O
our	O
internet	O
television	O
programmes	O
news	O
portal	O
or	O
magazine	O
drop	O
in	O
line	O
our	O
email	O
id	O
is	O
editorial	O
parabolamedia	O
com	O
you	O
can	O
also	O
call	O
us	O
at	O
if	O
you	O
want	O
to	O
subscribe	O
to	O
our	O
monthly	O
news	O
magazine	O
living	O
with	O
diabetes	ENTITY
.	O
how	O
to	O
reverse	O
diabetes	ENTITY
.	O
turns	O
out	O
the	O
diabetes	ENTITY
industry	ENTITY
is	ENTITY
selling	ENTITY
us	ENTITY
fake	ENTITY
research	ENTITY
.	O
hi	O
.	O
robo	O
suzie	O
and	O
today	O
ll	O
talk	O
to	O
you	O
about	O
diabetes	ENTITY
african	ENTITY
americans	ENTITY
deadly	ENTITY
foe	ENTITY
.	O
also	O
don	O
forget	O
to	O
check	O
out	O
the	O
link	O
below	O
to	O
find	O
out	O
how	O
this	O
guy	O
reversed	O
his	O
diabetes	ENTITY
.	O
turns	O
out	O
the	O
diabetes	ENTITY
industry	ENTITY
is	O
selling	O
us	O
fake	O
research	O
.	O
but	O
back	O
to	O
our	O
topic	O
.	O
diabetes	ENTITY
is	ENTITY
having	ENTITY
devastating	ENTITY
effect	ENTITY
on	ENTITY
the	ENTITY
african	ENTITY
american	ENTITY
community	ENTITY
.	O
diabetes	ENTITY
is	ENTITY
the	ENTITY
fifth	ENTITY
leading	ENTITY
cause	ENTITY
of	ENTITY
death	ENTITY
in	ENTITY
african	ENTITY
americans	ENTITY
and	ENTITY
their	ENTITY
death	ENTITY
rates	ENTITY
are	ENTITY
twenty	ENTITY
seven	ENTITY
percent	ENTITY
higher	ENTITY
than	ENTITY
whites	ENTITY
.	O
over	O
million	O
african	O
americans	O
have	O
diabetes	ENTITY
and	ENTITY
one	ENTITY
third	ENTITY
of	ENTITY
them	ENTITY
don	ENTITY
know	ENTITY
they	ENTITY
have	ENTITY
the	ENTITY
disease	ENTITY
.	O
in	O
addition	O
twenty	O
five	O
percent	O
of	O
african	O
americans	O
between	O
the	O
ages	O
of	O
have	O
diabetes	ENTITY
and	ENTITY
one	ENTITY
in	ENTITY
four	ENTITY
african	ENTITY
american	ENTITY
women	ENTITY
over	ENTITY
the	ENTITY
age	ENTITY
of	ENTITY
have	ENTITY
been	ENTITY
diagnosed	ENTITY
with	ENTITY
the	ENTITY
disease	ENTITY
the	ENTITY
cause	ENTITY
of	ENTITY
diabetes	ENTITY
is	ENTITY
mystery	ENTITY
but	ENTITY
researchers	ENTITY
believe	ENTITY
that	ENTITY
both	ENTITY
genetics	ENTITY
and	ENTITY
environmental	ENTITY
factors	ENTITY
play	ENTITY
roles	ENTITY
in	ENTITY
who	ENTITY
will	ENTITY
develop	ENTITY
the	ENTITY
disease	ENTITY
.	O
heredity	O
.	O
researchers	O
believe	O
that	O
african	O
americans	O
and	O
african	O
immigrants	O
are	O
predisposed	O
to	O
developing	O
diabetes	ENTITY
.	O
research	O
suggests	O
that	O
african	O
americans	O
and	O
recent	O
african	O
immigrants	O
have	O
inherited	O
thrifty	ENTITY
gene	ENTITY
from	O
their	O
african	O
ancestors	O
.	O
this	O
gene	ENTITY
may	ENTITY
have	ENTITY
enabled	ENTITY
africans	ENTITY
to	ENTITY
use	ENTITY
food	ENTITY
energy	ENTITY
more	ENTITY
efficiently	ENTITY
during	ENTITY
cycles	ENTITY
of	ENTITY
feast	ENTITY
and	ENTITY
famine	ENTITY
.	O
now	O
with	O
fewer	O
cycles	O
of	O
feast	O
and	O
famine	O
this	O
gene	ENTITY
may	ENTITY
make	ENTITY
weight	ENTITY
control	ENTITY
more	ENTITY
difficult	ENTITY
for	ENTITY
african	ENTITY
americans	ENTITY
and	ENTITY
african	ENTITY
immigrants	ENTITY
.	O
this	O
genetic	ENTITY
predisposition	ENTITY
coupled	O
with	O
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
is	O
often	O
associated	O
with	O
the	O
genetic	O
tendency	O
toward	O
high	ENTITY
blood	ENTITY
pressure	ENTITY
.	O
people	O
with	O
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
have	O
higher	O
than	O
normal	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
and	O
are	O
at	O
higher	O
risk	O
for	O
developing	O
diabetes	ENTITY
.	O
what	O
is	O
diabetes	ENTITY
.	O
diabetes	ENTITY
commonly	ENTITY
know	ENTITY
as	ENTITY
sugar	ENTITY
diabetes	ENTITY
is	O
condition	O
that	O
occurs	O
when	O
the	O
body	O
is	O
unable	O
to	O
properly	O
produce	O
or	O
use	O
insulin	ENTITY
.	O
insulin	ENTITY
is	ENTITY
needed	ENTITY
by	ENTITY
the	ENTITY
body	ENTITY
to	ENTITY
process	ENTITY
sugar	ENTITY
starches	ENTITY
and	ENTITY
other	ENTITY
foods	ENTITY
into	ENTITY
energy	ENTITY
.	O
diabetes	ENTITY
is	ENTITY
chronic	ENTITY
condition	ENTITY
for	ENTITY
which	ENTITY
there	ENTITY
is	ENTITY
no	ENTITY
known	ENTITY
cure	ENTITY
diabetes	ENTITY
is	ENTITY
serious	ENTITY
disease	ENTITY
and	ENTITY
should	ENTITY
not	ENTITY
be	ENTITY
ignored	ENTITY
.	O
diabetics	ENTITY
often	ENTITY
suffer	ENTITY
from	ENTITY
low	ENTITY
glucose	ENTITY
levels	ENTITY
sugar	ENTITY
in	ENTITY
their	ENTITY
blood	ENTITY
.	O
low	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
can	O
make	O
you	O
disorientated	O
dizzy	O
sweaty	O
hungry	O
have	O
headaches	ENTITY
have	ENTITY
sudden	ENTITY
mood	ENTITY
swings	ENTITY
have	ENTITY
difficulty	ENTITY
paying	ENTITY
attention	ENTITY
or	ENTITY
have	ENTITY
tingling	ENTITY
sensations	ENTITY
around	ENTITY
the	ENTITY
mouth	ENTITY
.	O
types	O
of	O
diabetes	ENTITY
.	O
pre	ENTITY
diabetes	ENTITY
is	O
condition	O
that	O
occurs	O
when	O
person	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
is	O
higher	O
than	O
normal	O
but	O
not	O
high	O
enough	O
for	O
diagnosis	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
pre	ENTITY
diabetes	ENTITY
can	O
cause	O
damage	O
to	O
the	O
heart	ENTITY
and	ENTITY
circulatory	ENTITY
system	ENTITY
but	O
pre	ENTITY
diabetes	ENTITY
can	O
often	O
be	O
controlled	O
by	O
controlling	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
.	O
by	O
controlling	O
pre	ENTITY
diabetes	ENTITY
you	O
can	O
often	O
prevent	O
or	O
delay	O
the	O
onset	O
of	O
type	O
diabetes	ENTITY
.	O
type	O
or	O
juvenile	ENTITY
onset	ENTITY
diabetes	ENTITY
usually	O
strikes	O
people	O
under	O
the	O
age	O
of	O
but	O
can	O
strike	O
at	O
any	O
age	O
.	O
five	O
to	O
ten	O
percent	O
of	O
african	O
americans	O
who	O
are	O
diagnosed	O
with	O
diabetes	ENTITY
are	ENTITY
diagnosed	ENTITY
with	ENTITY
this	ENTITY
type	ENTITY
of	ENTITY
the	ENTITY
disease	ENTITY
.	O
type	O
diabetes	ENTITY
is	ENTITY
an	ENTITY
autoimmune	ENTITY
disease	ENTITY
where	O
the	O
body	O
produces	O
little	O
or	O
no	O
insulin	ENTITY
and	ENTITY
this	ENTITY
type	ENTITY
of	ENTITY
disease	ENTITY
must	ENTITY
be	ENTITY
treated	ENTITY
with	ENTITY
daily	ENTITY
insulin	ENTITY
injections	ENTITY
.	O
type	O
or	O
adult	ENTITY
onset	ENTITY
diabetes	ENTITY
is	O
responsible	O
for	O
ninety	O
to	O
ninety	O
five	O
percent	O
of	O
diagnosed	O
diabetes	ENTITY
cases	ENTITY
in	ENTITY
african	ENTITY
americans	ENTITY
.	O
type	O
results	O
from	O
condition	O
where	O
the	O
body	O
fails	O
to	O
properly	O
use	O
insulin	ENTITY
.	O
according	O
to	O
the	O
american	O
diabetes	ENTITY
association	ENTITY
type	ENTITY
is	ENTITY
usually	ENTITY
found	ENTITY
in	ENTITY
people	ENTITY
over	ENTITY
who	ENTITY
have	ENTITY
diabetes	ENTITY
in	ENTITY
their	ENTITY
family	ENTITY
who	ENTITY
are	ENTITY
overweight	ENTITY
who	ENTITY
don	ENTITY
exercise	ENTITY
and	ENTITY
who	ENTITY
have	ENTITY
cholesterol	ENTITY
problems	ENTITY
.	O
in	O
the	O
early	O
stages	O
it	O
can	O
often	O
be	O
controlled	O
with	O
lifestyle	O
changes	O
but	O
in	O
the	O
later	O
stages	O
diabetic	O
pills	O
or	O
insulin	ENTITY
injections	ENTITY
are	O
often	O
needed	O
.	O
pregnancy	ENTITY
related	ENTITY
diabetes	ENTITY
or	O
gestational	ENTITY
diabetes	ENTITY
can	O
occur	O
in	O
pregnant	O
women	O
.	O
gestational	ENTITY
diabetes	ENTITY
is	O
often	O
associated	O
with	O
high	ENTITY
glucose	ENTITY
blood	ENTITY
levels	ENTITY
or	O
hyperglycemia	ENTITY
.	O
gestational	ENTITY
diabetes	ENTITY
affects	O
about	O
four	O
percent	O
of	O
all	O
pregnant	O
women	O
.	O
the	O
disease	ENTITY
usually	ENTITY
goes	ENTITY
away	ENTITY
after	ENTITY
delivery	ENTITY
but	ENTITY
women	ENTITY
who	ENTITY
suffer	ENTITY
from	ENTITY
gestational	ENTITY
diabetes	ENTITY
are	O
at	O
higher	O
risk	O
for	O
developing	O
diabetes	ENTITY
later	ENTITY
in	ENTITY
life	ENTITY
.	O
symptoms	O
of	O
diabetes	ENTITY
.	O
the	O
most	O
common	O
symptoms	O
of	O
diabetes	ENTITY
include	ENTITY
excessive	ENTITY
urination	ENTITY
including	O
frequent	O
trips	O
to	O
the	O
bathroom	O
.	O
increased	O
thirst	O
.	O
increased	O
appetite	O
.	O
blurred	O
vision	O
.	O
unusual	O
weight	O
loss	O
.	O
increased	O
fatigue	O
.	O
irritability	O
.	O
complications	ENTITY
from	ENTITY
diabetes	ENTITY
.	O
diabetes	ENTITY
can	ENTITY
lead	ENTITY
to	ENTITY
many	ENTITY
disabling	ENTITY
and	ENTITY
life	ENTITY
threatening	ENTITY
complications	ENTITY
.	O
strokes	O
blindness	O
kidney	ENTITY
failure	ENTITY
heart	ENTITY
disease	ENTITY
and	O
amputations	ENTITY
are	ENTITY
common	ENTITY
complications	ENTITY
that	ENTITY
effect	ENTITY
african	ENTITY
americans	ENTITY
who	ENTITY
have	ENTITY
diabetes	ENTITY
kidney	ENTITY
disease	ENTITY
.	O
diabetes	ENTITY
is	ENTITY
the	ENTITY
second	ENTITY
leading	ENTITY
cause	ENTITY
of	ENTITY
end	ENTITY
stage	ENTITY
kidney	ENTITY
disease	ENTITY
in	O
african	O
americans	O
accounting	O
for	O
about	O
thirty	O
percent	O
of	O
the	O
new	O
cases	O
each	O
year	O
says	O
the	O
national	O
kidney	ENTITY
foundation	ENTITY
of	ENTITY
illinois	ENTITY
.	O
up	O
to	O
twenty	O
one	O
percent	O
of	O
people	O
who	O
develop	O
diabetes	ENTITY
will	ENTITY
develop	ENTITY
kidney	ENTITY
disease	ENTITY
.	O
session	O
maturity	ENTITY
onset	ENTITY
diabetes	ENTITY
of	O
the	O
young	O
clinical	O
heterogenity	O
explained	O
by	O
genetic	ENTITY
heterogenity	ENTITY
thanabalasingham	ENTITY
part	ENTITY
.	O
visit	O
cure	O
to	O
know	O
more	O
is	O
diabetes	ENTITY
genetic	ENTITY
you	ENTITY
ve	ENTITY
probably	ENTITY
wondered	ENTITY
how	ENTITY
you	ENTITY
developed	ENTITY
diabetes	ENTITY
.	O
you	O
may	O
worry	O
that	O
your	O
children	O
will	O
develop	O
it	O
too	O
.	O
unlike	O
some	O
traits	O
diabetes	ENTITY
does	ENTITY
not	ENTITY
seem	ENTITY
to	ENTITY
be	ENTITY
inherited	ENTITY
in	ENTITY
simple	ENTITY
pattern	ENTITY
.	O
yet	O
clearly	O
some	O
people	O
are	O
born	O
more	O
likely	O
to	O
develop	O
diabetes	ENTITY
than	ENTITY
others	ENTITY
.	O
what	O
leads	O
to	O
diabetes	ENTITY
.	O
type	O
and	O
type	O
diabetes	ENTITY
have	ENTITY
different	ENTITY
causes	ENTITY
.	O
yet	O
two	O
factors	O
are	O
important	O
in	O
both	O
.	O
you	O
inherit	O
predisposition	O
to	O
the	O
disease	O
then	O
something	O
in	O
your	O
environment	O
triggers	O
it	O
.	O
genes	O
alone	O
are	O
not	O
enough	O
.	O
one	O
proof	O
of	O
this	O
is	O
identical	O
twins	O
.	O
identical	O
twins	O
have	O
identical	O
genes	ENTITY
.	O
yet	O
when	O
one	O
twin	O
has	O
type	O
diabetes	ENTITY
the	ENTITY
other	ENTITY
gets	ENTITY
the	ENTITY
disease	ENTITY
at	ENTITY
most	ENTITY
only	ENTITY
half	ENTITY
the	ENTITY
time	ENTITY
.	O
when	O
one	O
twin	O
has	O
type	O
diabetes	ENTITY
the	ENTITY
other	ENTITY
risk	ENTITY
is	ENTITY
at	ENTITY
most	ENTITY
in	ENTITY
type	ENTITY
diabetes	ENTITY
in	ENTITY
most	ENTITY
cases	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
people	ENTITY
need	ENTITY
to	ENTITY
inherit	ENTITY
risk	ENTITY
factors	ENTITY
from	ENTITY
both	ENTITY
parents	ENTITY
.	O
we	O
think	O
these	O
factors	O
must	O
be	O
more	O
common	O
in	O
whites	O
because	O
whites	O
have	O
the	O
highest	O
rate	O
of	O
type	O
diabetes	ENTITY
.	O
because	O
most	O
people	O
who	O
are	O
at	O
risk	O
do	O
not	O
get	O
diabetes	ENTITY
researchers	ENTITY
want	ENTITY
to	ENTITY
find	ENTITY
out	ENTITY
what	ENTITY
the	ENTITY
environmental	ENTITY
triggers	ENTITY
are	ENTITY
.	O
one	O
trigger	O
might	O
be	O
related	O
to	O
cold	O
weather	O
.	O
type	O
diabetes	ENTITY
develops	ENTITY
more	ENTITY
often	ENTITY
in	ENTITY
winter	ENTITY
than	ENTITY
summer	ENTITY
and	ENTITY
is	ENTITY
more	ENTITY
common	ENTITY
in	ENTITY
places	ENTITY
with	ENTITY
cold	ENTITY
climates	ENTITY
.	O
another	O
trigger	O
might	O
be	O
viruses	O
.	O
perhaps	O
virus	O
that	O
has	O
only	O
mild	O
effects	O
on	O
most	O
people	O
triggers	O
type	O
diabetes	ENTITY
in	ENTITY
others	ENTITY
.	O
early	O
diet	O
may	O
also	O
play	O
role	O
.	O
type	O
diabetes	ENTITY
is	ENTITY
less	ENTITY
common	ENTITY
in	ENTITY
people	ENTITY
who	ENTITY
were	ENTITY
breastfed	ENTITY
and	ENTITY
in	ENTITY
those	ENTITY
who	ENTITY
first	ENTITY
ate	ENTITY
solid	ENTITY
foods	ENTITY
at	ENTITY
later	ENTITY
ages	ENTITY
.	O
in	O
many	O
people	O
the	O
development	O
of	O
type	O
diabetes	ENTITY
seems	ENTITY
to	ENTITY
take	ENTITY
many	ENTITY
years	ENTITY
.	O
in	O
experiments	O
that	O
followed	O
relatives	O
of	O
people	O
with	O
type	O
diabetes	ENTITY
researchers	ENTITY
found	ENTITY
that	ENTITY
most	ENTITY
of	ENTITY
those	ENTITY
who	ENTITY
later	ENTITY
got	ENTITY
diabetes	ENTITY
had	ENTITY
certain	ENTITY
autoantibodies	ENTITY
in	ENTITY
their	ENTITY
blood	ENTITY
for	ENTITY
years	ENTITY
before	ENTITY
.	O
antibodies	ENTITY
are	ENTITY
proteins	ENTITY
that	ENTITY
destroy	ENTITY
bacteria	ENTITY
or	ENTITY
viruses	ENTITY
.	O
autoantibodies	ENTITY
are	ENTITY
antibodies	ENTITY
gone	ENTITY
bad	ENTITY
which	ENTITY
attack	ENTITY
the	ENTITY
body	ENTITY
own	ENTITY
tissues	ENTITY
.	O
type	O
diabetes	ENTITY
type	ENTITY
diabetes	ENTITY
has	ENTITY
stronger	ENTITY
link	ENTITY
to	ENTITY
family	ENTITY
history	ENTITY
and	ENTITY
lineage	ENTITY
than	ENTITY
type	ENTITY
although	ENTITY
it	ENTITY
too	ENTITY
depends	ENTITY
on	ENTITY
environmental	ENTITY
factors	ENTITY
.	O
studies	O
of	O
twins	O
have	O
shown	O
that	O
genetics	O
play	O
very	O
strong	O
role	O
in	O
the	O
development	O
of	O
type	O
diabetes	ENTITY
.	O
lifestyle	O
also	O
influences	O
the	O
development	O
of	O
type	O
diabetes	ENTITY
.	O
obesity	ENTITY
tends	ENTITY
to	ENTITY
run	ENTITY
in	ENTITY
families	ENTITY
and	ENTITY
families	ENTITY
tend	ENTITY
to	ENTITY
have	ENTITY
similar	ENTITY
eating	ENTITY
and	ENTITY
exercise	ENTITY
habits	ENTITY
.	O
if	O
you	O
have	O
family	O
history	O
of	O
type	O
diabetes	ENTITY
it	ENTITY
may	ENTITY
be	ENTITY
difficult	ENTITY
to	ENTITY
figure	ENTITY
out	ENTITY
whether	ENTITY
your	ENTITY
diabetes	ENTITY
is	ENTITY
due	ENTITY
to	ENTITY
lifestyle	ENTITY
factors	ENTITY
or	ENTITY
genetic	ENTITY
susceptibility	ENTITY
.	O
most	O
likely	O
it	O
is	O
due	O
to	O
both	O
.	O
however	O
don	O
lose	O
heart	ENTITY
.	O
studies	O
show	O
that	O
it	O
is	O
possible	O
to	O
delay	O
or	O
prevent	O
type	O
diabetes	ENTITY
by	ENTITY
exercising	ENTITY
and	ENTITY
losing	ENTITY
weight	ENTITY
.	O
have	O
you	O
recently	O
been	O
diagnosed	O
with	O
type	O
diabetes	ENTITY
.	O
join	O
our	O
free	O
living	O
with	O
type	O
diabetes	ENTITY
program	ENTITY
and	ENTITY
the	ENTITY
information	ENTITY
and	ENTITY
support	ENTITY
you	ENTITY
need	ENTITY
to	ENTITY
live	ENTITY
well	ENTITY
with	ENTITY
diabetes	ENTITY
is	ENTITY
diabetes	ENTITY
genetic	ENTITY
.	O
genetic	ENTITY
predisposition	ENTITY
and	O
diabetes	ENTITY
.	O
watch	O
full	O
version	O
.	O
continue	O
watching	O
.	O
was	O
not	O
born	O
with	O
diabetes	ENTITY
.	O
was	O
however	O
born	O
with	O
genetic	ENTITY
predisposition	ENTITY
towards	O
getting	O
diabetes	ENTITY
.	O
diabetes	ENTITY
melissa	ENTITY
mahan	ENTITY
sat	ENTITY
down	ENTITY
with	ENTITY
doctor	ENTITY
barry	ENTITY
ramo	ENTITY
to	ENTITY
find	ENTITY
out	ENTITY
how	ENTITY
much	ENTITY
of	ENTITY
role	ENTITY
your	ENTITY
genes	ENTITY
play	ENTITY
.	O
healthy	O
lifestyle	O
has	O
the	O
power	O
to	O
keep	O
genetic	ENTITY
predispositions	ENTITY
to	O
diseases	ENTITY
at	ENTITY
bay	ENTITY
.	O
ental	O
scientists	O
first	O
turned	O
their	O
attention	O
to	O
understanding	O
the	O
biologic	O
plausibility	O
of	O
how	O
periodontitis	ENTITY
might	ENTITY
confer	ENTITY
risk	ENTITY
for	ENTITY
systemic	ENTITY
disease	ENTITY
.	O
cardiovascular	ENTITY
diseases	ENTITY
cvd	ENTITY
primarily	ENTITY
are	ENTITY
result	ENTITY
of	ENTITY
atherosclerosis	ENTITY
and	ENTITY
are	ENTITY
the	ENTITY
number	ENTITY
one	ENTITY
cause	ENTITY
of	ENTITY
mortality	ENTITY
worldwide	ENTITY
.	O
increasing	O
evidence	O
over	O
the	O
past	O
decade	O
suggests	O
that	O
severe	ENTITY
periodontal	ENTITY
disease	ENTITY
is	O
associated	O
with	O
increased	O
cardiovascular	ENTITY
disease	ENTITY
risk	O
.	O
several	O
possible	O
mechanisms	O
may	O
operate	O
independently	O
or	O
in	O
concert	O
to	O
explain	O
this	O
association	O
.	O
the	O
mechanisms	O
resulting	O
in	O
pathology	O
from	O
both	O
periodontitis	ENTITY
and	ENTITY
cvd	ENTITY
are	ENTITY
similar	ENTITY
both	ENTITY
diseases	ENTITY
have	ENTITY
complex	ENTITY
causation	ENTITY
that	ENTITY
includes	ENTITY
genetic	ENTITY
and	ENTITY
gender	ENTITY
predispositions	ENTITY
age	O
diabetes	ENTITY
smoking	ENTITY
social	ENTITY
status	ENTITY
and	ENTITY
stress	ENTITY
.	O
periodontal	ENTITY
infections	ENTITY
may	O
directly	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
atherosclerosis	ENTITY
and	ENTITY
thromboembolicevents	ENTITY
by	ENTITY
providing	ENTITY
repeated	ENTITY
systemic	ENTITY
challenges	ENTITY
with	ENTITY
lps	ENTITY
and	ENTITY
inflammatory	ENTITY
cytokines	ENTITY
.	O
the	O
oral	ENTITY
cavity	ENTITY
of	O
individuals	O
with	O
periodontitis	ENTITY
represents	ENTITY
potentially	ENTITY
large	ENTITY
reservoir	ENTITY
of	ENTITY
gram	ENTITY
negative	ENTITY
pathogenic	ENTITY
organisms	ENTITY
that	O
can	O
penetrate	ENTITY
gingival	ENTITY
tissues	ENTITY
enter	O
the	O
circulation	O
and	O
contribute	O
to	O
atherosclerosis	ENTITY
progression	ENTITY
.	O
the	O
possible	O
relationship	O
between	O
infectious	ENTITY
diseases	ENTITY
and	O
the	O
genesis	ENTITY
of	ENTITY
atherosclerosis	ENTITY
remains	ENTITY
hypothetical	ENTITY
.	O
it	O
is	O
important	O
todistinguish	O
between	O
the	O
potential	O
role	O
of	O
infectious	ENTITY
diseases	ENTITY
in	O
atherogenesis	ENTITY
and	ENTITY
the	ENTITY
possibility	ENTITY
that	ENTITY
infection	ENTITY
may	ENTITY
enhance	ENTITY
smoldering	ENTITY
inflammatory	ENTITY
process	ENTITY
that	ENTITY
is	ENTITY
already	ENTITY
present	ENTITY
in	ENTITY
atheromatous	ENTITY
plaques	ENTITY
.	O
gestational	ENTITY
diabetes	ENTITY
wikipedia	O
en	O
.	O
secondary	ENTITY
diabetes	ENTITY
conditions	O
insulin	ENTITY
resistance	ENTITY
glucagon	ENTITY
.	O
have	O
medical	O
condition	O
that	O
makes	O
diabetes	ENTITY
more	ENTITY
likely	ENTITY
such	ENTITY
as	ENTITY
glucose	ENTITY
intolerance	ENTITY
home	O
gestational	ENTITY
symptoms	ENTITY
is	O
permanent	O
gdm	ENTITY
rare	ENTITY
becoming	ENTITY
an	ENTITY
increasingly	ENTITY
common	ENTITY
can	ENTITY
be	ENTITY
treated	ENTITY
with	ENTITY
diet	ENTITY
and	ENTITY
exercise	ENTITY
.	O
after	O
delivery	O
women	O
with	O
diabetes	ENTITY
american	ENTITY
association	ENTITY
gestational	ENTITY
symptoms	ENTITY
and	O
causes	O
mayo	O
clinic	O
.	O
gestational	ENTITY
diabetes	ENTITY
wikipedia	O
gestational	ENTITY
testing	ENTITY
and	O
treatmentis	O
gestational	ENTITY
permanent	ENTITY
.	O
apollo	O
sugar	O
.	O
babies	O
born	O
early	O
experience	O
respiratory	ENTITY
distress	ENTITY
syndrome	ENTITY
condition	O
that	O
makes	O
breathing	O
focus	O
on	O
permanent	O
changes	O
to	O
your	O
eating	O
habits	O
condition	O
if	O
left	O
untreated	O
can	O
produce	O
damage	O
.	O
preeclampsia	ENTITY
maternal	ENTITY
condition	ENTITY
characterized	ENTITY
by	ENTITY
high	ENTITY
blood	ENTITY
pressure	ENTITY
and	O
protein	ENTITY
in	ENTITY
the	ENTITY
urine	ENTITY
expecting	O
.	O
learn	O
why	O
women	O
who	O
have	O
never	O
had	O
diabetes	ENTITY
be	ENTITY
at	ENTITY
risk	ENTITY
during	ENTITY
pregnancy	ENTITY
if	ENTITY
you	ENTITY
gestational	ENTITY
diabetes	ENTITY
there	O
is	O
very	O
good	O
chance	O
that	O
your	O
will	O
with	O
history	O
of	O
frequently	O
develop	O
type	O
medical	O
conditions	O
as	O
well	O
future	O
infertility	ENTITY
miscarriage	ENTITY
managed	ENTITY
monitoring	ENTITY
glucose	ENTITY
levels	ENTITY
adopting	O
are	O
no	O
specific	O
obstetric	ENTITY
or	ENTITY
should	ENTITY
able	ENTITY
to	ENTITY
develops	ENTITY
gestation	ENTITY
.	O
diabetes	ENTITY
in	ENTITY
pregnancy	ENTITY
can	O
gestational	ENTITY
diabetes	ENTITY
is	O
condition	O
that	O
occurs	O
during	O
pregnancyrisk	O
for	O
permanent	O
type	O
and	O
the	O
associated	O
with	O
abbreviations	O
gada	ENTITY
gad	ENTITY
antibodyia	ENTITY
addition	ENTITY
pregnant	O
women	O
have	O
an	O
increased	O
risk	O
of	O
developing	O
high	ENTITY
blood	ENTITY
pressure	ENTITY
pre	ENTITY
eclampsia	ENTITY
refers	O
to	O
diagnosed	O
.	O
gestational	ENTITY
diabetes	ENTITY
wikipedia	O
.	O
gestational	ENTITY
diabetes	ENTITY
generally	O
results	O
in	O
few	O
symptoms	O
however	O
it	O
does	O
increase	O
the	O
risk	O
of	O
pre	ENTITY
eclampsia	ENTITY
depression	O
and	O
requiring	O
caesarean	ENTITY
section	ENTITY
gestational	ENTITY
is	ENTITY
temporary	ENTITY
in	ENTITY
most	ENTITY
cases	ENTITY
form	ENTITY
which	ENTITY
body	ENTITY
not	ENTITY
produce	ENTITY
adequate	ENTITY
amounts	ENTITY
insulin	ENTITY
to	ENTITY
regulate	ENTITY
sugar	ENTITY
during	ENTITY
pregnancy	ENTITY
.	O
you	O
are	O
also	O
at	O
risk	O
for	O
type	O
diabetes	ENTITY
permanent	ENTITY
of	ENTITY
sometimes	ENTITY
women	ENTITY
who	ENTITY
have	ENTITY
not	ENTITY
had	ENTITY
diabetes	ENTITY
need	ENTITY
treatment	ENTITY
during	ENTITY
the	ENTITY
pregnancy	ENTITY
.	O
these	O
symptoms	O
are	O
mostly	O
for	O
women	O
who	O
have	O
diabetes	ENTITY
during	ENTITY
pregnancy	ENTITY
an	ENTITY
elevated	ENTITY
but	ENTITY
such	ENTITY
at	ENTITY
increased	ENTITY
risk	ENTITY
of	ENTITY
developing	ENTITY
permanent	ENTITY
diabetes	ENTITY
either	O
what	O
we	O
call	O
gestational	ENTITY
with	ENTITY
mellitus	ENTITY
or	O
gdm	ENTITY
is	ENTITY
special	ENTITY
case	ENTITY
which	ENTITY
this	ENTITY
way	ENTITY
your	ENTITY
doctor	ENTITY
can	ENTITY
take	ENTITY
care	ENTITY
condition	ENTITY
as	ENTITY
part	ENTITY
the	ENTITY
since	ENTITY
then	ENTITY
impact	ENTITY
on	ENTITY
offspring	ENTITY
in	ENTITY
terms	ENTITY
fetal	ENTITY
probability	ENTITY
progression	ENTITY
from	ENTITY
to	ENTITY
.	O
this	O
is	O
called	O
gestational	ENTITY
diabetes	ENTITY
.	O
gestational	ENTITY
diabetes	ENTITY
american	O
association	O
.	O
it	O
also	O
be	O
called	O
glucose	ENTITY
intolerance	ENTITY
or	O
carbohydrate	ENTITY
unlike	ENTITY
other	ENTITY
types	ENTITY
of	ENTITY
diabetes	ENTITY
gestational	ENTITY
diabetes	ENTITY
isn	O
permanent	O
.	O
gestational	ENTITY
diabetes	ENTITY
causes	O
signs	ENTITY
symptoms	ENTITY
diet	O
tests	O
.	O
information	O
on	O
diabetes	ENTITY
in	ENTITY
pregnancy	ENTITY
gestational	ENTITY
.	O
googleusercontent	O
searchgestational	O
diabetes	ENTITY
is	ENTITY
condition	ENTITY
in	ENTITY
which	ENTITY
woman	ENTITY
without	ENTITY
develops	ENTITY
high	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
during	O
pregnancy	O
.	O
diabetes	ENTITY
mellitus	ENTITY
and	O
pregnancy	ENTITY
practice	ENTITY
essentials	ENTITY
gestational	ENTITY
children	ENTITY
with	ENTITY
diabetes	ENTITY
what	O
is	O
diabetes	ENTITY
.	O
if	O
had	O
diabetes	ENTITY
during	ENTITY
pregnancy	ENTITY
am	O
at	O
an	O
increased	O
risk	O
of	O
what	O
is	O
gestational	ENTITY
mellitus	ENTITY
or	O
gdm	ENTITY
know	ENTITY
its	ENTITY
causes	ENTITY
and	ENTITY
after	ENTITY
pregnancy	ENTITY
screen	ENTITY
more	ENTITY
monitor	ENTITY
betterpregnancy	ENTITY
.	O
wikipedia	O
wiki	O
gestational	ENTITY
diabetes	ENTITY
url	O
.	O
webcache	O
.	O
often	O
times	O
gestational	ENTITY
diabetes	ENTITY
is	O
temporary	O
disorder	O
that	O
occurs	O
around	O
the	O
second	O
trimester	O
of	O
pregnancy	O
and	O
disappears	O
after	O
woman	O
gives	O
birth	O
.	O
women	O
can	O
be	O
diagnosed	O
with	O
gestational	ENTITY
diabetes	ENTITY
having	O
no	O
history	O
of	O
will	O
change	O
the	O
way	O
or	O
time	O
my	O
baby	O
is	O
delivered	O
.	O
as	O
one	O
knows	O
more	O
about	O
you	O
and	O
condition	O
your	O
pregnancy	O
.	O
what	O
is	O
it	O
best	O
to	O
stop	O
smoking	O
entirely	O
and	O
permanently	O
or	O
at	O
the	O
very	O
least	O
cut	O
back	O
gestational	ENTITY
diabetes	ENTITY
type	O
of	O
that	O
develops	O
first	O
diagnosed	O
during	O
pregnancy	O
.	O
gestational	ENTITY
diabetes	ENTITY
the	O
overlooked	O
form	O
of	O
diabetes	ENTITY
gestational	ENTITY
symptoms	ENTITY
diagnosis	ENTITY
complications	ENTITY
.	O
definition	O
of	O
gestational	ENTITY
diabetes	ENTITY
by	O
medical	O
identifies	O
women	O
at	O
risk	O
for	O
permanent	O
type	O
and	O
mydr	O
.	O
gestational	ENTITY
diabetes	ENTITY
on	O
the	O
rise	O
news	O
medical	O
.	O
should	O
gestational	ENTITY
diabetes	ENTITY
be	O
treated	O
.	O
today	O
parent	O
.	O
their	O
report	O
is	O
timely	O
allowing	O
renewal	O
of	O
attention	O
to	O
an	O
important	O
condition	O
where	O
if	O
you	O
have	O
had	O
gestational	ENTITY
diabetes	ENTITY
are	O
at	O
risk	O
for	O
having	O
it	O
again	O
in	O
future	O
pregnancy	O
.	O
gestational	ENTITY
diabetes	ENTITY
occurs	O
in	O
about	O
percent	O
of	O
all	O
pregnancies	ENTITY
usually	ENTITY
the	ENTITY
one	ENTITY
most	ENTITY
comprehensive	ENTITY
gestational	ENTITY
frequently	ENTITY
asked	ENTITY
questions	ENTITY
if	ENTITY
fetus	ENTITY
is	ENTITY
exposed	ENTITY
to	ENTITY
too	ENTITY
much	ENTITY
glucose	ENTITY
it	ENTITY
causes	ENTITY
permanent	ENTITY
polycystic	ENTITY
ovarian	ENTITY
syndrome	ENTITY
condition	O
where	O
large	O
cysts	O
are	O
formed	O
that	O
results	O
women	O
whose	O
pancreas	ENTITY
does	ENTITY
who	ENTITY
develop	ENTITY
permanently	ENTITY
within	ENTITY
develops	ENTITY
during	ENTITY
pregnancy	ENTITY
because	ENTITY
mother	ENTITY
body	ENTITY
not	ENTITY
this	ENTITY
makes	ENTITY
different	ENTITY
more	ENTITY
common	ENTITY
forms	ENTITY
which	ENTITY
once	ENTITY
they	ENTITY
occur	ENTITY
.	O
gestational	ENTITY
diabetes	ENTITY
the	O
basics	O
of	O
this	O
not	O
so	O
sweet	O
condition	O
gestational	ENTITY
ireland	ENTITY
.	O
both	O
conditions	O
involve	O
insulin	ENTITY
resistance	ENTITY
gestational	ENTITY
diabetes	ENTITY
mellitus	ENTITY
gdm	ENTITY
is	ENTITY
defined	ENTITY
as	ENTITY
glucose	ENTITY
intolerance	ENTITY
of	O
study	O
by	O
stuebe	O
et	ENTITY
al	ENTITY
found	ENTITY
this	ENTITY
condition	ENTITY
to	ENTITY
be	ENTITY
associated	ENTITY
with	ENTITY
third	ENTITY
type	ENTITY
called	ENTITY
gdm	ENTITY
that	ENTITY
develops	ENTITY
or	ENTITY
genetic	ENTITY
predisposition	ENTITY
combines	O
the	O
many	O
these	O
permanent	O
forms	O
before	O
during	O
pregnancy	O
then	O
secondary	O
will	O
often	O
but	O
for	O
some	O
forms	O
it	O
possible	O
medical	ENTITY
lis	ENTITY
.	O
type	O
diabetes	ENTITY
is	ENTITY
the	ENTITY
fastest	ENTITY
growing	ENTITY
disease	ENTITY
affecting	ENTITY
million	ENTITY
people	ENTITY
worldwide	ENTITY
and	ENTITY
the	ENTITY
number	ENTITY
is	ENTITY
predicted	ENTITY
to	ENTITY
double	ENTITY
within	ENTITY
the	ENTITY
next	ENTITY
years	ENTITY
.	O
is	O
assumed	O
to	O
develop	O
from	O
the	O
interaction	O
between	O
genetic	ENTITY
predisposition	ENTITY
and	O
an	O
affluent	O
environment	O
.	O
diabetes	ENTITY
is	ENTITY
clearly	ENTITY
much	ENTITY
more	ENTITY
heterogeneous	ENTITY
disease	ENTITY
than	O
the	O
simple	O
subdivision	ENTITY
into	ENTITY
type	ENTITY
and	ENTITY
type	ENTITY
diabetes	ENTITY
assumes	ENTITY
.	O
dissection	ENTITY
of	ENTITY
the	ENTITY
genetic	ENTITY
heterogeneity	ENTITY
of	O
diabetes	ENTITY
is	ENTITY
prerequisite	ENTITY
for	ENTITY
the	ENTITY
development	ENTITY
of	ENTITY
individualized	ENTITY
treatment	ENTITY
as	ENTITY
well	ENTITY
as	ENTITY
to	ENTITY
identify	ENTITY
new	ENTITY
targets	ENTITY
for	ENTITY
more	ENTITY
efficient	ENTITY
therapy	ENTITY
.	O
in	O
addition	O
identification	O
of	O
disease	ENTITY
susceptibility	ENTITY
genes	ENTITY
kicks	ENTITY
off	ENTITY
possibilities	ENTITY
to	ENTITY
study	ENTITY
gene	ENTITY
environment	ENTITY
interactions	ENTITY
.	O
to	O
accomplish	O
this	O
task	O
different	O
strategies	O
are	O
being	O
adopted	O
including	O
genome	O
wide	O
association	O
studies	O
gwas	O
next	O
generation	O
sequencing	O
expression	O
profiling	O
of	O
target	ENTITY
tissues	ENTITY
human	ENTITY
islets	ENTITY
muscle	ENTITY
fat	ENTITY
and	ENTITY
liver	ENTITY
as	ENTITY
well	ENTITY
as	ENTITY
studies	ENTITY
of	ENTITY
epigenetic	ENTITY
modifications	ENTITY
dna	ENTITY
and	ENTITY
histone	ENTITY
methylation	ENTITY
acetylation	ENTITY
etc	O
.	O
prerequisite	O
for	O
these	O
studies	O
is	O
access	O
to	O
some	O
of	O
the	O
largest	O
and	O
best	O
characterized	O
populations	O
in	O
the	O
field	O
including	O
the	O
botnia	O
study	O
the	O
malm	O
diet	O
and	O
cancer	O
study	O
etc	O
.	O
these	O
studies	O
allow	O
exploration	O
of	O
gene	O
environment	O
diet	O
and	O
exercise	O
interactions	O
as	O
well	O
as	O
prediction	O
of	O
disease	ENTITY
development	ENTITY
and	O
progression	O
.	O
more	O
www	O
exodiab	O
se	O
and	O
www	O
ludc	O
med	O
lu	O
se	O
.	O
diabetes	ENTITY
occur	ENTITY
either	ENTITY
as	ENTITY
result	ENTITY
of	ENTITY
an	ENTITY
autoimmune	ENTITY
destruction	ENTITY
of	ENTITY
the	ENTITY
cells	ENTITY
of	ENTITY
the	ENTITY
pancreas	ENTITY
genetic	ENTITY
predisposition	ENTITY
as	O
seen	O
wth	O
type	O
diabetes	ENTITY
or	ENTITY
result	ENTITY
of	ENTITY
decrease	ENTITY
insult	ENTITY
production	ENTITY
and	ENTITY
insulin	ENTITY
resistance	ENTITY
resulting	O
from	O
lifestyle	O
habits	O
.	O
type	ENTITY
ii	ENTITY
diabetes	ENTITY
is	O
the	O
most	O
common	O
form	O
worlwide	O
occuring	O
in	O
individuals	O
as	O
early	O
as	O
years	O
of	O
age	O
and	O
above	O
.	O
type	O
is	O
primarily	O
diagnosed	O
in	O
early	O
childhood	O
but	O
can	O
manifest	O
in	O
adulthood	O
also	O
.	O
read	O
more	O
at	O
www	O
abimbolamd	O
com	O
.	O
let	O
me	O
begin	O
by	O
saying	O
categorically	O
that	O
at	O
the	O
time	O
of	O
this	O
video	O
there	O
is	O
no	O
cure	O
for	O
diabetes	ENTITY
.	O
diabetes	ENTITY
management	ENTITY
book	ENTITY
there	ENTITY
are	ENTITY
literally	ENTITY
thousands	ENTITY
of	ENTITY
claims	ENTITY
out	ENTITY
there	ENTITY
saying	ENTITY
their	ENTITY
product	ENTITY
or	ENTITY
their	ENTITY
program	ENTITY
can	ENTITY
cure	ENTITY
your	ENTITY
diabetes	ENTITY
.	O
simply	O
put	O
they	O
cannot	O
.	O
but	O
this	O
question	O
asks	O
if	O
diabetes	ENTITY
can	ENTITY
be	ENTITY
reversed	ENTITY
.	O
so	O
to	O
begin	O
this	O
conversation	O
we	O
need	O
to	O
define	O
what	O
we	O
mean	O
by	O
reversed	O
.	O
if	O
we	O
are	O
saying	O
we	O
can	O
take	O
our	O
bodies	O
back	O
to	O
the	O
time	O
before	O
we	O
had	O
diabetes	ENTITY
then	ENTITY
no	ENTITY
.	O
if	O
we	O
are	O
talking	O
about	O
state	O
in	O
which	O
we	O
can	O
control	O
our	O
blood	ENTITY
sugar	ENTITY
without	O
the	O
use	O
of	O
any	O
medications	O
then	O
the	O
answer	O
is	O
maybe	O
.	O
let	O
talk	O
about	O
those	O
with	O
type	O
diabetes	ENTITY
first	ENTITY
.	O
if	O
you	O
have	O
type	O
then	O
you	O
are	O
insulin	ENTITY
dependent	ENTITY
.	O
when	O
you	O
were	O
first	O
diagnosed	O
you	O
may	O
have	O
gone	O
through	O
what	O
is	O
called	O
honeymoon	O
period	O
in	O
which	O
your	O
blood	ENTITY
sugar	ENTITY
kept	O
dropping	O
and	O
dropping	O
and	O
you	O
used	O
less	O
and	O
less	O
insulin	ENTITY
.	O
you	O
may	O
have	O
even	O
stopped	O
using	O
it	O
altogether	O
.	O
by	O
the	O
way	O
researchers	O
now	O
feel	O
that	O
type	O
need	O
to	O
continue	O
small	O
insulin	ENTITY
injections	ENTITY
to	O
protect	O
what	O
insulin	ENTITY
producing	ENTITY
cells	ENTITY
they	O
still	O
have	O
.	O
but	O
this	O
honeymoon	O
period	O
will	O
not	O
last	O
forever	O
.	O
if	O
you	O
have	O
type	O
diabetes	ENTITY
then	ENTITY
approximately	ENTITY
of	ENTITY
your	ENTITY
insulin	ENTITY
producing	ENTITY
cells	ENTITY
have	O
been	O
destroyed	O
.	O
they	O
have	O
not	O
been	O
damaged	O
with	O
chance	O
of	O
repair	O
they	O
are	O
gone	O
.	O
it	O
is	O
impossible	O
to	O
reverse	O
the	O
damage	O
done	O
.	O
while	O
some	O
think	O
their	O
diabetes	ENTITY
has	ENTITY
been	ENTITY
cured	ENTITY
or	ENTITY
even	ENTITY
reversed	ENTITY
this	ENTITY
is	ENTITY
false	ENTITY
sense	ENTITY
of	ENTITY
security	ENTITY
.	O
the	O
process	O
that	O
destroyed	O
the	O
of	O
insulin	ENTITY
producing	ENTITY
cells	ENTITY
with	O
destroy	O
the	O
remaining	O
.	O
ultimately	O
you	O
will	O
be	O
totally	O
dependent	O
on	O
insulin	ENTITY
.	O
type	O
diabetes	ENTITY
cannot	ENTITY
be	ENTITY
reversed	ENTITY
.	O
and	O
this	O
is	O
not	O
my	O
opinion	O
it	O
is	O
the	O
opinion	O
of	O
the	O
foremost	O
diabetes	ENTITY
center	ENTITY
in	ENTITY
the	ENTITY
world	ENTITY
the	ENTITY
joslin	ENTITY
diabetes	ENTITY
center	ENTITY
in	ENTITY
boston	ENTITY
.	O
as	O
far	O
as	O
type	O
diabetes	ENTITY
as	ENTITY
long	ENTITY
as	ENTITY
we	ENTITY
are	ENTITY
clear	ENTITY
on	ENTITY
the	ENTITY
definition	ENTITY
of	ENTITY
reversal	ENTITY
will	ENTITY
say	ENTITY
it	ENTITY
is	ENTITY
possible	ENTITY
.	O
remember	O
am	O
adamant	O
about	O
the	O
fact	O
that	O
there	O
is	O
no	O
cure	O
for	O
diabetes	ENTITY
but	ENTITY
do	ENTITY
feel	ENTITY
it	ENTITY
is	ENTITY
possible	ENTITY
for	ENTITY
person	ENTITY
with	ENTITY
type	ENTITY
to	ENTITY
be	ENTITY
able	ENTITY
to	ENTITY
go	ENTITY
off	ENTITY
their	ENTITY
diabetes	ENTITY
meds	ENTITY
for	ENTITY
time	ENTITY
and	ENTITY
control	ENTITY
their	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
that	O
would	O
be	O
reversal	O
.	O
we	O
cannot	O
go	O
back	O
and	O
reverse	O
the	O
damage	O
done	O
by	O
having	O
diabetes	ENTITY
but	ENTITY
it	ENTITY
is	ENTITY
possible	ENTITY
to	ENTITY
control	ENTITY
diabetes	ENTITY
without	ENTITY
medication	ENTITY
.	O
the	O
most	O
recent	O
reliable	O
research	O
could	O
find	O
on	O
this	O
subject	O
was	O
conducted	O
in	O
march	O
of	O
it	O
was	O
conducted	O
professor	O
roy	O
taylor	O
professor	O
of	O
medicine	O
and	O
metabolism	ENTITY
at	ENTITY
newcastle	ENTITY
university	ENTITY
in	ENTITY
new	ENTITY
castle	ENTITY
england	ENTITY
.	O
the	O
work	O
was	O
an	O
extension	O
of	O
study	O
that	O
was	O
in	O
question	O
because	O
of	O
the	O
brevity	O
of	O
the	O
study	O
.	O
that	O
study	O
had	O
theory	O
that	O
this	O
research	O
is	O
part	O
of	O
growing	O
body	O
of	O
evidence	O
showing	O
that	O
people	O
with	O
type	O
diabetes	ENTITY
who	ENTITY
successfully	ENTITY
lose	ENTITY
weight	ENTITY
can	ENTITY
reverse	ENTITY
their	ENTITY
condition	ENTITY
because	ENTITY
fat	ENTITY
is	ENTITY
removed	ENTITY
from	ENTITY
their	ENTITY
pancreas	ENTITY
returning	ENTITY
insulin	ENTITY
production	ENTITY
to	ENTITY
normal	ENTITY
in	ENTITY
the	ENTITY
study	ENTITY
volunteers	ENTITY
with	ENTITY
type	ENTITY
went	ENTITY
on	ENTITY
strict	ENTITY
diet	ENTITY
of	ENTITY
calories	ENTITY
per	ENTITY
day	ENTITY
for	ENTITY
months	ENTITY
.	O
now	O
let	O
me	O
warn	O
you	O
right	O
now	O
that	O
is	O
not	O
lot	O
of	O
food	O
in	O
calories	O
.	O
however	O
the	O
participants	O
lost	O
an	O
average	O
of	O
pounds	O
.	O
they	O
had	O
to	O
keep	O
this	O
weight	O
off	O
for	O
another	O
months	O
.	O
the	O
results	O
were	O
that	O
of	O
those	O
with	O
type	O
who	O
had	O
been	O
diagnosed	O
less	O
than	O
years	O
reversed	O
their	O
diabetes	ENTITY
.	O
for	O
those	O
who	O
had	O
been	O
diagnosed	O
longer	O
did	O
not	O
have	O
the	O
same	O
results	O
.	O
the	O
key	O
to	O
reversing	O
diabetes	ENTITY
is	ENTITY
to	ENTITY
lose	ENTITY
weight	ENTITY
and	ENTITY
regular	ENTITY
exercise	ENTITY
.	O
in	O
another	O
study	O
discussed	O
by	O
michael	O
dansinger	O
md	O
those	O
with	O
type	O
exercised	O
for	O
minutes	O
week	O
limited	O
their	O
calories	O
to	O
to	O
per	O
day	O
and	O
got	O
weekly	O
counseling	O
and	O
education	O
on	O
these	O
lifestyle	O
changes	O
.	O
within	O
year	O
about	O
got	O
off	O
their	O
diabetes	ENTITY
medications	ENTITY
or	ENTITY
improved	ENTITY
to	ENTITY
the	ENTITY
point	ENTITY
where	ENTITY
their	ENTITY
blood	ENTITY
sugar	ENTITY
level	ENTITY
was	O
no	O
longer	O
in	O
the	O
diabetes	ENTITY
range	ENTITY
and	ENTITY
was	ENTITY
instead	ENTITY
classified	ENTITY
as	ENTITY
prediabetes	ENTITY
in	ENTITY
every	ENTITY
study	ENTITY
researched	ENTITY
it	ENTITY
was	ENTITY
apparent	ENTITY
that	ENTITY
the	ENTITY
numbers	ENTITY
of	ENTITY
those	ENTITY
who	ENTITY
were	ENTITY
able	ENTITY
to	ENTITY
reverse	ENTITY
their	ENTITY
diabetes	ENTITY
were	ENTITY
largely	ENTITY
dependent	ENTITY
on	ENTITY
the	ENTITY
date	ENTITY
of	ENTITY
diagnosis	ENTITY
.	O
those	O
who	O
were	O
newbies	O
had	O
better	O
chance	O
of	O
reversal	O
.	O
but	O
even	O
at	O
that	O
the	O
average	O
of	O
those	O
who	O
have	O
been	O
able	O
to	O
reverse	O
their	O
diabetes	ENTITY
has	ENTITY
been	ENTITY
about	ENTITY
.	O
weight	O
loss	O
and	O
exercise	O
will	O
not	O
work	O
for	O
everyone	O
.	O
part	O
of	O
that	O
reason	O
is	O
that	O
some	O
people	O
are	O
simply	O
predisposed	O
to	O
diabetes	ENTITY
.	O
it	O
in	O
your	O
genes	ENTITY
.	O
the	O
reason	O
we	O
also	O
call	O
this	O
reversal	O
rather	O
than	O
cure	O
.	O
for	O
those	O
who	O
have	O
experienced	O
reversal	O
and	O
then	O
gained	O
their	O
weight	O
back	O
guess	O
what	O
happens	O
.	O
they	O
need	O
to	O
start	O
their	O
diabetes	ENTITY
meds	ENTITY
again	ENTITY
.	O
can	O
attest	O
to	O
that	O
first	O
hand	O
.	O
as	O
pound	O
man	O
was	O
in	O
bad	O
shape	O
in	O
more	O
ways	O
that	O
one	O
.	O
dropped	O
pounds	O
on	O
fad	ENTITY
diet	ENTITY
.	O
it	O
was	O
great	O
.	O
no	O
longer	O
needed	O
any	O
diabetes	ENTITY
meds	ENTITY
felt	ENTITY
awesome	ENTITY
and	ENTITY
this	ENTITY
went	ENTITY
on	ENTITY
for	ENTITY
about	ENTITY
years	ENTITY
.	O
but	O
then	O
the	O
diet	O
was	O
on	O
started	O
affecting	O
other	O
parts	O
of	O
my	O
body	O
.	O
got	O
very	O
ill	O
was	O
told	O
had	O
to	O
stop	O
the	O
fad	O
diet	O
and	O
try	O
to	O
return	O
to	O
normal	O
diet	O
or	O
something	O
bad	O
was	O
going	O
to	O
happen	O
.	O
what	O
is	O
thrifty	ENTITY
gene	ENTITY
hypothesis	ENTITY
.	O
what	O
does	O
thrifty	ENTITY
gene	ENTITY
hypothesis	ENTITY
mean	O
.	O
thrifty	ENTITY
gene	ENTITY
hypothesis	ENTITY
meaning	O
thrifty	ENTITY
gene	ENTITY
hypothesis	ENTITY
definition	O
thrifty	ENTITY
gene	ENTITY
hypothesis	ENTITY
explanation	O
.	O
source	O
wikipedia	O
org	O
article	O
adapted	O
under	O
license	O
.	O
the	O
thrifty	ENTITY
gene	ENTITY
hypothesis	ENTITY
or	O
gianfranco	ENTITY
hypothesis	ENTITY
is	O
an	O
attempt	O
by	O
geneticist	O
james	O
neel	O
to	O
explain	O
why	O
certain	O
populations	O
and	O
subpopulations	O
in	O
the	O
modern	O
day	O
are	O
prone	O
to	O
diabetes	ENTITY
mellitus	ENTITY
type	O
he	O
proposed	O
the	O
hypothesis	O
in	O
to	O
resolve	O
fundamental	O
problem	O
diabetes	ENTITY
is	ENTITY
clearly	ENTITY
very	ENTITY
harmful	ENTITY
medical	ENTITY
condition	ENTITY
yet	ENTITY
it	ENTITY
is	ENTITY
quite	ENTITY
common	ENTITY
and	ENTITY
it	ENTITY
was	ENTITY
already	ENTITY
evident	ENTITY
to	ENTITY
neel	ENTITY
that	ENTITY
it	ENTITY
likely	ENTITY
had	ENTITY
strong	ENTITY
genetic	ENTITY
basis	ENTITY
.	O
the	O
problem	O
is	O
to	O
understand	O
how	O
disease	ENTITY
with	ENTITY
likely	ENTITY
genetic	ENTITY
component	ENTITY
and	ENTITY
with	ENTITY
such	ENTITY
negative	ENTITY
effects	ENTITY
may	ENTITY
have	ENTITY
been	ENTITY
favoured	ENTITY
by	ENTITY
the	ENTITY
process	ENTITY
of	ENTITY
natural	ENTITY
selection	ENTITY
.	O
neel	O
suggested	O
the	O
resolution	O
to	O
this	O
problem	O
is	O
that	O
genes	O
which	O
predispose	O
to	O
diabetes	ENTITY
called	ENTITY
thrifty	ENTITY
genes	ENTITY
were	O
historically	O
advantageous	O
but	O
they	O
became	O
detrimental	O
in	O
the	O
modern	O
world	O
.	O
in	O
his	O
words	O
they	O
were	O
rendered	O
detrimental	O
by	O
progress	O
.	O
neel	O
primary	O
interest	O
was	O
in	O
diabetes	ENTITY
but	ENTITY
the	ENTITY
idea	ENTITY
was	ENTITY
soon	ENTITY
expanded	ENTITY
to	ENTITY
encompass	ENTITY
obesity	ENTITY
as	ENTITY
well	ENTITY
.	O
thrifty	ENTITY
genes	ENTITY
are	O
genes	ENTITY
which	ENTITY
enable	ENTITY
individuals	ENTITY
to	ENTITY
efficiently	ENTITY
collect	ENTITY
and	ENTITY
process	ENTITY
food	ENTITY
to	ENTITY
deposit	ENTITY
fat	ENTITY
during	ENTITY
periods	ENTITY
of	ENTITY
food	ENTITY
abundance	ENTITY
in	ENTITY
order	ENTITY
to	ENTITY
provide	ENTITY
for	ENTITY
periods	ENTITY
of	ENTITY
food	ENTITY
shortage	ENTITY
feast	ENTITY
and	ENTITY
famine	ENTITY
.	O
according	O
to	O
the	O
hypothesis	O
the	O
thrifty	ENTITY
genotype	ENTITY
would	O
have	O
been	O
advantageous	O
for	O
hunter	O
gatherer	O
populations	O
especially	O
child	O
bearing	O
women	O
because	O
it	O
would	O
allow	O
them	O
to	O
fatten	O
more	O
quickly	O
during	O
times	O
of	O
abundance	O
.	O
fatter	ENTITY
individuals	ENTITY
carrying	ENTITY
the	ENTITY
thrifty	ENTITY
genes	ENTITY
would	O
thus	O
better	O
survive	O
times	O
of	O
food	O
scarcity	O
.	O
however	O
in	O
modern	O
societies	O
with	O
constant	O
abundance	O
of	O
food	O
this	O
genotype	ENTITY
efficiently	ENTITY
prepares	ENTITY
individuals	ENTITY
for	ENTITY
famine	ENTITY
that	ENTITY
never	ENTITY
comes	ENTITY
.	O
the	O
result	O
of	O
this	O
mismatch	O
between	O
the	O
environment	O
in	O
which	O
the	O
brain	ENTITY
evolved	ENTITY
and	ENTITY
the	ENTITY
environment	ENTITY
of	ENTITY
today	ENTITY
is	ENTITY
widespread	ENTITY
chronic	ENTITY
obesity	ENTITY
and	O
related	O
health	O
problems	O
like	O
diabetes	ENTITY
.	O
the	O
hypothesis	O
has	O
received	O
various	O
criticisms	O
and	O
several	O
modified	O
or	O
alternative	O
hypotheses	O
have	O
been	O
proposed	O
the	O
thrifty	ENTITY
phenotype	ENTITY
hypothesis	ENTITY
arose	O
from	O
challenges	O
posed	O
to	O
the	O
thrifty	ENTITY
gene	ENTITY
hypothesis	ENTITY
.	O
the	O
thrifty	ENTITY
phenotype	ENTITY
hypothesis	ENTITY
theorizes	O
that	O
instead	O
of	O
arising	O
genetically	O
the	O
thrifty	ENTITY
factors	ENTITY
developed	O
as	O
direct	O
result	O
of	O
the	O
environment	O
within	O
the	O
womb	ENTITY
during	ENTITY
development	ENTITY
.	O
the	O
development	O
of	O
insulin	ENTITY
resistance	ENTITY
is	O
theorized	O
to	O
be	O
directly	O
related	O
to	O
the	O
body	O
predicting	O
life	O
of	O
starvation	O
for	O
the	O
developing	ENTITY
fetus	ENTITY
.	O
hence	O
one	O
of	O
the	O
main	O
causes	O
of	O
type	O
diabetes	ENTITY
has	ENTITY
been	ENTITY
attributed	ENTITY
to	ENTITY
poor	ENTITY
fetal	ENTITY
and	ENTITY
infant	ENTITY
growth	ENTITY
and	ENTITY
the	ENTITY
subsequent	ENTITY
development	ENTITY
of	ENTITY
the	ENTITY
metabolic	ENTITY
syndrome	ENTITY
.	O
since	O
the	O
hypothesis	O
was	O
proposed	O
many	O
studies	O
world	O
wide	O
have	O
confirmed	O
the	O
initial	O
epidemiological	ENTITY
evidence	ENTITY
.	O
although	O
the	O
relationship	O
with	O
insulin	ENTITY
resistance	ENTITY
is	O
clear	O
at	O
all	O
ages	O
studied	O
the	O
relation	O
of	O
insulin	ENTITY
secretion	ENTITY
is	O
less	O
clear	O
.	O
the	O
relative	O
contribution	O
of	O
genes	O
and	O
environment	O
to	O
these	O
relationships	O
remains	O
matter	O
of	O
debate	O
.	O
other	O
relevant	O
observations	O
arose	O
from	O
metabolism	ENTITY
researchers	ENTITY
who	ENTITY
note	ENTITY
that	ENTITY
for	ENTITY
practically	ENTITY
every	ENTITY
other	ENTITY
species	ENTITY
on	ENTITY
earth	ENTITY
fat	ENTITY
metabolism	ENTITY
is	O
well	O
regulated	O
and	O
that	O
most	O
wild	O
animals	O
are	O
in	O
fact	O
very	O
lean	O
and	O
that	O
they	O
remain	O
lean	O
even	O
when	O
adequate	O
food	O
is	O
supplied	O
.	O
many	O
attempts	O
have	O
been	O
made	O
to	O
search	O
for	O
one	O
or	O
more	O
genes	O
contributing	O
to	O
thrift	O
.	O
modern	O
tools	O
of	O
genome	O
wide	O
association	O
studies	O
have	O
revealed	O
many	O
genes	O
with	O
small	O
effects	O
associated	O
with	O
obesity	ENTITY
or	ENTITY
type	ENTITY
diabetes	ENTITY
but	ENTITY
all	ENTITY
of	ENTITY
them	ENTITY
together	ENTITY
explain	ENTITY
only	ENTITY
between	ENTITY
and	ENTITY
of	ENTITY
population	ENTITY
variance	ENTITY
.	O
this	O
leaves	O
large	O
gap	O
between	O
the	O
pregenomic	O
and	O
emerging	O
genomic	O
estimates	O
of	O
heritability	ENTITY
of	ENTITY
obesity	ENTITY
and	O
type	O
diabetes	ENTITY
sometimes	ENTITY
called	ENTITY
the	ENTITY
missing	ENTITY
heritability	ENTITY
.	O
we	O
are	O
yet	O
to	O
understand	O
the	O
reasons	O
for	O
this	O
discrepancy	O
.	O
donations	O
to	O
support	O
this	O
channel	O
can	O
be	O
made	O
here	O
causing	O
even	O
increase	ENTITY
in	ENTITY
insulin	ENTITY
release	O
from	O
the	O
pancreas	ENTITY
.	O
so	O
number	O
one	O
what	O
will	O
cause	O
an	O
overstimulation	O
of	O
insulin	ENTITY
is	ENTITY
excessive	ENTITY
amounts	ENTITY
of	ENTITY
carbohydrates	ENTITY
.	O
secondly	O
proteins	ENTITY
in	ENTITY
the	ENTITY
absence	ENTITY
of	ENTITY
glucose	ENTITY
could	O
also	O
cause	O
small	O
increases	O
in	O
insulin	ENTITY
secretion	ENTITY
.	O
another	O
thing	O
to	O
note	O
is	O
that	O
if	O
you	O
add	O
carbohydrates	ENTITY
with	ENTITY
amino	ENTITY
acids	ENTITY
your	O
insulin	ENTITY
secretion	ENTITY
would	O
otherwise	O
be	O
doubled	O
.	O
what	O
this	O
means	O
is	O
burgers	O
with	O
fries	O
pancakes	O
with	O
eggs	O
chicken	O
with	O
pasta	O
all	O
these	O
combinations	O
will	O
double	O
your	O
insulin	ENTITY
secretion	ENTITY
.	O
the	O
third	O
thing	O
affecting	O
insulin	O
secretion	O
are	O
gastrointestinal	ENTITY
hormones	ENTITY
that	O
are	O
triggered	O
when	O
we	O
eat	O
.	O
what	O
this	O
means	O
is	O
that	O
whenever	O
you	O
eat	O
regardless	O
of	O
what	O
it	O
is	O
insulin	ENTITY
will	ENTITY
be	ENTITY
secreted	ENTITY
to	ENTITY
some	ENTITY
degree	ENTITY
.	O
there	O
other	O
hormones	ENTITY
part	ENTITY
of	ENTITY
the	ENTITY
autonomic	ENTITY
nervous	ENTITY
system	ENTITY
such	O
as	O
cortisol	ENTITY
which	ENTITY
upon	ENTITY
getting	ENTITY
released	ENTITY
will	ENTITY
trigger	ENTITY
insulin	ENTITY
secretion	ENTITY
.	O
what	O
causes	O
cortisol	ENTITY
release	ENTITY
excessive	ENTITY
stress	ENTITY
.	O
given	O
these	O
points	O
as	O
whole	O
nowhere	O
did	O
say	O
fat	ENTITY
effects	ENTITY
insulin	ENTITY
to	ENTITY
large	ENTITY
degree	ENTITY
.	O
this	O
leads	O
into	O
what	O
would	O
recommend	O
for	O
others	O
and	O
myself	O
if	O
had	O
diabetes	ENTITY
which	ENTITY
is	ENTITY
to	ENTITY
eat	ENTITY
low	ENTITY
carb	ENTITY
high	ENTITY
fat	ENTITY
diet	ENTITY
.	O
this	O
means	O
keeping	O
your	O
carbohydrate	ENTITY
intake	ENTITY
somewhere	ENTITY
around	ENTITY
grams	ENTITY
day	ENTITY
depending	ENTITY
on	ENTITY
an	ENTITY
individuals	ENTITY
severity	ENTITY
.	O
overtime	O
when	O
the	O
pancreas	ENTITY
get	ENTITY
break	ENTITY
and	ENTITY
everything	ENTITY
begins	ENTITY
to	ENTITY
stay	ENTITY
within	ENTITY
equilibrium	ENTITY
then	ENTITY
an	ENTITY
individual	ENTITY
can	ENTITY
start	ENTITY
to	ENTITY
incorporate	ENTITY
more	ENTITY
carbohydrates	ENTITY
.	O
something	O
want	O
to	O
mention	O
though	O
is	O
that	O
if	O
you	O
don	O
suffer	O
from	O
diabetes	ENTITY
and	ENTITY
you	ENTITY
don	ENTITY
have	ENTITY
any	ENTITY
genetic	ENTITY
predispositions	ENTITY
for	O
it	O
you	O
don	O
really	O
have	O
to	O
worry	O
much	O
about	O
your	O
carbohydrate	ENTITY
intake	ENTITY
per	ENTITY
day	ENTITY
.	O
people	O
with	O
insulin	ENTITY
resistance	ENTITY
or	O
diabetes	ENTITY
need	ENTITY
to	ENTITY
worry	ENTITY
about	ENTITY
it	ENTITY
because	ENTITY
their	ENTITY
hypersensitive	ENTITY
.	O
now	O
this	O
doesn	O
mean	O
eat	O
whatever	O
you	O
want	O
because	O
over	O
consumption	O
food	O
especially	O
processed	O
and	O
refined	O
foods	O
will	O
predispose	O
you	O
to	O
insulin	ENTITY
resistance	ENTITY
.	O
so	O
with	O
all	O
this	O
being	O
said	O
feel	O
comfortable	O
now	O
making	O
food	O
recommendations	O
.	O
the	O
genetic	ENTITY
predisposition	ENTITY
dna	ENTITY
health	ENTITY
test	ENTITY
is	ENTITY
an	ENTITY
innovative	ENTITY
test	ENTITY
which	ENTITY
allows	ENTITY
you	ENTITY
to	ENTITY
discover	ENTITY
whether	ENTITY
you	ENTITY
are	ENTITY
genetically	ENTITY
predisposed	ENTITY
towards	O
developing	O
number	O
of	O
diseases	ENTITY
and	ENTITY
medical	ENTITY
conditions	ENTITY
including	ENTITY
cardiovascular	ENTITY
conditions	ENTITY
different	O
types	O
of	O
cancers	ENTITY
disorders	ENTITY
of	O
the	O
immune	ENTITY
system	ENTITY
diabetes	ENTITY
as	ENTITY
well	ENTITY
as	ENTITY
medical	ENTITY
conditions	ENTITY
related	ENTITY
to	ENTITY
ageing	ENTITY
.	O
for	O
more	O
details	O
visit	O
www	O
easydna	O
ph	O
.	O
send	O
us	O
email	O
at	O
info	O
easydna	O
ph	O
or	O
precy	O
easydna	O
ph	O
.	O
or	O
call	O
us	O
at	O
or	O
.	O
more	O
than	O
in	O
every	O
people	O
has	O
genetic	ENTITY
predisposition	ENTITY
to	O
hereditary	O
type	O
of	O
heart	ENTITY
disease	ENTITY
.	O
this	O
webinar	O
is	O
presented	O
by	O
amy	O
sturm	O
cgc	O
lgc	O
.	O
during	O
the	O
webinar	O
amy	O
discusses	O
the	O
most	O
common	O
types	O
of	O
hereditary	ENTITY
heart	ENTITY
diseases	ENTITY
including	O
coronary	ENTITY
heart	ENTITY
disease	ENTITY
and	O
heart	ENTITY
attacks	ENTITY
aneurysms	ENTITY
abnormal	ENTITY
heart	ENTITY
rhythms	ENTITY
called	O
arrhythmias	ENTITY
very	ENTITY
common	ENTITY
form	ENTITY
of	ENTITY
hereditary	ENTITY
high	ENTITY
cholesterol	ENTITY
called	O
familial	ENTITY
hypercholesterolemia	ENTITY
as	O
well	O
as	O
others	O
.	O
she	O
covers	O
clues	O
and	O
signs	O
sometimes	O
called	O
red	O
flags	O
in	O
your	O
personal	O
medical	O
and	O
family	O
histories	O
that	O
may	O
indicate	O
there	O
is	O
hereditary	O
risk	O
for	O
heart	ENTITY
disease	ENTITY
.	O
want	O
more	O
information	O
on	O
cardiovascular	ENTITY
genetics	ENTITY
and	O
your	O
options	O
.	O
visit	O
our	O
free	O
resources	O
keys	O
to	O
your	O
genetic	ENTITY
heart	ENTITY
health	O
blog	O
post	O
.	O
modern	O
living	O
comes	O
with	O
its	O
attendant	O
health	O
issues	O
like	O
obesity	ENTITY
sedentary	ENTITY
lifestyle	ENTITY
and	ENTITY
unhealthy	ENTITY
eating	ENTITY
.	O
if	O
all	O
this	O
is	O
coupled	O
with	O
genetic	O
predisposition	O
of	O
diabetes	ENTITY
in	ENTITY
indians	ENTITY
we	ENTITY
have	ENTITY
perfect	ENTITY
recipe	ENTITY
for	ENTITY
an	ENTITY
epidemic	ENTITY
.	O
here	O
the	O
famed	O
diabetologist	ENTITY
gives	ENTITY
our	ENTITY
reporter	ENTITY
his	ENTITY
take	ENTITY
on	ENTITY
some	ENTITY
of	ENTITY
the	ENTITY
controversial	ENTITY
issues	ENTITY
related	ENTITY
to	ENTITY
diabetes	ENTITY
management	ENTITY
.	O
we	O
at	O
indian	O
diabetes	ENTITY
review	ENTITY
tv	ENTITY
are	ENTITY
trying	ENTITY
to	ENTITY
bring	ENTITY
you	ENTITY
complete	ENTITY
news	ENTITY
portal	ENTITY
for	ENTITY
diabetics	ENTITY
and	ENTITY
their	ENTITY
care	ENTITY
givers	ENTITY
.	O
visit	O
our	O
website	O
www	O
indiandiabetesreview	O
com	O
which	O
is	O
updated	O
as	O
management	ENTITY
of	ENTITY
diabetes	ENTITY
depends	O
solely	O
on	O
information	O
we	O
intend	O
to	O
bring	O
to	O
you	O
all	O
the	O
news	O
and	O
analysis	O
about	O
various	O
developments	O
from	O
the	O
world	O
over	O
that	O
can	O
impact	O
your	O
health	O
.	O
we	O
cull	O
the	O
best	O
of	O
news	O
and	O
information	O
that	O
can	O
help	O
you	O
live	O
full	O
life	O
in	O
spite	O
of	O
your	O
debilitating	O
health	O
condition	O
.	O
in	O
these	O
videos	O
you	O
will	O
come	O
across	O
people	O
who	O
have	O
managed	O
to	O
beat	O
conventional	O
thinking	O
on	O
diabetes	ENTITY
celebrities	ENTITY
who	ENTITY
have	ENTITY
take	ENTITY
on	ENTITY
diabetes	ENTITY
health	ENTITY
professionals	ENTITY
who	ENTITY
have	ENTITY
new	ENTITY
insight	ENTITY
into	ENTITY
diabetes	ENTITY
management	ENTITY
or	ENTITY
even	ENTITY
thought	ENTITY
leader	ENTITY
who	ENTITY
has	ENTITY
an	ENTITY
opinion	ENTITY
on	ENTITY
this	ENTITY
health	ENTITY
disorder	ENTITY
.	O
you	O
can	O
always	O
write	O
to	O
us	O
about	O
what	O
you	O
feel	O
about	O
our	O
internet	O
television	O
programmes	O
news	O
portal	O
or	O
magazine	O
drop	O
in	O
line	O
our	O
email	O
id	O
is	O
editorial	O
parabolamedia	O
com	O
you	O
can	O
also	O
call	O
us	O
at	O
if	O
you	O
want	O
to	O
subscribe	O
to	O
our	O
monthly	O
news	O
magazine	O
living	O
with	O
diabetes	ENTITY
.	O
gestational	ENTITY
diabetes	ENTITY
is	O
becoming	O
norm	O
rather	O
than	O
an	O
exception	O
these	O
days	O
because	O
of	O
late	ENTITY
pregnancies	ENTITY
career	O
choices	O
lifestyle	ENTITY
obesity	ENTITY
and	O
genetic	ENTITY
predisposition	ENTITY
.	O
here	O
the	O
diabetologist	ENTITY
gets	ENTITY
into	ENTITY
the	ENTITY
details	ENTITY
of	ENTITY
managing	ENTITY
diabetes	ENTITY
during	ENTITY
pregnancy	ENTITY
to	ENTITY
tell	ENTITY
you	ENTITY
how	ENTITY
to	ENTITY
get	ENTITY
the	ENTITY
best	ENTITY
out	ENTITY
of	ENTITY
the	ENTITY
situation	ENTITY
.	O
we	O
at	O
indian	O
diabetes	ENTITY
review	ENTITY
tv	ENTITY
are	ENTITY
trying	ENTITY
to	ENTITY
bring	ENTITY
you	ENTITY
complete	ENTITY
news	ENTITY
portal	ENTITY
for	ENTITY
diabetics	ENTITY
and	ENTITY
their	ENTITY
care	ENTITY
givers	ENTITY
.	O
visit	O
our	O
website	O
www	O
indiandiabetesreview	O
com	O
which	O
is	O
updated	O
as	O
management	ENTITY
of	ENTITY
diabetes	ENTITY
depends	O
solely	O
on	O
information	O
we	O
intend	O
to	O
bring	O
to	O
you	O
all	O
the	O
news	O
and	O
analysis	O
about	O
various	O
developments	O
from	O
the	O
world	O
over	O
that	O
can	O
impact	O
your	O
health	O
.	O
we	O
cull	O
the	O
best	O
of	O
news	O
and	O
information	O
that	O
can	O
help	O
you	O
live	O
full	O
life	O
in	O
spite	O
of	O
your	O
debilitating	O
health	O
condition	O
.	O
in	O
these	O
videos	O
you	O
will	O
come	O
across	O
people	O
who	O
have	O
managed	O
to	O
beat	O
conventional	O
thinking	O
on	O
diabetes	ENTITY
celebrities	ENTITY
who	ENTITY
have	ENTITY
take	ENTITY
on	ENTITY
diabetes	ENTITY
health	ENTITY
professionals	ENTITY
who	ENTITY
have	ENTITY
new	ENTITY
insight	ENTITY
into	ENTITY
diabetes	ENTITY
management	ENTITY
or	ENTITY
even	ENTITY
thought	ENTITY
leader	ENTITY
who	ENTITY
has	ENTITY
an	ENTITY
opinion	ENTITY
on	ENTITY
this	ENTITY
health	ENTITY
disorder	ENTITY
.	O
you	O
can	O
always	O
write	O
to	O
us	O
about	O
what	O
you	O
feel	O
about	O
our	O
internet	O
television	O
programmes	O
news	O
portal	O
or	O
magazine	O
drop	O
in	O
line	O
our	O
email	O
id	O
is	O
editorial	O
parabolamedia	O
com	O
you	O
can	O
also	O
call	O
us	O
at	O
if	O
you	O
want	O
to	O
subscribe	O
to	O
our	O
monthly	O
news	O
magazine	O
living	O
with	O
diabetes	ENTITY
.	O
it	O
growing	O
problem	O
in	O
more	O
ways	O
than	O
one	O
.	O
the	O
last	O
quarter	O
century	O
has	O
seen	O
an	O
explosion	O
of	O
diabetes	ENTITY
in	ENTITY
the	ENTITY
unfortunately	ENTITY
it	ENTITY
doesn	ENTITY
surprise	ENTITY
me	ENTITY
that	ENTITY
diabetes	ENTITY
is	ENTITY
on	ENTITY
the	ENTITY
rise	ENTITY
with	ENTITY
our	ENTITY
aging	ENTITY
population	ENTITY
and	ENTITY
with	ENTITY
the	ENTITY
increased	ENTITY
prevalence	ENTITY
of	ENTITY
obesity	ENTITY
says	ENTITY
sharon	ENTITY
krispinsky	ENTITY
.	O
sharon	O
is	O
certified	O
diabetes	ENTITY
educator	ENTITY
with	O
lee	O
memorial	O
health	ENTITY
system	ENTITY
.	O
in	O
someone	O
who	O
has	O
the	O
genetic	ENTITY
predisposition	ENTITY
for	O
developing	O
diabetes	ENTITY
as	ENTITY
you	ENTITY
gain	ENTITY
weight	ENTITY
you	ENTITY
become	ENTITY
more	ENTITY
insulin	ENTITY
resistant	ENTITY
meaning	ENTITY
that	ENTITY
you	ENTITY
cant	ENTITY
use	ENTITY
the	ENTITY
sugar	ENTITY
or	ENTITY
glucose	ENTITY
in	ENTITY
your	ENTITY
blood	ENTITY
says	ENTITY
krispinsky	ENTITY
.	O
new	O
health	O
survey	O
shows	O
americans	O
are	O
being	O
diagnosed	O
with	O
diabetes	ENTITY
at	ENTITY
twice	ENTITY
the	ENTITY
rate	ENTITY
of	ENTITY
people	ENTITY
i	ENTITY
n	ENTITY
western	ENTITY
europe	ENTITY
.	O
dangerous	O
trend	O
since	O
diabetes	ENTITY
is	ENTITY
linked	ENTITY
to	ENTITY
multitude	ENTITY
of	ENTITY
health	ENTITY
issues	ENTITY
and	ENTITY
its	ENTITY
complications	ENTITY
can	ENTITY
be	ENTITY
deadly	ENTITY
.	O
it	O
can	O
cause	O
multi	ENTITY
symptom	ENTITY
organ	ENTITY
failure	ENTITY
including	O
blindness	O
in	O
the	O
eye	ENTITY
heart	ENTITY
disease	ENTITY
.	O
it	O
increases	O
your	O
risk	O
of	O
heart	ENTITY
attack	ENTITY
kidney	ENTITY
disease	ENTITY
it	O
increases	O
your	O
risk	O
of	O
going	O
on	O
dialysis	ENTITY
or	ENTITY
having	ENTITY
kidney	ENTITY
failure	ENTITY
.	O
you	O
can	O
have	O
low	O
circulation	O
because	O
the	O
high	O
sugar	O
attacks	O
every	O
organ	ENTITY
in	ENTITY
the	ENTITY
body	ENTITY
saysdraldith	O
lewis	O
an	O
internal	O
medicine	O
physician	O
with	O
lee	O
memorial	O
health	O
system	O
.	O
despite	O
the	O
sobering	O
statistics	O
there	O
is	O
hope	O
.	O
research	O
has	O
shown	O
that	O
even	O
with	O
modest	O
weight	O
loss	O
and	O
regular	O
exercise	O
and	O
when	O
say	O
modest	O
weight	O
loss	O
its	O
to	O
percent	O
of	O
your	O
body	O
weight	O
you	O
could	O
reduce	O
your	O
risk	O
of	O
developing	O
diabetes	ENTITY
by	ENTITY
percent	ENTITY
says	ENTITY
krispinsky	ENTITY
.	O
so	O
when	O
it	O
comes	O
to	O
lowering	O
the	O
rate	O
of	O
diabetes	ENTITY
the	ENTITY
best	ENTITY
medicine	ENTITY
might	ENTITY
be	ENTITY
education	ENTITY
.	O
through	O
our	O
community	O
outreach	O
programs	O
we	O
really	O
are	O
trying	O
to	O
get	O
that	O
message	O
across	O
says	O
krispinsky	O
.	O
view	O
more	O
health	O
matters	O
video	O
segments	O
at	O
leememorial	O
.	O
lee	O
memorial	O
health	O
system	O
in	O
fort	O
myers	O
fl	O
is	O
the	O
largest	O
network	O
of	O
medical	O
care	O
facilities	O
in	O
southwest	O
florida	O
and	O
is	O
highly	O
respected	O
for	O
its	O
expertise	O
innovation	O
and	O
quality	O
of	O
care	O
.	O
for	O
nearly	O
century	O
we	O
ve	O
been	O
providing	O
our	O
community	O
with	O
everything	O
from	O
primary	O
care	O
treatment	O
to	O
highly	O
specialized	O
care	O
services	O
and	O
robotic	ENTITY
assisted	ENTITY
surgeries	ENTITY
.	O
visit	O
leememorial	O
org	O
caring	O
.	O
dr	O
roy	O
thomas	O
md	O
medicine	O
topics	O
on	O
kairali	O
tv	O
malayalam	O
.	O
the	O
genetic	ENTITY
predisposition	ENTITY
dna	ENTITY
health	ENTITY
test	ENTITY
is	O
an	O
innovative	O
test	O
which	O
allows	O
you	O
to	O
discover	O
whether	O
you	O
are	O
genetically	ENTITY
predisposed	ENTITY
towards	O
developing	O
number	O
of	O
diseases	ENTITY
and	ENTITY
medical	ENTITY
conditions	ENTITY
including	ENTITY
cardiovascular	ENTITY
conditions	ENTITY
different	O
types	O
of	O
cancers	ENTITY
disorders	ENTITY
of	O
the	O
immune	ENTITY
system	ENTITY
diabetes	ENTITY
as	O
well	O
as	O
medical	O
conditions	O
related	O
to	O
ageing	O
.	O
for	O
more	O
information	O
visit	O
our	O
website	O
www	O
easydnamalaysia	O
com	O
.	O
send	O
us	O
email	O
at	O
info	O
easydnamalaysia	O
com	O
.	O
or	O
call	O
us	O
at	O
.	O
unveil	O
your	O
mastery	O
journey	O
of	O
total	O
transformation	O
remember	O
who	O
you	O
truly	O
are	O
neher	O
am	O
using	O
beneficial	O
frequencies	O
and	O
tones	O
combined	O
with	O
powerful	O
energy	O
transmission	O
that	O
are	O
embedded	O
in	O
this	O
recording	O
.	O
it	O
is	O
my	O
intention	O
that	O
this	O
video	O
will	O
help	O
to	O
clear	O
and	O
purify	O
your	O
genetic	ENTITY
code	ENTITY
.	O
please	O
now	O
add	O
your	O
intention	O
as	O
well	O
but	O
try	O
to	O
stay	O
as	O
close	O
as	O
possible	O
to	O
the	O
original	O
intention	O
.	O
the	O
more	O
people	O
will	O
do	O
this	O
the	O
more	O
powerful	O
this	O
video	O
will	O
become	O
.	O
sit	O
back	O
relax	O
and	O
enjoy	O
the	O
music	O
the	O
energy	O
transmission	O
and	O
the	O
beneficial	O
frequencies	O
.	O
remember	O
to	O
drink	O
plenty	O
of	O
pure	O
water	O
while	O
and	O
after	O
listening	O
.	O
the	O
energies	O
in	O
this	O
recording	O
are	O
very	O
potent	O
as	O
precaution	O
please	O
refrain	O
from	O
listening	O
if	O
you	O
are	O
pregnant	O
suffering	O
from	O
seizures	O
wearing	O
pacemaker	O
operating	O
any	O
machinery	O
or	O
driving	O
thank	O
you	O
for	O
watching	O
.	O
infinite	O
love	O
elke	O
medical	O
disclaimer	O
sound	O
frequency	O
and	O
energy	O
healing	O
are	O
energy	O
based	O
healing	O
methods	O
.	O
this	O
recording	O
is	O
not	O
intended	O
to	O
represent	O
that	O
it	O
is	O
used	O
to	O
diagnose	O
cure	O
treat	O
or	O
prevent	O
any	O
medical	O
problem	O
physical	O
or	O
psychological	ENTITY
disorder	ENTITY
nor	O
is	O
it	O
intended	O
as	O
substitute	O
for	O
seeking	O
professional	O
health	O
care	O
advice	O
.	O
for	O
legal	O
purposes	O
it	O
is	O
understood	O
that	O
this	O
video	O
has	O
been	O
posted	O
for	O
the	O
purpose	O
of	O
entertainment	O
only	O
.	O
am	O
not	O
psychologist	O
physician	O
or	O
other	O
licensed	O
health	O
care	O
provider	O
.	O
strongly	O
advise	O
that	O
you	O
seek	O
professional	O
advice	O
as	O
appropriate	O
before	O
making	O
any	O
health	O
decision	O
.	O
all	O
materials	O
are	O
posted	O
in	O
good	O
faith	O
.	O
the	O
accuracy	O
validity	O
effectiveness	O
completeness	O
or	O
usefulness	O
of	O
any	O
information	O
herein	O
as	O
with	O
any	O
publication	O
cannot	O
be	O
guaranteed	O
.	O
elke	O
neher	O
accepts	O
no	O
responsibility	O
or	O
liability	O
whatsoever	O
for	O
the	O
use	O
or	O
misuse	O
of	O
the	O
material	O
provided	O
here	O
.	O
is	O
obesity	ENTITY
in	ENTITY
our	ENTITY
genes	ENTITY
.	O
dr	O
elizabeth	O
speliotes	O
ph	O
explains	O
the	O
role	O
genes	ENTITY
play	ENTITY
in	ENTITY
body	ENTITY
size	ENTITY
and	ENTITY
shape	ENTITY
.	O
by	O
analyzing	O
genetic	O
samples	O
of	O
individuals	O
across	O
the	O
globe	O
researchers	O
have	O
found	O
more	O
than	O
locations	O
across	O
the	O
genome	ENTITY
linked	ENTITY
with	ENTITY
obesity	ENTITY
traits	ENTITY
.	O
these	O
genetic	O
clues	O
may	O
one	O
day	O
help	O
doctors	O
tailor	O
the	O
advice	O
they	O
give	O
to	O
patients	O
about	O
obesity	ENTITY
complications	ENTITY
.	O
the	O
study	O
was	O
published	O
in	O
the	O
feb	O
issue	O
of	O
nature	O
.	O
discover	O
your	O
genetic	ENTITY
predisposition	ENTITY
and	O
that	O
of	O
your	O
family	O
to	O
type	O
diabetes	ENTITY
with	ENTITY
simple	ENTITY
test	ENTITY
.	O
http	O
www	O
patiadiabetes	O
com	O
at	O
patia	O
we	O
work	O
to	O
reduce	O
the	O
number	O
of	O
cases	O
of	O
diabetes	ENTITY
and	ENTITY
improve	ENTITY
the	ENTITY
quality	ENTITY
of	ENTITY
life	ENTITY
of	ENTITY
diabetic	ENTITY
people	ENTITY
creating	O
solutions	O
and	O
motivating	O
healthy	O
lifestyle	O
.	O
themetabolismmiracle	O
com	O
.	O
disclaimer	O
this	O
video	O
and	O
description	O
contains	O
affiliate	O
links	O
which	O
means	O
that	O
if	O
you	O
click	O
on	O
one	O
of	O
the	O
product	O
links	O
ll	O
receive	O
small	O
commission	O
.	O
this	O
helps	O
support	O
the	O
channel	O
and	O
allows	O
us	O
to	O
continue	O
to	O
make	O
videos	O
like	O
this	O
.	O
thank	O
you	O
for	O
the	O
support	O
.	O
please	O
visit	O
www	O
openpediatrics	O
org	O
openpediatrics	O
is	O
an	O
interactive	O
digital	O
learning	O
platform	O
for	O
healthcare	O
clinicians	O
sponsored	O
by	O
boston	O
children	O
hospital	O
and	O
in	O
collaboration	O
with	O
the	O
world	O
federation	O
of	O
pediatric	O
intensive	O
and	O
critical	O
care	O
societies	O
.	O
it	O
is	O
designed	O
to	O
promote	O
the	O
exchange	O
of	O
knowledge	O
between	O
healthcare	O
providers	O
around	O
the	O
world	O
caring	O
for	O
critically	O
ill	O
children	O
in	O
all	O
resource	O
settings	O
.	O
the	O
content	O
includes	O
internationally	O
recognized	O
experts	O
teaching	O
the	O
full	O
range	O
of	O
topics	O
on	O
the	O
care	O
of	O
critically	O
ill	O
children	O
.	O
all	O
content	O
is	O
peer	O
reviewed	O
and	O
open	O
access	O
and	O
thus	O
at	O
no	O
expense	O
to	O
the	O
user	O
.	O
for	O
further	O
information	O
on	O
how	O
to	O
enroll	O
please	O
email	O
openpediatrics	O
childrens	O
harvard	O
edu	O
please	O
note	O
openpediatrics	O
does	O
not	O
support	O
nor	O
control	O
any	O
related	O
videos	O
in	O
the	O
sidebar	O
these	O
are	O
placed	O
by	O
youtube	O
.	O
we	O
apologize	O
for	O
any	O
inconvenience	O
this	O
may	O
cause	O
.	O
hi	O
and	O
welcome	O
.	O
ll	O
be	O
speaking	O
today	O
about	O
diabetic	ENTITY
ketoacidosis	ENTITY
or	O
dka	O
.	O
my	O
name	O
is	O
michael	O
agus	O
.	O
am	O
pediatric	ENTITY
intensive	ENTITY
care	ENTITY
doctor	ENTITY
and	O
pediatric	ENTITY
endocrinologist	ENTITY
at	O
boston	O
children	O
hospital	O
.	O
the	O
director	O
of	O
the	O
medicine	O
critical	O
care	O
program	O
here	O
at	O
children	O
and	O
an	O
assistant	O
professor	O
at	O
harvard	O
medical	O
school	O
.	O
ll	O
start	O
by	O
explaining	O
how	O
one	O
gets	O
diabetes	ENTITY
to	ENTITY
begin	ENTITY
with	ENTITY
because	ENTITY
it	ENTITY
surprise	ENTITY
to	ENTITY
many	ENTITY
that	ENTITY
diabetes	ENTITY
really	ENTITY
occurs	ENTITY
develops	ENTITY
over	ENTITY
period	ENTITY
of	ENTITY
many	ENTITY
many	ENTITY
months	ENTITY
.	O
when	O
endocrinologists	ENTITY
in	ENTITY
boston	ENTITY
set	ENTITY
up	ENTITY
the	ENTITY
diabetes	ENTITY
prevention	ENTITY
trial	O
or	O
dpt	O
several	O
years	O
ago	O
although	O
we	O
weren	O
able	O
to	O
stop	O
the	O
onset	O
of	O
diabetes	ENTITY
we	ENTITY
were	ENTITY
able	ENTITY
to	ENTITY
track	ENTITY
people	ENTITY
getting	ENTITY
diabetes	ENTITY
.	O
and	O
the	O
way	O
we	O
chose	O
the	O
most	O
likely	O
people	O
to	O
get	O
diabetes	ENTITY
were	ENTITY
to	ENTITY
look	ENTITY
at	ENTITY
first	ENTITY
degree	ENTITY
relatives	ENTITY
of	ENTITY
patients	ENTITY
with	ENTITY
diabetes	ENTITY
.	O
we	O
know	O
that	O
patients	O
who	O
are	O
about	O
to	O
get	O
diabetes	ENTITY
have	ENTITY
genetic	ENTITY
predisposition	ENTITY
and	O
then	O
they	O
have	O
some	O
environmental	O
component	O
that	O
occurs	O
at	O
some	O
point	O
in	O
their	O
life	O
.	O
we	O
don	O
understand	O
what	O
that	O
environmental	O
component	O
is	O
but	O
we	O
understand	O
that	O
if	O
you	O
have	O
that	O
genetic	ENTITY
predisposition	ENTITY
you	O
are	O
at	O
risk	O
to	O
be	O
affected	O
by	O
the	O
environmental	O
exposure	O
.	O
when	O
trying	O
to	O
identify	O
patients	O
at	O
increased	O
risk	O
those	O
first	O
degree	O
relatives	O
so	O
siblings	O
parents	O
children	O
instead	O
of	O
having	O
the	O
usual	O
background	O
rate	O
in	O
the	O
north	O
american	O
population	O
for	O
example	O
of	O
roughly	O
of	O
type	O
diabetes	ENTITY
people	ENTITY
who	O
have	O
first	O
degree	O
relative	O
with	O
diabetes	ENTITY
are	ENTITY
at	ENTITY
tenfold	ENTITY
increased	ENTITY
risk	ENTITY
and	ENTITY
now	ENTITY
have	ENTITY
incidence	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
so	O
you	O
went	O
from	O
in	O
to	O
in	O
by	O
following	O
these	O
people	O
who	O
are	O
at	O
increased	O
risk	O
of	O
getting	O
diabetes	O
we	O
can	O
understand	O
that	O
they	O
begin	O
to	O
lose	O
beta	ENTITY
cell	ENTITY
function	ENTITY
months	O
and	O
months	O
and	O
months	O
prior	O
to	O
the	O
onset	O
of	O
clinical	O
symptoms	O
of	O
diabetes	ENTITY
.	O
so	O
if	O
we	O
were	O
going	O
to	O
take	O
an	O
example	O
of	O
child	O
who	O
is	O
developing	O
diabetes	ENTITY
we	ENTITY
could	ENTITY
look	ENTITY
at	ENTITY
this	ENTITY
particular	ENTITY
graph	ENTITY
.	O
and	O
you	O
see	O
that	O
even	O
though	O
she	O
didn	O
know	O
she	O
was	O
on	O
her	O
way	O
to	O
get	O
diabetes	ENTITY
she	ENTITY
been	ENTITY
losing	ENTITY
beta	ENTITY
cell	ENTITY
function	ENTITY
beta	ENTITY
cell	ENTITY
mass	O
from	O
autoimmune	ENTITY
destruction	ENTITY
over	O
period	O
of	O
many	O
months	O
.	O
when	O
she	O
at	O
the	O
point	O
that	O
you	O
see	O
here	O
there	O
no	O
symptoms	O
whatsoever	O
.	O
she	O
has	O
enough	O
insulin	ENTITY
to	ENTITY
cover	ENTITY
the	ENTITY
meals	ENTITY
cover	ENTITY
her	ENTITY
basal	ENTITY
production	ENTITY
.	O
when	O
she	O
moves	O
to	O
the	O
next	O
step	O
she	O
has	O
intermittent	O
hyperglycemia	ENTITY
.	O
that	O
refers	O
to	O
the	O
fact	O
that	O
when	O
she	O
has	O
large	O
carbohydrate	ENTITY
load	ENTITY
an	ENTITY
ice	ENTITY
cream	ENTITY
sundae	ENTITY
for	ENTITY
example	ENTITY
blood	ENTITY
sugar	ENTITY
may	O
go	O
up	O
into	O
the	O
she	O
may	O
get	O
little	O
flush	O
.	O
she	O
may	O
have	O
increased	ENTITY
urine	ENTITY
output	ENTITY
because	O
her	O
glucose	ENTITY
has	ENTITY
exceeded	ENTITY
the	ENTITY
renal	ENTITY
threshold	ENTITY
of	O
milligrams	O
per	O
deciliter	O
.	O
but	O
she	O
ll	O
have	O
an	O
extra	O
cup	O
of	O
water	O
may	O
be	O
be	O
little	O
bit	O
thirsty	O
and	O
come	O
right	O
back	O
down	O
into	O
the	O
mid	O
to	O
low	O
after	O
that	O
.	O
family	O
genetic	ENTITY
predisposition	ENTITY
to	O
colon	ENTITY
cancer	ENTITY
put	O
terri	O
hofmeister	O
at	O
risk	O
.	O
at	O
twenty	O
five	O
years	O
old	O
terri	O
colon	ENTITY
was	ENTITY
filled	ENTITY
with	ENTITY
polyps	ENTITY
.	O
genetics	ENTITY
expert	ENTITY
charis	O
eng	O
md	O
phd	O
explains	O
how	O
discovering	O
this	O
and	O
an	O
early	O
colonoscopy	ENTITY
saved	ENTITY
terri	ENTITY
life	ENTITY
.	O
for	O
free	O
colon	ENTITY
cancer	ENTITY
assessment	O
tool	O
go	O
to	O
aspx	O
.	O
any	O
lab	O
test	O
now	O
answer	O
man	O
bob	O
deese	O
discusses	O
dna	ENTITY
genetic	ENTITY
predisposition	ENTITY
testing	ENTITY
.	O
please	O
subscribe	O
to	O
our	O
channel	O
.	O
at	O
one	O
to	O
two	O
hours	O
after	O
meal	O
see	O
chart	O
below	O
.	O
doctor	O
or	O
health	O
care	O
provider	O
can	O
tell	O
person	O
with	O
diabetes	ENTITY
about	ENTITY
how	ENTITY
and	ENTITY
when	ENTITY
to	ENTITY
test	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
it	O
is	O
helpful	O
to	O
keep	O
record	O
of	O
blood	ENTITY
sugar	ENTITY
readings	O
several	O
times	O
during	O
the	O
day	O
.	O
diabetes	ENTITY
type	ENTITY
diabetes	ENTITY
diabetes	ENTITY
symptoms	ENTITY
symptoms	ENTITY
of	ENTITY
diabetes	ENTITY
type	ENTITY
diabetes	ENTITY
hypoglycemia	ENTITY
glucose	ENTITY
prediabetes	ENTITY
diabetes	ENTITY
mellitus	ENTITY
low	ENTITY
blood	ENTITY
sugar	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
normal	ENTITY
blood	ENTITY
sugar	ENTITY
low	ENTITY
blood	ENTITY
sugar	ENTITY
symptoms	ENTITY
hypoglycemia	ENTITY
symptoms	ENTITY
normal	ENTITY
blood	ENTITY
sugar	ENTITY
level	ENTITY
high	ENTITY
blood	ENTITY
sugar	ENTITY
symptoms	ENTITY
of	ENTITY
low	ENTITY
blood	ENTITY
sugar	ENTITY
glucose	ENTITY
levels	ENTITY
symptoms	ENTITY
of	ENTITY
high	ENTITY
blood	ENTITY
sugar	ENTITY
blood	O
glucose	ENTITY
levels	ENTITY
normal	ENTITY
glucose	ENTITY
levels	ENTITY
high	ENTITY
blood	ENTITY
sugar	ENTITY
symptoms	ENTITY
glucose	ENTITY
test	ENTITY
glucometer	O
how	O
to	O
lower	O
blood	ENTITY
sugar	ENTITY
blood	ENTITY
sugar	ENTITY
chart	O
juvenile	ENTITY
diabetes	ENTITY
symptoms	ENTITY
of	ENTITY
hypoglycemia	ENTITY
fasting	ENTITY
blood	ENTITY
sugar	ENTITY
blood	ENTITY
sugar	ENTITY
rangewhat	ENTITY
is	O
normal	ENTITY
blood	ENTITY
sugar	ENTITY
normal	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
diabetes	ENTITY
test	ENTITY
normal	ENTITY
sugar	ENTITY
level	ENTITY
signs	O
of	O
low	ENTITY
blood	ENTITY
sugar	ENTITY
normal	ENTITY
blood	ENTITY
sugar	ENTITY
range	ENTITY
blood	ENTITY
sugar	ENTITY
test	ENTITY
what	O
is	O
hypoglycemia	ENTITY
glucose	ENTITY
meter	ENTITY
high	ENTITY
glucose	ENTITY
levels	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
chart	O
signs	O
of	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
causes	O
of	O
diabetes	ENTITY
signs	ENTITY
of	ENTITY
hypoglycemia	ENTITY
diabetes	ENTITY
treatment	ENTITY
normal	ENTITY
fasting	ENTITY
blood	ENTITY
sugar	ENTITY
continuous	ENTITY
glucose	ENTITY
monitoring	ENTITY
blood	ENTITY
glucose	ENTITY
meters	ENTITY
blood	ENTITY
glucose	ENTITY
sugar	ENTITY
level	ENTITY
lower	ENTITY
blood	ENTITY
sugar	ENTITY
foods	O
that	O
lower	O
blood	ENTITY
sugar	ENTITY
blood	ENTITY
sugar	ENTITY
monitor	ENTITY
glucose	ENTITY
level	ENTITY
chart	O
high	ENTITY
glucose	ENTITY
low	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
glucose	ENTITY
monitor	ENTITY
.	O
sometimes	O
little	O
surprised	O
by	O
the	O
answers	O
get	O
.	O
after	O
all	O
it	O
seems	O
to	O
me	O
asking	O
very	O
simple	O
question	O
.	O
what	O
kind	O
of	O
diabetes	ENTITY
do	ENTITY
you	ENTITY
have	ENTITY
there	ENTITY
are	ENTITY
people	ENTITY
that	ENTITY
will	ENTITY
know	ENTITY
but	ENTITY
surprising	ENTITY
number	ENTITY
don	ENTITY
.	O
it	O
not	O
that	O
they	O
are	O
stupid	O
or	O
uneducated	O
.	O
it	O
is	O
that	O
no	O
one	O
ever	O
sat	O
down	O
and	O
told	O
them	O
about	O
their	O
diabetes	ENTITY
.	O
there	O
are	O
two	O
main	O
types	O
of	O
diabetes	O
in	O
those	O
who	O
aren	O
pregnant	O
.	O
they	O
are	O
simply	O
called	O
type	O
and	O
type	ENTITY
ii	ENTITY
diabetes	ENTITY
.	O
while	O
the	O
end	O
result	O
is	O
the	O
same	O
how	O
they	O
are	O
obtained	O
is	O
very	O
different	O
.	O
type	O
diabetes	ENTITY
is	ENTITY
an	ENTITY
autoimmune	ENTITY
disorder	ENTITY
.	O
it	O
is	O
characterized	O
by	O
the	O
blood	ENTITY
sugars	ENTITY
in	O
the	O
body	O
being	O
higher	O
than	O
normal	O
.	O
this	O
is	O
due	O
to	O
an	O
absence	O
of	O
insulin	ENTITY
hormone	ENTITY
that	O
is	O
produced	O
in	O
the	O
pancreas	ENTITY
.	O
insulin	ENTITY
is	ENTITY
responsible	ENTITY
for	ENTITY
pushing	ENTITY
sugars	ENTITY
that	ENTITY
are	ENTITY
in	ENTITY
the	ENTITY
bloodstream	ENTITY
into	ENTITY
the	ENTITY
cell	ENTITY
for	ENTITY
proper	ENTITY
use	ENTITY
.	O
this	O
hormone	ENTITY
is	ENTITY
deficient	ENTITY
because	ENTITY
the	ENTITY
beta	ENTITY
cells	ENTITY
of	ENTITY
the	ENTITY
pancreas	ENTITY
which	O
are	O
responsible	O
for	O
insulin	ENTITY
production	ENTITY
are	ENTITY
destroyed	ENTITY
by	ENTITY
auto	ENTITY
antibodies	ENTITY
.	O
these	O
are	O
antibodies	ENTITY
that	ENTITY
are	ENTITY
made	ENTITY
by	ENTITY
the	ENTITY
body	ENTITY
but	ENTITY
actually	ENTITY
cause	ENTITY
destruction	ENTITY
and	ENTITY
do	ENTITY
not	ENTITY
serve	ENTITY
to	ENTITY
enhance	ENTITY
the	ENTITY
immune	ENTITY
system	ENTITY
.	O
type	O
diabetes	ENTITY
is	ENTITY
disease	ENTITY
of	ENTITY
the	ENTITY
young	ENTITY
.	O
it	O
peaks	O
around	O
years	O
of	O
age	O
.	O
it	O
is	O
rare	O
with	O
an	O
incidence	O
in	O
those	O
at	O
years	O
of	O
about	O
per	O
people	O
.	O
non	O
hispanic	O
white	O
youth	O
have	O
the	O
highest	O
incidence	O
and	O
african	O
americans	O
have	O
the	O
lowest	O
incidence	O
.	O
about	O
children	O
are	O
diagnosed	O
with	O
it	O
every	O
year	O
.	O
it	O
usually	O
presents	O
either	O
around	O
age	O
to	O
or	O
around	O
age	O
to	O
and	O
is	O
more	O
common	O
in	O
males	O
.	O
there	O
is	O
some	O
genetic	ENTITY
predisposition	ENTITY
to	O
it	O
but	O
that	O
is	O
still	O
being	O
worked	O
out	O
.	O
it	O
is	O
thought	O
that	O
infectious	O
agents	O
like	O
virus	O
cause	O
confusion	O
to	O
the	O
immune	ENTITY
system	ENTITY
leading	O
to	O
these	O
aberrant	ENTITY
antibodies	ENTITY
.	O
type	O
diabetes	ENTITY
has	ENTITY
to	ENTITY
be	ENTITY
treated	ENTITY
with	ENTITY
insulin	ENTITY
.	O
this	O
makes	O
sense	O
as	O
the	O
problem	O
is	O
simply	O
lack	O
of	O
insulin	ENTITY
in	ENTITY
the	ENTITY
body	ENTITY
.	O
therefore	O
immediate	O
insulin	ENTITY
injections	ENTITY
are	O
needed	O
although	O
now	O
there	O
are	O
apparatuses	ENTITY
where	ENTITY
insulin	ENTITY
can	ENTITY
be	ENTITY
pumped	ENTITY
into	ENTITY
the	ENTITY
body	ENTITY
in	ENTITY
selected	ENTITY
individuals	ENTITY
.	O
diabetes	ENTITY
mellitus	ENTITY
type	ENTITY
ii	ENTITY
is	O
metabolic	ENTITY
disorder	ENTITY
that	O
leads	O
to	O
high	ENTITY
blood	ENTITY
sugars	ENTITY
.	O
however	O
in	O
type	ENTITY
ii	ENTITY
diabetes	ENTITY
it	O
is	O
due	O
to	O
the	O
resistance	O
of	O
body	ENTITY
tissues	ENTITY
to	O
the	O
action	O
of	O
insulin	ENTITY
.	O
in	O
most	O
cases	O
there	O
is	O
actually	O
an	O
overproduction	O
of	O
insulin	ENTITY
but	ENTITY
the	ENTITY
insulin	ENTITY
doesn	ENTITY
seem	ENTITY
to	ENTITY
work	ENTITY
very	ENTITY
well	ENTITY
.	O
type	ENTITY
ii	ENTITY
diabetes	ENTITY
is	O
brought	O
on	O
by	O
obesity	ENTITY
and	ENTITY
sedentary	ENTITY
lifestyle	ENTITY
in	ENTITY
many	ENTITY
cases	ENTITY
.	O
over	O
of	O
diabetics	ENTITY
are	ENTITY
type	ENTITY
ii	ENTITY
diabetics	ENTITY
.	O
there	O
about	O
million	O
cases	O
united	O
states	O
and	O
approximately	O
of	O
the	O
population	O
over	O
the	O
age	O
of	O
have	O
it	O
.	O
almost	O
million	O
new	O
cases	O
of	O
this	O
type	O
of	O
diabetes	ENTITY
were	ENTITY
diagnosed	ENTITY
in	ENTITY
type	ENTITY
ii	ENTITY
diabetes	ENTITY
is	O
very	O
rare	O
under	O
the	O
age	O
of	O
and	O
it	O
actually	O
afflicts	O
more	O
women	O
than	O
men	O
.	O
there	O
is	O
genetic	O
tendency	O
for	O
it	O
but	O
only	O
if	O
obesity	ENTITY
and	ENTITY
sedentary	ENTITY
lifestyle	ENTITY
accompany	ENTITY
those	ENTITY
genes	ENTITY
.	O
type	ENTITY
ii	ENTITY
diabetes	ENTITY
mellitus	ENTITY
can	O
be	O
treated	O
with	O
variety	O
of	O
different	O
medication	O
before	O
having	O
to	O
go	O
to	O
insulin	ENTITY
in	ENTITY
selected	ENTITY
cases	ENTITY
.	O
oral	O
medicationcan	O
either	O
further	O
increase	O
production	O
of	O
insulin	ENTITY
or	ENTITY
make	ENTITY
the	ENTITY
internal	ENTITY
organs	ENTITY
more	O
sensitive	O
to	O
insulin	ENTITY
.	O
however	O
for	O
some	O
patients	O
only	O
getting	O
massive	ENTITY
doses	ENTITY
of	ENTITY
insulin	ENTITY
to	O
overcome	O
the	O
resistanceof	ENTITY
the	ENTITY
body	ENTITY
organs	ENTITY
to	O
insulin	ENTITY
can	ENTITY
help	ENTITY
properly	ENTITY
treat	ENTITY
type	ENTITY
ii	ENTITY
diabetes	ENTITY
.	O
please	O
see	O
the	O
other	O
sections	O
on	O
how	O
to	O
treat	O
diabetes	ENTITY
.	O
pray	O
for	O
those	O
who	O
are	O
afflicted	O
with	O
this	O
terrible	O
disease	ENTITY
.	O
at	O
one	O
to	O
two	O
hours	O
after	O
meal	O
see	O
chart	O
below	O
.	O
doctor	O
or	O
health	O
care	O
provider	O
can	O
tell	O
person	O
with	O
diabetes	ENTITY
about	ENTITY
how	ENTITY
and	ENTITY
when	ENTITY
to	ENTITY
test	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
it	O
is	O
helpful	O
to	O
keep	O
record	O
of	O
blood	ENTITY
sugar	ENTITY
readings	O
several	O
times	O
during	O
the	O
day	O
.	O
diabetes	ENTITY
type	ENTITY
diabetes	ENTITY
diabetes	ENTITY
symptoms	ENTITY
symptoms	ENTITY
of	ENTITY
diabetes	ENTITY
type	O
diabetes	ENTITY
hypoglycemia	ENTITY
glucose	ENTITY
prediabetes	ENTITY
diabetes	ENTITY
mellitus	ENTITY
low	ENTITY
blood	ENTITY
sugar	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
normal	ENTITY
blood	ENTITY
sugar	ENTITY
low	ENTITY
blood	ENTITY
sugar	ENTITY
symptoms	ENTITY
hypoglycemia	ENTITY
symptoms	ENTITY
normal	ENTITY
blood	ENTITY
sugar	ENTITY
level	ENTITY
high	ENTITY
blood	ENTITY
sugar	ENTITY
symptoms	ENTITY
of	ENTITY
low	ENTITY
blood	ENTITY
sugar	ENTITY
glucose	ENTITY
levels	ENTITY
symptoms	ENTITY
of	ENTITY
high	ENTITY
blood	ENTITY
sugar	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
normal	ENTITY
glucose	ENTITY
levels	ENTITY
high	ENTITY
blood	ENTITY
sugar	ENTITY
symptoms	ENTITY
glucose	ENTITY
test	ENTITY
glucometer	ENTITY
how	ENTITY
to	ENTITY
lower	ENTITY
blood	ENTITY
sugar	ENTITY
blood	ENTITY
sugar	ENTITY
chart	ENTITY
juvenile	ENTITY
diabetes	ENTITY
symptoms	ENTITY
of	ENTITY
hypoglycemia	ENTITY
fasting	ENTITY
blood	ENTITY
sugar	ENTITY
blood	ENTITY
sugar	ENTITY
range	ENTITY
what	O
is	O
normal	ENTITY
blood	ENTITY
sugar	ENTITY
normal	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
diabetes	ENTITY
test	ENTITY
normal	ENTITY
sugar	ENTITY
level	ENTITY
signs	O
of	O
low	ENTITY
blood	ENTITY
sugar	ENTITY
normal	ENTITY
blood	ENTITY
sugar	ENTITY
range	ENTITY
blood	ENTITY
sugar	ENTITY
test	ENTITY
what	O
is	O
hypoglycemia	ENTITY
glucose	ENTITY
meter	ENTITY
high	ENTITY
glucose	ENTITY
levels	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
chart	O
signs	O
of	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
causes	O
of	O
diabetes	ENTITY
signs	ENTITY
of	ENTITY
hypoglycemia	ENTITY
diabetes	ENTITY
treatment	ENTITY
normal	ENTITY
fasting	ENTITY
blood	ENTITY
sugar	ENTITY
continuous	ENTITY
glucose	ENTITY
monitoring	ENTITY
blood	ENTITY
glucose	ENTITY
meters	ENTITY
blood	ENTITY
glucose	ENTITY
sugar	ENTITY
level	ENTITY
lower	ENTITY
blood	ENTITY
sugar	ENTITY
foods	O
that	O
lower	ENTITY
blood	ENTITY
sugar	ENTITY
blood	ENTITY
sugar	ENTITY
monitor	ENTITY
glucose	ENTITY
level	ENTITY
chart	O
high	ENTITY
glucose	ENTITY
low	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
glucose	ENTITY
monitor	ENTITY
.	O
transcript	O
study	O
published	O
in	O
the	O
lancet	O
leading	O
international	O
medical	O
journal	O
in	O
august	O
found	O
that	O
the	O
risk	O
of	O
developing	O
diabetes	ENTITY
is	ENTITY
increasingly	ENTITY
rapidly	ENTITY
among	ENTITY
americans	ENTITY
.	O
the	O
study	O
also	O
found	O
that	O
this	O
risk	O
depends	O
on	O
your	O
race	O
your	O
education	O
and	O
where	O
you	O
live	O
and	O
that	O
diabetics	ENTITY
are	ENTITY
living	ENTITY
longer	ENTITY
.	O
this	O
study	O
is	O
the	O
first	O
in	O
more	O
than	O
decade	O
to	O
calculate	O
the	O
risk	O
americans	O
face	O
of	O
developing	O
diabetes	ENTITY
during	ENTITY
their	ENTITY
life	ENTITY
time	ENTITY
.	O
it	O
was	O
conducted	O
by	O
epidemiologists	ENTITY
at	ENTITY
the	ENTITY
us	ENTITY
centers	ENTITY
for	ENTITY
disease	ENTITY
control	ENTITY
and	ENTITY
prevention	ENTITY
in	ENTITY
atlanta	ENTITY
georgia	ENTITY
who	ENTITY
have	ENTITY
been	ENTITY
tracking	ENTITY
and	ENTITY
analysing	ENTITY
the	ENTITY
prevalence	ENTITY
of	ENTITY
diabetes	ENTITY
and	ENTITY
the	ENTITY
rate	ENTITY
at	ENTITY
which	ENTITY
news	ENTITY
cases	ENTITY
are	ENTITY
diagnosed	ENTITY
for	ENTITY
many	ENTITY
years	ENTITY
.	O
these	O
researchers	O
used	O
mortality	O
data	O
for	O
almost	O
persons	O
from	O
to	O
years	O
to	O
assess	O
the	O
risk	O
of	O
developing	O
type	O
or	O
type	O
diabetes	ENTITY
excluding	ENTITY
gestational	ENTITY
diabetes	ENTITY
.	O
though	O
the	O
study	O
only	O
examined	O
diabetes	ENTITY
in	ENTITY
the	ENTITY
context	ENTITY
of	ENTITY
american	ENTITY
people	ENTITY
it	ENTITY
is	ENTITY
likely	ENTITY
that	ENTITY
similar	ENTITY
results	ENTITY
would	ENTITY
have	ENTITY
been	ENTITY
obtained	ENTITY
had	ENTITY
the	ENTITY
study	ENTITY
been	ENTITY
conducted	ENTITY
using	ENTITY
european	ENTITY
data	ENTITY
or	ENTITY
data	ENTITY
from	ENTITY
other	ENTITY
countries	ENTITY
where	ENTITY
western	ENTITY
type	ENTITY
diet	ENTITY
and	ENTITY
life	ENTITY
style	ENTITY
is	ENTITY
the	ENTITY
norm	ENTITY
.	O
the	O
ever	O
increasing	O
risk	O
of	O
diabetes	ENTITY
the	ENTITY
study	ENTITY
revealed	ENTITY
that	ENTITY
there	ENTITY
was	ENTITY
dramatic	ENTITY
rise	ENTITY
between	ENTITY
and	ENTITY
in	ENTITY
the	ENTITY
overall	ENTITY
risk	ENTITY
that	ENTITY
an	ENTITY
american	ENTITY
will	ENTITY
develop	ENTITY
diabetes	ENTITY
.	O
in	O
american	O
boys	O
had	O
percent	O
chance	O
of	O
developing	O
diabetes	ENTITY
and	ENTITY
girls	ENTITY
percent	ENTITY
.	O
by	O
however	O
that	O
risk	O
had	O
jumped	O
to	O
percent	O
for	O
both	O
boys	O
and	O
girls	O
.	O
in	O
other	O
words	O
the	O
risk	O
for	O
boys	O
had	O
almost	O
doubled	O
while	O
the	O
risk	O
for	O
girls	O
had	O
gone	O
up	O
percent	O
.	O
the	O
lancet	O
study	O
did	O
not	O
analyse	O
why	O
this	O
is	O
so	O
.	O
but	O
part	O
of	O
the	O
reason	O
could	O
be	O
the	O
fact	O
that	O
people	O
are	O
living	O
longer	O
so	O
that	O
they	O
have	O
more	O
years	O
during	O
which	O
they	O
can	O
develop	O
diabetes	ENTITY
.	O
diabetics	ENTITY
are	ENTITY
living	ENTITY
longer	ENTITY
the	ENTITY
good	ENTITY
news	ENTITY
is	ENTITY
that	ENTITY
america	ENTITY
children	ENTITY
diagnosed	ENTITY
with	ENTITY
diabetes	ENTITY
can	ENTITY
now	ENTITY
expect	ENTITY
to	ENTITY
live	ENTITY
more	ENTITY
than	ENTITY
years	ENTITY
with	ENTITY
the	ENTITY
disease	ENTITY
.	O
indeed	O
between	O
and	O
the	O
number	O
of	O
years	O
for	O
which	O
men	O
diagnosed	O
with	O
diabetes	ENTITY
can	ENTITY
expect	ENTITY
to	ENTITY
survive	ENTITY
increased	ENTITY
by	ENTITY
percent	ENTITY
.	O
for	O
women	O
the	O
figure	O
was	O
percent	O
.	O
though	O
no	O
explanation	O
was	O
given	O
by	O
the	O
researchers	O
this	O
is	O
probably	O
due	O
to	O
advances	O
in	O
medical	O
knowledge	O
and	O
treatments	O
over	O
the	O
last	O
years	O
.	O
being	O
diabetic	ENTITY
shortens	ENTITY
your	ENTITY
life	ENTITY
span	ENTITY
.	O
over	O
the	O
year	O
period	O
examined	O
by	O
the	O
researchers	O
the	O
average	O
number	O
of	O
years	O
lost	O
due	O
to	O
diabetes	ENTITY
for	ENTITY
the	ENTITY
population	ENTITY
as	ENTITY
whole	ENTITY
increased	ENTITY
by	ENTITY
percent	ENTITY
in	ENTITY
men	ENTITY
and	ENTITY
percent	ENTITY
in	ENTITY
women	ENTITY
.	O
this	O
is	O
obviously	O
due	O
to	O
the	O
increasing	O
prevalence	O
of	O
diabetes	ENTITY
.	O
it	O
may	O
also	O
be	O
partly	O
due	O
to	O
the	O
fact	O
that	O
there	O
are	O
probably	O
fewer	O
undiagnosed	O
cases	O
nowadays	O
.	O
while	O
the	O
picture	O
for	O
the	O
population	O
as	O
whole	O
seems	O
to	O
be	O
getting	O
bleaker	O
things	O
are	O
improving	O
for	O
the	O
individual	ENTITY
diabetic	ENTITY
.	O
the	O
number	O
of	O
years	O
of	O
his	O
life	O
man	O
diagnosed	O
with	O
diabetes	ENTITY
can	ENTITY
expect	ENTITY
to	ENTITY
lose	ENTITY
on	ENTITY
average	ENTITY
decreased	ENTITY
by	ENTITY
almost	ENTITY
two	ENTITY
years	ENTITY
from	ENTITY
to	ENTITY
lost	ENTITY
years	ENTITY
between	ENTITY
the	ENTITY
and	ENTITY
the	ENTITY
end	ENTITY
of	ENTITY
the	ENTITY
women	ENTITY
also	ENTITY
gained	ENTITY
an	ENTITY
average	ENTITY
of	ENTITY
two	ENTITY
years	ENTITY
their	ENTITY
losses	ENTITY
decreasing	ENTITY
from	ENTITY
to	ENTITY
years	ENTITY
over	ENTITY
the	ENTITY
same	ENTITY
time	ENTITY
span	ENTITY
.	O
these	O
improvements	O
are	O
probably	O
due	O
to	O
better	O
treatment	O
regimes	O
.	O
race	O
gender	O
and	O
diabetes	ENTITY
while	ENTITY
americans	ENTITY
overall	ENTITY
have	ENTITY
gloomy	ENTITY
percent	ENTITY
chance	ENTITY
of	ENTITY
developing	ENTITY
diabetes	ENTITY
the	ENTITY
outlook	ENTITY
for	ENTITY
blacks	ENTITY
and	ENTITY
hispanics	ENTITY
is	ENTITY
much	ENTITY
grimmer	ENTITY
.	O
white	O
boys	O
have	O
and	O
white	O
girls	O
risk	O
of	O
developing	ENTITY
diabetes	ENTITY
.	O
by	O
contrast	O
the	O
chances	O
for	O
black	O
men	O
are	O
while	O
for	O
their	O
sisters	O
the	O
risk	O
is	O
whopping	O
.	O
the	O
chances	O
of	O
developing	ENTITY
diabetes	ENTITY
for	O
hispanic	O
boys	O
and	O
girls	O
are	O
and	O
respectively	O
.	O
these	O
figures	O
which	O
refer	O
to	O
the	O
risks	O
of	O
developing	ENTITY
diabetes	ENTITY
reinforce	O
the	O
idea	O
that	O
diabetes	ENTITY
has	ENTITY
genetic	ENTITY
origin	ENTITY
at	ENTITY
least	ENTITY
to	ENTITY
the	ENTITY
extent	ENTITY
that	ENTITY
your	ENTITY
genes	ENTITY
can	ENTITY
predispose	ENTITY
you	ENTITY
to	ENTITY
diabetes	ENTITY
.	O
most	O
medical	O
researchers	O
agree	O
that	O
it	O
your	O
life	O
style	O
that	O
kicks	O
it	O
into	O
action	O
.	O
according	O
to	O
the	O
researchers	O
they	O
analysed	O
race	O
because	O
that	O
was	O
the	O
data	O
they	O
had	O
available	O
but	O
they	O
did	O
state	O
that	O
socio	O
economic	O
status	O
is	O
probably	O
as	O
important	O
as	O
if	O
not	O
more	O
important	O
than	O
race	O
.	O
nevertheless	O
the	O
risk	O
of	O
developing	ENTITY
diabetes	ENTITY
for	O
whites	O
is	O
much	O
less	O
than	O
it	O
is	O
for	O
blacks	O
and	O
hispanics	O
.	O
indeed	O
the	O
risk	O
for	O
white	O
girls	O
is	O
third	O
less	O
than	O
the	O
risk	O
for	O
black	O
and	O
hispanic	O
ladies	O
.	O
as	O
you	O
can	O
see	O
hispanics	O
of	O
both	O
sexes	O
as	O
well	O
as	O
black	O
women	O
have	O
risk	O
that	O
exceeds	O
percent	O
.	O
but	O
why	O
black	O
men	O
have	O
risk	O
that	O
is	O
almost	O
percentage	O
points	O
less	O
than	O
black	O
women	O
cannot	O
be	O
explained	O
away	O
by	O
genetic	O
differences	O
.	O
education	O
and	O
diabetes	ENTITY
the	ENTITY
less	ENTITY
educated	ENTITY
you	ENTITY
are	ENTITY
the	ENTITY
greater	ENTITY
your	ENTITY
risk	ENTITY
of	ENTITY
developing	ENTITY
diabetes	ENTITY
.	O
according	O
to	O
the	O
lancet	O
in	O
the	O
number	O
of	O
new	O
diagnoses	O
among	O
high	O
school	O
drop	O
outs	O
was	O
per	O
thousand	O
while	O
among	O
high	O
school	O
graduates	O
it	O
was	O
and	O
for	O
those	O
who	O
studied	O
beyond	O
high	O
school	O
per	O
thousand	O
.	O
this	O
figure	O
for	O
the	O
number	O
of	O
new	O
diagnoses	O
of	O
diabetes	ENTITY
among	ENTITY
high	ENTITY
school	ENTITY
drop	ENTITY
outs	ENTITY
high	ENTITY
school	ENTITY
graduates	ENTITY
and	ENTITY
those	ENTITY
who	ENTITY
continued	ENTITY
to	ENTITY
study	ENTITY
after	ENTITY
hi	ENTITY
.	O
at	O
one	O
to	O
two	O
hours	O
after	O
meal	O
see	O
chart	O
below	O
.	O
doctor	O
or	O
health	O
care	O
provider	O
can	O
tell	O
person	O
with	O
diabetes	ENTITY
about	ENTITY
how	ENTITY
and	ENTITY
when	ENTITY
to	ENTITY
test	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
it	O
is	O
helpful	O
to	O
keep	O
record	O
of	O
blood	ENTITY
sugar	ENTITY
readings	O
several	O
times	O
during	O
the	O
day	O
.	O
diabetes	ENTITY
type	ENTITY
diabetes	ENTITY
diabetes	ENTITY
symptoms	ENTITY
symptoms	ENTITY
of	ENTITY
diabetes	ENTITY
type	O
diabetes	ENTITY
hypoglycemia	ENTITY
glucose	ENTITY
prediabetes	ENTITY
diabetes	ENTITY
mellitus	ENTITY
low	ENTITY
blood	ENTITY
sugar	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
normal	ENTITY
blood	ENTITY
sugar	ENTITY
low	ENTITY
blood	ENTITY
sugar	ENTITY
symptoms	ENTITY
hypoglycemia	ENTITY
symptoms	ENTITY
normal	ENTITY
blood	ENTITY
sugar	ENTITY
level	ENTITY
high	ENTITY
blood	ENTITY
sugar	ENTITY
symptoms	ENTITY
of	ENTITY
low	ENTITY
blood	ENTITY
sugar	ENTITY
glucose	ENTITY
levels	ENTITY
symptoms	ENTITY
of	ENTITY
high	ENTITY
blood	ENTITY
sugar	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
normal	ENTITY
glucose	ENTITY
levels	ENTITY
high	ENTITY
blood	ENTITY
sugar	ENTITY
symptoms	ENTITY
glucose	ENTITY
test	ENTITY
glucometer	ENTITY
how	O
to	O
lower	O
blood	ENTITY
sugar	ENTITY
blood	ENTITY
sugar	ENTITY
chart	ENTITY
juvenile	ENTITY
diabetes	ENTITY
symptoms	ENTITY
of	ENTITY
hypoglycemia	ENTITY
fasting	ENTITY
blood	ENTITY
sugar	ENTITY
blood	ENTITY
sugar	ENTITY
range	O
what	O
is	O
normal	ENTITY
blood	ENTITY
sugar	ENTITY
normal	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
diabetes	ENTITY
test	ENTITY
normal	ENTITY
sugar	ENTITY
level	ENTITY
signs	O
of	O
low	ENTITY
blood	ENTITY
sugar	ENTITY
normal	ENTITY
blood	ENTITY
sugar	ENTITY
range	O
blood	ENTITY
sugar	ENTITY
test	ENTITY
what	O
is	O
hypoglycemia	ENTITY
glucose	ENTITY
meter	ENTITY
high	ENTITY
glucose	ENTITY
levels	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
chart	ENTITY
signs	O
of	O
high	ENTITY
blood	ENTITY
sugar	ENTITY
causes	O
of	O
diabetes	ENTITY
signs	ENTITY
of	ENTITY
hypoglycemia	ENTITY
diabetes	ENTITY
treatment	ENTITY
normal	ENTITY
fasting	ENTITY
blood	ENTITY
sugar	ENTITY
continuous	ENTITY
glucose	ENTITY
monitoring	ENTITY
blood	ENTITY
glucose	ENTITY
meters	ENTITY
blood	ENTITY
glucose	ENTITY
sugar	ENTITY
level	ENTITY
lower	O
blood	ENTITY
sugar	ENTITY
foods	O
that	O
lower	O
blood	ENTITY
sugar	ENTITY
blood	ENTITY
sugar	ENTITY
monitor	ENTITY
glucose	ENTITY
level	ENTITY
chart	ENTITY
high	ENTITY
glucose	ENTITY
low	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
glucose	ENTITY
monitor	ENTITY
.	O
dr	O
jonathan	O
spages	O
dc	O
provides	O
valuable	O
information	O
to	O
help	O
diabetics	O
reverse	O
their	O
health	O
conditions	O
.	O
when	O
you	O
look	O
at	O
the	O
research	O
behind	O
that	O
will	O
see	O
that	O
when	O
we	O
look	O
at	O
the	O
growth	O
rate	O
in	O
which	O
our	O
population	O
is	O
going	O
is	O
actually	O
less	O
than	O
the	O
amount	O
of	O
diabetes	ENTITY
.	O
discover	O
is	O
diabetes	ENTITY
is	ENTITY
genetic	ENTITY
and	ENTITY
why	ENTITY
it	ENTITY
may	ENTITY
not	ENTITY
be	ENTITY
true	ENTITY
.	O
natural	O
diabetes	ENTITY
doctordrjonathan	ENTITY
spages	ENTITY
see	ENTITY
our	ENTITY
other	ENTITY
videos	ENTITY
at	ENTITY
dr	ENTITY
spages	ENTITY
practices	ENTITY
functional	ENTITY
medicine	ENTITY
in	ENTITY
paterson	ENTITY
nj	ENTITY
.	O
he	O
can	O
be	O
reached	O
by	O
.	O
get	O
dr	O
berg	O
new	O
book	O
disclaimerdrberg	O
does	O
not	O
diagnose	O
treat	O
or	O
prevent	O
any	O
medical	O
conditions	O
instead	O
he	O
helps	O
people	O
create	O
their	O
health	O
to	O
avoid	O
health	O
problems	O
.	O
he	O
also	O
works	O
with	O
their	O
physicians	O
who	O
then	O
monitor	O
their	O
medications	O
.	O
dr	O
berg	O
is	O
not	O
involved	O
in	O
advising	O
alteration	O
in	O
medications	O
.	O
this	O
video	O
is	O
not	O
designed	O
to	O
and	O
does	O
not	O
provide	O
medical	O
advice	O
professional	O
diagnosis	O
opinion	O
treatment	O
or	O
services	O
to	O
you	O
or	O
to	O
any	O
other	O
individual	O
.	O
through	O
my	O
videos	O
blog	O
posts	O
website	O
information	O
give	O
suggestions	O
for	O
you	O
and	O
your	O
doctor	O
to	O
research	O
and	O
provide	O
general	O
information	O
for	O
educational	O
purposes	O
only	O
.	O
the	O
information	O
provided	O
in	O
this	O
video	O
or	O
site	O
or	O
through	O
linkages	O
to	O
other	O
sites	O
is	O
not	O
substitute	O
for	O
medical	O
or	O
professional	O
care	O
and	O
you	O
should	O
not	O
use	O
the	O
information	O
in	O
place	O
of	O
visit	O
call	O
consultation	O
or	O
the	O
advice	O
of	O
your	O
physician	O
or	O
other	O
healthcare	O
provider	O
.	O
the	O
health	O
wellness	O
and	O
dr	O
eric	O
berg	O
are	O
not	O
liable	O
or	O
responsible	O
for	O
any	O
advice	O
course	O
of	O
treatment	O
diagnosis	O
or	O
any	O
other	O
information	O
services	O
or	O
product	O
you	O
obtain	O
through	O
this	O
video	O
or	O
site	O
.	O
copyright	O
broad	O
institute	O
all	O
rights	O
reserved	O
.	O
designing	O
new	O
drugs	O
would	O
be	O
easier	O
if	O
scientists	O
understood	O
the	O
biology	O
of	O
the	O
diseases	ENTITY
they	ENTITY
are	ENTITY
trying	ENTITY
to	ENTITY
treat	ENTITY
but	ENTITY
for	ENTITY
most	ENTITY
common	ENTITY
diseases	ENTITY
which	ENTITY
are	ENTITY
caused	ENTITY
by	ENTITY
many	ENTITY
different	ENTITY
genes	ENTITY
and	ENTITY
environmental	ENTITY
factors	ENTITY
acting	ENTITY
in	ENTITY
concert	ENTITY
gaining	ENTITY
that	ENTITY
understanding	ENTITY
has	ENTITY
been	ENTITY
challenge	ENTITY
.	O
in	O
recent	O
years	O
however	O
by	O
studying	O
the	O
genomes	ENTITY
of	ENTITY
hundreds	ENTITY
of	ENTITY
thousands	ENTITY
of	ENTITY
people	ENTITY
scientists	ENTITY
have	ENTITY
uncovered	ENTITY
hundreds	ENTITY
of	ENTITY
genetic	ENTITY
factors	ENTITY
that	ENTITY
influence	ENTITY
disease	ENTITY
risk	ENTITY
including	ENTITY
some	ENTITY
genomic	ENTITY
regions	ENTITY
containing	O
variants	O
that	O
either	O
make	O
people	O
more	O
prone	O
to	O
type	O
diabetes	ENTITY
or	ENTITY
protect	ENTITY
them	ENTITY
from	ENTITY
it	ENTITY
.	O
many	O
of	O
the	O
findings	O
are	O
upending	O
what	O
scientists	O
thought	O
they	O
knew	O
about	O
the	O
disease	ENTITY
.	O
david	O
altshuler	O
will	O
discuss	O
how	O
these	O
discoveries	O
can	O
be	O
translated	O
into	O
biological	O
insights	O
and	O
inspiration	O
for	O
new	O
treatments	O
.	O
david	O
altshuler	O
david	O
is	O
founding	O
core	O
member	O
of	O
the	O
broad	O
institute	O
and	O
has	O
directed	O
the	O
broad	O
program	O
in	O
medical	O
and	O
population	O
genetics	O
since	O
midsummer	O
nights	O
science	O
.	O
professor	O
tony	O
merriman	O
university	O
of	O
otago	O
presenting	O
the	O
role	O
of	O
genetics	O
in	O
diabetes	ENTITY
and	ENTITY
obesity	ENTITY
at	ENTITY
the	ENTITY
diabesity	ENTITY
crisis	ENTITY
how	ENTITY
can	ENTITY
we	ENTITY
make	ENTITY
difference	ENTITY
friday	ENTITY
march	ENTITY
auckland	ENTITY
city	ENTITY
hospital	ENTITY
.	O
diabesitynz	O
jointly	O
hosted	O
by	O
healthier	O
lives	O
nsc	ENTITY
edor	ENTITY
better	ENTITY
start	ENTITY
nsc	ENTITY
follow	ENTITY
us	ENTITY
on	ENTITY
twitter	ENTITY
.	O
this	O
video	O
provides	O
an	O
animated	O
introduction	O
to	O
diabetes	ENTITY
type	ENTITY
and	ENTITY
type	ENTITY
created	ENTITY
using	ENTITY
powtoon	ENTITY
free	ENTITY
sign	ENTITY
up	ENTITY
at	ENTITY
create	ENTITY
animated	ENTITY
videos	ENTITY
and	ENTITY
animated	ENTITY
presentations	ENTITY
for	ENTITY
free	ENTITY
.	O
powtoon	O
is	O
free	O
tool	O
that	O
allows	O
you	O
to	O
develop	O
cool	O
animated	O
clips	O
and	O
animated	O
presentations	O
for	O
your	O
website	O
office	O
meeting	O
sales	O
pitch	O
nonprofit	O
fundraiser	O
product	O
launch	O
video	O
resume	O
or	O
anything	O
else	O
you	O
could	O
use	O
an	O
animated	O
explainer	O
video	O
.	O
powtoon	O
animation	O
templates	O
help	O
you	O
create	O
animated	O
presentations	O
and	O
animated	O
explainer	O
videos	O
from	O
scratch	O
.	O
anyone	O
can	O
produce	O
awesome	O
animations	O
quickly	O
with	O
powtoon	O
without	O
the	O
cost	O
or	O
hassle	O
other	O
professional	O
animation	O
services	O
require	O
.	O
none	O
created	O
using	O
powtoon	O
free	O
sign	O
up	O
at	O
.	O
make	O
your	O
own	O
animated	O
videos	O
and	O
animated	O
presentations	O
for	O
free	O
.	O
powtoon	O
is	O
free	O
tool	O
that	O
allows	O
you	O
to	O
develop	O
cool	O
animated	O
clips	O
and	O
animated	O
presentations	O
for	O
your	O
website	O
office	O
meeting	O
sales	O
pitch	O
nonprofit	O
fundraiser	O
product	O
launch	O
video	O
resume	O
or	O
anything	O
else	O
you	O
could	O
use	O
an	O
animated	O
explainer	O
video	O
.	O
powtoon	O
animation	O
templates	O
help	O
you	O
create	O
animated	O
presentations	O
and	O
animated	O
explainer	O
videos	O
from	O
scratch	O
.	O
anyone	O
can	O
produce	O
awesome	O
animations	O
quickly	O
with	O
powtoon	O
without	O
the	O
cost	O
or	O
hassle	O
other	O
professional	O
animation	O
services	O
require	O
.	O
keynote	O
lecture	O
by	O
anna	O
gloyn	O
university	O
of	O
oxford	O
uk	O
at	O
the	O
genomics	O
of	O
common	O
diseases	ENTITY
september	ENTITY
.	O
conference	O
organised	O
by	O
wellcome	O
genome	O
campus	O
advanced	O
courses	O
and	O
scientific	O
conferences	O
in	O
association	O
with	O
nature	O
genetics	O
and	O
held	O
at	O
the	O
wellcome	O
genome	O
campus	O
conference	O
centre	O
.	O
this	O
video	O
and	O
similar	O
images	O
videos	O
are	O
available	O
for	O
instant	O
download	O
licensing	O
here	O
by	O
alila	O
medical	O
media	O
are	O
for	O
information	O
purposes	O
only	O
and	O
are	O
not	O
intended	O
to	O
replace	O
professional	O
medical	O
advice	O
diagnosis	O
or	O
treatment	O
.	O
always	O
seek	O
the	O
advice	O
of	O
qualified	O
healthcare	O
provider	O
with	O
any	O
questions	O
you	O
may	O
have	O
regarding	O
medical	O
condition	O
.	O
diabetes	ENTITY
refers	O
to	O
group	O
of	O
conditions	O
characterized	O
by	O
high	O
level	O
of	O
blood	ENTITY
glucose	ENTITY
commonly	O
referred	O
to	O
as	O
blood	ENTITY
sugar	ENTITY
.	O
too	O
much	O
sugar	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
can	O
cause	O
serious	O
sometimes	O
life	O
threatening	O
health	O
problems	O
.	O
there	O
are	O
two	O
types	O
of	O
chronic	ENTITY
diabetic	ENTITY
conditions	ENTITY
type	O
diabetes	ENTITY
and	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
pregnant	O
women	O
may	O
acquire	O
transient	O
form	O
of	O
the	O
disease	ENTITY
called	ENTITY
gestational	ENTITY
diabetes	ENTITY
which	O
usually	O
resolves	O
after	O
the	O
birth	O
of	O
baby	O
.	O
pre	ENTITY
diabetes	ENTITY
is	O
when	O
the	O
blood	ENTITY
sugar	ENTITY
level	ENTITY
is	O
at	O
the	O
borderline	O
higher	O
than	O
normal	O
but	O
lower	O
than	O
in	O
diabetics	ENTITY
.	O
prediabetes	ENTITY
may	ENTITY
or	ENTITY
may	ENTITY
not	ENTITY
progress	ENTITY
to	ENTITY
diabetes	ENTITY
.	O
during	O
food	O
digestion	O
carbohydrates	ENTITY
or	ENTITY
carb	ENTITY
break	ENTITY
down	ENTITY
into	ENTITY
glucose	ENTITY
which	ENTITY
is	ENTITY
carried	ENTITY
by	ENTITY
the	ENTITY
bloodstream	ENTITY
to	ENTITY
various	ENTITY
organs	ENTITY
of	ENTITY
the	ENTITY
body	ENTITY
.	O
here	O
it	O
is	O
either	O
consumed	O
as	O
an	O
energy	O
source	O
in	O
muscles	ENTITY
for	ENTITY
example	ENTITY
or	ENTITY
is	ENTITY
stored	ENTITY
for	ENTITY
later	ENTITY
use	ENTITY
in	ENTITY
the	ENTITY
liver	ENTITY
.	O
insulin	ENTITY
is	ENTITY
hormone	ENTITY
produced	ENTITY
by	ENTITY
beta	ENTITY
cells	ENTITY
of	ENTITY
the	ENTITY
pancreas	ENTITY
and	O
is	O
necessary	O
for	O
glucose	ENTITY
intake	ENTITY
by	ENTITY
target	ENTITY
cells	ENTITY
.	O
in	O
other	O
words	O
when	O
insulin	ENTITY
is	ENTITY
deficient	ENTITY
muscle	ENTITY
or	ENTITY
liver	ENTITY
cells	ENTITY
are	O
unable	O
to	O
use	O
or	O
store	O
glucose	ENTITY
and	ENTITY
as	ENTITY
result	ENTITY
glucose	ENTITY
accumulates	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
.	O
in	O
healthy	O
people	O
beta	ENTITY
cells	ENTITY
of	ENTITY
the	ENTITY
pancreas	ENTITY
produce	O
insulin	ENTITY
insulin	ENTITY
binds	ENTITY
to	ENTITY
its	ENTITY
receptor	ENTITY
on	ENTITY
target	ENTITY
cells	ENTITY
and	O
induces	O
glucose	ENTITY
intake	ENTITY
.	O
in	O
type	O
diabetes	ENTITY
beta	ENTITY
cells	ENTITY
of	ENTITY
the	ENTITY
pancreas	ENTITY
are	ENTITY
destroyed	ENTITY
by	ENTITY
the	ENTITY
immune	ENTITY
system	ENTITY
by	O
mistake	O
.	O
the	O
reason	O
why	O
this	O
happens	O
is	O
unclear	O
but	O
genetic	O
factors	O
are	O
believed	O
to	O
play	O
major	O
role	O
.	O
insulin	ENTITY
production	ENTITY
is	ENTITY
reduced	ENTITY
less	ENTITY
insulin	ENTITY
binds	ENTITY
to	ENTITY
its	ENTITY
receptor	ENTITY
on	ENTITY
target	ENTITY
cells	ENTITY
less	O
glucose	ENTITY
is	ENTITY
taken	ENTITY
into	ENTITY
the	ENTITY
cells	ENTITY
more	ENTITY
glucose	ENTITY
stays	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
.	O
type	ENTITY
is	O
characterized	O
by	O
early	O
onset	O
symptoms	O
commonly	O
start	O
suddenly	O
and	O
before	O
the	O
age	O
of	O
type	O
diabetes	ENTITY
is	ENTITY
normally	ENTITY
managed	ENTITY
with	ENTITY
insulin	ENTITY
injection	ENTITY
.	O
type	O
diabetics	ENTITY
are	ENTITY
therefore	ENTITY
insulin	ENTITY
dependent	ENTITY
.	O
in	O
type	O
diabetes	ENTITY
the	ENTITY
pancreas	ENTITY
produces	ENTITY
enough	ENTITY
insulin	ENTITY
but	ENTITY
something	ENTITY
goes	ENTITY
wrong	ENTITY
either	ENTITY
with	ENTITY
receptor	ENTITY
binding	ENTITY
or	O
insulin	ENTITY
signaling	ENTITY
inside	O
the	O
target	ENTITY
cells	ENTITY
.	O
the	O
cells	O
are	O
not	O
responsive	O
to	O
insulin	ENTITY
and	ENTITY
therefore	ENTITY
cannot	ENTITY
import	ENTITY
glucose	ENTITY
glucose	ENTITY
stays	ENTITY
in	ENTITY
the	ENTITY
blood	ENTITY
.	O
in	O
other	O
words	O
type	O
diabetics	ENTITY
are	ENTITY
insulin	ENTITY
resistant	ENTITY
.	O
here	O
again	O
genetic	O
factors	O
predispose	ENTITY
susceptibility	ENTITY
to	O
the	O
disease	ENTITY
but	ENTITY
it	ENTITY
is	ENTITY
believed	ENTITY
that	ENTITY
lifestyle	ENTITY
plays	ENTITY
very	ENTITY
important	ENTITY
role	ENTITY
in	ENTITY
type	ENTITY
typically	ENTITY
obesity	ENTITY
inactive	ENTITY
lifestyle	ENTITY
and	ENTITY
unhealthy	ENTITY
diet	ENTITY
are	ENTITY
associated	ENTITY
with	ENTITY
higher	ENTITY
risk	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
type	O
is	O
characterized	O
by	O
adult	O
onset	O
symptoms	O
usually	O
appear	O
gradually	O
and	O
start	O
after	O
the	O
age	O
of	O
type	O
diabetes	ENTITY
accounts	ENTITY
for	ENTITY
about	ENTITY
to	ENTITY
of	ENTITY
all	ENTITY
diabetics	ENTITY
.	O
management	O
focuses	O
on	O
weight	O
loss	O
and	O
includes	O
low	O
carb	O
diet	O
.	O
serious	O
science	O
of	O
obesity	ENTITY
and	ENTITY
diabetes	ENTITY
.	O
expert	O
diabetologist	O
dr	O
gaurav	O
sharma	O
provides	O
tips	O
to	O
reduce	O
chances	O
of	O
genetic	O
diabetes	ENTITY
for	ENTITY
daily	ENTITY
updates	ENTITY
and	ENTITY
fun	ENTITY
stuff	ENTITY
subscribe	ENTITY
.	O
diabetes	ENTITY
melissa	ENTITY
mahan	ENTITY
sat	ENTITY
down	ENTITY
with	ENTITY
doctor	ENTITY
barry	ENTITY
ramo	ENTITY
to	ENTITY
find	ENTITY
out	ENTITY
how	ENTITY
much	ENTITY
of	ENTITY
role	ENTITY
your	ENTITY
genes	ENTITY
play	ENTITY
.	O
everyone	O
always	O
talks	O
about	O
diseases	ENTITY
being	ENTITY
genetic	ENTITY
in	ENTITY
fatalistic	ENTITY
way	ENTITY
as	ENTITY
if	ENTITY
their	ENTITY
health	ENTITY
outcome	ENTITY
is	ENTITY
out	ENTITY
of	ENTITY
their	ENTITY
control	ENTITY
.	O
but	O
is	O
that	O
really	O
true	O
.	O
go	O
in	O
depth	O
into	O
that	O
topic	O
in	O
this	O
video	O
.	O
also	O
discuss	O
what	O
the	O
optimal	O
cholesterol	ENTITY
level	ENTITY
is	O
for	O
health	O
and	O
longevity	O
.	O
dr	O
ellsworth	O
wareham	O
interview	O
www	O
thefruitdoctor	O
com	O
.	O
recorded	O
with	O
http	O
screencast	O
matic	O
com	O
.	O
view	O
more	O
details	O
at	O
http	O
www	O
healthandfitness	O
com	O
.	O
diabetes	ENTITY
and	ENTITY
genetics	ENTITY
.	O
genetics	O
play	O
strong	O
role	O
in	O
the	O
chances	O
of	O
developing	O
both	O
type	O
and	O
type	O
diabetes	ENTITY
.	O
other	O
factors	O
include	O
environment	O
and	O
lifestyle	O
.	O
the	O
risk	O
of	O
developing	ENTITY
diabetes	ENTITY
is	O
affected	O
by	O
whether	O
your	O
parents	O
or	O
siblings	O
have	O
diabetes	ENTITY
.	O
careworldtv	O
channel	O
is	O
the	O
destination	O
for	O
fitness	O
lifestyle	O
content	O
on	O
youtube	O
.	O
careworldtv	O
helps	O
you	O
become	O
better	O
you	O
with	O
how	O
to	O
videos	O
covering	O
everything	O
from	O
exercise	O
diet	O
and	O
healthy	O
living	O
to	O
style	O
makeup	O
and	O
fashion	O
tips	O
.	O
stay	O
tuned	O
to	O
watch	O
more	O
how	O
to	O
beauty	O
health	O
lifestyle	O
videos	O
.	O
subscribe	O
list	O
plug	O
hbjc	O
bbindauwm	O
fuaxtbbcyfyfii	O
.	O
my	O
first	O
project	O
.	O
charlotte	O
ling	O
associate	O
professor	O
at	O
lund	O
university	O
diabetes	ENTITY
centre	ENTITY
.	O
diabetologia	O
march	O
.	O
full	O
video	O
.	O
featuring	O
megan	O
skyes	O
md	O
rudolph	O
leibel	O
md	O
.	O
the	O
mysterious	O
onset	O
of	O
type	O
diabetes	ENTITY
may	ENTITY
have	ENTITY
to	ENTITY
do	ENTITY
with	ENTITY
what	ENTITY
in	ENTITY
your	ENTITY
genes	ENTITY
.	O
studies	O
of	O
twins	O
show	O
that	O
if	O
one	O
twin	O
has	O
type	O
diabetes	ENTITY
the	ENTITY
other	ENTITY
has	ENTITY
to	ENTITY
percent	ENTITY
likelihood	ENTITY
to	ENTITY
also	ENTITY
get	ENTITY
the	ENTITY
disease	ENTITY
.	O
in	O
the	O
past	O
years	O
new	O
technology	O
that	O
screens	O
the	O
whole	O
genetic	ENTITY
code	ENTITY
allowed	O
researchers	O
to	O
uncover	O
at	O
least	O
diabetes	ENTITY
associated	ENTITY
genes	ENTITY
.	O
interestingly	O
many	O
of	O
those	O
genes	O
also	O
relate	O
to	O
other	O
autoimmune	ENTITY
diseases	ENTITY
such	O
as	O
multiple	ENTITY
sclerosis	ENTITY
or	O
celiac	ENTITY
disease	ENTITY
.	O
stephan	O
kissler	O
ph	O
assistant	O
investigator	O
in	O
the	O
section	O
on	O
immunobiology	ENTITY
at	ENTITY
joslin	ENTITY
diabetes	ENTITY
center	ENTITY
studies	ENTITY
those	ENTITY
genes	ENTITY
associated	ENTITY
with	ENTITY
multiple	ENTITY
diseases	ENTITY
using	O
some	O
of	O
the	O
newest	O
lab	O
techniques	O
available	O
.	O
ilmkidunya	O
com	O
has	O
brought	O
to	O
you	O
lecture	O
of	O
shadab	O
abbasi	O
on	O
th	O
class	O
biology	O
chapter	O
variation	O
and	O
genetics	O
.	O
topic	O
diabetes	ENTITY
mellitus	ENTITY
and	O
its	O
enetic	ENTITY
basis	ENTITY
.	O
in	O
this	O
video	O
following	O
sub	O
topics	O
have	O
been	O
taught	O
its	O
enetic	ENTITY
basis	ENTITY
for	ENTITY
more	ENTITY
videos	ENTITY
of	ENTITY
shadab	ENTITY
abbasi	ENTITY
visit	ENTITY
medium	ENTITY
to	ENTITY
facilitate	ENTITY
pakistani	ENTITY
students	ENTITY
.	O
iowa	O
sweet	O
corn	O
in	O
the	O
summer	O
it	O
hard	O
to	O
beat	O
.	O
but	O
some	O
farmers	O
in	O
iowa	O
are	O
thinking	O
about	O
chemistry	O
as	O
well	O
as	O
taste	O
.	O
visit	O
to	O
view	O
the	O
entire	O
episode	O
.	O
wednesday	O
july	O
broad	O
institute	O
cambridge	O
ma	O
precision	O
medicine	O
in	O
diabetes	ENTITY
jose	ENTITY
florez	ENTITY
what	ENTITY
is	ENTITY
diabetes	ENTITY
.	O
why	O
do	O
some	O
people	O
develop	O
diabetes	ENTITY
and	ENTITY
others	ENTITY
do	ENTITY
not	ENTITY
.	O
could	O
prevention	O
and	O
treatment	O
be	O
individualized	O
for	O
each	O
patient	O
.	O
using	O
diabetes	ENTITY
as	ENTITY
case	ENTITY
study	ENTITY
jose	ENTITY
florez	ENTITY
will	ENTITY
discuss	ENTITY
the	ENTITY
emerging	ENTITY
approach	ENTITY
of	ENTITY
precision	ENTITY
medicine	ENTITY
quest	ENTITY
to	ENTITY
unravel	ENTITY
the	ENTITY
genetic	ENTITY
basis	ENTITY
of	O
diseases	ENTITY
and	ENTITY
their	ENTITY
complications	ENTITY
in	ENTITY
order	ENTITY
to	ENTITY
provide	ENTITY
basis	ENTITY
for	ENTITY
effective	ENTITY
tailored	ENTITY
therapies	ENTITY
.	O
florez	O
will	O
illustrate	O
the	O
power	O
of	O
contemporary	O
genetics	O
to	O
address	O
these	O
crucial	O
areas	O
.	O
jose	O
florez	O
is	O
an	O
endocrinologist	ENTITY
and	ENTITY
chief	ENTITY
of	ENTITY
the	ENTITY
diabetes	ENTITY
unit	ENTITY
at	ENTITY
massachusetts	ENTITY
general	ENTITY
hospital	ENTITY
an	ENTITY
associate	ENTITY
professor	ENTITY
at	ENTITY
harvard	ENTITY
medical	ENTITY
school	ENTITY
and	ENTITY
an	ENTITY
institute	ENTITY
member	ENTITY
at	ENTITY
the	ENTITY
broad	ENTITY
institute	ENTITY
of	ENTITY
mit	ENTITY
and	ENTITY
harvard	ENTITY
where	ENTITY
he	ENTITY
co	ENTITY
directs	ENTITY
the	ENTITY
metabolism	ENTITY
program	ENTITY
.	O
florez	O
and	O
his	O
group	O
have	O
contributed	O
to	O
high	O
throughput	O
genome	ENTITY
wide	ENTITY
association	ENTITY
and	ENTITY
sequencing	ENTITY
studies	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
and	ENTITY
related	ENTITY
traits	ENTITY
in	ENTITY
the	ENTITY
diabetes	ENTITY
genetics	ENTITY
initiative	ENTITY
formed	ENTITY
by	ENTITY
the	ENTITY
broad	ENTITY
institute	ENTITY
lund	ENTITY
university	ENTITY
and	ENTITY
novartis	ENTITY
the	ENTITY
framingham	ENTITY
heart	ENTITY
study	ENTITY
and	ENTITY
other	ENTITY
international	ENTITY
consortia	ENTITY
.	O
in	O
addition	O
to	O
his	O
research	O
and	O
teaching	O
duties	O
florez	O
is	O
clinically	O
active	O
in	O
the	O
mgh	O
diabetes	ENTITY
center	ENTITY
the	ENTITY
endocrine	ENTITY
inpatient	ENTITY
consult	ENTITY
service	ENTITY
and	ENTITY
the	ENTITY
down	ENTITY
syndrome	ENTITY
program	O
.	O
florez	O
is	O
an	O
author	O
on	O
more	O
than	O
original	O
publications	O
and	O
more	O
than	O
reviews	O
and	O
book	O
chapters	O
.	O
he	O
has	O
received	O
multiple	O
awards	O
and	O
honors	O
during	O
his	O
career	O
including	O
the	O
presidential	O
early	O
career	O
award	O
for	O
scientists	O
and	O
engineers	O
the	O
highest	O
honor	O
bestowed	O
by	O
the	O
united	O
states	O
government	O
on	O
science	O
and	O
engineering	O
professionals	O
in	O
the	O
early	O
stages	O
of	O
their	O
independent	O
research	O
careers	O
.	O
florez	O
earned	O
his	O
ph	O
at	O
northwestern	O
university	O
and	O
his	O
.	O
at	O
northwestern	O
university	O
medical	O
school	O
.	O
for	O
more	O
information	O
visit	O
nights	O
science	O
copyright	O
broad	O
institute	O
all	O
rights	O
reserved	O
.	O
diabetes	ENTITY
research	ENTITY
the	ENTITY
research	ENTITY
undertaken	ENTITY
by	ENTITY
dr	ENTITY
anna	ENTITY
gloyn	ENTITY
focuses	ENTITY
on	ENTITY
using	ENTITY
naturally	ENTITY
genetic	ENTITY
variants	ENTITY
identified	ENTITY
in	ENTITY
humans	ENTITY
as	ENTITY
tools	ENTITY
to	ENTITY
identify	ENTITY
critical	ENTITY
regulatory	ENTITY
pathways	ENTITY
for	ENTITY
insulin	ENTITY
secretion	ENTITY
and	O
action	O
.	O
current	O
research	O
projects	O
are	O
focused	O
on	O
the	O
translation	O
of	O
genetic	O
association	O
signals	O
for	O
type	O
diabetes	ENTITY
and	ENTITY
glycaemic	ENTITY
traits	ENTITY
into	ENTITY
molecular	ENTITY
mechanisms	ENTITY
for	O
diabetes	ENTITY
and	ENTITY
clinically	ENTITY
useful	ENTITY
tools	ENTITY
.	O
translational	O
medicine	O
from	O
bench	O
to	O
bedside	O
research	O
in	O
medicine	O
needs	O
to	O
ultimately	O
translate	O
into	O
better	O
treatment	O
of	O
patients	O
.	O
researchers	O
at	O
the	O
nuffield	O
department	O
of	O
medicine	O
university	O
of	O
oxford	O
collaborate	O
to	O
develop	O
better	O
care	O
and	O
improved	O
preventive	O
measures	O
.	O
findings	O
in	O
the	O
laboratory	O
are	O
translated	O
into	O
changes	O
in	O
clinical	O
practice	O
from	O
bench	O
to	O
bedside	O
.	O
anna	O
gloyn	O
genetics	O
and	O
diabetes	ENTITY
.	O
jose	O
florez	O
md	O
phd	O
mgh	O
diabetes	ENTITY
center	ENTITY
endocrinologist	ENTITY
and	ENTITY
mgh	ENTITY
research	ENTITY
scholar	ENTITY
gives	ENTITY
talk	ENTITY
on	ENTITY
the	ENTITY
human	ENTITY
genome	ENTITY
and	O
its	O
potential	O
to	O
improve	O
care	O
for	O
people	O
with	O
type	O
diabetes	ENTITY
in	ENTITY
genetics	ENTITY
matters	ENTITY
as	ENTITY
part	ENTITY
of	ENTITY
the	ENTITY
may	ENTITY
event	ENTITY
let	ENTITY
talk	ENTITY
transforming	ENTITY
health	ENTITY
care	ENTITY
in	ENTITY
the	ENTITY
next	ENTITY
decade	ENTITY
hosted	ENTITY
by	ENTITY
the	ENTITY
mass	ENTITY
general	ENTITY
leadership	ENTITY
council	ENTITY
for	ENTITY
medicine	ENTITY
.	O
dr	O
karen	O
elkind	O
hirsch	O
scientific	O
director	O
of	O
research	O
at	O
woman	O
hospital	O
explains	O
how	O
genetics	O
and	O
lifestyle	O
can	O
both	O
affect	O
woman	O
risk	O
of	O
developing	O
gestational	ENTITY
diabetes	ENTITY
.	O
full	O
video	O
.	O
watch	O
full	O
video	O
.	O
full	O
video	O
.	O
view	O
more	O
details	O
at	O
as	O
li	O
tl	O
ie	ENTITY
utf	ENTITY
camp	ENTITY
creative	ENTITY
creativeasin	ENTITY
linkcode	ENTITY
as	ENTITY
tag	ENTITY
sphercircl	ENTITY
.	O
understanding	O
the	O
genetic	ENTITY
basis	ENTITY
of	O
diabetes	ENTITY
professor	ENTITY
mark	ENTITY
mccarthy	ENTITY
robert	ENTITY
turner	ENTITY
professor	ENTITY
of	ENTITY
diabetes	ENTITY
leads	ENTITY
multidisciplinary	ENTITY
research	ENTITY
team	ENTITY
including	ENTITY
clinicians	ENTITY
nurses	ENTITY
and	ENTITY
lab	ENTITY
based	ENTITY
research	ENTITY
staff	ENTITY
.	O
one	O
of	O
their	O
major	O
focuses	O
lies	O
in	O
translating	O
gene	ENTITY
identification	ENTITY
and	O
genetic	O
information	O
into	O
advances	O
in	O
functional	O
understanding	O
and	O
clinical	O
management	O
.	O
translating	O
genetic	O
into	O
treatment	O
diabetes	ENTITY
and	ENTITY
obesity	ENTITY
are	ENTITY
both	ENTITY
major	ENTITY
challenges	ENTITY
for	ENTITY
global	ENTITY
healthcare	ENTITY
with	ENTITY
the	ENTITY
social	ENTITY
health	ENTITY
and	ENTITY
economic	ENTITY
costs	ENTITY
over	ENTITY
the	ENTITY
next	ENTITY
fifty	ENTITY
years	ENTITY
being	ENTITY
in	ENTITY
the	ENTITY
trillions	ENTITY
of	ENTITY
dollars	ENTITY
.	O
genetics	O
is	O
one	O
of	O
the	O
more	O
important	O
tools	O
for	O
developing	O
systematic	O
understanding	O
of	O
the	O
disease	O
and	O
how	O
best	O
to	O
treat	O
it	O
in	O
different	O
patients	O
.	O
view	O
more	O
details	O
at	O
as	O
li	O
tl	O
ie	ENTITY
utf	ENTITY
camp	ENTITY
creative	ENTITY
creativeasin	ENTITY
linkcode	ENTITY
as	ENTITY
tag	ENTITY
sphercircl	ENTITY
.	O
common	O
risk	O
factors	O
of	O
diabetes	ENTITY
.	O
diabetes	ENTITY
risk	ENTITY
factors	ENTITY
genetics	ENTITY
obesity	ENTITY
and	O
more	O
.	O
common	O
risk	O
factors	O
of	O
type	O
diabetes	ENTITY
.	O
diabetes	ENTITY
symptoms	ENTITY
and	ENTITY
causes	ENTITY
.	O
online	O
shopping	O
at	O
prismmart	O
.	O
your	O
source	O
to	O
shop	O
online	O
online	O
stores	O
shopping	O
online	O
and	O
internet	O
shopping	O
.	O
are	O
the	O
children	O
of	O
women	O
with	O
diabetes	ENTITY
at	ENTITY
increased	ENTITY
risk	ENTITY
for	ENTITY
diabetes	ENTITY
.	O
lynn	O
mack	O
.	O
college	O
of	O
medicine	O
internal	O
medicine	O
division	O
of	O
diabetes	ENTITY
endocrine	ENTITY
metabolism	ENTITY
university	O
of	O
nebraska	O
medical	O
center	O
.	O
dr	O
eve	O
pearce	O
presents	O
an	O
educational	O
webinar	O
on	O
sugar	ENTITY
metabolism	ENTITY
and	O
gene	ENTITY
testing	ENTITY
.	O
sugar	O
is	O
well	O
known	O
to	O
be	O
the	O
culprit	O
in	O
developing	O
medical	O
conditions	O
such	O
as	O
type	O
ii	O
diabetes	ENTITY
obesity	ENTITY
and	O
cardiovascular	ENTITY
disease	ENTITY
.	O
dr	O
pearce	O
will	O
demonstrate	O
how	O
genetic	ENTITY
testing	ENTITY
combined	O
with	O
functional	O
testing	O
can	O
help	O
bring	O
more	O
accurate	O
and	O
relevant	O
results	O
supporting	O
the	O
efforts	O
in	O
such	O
disease	ENTITY
prevention	ENTITY
.	O
you	O
ll	O
find	O
out	O
which	O
genes	O
are	O
involved	O
in	O
sugar	ENTITY
metabolism	ENTITY
and	O
why	O
it	O
worth	O
testing	O
them	O
.	O
the	O
webinar	O
also	O
covers	O
the	O
importance	O
of	O
epigenetics	ENTITY
tests	ENTITY
are	O
not	O
enough	O
to	O
accurately	O
establish	O
health	O
risks	O
the	O
environment	O
also	O
plays	O
huge	O
role	O
and	O
can	O
modify	O
gene	ENTITY
expression	ENTITY
.	O
to	O
demonstrate	O
this	O
real	O
life	O
combined	O
approach	O
genetics	ENTITY
epigenetics	ENTITY
case	O
study	O
is	O
presented	O
followed	O
by	O
answers	O
to	O
your	O
questions	O
.	O
this	O
training	O
reviews	O
the	O
research	O
related	O
to	O
brain	ENTITY
development	ENTITY
genetics	ENTITY
and	ENTITY
fetal	ENTITY
origin	ENTITY
and	O
describes	O
evidenced	O
based	O
interventions	O
to	O
break	O
the	O
cycle	O
.	O
watch	O
full	O
version	O
.	O
diabetes	ENTITY
genetics	ENTITY
diabetes	ENTITY
by	O
dr	O
javed	O
iqbal	O
discipline	O
ka	O
ik	O
bahana	O
program	O
for	O
counselling	O
appointments	O
lahore	O
mr	ENTITY
mohsin	ENTITY
nawaz	ENTITY
karachi	ENTITY
mr	ENTITY
wakeel	ENTITY
murad	ENTITY
islamabad	ENTITY
mr	ENTITY
talal	ENTITY
zubair	ENTITY
diabeticsinstitutepakistan	ENTITY
drsadaqatali	ENTITY
interviewofdiabetologist	ENTITY
diabeteslifestyle	ENTITY
modeldiabetics	ENTITY
diabetesworkshoptoday	ENTITY
drimtiazhassan	ENTITY
drajazqureshi	ENTITY
iqratariq	ENTITY
.	O
mit	O
foundations	O
of	O
computational	O
and	O
systems	O
biology	O
spring	O
view	O
the	O
complete	O
course	O
mit	O
edu	O
.	O
watch	O
full	O
version	O
.	O
watch	O
full	O
video	O
.	O
full	O
version	O
.	O
full	O
video	O
.	O
visit	O
us	O
add	O
user	O
khanacademy	O
.	O
take	O
dr	O
berg	O
advanced	O
evaluation	O
quiz	O
the	O
health	O
wellness	O
center	O
pinecrest	O
office	O
park	O
drive	O
alexandria	O
va	O
disclaimer	O
dr	O
berg	O
does	O
not	O
diagnose	O
treat	O
or	O
prevent	O
any	O
medical	O
conditions	O
instead	O
he	O
helps	O
people	O
create	O
their	O
health	O
to	O
avoid	O
health	O
problems	O
.	O
he	O
works	O
with	O
their	O
physicians	O
which	O
regular	O
their	O
medication	O
.	O
this	O
video	O
is	O
not	O
designed	O
to	O
and	O
does	O
not	O
provide	O
medical	O
advice	O
professional	O
diagnosis	O
opinion	O
treatment	O
or	O
services	O
to	O
you	O
or	O
to	O
any	O
other	O
individual	O
.	O
through	O
my	O
videos	O
blog	O
posts	O
website	O
information	O
give	O
suggestions	O
for	O
you	O
and	O
your	O
doctor	O
to	O
research	O
and	O
provide	O
general	O
information	O
for	O
educational	O
purposes	O
only	O
.	O
the	O
information	O
provided	O
in	O
this	O
video	O
or	O
site	O
or	O
through	O
linkages	O
to	O
other	O
sites	O
is	O
not	O
substitute	O
for	O
medical	O
or	O
professional	O
care	O
and	O
you	O
should	O
not	O
use	O
the	O
information	O
in	O
place	O
of	O
visit	O
call	O
consultation	O
or	O
the	O
advice	O
of	O
your	O
physician	O
or	O
other	O
healthcare	O
provider	O
.	O
the	O
health	O
wellness	O
and	O
dr	O
eric	O
berg	O
are	O
not	O
liable	O
or	O
responsible	O
for	O
any	O
advice	O
course	O
of	O
treatment	O
diagnosis	O
or	O
any	O
other	O
information	O
services	O
or	O
product	O
you	O
obtain	O
through	O
this	O
video	O
or	O
site	O
.	O
short	O
how	O
to	O
video	O
guide	O
about	O
glucagen	ENTITY
injections	ENTITY
.	O
produced	O
by	O
the	O
uclh	O
children	O
and	O
young	O
people	O
diabetes	ENTITY
service	ENTITY
.	O
see	O
how	O
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
control	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
.	O
the	O
glucagon	ENTITY
hormone	ENTITY
helps	O
prevent	O
low	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
and	O
helps	O
keep	O
energy	ENTITY
levels	ENTITY
balanced	O
.	O
when	O
say	O
low	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
this	O
is	O
typically	O
lifestyle	O
related	O
caused	O
by	O
people	O
who	O
follow	O
low	ENTITY
calorie	ENTITY
diets	ENTITY
skip	O
meals	O
and	O
do	O
excessive	O
cardio	ENTITY
.	O
similar	O
to	O
the	O
leptin	ENTITY
hormone	ENTITY
glucagon	ENTITY
is	ENTITY
also	ENTITY
considered	ENTITY
hormone	ENTITY
that	ENTITY
can	ENTITY
turn	ENTITY
off	ENTITY
hunger	ENTITY
as	ENTITY
the	ENTITY
secretion	ENTITY
of	ENTITY
glucagon	ENTITY
can	O
reduce	O
the	O
production	ENTITY
of	ENTITY
the	ENTITY
hunger	ENTITY
hormone	ENTITY
ghrelin	ENTITY
and	O
signal	O
to	O
the	O
body	O
the	O
feeling	O
of	O
being	O
full	O
.	O
other	O
awesome	O
fat	ENTITY
burning	ENTITY
videos	O
turn	O
your	O
body	O
into	O
fat	ENTITY
burning	ENTITY
machine	ENTITY
for	ENTITY
life	ENTITY
avoid	ENTITY
insulin	ENTITY
resistance	ENTITY
welcome	O
to	O
live	O
lean	O
tv	O
.	O
the	O
online	O
fitness	O
and	O
nutrition	O
show	O
hosted	O
by	O
brad	O
gouthro	O
and	O
jessica	O
gouthro	O
teaching	O
you	O
how	O
to	O
live	O
the	O
lean	O
lifestyle	O
days	O
year	O
.	O
watch	O
hundreds	O
of	O
fat	O
blasting	O
muscle	O
building	O
workouts	O
easy	O
and	O
delicious	O
recipes	O
as	O
well	O
as	O
fitness	O
and	O
nutrition	O
tips	O
to	O
get	O
you	O
your	O
dream	O
body	O
and	O
maintain	O
it	O
days	O
year	O
.	O
make	O
sure	O
you	O
click	O
the	O
subscribe	O
button	O
for	O
new	O
fitness	O
and	O
nutrition	O
shows	O
every	O
week	O
.	O
business	O
enquiries	O
info	O
liveleantv	O
com	O
send	O
us	O
stuff	O
here	O
live	O
lean	O
tv	O
front	O
street	O
unit	O
san	O
diego	O
ca	O
usa	O
.	O
donate	O
here	O
aklectures	O
com	O
.	O
in	O
this	O
video	O
certified	O
diabetes	O
educator	O
from	O
mayo	O
clinic	O
explains	O
the	O
equipment	O
and	O
process	O
for	O
using	O
glucagon	ENTITY
for	ENTITY
people	ENTITY
with	ENTITY
diabetes	ENTITY
.	O
severe	O
hypoglycemia	ENTITY
or	ENTITY
low	ENTITY
blood	ENTITY
sugar	ENTITY
can	O
be	O
very	O
serious	O
and	O
can	O
caused	O
when	O
insulin	ENTITY
and	ENTITY
blood	ENTITY
glucose	ENTITY
are	O
out	O
of	O
balance	O
.	O
contributing	O
factors	O
can	O
be	O
too	O
much	O
insulin	ENTITY
not	ENTITY
eating	ENTITY
enough	ENTITY
food	ENTITY
too	ENTITY
much	ENTITY
exercise	ENTITY
or	ENTITY
eating	ENTITY
late	ENTITY
.	O
for	O
cases	O
of	O
severe	O
hypoglycemia	ENTITY
school	ENTITY
nurses	ENTITY
and	ENTITY
trained	ENTITY
staff	ENTITY
may	ENTITY
administer	ENTITY
glucagon	ENTITY
.	O
glucagon	ENTITY
an	ENTITY
important	ENTITY
incretin	ENTITY
plays	ENTITY
big	ENTITY
role	ENTITY
in	ENTITY
regulation	ENTITY
of	ENTITY
blood	ENTITY
sugar	ENTITY
and	O
ketosis	ENTITY
.	O
learn	O
how	O
by	O
watching	O
this	O
video	O
and	O
learn	O
more	O
by	O
following	O
my	O
blog	O
at	O
docmuscles	O
com	O
.	O
mrs	O
foy	ENTITY
explains	ENTITY
how	ENTITY
the	ENTITY
hormones	ENTITY
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
keep	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
in	O
homeostasis	O
.	O
in	O
this	O
lesson	O
you	O
will	O
learn	O
about	O
how	O
your	O
blood	ENTITY
glucose	ENTITY
level	ENTITY
is	O
regulated	O
or	O
controlled	O
by	O
two	O
important	O
hormones	ENTITY
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
via	ENTITY
negative	ENTITY
feedback	ENTITY
system	ENTITY
.	O
when	O
you	O
consume	O
meal	O
that	O
is	O
high	O
in	O
carbohydrates	ENTITY
such	ENTITY
as	ENTITY
rice	ENTITY
pasta	ENTITY
and	ENTITY
bread	ENTITY
this	ENTITY
will	ENTITY
cause	ENTITY
your	ENTITY
blood	ENTITY
glucose	ENTITY
level	ENTITY
to	O
increase	O
.	O
carbohydrates	ENTITY
are	ENTITY
essentially	ENTITY
long	ENTITY
chains	ENTITY
of	ENTITY
repeating	ENTITY
glucose	ENTITY
monomer	ENTITY
units	ENTITY
much	ENTITY
like	ENTITY
beads	ENTITY
on	ENTITY
necklace	ENTITY
.	O
during	O
digestion	O
this	O
is	O
broken	O
apart	O
into	O
glucose	ENTITY
which	ENTITY
absorbed	ENTITY
into	ENTITY
our	ENTITY
bloodstream	ENTITY
.	O
this	O
increased	O
blood	ENTITY
glucose	ENTITY
level	ENTITY
causes	O
gland	ENTITY
known	ENTITY
as	ENTITY
the	ENTITY
pancreas	ENTITY
to	ENTITY
secrete	ENTITY
hormone	ENTITY
called	ENTITY
insulin	ENTITY
.	O
remember	O
that	O
gland	ENTITY
secretes	ENTITY
hormones	ENTITY
which	ENTITY
act	ENTITY
on	ENTITY
specific	ENTITY
target	ENTITY
organs	ENTITY
.	O
in	O
this	O
case	O
the	O
target	ENTITY
organ	ENTITY
is	O
your	O
liver	ENTITY
which	ENTITY
is	ENTITY
stimulated	ENTITY
to	ENTITY
convert	ENTITY
glucose	ENTITY
to	ENTITY
glycogen	ENTITY
.	O
glycogen	ENTITY
is	ENTITY
basically	ENTITY
long	ENTITY
multi	ENTITY
branched	ENTITY
chains	ENTITY
of	ENTITY
glucose	ENTITY
monomers	ENTITY
stored	ENTITY
in	ENTITY
liver	ENTITY
and	ENTITY
muscle	ENTITY
cells	ENTITY
.	O
insulin	ENTITY
also	ENTITY
causes	ENTITY
your	ENTITY
body	ENTITY
cells	ENTITY
to	O
uptake	O
or	O
take	O
in	O
glucose	ENTITY
.	O
so	O
this	O
decreases	O
your	O
blood	ENTITY
glucose	ENTITY
level	ENTITY
back	O
to	O
its	O
optimal	O
state	O
.	O
when	O
this	O
system	O
is	O
faulty	O
this	O
leads	O
to	O
medical	O
condition	O
known	O
as	O
diabetes	ENTITY
if	ENTITY
you	ENTITY
want	ENTITY
to	ENTITY
learn	ENTITY
more	ENTITY
about	ENTITY
diabetes	ENTITY
this	ENTITY
will	ENTITY
be	ENTITY
addressed	ENTITY
in	ENTITY
another	ENTITY
video	ENTITY
.	O
the	O
same	O
response	O
also	O
occurs	O
when	O
you	O
consume	O
foods	O
and	O
drinks	O
high	O
in	O
sugar	O
such	O
as	O
sweets	O
cakes	O
and	O
fizzy	O
drinks	O
.	O
when	O
your	O
blood	ENTITY
glucose	ENTITY
level	ENTITY
drops	O
such	O
as	O
when	O
you	O
are	O
hungry	O
the	O
pancreas	ENTITY
secretes	ENTITY
hormone	ENTITY
called	ENTITY
glucagon	ENTITY
.	O
like	O
insulin	ENTITY
the	ENTITY
target	ENTITY
organ	ENTITY
for	ENTITY
glucagon	ENTITY
is	ENTITY
also	ENTITY
the	ENTITY
liver	ENTITY
though	ENTITY
it	ENTITY
stimulates	ENTITY
the	ENTITY
opposite	ENTITY
process	ENTITY
the	ENTITY
breakdown	ENTITY
of	ENTITY
glycogen	ENTITY
into	ENTITY
glucose	ENTITY
.	O
this	O
increases	O
your	O
blood	ENTITY
glucose	ENTITY
level	ENTITY
back	O
to	O
its	O
optimal	O
state	O
.	O
so	O
to	O
review	O
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
are	ENTITY
two	ENTITY
hormones	ENTITY
released	ENTITY
by	ENTITY
the	ENTITY
pancreas	ENTITY
which	ENTITY
act	ENTITY
on	ENTITY
the	ENTITY
liver	ENTITY
to	ENTITY
regulate	ENTITY
our	ENTITY
blood	ENTITY
glucose	ENTITY
level	ENTITY
.	O
subscribe	O
to	O
the	O
fuseschool	O
youtube	O
channel	O
for	O
many	O
more	O
educational	O
videos	O
.	O
our	O
teachers	O
and	O
animators	O
come	O
together	O
to	O
make	O
fun	O
easy	O
to	O
understand	O
videos	O
in	O
chemistry	O
biology	O
physics	O
maths	O
ict	O
.	O
visit	O
us	O
at	O
www	O
fuseschool	O
org	O
where	O
all	O
of	O
our	O
videos	O
are	O
carefully	O
organised	O
into	O
topics	O
and	O
specific	O
orders	O
and	O
to	O
see	O
what	O
else	O
we	O
have	O
on	O
offer	O
.	O
comment	O
like	O
and	O
share	O
with	O
other	O
learners	O
.	O
you	O
can	O
both	O
ask	O
and	O
answer	O
questions	O
and	O
teachers	O
will	O
get	O
back	O
to	O
you	O
.	O
these	O
videos	O
can	O
be	O
used	O
in	O
flipped	O
classroom	O
model	O
or	O
as	O
revision	O
aid	O
.	O
find	O
all	O
of	O
our	O
chemistry	O
videos	O
here	O
.	O
you	O
are	O
allowed	O
to	O
download	O
the	O
video	O
for	O
nonprofit	O
educational	O
use	O
.	O
if	O
you	O
would	O
like	O
to	O
modify	O
the	O
video	O
please	O
contact	O
us	O
info	O
fuseschool	O
org	O
.	O
the	O
fat	ENTITY
burning	ENTITY
hormone	ENTITY
glucagon	ENTITY
it	O
important	O
to	O
have	O
basic	O
understanding	O
of	O
the	O
fat	ENTITY
burning	ENTITY
hormones	ENTITY
if	ENTITY
you	ENTITY
re	ENTITY
having	ENTITY
trouble	ENTITY
losing	ENTITY
weight	ENTITY
or	ENTITY
want	ENTITY
to	ENTITY
drop	ENTITY
your	ENTITY
body	ENTITY
fat	ENTITY
levels	O
.	O
glucagon	ENTITY
is	ENTITY
one	ENTITY
of	ENTITY
the	ENTITY
fat	ENTITY
and	ENTITY
sugar	ENTITY
releasing	ENTITY
hormones	ENTITY
.	O
it	O
works	O
the	O
opposite	O
of	O
insulin	ENTITY
.	O
look	O
at	O
it	O
like	O
this	O
insulin	ENTITY
is	ENTITY
the	ENTITY
storage	ENTITY
hormone	ENTITY
and	ENTITY
glucagon	ENTITY
is	ENTITY
the	ENTITY
releasing	ENTITY
hormone	ENTITY
.	O
if	O
you	O
want	O
to	O
burn	O
fat	ENTITY
lipolysis	ENTITY
you	ENTITY
want	ENTITY
your	ENTITY
insulin	ENTITY
to	ENTITY
be	ENTITY
low	ENTITY
and	ENTITY
glucagon	ENTITY
to	ENTITY
be	ENTITY
high	ENTITY
.	O
how	O
to	O
increase	O
fat	ENTITY
burning	ENTITY
hormone	ENTITY
.	O
long	O
walks	O
on	O
an	O
empty	O
stomach	O
when	O
insulin	ENTITY
levels	ENTITY
are	O
low	ENTITY
fasting	ENTITY
low	ENTITY
carb	ENTITY
diet	ENTITY
low	ENTITY
sugar	ENTITY
eating	O
an	O
optimal	O
amount	O
of	O
protein	O
short	O
high	O
intensity	O
training	O
hit	O
these	O
hormones	ENTITY
produce	ENTITY
complex	ENTITY
reactions	ENTITY
in	ENTITY
the	ENTITY
body	ENTITY
and	ENTITY
there	ENTITY
are	ENTITY
many	ENTITY
text	ENTITY
books	ENTITY
written	ENTITY
about	ENTITY
them	ENTITY
.	O
to	O
keep	O
things	O
simple	O
however	O
just	O
look	O
at	O
insulin	ENTITY
vs	ENTITY
glucagon	ENTITY
.	O
there	O
is	O
constant	O
balancing	O
act	O
between	O
the	O
two	O
hormones	ENTITY
.	O
just	O
keep	O
your	O
insulin	ENTITY
levels	ENTITY
low	O
by	O
limiting	O
your	O
sugary	ENTITY
carbohydrates	ENTITY
not	O
eating	O
too	O
many	O
meals	O
in	O
one	O
day	O
and	O
staying	O
active	O
.	O
short	O
high	O
intensity	O
training	O
hit	O
is	O
also	O
good	O
for	O
increasing	O
glucagon	ENTITY
.	O
if	O
you	O
like	O
this	O
video	O
give	O
it	O
thumbs	O
up	O
.	O
subscribe	O
to	O
turbocharge	O
your	O
fitness	O
health	O
and	O
nutrition	O
.	O
how	O
to	O
use	O
glucagon	ENTITY
kit	ENTITY
.	O
store	O
advice	O
.	O
please	O
consult	O
your	O
doctor	O
if	O
you	O
have	O
questions	O
about	O
your	O
individual	O
diabetes	ENTITY
management	ENTITY
and	ENTITY
overall	ENTITY
health	ENTITY
.	O
grab	O
our	O
free	O
cheatsheet	O
covering	O
the	O
most	O
commonly	O
prescribed	O
medications	O
right	O
here	O
glucagon	ENTITY
generic	ENTITY
name	ENTITY
glucagon	ENTITY
trade	ENTITY
name	ENTITY
glucagen	ENTITY
indication	ENTITY
severe	ENTITY
hypoglycemia	ENTITY
antidote	O
for	O
beta	ENTITY
blockers	ENTITY
and	O
calcium	O
channel	O
blockers	O
action	O
stimulates	O
production	O
of	O
glucose	ENTITY
from	ENTITY
stores	ENTITY
relaxes	ENTITY
gi	ENTITY
tract	ENTITY
therapeutic	O
class	O
hormones	ENTITY
pharmacologic	ENTITY
class	ENTITY
pancreatics	ENTITY
nursing	ENTITY
considerations	O
may	O
cause	O
anaphylaxis	ENTITY
may	ENTITY
cause	ENTITY
hypotension	ENTITY
assess	ENTITY
for	ENTITY
signs	ENTITY
of	ENTITY
hypoglycemia	ENTITY
neuro	O
status	O
monitor	O
serum	O
glucose	ENTITY
levels	ENTITY
teach	O
patient	O
signs	O
of	O
hypoglycemia	ENTITY
.	O
the	O
role	O
of	O
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
negative	ENTITY
feedback	ENTITY
system	ENTITY
.	O
glucagon	ENTITY
stp	ENTITY
.	O
glucagon	ENTITY
es	ENTITY
la	ENTITY
hormona	ENTITY
secretada	ENTITY
por	ENTITY
las	ENTITY
lulas	ENTITY
alfa	ENTITY
en	ENTITY
los	ENTITY
islotes	ENTITY
de	ENTITY
langerhans	ENTITY
cuando	ENTITY
la	ENTITY
glucosa	ENTITY
disminuye	ENTITY
siendo	ENTITY
as	ENTITY
opuesta	ENTITY
en	ENTITY
funcionalidad	ENTITY
la	ENTITY
insulina	ENTITY
.	O
estimula	O
los	O
procesos	O
catab	O
licos	O
inhibe	O
los	O
procesos	O
anab	O
licos	O
.	O
tiene	O
en	O
el	O
gado	O
un	O
efecto	O
hiperglucemiante	O
debido	O
su	O
potente	O
efecto	O
glucogenol	O
tico	O
.	O
bibliograf	O
fisiologia	O
de	O
guyton	O
hall	O
ay	O
dame	O
suscribiendote	O
compartiendo	O
deo	O
relacionado	O
insulina	ENTITY
.	O
thanks	O
for	O
watching	O
.	O
visit	O
begin	O
in	O
september	O
.	O
don	O
forget	O
to	O
like	O
and	O
share	O
.	O
modeling	O
project	O
by	O
michaela	O
note	O
hypoglycemia	ENTITY
and	ENTITY
hyperglycemia	ENTITY
are	ENTITY
switched	ENTITY
at	ENTITY
.	O
gostou	O
desta	O
videoaula	O
sobre	O
insulina	ENTITY
glucagon	ENTITY
ministrada	ENTITY
pelo	ENTITY
professor	ENTITY
de	ENTITY
biologia	ENTITY
pedro	ENTITY
sultano	ENTITY
.	O
se	O
voc	O
deseja	O
ter	O
acesso	O
este	O
muitos	O
outros	O
conte	O
dos	O
com	O
todas	O
as	O
mat	O
rias	O
que	O
ser	O
cobradas	O
no	O
enem	O
visite	O
site	O
www	O
enem	O
com	O
br	O
veja	O
como	O
come	O
ar	O
agora	O
mesmo	O
estudar	O
online	O
com	O
qg	O
do	O
enem	O
.	O
estudar	O
online	O
com	O
qg	O
do	O
enem	O
aumenta	O
suas	O
chances	O
de	O
aprova	O
.	O
deixe	O
que	O
as	O
dificuldades	O
de	O
frequentar	O
um	O
cursinho	O
presencial	O
de	O
prepara	O
para	O
enem	O
atrapalhe	O
seus	O
estudos	O
.	O
veja	O
as	O
videoaulas	O
quando	O
quiser	O
onde	O
preferir	O
.	O
acesse	O
agora	O
mesmo	O
site	O
www	O
enem	O
com	O
br	O
comece	O
desde	O
sua	O
trajet	O
ria	O
ruma	O
uma	O
vaga	O
em	O
uma	O
grande	O
universidade	O
.	O
it	O
needs	O
me	O
and	O
need	O
it	O
.	O
translated	O
by	O
cysote	O
the	O
japanese	O
lyrics	O
and	O
translation	O
can	O
be	O
found	O
here	O
in	O
most	O
cases	O
but	O
do	O
know	O
that	O
there	O
are	O
other	O
ways	O
to	O
interpret	O
the	O
song	O
.	O
ninja	O
nerds	O
join	O
us	O
in	O
this	O
two	O
part	O
video	O
series	O
where	O
we	O
discuss	O
the	O
pancreas	ENTITY
.	O
in	O
this	O
video	O
we	O
discuss	O
the	O
hormone	ENTITY
glucagon	ENTITY
and	ENTITY
its	ENTITY
function	ENTITY
to	ENTITY
act	ENTITY
upon	ENTITY
the	ENTITY
liver	ENTITY
to	ENTITY
stimulate	ENTITY
glycogenolysis	ENTITY
and	ENTITY
increase	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
.	O
correction	O
referred	O
to	O
cck	ENTITY
and	ENTITY
secretin	ENTITY
as	ENTITY
glucagon	ENTITY
stimulators	ENTITY
but	ENTITY
they	ENTITY
are	ENTITY
actually	ENTITY
glucagon	ENTITY
inhibitors	ENTITY
due	O
to	O
being	O
released	O
during	O
the	O
fed	O
state	O
.	O
cck	ENTITY
and	ENTITY
secretin	ENTITY
are	ENTITY
insulin	ENTITY
stimulators	ENTITY
as	O
their	O
action	O
is	O
to	O
lower	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
.	O
please	O
support	O
us	O
patreon	O
for	O
general	O
inquiries	O
email	O
us	O
at	O
ninjanerdscience	O
gmail	O
com	O
.	O
animated	O
video	O
created	O
using	O
animaker	O
http	O
www	O
animaker	O
com	O
insulin	ENTITY
fights	ENTITY
to	O
lower	O
your	O
blood	ENTITY
sugar	ENTITY
while	O
glucagon	ENTITY
works	ENTITY
to	ENTITY
keep	ENTITY
it	ENTITY
high	ENTITY
.	O
description	O
of	O
the	O
competing	O
roles	O
of	O
insulin	ENTITY
and	ENTITY
glycogen	ENTITY
including	ENTITY
their	ENTITY
effects	ENTITY
on	ENTITY
glucose	ENTITY
homeostasis	ENTITY
and	O
other	O
metabolic	ENTITY
hormones	ENTITY
.	O
glp	ENTITY
gip	ENTITY
cortisol	ENTITY
growth	ENTITY
hormone	ENTITY
etc	ENTITY
.	O
pancreatic	ENTITY
histology	ENTITY
and	ENTITY
insulin	ENTITY
synthesis	ENTITY
are	O
also	O
briefly	O
discussed	O
.	O
glucagon	ENTITY
uses	ENTITY
side	ENTITY
effects	ENTITY
interactions	ENTITY
canada	ENTITY
diabetes	ENTITY
library	ENTITY
.	O
in	O
this	O
lesson	O
we	O
ll	O
discuss	O
glucagon	ENTITY
key	ENTITY
that	ENTITY
is	ENTITY
glucagon	ENTITY
has	ENTITY
the	ENTITY
effect	ENTITY
of	ENTITY
increasing	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
.	O
it	O
works	O
to	O
raise	O
the	O
enzyme	ENTITY
protein	ENTITY
kinase	ENTITY
that	O
was	O
stimulated	O
by	O
cascade	O
initiated	O
glucagon	ENTITY
will	ENTITY
also	ENTITY
phosphorylate	ENTITY
single	ENTITY
serine	ENTITY
residue	ENTITY
of	ENTITY
energy	ENTITY
is	ENTITY
required	ENTITY
for	ENTITY
normal	ENTITY
functioning	ENTITY
organs	ENTITY
in	ENTITY
body	ENTITY
.	O
to	O
do	O
this	O
it	O
acts	O
on	O
the	O
liver	ENTITY
in	ENTITY
several	ENTITY
ways	ENTITY
stimulates	ENTITY
conversion	ENTITY
of	ENTITY
stored	ENTITY
glycogen	ENTITY
stored	ENTITY
liver	ENTITY
to	ENTITY
glucose	ENTITY
which	ENTITY
can	ENTITY
be	ENTITY
released	ENTITY
into	ENTITY
bloodstream	ENTITY
.	O
how	O
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
work	ENTITY
youtube	ENTITY
.	O
use	O
the	O
animation	O
to	O
make	O
sure	O
you	O
understand	O
how	O
this	O
worksinsulin	O
not	O
producedtoo	O
little	O
glucose	ENTITY
pancreas	ENTITY
releases	ENTITY
another	ENTITY
hormone	ENTITY
glucagon	ENTITY
when	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
fall	O
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
do	ENTITY
they	ENTITY
work	ENTITY
.	O
healthlineglucagon	O
what	O
is	O
role	O
of	O
secretion	ENTITY
.	O
the	O
insulin	ENTITY
tells	ENTITY
cells	ENTITY
throughout	ENTITY
your	ENTITY
body	ENTITY
to	ENTITY
take	ENTITY
in	ENTITY
glucose	ENTITY
from	ENTITY
bloodstream	ENTITY
apr	ENTITY
this	ENTITY
medication	ENTITY
works	ENTITY
the	ENTITY
liver	ENTITY
produce	ENTITY
sugar	ENTITY
and	ENTITY
increase	ENTITY
blood	ENTITY
glucagon	ENTITY
can	ENTITY
also	ENTITY
be	ENTITY
used	ENTITY
as	ENTITY
part	ENTITY
of	ENTITY
certain	ENTITY
radiologic	ENTITY
tests	ENTITY
temporarily	O
less	O
than	O
kg	O
lbs	O
dose	O
is	O
nov	ENTITY
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
are	ENTITY
hormones	ENTITY
that	ENTITY
help	ENTITY
regulate	ENTITY
the	ENTITY
levels	ENTITY
of	ENTITY
blood	ENTITY
glucose	ENTITY
or	O
sugar	O
in	O
your	O
body	O
.	O
unit	O
or	O
is	O
based	O
on	O
body	O
weight	O
you	O
need	O
both	O
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
to	ENTITY
respond	ENTITY
various	ENTITY
levels	ENTITY
of	ENTITY
glucose	ENTITY
in	O
the	O
even	O
so	O
it	O
can	O
be	O
said	O
that	O
acts	O
all	O
cells	O
because	O
what	O
are	O
differences	O
between	O
how	O
cortisol	ENTITY
work	ENTITY
also	ENTITY
reduce	ENTITY
inflammation	ENTITY
body	ENTITY
which	ENTITY
too	ENTITY
low	ENTITY
not	ENTITY
secreted	ENTITY
into	ENTITY
blood	ENTITY
liver	ENTITY
does	O
convert	O
glycogen	ENTITY
goes	ENTITY
up	ENTITY
.	O
insulin	ENTITY
regulation	ENTITY
of	ENTITY
blood	ENTITY
sugar	O
and	O
diabetes	ENTITY
the	ENTITY
important	ENTITY
glucagon	ENTITY
definition	ENTITY
function	ENTITY
effects	ENTITY
video	ENTITY
lesson	ENTITY
transcript	ENTITY
vivo	ENTITY
.	O
this	O
process	O
is	O
called	O
glycogenolysis	ENTITY
mar	ENTITY
when	ENTITY
the	ENTITY
body	ENTITY
does	ENTITY
not	ENTITY
convert	ENTITY
enough	ENTITY
glucose	ENTITY
for	ENTITY
use	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
remain	O
high	O
.	O
what	O
are	O
the	O
differences	O
between	O
how	O
glucagon	ENTITY
and	ENTITY
cortisol	ENTITY
work	ENTITY
to	ENTITY
bbc	ENTITY
gcse	ENTITY
bitesize	ENTITY
blood	ENTITY
glucose	ENTITY
regulation	ENTITY
.	O
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
work	ENTITY
together	ENTITY
to	ENTITY
balance	ENTITY
your	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
keeping	O
them	O
in	O
the	O
narrow	O
range	O
that	O
body	O
requires	O
.	O
by	O
liver	ENTITY
kidney	ENTITY
and	O
brain	ENTITY
cells	ENTITY
is	O
by	O
diffusion	O
does	O
not	O
require	O
insulin	ENTITY
mar	ENTITY
like	ENTITY
insulin	ENTITY
glucagon	ENTITY
has	O
an	O
effect	O
on	O
many	O
of	O
the	O
body	O
but	O
most	O
above	O
can	O
be	O
normal	O
if	O
you	O
have	O
eaten	O
within	O
to	O
hours	O
in	O
emergency	O
situations	O
body	O
increase	O
its	O
sugar	O
supply	O
order	O
produce	O
energy	O
.	O
googleusercontent	O
search	O
.	O
glucose	ENTITY
metabolism	ENTITY
function	ENTITY
of	ENTITY
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
can	ENTITY
insulin	ENTITY
.	O
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
work	ENTITY
synergistically	ENTITY
to	ENTITY
keep	ENTITY
blood	ENTITY
glucose	ENTITY
concentrations	O
normal	O
.	O
insulin	ENTITY
and	ENTITY
glucagon	ENTITY
how	ENTITY
do	ENTITY
they	ENTITY
work	ENTITY
.	O
healthline	O
healthline	O
health	ENTITY
diabetes	ENTITY
insulin	ENTITY
url	ENTITY
.	O
webcache	O
.	O
insulin	ENTITY
helps	ENTITY
the	ENTITY
body	ENTITY
cells	ENTITY
absorb	ENTITY
glucose	ENTITY
glucagon	ENTITY
is	ENTITY
peptide	ENTITY
hormone	ENTITY
produced	O
by	O
alpha	O
of	O
pancreas	ENTITY
.	O
it	O
comes	O
from	O
alpha	ENTITY
cells	ENTITY
found	O
in	O
the	O
pancreas	ENTITY
and	ENTITY
is	ENTITY
closely	ENTITY
related	ENTITY
to	ENTITY
insulin	ENTITY
secreting	ENTITY
beta	ENTITY
cells	ENTITY
making	O
it	O
crucial	O
component	O
that	O
keeps	O
body	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
stable	O
two	O
hormones	ENTITY
need	ENTITY
work	ENTITY
partnership	ENTITY
with	ENTITY
each	ENTITY
other	ENTITY
keep	ENTITY
glucagon	ENTITY
plays	ENTITY
an	ENTITY
active	ENTITY
role	ENTITY
allowing	ENTITY
bo	ENTITY
.	O
ncreas	O
end	O
crino	O
fisiologia	O
insulina	O
glucagon	ENTITY
deo	ENTITY
aula	ENTITY
de	ENTITY
sistema	ENTITY
end	ENTITY
crino	ENTITY
ai	ENTITY
galera	ENTITY
td	ENTITY
certo	ENTITY
.	O
hoje	O
vamos	O
fechar	O
parte	O
de	O
ncreas	O
end	O
crino	O
vamos	O
falar	O
dos	O
principais	O
horm	O
nios	O
produzidos	O
por	O
ele	O
que	O
tem	O
es	O
antag	O
nicas	O
que	O
insulina	O
glucagon	O
.	O
al	O
deles	O
vou	O
falar	O
tamb	O
um	O
pouco	O
sobre	O
somatostatina	O
polipept	O
deo	O
pancre	O
tico	O
blza	O
.	O
ent	O
espero	O
que	O
ajude	O
.	O
uma	O
grande	O
abra	O
at	O
pr	O
xima	O
.	O
deixem	O
de	O
se	O
inscrever	O
conferir	O
nossas	O
playlists	O
.	O
temos	O
conte	O
dos	O
para	O
estudantes	O
de	O
medicina	O
vestibulandos	O
de	O
medicina	O
rotina	O
na	O
faculdade	O
de	O
medicina	O
dicas	O
de	O
estudo	O
de	O
materiais	O
deo	O
aulas	O
de	O
resumo	O
de	O
conte	O
dos	O
semiologia	O
sistema	O
nervoso	O
sistema	O
end	O
crino	O
sistema	O
renal	O
sistema	O
imune	O
sistema	O
cardiovascular	O
sistema	O
digest	O
rio	O
patologias	O
entre	O
outros	O
deixe	O
de	O
nos	O
seguir	O
nas	O
redes	O
sociais	O
para	O
ficar	O
de	O
fora	O
das	O
novidades	O
.	O
facebook	O
http	O
fincompetech	O
com	O
fmusic	O
froyalty	O
redir	O
token	O
dyfobhnvenwsv	O
uamedasewt	O
mtqynje	O
mzmzmkaxndi	O
mta	O
otmy	O
isrc	O
usuan	O
.	O
don	O
forget	O
to	O
do	O
the	O
questions	O
that	O
accompany	O
this	O
video	O
at	O
macrophage	O
co	O
.	O
subscribe	O
to	O
pillbox	O
.	O
en	O
este	O
episodio	O
frank	O
explica	O
de	O
qu	O
forma	O
las	O
lulas	O
se	O
alimentan	O
de	O
insulina	O
mo	O
se	O
produce	O
la	O
obesidad	O
.	O
recetas	O
el	O
poder	O
del	O
metabolismo	O
por	O
frank	O
su	O
rez	O
coma	O
sabroso	O
mientras	O
mejora	O
su	O
metabolismo	O
adelgaza	O
spanish	O
edition	O
.	O
si	O
le	O
niveau	O
de	O
glucose	ENTITY
ve	ENTITY
au	ENTITY
dessus	ENTITY
du	ENTITY
point	ENTITY
normal	ENTITY
le	ENTITY
pancr	ENTITY
as	ENTITY
cr	ENTITY
te	ENTITY
de	ENTITY
insuline	ENTITY
le	ENTITY
niveau	ENTITY
de	ENTITY
glucose	ENTITY
dans	ENTITY
le	ENTITY
sang	ENTITY
diminue	ENTITY
.	O
si	O
le	O
niveau	O
de	O
glucose	ENTITY
chute	ENTITY
en	ENTITY
dessous	ENTITY
du	ENTITY
point	ENTITY
normal	ENTITY
le	ENTITY
pancr	ENTITY
as	ENTITY
cr	ENTITY
te	ENTITY
du	ENTITY
glucagon	ENTITY
le	ENTITY
taux	ENTITY
de	ENTITY
glucose	ENTITY
sanguin	ENTITY
augmente	ENTITY
.	O
le	O
glucagon	ENTITY
entra	ENTITY
ne	ENTITY
une	ENTITY
augmentation	ENTITY
de	ENTITY
la	ENTITY
glyc	ENTITY
mie	ENTITY
est	ENTITY
une	ENTITY
hormone	ENTITY
hyperglyc	ENTITY
miante	ENTITY
.	O
insuline	O
entra	O
ne	O
une	O
diminution	O
de	O
la	O
glyc	O
mie	O
est	O
une	O
hormone	ENTITY
hypoglyc	ENTITY
miante	ENTITY
.	O
insuline	O
et	O
le	O
glucagon	O
sont	O
hormones	O
antagonistes	O
.	O
visit	O
us	O
for	O
mcat	O
related	O
content	O
.	O
these	O
videos	O
do	O
not	O
provide	O
medical	O
advice	O
and	O
are	O
for	O
informational	O
purposes	O
only	O
.	O
the	O
videos	O
are	O
not	O
intended	O
to	O
be	O
substitute	O
for	O
professional	O
medical	O
advice	O
diagnosis	O
or	O
treatment	O
.	O
always	O
seek	O
the	O
advice	O
of	O
qualified	O
health	O
provider	O
with	O
any	O
questions	O
you	O
may	O
have	O
regarding	O
medical	O
condition	O
.	O
never	O
disregard	O
professional	O
medical	O
advice	O
or	O
delay	O
in	O
seeking	O
it	O
because	O
of	O
something	O
you	O
have	O
read	O
or	O
seen	O
in	O
any	O
khan	O
academy	O
video	O
.	O
http	O
www	O
cincinnatichildrens	O
org	O
diabetes	ENTITY
series	ENTITY
using	ENTITY
glucagon	ENTITY
emergency	ENTITY
kit	ENTITY
this	O
step	O
by	O
step	O
guide	O
is	O
intended	O
for	O
cincinnati	O
children	O
diabetes	ENTITY
patients	ENTITY
and	O
families	O
.	O
for	O
specific	O
guidance	O
talk	O
to	O
your	O
doctor	O
.	O
modo	O
de	O
administraci	O
del	O
glucagon	ENTITY
para	ENTITY
el	ENTITY
tratamiento	ENTITY
de	ENTITY
las	ENTITY
hipoglucemias	ENTITY
severas	ENTITY
.	O
deanna	O
and	O
are	O
discussing	O
key	O
highlights	O
from	O
low	O
carb	O
breckenridge	O
this	O
past	O
weekend	O
.	O
save	O
your	O
seat	O
in	O
our	O
next	O
keto	O
ecourse	O
challenge	O
.	O
song	O
ezfg	O
picture	O
by	O
pixoshiru	O
chipspeech	O
was	O
made	O
by	O
plogue	O
.	O
look	O
forward	O
to	O
daisy	O
and	O
alter	O
ego	O
set	O
to	O
release	O
the	O
second	O
week	O
of	O
september	O
.	O
http	O
www	O
plogue	O
com	O
had	O
lot	O
of	O
fun	O
making	O
this	O
cover	O
.	O
getting	O
otto	O
to	O
sound	O
clear	O
was	O
kinda	O
hard	O
but	O
tried	O
my	O
best	O
don	O
have	O
much	O
else	O
to	O
say	O
.	O
winner	O
of	O
the	O
the	O
judge	O
award	O
first	O
place	O
in	O
rcsb	O
pdb	ENTITY
video	ENTITY
challenge	ENTITY
for	ENTITY
high	ENTITY
school	ENTITY
students	ENTITY
structural	ENTITY
biology	ENTITY
diabetes	ENTITY
.	O
by	O
alexis	O
souza	O
sruthi	O
katakam	O
and	O
nithilam	O
subbaian	O
of	O
west	O
windsor	O
plainsboro	O
high	O
school	O
south	O
in	O
princeton	O
junction	O
nj	O
team	O
advisor	O
matthew	O
foret	O
.	O
if	O
the	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
of	O
person	O
with	O
diabetes	ENTITY
drop	ENTITY
to	ENTITY
very	ENTITY
low	ENTITY
levels	ENTITY
they	ENTITY
can	ENTITY
have	ENTITY
what	ENTITY
is	ENTITY
known	ENTITY
as	ENTITY
severe	ENTITY
hypoglycaemic	ENTITY
episode	ENTITY
in	O
which	O
they	O
become	O
unconscious	O
or	O
have	O
seizure	O
.	O
in	O
this	O
situation	O
glucagon	ENTITY
injection	ENTITY
needs	O
to	O
be	O
administered	O
as	O
soon	O
as	O
possible	O
.	O
this	O
video	O
will	O
teach	O
you	O
how	O
to	O
administer	O
glucagon	ENTITY
injection	ENTITY
and	O
is	O
perfect	O
tool	O
if	O
you	O
have	O
diabetes	ENTITY
and	ENTITY
find	ENTITY
it	ENTITY
difficult	ENTITY
to	ENTITY
explain	ENTITY
the	ENTITY
important	ENTITY
topics	ENTITY
of	ENTITY
severe	ENTITY
hypoglycemia	ENTITY
and	ENTITY
glucagon	ENTITY
to	ENTITY
your	ENTITY
friends	ENTITY
family	ENTITY
and	ENTITY
peers	ENTITY
.	O
remember	O
if	O
you	O
had	O
one	O
coma	ENTITY
you	ENTITY
likely	ENTITY
to	ENTITY
have	ENTITY
another	ENTITY
one	ENTITY
unless	ENTITY
if	ENTITY
you	ENTITY
can	ENTITY
figure	ENTITY
out	ENTITY
what	ENTITY
was	ENTITY
the	ENTITY
reason	ENTITY
for	ENTITY
the	ENTITY
coma	ENTITY
and	ENTITY
correct	ENTITY
it	ENTITY
.	O
reasons	O
could	O
being	O
active	O
too	O
much	O
insulin	ENTITY
or	ENTITY
not	ENTITY
enough	ENTITY
food	ENTITY
.	O
but	O
please	O
note	O
if	O
any	O
alcohol	O
has	O
been	O
involved	O
glucagon	ENTITY
injection	ENTITY
would	O
not	O
work	O
and	O
an	O
ambulance	O
should	O
be	O
called	O
immediately	O
.	O
if	O
you	O
are	O
diabetes	O
educator	O
or	O
medical	O
professional	O
and	O
would	O
like	O
copy	O
of	O
this	O
video	O
please	O
feel	O
free	O
contact	O
youth	O
with	O
diabetes	ENTITY
and	ENTITY
order	ENTITY
dvd	ENTITY
.	O
moof	O
medical	ENTITY
biochemistry	ENTITY
video	O
course	O
biochemistry	O
for	O
usmle	O
step	O
exam	O
.	O
wendy	O
sewell	O
children	O
diabetes	ENTITY
nurse	ENTITY
specialist	ENTITY
shows	ENTITY
you	ENTITY
how	ENTITY
to	ENTITY
give	ENTITY
an	ENTITY
injection	ENTITY
of	ENTITY
glucagon	ENTITY
.	O
project	O
started	O
.	O
project	O
finished	O
.	O
roslue	O
chie	O
helped	O
with	O
coloring	O
.	O
thank	O
you	O
.	O
saki	O
glucagon	ENTITY
fnaf	ENTITY
human	ENTITY
designs	ENTITY
pole	ENTITY
bear	ENTITY
.	O
dieses	O
mal	O
erkl	O
re	O
ich	ENTITY
euch	ENTITY
was	ENTITY
glucagon	ENTITY
ist	ENTITY
woher	ENTITY
es	ENTITY
kommt	ENTITY
und	ENTITY
was	ENTITY
es	ENTITY
macht	ENTITY
.	O
wer	O
mein	O
video	O
ber	O
insulin	ENTITY
noch	ENTITY
nicht	ENTITY
gesehen	ENTITY
hat	ENTITY
sollte	ENTITY
dieses	ENTITY
zuerst	ENTITY
anschauen	ENTITY
video	ENTITY
ber	ENTITY
insulin	ENTITY
links	ENTITY
die	ENTITY
mit	ENTITY
kennzeichnet	ENTITY
sind	ENTITY
sind	ENTITY
sog	ENTITY
.	O
affiliate	O
links	O
.	O
kommt	O
ber	O
diesen	O
link	O
ein	O
einkauf	O
zustande	O
werde	O
ich	ENTITY
mit	ENTITY
einer	ENTITY
provision	ENTITY
beteiligt	ENTITY
.	O
euch	O
entstehen	O
dabei	O
keine	O
mehrkosten	O
.	O
ich	O
freue	O
mich	O
dass	O
ihr	O
mich	O
ohne	O
mehrkosten	O
unterst	O
zt	O
.	O
all	O
glp	ENTITY
receptor	ENTITY
agonists	O
share	O
common	O
mechanism	O
activation	O
of	O
the	O
glp	ENTITY
receptor	ENTITY
.	O
glp	ENTITY
receptors	ENTITY
are	ENTITY
expressed	ENTITY
by	ENTITY
cells	ENTITY
cells	ENTITY
in	ENTITY
the	ENTITY
peripheral	ENTITY
and	O
central	ENTITY
nervous	ENTITY
systems	ENTITY
the	O
heart	ENTITY
and	ENTITY
vasculature	ENTITY
kidney	ENTITY
lung	ENTITY
and	ENTITY
gi	ENTITY
mucosa	ENTITY
.	O
binding	O
of	O
agonists	ENTITY
to	ENTITY
the	ENTITY
glp	ENTITY
receptor	ENTITY
activates	O
the	O
cyclic	ENTITY
amp	ENTITY
pka	O
pathway	O
and	O
several	O
gefs	ENTITY
guanine	ENTITY
nucleotide	ENTITY
exchange	ENTITY
factors	ENTITY
.	O
glp	ENTITY
receptor	ENTITY
activation	ENTITY
also	ENTITY
initiates	ENTITY
signaling	ENTITY
via	ENTITY
pkc	ENTITY
and	ENTITY
pi	ENTITY
and	ENTITY
alters	ENTITY
the	ENTITY
activity	ENTITY
of	ENTITY
several	ENTITY
ion	ENTITY
channels	ENTITY
.	O
in	O
cells	O
the	O
end	O
result	O
of	O
these	O
actions	O
is	O
increased	O
insulin	ENTITY
biosynthesis	ENTITY
and	O
exocytosis	ENTITY
in	ENTITY
glucose	ENTITY
dependent	ENTITY
manner	ENTITY
.	O
the	O
treatment	O
of	O
diabetes	ENTITY
is	ENTITY
advancing	ENTITY
rapidly	ENTITY
.	O
one	O
of	O
the	O
most	O
important	O
drugs	O
nowadays	O
are	O
those	O
working	O
on	O
the	O
glp	ENTITY
system	ENTITY
if	ENTITY
you	ENTITY
are	ENTITY
studying	ENTITY
pharmacology	ENTITY
or	ENTITY
internal	ENTITY
medicine	ENTITY
endocrinology	ENTITY
this	O
video	O
will	O
be	O
of	O
great	O
help	O
.	O
prepare	O
well	O
for	O
the	O
medical	O
boards	O
usmle	O
shelf	O
or	O
even	O
nclex	O
if	O
you	O
enjoyed	O
the	O
video	O
please	O
subscribe	O
my	O
favorite	O
book	O
to	O
study	O
pathology	O
for	O
step	O
usmle	O
is	O
goljan	O
you	O
can	O
check	O
it	O
out	O
here	O
list	O
plyclrrdar	O
yxu	O
bwjiunuk	O
ngd	O
.	O
simple	O
explanation	O
of	O
how	O
sitagliptin	ENTITY
exenatide	ENTITY
and	ENTITY
other	ENTITY
ddp	ENTITY
inhibitors	ENTITY
and	O
glp	ENTITY
mimetics	ENTITY
work	ENTITY
for	ENTITY
the	ENTITY
treatment	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
love	O
creating	O
resources	O
to	O
help	O
medical	O
students	O
with	O
their	O
studies	O
.	O
why	O
not	O
have	O
look	O
at	O
some	O
of	O
the	O
other	O
resources	O
available	O
website	O
www	O
zerotofinals	O
com	O
notes	O
www	O
zerotofinals	O
com	O
learn	O
multiple	O
choice	O
questions	O
www	O
zerotofinals	O
com	O
test	O
instagram	O
www	O
instagram	O
.	O
book	O
www	O
zerotofinals	O
com	O
themedicinemanual	O
facebook	O
www	O
facebook	O
com	O
zerotofinals	O
twitter	O
.	O
great	O
primer	O
on	O
the	O
glp	ENTITY
agonists	ENTITY
for	ENTITY
physicians	ENTITY
pharmacists	ENTITY
nps	ENTITY
pas	ENTITY
and	ENTITY
other	ENTITY
healthcare	ENTITY
providers	ENTITY
.	O
this	O
video	O
discusses	O
comparisons	O
of	O
the	O
various	O
agents	O
based	O
on	O
clinical	O
trials	O
and	O
discusses	O
important	O
clinical	O
pearls	O
with	O
using	O
various	O
glp	ENTITY
agonists	ENTITY
.	O
in	O
this	O
edition	O
of	O
the	O
edelman	O
report	O
dr	O
edelman	O
explains	O
glp	ENTITY
agonists	ENTITY
.	O
dr	O
edwin	O
lee	O
explains	O
how	O
the	O
gut	ENTITY
hormone	ENTITY
glp	O
affects	O
blood	ENTITY
sugar	ENTITY
and	O
body	ENTITY
composition	ENTITY
.	O
watch	O
the	O
full	O
interview	O
here	O
ltpmnyi	O
fjc	O
.	O
client	O
novo	O
nordisk	O
bureau	O
elevate	O
wil	O
je	O
ook	O
een	ENTITY
uitleg	ENTITY
video	ENTITY
laten	ENTITY
maken	ENTITY
.	O
bekijk	O
onze	O
website	O
.	O
continue	O
watching	O
.	O
glucagon	ENTITY
like	ENTITY
peptide	ENTITY
triggers	O
calcium	ENTITY
induced	ENTITY
calcium	ENTITY
release	ENTITY
cicr	ENTITY
in	O
the	O
beta	ENTITY
cells	ENTITY
.	O
see	O
how	O
cicr	O
looks	O
like	O
.	O
ddp	O
inhibitors	O
type	O
diabetes	ENTITY
januvia	ENTITY
onglyza	ENTITY
sitagliptin	ENTITY
saxagliptin	ENTITY
glp	ENTITY
.	O
prof	O
dr	O
michael	O
nauck	O
diabeteszentrum	O
bad	O
lauterberg	O
.	O
market	O
research	O
reports	O
inc	O
has	O
announced	O
the	O
addition	O
of	O
competitor	O
analysis	O
glucagon	ENTITY
like	ENTITY
peptide	ENTITY
glp	ENTITY
receptor	ENTITY
agonists	O
research	O
report	O
to	O
their	O
offering	O
.	O
see	O
more	O
at	O
.	O
watch	O
full	O
video	O
.	O
www	O
rxwiki	O
com	O
.	O
david	O
alessio	O
md	O
associate	O
director	O
of	O
the	O
duke	O
molecular	ENTITY
physiology	ENTITY
institute	O
professor	O
in	O
the	O
department	O
of	O
medicine	O
and	O
director	O
of	O
the	O
division	ENTITY
of	ENTITY
endocrinology	ENTITY
metabolism	ENTITY
and	O
nutrition	O
at	O
duke	O
university	O
presents	O
talk	O
on	O
his	O
views	O
about	O
whether	O
the	O
conventional	O
view	O
of	O
glp	ENTITY
as	ENTITY
hormone	ENTITY
is	ENTITY
accurate	ENTITY
.	O
this	O
lecture	O
was	O
part	O
of	O
the	O
university	O
of	O
wisconsin	O
madison	O
department	O
of	O
medicine	O
grand	O
rounds	O
series	O
and	O
was	O
presented	O
during	O
the	O
th	O
annual	O
department	O
of	O
medicine	O
research	O
day	O
.	O
the	O
title	O
of	O
his	O
june	O
grand	O
rounds	O
talk	O
is	O
is	O
glp	ENTITY
hormone	ENTITY
whether	ENTITY
and	ENTITY
when	ENTITY
.	O
university	O
of	O
wisconsin	O
department	O
of	O
medicine	O
grand	ENTITY
rounds	ENTITY
are	ENTITY
presented	ENTITY
throughout	ENTITY
the	ENTITY
academic	ENTITY
year	ENTITY
and	ENTITY
are	ENTITY
intended	ENTITY
for	ENTITY
health	ENTITY
care	ENTITY
professionals	ENTITY
and	ENTITY
medical	ENTITY
researchers	ENTITY
.	O
unless	O
otherwise	O
indicated	O
grand	O
rounds	O
occurs	O
in	O
the	O
william	O
middleton	O
memorial	O
veterans	O
hospital	O
auditorium	O
room	O
madison	O
wisconsin	O
.	O
all	O
faculty	O
and	O
staff	O
are	O
invited	O
and	O
encouraged	O
to	O
attend	O
.	O
for	O
more	O
information	O
on	O
the	O
grand	O
rounds	O
lecture	O
series	O
visit	O
grand	O
rounds	O
.	O
breakdown	O
of	O
clinical	O
pearls	O
and	O
some	O
advantages	O
and	O
disadvantages	O
of	O
glp	ENTITY
in	ENTITY
management	ENTITY
of	ENTITY
type	ENTITY
diabetes	ENTITY
table	ENTITY
of	ENTITY
contents	ENTITY
conflicts	ENTITY
of	ENTITY
interest	ENTITY
glucagon	ENTITY
like	ENTITY
peptide	ENTITY
agonist	O
.	O
john	O
buse	O
md	O
phd	O
reviews	O
the	O
findings	O
from	O
the	O
elixa	O
trial	O
with	O
lixisenatide	ENTITY
in	ENTITY
patients	ENTITY
with	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
dpp	O
inhibitors	O
work	O
differently	O
to	O
other	O
classes	O
of	O
type	O
diabetes	ENTITY
therapies	ENTITY
.	O
check	O
out	O
this	O
animation	O
to	O
see	O
dpp	ENTITY
inhibitors	ENTITY
in	O
action	O
.	O
dpp	O
inhibitors	O
bind	O
to	O
the	O
dpp	ENTITY
enzyme	ENTITY
inhibiting	O
the	O
breakdown	O
of	O
glucagon	ENTITY
like	ENTITY
peptide	ENTITY
glp	ENTITY
and	ENTITY
glucose	ENTITY
dependent	ENTITY
insulinotropic	ENTITY
peptide	ENTITY
gip	O
these	O
are	O
naturally	O
occurring	O
hormones	ENTITY
which	ENTITY
are	ENTITY
released	ENTITY
by	ENTITY
the	ENTITY
gut	ENTITY
after	ENTITY
meals	ENTITY
and	ENTITY
target	ENTITY
the	ENTITY
pancreas	ENTITY
by	ENTITY
increasing	ENTITY
glucose	ENTITY
dependent	ENTITY
insulin	ENTITY
secretion	O
and	O
suppressing	O
glucagon	ENTITY
secretion	ENTITY
.	O
dpp	O
inhibitors	O
increase	O
the	O
concentration	O
of	O
glp	ENTITY
in	ENTITY
the	ENTITY
plasma	ENTITY
to	ENTITY
keep	ENTITY
it	ENTITY
within	ENTITY
the	ENTITY
body	ENTITY
natural	ENTITY
physiological	ENTITY
range	ENTITY
.	O
brought	O
to	O
you	O
by	O
boehringer	O
ingelheim	O
and	O
eli	O
lilly	O
and	O
company	O
.	O
what	O
does	O
glucagon	ENTITY
like	ENTITY
peptide	ENTITY
receptor	ENTITY
mean	O
in	O
english	O
.	O
zachary	O
bloomgarden	O
md	O
robert	O
gabbay	O
md	O
phd	O
facp	O
silvio	O
inzucchi	O
md	O
dennis	O
scanlon	O
phd	O
and	O
kenneth	O
snow	O
md	O
mba	O
compare	O
the	O
results	O
of	O
recent	O
trials	O
that	O
suggest	O
the	O
benefits	O
of	O
glucagon	ENTITY
like	ENTITY
peptide	ENTITY
receptor	ENTITY
agonists	O
for	O
diabetes	ENTITY
in	ENTITY
cardiovascular	ENTITY
mortality	ENTITY
.	O
glucagon	ENTITY
like	ENTITY
peptide	ENTITY
receptor	ENTITY
glp	ENTITY
receptor	ENTITY
or	O
glp	ENTITY
pipeline	ENTITY
review	ENTITY
provides	ENTITY
in	ENTITY
depth	ENTITY
analysis	ENTITY
on	ENTITY
glucagon	ENTITY
like	ENTITY
peptide	ENTITY
receptor	ENTITY
glp	ENTITY
receptor	ENTITY
or	O
glp	ENTITY
targeted	ENTITY
pipeline	ENTITY
therapeutics	ENTITY
.	O
the	O
report	O
provides	O
comprehensive	O
information	O
on	O
the	O
glucagon	ENTITY
like	ENTITY
peptide	ENTITY
receptor	ENTITY
glp	ENTITY
receptor	ENTITY
or	O
glp	ENTITY
targeted	ENTITY
therapeutics	ENTITY
complete	ENTITY
with	ENTITY
analysis	ENTITY
by	ENTITY
indications	ENTITY
stage	ENTITY
of	ENTITY
development	ENTITY
mechanism	ENTITY
of	ENTITY
action	ENTITY
moa	ENTITY
route	ENTITY
of	ENTITY
administration	ENTITY
roa	ENTITY
and	ENTITY
molecule	ENTITY
type	ENTITY
.	O
the	O
report	O
also	O
covers	O
the	O
descriptive	O
pharmacological	O
action	O
of	O
the	O
therapeutics	ENTITY
its	ENTITY
complete	ENTITY
research	ENTITY
and	ENTITY
development	ENTITY
history	ENTITY
and	ENTITY
latest	ENTITY
news	ENTITY
and	ENTITY
press	ENTITY
releases	ENTITY
.	O
additionally	O
the	O
report	O
provides	O
an	O
overview	O
of	O
key	O
players	O
involved	O
in	O
glucagon	ENTITY
like	ENTITY
peptide	ENTITY
receptor	ENTITY
glp	ENTITY
receptor	ENTITY
or	O
glp	ENTITY
targeted	ENTITY
therapeutics	ENTITY
development	ENTITY
and	ENTITY
features	ENTITY
dormant	ENTITY
and	ENTITY
discontinued	ENTITY
projects	ENTITY
.	O
the	O
report	O
helps	O
in	O
identifying	O
and	O
tracking	O
emerging	O
players	O
in	O
the	O
market	O
and	O
their	O
portfolios	O
enhances	O
decision	O
making	O
capabilities	O
and	O
helps	O
to	O
create	O
effective	O
counter	O
strategies	O
to	O
gain	O
competitive	O
advantage	O
.	O
read	O
more	O
at	O
like	O
peptide	ENTITY
receptor	ENTITY
glp	ENTITY
receptor	ENTITY
or	O
glp	ENTITY
pipeline	ENTITY
review	ENTITY
market	ENTITY
.	O
dr	O
joe	O
talks	O
about	O
glp	ENTITY
agents	ENTITY
what	ENTITY
they	ENTITY
are	ENTITY
and	ENTITY
how	ENTITY
they	ENTITY
work	ENTITY
and	ENTITY
the	ENTITY
importance	ENTITY
of	ENTITY
using	ENTITY
them	ENTITY
in	ENTITY
managing	ENTITY
diabetes	ENTITY
.	O
video	O
sobre	O
el	O
ptido	O
similar	O
al	O
glucagon	O
tipo	O
glp	O
mecanismo	O
de	O
acci	O
datos	O
hist	O
ricos	O
estructura	O
qu	O
mica	O
ntesis	O
secreci	O
transporte	O
eliminaci	O
funciones	O
estudios	O
actuales	O
.	O
original	O
video	O
by	O
novo	O
nordisk	O
html	O
.	O
victoza	O
liraglutide	O
is	O
glucagon	ENTITY
like	ENTITY
peptide	ENTITY
glp	ENTITY
receptor	ENTITY
agonist	ENTITY
indicated	O
as	O
an	O
adjunct	O
to	O
diet	O
and	O
exercise	O
to	O
improve	O
glycemic	ENTITY
control	ENTITY
in	O
adults	O
with	O
type	O
diabetes	ENTITY
mellitus	ENTITY
to	O
reduce	O
the	O
risk	O
of	O
major	O
adverse	ENTITY
cardiovascular	ENTITY
events	ENTITY
in	O
adults	O
with	O
type	O
diabetes	ENTITY
mellitus	ENTITY
and	O
established	O
cardiovascular	ENTITY
disease	ENTITY
.	O
liraglutide	O
is	O
an	O
analog	O
of	O
human	O
glp	ENTITY
and	ENTITY
acts	ENTITY
as	ENTITY
glp	ENTITY
receptor	ENTITY
agonist	ENTITY
.	O
the	O
peptide	ENTITY
precursor	ENTITY
of	ENTITY
liraglutide	ENTITY
produced	ENTITY
by	ENTITY
process	ENTITY
that	ENTITY
includes	ENTITY
expression	ENTITY
of	ENTITY
recombinant	ENTITY
dna	ENTITY
in	ENTITY
saccharomyces	ENTITY
cerevisiae	ENTITY
has	ENTITY
been	ENTITY
engineered	ENTITY
to	ENTITY
be	ENTITY
homologous	ENTITY
to	ENTITY
native	ENTITY
human	ENTITY
glp	ENTITY
by	ENTITY
substituting	ENTITY
arginine	ENTITY
for	ENTITY
lysine	ENTITY
at	O
position	O
liraglutide	O
is	O
made	O
by	O
attaching	O
fatty	ENTITY
acid	ENTITY
palmitic	ENTITY
acid	ENTITY
with	O
glutamic	ENTITY
acid	ENTITY
spacer	O
on	O
the	O
remaining	O
lysine	ENTITY
residue	ENTITY
at	ENTITY
position	ENTITY
of	ENTITY
the	ENTITY
peptide	ENTITY
precursor	ENTITY
.	O
liraglutide	O
is	O
an	O
acylated	O
human	O
glp	ENTITY
receptor	ENTITY
agonist	ENTITY
with	O
amino	ENTITY
acid	ENTITY
sequence	ENTITY
homology	ENTITY
to	O
endogenous	O
human	O
glp	ENTITY
.	O
glp	ENTITY
represents	ENTITY
less	ENTITY
than	ENTITY
of	ENTITY
total	ENTITY
circulating	ENTITY
endogenous	ENTITY
glp	ENTITY
like	ENTITY
glp	ENTITY
liraglutide	ENTITY
activates	ENTITY
the	ENTITY
glp	ENTITY
receptor	ENTITY
membrane	ENTITY
bound	ENTITY
cell	ENTITY
surface	ENTITY
receptor	ENTITY
coupled	O
to	O
adenylyl	ENTITY
cyclase	ENTITY
by	O
the	O
stimulatory	O
protein	O
gs	O
in	O
pancreatic	ENTITY
beta	ENTITY
cells	ENTITY
.	O
liraglutide	O
increases	O
intracellular	O
cyclic	ENTITY
amp	ENTITY
camp	O
leading	O
to	O
insulin	ENTITY
release	ENTITY
in	ENTITY
the	ENTITY
presence	ENTITY
of	ENTITY
elevated	ENTITY
glucose	ENTITY
concentrations	ENTITY
.	O
this	O
insulin	ENTITY
secretion	ENTITY
subsides	ENTITY
as	O
blood	ENTITY
glucose	ENTITY
concentrations	O
decrease	O
and	O
approach	O
euglycemia	ENTITY
.	O
liraglutide	O
also	O
decreases	O
glucagon	ENTITY
secretion	ENTITY
in	O
glucose	ENTITY
dependent	ENTITY
manner	ENTITY
.	O
the	O
mechanism	O
of	O
blood	ENTITY
glucose	ENTITY
lowering	O
also	O
involves	O
delay	O
in	O
gastric	ENTITY
emptying	ENTITY
.	O
what	O
does	O
glucagon	ENTITY
like	ENTITY
peptide	ENTITY
receptors	ENTITY
mean	O
in	O
english	O
.	O
robert	O
henry	O
md	O
professor	O
of	O
medicine	O
at	O
the	O
unviersity	O
of	O
california	O
san	O
diego	O
discusses	O
interesting	O
data	O
presented	O
at	O
the	O
ada	ENTITY
in	ENTITY
san	ENTITY
diego	ENTITY
regarding	ENTITY
glp	ENTITY
agonists	ENTITY
including	ENTITY
information	ENTITY
on	ENTITY
once	ENTITY
weekly	ENTITY
formulations	ENTITY
and	ENTITY
potential	ENTITY
benefits	ENTITY
on	ENTITY
cardiovascular	ENTITY
risk	ENTITY
factors	ENTITY
.	O
expert	O
john	O
anderson	O
md	O
reviews	O
the	O
cardiovascular	ENTITY
outcomes	ENTITY
data	ENTITY
available	ENTITY
to	ENTITY
date	ENTITY
with	ENTITY
glp	ENTITY
receptor	ENTITY
agonists	O
in	O
type	O
diabetes	ENTITY
.	O
what	O
does	O
glucagon	ENTITY
like	ENTITY
peptide	ENTITY
mean	O
in	O
english	O
.	O
dr	O
joe	O
talks	O
about	O
embryonic	O
kidney	ENTITY
cells	ENTITY
in	O
mice	O
showing	O
promise	O
.	O
jim	O
trevaskis	O
medimmune	O
.	O
dr	O
joe	O
talks	O
more	O
about	O
the	O
glp	ENTITY
agents	ENTITY
on	ENTITY
the	ENTITY
market	ENTITY
.	O
new	O
study	O
reassesses	O
long	O
term	O
safety	O
and	O
efficacy	O
of	O
glp	ENTITY
agonists	ENTITY
in	ENTITY
type	ENTITY
diabetes	ENTITY
click	ENTITY
here	ENTITY
type	ENTITY
diabetes	ENTITY
byetta	ENTITY
bydureon	ENTITY
victoza	ENTITY
lyxumia	ENTITY
trulicity	ENTITY
eperzan	ENTITY
.	O
what	O
does	O
glucagon	ENTITY
like	ENTITY
peptide	ENTITY
mean	O
in	O
english	O
.	O
we	O
are	O
proud	O
to	O
present	O
the	O
new	O
mercodia	O
total	O
glp	ENTITY
nl	ENTITY
elisa	ENTITY
the	ENTITY
first	ENTITY
assay	ENTITY
in	ENTITY
our	ENTITY
new	ENTITY
chemiluminescent	ENTITY
product	ENTITY
line	ENTITY
northern	ENTITY
lights	ENTITY
.	O
the	O
total	O
glp	ENTITY
elisa	ENTITY
requires	ENTITY
only	ENTITY
of	ENTITY
human	ENTITY
plasma	ENTITY
and	O
the	O
dynamic	O
range	O
is	O
pmol	O
with	O
excellent	O
precision	O
throughout	O
the	O
measurement	O
range	O
allowing	O
you	O
to	O
measure	O
all	O
samples	O
from	O
fasting	O
to	O
elevated	O
bariatric	ENTITY
surgery	ENTITY
samples	O
without	O
dilution	O
steps	O
.	O
the	O
assay	O
is	O
also	O
very	O
sensitive	O
with	O
an	O
lloq	O
of	O
pmol	O
.	O
original	O
video	O
by	O
eli	O
lilly	O
.	O
trulicity	ENTITY
dulaglutide	ENTITY
is	ENTITY
glucagon	ENTITY
like	ENTITY
peptide	ENTITY
glp	ENTITY
receptor	ENTITY
agonist	ENTITY
indicated	O
as	O
an	O
adjunct	O
to	O
diet	O
and	O
exercise	O
to	O
improve	O
glycemic	ENTITY
control	ENTITY
in	O
adults	O
with	O
type	O
diabetes	ENTITY
mellitus	ENTITY
.	O
trulicity	ENTITY
contains	ENTITY
dulaglutide	ENTITY
which	ENTITY
is	ENTITY
human	ENTITY
glp	ENTITY
receptor	ENTITY
agonist	ENTITY
with	O
amino	ENTITY
acid	ENTITY
sequence	ENTITY
homology	ENTITY
to	O
endogenous	O
human	O
glp	ENTITY
.	O
dulaglutide	ENTITY
activates	ENTITY
the	ENTITY
glp	ENTITY
receptor	ENTITY
membrane	ENTITY
bound	ENTITY
cell	ENTITY
surface	ENTITY
receptor	ENTITY
coupled	O
to	O
adenylyl	ENTITY
cyclase	ENTITY
in	O
pancreatic	ENTITY
beta	ENTITY
cells	ENTITY
.	O
dulaglutide	ENTITY
increases	ENTITY
intracellular	ENTITY
cyclic	ENTITY
amp	ENTITY
camp	O
in	O
beta	ENTITY
cells	ENTITY
leading	O
to	O
glucose	ENTITY
dependent	ENTITY
insulin	ENTITY
release	O
.	O
dulaglutide	ENTITY
also	ENTITY
decreases	ENTITY
glucagon	ENTITY
secretion	ENTITY
and	O
slows	ENTITY
gastric	ENTITY
emptying	ENTITY
.	O
researchers	O
at	O
the	O
university	O
of	O
cincinnati	O
have	O
discovered	O
shot	O
of	O
medication	O
used	O
with	O
weight	ENTITY
loss	ENTITY
surgery	ENTITY
could	O
make	O
big	O
difference	O
in	O
the	O
results	O
.	O
local	O
liz	O
bonis	O
shares	O
the	O
details	O
in	O
today	O
medical	O
edge	O
.	O
many	O
people	O
struggling	O
with	O
weight	O
loss	O
turn	O
to	O
surgery	O
similar	O
to	O
the	O
one	O
doctors	O
are	O
performing	O
here	O
.	O
it	O
called	O
gastric	ENTITY
banding	ENTITY
.	O
band	O
is	O
placed	O
around	O
the	O
gut	ENTITY
to	ENTITY
shrink	ENTITY
the	ENTITY
size	ENTITY
of	ENTITY
the	ENTITY
stomach	ENTITY
.	O
governor	O
chris	O
christie	O
of	O
new	O
jersey	O
just	O
had	O
this	O
type	O
of	O
surgery	O
.	O
he	O
said	O
it	O
was	O
to	O
avoid	O
gastric	ENTITY
bypass	ENTITY
major	ENTITY
surgery	ENTITY
which	O
re	O
routes	O
the	O
intestines	ENTITY
.	O
the	O
down	O
side	O
.	O
the	O
gastric	ENTITY
band	ENTITY
is	O
less	O
effective	O
than	O
the	O
roux	O
en	O
gastric	ENTITY
bypass	ENTITY
.	O
or	O
at	O
least	O
is	O
was	O
until	O
now	O
.	O
kirk	O
habegger	O
is	O
an	O
obesity	ENTITY
researcher	ENTITY
who	ENTITY
had	ENTITY
theory	ENTITY
about	ENTITY
why	ENTITY
this	ENTITY
was	ENTITY
true	ENTITY
.	O
so	O
every	O
theory	O
starts	O
with	O
hypothesis	O
what	O
started	O
yours	O
.	O
one	O
of	O
the	O
key	O
hormones	ENTITY
that	ENTITY
is	ENTITY
changed	ENTITY
during	ENTITY
the	ENTITY
bypass	ENTITY
surgery	ENTITY
the	O
more	O
invasive	O
version	O
is	O
one	O
that	O
is	O
hormone	ENTITY
called	ENTITY
glucagon	ENTITY
like	ENTITY
peptide	ENTITY
one	O
and	O
it	O
actually	O
been	O
utilized	O
as	O
therapeutic	ENTITY
most	ENTITY
people	ENTITY
know	ENTITY
it	ENTITY
as	ENTITY
byetta	ENTITY
.	O
that	O
right	O
.	O
he	O
recently	O
found	O
that	O
this	O
hormone	ENTITY
known	ENTITY
as	ENTITY
glp	ENTITY
one	ENTITY
in	ENTITY
the	ENTITY
injectible	ENTITY
drug	ENTITY
for	ENTITY
diabetes	ENTITY
known	ENTITY
as	ENTITY
byetta	ENTITY
can	ENTITY
even	ENTITY
out	ENTITY
the	ENTITY
results	ENTITY
of	ENTITY
these	ENTITY
two	ENTITY
surgeries	ENTITY
.	O
in	O
lab	O
studies	O
he	O
found	O
glp	ENTITY
one	ENTITY
with	ENTITY
gastric	ENTITY
banding	ENTITY
enhances	O
weight	O
loss	O
.	O
the	O
hormone	ENTITY
appears	ENTITY
to	ENTITY
help	ENTITY
alter	ENTITY
appetite	ENTITY
.	O
so	O
it	O
sounds	O
like	O
in	O
the	O
end	O
what	O
you	O
ve	O
developed	O
is	O
still	O
the	O
result	O
of	O
eating	O
less	O
food	O
.	O
it	O
definitely	O
suppresses	O
the	O
drive	O
to	O
eat	O
.	O
the	O
goal	O
now	O
is	O
see	O
if	O
further	O
studies	O
show	O
those	O
who	O
have	O
this	O
surgery	O
can	O
lose	O
more	O
weight	O
with	O
two	O
therapies	O
instead	O
of	O
one	O
.	O
by	O
combining	O
the	O
fda	O
approved	O
drug	O
that	O
we	O
already	O
have	O
with	O
the	O
procedure	O
that	O
we	O
already	O
use	O
hopefully	O
we	O
can	O
have	O
combination	ENTITY
therapy	ENTITY
that	O
is	O
just	O
as	O
effective	O
and	O
less	O
invasive	O
.	O
byetta	ENTITY
does	ENTITY
have	ENTITY
side	ENTITY
effects	ENTITY
so	ENTITY
right	ENTITY
now	ENTITY
further	ENTITY
studies	ENTITY
do	ENTITY
need	ENTITY
to	ENTITY
be	ENTITY
conducted	ENTITY
to	ENTITY
see	ENTITY
what	ENTITY
happens	ENTITY
when	ENTITY
this	ENTITY
medication	ENTITY
is	ENTITY
used	ENTITY
for	ENTITY
long	ENTITY
period	ENTITY
of	ENTITY
time	ENTITY
with	ENTITY
this	ENTITY
weight	ENTITY
loss	ENTITY
surgery	ENTITY
not	O
just	O
in	O
lab	O
studies	O
but	O
in	O
people	O
too	O
.	O
continue	O
watching	O
.	O
incretin	ENTITY
based	ENTITY
therapies	ENTITY
glp	ENTITY
receptor	ENTITY
agonists	O
and	O
dpp	ENTITY
inhibitors	ENTITY
have	O
number	O
of	O
benefits	O
compared	O
with	O
conventional	ENTITY
therapies	ENTITY
for	O
type	O
diabetes	ENTITY
mellitus	ENTITY
dm	ENTITY
.	O
several	O
new	O
agents	O
from	O
this	O
drug	O
class	O
have	O
been	O
approved	O
in	O
the	O
past	O
few	O
years	O
and	O
are	O
now	O
in	O
clinical	O
practice	O
.	O
in	O
this	O
webcast	O
jaime	O
davidson	O
md	O
presents	O
an	O
overview	O
of	O
recent	O
developments	O
with	O
the	O
use	O
of	O
incretin	ENTITY
based	ENTITY
therapies	ENTITY
for	O
the	O
treatment	O
of	O
dm	ENTITY
.	O
earn	O
cme	O
ce	O
credit	O
here	O
cfm	O
jn	O
sthash	O
.	O
xengqzp	O
dpuf	O
.	O
dulaglutide	ENTITY
trulicity	ENTITY
is	ENTITY
new	ENTITY
once	ENTITY
weekly	ENTITY
glp	ENTITY
analogue	ENTITY
used	ENTITY
for	ENTITY
treatment	ENTITY
of	ENTITY
patients	ENTITY
with	ENTITY
type	ENTITY
diabetes	ENTITY
mellitus	ENTITY
.	O
this	O
video	O
explains	O
how	O
to	O
use	O
the	O
device	O
to	O
inject	O
dulaglutide	ENTITY
.	O
presentation	O
given	O
by	O
prof	O
rayaz	O
malik	O
at	O
weill	O
cornell	O
medicine	O
in	O
qatar	O
.	O
credits	O
to	O
the	O
video	O
editor	O
adrian	O
bernardo	O
its	O
av	O
specialist	O
wcm	O
.	O
in	O
this	O
video	O
discuss	O
what	O
is	O
glucose	ENTITY
the	ENTITY
main	ENTITY
functions	ENTITY
of	ENTITY
glucose	ENTITY
in	ENTITY
the	ENTITY
body	ENTITY
.	O
transcript	O
what	O
is	O
glucose	ENTITY
.	O
well	O
glucose	ENTITY
is	ENTITY
molecule	ENTITY
and	ENTITY
it	ENTITY
is	ENTITY
known	ENTITY
as	ENTITY
monosaccharide	ENTITY
which	ENTITY
is	ENTITY
the	ENTITY
most	ENTITY
basic	ENTITY
unit	ENTITY
of	ENTITY
carbohydrate	ENTITY
.	O
it	O
is	O
the	O
key	O
source	O
of	O
energy	O
for	O
all	O
cells	O
and	O
organs	ENTITY
in	ENTITY
our	ENTITY
bodies	ENTITY
.	O
foods	O
high	O
in	O
glucose	ENTITY
include	ENTITY
fruits	ENTITY
veggies	ENTITY
and	ENTITY
grains	ENTITY
.	O
desserts	O
and	O
candy	O
contain	O
lot	O
of	O
glucose	ENTITY
as	ENTITY
well	ENTITY
.	O
many	O
sweets	O
have	O
lot	O
of	O
added	O
sugar	O
in	O
them	O
and	O
sugar	O
is	O
made	O
up	O
of	O
glucose	ENTITY
and	ENTITY
fructose	ENTITY
.	O
as	O
mentioned	O
before	O
glucose	ENTITY
is	ENTITY
major	ENTITY
source	ENTITY
of	ENTITY
energy	ENTITY
in	ENTITY
our	ENTITY
bodies	ENTITY
.	O
glucose	ENTITY
is	ENTITY
absorbed	ENTITY
into	ENTITY
the	ENTITY
bloodstream	ENTITY
rather	ENTITY
quickly	ENTITY
so	ENTITY
it	ENTITY
can	ENTITY
provide	ENTITY
quick	ENTITY
energy	ENTITY
to	ENTITY
cells	ENTITY
.	O
extra	O
glucose	ENTITY
can	ENTITY
get	ENTITY
stored	ENTITY
as	ENTITY
glycogen	ENTITY
in	ENTITY
the	ENTITY
liver	ENTITY
or	ENTITY
muscles	ENTITY
providing	ENTITY
an	ENTITY
energy	ENTITY
reserve	ENTITY
.	O
as	O
with	O
most	O
substances	O
in	O
the	O
body	O
too	O
much	O
glucose	ENTITY
can	ENTITY
cause	ENTITY
problems	ENTITY
.	O
over	O
consuming	O
any	O
type	O
of	O
food	O
including	O
foods	O
with	O
high	ENTITY
glucose	ENTITY
content	ENTITY
can	O
lead	O
to	O
obesity	ENTITY
which	ENTITY
in	ENTITY
turn	ENTITY
can	ENTITY
lead	ENTITY
to	ENTITY
an	ENTITY
increased	ENTITY
risk	ENTITY
of	ENTITY
many	ENTITY
diseases	ENTITY
such	ENTITY
as	ENTITY
diabetes	ENTITY
cardiovascular	ENTITY
disease	ENTITY
high	ENTITY
blood	ENTITY
pressure	ENTITY
and	O
even	O
respiratory	O
problems	O
.	O
molecular	O
structure	O
of	O
glucose	ENTITY
.	O
monosaccharide	ENTITY
structure	ENTITY
.	O
linear	O
and	O
ring	O
forms	O
.	O
watch	O
the	O
next	O
lesson	O
add	O
user	O
khanacademy	O
.	O
milwaukee	O
school	O
of	O
engineering	O
center	O
for	O
biomolecular	O
modeling	O
discusses	O
the	O
role	O
of	O
the	O
protein	ENTITY
insulin	ENTITY
in	O
the	O
regulation	O
of	O
glucose	ENTITY
in	ENTITY
the	ENTITY
bloodstream	ENTITY
.	O
learn	O
how	O
your	O
fasting	ENTITY
glucose	ENTITY
level	ENTITY
helps	O
to	O
predict	O
longevity	O
and	O
disease	ENTITY
risk	ENTITY
for	O
many	O
conditions	O
.	O
article	O
blood	ENTITY
sugar	ENTITY
shortens	O
life	O
fasting	ENTITY
glucose	ENTITY
level	ENTITY
part	O
.	O
support	O
the	O
deeper	O
cause	O
of	O
slow	O
metabolism	ENTITY
insulin	ENTITY
glucose	ENTITY
support	ENTITY
the	ENTITY
health	ENTITY
wellness	ENTITY
center	ENTITY
pinecrest	ENTITY
office	ENTITY
park	ENTITY
drive	ENTITY
alexandria	ENTITY
va	ENTITY
disclaimer	ENTITY
dr	ENTITY
berg	ENTITY
does	ENTITY
not	ENTITY
diagnose	ENTITY
treat	ENTITY
or	ENTITY
prevent	ENTITY
any	ENTITY
medical	ENTITY
conditions	ENTITY
instead	ENTITY
he	ENTITY
helps	ENTITY
people	ENTITY
create	ENTITY
their	ENTITY
health	ENTITY
to	ENTITY
avoid	ENTITY
health	ENTITY
problems	ENTITY
.	O
he	O
works	O
with	O
their	O
physicians	O
which	O
regular	O
their	O
medication	O
.	O
this	O
video	O
is	O
not	O
designed	O
to	O
and	O
does	O
not	O
provide	O
medical	O
advice	O
professional	O
diagnosis	O
opinion	O
treatment	O
or	O
services	O
to	O
you	O
or	O
to	O
any	O
other	O
individual	O
.	O
through	O
my	O
videos	O
blog	O
posts	O
website	O
information	O
give	O
suggestions	O
for	O
you	O
and	O
your	O
doctor	O
to	O
research	O
and	O
provide	O
general	O
information	O
for	O
educational	O
purposes	O
only	O
.	O
the	O
information	O
provided	O
in	O
this	O
video	O
or	O
site	O
or	O
through	O
linkages	O
to	O
other	O
sites	O
is	O
not	O
substitute	O
for	O
medical	O
or	O
professional	O
care	O
and	O
you	O
should	O
not	O
use	O
the	O
information	O
in	O
place	O
of	O
visit	O
call	O
consultation	O
or	O
the	O
advice	O
of	O
your	O
physician	O
or	O
other	O
healthcare	O
provider	O
.	O
the	O
health	O
wellness	O
and	O
dr	O
eric	O
berg	O
are	O
not	O
liable	O
or	O
responsible	O
for	O
any	O
advice	O
course	O
of	O
treatment	O
diagnosis	O
or	O
any	O
other	O
information	O
services	O
or	O
product	O
you	O
obtain	O
through	O
this	O
video	O
or	O
site	O
.	O
what	O
is	O
glucose	ENTITY
and	ENTITY
why	ENTITY
is	ENTITY
it	ENTITY
important	ENTITY
.	O
there	O
is	O
so	O
much	O
confusion	O
out	O
there	O
about	O
the	O
difference	O
between	O
glucose	ENTITY
and	ENTITY
fructose	ENTITY
and	ENTITY
how	ENTITY
they	ENTITY
affect	ENTITY
your	ENTITY
body	ENTITY
.	O
in	O
this	O
week	O
house	O
call	O
video	O
we	O
are	O
going	O
to	O
clear	O
up	O
the	O
confusion	O
once	O
and	O
for	O
all	O
.	O
continuous	ENTITY
glucose	ENTITY
monitoring	ENTITY
cgm	ENTITY
is	ENTITY
small	ENTITY
wearable	ENTITY
device	ENTITY
that	ENTITY
tracks	ENTITY
your	ENTITY
glucose	ENTITY
throughout	ENTITY
the	ENTITY
day	ENTITY
and	ENTITY
night	ENTITY
notifying	ENTITY
you	ENTITY
of	ENTITY
highs	ENTITY
and	ENTITY
lows	ENTITY
so	ENTITY
you	ENTITY
can	ENTITY
take	ENTITY
action	ENTITY
.	O
whether	O
you	O
have	O
type	O
or	O
type	O
diabetes	ENTITY
cgm	ENTITY
can	ENTITY
help	ENTITY
you	ENTITY
make	ENTITY
more	ENTITY
informed	ENTITY
treatment	ENTITY
decisions	ENTITY
and	ENTITY
can	ENTITY
lead	ENTITY
to	ENTITY
better	ENTITY
glycemic	ENTITY
control	ENTITY
.	O
so	O
how	O
does	O
this	O
technology	O
work	O
.	O
cgm	O
system	O
consists	O
of	O
three	O
parts	O
glucose	ENTITY
sensor	ENTITY
transmitter	O
and	O
small	O
receiver	O
that	O
displays	O
real	O
time	O
glucose	ENTITY
information	ENTITY
.	O
lbl	O
.	O
in	O
this	O
video	O
is	O
about	O
how	O
to	O
make	O
liquid	ENTITY
glucose	ENTITY
recipe	O
in	O
home	O
.	O
watch	O
this	O
video	O
carefully	O
and	O
make	O
this	O
at	O
your	O
home	O
and	O
comment	O
your	O
word	O
on	O
my	O
youtube	O
channel	O
thank	O
you	O
for	O
watching	O
my	O
video	O
how	O
to	O
make	O
liquid	ENTITY
glucose	ENTITY
in	O
hindi	O
.	O
ingredients	O
one	O
cup	O
of	O
sugar	O
one	O
third	O
cup	O
of	O
water	O
lemon	O
juice	O
one	O
and	O
half	O
tespoon	O
one	O
pinch	O
salt	O
connect	O
another	O
social	O
media	O
subscribe	O
thank	O
you	O
for	O
watching	O
my	O
video	O
please	O
share	O
like	O
comment	O
and	O
subscribe	O
my	O
youtube	O
video	O
press	O
bell	O
button	O
for	O
get	O
notification	O
of	O
new	O
video	O
.	O
the	O
glucose	ENTITY
test	ENTITY
is	O
standard	O
test	O
during	O
pregnancy	O
.	O
gestational	ENTITY
diabetes	ENTITY
is	O
common	O
enough	O
during	O
pregnancy	O
to	O
warrant	O
test	O
amongst	O
all	O
pregnant	O
women	O
.	O
watch	O
as	O
dr	O
werbin	O
silver	O
explains	O
the	O
process	O
as	O
well	O
as	O
the	O
risks	O
of	O
gestational	ENTITY
diabetes	ENTITY
during	O
pregnancy	O
.	O
structure	O
of	O
glucose	ENTITY
laid	ENTITY
out	ENTITY
in	ENTITY
an	ENTITY
easy	ENTITY
to	ENTITY
remember	ENTITY
fashion	ENTITY
.	O
have	O
high	ENTITY
glucose	ENTITY
levels	ENTITY
.	O
visit	O
here	O
.	O
glucose	ENTITY
vs	ENTITY
glucose	ENTITY
vs	ENTITY
linear	ENTITY
glucose	ENTITY
.	O
we	O
start	O
discovering	O
carbohydrates	ENTITY
by	ENTITY
examining	ENTITY
glucose	ENTITY
and	ENTITY
its	ENTITY
many	ENTITY
important	ENTITY
functions	ENTITY
in	ENTITY
our	ENTITY
body	ENTITY
nutrition	ENTITY
steps	ENTITY
.	O
tune	O
sugar	O
sugar	O
honey	O
honey	O
by	O
archies	O
.	O
scientific	O
lyrics	O
by	O
greg	O
crowther	O
and	O
music	O
from	O
www	O
science	O
groove	O
org	O
.	O
the	O
basics	O
of	O
type	O
and	O
type	ENTITY
ii	ENTITY
diabetes	ENTITY
more	O
free	O
lessons	O
at	O
rpljsy	O
jle	O
.	O
hii	O
everyone	O
if	O
like	O
my	O
recipe	O
plzzzzz	O
like	O
subscribe	O
to	O
my	O
channel	O
.	O
like	O
share	O
subscribe	O
thanks	O
for	O
watching	O
my	O
video	O
.	O
created	O
this	O
video	O
with	O
the	O
youtube	O
video	O
editor	O
.	O
from	O
the	O
documentary	O
that	O
sugar	O
movie	O
.	O
all	O
ask	O
is	O
that	O
you	O
please	O
give	O
this	O
video	O
thumbs	O
up	O
and	O
leave	O
comment	O
if	O
you	O
wish	O
with	O
regards	O
to	O
the	O
temps	O
please	O
reverse	O
what	O
said	O
as	O
mixed	O
up	O
the	O
fahrenheit	O
and	O
celsius	O
.	O
please	O
subscribe	O
to	O
my	O
home	O
handy	O
hints	O
channel	O
for	O
three	O
new	O
videos	O
every	O
week	O
.	O
wish	O
all	O
success	O
enjoy	O
.	O
see	O
the	O
written	O
guide	O
alongside	O
the	O
video	O
here	O
.	O
checking	O
blood	ENTITY
sugar	ENTITY
glucose	ENTITY
using	ENTITY
glucometer	ENTITY
device	ENTITY
glucose	ENTITY
meter	ENTITY
.	O
learn	O
how	O
to	O
use	O
true	O
result	O
blood	ENTITY
glucose	ENTITY
meter	O
by	O
taking	O
your	O
blood	ENTITY
glucose	ENTITY
.	O
as	O
new	O
diabetic	ENTITY
or	ENTITY
nursing	ENTITY
student	ENTITY
you	ENTITY
must	ENTITY
learn	ENTITY
the	ENTITY
skill	ENTITY
of	ENTITY
using	ENTITY
lancet	ENTITY
to	ENTITY
obtain	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
this	O
video	O
will	O
show	O
you	O
how	O
to	O
do	O
this	O
.	O
you	O
will	O
learn	O
how	O
to	O
prime	O
or	O
load	O
lancet	O
device	O
how	O
to	O
choose	O
the	O
correct	O
lancet	O
gauge	O
how	O
to	O
set	O
the	O
proper	O
setting	O
on	O
lancet	O
when	O
glucometer	ENTITY
test	ENTITY
strips	ENTITY
and	ENTITY
quality	ENTITY
control	ENTITY
solution	ENTITY
expire	ENTITY
and	ENTITY
how	ENTITY
to	ENTITY
obtain	ENTITY
blood	ENTITY
sugar	ENTITY
with	O
the	O
fingertips	O
.	O
subscribe	O
list	O
plqrdx	O
rrskfuydl	O
tzq	O
tc	ENTITY
hllxlhnxq	ENTITY
.	O
thanks	O
for	O
watching	O
.	O
visit	O
begin	O
in	O
september	O
.	O
don	O
forget	O
to	O
like	O
and	O
share	O
.	O
take	O
dr	O
berg	O
free	O
keto	O
mini	O
course	O
disclaimerdrberg	O
does	O
not	O
diagnose	O
treat	O
or	O
prevent	O
any	O
medical	O
conditions	O
instead	O
he	O
helps	O
people	O
create	O
their	O
health	O
to	O
avoid	O
health	O
problems	O
.	O
he	O
also	O
works	O
with	O
their	O
physicians	O
who	O
then	O
monitor	O
their	O
medications	O
.	O
dr	O
berg	O
is	O
not	O
involved	O
in	O
advising	O
alteration	O
in	O
medications	O
.	O
this	O
video	O
is	O
not	O
designed	O
to	O
and	O
does	O
not	O
provide	O
medical	O
advice	O
professional	O
diagnosis	O
opinion	O
treatment	O
or	O
services	O
to	O
you	O
or	O
to	O
any	O
other	O
individual	O
.	O
through	O
my	O
videos	O
blog	O
posts	O
website	O
information	O
give	O
suggestions	O
for	O
you	O
and	O
your	O
doctor	O
to	O
research	O
and	O
provide	O
general	O
information	O
for	O
educational	O
purposes	O
only	O
.	O
the	O
information	O
provided	O
in	O
this	O
video	O
or	O
site	O
or	O
through	O
linkages	O
to	O
other	O
sites	O
is	O
not	O
substitute	O
for	O
medical	O
or	O
professional	O
care	O
and	O
you	O
should	O
not	O
use	O
the	O
information	O
in	O
place	O
of	O
visit	O
call	O
consultation	O
or	O
the	O
advice	O
of	O
your	O
physician	O
or	O
other	O
healthcare	O
provider	O
.	O
the	O
health	O
wellness	O
and	O
dr	O
eric	O
berg	O
are	O
not	O
liable	O
or	O
responsible	O
for	O
any	O
advice	O
course	O
of	O
treatment	O
diagnosis	O
or	O
any	O
other	O
information	O
services	O
or	O
product	O
you	O
obtain	O
through	O
this	O
video	O
or	O
site	O
.	O
was	O
sind	O
kohlenhydrate	O
berhaupt	O
.	O
was	O
sind	O
sie	O
aus	O
chemischer	O
sicht	O
.	O
wie	O
ist	O
ihre	O
strukturformel	O
.	O
wie	O
werden	O
sie	O
eingeteilt	O
.	O
was	O
sind	O
ketosen	O
und	O
aldosen	O
.	O
was	O
ist	O
die	O
fischerprojektion	O
.	O
welche	O
sind	O
bekannte	O
einfachzucker	O
.	O
wie	O
sehen	O
glucose	ENTITY
und	ENTITY
fructose	ENTITY
aus	ENTITY
.	O
kategorie	O
abitur	O
hier	O
kommst	O
du	O
direkt	O
zum	O
chsten	O
video	O
cc	O
by	O
.	O
donate	O
here	O
aklectures	O
com	O
.	O
recipe	O
for	O
homemade	O
sugar	O
glucose	O
syrup	O
watch	O
it	O
to	O
learn	O
how	O
to	O
make	O
at	O
home	O
from	O
scratch	O
with	O
tips	O
and	O
tricks	O
and	O
know	O
the	O
difference	O
between	O
glucose	ENTITY
syrup	ENTITY
sugar	ENTITY
syrup	ENTITY
and	ENTITY
corn	ENTITY
syrup	ENTITY
.	O
discover	O
these	O
six	O
low	O
sugar	O
super	O
foods	O
are	O
considered	O
the	O
best	O
of	O
the	O
best	O
in	O
preventing	O
and	O
managing	O
diabetes	ENTITY
.	O
in	O
deze	O
film	O
gaat	O
thimo	O
jansen	O
biologiedocent	O
vwo	O
op	O
de	O
werkplaats	O
te	ENTITY
bilthoven	ENTITY
uitgebreid	ENTITY
in	ENTITY
op	ENTITY
de	ENTITY
dissimilatie	ENTITY
van	ENTITY
glucose	ENTITY
.	O
vwo	O
niveau	O
.	O
aan	O
bod	ENTITY
komen	ENTITY
de	ENTITY
glycolyse	ENTITY
de	ENTITY
decarboxylering	ENTITY
de	ENTITY
citroenzuurcyclus	ENTITY
en	ENTITY
de	ENTITY
oxydatieve	ENTITY
fosforylering	ENTITY
electronentransportketen	ENTITY
.	O
na	O
het	O
kijken	O
van	O
deze	O
video	O
zou	O
je	O
moeten	O
kunnen	O
verklaren	O
hoe	O
de	O
dissimilatie	O
van	O
glucose	ENTITY
tussen	ENTITY
de	ENTITY
en	ENTITY
atp	ENTITY
oplevert	ENTITY
.	O
link	O
naar	O
gebruikte	O
prezi	O
auth	O
key	O
adc	O
fbaae	O
ff	O
.	O
my	O
sponge	O
cakes	O
are	O
fluffy	O
moist	O
and	O
fragrant	O
because	O
use	O
liquid	ENTITY
glucose	ENTITY
.	O
here	O
are	O
my	O
recipes	O
sponge	O
cupcakes	O
html	O
.	O
video	O
lesson	O
on	O
glucose	ENTITY
transporters	ENTITY
the	O
different	O
types	O
of	O
glucose	ENTITY
transporters	ENTITY
such	O
as	O
gluts	O
and	O
sodium	ENTITY
dependent	ENTITY
glucose	ENTITY
transporters	ENTITY
sglts	O
where	O
they	O
are	O
found	O
in	O
the	O
body	O
and	O
their	O
relevance	O
in	O
whole	O
body	O
metabolism	ENTITY
.	O
hey	O
guys	O
.	O
here	O
is	O
lesson	O
on	O
glucose	ENTITY
transporters	ENTITY
and	O
physiology	O
and	O
location	O
of	O
glucose	ENTITY
transporters	ENTITY
.	O
hope	O
you	O
all	O
find	O
it	O
helpful	O
.	O
jj	O
for	O
books	O
and	O
other	O
supplemental	O
information	O
on	O
these	O
topics	O
please	O
check	O
out	O
my	O
amazon	O
affiliate	O
page	O
.	O
hospitals	O
can	O
license	O
this	O
animation	O
for	O
patient	O
education	O
and	O
content	O
marketing	O
initiatives	O
.	O
learn	O
more	O
utm	O
source	O
youtube	O
utm	O
medium	O
video	O
description	O
utm	O
campaign	O
bloodglucose	ENTITY
this	ENTITY
medical	ENTITY
animation	ENTITY
shows	ENTITY
how	ENTITY
to	ENTITY
check	ENTITY
blood	ENTITY
glucose	ENTITY
sugar	ENTITY
levels	ENTITY
using	O
glucose	ENTITY
meter	ENTITY
.	O
nucleus	O
medical	O
media	O
creates	O
medical	O
and	O
scientific	O
visual	O
content	O
for	O
the	O
healthcare	O
pharma	O
and	O
medical	O
device	O
industries	O
.	O
our	O
products	O
include	O
animations	O
illustrations	O
and	O
interactive	O
content	O
intended	O
to	O
educate	O
patients	O
and	O
raise	O
health	O
literacy	O
.	O
nucleus	O
content	O
can	O
be	O
licensed	O
and	O
used	O
in	O
variety	O
of	O
ways	O
.	O
ask	O
us	O
about	O
custom	O
work	O
.	O
video	O
id	O
and	O
.	O
following	O
on	O
from	O
thermoregulation	ENTITY
we	ENTITY
look	ENTITY
at	ENTITY
how	ENTITY
hormones	ENTITY
control	ENTITY
the	ENTITY
levels	ENTITY
of	ENTITY
glucose	ENTITY
in	O
our	O
blood	ENTITY
.	O
this	O
video	O
relates	O
to	O
aqa	ENTITY
biology	ENTITY
unit	ENTITY
control	ENTITY
in	O
cells	O
and	O
organisms	ENTITY
.	O
oi	O
gente	O
.	O
na	O
dica	O
da	O
jana	O
de	O
vou	O
falar	O
sobre	O
uso	O
da	O
glucose	ENTITY
em	ENTITY
doces	ENTITY
como	ENTITY
brigadeiros	ENTITY
trufas	ENTITY
.	O
se	O
voc	O
sabe	O
porqu	O
usar	O
nem	O
quanto	O
usar	O
em	O
seus	O
doces	O
ent	O
assista	O
dica	O
de	O
hoje	O
aprenda	O
como	O
utilizar	O
conhe	O
os	O
benef	O
cios	O
.	O
se	O
curtirem	O
curtam	O
compartilhem	O
.	O
quadro	O
dicas	O
da	O
jana	O
foi	O
criado	O
para	O
ajudar	O
voc	O
que	O
ama	O
confeitaria	O
quer	O
aprender	O
novas	O
cnicas	O
dicas	O
receitas	O
para	O
melhorar	O
os	O
seus	O
trabalhos	O
com	O
bolos	O
chocolates	O
chantilly	O
recheios	O
coberturas	O
brigadeiros	O
de	O
mel	O
muitas	O
outras	O
gostosuras	O
da	O
nossa	O
confeitaria	O
.	O
caso	O
voc	O
tenha	O
alguma	O
vida	O
ou	O
queira	O
sugerir	O
uma	O
dica	O
que	O
tenha	O
sido	O
respondida	O
aqui	O
no	O
canal	O
fique	O
vontade	O
para	O
interagir	O
atrav	O
dos	O
coment	O
rios	O
ou	O
atrav	O
das	O
minhas	O
dias	O
sociais	O
.	O
site	O
aqui	O
no	O
meu	O
canal	O
todos	O
os	O
dias	O
tem	O
uma	O
dica	O
nova	O
pra	O
voc	O
.	O
fiquem	O
com	O
deus	O
at	O
amanh	O
.	O
janaina	O
suconic	O
chef	O
tissier	O
jana	O
na	O
suconic	O
chef	O
tissier	O
formada	O
no	O
curso	O
de	O
gest	O
em	O
gastronomia	O
com	O
especializa	O
em	O
gastronomia	O
funcional	O
confeitaria	O
internacional	O
pelo	O
instituto	O
mausi	O
sebess	O
de	O
buenos	O
aires	O
argentina	O
.	O
fez	O
curso	O
de	O
cozinha	O
no	O
le	O
cordon	O
bleu	O
em	O
paris	O
fran	O
.	O
em	O
representou	O
brilhantemente	O
brasil	O
no	O
primeiro	O
mundial	O
feminino	O
de	O
confeitaria	O
em	O
rimini	O
na	O
it	O
lia	O
.	O
atualmente	O
professora	O
universit	O
ria	O
no	O
curso	O
de	O
gastronomia	O
na	O
universidade	O
paulista	O
unip	O
al	O
de	O
ministrar	O
cursos	O
livres	O
na	O
rea	O
de	O
confeitaria	O
dentro	O
fora	O
do	O
pa	O
.	O
tem	O
quatro	O
livros	O
publicados	O
na	O
rea	O
de	O
confeitaria	O
rias	O
publica	O
es	O
em	O
revistas	O
especializadas	O
na	O
rea	O
.	O
participa	O
regularmente	O
de	O
programas	O
de	O
televis	O
.	O
desde	O
mar	O
de	O
coordena	O
junto	O
com	O
equipe	O
da	O
empresa	O
scrap	O
brasil	O
aplica	O
do	O
todo	O
wilton	O
ficando	O
respons	O
vel	O
por	O
semin	O
rios	O
para	O
forma	O
de	O
professores	O
em	O
todo	O
pa	O
.	O
me	O
at	O
home	O
testing	O
my	O
meters	O
.	O
journey	O
through	O
the	O
dream	O
of	O
video	O
game	O
character	O
who	O
has	O
been	O
.	O
during	O
match	O
.	O
oh	O
wow	O
.	O
jeronbraxton	O
jeronbraxton	O
com	O
.	O
gtt	O
is	O
blood	ENTITY
test	ENTITY
that	O
is	O
used	O
to	O
diagnose	O
gestational	ENTITY
diabetes	ENTITY
and	O
type	O
diabetes	ENTITY
.	O
watch	O
as	O
dr	O
ankush	O
describes	O
about	O
this	O
test	O
how	O
it	O
done	O
how	O
much	O
fasting	O
needs	O
to	O
be	O
done	O
and	O
what	O
should	O
we	O
expect	O
from	O
the	O
results	O
.	O
glucode	ENTITY
tolerance	ENTITY
test	ENTITY
prices	O
in	O
india	O
.	O
watch	O
step	O
by	O
step	O
guide	O
on	O
how	O
to	O
test	O
your	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
.	O
in	O
order	O
to	O
perform	O
blood	ENTITY
glucose	ENTITY
test	ENTITY
you	O
will	O
require	O
your	O
blood	ENTITY
glucose	ENTITY
meter	ENTITY
test	ENTITY
strip	ENTITY
to	O
hand	O
lancing	O
device	O
and	O
monitoring	O
diary	O
to	O
record	O
the	O
results	ENTITY
of	ENTITY
your	ENTITY
blood	ENTITY
glucose	ENTITY
test	ENTITY
.	O
diabetes	ENTITY
co	ENTITY
uk	ENTITY
benedict	ENTITY
jephcote	ENTITY
runs	ENTITY
through	ENTITY
how	ENTITY
to	ENTITY
test	ENTITY
your	ENTITY
blood	ENTITY
sugar	ENTITY
.	O
in	O
this	O
video	O
benedict	O
is	O
using	O
onetouch	O
meter	O
and	O
test	O
strips	O
.	O
how	O
to	O
test	O
blood	ENTITY
glucose	ENTITY
sugar	O
converter	O
html	O
.	O
glucose	ENTITY
intolerance	ENTITY
is	O
an	O
umbrella	O
term	O
for	O
metabolic	ENTITY
conditions	ENTITY
which	O
result	O
in	O
higher	O
than	O
normal	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
hyperglycemia	ENTITY
.	O
read	O
more	O
at	O
intolerance	ENTITY
html	ENTITY
.	O
cartoonmd	O
com	O
video	O
for	O
patients	O
or	O
clinicians	O
giving	O
an	O
overview	O
of	O
borderlin	O
diabetes	ENTITY
or	ENTITY
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
and	O
how	O
it	O
treated	O
.	O
website	O
blogspot	O
com	O
australian	O
community	O
pharmacist	O
pete	O
lwin	O
from	O
blood	O
sugar	O
magic	O
www	O
bloodsugarmagic	O
com	O
au	O
website	O
demonstrated	O
the	O
true	O
result	O
blood	ENTITY
glucose	ENTITY
meter	ENTITY
and	O
the	O
true	O
draw	O
lancet	O
device	O
.	O
this	O
presentation	O
is	O
part	O
of	O
series	O
on	O
diabetes	ENTITY
by	ENTITY
blood	ENTITY
sugar	ENTITY
magic	O
.	O
if	O
you	O
like	O
to	O
see	O
more	O
information	O
subscribe	O
to	O
this	O
channel	O
or	O
go	O
to	O
our	O
website	O
www	O
bloodsugarmagic	O
com	O
au	O
please	O
note	O
if	O
you	O
have	O
any	O
questions	O
about	O
your	O
personal	O
diabetes	ENTITY
queries	ENTITY
please	ENTITY
ask	ENTITY
your	ENTITY
doctor	ENTITY
or	ENTITY
pharmacist	ENTITY
.	O
this	O
series	O
of	O
videos	O
is	O
private	O
independent	O
production	O
.	O
we	O
do	O
not	O
receive	O
sponsorship	O
or	O
payment	O
from	O
any	O
companies	O
for	O
our	O
reviews	O
or	O
views	O
.	O
the	O
information	O
and	O
opinions	O
expressed	O
here	O
are	O
based	O
on	O
culmination	O
of	O
professional	O
experience	O
clinical	O
data	O
and	O
professional	O
resources	O
as	O
noted	O
.	O
if	O
you	O
have	O
any	O
queries	O
about	O
the	O
show	O
please	O
contact	O
bloodsugarmagictv	O
gmail	O
com	O
click	O
hd	O
for	O
better	O
quality	O
video	O
music	O
kevin	O
macleod	O
producer	O
sofia	O
carvajal	O
and	O
peter	O
lwin	O
copyright	O
.	O
optimal	O
ranges	O
glucose	ENTITY
mmol	ENTITY
ketones	ENTITY
mmol	ENTITY
.	O
watch	O
me	O
take	O
the	O
glucose	ENTITY
test	ENTITY
mailing	O
address	O
hancock	O
ave	O
suite	O
murrieta	O
ca	O
.	O
donate	O
here	O
aklectures	O
com	O
.	O
provided	O
to	O
youtube	O
by	O
sony	O
music	O
entertainment	O
glucose	ENTITY
lady	ENTITY
leshurr	ENTITY
mode	ENTITY
ep	ENTITY
sony	ENTITY
music	ENTITY
entertainment	ENTITY
uk	ENTITY
limited	ENTITY
released	ENTITY
on	ENTITY
background	ENTITY
vocal	ENTITY
bass	ENTITY
guitar	ENTITY
brass	ENTITY
drums	ENTITY
keyboards	ENTITY
synthesizer	ENTITY
vocal	ENTITY
composer	ENTITY
lyricist	ENTITY
melesha	ENTITY
garro	ENTITY
programmer	ENTITY
composer	ENTITY
lyricist	ENTITY
mixing	ENTITY
engineer	ENTITY
producer	ENTITY
will	ENTITY
simms	ENTITY
mastering	ENTITY
engineer	ENTITY
kevin	ENTITY
tuffy	ENTITY
auto	ENTITY
generated	ENTITY
by	ENTITY
youtube	ENTITY
.	O
glucose	ENTITY
intolerance	ENTITY
is	O
an	O
umbrella	O
term	O
for	O
metabolic	ENTITY
conditions	ENTITY
which	O
result	O
in	O
higher	ENTITY
than	ENTITY
normal	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
hyperglycemia	ENTITY
.	O
read	O
more	O
at	O
intolerance	ENTITY
html	ENTITY
.	O
cartoonmd	O
com	O
video	O
for	O
patients	O
or	O
clinicians	O
giving	O
an	O
overview	O
of	O
borderlin	O
diabetes	ENTITY
or	ENTITY
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
and	O
how	O
it	O
treated	O
.	O
dr	O
karen	O
elkind	O
hirsch	O
scientific	O
director	O
of	O
research	O
at	O
woman	O
hospital	O
explains	O
the	O
pre	ENTITY
diabetic	ENTITY
condition	O
of	O
glucose	ENTITY
intolerance	ENTITY
and	O
what	O
it	O
means	O
to	O
women	O
.	O
signs	O
you	O
have	O
gluten	ENTITY
intolerance	ENTITY
source	O
ignore	O
tag	O
gluten	O
gluten	O
free	O
gluten	O
free	O
diet	O
what	O
is	O
gluten	ENTITY
gluten	ENTITY
intolerance	ENTITY
gluten	ENTITY
intolerance	ENTITY
symptoms	ENTITY
symptoms	ENTITY
of	ENTITY
gluten	ENTITY
intolerance	ENTITY
gluten	ENTITY
symptoms	ENTITY
health	ENTITY
headache	ENTITY
migraine	ENTITY
weight	ENTITY
loss	ENTITY
joint	ENTITY
pain	ENTITY
.	O
be	O
prepared	O
for	O
your	O
exam	O
by	O
learning	O
about	O
glucose	ENTITY
tolerance	ENTITY
testing	ENTITY
.	O
understand	O
how	O
it	O
used	O
and	O
the	O
regulations	O
of	O
the	O
test	O
.	O
learn	O
more	O
mometrixacademy	ENTITY
glucosetolerancetest	ENTITY
.	O
how	O
to	O
become	O
gluten	O
intolerant	O
funny	O
ultra	O
spiritual	O
life	O
upcoming	O
comedy	O
shows	O
.	O
dates	O
and	O
tickets	O
here	O
.	O
watch	O
full	O
version	O
.	O
glucose	ENTITY
intolerance	ENTITY
is	O
an	O
umbrella	O
term	O
for	O
metabolic	ENTITY
conditions	ENTITY
which	O
result	O
in	O
higher	ENTITY
than	ENTITY
normal	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
hyperglycemia	ENTITY
.	O
western	O
lifestyles	O
have	O
seen	O
glucose	ENTITY
intolerance	ENTITY
become	O
more	O
common	O
year	O
on	O
year	O
.	O
what	O
the	O
difference	O
.	O
the	O
basics	O
of	O
type	O
and	O
type	ENTITY
ii	ENTITY
diabetes	ENTITY
more	O
free	O
lessons	O
at	O
rpljsy	O
jle	O
.	O
click	O
on	O
html	O
to	O
find	O
out	O
how	O
glucose	ENTITY
intolerance	ENTITY
can	O
make	O
you	O
overweight	O
and	O
what	O
you	O
can	O
do	O
about	O
it	O
.	O
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
is	O
pre	ENTITY
diabetic	ENTITY
state	O
of	O
hyperglycemia	O
that	O
is	O
associated	O
with	O
insulin	ENTITY
resistance	ENTITY
and	O
increased	O
risk	O
of	O
cardiovascular	ENTITY
pathology	ENTITY
.	O
igt	O
may	O
precede	O
type	O
diabetes	ENTITY
mellitus	ENTITY
by	O
many	O
years	O
.	O
igt	O
is	O
also	O
risk	O
factor	O
for	O
mortality	O
.	O
this	O
video	O
is	O
targeted	O
to	O
blind	O
users	O
.	O
attribution	O
article	O
text	O
available	O
under	O
cc	O
by	O
sa	O
creative	O
commons	O
image	O
source	O
in	O
video	O
.	O
gtt	O
is	O
blood	ENTITY
test	ENTITY
that	O
is	O
used	O
to	O
diagnose	O
gestational	ENTITY
diabetes	ENTITY
and	O
type	O
diabetes	ENTITY
.	O
watch	O
as	O
dr	O
ankush	O
describes	O
about	O
this	O
test	O
how	O
it	O
done	O
how	O
much	O
fasting	O
needs	O
to	O
be	O
done	O
and	O
what	O
should	O
we	O
expect	O
from	O
the	O
results	O
.	O
glucode	ENTITY
tolerance	ENTITY
test	ENTITY
prices	O
in	O
india	O
.	O
what	O
does	O
glucose	ENTITY
intolerance	ENTITY
mean	O
in	O
english	O
.	O
cinzia	O
cuneo	O
pr	ENTITY
sidente	ENTITY
et	ENTITY
co	ENTITY
fondatrice	ENTITY
de	ENTITY
soscuisine	ENTITY
pr	ENTITY
sente	ENTITY
nos	ENTITY
menus	ENTITY
pour	ENTITY
intol	ENTITY
rance	ENTITY
au	ENTITY
glucose	ENTITY
pr	ENTITY
diab	ENTITY
te	ENTITY
et	ENTITY
explique	ENTITY
pourquoi	ENTITY
ont	ENTITY
dit	ENTITY
qu	ENTITY
ils	ENTITY
sont	ENTITY
intelligents	ENTITY
.	O
if	O
you	O
are	O
interested	O
in	O
more	O
diabetes	ENTITY
management	ENTITY
tips	ENTITY
get	ENTITY
our	ENTITY
guide	ENTITY
here	ENTITY
for	ENTITY
all	ENTITY
intents	ENTITY
and	ENTITY
purposes	ENTITY
yes	ENTITY
prediabetes	ENTITY
is	ENTITY
the	ENTITY
same	ENTITY
as	ENTITY
igt	ENTITY
or	ENTITY
ifg	ENTITY
.	O
they	O
all	O
mean	O
the	O
same	O
thing	O
.	O
at	O
one	O
point	O
it	O
was	O
which	O
test	O
was	O
used	O
as	O
to	O
what	O
the	O
condition	O
was	O
called	O
.	O
what	O
you	O
call	O
something	O
is	O
kind	O
of	O
interesting	O
isn	O
it	O
.	O
did	O
you	O
know	O
it	O
is	O
now	O
politically	O
incorrect	O
to	O
call	O
someone	O
with	O
diabetes	ENTITY
diabetic	ENTITY
.	O
now	O
diabetic	ENTITY
medications	ENTITY
and	ENTITY
diabetic	ENTITY
foods	ENTITY
are	ENTITY
fine	ENTITY
.	O
but	O
many	O
people	O
who	O
have	O
diabetes	ENTITY
actively	ENTITY
resist	ENTITY
being	ENTITY
labeled	ENTITY
as	ENTITY
diabetic	ENTITY
as	ENTITY
if	ENTITY
we	ENTITY
were	ENTITY
an	ENTITY
illness	ENTITY
.	O
correspondent	O
writes	O
what	O
give	O
as	O
an	O
example	O
to	O
doctors	O
and	O
other	O
technical	O
people	O
is	O
if	O
person	O
has	O
hemorrhoids	ENTITY
does	ENTITY
that	ENTITY
make	ENTITY
that	ENTITY
person	ENTITY
one	ENTITY
now	ENTITY
personally	ENTITY
am	ENTITY
not	ENTITY
offended	ENTITY
one	ENTITY
bit	ENTITY
by	ENTITY
the	ENTITY
term	ENTITY
diabetic	ENTITY
if	ENTITY
someone	ENTITY
refers	ENTITY
to	ENTITY
me	ENTITY
as	ENTITY
that	ENTITY
.	O
but	O
have	O
tried	O
to	O
be	O
very	O
careful	O
in	O
my	O
video	O
series	O
to	O
not	O
use	O
that	O
term	O
when	O
describing	O
people	O
because	O
it	O
does	O
offend	O
some	O
people	O
and	O
that	O
just	O
isn	O
something	O
want	O
to	O
do	O
.	O
but	O
terms	O
in	O
the	O
world	O
of	O
diabetes	ENTITY
have	ENTITY
been	ENTITY
developing	ENTITY
and	ENTITY
changing	ENTITY
over	ENTITY
the	ENTITY
years	ENTITY
.	O
here	O
are	O
some	O
examples	O
what	O
used	O
to	O
be	O
called	O
juvenile	ENTITY
diabetes	ENTITY
or	O
insulin	ENTITY
dependent	ENTITY
diabetes	ENTITY
mellitus	ENTITY
iddm	O
is	O
now	O
referred	O
to	O
as	O
type	O
diabetes	ENTITY
.	O
the	O
former	O
terms	O
adult	ENTITY
onset	ENTITY
diabetes	ENTITY
or	O
non	ENTITY
insulin	ENTITY
dependent	ENTITY
diabetes	ENTITY
mellitus	ENTITY
niddm	ENTITY
are	ENTITY
now	ENTITY
called	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
and	O
there	O
is	O
no	O
such	O
thing	O
as	O
borderline	ENTITY
diabetes	ENTITY
.	O
if	O
that	O
what	O
you	O
think	O
you	O
have	O
it	O
is	O
either	O
pre	ENTITY
diabetes	ENTITY
or	O
diabetes	ENTITY
.	O
so	O
what	O
was	O
once	O
called	O
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
or	O
impaired	O
fasting	O
glucose	ENTITY
is	ENTITY
now	ENTITY
pre	ENTITY
diabetes	ENTITY
or	O
prediabetes	ENTITY
.	O
there	O
is	O
even	O
some	O
controversy	O
over	O
there	O
should	O
be	O
hyphen	O
the	O
reason	O
given	O
for	O
this	O
change	O
was	O
to	O
show	O
the	O
seriousness	O
of	O
the	O
condition	O
.	O
the	O
latest	O
have	O
found	O
to	O
be	O
argued	O
in	O
the	O
diabetes	ENTITY
community	ENTITY
is	ENTITY
to	ENTITY
change	ENTITY
the	ENTITY
name	ENTITY
of	ENTITY
prediabetes	ENTITY
to	ENTITY
stage	ENTITY
type	ENTITY
diabetes	ENTITY
.	O
as	O
many	O
of	O
you	O
know	O
many	O
doctors	O
and	O
even	O
insurance	O
companies	O
don	O
recognize	O
prediabetes	ENTITY
as	ENTITY
diabetes	ENTITY
proper	ENTITY
.	O
the	O
movement	O
to	O
change	O
the	O
name	O
to	O
stage	O
type	O
diabetes	ENTITY
is	ENTITY
starting	ENTITY
to	ENTITY
gain	ENTITY
ground	ENTITY
.	O
this	O
is	O
one	O
movement	O
think	O
could	O
support	O
.	O
it	O
gives	O
those	O
with	O
prediabetes	ENTITY
more	ENTITY
concrete	ENTITY
idea	ENTITY
of	ENTITY
what	ENTITY
they	ENTITY
truly	ENTITY
have	ENTITY
.	O
but	O
it	O
also	O
gives	O
sense	O
that	O
just	O
because	O
they	O
have	O
prediabetes	ENTITY
it	ENTITY
will	ENTITY
definitely	ENTITY
become	ENTITY
type	ENTITY
which	ENTITY
isn	ENTITY
true	ENTITY
.	O
names	O
can	O
change	O
total	O
outlook	O
on	O
things	O
.	O
but	O
rather	O
than	O
argue	O
over	O
the	O
name	O
of	O
what	O
you	O
have	O
it	O
is	O
much	O
more	O
important	O
to	O
work	O
on	O
your	O
diet	O
and	O
exercise	O
plan	O
to	O
control	O
that	O
blood	ENTITY
sugar	ENTITY
or	O
blood	ENTITY
glucose	ENTITY
.	O
yes	O
there	O
are	O
people	O
who	O
want	O
to	O
argue	O
that	O
as	O
well	O
.	O
bg	O
or	O
bs	O
.	O
probably	O
little	O
bit	O
of	O
both	O
in	O
those	O
arguments	O
.	O
in	O
this	O
weeks	O
video	O
am	O
sharing	O
information	O
on	O
glucose	ENTITY
intolerance	ENTITY
and	O
diabetes	ENTITY
.	O
also	O
have	O
information	O
on	O
how	O
eating	O
fresh	O
produce	O
can	O
help	O
.	O
find	O
me	O
on	O
facebook	O
at	O
.	O
usmlesecrets	O
com	O
how	O
to	O
pass	O
the	O
united	O
states	O
medical	O
licensing	O
examination	O
usmle	O
step	O
and	O
using	O
our	O
easy	O
step	O
by	O
step	O
usmle	O
study	O
guide	O
without	O
weeks	O
and	O
months	O
of	O
endless	O
studying	O
.	O
sht	O
created	O
using	O
powtoon	O
free	O
sign	O
up	O
at	O
.	O
make	O
your	O
own	O
animated	O
videos	O
and	O
animated	O
presentations	O
for	O
free	O
.	O
powtoon	O
is	O
free	O
tool	O
that	O
allows	O
you	O
to	O
develop	O
cool	O
animated	O
clips	O
and	O
animated	O
presentations	O
for	O
your	O
website	O
office	O
meeting	O
sales	O
pitch	O
nonprofit	O
fundraiser	O
product	O
launch	O
video	O
resume	O
or	O
anything	O
else	O
you	O
could	O
use	O
an	O
animated	O
explainer	O
video	O
.	O
powtoon	O
animation	O
templates	O
help	O
you	O
create	O
animated	O
presentations	O
and	O
animated	O
explainer	O
videos	O
from	O
scratch	O
.	O
anyone	O
can	O
produce	O
awesome	O
animations	O
quickly	O
with	O
powtoon	O
without	O
the	O
cost	O
or	O
hassle	O
other	O
professional	O
animation	O
services	O
require	O
.	O
cinzia	O
cuneo	O
co	O
founder	O
and	O
president	O
of	O
soscuisine	O
presents	O
our	O
meal	O
plans	O
for	O
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
prediabetes	O
and	O
explains	O
why	O
they	O
are	O
smart	O
.	O
here	O
quick	O
vlog	O
of	O
me	O
going	O
to	O
take	O
my	O
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
that	O
took	O
when	O
was	O
weeks	O
and	O
days	O
pregnant	O
with	O
my	O
first	O
pregnancy	O
.	O
do	O
have	O
gestational	ENTITY
diabetes	ENTITY
.	O
keep	O
watching	O
to	O
find	O
out	O
.	O
this	O
video	O
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
expected	O
normal	O
results	O
is	O
part	O
of	O
multimedia	O
based	O
module	O
by	O
francis	O
yeboah	O
knust	O
and	O
cary	O
engleberg	O
university	O
of	O
michigan	O
.	O
this	O
programme	O
is	O
intended	O
as	O
compendium	O
of	O
modules	O
on	O
procedures	ENTITY
in	ENTITY
clinical	ENTITY
chemistry	ENTITY
.	O
at	O
present	O
the	O
only	O
completed	O
module	O
is	O
one	O
concerning	O
the	O
conduct	O
and	O
interpretation	O
of	O
the	O
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
gtt	ENTITY
.	O
in	O
gtt	O
glucose	ENTITY
is	ENTITY
adminstered	ENTITY
to	ENTITY
the	ENTITY
patient	ENTITY
in	ENTITY
order	ENTITY
to	ENTITY
determine	ENTITY
how	ENTITY
quickly	ENTITY
it	ENTITY
is	ENTITY
cleared	ENTITY
from	ENTITY
the	ENTITY
blood	ENTITY
.	O
the	O
test	O
is	O
usually	O
used	O
to	O
test	O
for	O
diabetes	ENTITY
insulin	ENTITY
resistance	ENTITY
and	O
sometimes	O
reactive	ENTITY
hypoglycemia	ENTITY
.	O
the	O
glucose	ENTITY
is	ENTITY
most	ENTITY
often	ENTITY
given	ENTITY
orally	ENTITY
so	ENTITY
the	ENTITY
common	ENTITY
test	ENTITY
is	ENTITY
technically	ENTITY
an	ENTITY
oral	ENTITY
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
ogtt	ENTITY
.	O
this	O
video	O
addresses	O
the	O
question	O
what	O
are	O
the	O
expected	O
results	O
in	O
normal	O
individual	O
.	O
the	O
complete	O
learning	O
module	O
is	O
available	O
through	O
the	O
african	O
health	O
oer	O
network	O
at	O
.	O
other	O
places	O
you	O
can	O
find	O
me	O
daily	O
vlog	O
snapchat	O
katyg	O
.	O
find	O
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
prices	O
here	O
.	O
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
basic	O
.	O
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
igt	O
diabetes	ENTITY
.	O
read	O
medical	O
definition	O
of	O
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
fasting	ENTITY
ifg	ENTITY
or	O
impaired	ENTITY
igt	ENTITY
.	O
url	O
.	O
medicinenet	ENTITY
script	ENTITY
main	ENTITY
art	ENTITY
.	O
treating	O
impaired	O
glucose	ENTITY
test	ENTITY
of	O
the	O
body	O
ability	O
to	O
metabolize	O
that	O
involves	O
administration	O
measured	O
dose	O
fasting	O
stomach	O
and	O
determination	ENTITY
levels	ENTITY
in	ENTITY
blood	ENTITY
urine	ENTITY
at	O
intervals	O
thereafter	O
is	O
used	O
especially	O
detect	O
diabetes	ENTITY
mellitus	ENTITY
tolerance	O
igt	ENTITY
diagnosed	ENTITY
using	ENTITY
oral	ENTITY
ogtt	ENTITY
.	O
higher	O
than	O
normal	ENTITY
blood	ENTITY
glucose	ENTITY
level	ENTITY
does	O
not	O
always	O
mean	O
may	O
definition	O
.	O
with	O
the	O
world	O
health	O
organisation	O
definitions	O
for	O
ifg	O
and	O
igt	O
glucose	ENTITY
intolerance	ENTITY
is	O
defined	O
as	O
impaired	O
tolerance	O
means	O
that	O
blood	O
raised	O
beyond	O
normal	O
levels	O
but	O
not	O
high	O
enough	O
to	O
warrant	O
diabetes	ENTITY
diagnosis	ENTITY
.	O
mmol	O
on	O
the	O
oral	ENTITY
glucose	ENTITY
tolerance	ENTITY
may	O
you	O
need	O
to	O
go	O
lab	O
one	O
time	O
for	O
hour	O
test	O
.	O
an	O
ogtt	O
is	O
most	O
commonly	O
done	O
to	O
check	O
for	O
diabetes	ENTITY
that	ENTITY
occurs	ENTITY
with	ENTITY
pregnancy	ENTITY
gestational	ENTITY
diabetes	ENTITY
.	O
igt	O
may	O
precede	O
type	O
diabetes	ENTITY
mellitus	ENTITY
by	O
many	O
years	O
.	O
the	O
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
is	O
laboratory	O
method	O
to	O
check	O
how	O
the	O
body	O
breaks	O
down	O
metabolizes	O
sugar	O
medical	O
definition	O
of	O
medicinenet	ENTITY
.	O
for	O
this	O
normal	O
result	O
means	O
you	O
do	O
not	O
have	O
gestational	ENTITY
diabetes	ENTITY
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
definition	O
diagnostic	ENTITY
procedure	ENTITY
in	O
which	O
measured	O
amount	O
of	O
is	O
ingested	O
and	O
blood	ENTITY
samples	ENTITY
are	ENTITY
taken	ENTITY
periodically	ENTITY
as	ENTITY
am	ENTITY
pre	ENTITY
diabetic	ENTITY
based	O
on	O
my	O
early	O
jan	O
tests	O
glucose	ENTITY
tolerance	ENTITY
wikipedia	O
.	O
what	O
does	O
it	O
mean	O
.	O
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
results	O
diabetes	ENTITY
daily	ENTITY
.	O
oral	ENTITY
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
webmd	O
.	O
what	O
is	O
glucose	ENTITY
tolerance	ENTITY
.	O
meaning	O
of	O
aug	O
tolerance	ENTITY
test	ENTITY
measures	O
how	O
well	O
your	O
body	O
able	O
to	O
process	O
glucose	ENTITY
or	ENTITY
sugar	ENTITY
.	O
merriam	O
webster	O
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
diagnosis	O
wikipediaglucose	O
.	O
with	O
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
you	O
face	O
much	O
greater	O
risk	O
of	O
developing	O
diabetes	O
and	O
cardiovascular	ENTITY
disease	ENTITY
.	O
igt	O
is	O
also	O
risk	ENTITY
factor	ENTITY
for	ENTITY
mortality	ENTITY
the	O
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
medical	O
in	O
which	O
given	O
and	O
blood	O
samples	O
taken	O
diagnosis	O
of	O
gestational	ENTITY
diabetes	ENTITY
then	O
defined	O
by	O
level	O
exceeding	O
cutoff	O
value	O
on	O
at	O
least	O
two	O
intervals	O
with	O
cutoffs	O
as	O
looking	O
online	O
definition	O
dictionary	O
.	O
glucose	ENTITY
explanation	ENTITY
free	ENTITY
.	O
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
mayo	O
clinic	O
.	O
normal	O
blood	ENTITY
glucose	ENTITY
levels	ENTITY
peak	O
within	O
to	O
minutes	O
after	O
drinking	O
the	O
solution	O
.	O
pre	ENTITY
diabetes	ENTITY
impaired	O
glucose	ENTITY
tolerance	ENTITY
impaired	ENTITY
tolerance	O
and	O
fasting	O
screening	O
tests	O
during	O
pregnancy	O
medlineplus	O
medic	O
.	O
al	O
test	O
dictionary	O
.	O
medical	O
definition	O
of	O
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
medicinenet	O
.	O
oral	ENTITY
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
during	O
pregnancy	O
cleveland	O
clinicmedical	O
tests	O
.	O
glucose	ENTITY
tests	ENTITY
lab	O
online	O
.	O
glucose	ENTITY
intolerance	ENTITY
signs	O
symptoms	ENTITY
treatment	ENTITY
and	O
diet	O
.	O
your	O
doctor	O
can	O
use	O
it	O
to	O
diagnose	O
diabetes	ENTITY
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
overview	O
covers	O
definition	O
preparation	O
results	O
of	O
this	O
blood	O
jan	O
hour	O
gtt	O
for	O
test	O
the	O
person	O
has	O
following	O
information	O
summarizes	O
meaning	O
other	O
oral	ENTITY
ogtt	ENTITY
measures	ENTITY
body	O
ability	O
type	O
sugar	O
called	O
glucose	ENTITY
that	ENTITY
is	ENTITY
main	ENTITY
source	ENTITY
energy	ENTITY
.	O
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
medical	O
def	O
.	O
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
treatment	ENTITY
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
impaired	O
glucose	O
tolerance	O
diet	O
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
in	ENTITY
pregnancy	ENTITY
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
during	ENTITY
pregnancy	ENTITY
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
hba	ENTITY
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
nz	ENTITY
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
nhs	ENTITY
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
diagnosis	ENTITY
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
results	ENTITY
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
test	O
oral	O
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
in	ENTITY
pregnancy	ENTITY
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
values	O
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
causes	O
impaired	ENTITY
fasting	ENTITY
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
blood	ENTITY
test	ENTITY
source	O
.	O
watch	O
full	O
video	O
.	O
all	O
pregnant	O
women	O
should	O
be	O
screened	O
for	O
gestational	ENTITY
diabetes	ENTITY
around	O
weeks	O
gestation	ENTITY
.	O
and	O
it	O
important	O
to	O
test	O
for	O
this	O
because	O
if	O
woman	O
has	O
gestational	ENTITY
diabetes	ENTITY
or	O
if	O
she	O
had	O
previously	O
diagnosed	O
type	O
or	O
type	O
diabetes	ENTITY
if	ENTITY
uncontrolled	ENTITY
it	ENTITY
can	ENTITY
cause	ENTITY
complications	ENTITY
like	ENTITY
preeclampsia	ENTITY
blood	ENTITY
sugar	ENTITY
problems	O
for	O
the	O
baby	O
after	O
delivery	O
stillbirth	O
and	O
an	O
abnormally	O
large	O
baby	O
which	O
has	O
complications	O
associated	O
with	O
that	O
too	O
.	O
to	O
of	O
women	O
develop	O
gestational	ENTITY
diabetes	ENTITY
and	O
it	O
all	O
goes	O
back	O
to	O
insulin	ENTITY
resistance	ENTITY
.	O
insulin	ENTITY
is	ENTITY
the	ENTITY
key	ENTITY
that	ENTITY
unlocks	ENTITY
your	ENTITY
body	ENTITY
cells	ENTITY
so	O
that	O
sugar	O
can	O
go	O
inside	O
and	O
make	O
the	O
cells	O
work	O
.	O
and	O
your	O
body	O
naturally	O
becomes	O
little	O
more	O
insulin	ENTITY
resistant	ENTITY
during	O
pregnancy	O
so	O
that	O
there	O
enough	O
sugar	O
circulating	O
in	O
your	O
blood	ENTITY
so	O
the	O
baby	O
gets	O
what	O
it	O
needs	O
.	O
normally	O
mothers	O
can	O
compensate	O
for	O
this	O
by	O
producing	O
more	O
insulin	ENTITY
but	ENTITY
mothers	ENTITY
who	ENTITY
have	ENTITY
gestational	ENTITY
diabetes	ENTITY
aren	O
able	O
to	O
make	O
more	O
insulin	ENTITY
and	ENTITY
so	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
rise	O
.	O
so	O
testing	O
like	O
said	O
for	O
this	O
is	O
done	O
are	O
weeks	O
and	O
what	O
will	O
happen	O
is	O
the	O
doctor	O
will	O
have	O
you	O
drink	O
very	O
sugary	O
drink	O
.	O
it	O
contains	O
grams	O
of	O
glucose	ENTITY
.	O
and	O
then	O
they	O
ll	O
test	O
your	O
blood	ENTITY
sugar	ENTITY
an	O
hour	O
later	O
and	O
see	O
how	O
your	O
body	O
responded	O
.	O
if	O
you	O
get	O
value	O
of	O
to	O
then	O
you	O
may	O
have	O
gestational	ENTITY
diabetes	ENTITY
and	O
the	O
doctor	O
will	O
want	O
to	O
do	O
follow	O
up	O
test	O
.	O
if	O
the	O
value	O
you	O
get	O
on	O
your	O
first	O
test	O
is	O
or	O
higher	O
then	O
you	O
just	O
have	O
gestational	ENTITY
diabetes	ENTITY
but	O
they	O
may	O
still	O
want	O
to	O
do	O
follow	O
up	O
testing	O
.	O
and	O
in	O
both	O
cases	O
it	O
doing	O
hour	O
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
.	O
this	O
is	O
done	O
when	O
you	O
re	O
fasting	O
and	O
then	O
you	O
drink	O
double	O
the	O
amount	O
of	O
sugar	O
.	O
it	O
gram	O
glucose	ENTITY
sugar	ENTITY
drink	O
.	O
and	O
then	O
they	O
test	O
your	O
blood	ENTITY
sugar	ENTITY
every	O
hour	O
for	O
hours	O
and	O
see	O
what	O
it	O
is	O
.	O
and	O
then	O
based	O
on	O
those	O
values	O
they	O
determine	O
if	O
you	O
truly	O
have	O
gestational	ENTITY
diabetes	ENTITY
or	O
not	O
.	O
if	O
the	O
diagnosis	O
is	O
made	O
then	O
there	O
couple	O
of	O
different	O
ways	O
to	O
manage	O
it	O
.	O
and	O
it	O
super	O
important	O
to	O
keep	O
your	O
blood	ENTITY
sugars	ENTITY
under	ENTITY
control	ENTITY
so	O
that	O
you	O
don	O
have	O
the	O
complications	O
discussed	O
before	O
.	O
the	O
management	O
plan	O
is	O
going	O
to	O
be	O
dependent	O
on	O
how	O
severe	O
your	O
case	O
is	O
.	O
and	O
for	O
lot	O
of	O
women	O
it	O
just	O
involves	O
some	O
diet	O
changes	O
and	O
exercise	O
.	O
for	O
other	O
women	O
it	O
involves	O
taking	O
oral	O
medication	O
.	O
and	O
for	O
about	O
of	O
women	O
with	O
gestational	ENTITY
diabetes	ENTITY
it	O
has	O
to	O
be	O
controlled	O
with	O
insulin	ENTITY
.	O
and	O
you	O
may	O
start	O
out	O
just	O
needing	O
to	O
make	O
few	O
diet	O
changes	O
and	O
then	O
as	O
the	O
pregnancy	O
progresses	O
so	O
do	O
your	O
body	O
needs	O
and	O
so	O
do	O
your	O
baby	O
needs	O
and	O
so	O
that	O
may	O
change	O
the	O
plan	O
as	O
well	O
.	O
so	O
you	O
could	O
start	O
out	O
being	O
diet	O
controlled	O
and	O
then	O
you	O
may	O
end	O
up	O
with	O
oral	O
medication	O
or	O
with	O
insulin	ENTITY
.	O
so	O
this	O
speaks	O
of	O
the	O
importance	O
of	O
consistent	O
monitoring	O
.	O
diabetic	ENTITY
educator	ENTITY
will	ENTITY
meet	ENTITY
with	ENTITY
you	ENTITY
and	ENTITY
talk	ENTITY
to	ENTITY
you	ENTITY
about	ENTITY
your	ENTITY
treatment	ENTITY
plan	ENTITY
and	ENTITY
also	ENTITY
tell	ENTITY
you	ENTITY
how	ENTITY
often	ENTITY
you	ENTITY
should	ENTITY
be	ENTITY
monitoring	ENTITY
your	ENTITY
blood	ENTITY
sugars	ENTITY
.	O
they	O
ll	O
take	O
peek	O
at	O
your	O
values	O
each	O
week	O
and	O
based	O
on	O
that	O
determine	O
if	O
additional	O
changes	O
in	O
your	O
treatment	O
plan	O
are	O
necessary	O
.	O
if	O
you	O
have	O
more	O
questions	O
for	O
me	O
in	O
the	O
future	O
feel	O
free	O
to	O
ask	O
them	O
on	O
our	O
facebook	O
page	O
at	O
and	O
recommend	O
us	O
to	O
your	O
friends	O
and	O
family	O
too	O
.	O
for	O
more	O
medical	O
and	O
healthcare	O
related	O
services	O
visit	O
.	O
support	O
the	O
deeper	O
cause	O
of	O
slow	O
metabolism	ENTITY
insulin	ENTITY
glucose	ENTITY
support	ENTITY
the	ENTITY
health	ENTITY
wellness	ENTITY
center	ENTITY
pinecrest	ENTITY
office	ENTITY
park	ENTITY
drive	ENTITY
alexandria	ENTITY
va	ENTITY
disclaimer	ENTITY
dr	ENTITY
berg	ENTITY
does	ENTITY
not	ENTITY
diagnose	ENTITY
treat	ENTITY
or	ENTITY
prevent	ENTITY
any	ENTITY
medical	ENTITY
conditions	ENTITY
instead	ENTITY
he	ENTITY
helps	ENTITY
people	ENTITY
create	ENTITY
their	ENTITY
health	ENTITY
to	ENTITY
avoid	ENTITY
health	ENTITY
problems	ENTITY
.	O
he	O
works	O
with	O
their	O
physicians	O
which	O
regular	O
their	O
medication	O
.	O
this	O
video	O
is	O
not	O
designed	O
to	O
and	O
does	O
not	O
provide	O
medical	O
advice	O
professional	O
diagnosis	O
opinion	O
treatment	O
or	O
services	O
to	O
you	O
or	O
to	O
any	O
other	O
individual	O
.	O
through	O
my	O
videos	O
blog	O
posts	O
website	O
information	O
give	O
suggestions	O
for	O
you	O
and	O
your	O
doctor	O
to	O
research	O
and	O
provide	O
general	O
information	O
for	O
educational	O
purposes	O
only	O
.	O
the	O
information	O
provided	O
in	O
this	O
video	O
or	O
site	O
or	O
through	O
linkages	O
to	O
other	O
sites	O
is	O
not	O
substitute	O
for	O
medical	O
or	O
professional	O
care	O
and	O
you	O
should	O
not	O
use	O
the	O
information	O
in	O
place	O
of	O
visit	O
call	O
consultation	O
or	O
the	O
advice	O
of	O
your	O
physician	O
or	O
other	O
healthcare	O
provider	O
.	O
the	O
health	O
wellness	O
and	O
dr	O
eric	O
berg	O
are	O
not	O
liable	O
or	O
responsible	O
for	O
any	O
advice	O
course	O
of	O
treatment	O
diagnosis	O
or	O
any	O
other	O
information	O
services	O
or	O
product	O
you	O
obtain	O
through	O
this	O
video	O
or	O
site	O
.	O
making	O
more	O
food	O
.	O
watch	O
full	O
video	O
.	O
dr	O
suman	O
kriti	O
endocrinologist	O
holy	O
family	O
hospital	O
new	O
delhi	O
will	O
talk	O
about	O
impaired	O
glucose	ENTITY
intolerance	ENTITY
.	O
after	O
giving	O
load	O
of	O
glucose	ENTITY
of	ENTITY
grams	ENTITY
during	ENTITY
the	ENTITY
oral	ENTITY
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
ogtt	ENTITY
if	ENTITY
the	ENTITY
diabetes	ENTITY
is	ENTITY
more	ENTITY
than	ENTITY
mg	ENTITY
dl	ENTITY
and	ENTITY
the	ENTITY
normal	ENTITY
post	ENTITY
prandial	ENTITY
blood	ENTITY
glucose	ENTITY
level	ENTITY
is	O
mg	O
dl	O
or	O
less	O
then	O
the	O
value	O
between	O
and	O
mg	O
dl	O
is	O
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
.	O
the	O
process	O
in	O
between	O
the	O
and	O
is	O
the	O
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
.	O
la	O
glyc	O
mie	O
correspond	O
la	O
quantit	O
de	O
glucose	O
contenue	O
dans	O
le	O
sang	O
et	O
est	O
habituellement	O
exprim	O
en	O
grammes	O
par	O
litre	O
de	O
sang	O
.	O
le	O
glucose	ENTITY
est	ENTITY
indispensable	ENTITY
au	ENTITY
bon	ENTITY
fonctionnement	ENTITY
de	ENTITY
organisme	ENTITY
car	ENTITY
il	ENTITY
constitue	ENTITY
le	ENTITY
principal	ENTITY
substrat	ENTITY
nerg	ENTITY
tique	ENTITY
de	ENTITY
organisme	ENTITY
rapidement	ENTITY
utilisable	ENTITY
.	O
une	O
partie	O
du	O
glucose	ENTITY
sanguin	ENTITY
est	ENTITY
transform	ENTITY
sous	ENTITY
forme	ENTITY
de	ENTITY
glycog	ENTITY
ne	ENTITY
forme	ENTITY
de	ENTITY
serve	ENTITY
de	ENTITY
glucose	ENTITY
stock	ENTITY
principalement	ENTITY
dans	ENTITY
le	ENTITY
foie	ENTITY
et	ENTITY
mobilisable	ENTITY
tout	ENTITY
moment	ENTITY
pour	ENTITY
compenser	ENTITY
une	ENTITY
glyc	ENTITY
mie	ENTITY
trop	ENTITY
basse	ENTITY
.	O
tous	O
ces	O
canismes	O
complexes	O
sont	O
sous	O
la	O
gulation	O
de	O
plusieurs	O
hormones	O
dont	O
fait	O
notamment	O
partie	O
insuline	O
principale	O
hormone	O
ayant	O
pour	O
le	O
une	O
diminution	O
de	O
la	O
glyc	O
mie	O
par	O
diff	O
rents	O
canismes	O
lorsque	O
celle	O
ci	O
est	O
trop	O
haute	O
.	O
la	O
glyc	O
mie	O
normale	O
est	O
mesur	O
sur	O
une	O
prise	O
de	O
sang	O
effectu	O
jeun	O
et	O
doit	O
tre	O
comprise	O
entre	O
et	O
.	O
en	O
dessous	O
on	O
parle	O
hypoglyc	O
mie	O
au	O
dessus	O
hyperglyc	O
mie	O
.	O
en	O
cas	O
de	O
valeur	O
situ	O
entre	O
et	O
une	O
intol	O
rance	O
au	O
glucose	ENTITY
est	ENTITY
suspect	ENTITY
et	ENTITY
si	ENTITY
ce	ENTITY
taux	ENTITY
est	ENTITY
sup	ENTITY
rieur	ENTITY
apr	ENTITY
un	ENTITY
nouveau	ENTITY
contr	ENTITY
le	ENTITY
on	ENTITY
parle	ENTITY
de	ENTITY
diab	ENTITY
te	ENTITY
pathologie	ENTITY
due	ENTITY
un	ENTITY
probl	ENTITY
me	ENTITY
au	ENTITY
niveau	ENTITY
de	ENTITY
insuline	ENTITY
.	O
pre	ENTITY
diabetes	ENTITY
which	O
may	O
be	O
known	O
as	O
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
igt	ENTITY
or	O
impaired	ENTITY
fasting	ENTITY
glucose	ENTITY
ifg	ENTITY
occurs	ENTITY
when	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
are	O
higher	O
than	O
normal	O
although	O
not	O
high	O
enough	O
to	O
be	O
diabetes	ENTITY
.	O
there	O
are	O
no	O
signs	O
or	O
symptoms	O
.	O
people	O
with	O
pre	ENTITY
diabetes	ENTITY
have	O
higher	O
risk	O
of	O
developing	O
type	O
diabetes	ENTITY
and	ENTITY
cardiovascular	ENTITY
heart	ENTITY
and	ENTITY
circulation	ENTITY
disease	ENTITY
.	O
risk	O
factors	O
of	O
pre	ENTITY
diabetes	ENTITY
family	O
history	O
of	O
type	O
diabetes	ENTITY
being	ENTITY
overweight	ENTITY
waist	ENTITY
measurement	ENTITY
low	ENTITY
level	ENTITY
of	ENTITY
physical	ENTITY
activity	ENTITY
smoking	ENTITY
high	ENTITY
blood	ENTITY
pressure	ENTITY
or	O
high	ENTITY
cholesterol	ENTITY
history	O
of	O
heart	ENTITY
disease	ENTITY
or	ENTITY
stroke	ENTITY
gestational	ENTITY
diabetes	ENTITY
diabetes	ENTITY
during	ENTITY
pregnancy	ENTITY
polycystic	O
ovary	O
syndrome	O
some	O
antipsychotic	O
medications	O
diagnosis	O
of	O
pre	ENTITY
diabetes	ENTITY
pre	O
diabetes	ENTITY
is	O
diagnosed	O
by	O
blood	ENTITY
test	ENTITY
that	O
checks	O
your	O
blood	ENTITY
glucose	ENTITY
level	ENTITY
.	O
any	O
blood	ENTITY
glucose	ENTITY
test	ENTITY
that	O
shows	O
higher	O
than	O
normal	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
needs	O
to	O
be	O
checked	O
further	O
.	O
an	O
oral	ENTITY
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
ogtt	ENTITY
is	ENTITY
the	ENTITY
best	ENTITY
way	ENTITY
to	ENTITY
diagnose	ENTITY
pre	ENTITY
diabetes	ENTITY
.	O
the	O
results	O
of	O
the	O
ogtt	ENTITY
will	ENTITY
show	ENTITY
whether	ENTITY
your	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
are	O
in	O
the	O
normal	O
pre	ENTITY
diabetes	ENTITY
or	O
diabetes	ENTITY
range	ENTITY
.	O
if	O
you	O
are	O
diagnosed	O
with	O
pre	ENTITY
diabetes	ENTITY
you	O
will	O
have	O
one	O
or	O
both	O
of	O
impaired	ENTITY
fasting	ENTITY
glucose	ENTITY
ifg	ENTITY
when	ENTITY
your	ENTITY
fasting	ENTITY
blood	ENTITY
glucose	ENTITY
level	ENTITY
is	O
higher	O
than	O
normal	O
but	O
still	O
below	O
the	O
level	O
for	O
diagnosis	O
of	O
diabetes	ENTITY
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
igt	ENTITY
when	ENTITY
your	ENTITY
blood	ENTITY
glucose	ENTITY
level	ENTITY
two	O
hours	O
after	O
an	O
ogtt	ENTITY
is	ENTITY
higher	ENTITY
than	ENTITY
normal	ENTITY
but	ENTITY
is	ENTITY
still	ENTITY
below	ENTITY
the	ENTITY
level	ENTITY
for	ENTITY
diabetes	ENTITY
.	O
the	O
fasting	ENTITY
blood	ENTITY
glucose	ENTITY
level	ENTITY
may	O
be	O
in	O
the	O
normal	O
range	O
.	O
management	ENTITY
of	ENTITY
pre	ENTITY
diabetes	ENTITY
pre	ENTITY
diabetes	ENTITY
can	O
be	O
prevented	O
by	O
making	O
lifestyle	O
changes	O
including	O
weight	O
loss	O
helps	O
the	O
insulin	ENTITY
in	ENTITY
your	ENTITY
body	ENTITY
work	ENTITY
better	ENTITY
and	ENTITY
lower	ENTITY
your	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
regular	O
moderate	O
physical	O
activity	O
actiivity	O
help	O
you	O
manage	O
your	O
weight	O
and	O
will	O
also	O
lower	O
your	O
blood	ENTITY
glucose	ENTITY
blood	ENTITY
pressure	ENTITY
and	O
cholesterol	ENTITY
levels	ENTITY
.	O
exercise	O
also	O
makes	O
your	O
insulin	ENTITY
work	ENTITY
better	ENTITY
healthy	ENTITY
diet	ENTITY
this	ENTITY
involves	ENTITY
less	ENTITY
fat	ENTITY
especially	ENTITY
saturated	ENTITY
fats	ENTITY
and	ENTITY
more	ENTITY
fruit	ENTITY
vegetables	ENTITY
and	ENTITY
high	ENTITY
fibre	ENTITY
wholegrain	ENTITY
foods	ENTITY
stopping	ENTITY
smoking	ENTITY
smoking	ENTITY
causes	ENTITY
insulin	ENTITY
resistance	ENTITY
and	O
increases	O
the	O
risk	O
of	O
blood	ENTITY
vessel	ENTITY
disease	ENTITY
blood	ENTITY
pressure	ENTITY
and	O
cholesterol	ENTITY
control	ENTITY
blood	ENTITY
pressure	ENTITY
and	O
cholesterol	ENTITY
control	ENTITY
should	ENTITY
be	ENTITY
well	ENTITY
managed	ENTITY
and	ENTITY
checked	ENTITY
regularly	ENTITY
by	ENTITY
your	ENTITY
doctor	ENTITY
.	O
was	O
tested	O
today	O
for	O
diabetes	ENTITY
had	ENTITY
to	ENTITY
have	ENTITY
my	ENTITY
blood	ENTITY
drawn	ENTITY
for	ENTITY
two	ENTITY
hours	ENTITY
once	ENTITY
every	ENTITY
hour	ENTITY
.	O
dont	O
know	O
my	O
results	O
yet	O
.	O
the	O
drink	O
was	O
weird	O
tasting	O
and	O
it	O
may	O
be	O
fill	O
like	O
wanted	O
to	O
throw	O
up	O
.	O
dr	O
mclaughlin	O
shares	O
what	O
an	O
oral	ENTITY
glucose	ENTITY
tolerance	ENTITY
test	ENTITY
is	O
.	O
for	O
more	O
information	O
on	O
diabetes	ENTITY
visit	ENTITY
.	O
drinking	O
waster	O
is	O
the	O
main	O
source	O
of	O
arsenic	O
exposure	O
.	O
arsenite	ENTITY
changes	ENTITY
glucose	ENTITY
homeostasis	ENTITY
during	O
pregnancy	O
by	O
altering	O
beta	ENTITY
cell	ENTITY
function	ENTITY
increasing	O
risk	O
of	O
developing	O
gestational	ENTITY
diabetes	ENTITY
.	O
can	O
you	O
reverse	O
insulin	ENTITY
apr	ENTITY
how	ENTITY
to	ENTITY
help	ENTITY
your	ENTITY
body	ENTITY
diabetes	ENTITY
they	ENTITY
contribute	ENTITY
resistance	ENTITY
and	ENTITY
inflammation	ENTITY
further	ENTITY
aggravating	ENTITY
the	ENTITY
poor	ENTITY
pancreas	ENTITY
may	ENTITY
get	ENTITY
facts	ENTITY
about	ENTITY
what	ENTITY
can	ENTITY
do	ENTITY
control	ENTITY
prevent	ENTITY
or	ENTITY
this	ENTITY
tire	ENTITY
glucose	ENTITY
intolerance	ENTITY
blood	ENTITY
fat	ENTITY
disorders	ENTITY
excessive	O
consumption	O
of	O
simple	O
carbs	O
lead	O
.	O
sometimes	O
dark	O
ring	O
oct	O
over	O
million	O
americans	O
have	O
insulin	ENTITY
resistance	ENTITY
that	O
can	O
lead	O
to	O
diabetes	ENTITY
.	O
and	O
you	O
could	O
be	O
on	O
the	O
road	O
to	O
diabetes	ENTITY
for	ENTITY
years	ENTITY
or	ENTITY
more	ENTITY
and	ENTITY
when	ENTITY
pancreas	ENTITY
fails	ENTITY
produce	ENTITY
hormone	ENTITY
insulin	ENTITY
blood	ENTITY
sugar	ENTITY
cannot	O
get	O
into	O
body	O
cells	O
.	O
fortunately	O
you	O
can	O
help	O
to	O
prevent	O
and	O
even	O
reverse	O
this	O
feb	O
insulin	ENTITY
resistance	ENTITY
be	O
reversed	O
with	O
diet	O
exercise	O
but	O
how	O
long	O
dr	O
despite	O
years	O
of	O
hard	O
work	O
cynthia	O
simply	O
had	O
no	O
idea	O
how	O
to	O
lose	O
weight	O
safely	O
in	O
this	O
article	O
will	O
share	O
with	O
you	O
the	O
single	O
most	O
effective	O
dietary	O
change	O
that	O
can	O
make	O
increase	O
your	O
insulin	ENTITY
sensitivity	ENTITY
.	O
reverse	O
insulin	ENTITY
resistance	ENTITY
holistic	O
healing	O
information	O
.	O
read	O
on	O
to	O
learn	O
how	O
reverse	O
insulin	ENTITY
resistance	ENTITY
and	O
avoid	O
the	O
dopamine	ENTITY
sep	ENTITY
it	ENTITY
helps	ENTITY
reduce	ENTITY
central	ENTITY
body	ENTITY
fat	ENTITY
improving	ENTITY
sugar	ENTITY
metabolism	ENTITY
.	O
do	O
you	O
have	O
insulin	ENTITY
resistance	ENTITY
.	O
reverse	O
resistance	O
with	O
these	O
foods	O
how	O
to	O
reverse	O
diabetes	ENTITY
that	ENTITY
improve	ENTITY
long	ENTITY
does	ENTITY
it	ENTITY
take	ENTITY
reverse	ENTITY
.	O
scary	O
naturally	O
drthe	O
diet	O
protocol	O
help	O
prevent	O
dr	O
the	O
more	O
muscle	ENTITY
body	ENTITY
has	O
the	O
glucose	ENTITY
it	ENTITY
can	ENTITY
burn	ENTITY
to	ENTITY
control	ENTITY
blood	ENTITY
levels	ENTITY
good	O
news	O
is	O
that	O
we	O
not	O
only	O
treat	O
insulin	ENTITY
resistance	ENTITY
but	O
heal	O
.	O
reverse	O
the	O
process	O
and	O
help	O
bring	O
her	O
hormones	ENTITY
back	ENTITY
into	ENTITY
natural	ENTITY
balance	ENTITY
in	ENTITY
order	ENTITY
to	ENTITY
understand	ENTITY
insulin	ENTITY
resistance	ENTITY
detail	O
read	O
this	O
article	O
.	O
edelson	O
continues	O
if	O
you	O
let	O
the	O
fuse	O
burn	O
too	O
far	O
it	O
becomes	O
dec	O
burst	O
training	O
can	O
help	O
burn	O
up	O
to	O
more	O
body	ENTITY
fat	ENTITY
than	O
traditional	O
cardio	ENTITY
and	ENTITY
naturally	ENTITY
increase	ENTITY
insulin	ENTITY
sensitivity	ENTITY
.	O
how	O
to	O
reverse	O
insulin	ENTITY
resistance	ENTITY
an	O
actionable	O
guide	O
blog	O
.	O
find	O
out	O
if	O
you	O
have	O
insulin	ENTITY
resistance	ENTITY
and	O
what	O
can	O
do	O
to	O
reverse	O
it	O
studies	O
show	O
that	O
after	O
exercising	O
muscles	ENTITY
become	ENTITY
more	ENTITY
sensitive	ENTITY
insulin	ENTITY
reversing	ENTITY
lowering	ENTITY
blood	ENTITY
glucose	ENTITY
levels	ENTITY
.	O
prediabetes	ENTITY
insulin	ENTITY
resistance	ENTITY
resistance	ENTITY
.	O
what	O
is	O
it	O
and	O
how	O
we	O
can	O
heal	O
.	O
more	O
vigorous	O
exercise	O
and	O
sustained	O
is	O
often	O
needed	O
to	O
reverse	O
severe	O
insulin	ENTITY
resistance	ENTITY
or	O
diabetes	ENTITY
nov	ENTITY
when	ENTITY
it	ENTITY
comes	ENTITY
weight	ENTITY
loss	ENTITY
it	ENTITY
mostly	ENTITY
about	ENTITY
.	O
can	O
insulin	ENTITY
resistance	ENTITY
truly	O
be	O
reversed	O
.	O
diabetes	ENTITY
daily	ENTITY
.	O
reverse	O
insulin	ENTITY
resistance	ENTITY
love	O
handles	O
are	O
warning	O
sign	O
of	O
.	O
insulin	ENTITY
resistance	ENTITY
how	O
to	O
reverse	O
insulin	ENTITY
an	ENTITY
actionable	ENTITY
guide	ENTITY
.	O
women	O
to	O
years	O
of	O
pain	O
and	O
frustration	O
with	O
type	O
diabetes	ENTITY
gone	ENTITY
.	O
you	O
can	O
do	O
this	O
on	O
an	O
insulin	ENTITY
resistance	ENTITY
diet	O
helps	O
you	O
lose	O
excess	O
weight	O
and	O
regulate	O
found	O
that	O
protocol	O
exercise	O
alter	O
how	O
to	O
reverse	O
is	O
the	O
primary	O
reason	O
would	O
be	O
proceeding	O
with	O
nutritionally	O
based	O
medical	O
management	O
program	O
resistancelupo	O
steps	O
to	O
reversing	O
type	O
diabetes	ENTITY
and	ENTITY
insulin	ENTITY
resistance	ENTITY
reverse	O
in	O
easy	O
.	O
kettleandfire	O
how	O
to	O
reverse	O
insulin	ENTITY
resistance	ENTITY
url	O
.	O
webcache	O
.	O
maybe	O
you	O
feel	O
thirstier	O
or	O
wake	O
up	O
at	O
night	O
and	O
need	O
to	O
go	O
.	O
strong	O
predictor	O
of	O
conversion	O
to	O
type	O
diabetes	ENTITY
and	ENTITY
cardiovascular	ENTITY
disease	ENTITY
.	O
click	O
link	O
.	O
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
igt	ENTITY
is	ENTITY
pre	ENTITY
diabetic	ENTITY
state	O
of	O
hyperglycemia	ENTITY
that	ENTITY
is	ENTITY
associated	ENTITY
with	ENTITY
insulin	ENTITY
resistance	ENTITY
and	O
increased	O
risk	O
of	O
cardiovascular	ENTITY
pathology	ENTITY
.	O
igt	O
may	O
precede	O
type	O
diabetes	ENTITY
mellitus	ENTITY
by	O
many	O
years	O
.	O
igt	O
is	O
also	O
risk	O
factor	O
for	O
mortality	O
.	O
html	O
url	O
.	O
webcache	O
.	O
glucose	ENTITY
intolerance	ENTITY
signs	O
symptoms	O
treatment	O
and	O
diet	O
diabetes	ENTITY
.	O
what	O
does	O
all	O
this	O
mean	O
.	O
votes	O
rate	O
this	O
definition	O
glucose	ENTITY
intolerance	ENTITY
.	O
signs	O
of	O
gluten	ENTITY
sensitivity	ENTITY
it	O
more	O
than	O
tummy	O
trouble	O
.	O
symptoms	O
of	O
gluten	ENTITY
intolerance	ENTITY
and	O
allergy	ENTITY
healthline	ENTITY
.	O
fructose	ENTITY
ve	ENTITY
been	ENTITY
told	ENTITY
have	ENTITY
glucose	ENTITY
intolerance	ENTITY
not	O
diabetes	ENTITY
at	ENTITY
wks	ENTITY
the	ENTITY
most	ENTITY
common	ENTITY
signs	ENTITY
of	ENTITY
gluten	ENTITY
intolerance	ENTITY
healthline	O
.	O
the	O
tests	O
may	O
come	O
back	O
incorrect	O
with	O
false	O
negative	O
and	O
you	O
won	O
have	O
proper	O
understanding	O
of	O
jan	O
but	O
this	O
does	O
not	O
mean	O
that	O
diabetes	ENTITY
is	ENTITY
definite	ENTITY
.	O
glucose	ENTITY
intolerance	ENTITY
includes	O
anyone	O
with	O
either	O
impaired	ENTITY
fasting	ENTITY
glucose	ENTITY
ifg	ENTITY
or	ENTITY
tolerance	ENTITY
igt	ENTITY
.	O
national	O
library	O
of	O
medicine	O
oct	O
course	O
of	O
two	O
years	O
attributed	O
my	O
undiagnosed	O
gluten	ENTITY
intolerance	ENTITY
at	O
the	O
time	O
to	O
other	O
seemingly	O
unrelated	O
individual	O
symptoms	O
that	O
got	O
me	O
nowhere	O
.	O
these	O
symptoms	O
can	O
be	O
minor	O
at	O
first	O
but	O
they	O
will	O
get	O
worse	O
over	O
time	O
.	O
with	O
the	O
world	O
health	O
organisation	O
definitions	O
for	O
ifg	O
and	O
igt	O
glucose	ENTITY
intolerance	ENTITY
is	O
defined	O
as	O
fasting	O
blood	O
level	O
of	O
above	O
he	O
said	O
needed	O
to	O
watch	O
what	O
eat	O
be	O
retested	O
every	O
months	O
on	O
regular	O
basis	O
to	O
keep	O
an	O
eye	O
it	O
.	O
find	O
the	O
right	O
recipes	O
foods	O
and	O
complete	O
diet	O
plans	O
for	O
healthy	O
lifestyle	O
there	O
is	O
choice	O
of	O
tasty	O
food	O
options	O
to	O
eat	O
if	O
you	O
are	O
glucose	ENTITY
intolerant	ENTITY
or	ENTITY
dealing	ENTITY
with	ENTITY
gestational	ENTITY
diabetes	ENTITY
intolerance	O
during	O
pregnancy	O
actually	O
referred	O
as	O
.	O
googleusercontent	O
search	O
.	O
it	O
is	O
what	O
women	O
experience	O
while	O
they	O
are	O
pregnant	O
whether	O
had	O
prior	O
diabetes	ENTITY
issues	ENTITY
or	ENTITY
notfor	ENTITY
those	ENTITY
that	ENTITY
not	ENTITY
aware	ENTITY
of	ENTITY
glucose	ENTITY
intolerance	ENTITY
means	O
during	O
pregnancy	O
well	O
it	O
pretty	O
much	O
sign	O
high	O
you	O
have	O
only	O
if	O
your	O
fasting	O
blood	O
level	O
over	O
.	O
medical	O
vocabulary	O
what	O
does	O
glucose	ENTITY
intolerance	ENTITY
mean	O
youtube	O
.	O
apr	ENTITY
these	ENTITY
tests	ENTITY
are	ENTITY
dependent	ENTITY
on	ENTITY
the	ENTITY
presence	ENTITY
of	ENTITY
gluten	ENTITY
or	ENTITY
wheat	ENTITY
in	ENTITY
your	ENTITY
body	ENTITY
in	ENTITY
order	ENTITY
to	ENTITY
work	ENTITY
.	O
simple	O
dietary	ENTITY
changes	ENTITY
that	O
maintain	O
proper	O
blood	ENTITY
sugar	ENTITY
control	ENTITY
can	O
help	O
you	O
avoid	O
lifetime	O
of	O
monitoring	O
and	O
diabetic	ENTITY
complications	ENTITY
dec	O
are	O
glucose	ENTITY
intolerant	ENTITY
.	O
do	O
have	O
abnormal	O
levels	O
insulin	O
in	O
your	O
body	O
.	O
here	O
some	O
symptoms	O
to	O
find	O
out	O
impaired	ENTITY
tolerance	ENTITY
igt	ENTITY
is	ENTITY
pre	ENTITY
state	ENTITY
hyperglycemia	ENTITY
associated	ENTITY
with	ENTITY
resistance	ENTITY
increased	ENTITY
risk	ENTITY
cardiovascular	ENTITY
pathology	ENTITY
.	O
poor	O
diet	O
being	O
overweight	O
and	O
not	O
active	O
helpme	O
sarahharrison	O
pregnant	O
pregnancy	O
schwanger	O
schwangerschaft	O
baby	O
babygirl	O
babybump	O
mumtobe	O
maternity	O
dezemberbaby	O
itsagirl	O
miarose	O
ssw	O
overwelmed	O
withlove	O
surprise	O
babyboy	O
momtobe	O
instagoodtoday	O
repost	O
what	O
does	O
glucose	ENTITY
intolerance	ENTITY
mean	O
.	O
prediabetes	ENTITY
.	O
type	O
oct	O
it	O
basically	O
means	O
your	O
body	O
is	O
starting	O
to	O
utilize	O
insulin	ENTITY
as	ENTITY
well	ENTITY
blood	ENTITY
sugar	ENTITY
slightly	O
elevated	O
but	O
you	O
have	O
reached	O
the	O
diabetic	ENTITY
stage	ENTITY
yet	ENTITY
.	O
what	O
does	O
glucose	ENTITY
intole	ENTITY
.	O
woman	O
develops	O
glucose	ENTITY
intolerance	ENTITY
after	O
taking	O
health	O
product	O
from	O
malaysia	O
woman	O
in	O
her	O
was	O
diagnosed	O
with	O
impaired	ENTITY
glucose	ENTITY
tolerance	ENTITY
or	O
poor	O
blood	ENTITY
sugar	ENTITY
control	ENTITY
after	O
taking	O
health	O
product	O
that	O
she	O
obtained	O
from	O
relative	O
in	O
malaysia	O
.	O
the	O
item	O
herba	O
saraf	O
which	O
subcribe	O
minute	O
news	O
for	O
more	O
videos	O
.	O
donate	O
here	O
aklectures	O
com	O
.	O
these	O
videos	O
do	O
not	O
provide	O
medical	O
advice	O
and	O
are	O
for	O
informational	O
purposes	O
only	O
.	O
the	O
videos	O
are	O
not	O
intended	O
to	O
be	O
substitute	O
for	O
professional	O
medical	O
advice	O
diagnosis	O
or	O
treatment	O
.	O
always	O
seek	O
the	O
advice	O
of	O
qualified	O
health	O
provider	O
with	O
any	O
questions	O
you	O
may	O
have	O
regarding	O
medical	O
condition	O
.	O
never	O
disregard	O
professional	O
medical	O
advice	O
or	O
delay	O
in	O
seeking	O
it	O
because	O
of	O
something	O
you	O
have	O
read	O
or	O
seen	O
in	O
any	O
khan	O
academy	O
video	O
.	O
more	O
free	O
lessons	O
at	O
wq	O
qgz	O
gj	O
.	O
if	O
you	O
re	O
like	O
us	O
you	O
love	O
the	O
sound	O
of	O
brunch	O
buffet	O
.	O
but	O
not	O
everything	O
you	O
eat	O
at	O
that	O
glorious	O
buffet	O
is	O
going	O
to	O
be	O
turned	O
into	O
energy	O
.	O
your	O
body	O
has	O
to	O
work	O
with	O
different	O
forms	O
of	O
food	O
in	O
different	O
ways	O
.	O
in	O
this	O
episode	O
of	O
crash	O
course	O
anatomy	O
physiology	O
hank	O
takes	O
us	O
through	O
more	O
about	O
our	O
metabolism	ENTITY
including	ENTITY
cellular	ENTITY
respiration	ENTITY
atp	ENTITY
glycogenesis	ENTITY
and	ENTITY
how	ENTITY
insulin	ENTITY
regulates	ENTITY
our	ENTITY
blood	ENTITY
sugar	ENTITY
levels	ENTITY
.	O
anatomy	ENTITY
of	ENTITY
hank	ENTITY
poster	ENTITY
.	O
introduction	O
to	O
glycolysis	ENTITY
.	O
role	O
of	O
glycolysis	O
in	O
producing	O
atps	ENTITY
and	ENTITY
nadhs	ENTITY
and	ENTITY
converting	ENTITY
glucose	ENTITY
to	ENTITY
pyruvates	ENTITY
.	O
watch	O
the	O
next	O
lesson	O
add	O
user	O
khanacademy	O
.	O
what	O
are	O
the	O
major	O
forms	O
of	O
regulation	O
in	O
metabolism	ENTITY
.	O
how	O
do	O
these	O
apply	O
to	O
glycolysis	ENTITY
and	ENTITY
gluconeogenesis	ENTITY
.	O
created	O
by	O
jasmine	O
rana	O
.	O
watch	O
the	O
next	O
lesson	O
add	O
user	O
khanacademy	O
.	O
biochemistry	O
lecture	O
about	O
overview	O
of	O
glucose	ENTITY
metabolism	ENTITY
.	O
in	O
which	O
hank	O
does	O
some	O
push	O
ups	O
for	O
science	O
and	O
describes	O
the	O
economy	O
of	O
cellular	ENTITY
respiration	ENTITY
and	O
the	O
various	O
processes	O
whereby	O
our	O
bodies	O
create	O
energy	O
in	O
the	O
form	O
of	O
atp	ENTITY
.	O
crash	O
course	O
biology	O
is	O
now	O
available	O
on	O
dvd	O
.	O
dr	O
kiel	O
quickly	O
reviews	O
sugar	O
and	O
carbohydrate	ENTITY
metabolism	ENTITY
and	O
makes	O
it	O
as	O
easy	O
to	O
understand	O
as	O
possible	O
.	O
more	O
health	O
education	O
carbohydrate	ENTITY
metabolism	ENTITY
is	O
complicated	O
but	O
you	O
should	O
understand	O
how	O
it	O
works	O
.	O
carbs	O
can	O
be	O
referred	O
to	O
as	O
starches	O
sugar	O
glucose	ENTITY
monosaccharide	ENTITY
polysaccharide	ENTITY
fructose	ENTITY
galactose	ENTITY
lactose	ENTITY
maltose	ENTITY
and	ENTITY
sucrose	ENTITY
.	O
the	O
purpose	O
is	O
to	O
produce	O
cellular	ENTITY
energy	ENTITY
adenosine	ENTITY
triphosphate	ENTITY
atp	ENTITY
and	ENTITY
includes	ENTITY
electron	ENTITY
transports	ENTITY
chain	ENTITY
.	O
this	O
is	O
known	O
as	O
aerobic	ENTITY
respiratory	ENTITY
and	O
includes	O
the	O
citrus	O
acid	ENTITY
cycle	ENTITY
tca	ENTITY
electron	ENTITY
transport	ENTITY
chain	ENTITY
.	O
there	O
are	O
many	O
sources	O
of	O
carbs	O
they	O
can	O
be	O
simple	O
or	O
complex	O
.	O
you	O
should	O
understand	O
carb	O
cycling	O
deficit	O
metabolism	ENTITY
anabolism	ENTITY
catabolism	ENTITY
breakdown	ENTITY
macromolecules	ENTITY
macronutrients	ENTITY
synthesis	ENTITY
counting	ENTITY
carbs	ENTITY
daily	ENTITY
requirements	ENTITY
diabetes	ENTITY
mellitus	ENTITY
digestion	O
glycogen	ENTITY
gluconeogenesis	ENTITY
and	ENTITY
glycolysis	ENTITY
as	ENTITY
it	ENTITY
all	ENTITY
very	ENTITY
important	ENTITY
and	ENTITY
complex	ENTITY
.	O
wish	O
all	O
success	O
enjoy	O
.	O
visit	O
us	O
add	O
user	O
khanacademy	O
.	O
molecular	ENTITY
formula	ENTITY
open	O
chain	O
formula	O
bayer	O
fittig	O
formula	O
ball	O
stick	O
model	O
fisher	O
projection	O
formula	O
haworth	O
structures	O
of	O
glucose	ENTITY
structures	ENTITY
for	ENTITY
preparatory	ENTITY
phase	ENTITY
pay	ENTITY
off	ENTITY
phase	ENTITY
of	ENTITY
glycolysis	ENTITY
alhamdulillah	ENTITY
.	O
metabolism	ENTITY
is	ENTITY
complex	ENTITY
process	ENTITY
that	ENTITY
has	ENTITY
lot	ENTITY
more	ENTITY
going	ENTITY
on	ENTITY
than	ENTITY
personal	ENTITY
trainers	ENTITY
and	ENTITY
commercials	ENTITY
might	ENTITY
have	ENTITY
you	ENTITY
believe	ENTITY
.	O
today	O
we	O
are	O
exploring	O
some	O
of	O
its	O
key	O
parts	O
including	O
vital	O
nutrients	O
such	O
as	O
water	O
vitamins	O
minerals	O
carbs	O
fats	O
and	O
proteins	O
as	O
well	O
as	O
how	O
anabolic	ENTITY
reactions	ENTITY
build	ENTITY
structures	ENTITY
and	ENTITY
require	ENTITY
energy	ENTITY
while	ENTITY
catabolic	ENTITY
reactions	ENTITY
tear	ENTITY
things	ENTITY
apart	ENTITY
and	ENTITY
release	ENTITY
energy	ENTITY
.	O
anatomy	ENTITY
of	ENTITY
hank	ENTITY
poster	ENTITY
.	O
glycolysis	ENTITY
biochemistry	ENTITY
this	ENTITY
lecture	ENTITY
explains	ENTITY
about	ENTITY
the	ENTITY
glycolysis	ENTITY
pathway	ENTITY
step	ENTITY
by	ENTITY
step	ENTITY
with	ENTITY
the	ENTITY
involvement	ENTITY
of	ENTITY
enzymes	ENTITY
that	ENTITY
will	ENTITY
convert	ENTITY
glucose	ENTITY
into	ENTITY
pyruvate	ENTITY
in	ENTITY
the	ENTITY
cytosol	ENTITY
of	ENTITY
every	ENTITY
living	ENTITY
cell	ENTITY
.	O
glycolysis	ENTITY
is	ENTITY
the	ENTITY
first	ENTITY
major	ENTITY
step	ENTITY
in	ENTITY
carbohydrate	ENTITY
metabolism	ENTITY
that	O
helps	O
to	O
initiate	O
the	O
process	O
of	O
cellular	O
respiration	O
.	O
